Allergic Diseases by unknown
Allergic Diseases 
Highlights in the Clinic,  
Mechanisms and Treatment
Edited by Celso Pereira
Edited by Celso Pereira
Photo by MiaZeus / iStock
The present Edition “Allergic diseases - highlights in the clinic, mechanisms and 
treatment” aims to present some recent aspects related to one of the most prevalent 
daily clinical expression disease. The effort of a group of outstanding experts from 
many countries reflects a set of scientific studies very promising for a better clinical 
care and also to the treatment and control of the allergy. This book provides a valuable 
reference text in several topics of the clinical allergy and basic issues related to the 
immune system response. The inflammatory reaction understanding in allergic disease 










ALLERGIC DISEASES – 








ALLERGIC DISEASES – 








Allergic Diseases - Highlights in the Clinic, Mechanisms and Treatment
http://dx.doi.org/10.5772/1441
Edited by Celso Pereira
Contributors
Anas M Abdel Rahman, Robert Helleur, Mohamed Fareed Jeebhay, Andreas Lopata, Marianna Kulka, Akio Matsuda, 
Kyoko Futamura, Blanca Cárdaba, Achsah Dorsey Keegan, Nicola Heller, Preeta Dasgupta, Nicolas Dorsey, Svetlana 
P. Chapoval, Gabriel Morán, Claudio Henriquez, Hugo Folch, Ana Maria Sell, Jeane Eliete Laguila Visentainer, Marcia 
Regina Piuvezam, Patricia Bozza, Christianne Bandeira-Melo, Giciane Vieira, Hermann Costa, Claudio Bezerra-Santos, 
Ute Langen, Bartira Rossi-Bergmann, Elaine Cruz, Alenka Kravos, Koichi Ueno, Katsunori Yamaura, Masahiko Suzuki, 
Takao Namiki, Chae-Seo Rhee, Doo Hee Han, Hein Raat, Esther Hafkamp - de Groen, Anne-Judith Waligora-Dupriet, 
Marie-José Butel, Hak Sun Yu, Celso Pereira, Beatriz Tavares, Filomena Botelho, Graça Loureiro, Lia Fernandes, Luis 
Garcia-Marcos, Barbara Bohle, Brinda Subbarayal, Marija Geroldinger-Simic, Yvan Vandenplas, Gigi Veereman-
Wauters, Veereman-Wauters, Asli Gelincik, Suna Buyukozturk, María L Sanz, Dragana Stanic-Vucinic, Tanja Cirkovic 
Velickovic, Tomoshige Matsumoto, Yukinori Yoshida, Makoto Kameda, Tomoki Nishikido, Isamu Takamatsu, Satoru 
Doi, Backer, Maria Fernanda Macedo Soares, Claudia Araujo
© The Editor(s) and the Author(s) 2012
The moral rights of the and the author(s) have been asserted.
All rights to the book as a whole are reserved by INTECH. The book as a whole (compilation) cannot be reproduced, 
distributed or used for commercial or non-commercial purposes without INTECH’s written permission.  
Enquiries concerning the use of the book should be directed to INTECH rights and permissions department 
(permissions@intechopen.com).
Violations are liable to prosecution under the governing Copyright Law.
Individual chapters of this publication are distributed under the terms of the Creative Commons Attribution 3.0 
Unported License which permits commercial use, distribution and reproduction of the individual chapters, provided 
the original author(s) and source publication are appropriately acknowledged. If so indicated, certain images may not 
be included under the Creative Commons license. In such cases users will need to obtain permission from the license 
holder to reproduce the material. More details and guidelines concerning content reuse and adaptation can be 
foundat http://www.intechopen.com/copyright-policy.html.
Notice
Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those 
of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published 
chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the 
use of any materials, instructions, methods or ideas contained in the book.
First published in Croatia, 2012 by INTECH d.o.o.
eBook (PDF) Published by  IN TECH d.o.o.
Place and year of publication of eBook (PDF): Rijeka, 2019.
IntechOpen is the global imprint of IN TECH d.o.o.
Printed in Croatia
Legal deposit, Croatia: National and University Library in Zagreb
Additional hard and PDF copies can be obtained from orders@intechopen.com
Allergic Diseases - Highlights in the Clinic, Mechanisms and Treatment
Edited by Celso Pereira
p. cm.
ISBN 978-953-51-0227-4
eBook (PDF) ISBN 978-953-51-6872-0
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
4,100+ 




Contributors from top 500 universities








the world’s leading publisher of 
Open Access books




Prof Celso Pereira is currently a graduated specialist 
in Immuno-allergy at Coimbra’s Universitary Hospital 
Centre, at Coimbra, Portugal. He is also the present 
elected president of the Immunoallergy Board of the 
Portuguese Medical Association. His main activities 
include clinical practice, education (pre and post gradu-
ate) and clinical and laboratorial research. He is member 
of national committee for vaccination. His scientific interests include the 
participation and development of several research projects, but now have 
focused his interest in the mechanisms of allergy and specific immuno-
therape has edited two scientific books, and has more than 90 scientific 
publications including book chapters, and scientific papers. He published 
over 300 abstracts related to the research projects developed and presented 
at scientific events. He was also honored with 31 scientific awards. He was 
responsible for the first subcutaneous application of latex immunotherapy 
and for the first long term sublingual native Pru p3 desensitization. During 
his Iberian Chapter Presidency of the Latin-American Allergy, Asthma and 
Immunology Society he coordinated an international multicentre study 
focusing aeroallergen sensitization in the Iberian Peninsula. He is an asso-
ciate editor of 4 scientific Journals related to Allergy and Clinical Immu-
nology. He has been participating in the organization of scientific meetings 












Part 1 Allergens, Inflammation and Basic Mechanisms 1 
 New Challenges for Old Diseases: The Impact of -Omics  Chapter 1
Technologies in the Understanding of Allergic Diseases 3 
Blanca Cárdaba, Miriam Aguerri, David Calzada and Carlos Lahoz 
 Expression of the Histamine H4 Receptor
 in Human Tissue 31 Chapter 2
Katsunori Yamaura, Masahiko Suzuki,  
Takao Namiki and Koichi Ueno 
 The Type I and Type II Receptor  Chapter 3
Complexes for IL-4 and IL-13 Differentially  
Regulate Allergic Lung Inflammation 43 
Nicola M. Heller, Preeta Dasgupta, Nicolas J. Dorsey,  
Svetlana P. Chapoval and Achsah D. Keegan 
 Enzymatic and Chemical Modifications of Food Allergens 83 Chapter 4
Dragana Stanić-Vučinić and Tanja Ćirković Veličković 
 Characterization of Seafood  Chapter 5
Proteins Causing Allergic Diseases 107 
Anas M. Abdel Rahman, Robert J. Helleur,  
Mohamed F. Jeebhay and Andreas L. Lopata 
 Birch Pollen-Related Food Allergy: An Excellent Disease  Chapter 6
Model to Understand the Relevance of Immunological  
Cross-Reactivity for Allergy 141 
Brinda Subbarayal, Marija Geroldinger-Simic and Barbara Bohle 
Part 2 Clinical Allergy 165 
 Anaphylaxis: Etiology, Clinical  Chapter 7
Manifestations, Diagnosis and Management 167 
Aslı Gelincik and Suna Büyüköztürk 
Contents 
Preface XIII 
Part 1 Allergens, Inflammation and Basic Mechanisms 1 
 New Challenges for Old Diseases: The Impact of -Omics Chapter 1
Technologies in the Understanding of Allergic Diseases 3 
Blanca Cárdaba, Miriam Aguerri, David Calzada and Carlos Lahoz 
 Expression of the Histamine H4 Receptor
 in Human Tissue 31 Chapter 2
Katsunori Yamaura, Masahiko Suzuki,  
Takao Namiki and Koichi Ueno 
 The Type I and Type II Receptor Chapter 3
Complexes for IL-4 and IL-13 Differentially  
Regulate Allergic Lung Inflammation 43 
Nicola M. Heller, Preeta Dasgupta, Nicolas J. Dorsey, 
Svetlana P. Chapoval and Achsah D. Keegan 
 Enzymatic and Chemical Modifications of Food Allergens 83 Chapter 4
Dragana Stanić-Vučinić and Tanja Ćirković Veličković 
 Characterization of Seafood Chapter 5
Proteins Causing Allergic Diseases 107 
Anas M. Abdel Rahman, Robert J. Helleur,  
Mohamed F. Jeebhay and Andreas L. Lopata 
 Birch Pollen-Related Food Allergy: An Excellent Disease Chapter 6
Model to Understand the Relevance of Immunological  
Cross-Reactivity for Allergy 141 
Brinda Subbarayal, Marija Geroldinger-Simic and Barbara Bohle 
Part 2 Clinical Allergy 165 
 Anaphylaxis: Etiology, Clinical Chapter 7
Manifestations, Diagnosis and Management 167 
Aslı Gelincik and Suna Büyüköztürk 
X Contents
 Allergic Airway Inflammation 195 Chapter 8
Gabriel Morán, Claudio Henriquez and Hugo Folch 
 Asthma and Sensitization Pattern in Children 209 Chapter 9
Ute Langen 
 Wheezing Infant 231 Chapter 10
Yukinori Yoshida, Tomoshige Matsumoto, 
Makoto Kameda, Tomoki Nishikido,  
Isamu Takamatsu and Satoru Doi 
 Comorbidities of Allergic Rhinitis 239 Chapter 11
Doo Hee Han and Chae-Seo Rhee 
 Allergy and Benign Lesions of the Vocal Cord Mucosa 255 Chapter 12
Alenka Kravos 
 Drug Hypersensitivity 261 Chapter 13
María L. Sanz, Cristobalina Mayorga,  
Ruben Martínez-Aranguren and Pedro M. Gamboa 
 Diagnosis and Management of Chapter 14
Cows’ Milk Protein Allergy in Infants 279 
Elisabeth De Greef, Gigi Veereman-Wauters,  
Thierry Devreker, Bruno Hauser and Yvan Vandenplas 
 Natural Rubber Latex Allergy 289 Chapter 15
Ana Maria Sell and Jeane Eliete Laguila Visentainer 
Part 3 Specific Aspects of Allergic Diseases 311 
 Psychological Factors in Asthma Chapter 16
and Psychoeducational Interventions 313 
Lia Fernandes 
 Obesity, Diet, Exercise and Asthma in Children 339 Chapter 17
Luis Garcia-Marcos and Manuel Sanchez-Solis 
 Asthma and Health Related Quality Chapter 18
of Life in Childhood and Adolescence 365 
Esther Hafkamp-de Groen and Hein Raat 
Part 4 Treatment Strategies 373 
 Specific Immunotherapy and Chapter 19
Central Immune System 375 
Celso Pereira, Graça Loureiro,  
Beatriz Tavares and Filomena Botelho 
Contents VII
β2-Adrenoceptor Agonists and Allergic Disease: Chapter 20
The Enhancing Effect of β2-Adrenoceptor 
Agonists on Cytokine-Induced TSLP Production 
by Human Lung Tissue Cells 403 
Akio Matsuda and Kyoko Futamura
Microbiota and Allergy: From Dysbiosis to Probiotics 413Chapter 21
Anne-Judith Waligora-Dupriet and Marie-José Butel
Natural Products Chapter 22
and Dermatological Hypersensitivity Diseases 435
Clayton MacDonald and Marianna Kulka
Preventive Phytotherapy Chapter 23
of Anaphylaxis and Allergic Reactions 461 
Elaine A. Cruz, Michelle F. Muzitano, 
Sonia S. Costa and Bartira Rossi-Bergmann
Cissampelos sympodialis (Menispermaceae): A Novel Chapter 24
Phytotherapic Weapon Against Allergic Diseases? 477 
M.R. Piuvezam, C.R. Bezerra-Santos, 
P.T. Bozza, C. Bandeira-Melo, G. Vieira and H.F. Costa
Derived Products of Helminth in the Treatment of Chapter 25
Inflammation, Allergic Reactions and Anaphylaxis 499
C.A. Araujo and M.F. Macedo-Soares
Parasite-Derived Proteins Inhibit Chapter 26
Allergic Specific Th2 Response 531 
Hak Sun Yu
Pharmaceutical Treatment of Asthma Chapter 27
Symptoms in Elite Athletes – Doping or Therapy 545
Jimmi Elers and Vibeke Backer
VI Contents
Allergic Airway Inflammation 195Chapter 8
Gabriel Morán, Claudio Henriquez and Hugo Folch
Asthma and Sensitization Pattern in Children 209Chapter 9
Ute Langen
Wheezing Infant 231 Chapter 10
Yukinori Yoshida, Tomoshige Matsumoto, 
Makoto Kameda, Tomoki Nishikido, 
Isamu Takamatsu and Satoru Doi
Comorbidities of Allergic Rhinitis 239 Chapter 11
Doo Hee Han and Chae-Seo Rhee
Allergy and Benign Lesions of the Vocal Cord Mucosa 255Chapter 12
Alenka Kravos
Drug Hypersensitivity 261Chapter 13
María L. Sanz, Cristobalina Mayorga, 
Ruben Martínez-Aranguren and Pedro M. Gamboa
Diagnosis and Management of Chapter 14
Cows’ Milk Protein Allergy in Infants 279 
Elisabeth De Greef, Gigi Veereman-Wauters,
Thierry Devreker, Bruno Hauser and Yvan Vandenplas
Natural Rubber Latex Allergy 289 Chapter 15
Ana Maria Sell and Jeane Eliete Laguila Visentainer
Part 3 Specific Aspects of Allergic Diseases 311
Psychological Factors in Asthma Chapter 16
and Psychoeducational Interventions 313 
Lia Fernandes
Obesity, Diet, Exercise and Asthma in Children 339Chapter 17
Luis Garcia-Marcos and Manuel Sanchez-Solis
Asthma and Health Related Quality Chapter 18
of Life in Childhood and Adolescence 365 
Esther Hafkamp-de Groen and Hein Raat
Part 4 Treatment Strategies 373
Specific Immunotherapy and Chapter 19
Central Immune System 375 
Celso Pereira, Graça Loureiro, 
Beatriz Tavares and Filomena Botelho
Contents      XI 
 β2-Adrenoceptor Agonists and Allergic Disease: Chapter 20
The Enhancing Effect of β2-Adrenoceptor  
Agonists on Cytokine-Induced TSLP Production 
by Human Lung Tissue Cells 403 
Akio Matsuda and Kyoko Futamura 
 Microbiota and Allergy: From Dysbiosis to Probiotics 413 Chapter 21
Anne-Judith Waligora-Dupriet and Marie-José Butel 
 Natural Products Chapter 22
and Dermatological Hypersensitivity Diseases 435 
Clayton MacDonald and Marianna Kulka 
 Preventive Phytotherapy Chapter 23
of Anaphylaxis and Allergic Reactions 461 
Elaine A. Cruz, Michelle F. Muzitano,  
Sonia S. Costa and Bartira Rossi-Bergmann 
 Cissampelos sympodialis (Menispermaceae): A Novel Chapter 24
Phytotherapic Weapon Against Allergic Diseases? 477 
M.R. Piuvezam, C.R. Bezerra-Santos,  
P.T. Bozza, C. Bandeira-Melo, G. Vieira and H.F. Costa 
 Derived Products of Helminth in the Treatment of Chapter 25
Inflammation, Allergic Reactions and Anaphylaxis 499 
C.A. Araujo and M.F. Macedo-Soares 
 Parasite-Derived Proteins Inhibit Chapter 26
Allergic Specific Th2 Response 531 
Hak Sun Yu 
 Pharmaceutical Treatment of Asthma Chapter 27
Symptoms in Elite Athletes – Doping or Therapy 545 
Jimmi Elers and Vibeke Backer 
Preface 
The clinical and basic science of allergic disease is moving and evolving so rapidly that 
it is nearly impossible to keep up full of information regarding the news mechanisms, 
signalling cell markers, cellular plasticity and expression, biological mediators targets 
or molecular and genetic discovers aspects related to the allergy. Moreover the 
systemic impact of this pathology determines the complexity of the more recent 
evidence demonstrates that the rapid regulation of central immune organs in clinical
response of the mucosa to the allergen or offending agent. The enormous diversity 
clinical, etiologic, pathogenic, diagnose and therapy is not possible to develop in a
sustainable way in this book all forms of allergic diseases present in the clinic.
Therefore, this book tried to incorporate into its own matrix the crucial issues that are
recent contributions to learning less frequent topics, with very promising therapy
approaches. So the aim and the project was at the final the scope of the title “Allergic 
diseases - highlights in the clinic, mechanisms and treatment”, since it would not be
possible to materialize a project that seeks to be a formal Medical Treaty covering the
full breadth and complexity of allergy. Nevertheless, this book provides an accurate
and current learning of many clinical issues. 
The quality and scientific preciseness of the authors coming from several countries,
does much to give strength to the whole book, especially as it reflects local and
regional realities that characterize the diversity of expression allergic. In fact, the 
etiology and clinical response of allergic patient is very different, depending on the
location, habits, socio-economic conditions and even the specific interests of key lines
of investigation developed that the authors have incorporated into the chapters, but 
always guided by higher values of accuracy. 
The basic and clinical aspects of allergic disease were described, namely concepts of 
innate and adaptive immune response, systemic and localized immune-mediated
allergic disease, including recent update on pathogenesis. The clinical aspects were 
also subject and comprehensive developed and described, affecting different organ 
systems, particularly the anaphylaxis the main severe form of allergy.
This book will provide a valuable reference text in allergy and immunology not only
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prevalent pathology, but also for residents in training as well for specialists. The 
chapters develop themes with enormous depth and expertise, supported by updated 
references, and often illustrated with personal research of great interest to further key 
points of clinical investigation. Our understanding of the inflammatory process in 
allergic disease is clearly defined in many of these chapters, as is the application of 
science to clinical treatment. The technologies enrolled in the genetic approach were 
also described as well highlight the tools for molecular study of allergy. 
Overall the allergy is a sustained process of chronic inflammation why aspects of 
quality of life and the contribution and understanding of the psychological dimension, 
emotional and psychiatric naturally had to be enrolled in this book. 
The chapters on treatment modalities and new strategies bring the latest concepts on 
the use of actual and very promising researches based on the better understanding of 
the mechanism of the allergic disease. Each of these topics is as current as possible and 
written by a leader in the field. Clinicians will all benefit from these reviews.  
The effort and dedication of the authors in the time expended in the writing of the 
different chapters is fully demonstrated by the final quality of this project. To them 
goes my greatest of gratitude. 
I am particularly indebted to Drs Graça Loureiro, Beatriz Tavares, Daniel Machado 
and Prof A Segorbe Luís, from Immunoallergy Departement of Coimbra University 
Hospital Center who willingly assisted me in the review and in the scientific 
discussion of some fundamental aspects that have benefited the final version. The 
preparation of this edition for publication depends heavily on the excellent 
professional secretarial work of Ms Molly Kaliman, Publishing Process Manager. Of 
course a special thanks to the Intech-Open Access Publisher who had honored me with 
that feat challenge. I am exceedingly grateful to my family and all those who are close 
to me for successfully enduring this ordeal yet again. 
In my humble opinion, “Allergic diseases - highlights in the clinic, mechanisms and 
treatment” represents a shining example of a productive international collaboration 
among colleagues, and the information inserted in this book should conduct to an 
improved health care for patients with allergic diseases which are the essence of our 
work.  
 
Celso Pereira, PhD, MD 
Immunoallergology 
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New Challenges for Old Diseases: 
The Impact of -Omics Technologies in the 
Understanding of Allergic Diseases 
Blanca Cárdaba1,2, Miriam Aguerri1, David Calzada1 and Carlos Lahoz1,2  
1Immunology Department, IIS-Fundación Jiménez Díaz, Madrid, 
2CIBER de Enfermedades Respiratorias, CIBERES, 
Spain 
1. Introduction 
Allergic diseases are an adverse reaction of the immune system against otherwise innocuous 
substances and are characterized by their high complexity. Patients can be asymptomatic or 
their involvement could be as severe as asthma. The complex nature of the phenotypes 
involved seems to point to genetic and environmental factors implication.  
Familiar aggregation or genetic implication in the development of these diseases is well 
reported, and experts seem to agree that atopic diseases affect homozygotic twins more than 
dizigotic twins (Ownby, 1990, Duffy et al., 1990).  
Allergic diseases are characterized by a Th2 inflammatory response involving several 
possible modulator factors (genetics and environmental factors), subject-related or antigen-
related modulators such as adjuvants, solubility in the microenvironment of mucosa, size of 
the sensitization agent, mucosa permeability, viral infections, and the greater or lesser 
ability of effectors cells to liberate mediators. 
Other factors include atmospheric pollution, exposure to tobacco, lifestyle-related diet and 
hygiene habits and maternal effects. The interaction between these factors produces the 
clinical picture of allergic disease. 
Great advances have been performed in the understanding, diagnosis and treatment of these 
diseases but the search of specific protective or risk biomarkers is an unsolved field.   
Since completion of the human genome project a rapid progress in genetics and 
bioinformatics have enabled the development of multiple tools as well as a large public 
databases, which include genetic and genomic data linked to clinical health data. The 
scientific revolution represented by the description of the human genome was largely 
facilitated by the use of DNA microarray technology, which made it possible to build a 
catalog of all genes within a given organism. The human genome project found that humans 
have an average of between 20,000 and 25,000 protein-coding genes (IHGSC, 2004). In 
addition, genetic variability between individuals is approximately 1% (Venter et al., 2001), 
suggesting that interactions between genes, proteins and the environment contribute to 
differences in human phenotype, maintenance of health and susceptibility to disease. On the 
other hand, the emergence of gene expression microarray technology in the mid-1990s has 
enabled genome-wide measurement of gene expression in a single experiment. This is turn 
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has allowed for significant advances in our understanding of gene expression, regulation, 
and function and continues to serve as an important tool in basic science research. This 
novel technology was subsequently extended from molecular genetics to proteomics, 
allowing the start of the Human Proteome Project, designed to determine protein function 
as essential elements in diagnosis and treatment.  
Mainly, the genome project has fundamentally changed the way in which we approach 
questions in biology. The technology that the genome project has enabled, rather than the 
data it has produced, has induced the most profound impact on our conduct of biological 
research. In particular, functional genomics approaches, suchs as DNA microarrays, 
proteomics and metabolomics have greatly increased the rate at which we can generate data 
on biological systems allowing us, to begin to observe on a molecular level the holistic 
response of an organism to a particular stimulus (Quackenbush, 2006).  
In this review, will be summarize the principle of these new methodologies and the impact 
of omics-techniques, mainly genomic-transcriptomics (analysis of single nucleotide 
polymorphisms or gene-expression) and proteomic (identification and quantification of 
proteins), in the knowledge of different aspects of allergy diseases (diagnosis, screening, 
monitoring of treatment, protective or risk biomarkers and drug development) and the 
advance to define the personalized and molecular medicine in this complex kind of diseases. 
2. High-throughput technologies: “Omics approaches” review 
During the last decade, high-throughput technologies including genomic, transcriptomic, 
epigenomic, and proteomic have been applied to further our understanding of molecular 
pathogenesis of heterogeneous disease, and to develop strategies that aim to improve the 
management of patients. These approaches called omics should lead to sensitive, specific 
and non-invasive methods for early diagnosis, and facilitate the prediction of response to 
therapy and outcome, as well as the identification of potential novel therapeutic targets 
(Ocak et al., 2009). 
Omics approaches to the study of complex biological systems with potential applications to 
molecular medicine are attracting great interest in clinical as well as in basic biological 
research. Genomics, transcriptomics and proteomics are characterized by the lack of an a 
priori definition of scope, and this gives sufficient leeway for investigators (a) to discern all 
at once a globally altered pattern of gene/protein expression and (b) to examine the 
complex interactions that regulate entire biological processes (Silvestri et al., 2011). All 
classes of biological compounds, from genes through mRNA to proteins and metabolites, 
can be analyzed by the respective “omic” approaches, namely, genomics (Study of genomes 
and the complete collection of genes that they contain), transcriptomics (or functional 
genomics, attempts to analyze patterns of gene expression and to correlate the patterns with 
the underlying biology), epigenomic (the large-scale study of epigenetic modifications), 
proteomics (examine the collection of proteins to determine how, when and where they are 
expressed) or metabolomics (or metabonomics, is a large-scale approach to characterize and 
to quantify the compounds involved in cellular processes in a single assay to derive 
metabolic profiles). Such an “omic” approach leads to a broader view of the biological 
system, including the pathology of diseases. 
Two popular platforms in “omics” are DNA microarray, which measure messenger RNA 
transcript levels, and proteomic analyses, which identify and quantify proteins. Because of 
their intrinsic strengths and weaknesses, no single approach can fully unravel the 
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complexities of fundamental biological events. However, an appropriate combination of 
different tools could lead to integrative analyses that would furnish new insights not 
accessible through one-dimensional datasets (Silvestri et al., 2011). Indeed, while the data 
obtained from genomics may explain the disposition of diseases (i.e., increasing risk of 
acquiring a certain disease), several other mechanisms that are not gene mediated may be 
involved in the onset of disease.  
Genomic studies were the first to move this field forward by providing novel insights into 
the molecular biology of cancer by generating candidate biomarkers of disease progression. 
Epigenetic regulation by DNA methylation and histone modifications modulate chromatin 
structure and, in turn, either activate or silence gene expression. Proteomic approaches 
critically complement these molecular studies, as the phenotype is determined by proteins 
and cannot be predicted by genomics or transcriptomics alone. Indeed, expression levels of 
proteins are commonly subject to post-transcriptional modifications that may modify their 
functions.  
Moreover, a single gene can be processed to result in several different mRNAs or proteins, 
which directly determine different cellular functions. Genomic and proteomic data analyses 
have proven to be essential for an understanding of the underlying factors involved in 
human disease and for the discovery of diagnostic biomarkers, as well as for the provision 
of further insights into signalling molecules. 
Therefore, while genomics/transcriptomics enables assessments of all potential information, 
proteomics enables us to assess the programs that are actually executed, and metabolomics 
will mostly display the results of such executions. 
In the postgenomic era, functional analysis of genes and their products constitutes a novel 
and powerful approach since the expression levels of multiple genes and proteins can 
thereby be analyzed simultaneously, in both health and disease. Among the techniques used 
in functional genomics, both DNA microarrays and classical and ongoing proteomic 
approaches hold great promise for the study of complex biological systems and have 
applications in molecular medicine. These technologies allow high-throughput analysis as 
they are complementary to each other, and they may lead to a better understanding of the 
regulatory events involved in physiological, and disease, processes.  
2.1 Genomic 
Genomic provides us with platforms to measure quantitatively the essential elements 
(genes) of the cell and includes haplotyping and single nucleotide polymorphism detection. 
Is the study of an organism’s entire genome. Some of the most important of the related 
technologies are high-throughput capillary sequencing and single-nucleotide polymorphism 
(SNP) arrays. 
2.1.1 Global genome sequencing 
This method has made major improvements from gel-based sequencing to automated 
reading of the four nucleotides (TGCA) (Wheeler et al., 2008, Wang J et al., 2008, Levy et al., 
2007), by sequencing-by-synthesis technology that binds short fragments of DNA to small 
beads that are dropped into wells in a fibreoptic chip. The DNA adds another molecule to its 
chain and the sequencer identifies the molecule used, indicating which base is next in the 
sequence. Although the assemble of these pieces of DNA is a major challenge and may 
require multiple runs through a sequencer before assembling all the sequence, the use of 
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has allowed for significant advances in our understanding of gene expression, regulation, 
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proteomics (examine the collection of proteins to determine how, when and where they are 
expressed) or metabolomics (or metabonomics, is a large-scale approach to characterize and 
to quantify the compounds involved in cellular processes in a single assay to derive 
metabolic profiles). Such an “omic” approach leads to a broader view of the biological 
system, including the pathology of diseases. 
Two popular platforms in “omics” are DNA microarray, which measure messenger RNA 
transcript levels, and proteomic analyses, which identify and quantify proteins. Because of 
their intrinsic strengths and weaknesses, no single approach can fully unravel the 
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applications in molecular medicine. These technologies allow high-throughput analysis as 
they are complementary to each other, and they may lead to a better understanding of the 
regulatory events involved in physiological, and disease, processes.  
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sequence. Although the assemble of these pieces of DNA is a major challenge and may 
require multiple runs through a sequencer before assembling all the sequence, the use of 
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capillary electrophoresis instead of a gel, has allowed the automation DNA loading system, 
leading to and increase in throughput and higher speeds. 
The systematic re-sequencing of genes tumours has provided in cancer field a rich source of 
clinically relevant information increasing the discovery of critical mutations as has been 
revised by Ocak et al., 2009. 
2.1.2 SNP arrays 
These arrays allow accurate measurement of specific loss of heterozygosity in a high-
throughput manner with the possibility to identify patterns of allelic imbalance and small 
regions of copy number alterations, with potential prognosis and diagnostic utilities. They 
are synthesised by photolithography and contain up to 40 separate oligonucleotide probes 
for each SNP locus, with up 2 million SNP loci formats. After DNA labelling and 
hybridisation, fluorescence intensities are measured for each allele of each SNP. 
This methodology is mainly used in the genome-wide association studies (GWASs) using 
case-control or case-only approaches. GWAS approaches are based on the ability to rapidly 
analyze genetic variants (mainly single nucleotide polymorphisms [SNPs], usually with a 
high degree of heterozygosity) across the whole genome to determine which genetic 
variants are associated with disease susceptibility (case-control studies) or which are 
associated with measures of disease severity or response to treatment (ie, pharmacogenetics; 
case-only studies). GWASs are also performed in families, especially trios, which are defined 
as an affected child with genotyping from both parents (eg, the National Heart, Lung, and 
Blood Institute [NHLBI]'s Childhood Asthma Management Program study identified PDE4 
(Himes et al., 2009) as an asthma susceptibility gene) but it is generally easier to ascertain 
and characterize a large number of unrelated cases and control subjects than to study 
multiple family members (Meyers, 2010). 
The basic principle of a GWAS is straightforward: the frequency of each genetic variant is 
compared between cases (ie, subjects with the disease under investigation) and control 
subjects without the disease. A statistically significant increased frequency in cases 
compared with control subjects provides evidence that the genetic variant is related to 
disease susceptibility. Because many genetic variants (SNPs) are tested (usually 300,000 to 1 
million), adjustment for multiple testing is required; for example, in the National Institutes 
of Health catalog of GWAS results, only those with P values of 5 × 10−8 or less are included 
in their chromosomal map of association results from many common diseases 
(www.genome.gov/GWAS). 
The results from GWASs are the first step. Replication studies are necessary, and meta-
analyses are useful to determine the importance of these variants in multiple populations.  
2.2 Transcriptomic 
Transcriptomic afford information about the expression of individual genes at the 
messenger RNA (mRNA) levels. 
Is the study of global analysis of gene expression or transcriptome, the complete set of 
mRNA transcript produced by the genome. The most common related high-throughput 
technologies are gene expression arrays or microRNA (miRNA) expression arrays. 
2.2.1 Gene expression arrays  
This methodology derivate from two families of technologies: the first for nucleic acid 
detection and the second for the development of multiplex solid-phase assays (Patel A, 
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2008). The technique for detection of specific nucleic acid sequences by hybridization of 
labels nucleic acid sequences to known sequences immobilized on a solid support was 
developed initially for DNA detection (Southern, 1975), adapted for messenger RNA 
detection (Alwine et al., 1977) (Northern blot), and modified for placing the detection 
reagent (antibody or nucleic acid probe) on the solid support and leave the analyte in the 
liquid phase (eg, reverse Northern blot, dot blot)(Catt et al.,1966, Engvall et al., 2005, Kafatos 
et al., 1979). 
The next significant technological development was the description of a system for detecting 
multiple analytes via the use of microspots (Ekins et al, 1990, 1999). Each microspot would 
contain a capture antibody to bind the analyte if present. A second antibody would be used 
to detect the presence of bound sensor antibody. If labelled fluorescently with different 
fluorophores, the ratio of fluorescence intensity between bound and unbound sensor 
antibody could be determined by laser scanning confocal microscopy, and with appropriate 
standards, this could be used to precisely quantify the amount of a given analyte. These 
were in essence the microarrays bases, the microspots, the bound detection reagent and the 
fluorescent readout.  
However, several new technologies and information resources were required, mainly 
related with the improvement in the platforms, with the use of impermeable support 
materials (smaller amount of probe material), the increase of information from probes used 
for each target (derived from sequencing projects), system for detection of small amounts of 
labelled nucleic acid bound to complementary probes on small spots via confocal or non-
confocal laser scanning techniques, and especially image analysis and data analysis 
techniques, that represent a significant challenge given the large number of variables, which 
has led to multiple approaches for microarrays data analysis (Patel A, 2008). 
These arrays mostly make use of matrix-bound probes to which processed mRNA templates 
of the analysed specimens will hybridise. Two major types of arrays have been developed: 
oligonucleotide (use short oligonucleotides synthesised on the array matrix) and cDNA 
arrays (employs probes of copy-DNA).  
There are two basic approaches to generate microarray data ( Quackenbush, 2006). In a two-
color array, two samples of RNA, each labelled with a different dye, are simultaneously 
hybridized to the array. Such an assay compares paired samples and reports expression as 
the logarithms of the ratio of RNA in a query sample to that in a control sample. For single-
colour arrays, such as the GeneChip (Affymetrix), each sample is labelled and individually 
incubated with an array. After non-hybridized material in the sample is removed by 
washing, the level of expression of each gene is reported as a single fluorescence intensity 
that represents an estimated level of gene expression. Regardless of the approach or 
technique, the data used in all subsequent analyses are expression measures for each gene in 
each sample. Following hybridisation of a pre-processed and fluorescently labelled mRNA 
sample, the arrays are scanned and transcript abundance is measured as a direct correlate of 
signal intensity. After data normalisation, data can be analysed using a virtually unlimited 
array of computational and statistical methods. Normalization and filtering transformations 
must be carefully applied, because they can have a profound effect on the results. Different 
methods of statistical analysis applied to the same data set may produce different (but 
usually overlapping) sets of significant genes. 
To ease interpretation of the results of multiple hybridizations, elements of the data in a 
matrix are often rendered in colour, which indicates the level of expression of each gene in 
each sample and yields a visual representation of gene-expression patterns in the sample 
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capillary electrophoresis instead of a gel, has allowed the automation DNA loading system, 
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case-only studies). GWASs are also performed in families, especially trios, which are defined 
as an affected child with genotyping from both parents (eg, the National Heart, Lung, and 
Blood Institute [NHLBI]'s Childhood Asthma Management Program study identified PDE4 
(Himes et al., 2009) as an asthma susceptibility gene) but it is generally easier to ascertain 
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million), adjustment for multiple testing is required; for example, in the National Institutes 
of Health catalog of GWAS results, only those with P values of 5 × 10−8 or less are included 
in their chromosomal map of association results from many common diseases 
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The results from GWASs are the first step. Replication studies are necessary, and meta-
analyses are useful to determine the importance of these variants in multiple populations.  
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Transcriptomic afford information about the expression of individual genes at the 
messenger RNA (mRNA) levels. 
Is the study of global analysis of gene expression or transcriptome, the complete set of 
mRNA transcript produced by the genome. The most common related high-throughput 
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detection (Alwine et al., 1977) (Northern blot), and modified for placing the detection 
reagent (antibody or nucleic acid probe) on the solid support and leave the analyte in the 
liquid phase (eg, reverse Northern blot, dot blot)(Catt et al.,1966, Engvall et al., 2005, Kafatos 
et al., 1979). 
The next significant technological development was the description of a system for detecting 
multiple analytes via the use of microspots (Ekins et al, 1990, 1999). Each microspot would 
contain a capture antibody to bind the analyte if present. A second antibody would be used 
to detect the presence of bound sensor antibody. If labelled fluorescently with different 
fluorophores, the ratio of fluorescence intensity between bound and unbound sensor 
antibody could be determined by laser scanning confocal microscopy, and with appropriate 
standards, this could be used to precisely quantify the amount of a given analyte. These 
were in essence the microarrays bases, the microspots, the bound detection reagent and the 
fluorescent readout.  
However, several new technologies and information resources were required, mainly 
related with the improvement in the platforms, with the use of impermeable support 
materials (smaller amount of probe material), the increase of information from probes used 
for each target (derived from sequencing projects), system for detection of small amounts of 
labelled nucleic acid bound to complementary probes on small spots via confocal or non-
confocal laser scanning techniques, and especially image analysis and data analysis 
techniques, that represent a significant challenge given the large number of variables, which 
has led to multiple approaches for microarrays data analysis (Patel A, 2008). 
These arrays mostly make use of matrix-bound probes to which processed mRNA templates 
of the analysed specimens will hybridise. Two major types of arrays have been developed: 
oligonucleotide (use short oligonucleotides synthesised on the array matrix) and cDNA 
arrays (employs probes of copy-DNA).  
There are two basic approaches to generate microarray data ( Quackenbush, 2006). In a two-
color array, two samples of RNA, each labelled with a different dye, are simultaneously 
hybridized to the array. Such an assay compares paired samples and reports expression as 
the logarithms of the ratio of RNA in a query sample to that in a control sample. For single-
colour arrays, such as the GeneChip (Affymetrix), each sample is labelled and individually 
incubated with an array. After non-hybridized material in the sample is removed by 
washing, the level of expression of each gene is reported as a single fluorescence intensity 
that represents an estimated level of gene expression. Regardless of the approach or 
technique, the data used in all subsequent analyses are expression measures for each gene in 
each sample. Following hybridisation of a pre-processed and fluorescently labelled mRNA 
sample, the arrays are scanned and transcript abundance is measured as a direct correlate of 
signal intensity. After data normalisation, data can be analysed using a virtually unlimited 
array of computational and statistical methods. Normalization and filtering transformations 
must be carefully applied, because they can have a profound effect on the results. Different 
methods of statistical analysis applied to the same data set may produce different (but 
usually overlapping) sets of significant genes. 
To ease interpretation of the results of multiple hybridizations, elements of the data in a 
matrix are often rendered in colour, which indicates the level of expression of each gene in 
each sample and yields a visual representation of gene-expression patterns in the sample 
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being analyzed. In the most common approach, the colours used for the genes are based on 
the log-ratio for each sample measured as compared with a control sample : close to zero in 
black, values greater than zero in red (indicating up-regulated genes) and those with 
negative values in green (down-regulated genes). The intensity of each element, as 
compared with the intensities of others, indicates the relative expression of the gene that the 
element represents. 
After the appropriate data have been recorded, normalized and filtered and a means of 
measuring similarity has been chosen, a variety of approaches are available for further 
analysis. These approaches are generally grouped into two types: supervised and 
unsupervised methods. Supervised methods depend on prior knowledge about the samples 
in order to search for genes that correlate with a diseases state, and they are useful for 
classification studies and can yield gene sets or signatures of genes that can distinguish 
between a priori defined subsets of samples. Unsupervised methods disregard prior 
knowledge and can be useful for identifying subgroups of samples that may represent 
unrecognized disease states. This method allow self-organisation of data matrices, group 
samples (or genes, or both), according to similarity of expression profiles features. This 
approached can help identify subgroups of samples not known a priori that are characterised 
by a typical transcriptional signature.  
In order to minimise the risk of over fitting the predictive signature, such approaches 
typically involve validation of the predictor in a separate dataset or by splitting the original 
dataset into a learning and test set. In the latter case, the predictor is built using the learning 
set and then validated in the test set.  
The discovery of biomarker signatures or panels for diagnosis by non-invasive methods is 
crucial for some diseases, as lung cancer, reason why these methodologies are very 
important. Soon after microarrays were introduced, many researchers realized with this 
technique could be used to find new subclasses in diseases states (Alon et al., 1999, Perou et 
al., 1999) and identify biological markers (biomarkers) associated with disease (Moch et al., 
1999) and that even the expression patterns of genes could be used to distinguish subclasses 
of disease (Khan et al., 1998, Goiub et al., 1999, Bloom et al .,2004). 
Many early studies focused an unsupervised approach to data-mining, such as hierarchical 
clustering for class discovery, because such studies take an unbiased approach to searching 
for subgroups in the data. The analysis was useful in lymphoma (Alizadeh et al., 2000) for 
identifying two subclasses related to a different stage of B-cell differentiation and showed 
the distinct clinical progress. 
Other kind of studies (Golub et al., 1999) showed that microarray-expression profiles can be 
used to classify disease states. This kind of studies made clear that disease classification 
according to expression profiles will be come an important area of application for 
microarrays, proteomics, metabolomics and other high-throughput genomic techniques. The 
question is whether a pattern can be found that can be used to distinguish biological 
samples on the basis of some inherent property.  
As will be remarked in the specific paragraph, this is one of the high-throughput 
methodologies more used in allergy diseases studies and with more interesting advances. 
2.2.2 miRNA expression arrays 
miRNAs are single-stranded, small (18 to 24 nucleotides in length), noncoding RNAs that 
negatively regulate gene expression by binding to and modulating the translation of specific 
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mRNAs. It is estimated that miRNAs may be responsible for regulating the expression of 
nearly one-third of the human genome. Each miRNA appears to regulate the translation of 
multiple genes, and many genes appear to be regulated by multiple miRNAs. The 
methodology is like gene expression arrays by using arrays with up to 1300 distinct probes 
of eight to nine nucleotides (Ocak et al., 2009). 
Although is estimated that miRNAs may be responsible for regulating the expression of 
nearly one-third of the human genome, few studies have explored their relevance to the 
pathogenesis of diseases and specifically in lung diseases (review in Serge  et al., 2009). 
However, miRNA may be considered as potential therapeutic targets, as regulators of gene 
transcription and protein production and their study could be very useful for understanding 
human health and disease. 
2.3 Epigenomics 
The field of epigenetic has emerged to explain how cells with the same DNA can 
differentiate into alternative cell types and how a phenotype can be passed from one cell to 
its daughter cells (Baye et al., 2010). Unlike genetic alterations, which are permanent and 
usually affect all cells, epigenetic modifications are cell type specific and epigenetic 
regulation of immune system occurs at many levels, including T cells (Locksley, 2009, Wells, 
2009). Epigenetic effects on gene expression can persist even after removal of the inducing 
agent and can be passed on through mitosis to subsequent cell generations, constituting a 
heritable change (Baye et al., 2010). The role of epigenetic in diseases, and specifically in 
allergic diseases is becoming increasingly evident (review in Kumar et al., 2009).  
Recent development of epigenomic or the large-scale study by high-troughput/genome 
wide detection of epigenetic modifications, as heritable changes in gene expression without 
DNA sequence alterations, mainly DNA methylation and histone post-translational 
modification, should bring out more data relevant to allergic diseases. 
Different techniques coupled to high-throughput technologies are available for the detection 
of DNA methylation, based on the ability to distinguish cytosine from 5-methylcytosine in 
the DNA sequence. To study histone modifications, there is a microarray platform of 
chromatin immuno-precipitation-on chip that allow the assessment of chromatin states. 
It should be very interesting to know how genetics, environmental factors and epigenetics 
regulate each other for understanding the molecular events that underlie complex diseases 
such allergy diseases. 
2.4 Proteomics 
Is the large-scale study of proteins, particularly their structure and function. Proteomics 
focuses on determination of individual protein concentrations present in the biological 
sample being investigated, whereas functional proteomic determines constituent protein-
protein, protein-DNA, and protein-RNA interactions and their resulting complexes.  
Proteins are excellent targets in disease diagnostics, prognostics, and therapeutics. 
Consequently, proteomic approaches (such as two-dimensional gel electrophoresis (2D-E), 
two-dimensional liquid chromatography (2-DL), and mass spectrometry (MS), which allow 
the simultaneous measurement  and comparison of the expression levels of hundreds of 
proteins, represent powerful tools for (a) the discovery of novel hormone/drug targets and 
biomarkers and (b) studies of cellular metabolisms and protein expression (Righetti et al., 
2004, Vlahou et al., 2005). Increasingly, proteomic techniques are being adopted to solve 
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mRNAs. It is estimated that miRNAs may be responsible for regulating the expression of 
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analytical problems and obtain a more comprehensive identification and characterization of 
molecular events associated with pathophysiological conditions.  
Several high-throughput technologies have been developed and a brief summary of the 
main technological characteristics is exposed.  
2.4.1 Two-dimensional gel electrophoresis  
This technique relies on polyacrilamide gels that separate proteins based first on their 
charge and then on their molecular weight. Gel are scanned with laser densitometers and 
analysed with software allowing the semiquantitative visualisation of >500-1000 proteins 
per gel (Bergman et al., 2000). Individual protein spots of interest can be digested into 
peptides for sequence analysis by mass spectrometry (MS). A modification of this technique 
is the differential in gel-electrophoresis (DIGE), used to compare two protein mixtures on 
the same gel, using different fluorescent dyes, mixed together and run on the same gel 
(Patton, 2002). Identical proteins from the two pools co-migrate and are independently 
detected by quantitative fluorometry. Differentially expressed proteins of interest are 
identified by alterations in the ratios of the two fluorescent signals.  
2.4.2 Matrix-assisted laser desorption ionisation time-of-flight MS (MALDI-TOF MS)  
Is a high-throughput technique that analyses with high sensitivity and specificity proteins 
expressed in complex biological mixtures, such as serum, urine and tissues (Caprioli et al., 
1997, Farmer et al., 1991). It requires sample co-crystallisation with a matrix that absorbs 
laser energy and subsequently ejects and ionises molecules into the gas phase. Ions are 
accelerated from the ion source by a fixed potential difference and travel a fixed-length, 
field-free distance before reaching the detector. The time taken by each ion permits its 
characterization. This methodology has been extensively applied to proteomic profiling of 
biological specimens. 
2.4.3 Liquid chromatography tandem MS  
This technique combines high-performance liquid chromatography (LC) with electrospray 
ionisation MS, ionising and vaporising proteins from liquid solutions. The shotgun proteomic 
analysis platform uses digestion of the sample with site-specific proteases, multidimensional 
separation of peptides by strong cation exchange chromatography (Link et al., 1999, Wolters et 
al., 2001, Cargile et al., 2004, Essader et al., 2005), followed by reverse phase LC separation 
coupled directly to a tandem MS instrument (MS/MS). The most abundant peptides are 
sequentially selected for MS/MS analyses. Resulting fragments ions are analysed in a MS scan 
and based on their molecular weight, the peptide sequence can be derived (Liebler, 2004). 
Through comparisons with predicted sequences of same nominal mass in databases, peptides 
are identified and the proteins from which they came are deduced. 
2.4.4 Protein arrays  
This is an efficient way of simultaneously analysing multiple samples or proteins in a high-
throughput manner. There are two main forms: 1. Forward-phase arrays where hundreds of 
specifics antibodies are arrayed on a glass slide and one complex protein sample could be 
analysed for expression levels of post-translational modifications of hundreds of proteins in 
a single experiments. 2. Reverse-phase arrays, where hundreds of proteins (natural or 
recombinants) are placed on glass slides and probed with a single sample.  
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Post-translational modifications of proteins, such as phosphorylation, glycosilation and 
proteolytic processing, are common events and have the potential to significantly modify 
protein functions as well as confer cellular or tissue specificity. Since these modifications are 
reversible, drugs inhibiting these modifications are developed and hold great promise for 
some therapies as lung cancer therapy. Proteomics strategies have an important role by 
allowing not only the identification of post-translational modifications, but also the 
quantification and monitoring of the changes induced by their regulators. 
2.5 Other complementary technologies 
2.5.1 Pharmacogenomics 
Is an emerging area of biomedical research, strongly influenced by growing availability of 
genomic databases, high-throughput genomic technologies, bioinformatics tools and artificial 
computational modelling approaches.  Pharmacogenomics offers a new tool for the discovery 
of new targets for drugs development purposes, and for the individual variation in drug 
response. One main area is the discovery of new drugs and drug targets with molecular 
genetic, genomic or even bioinformatics methods and the other is the study of how genomic 
differences influence the variability in patient´ responses to drugs. Genes that have been found 
implicated in the disease are potential new drug targets and several pharmacological 
investigations are underway to utilize these new discoveries (Szalai et al., 2008).  
2.5.2 Immunoinformatics, or computional immunology 
Is an emerging area that provides fundamental methodologies in the study of immunomics, 
that is, immune-related, genomics and proteomics. The integrations of immune informatics 
with system biology approach made lead to a better understanding of immune related 
diseases at various system levels. 
The information about genetic diversity of the immune system may help define patient’s 
subgroups for individualized vaccine or drug development. Cellular pathways and host 
immune-pathogens interactions have a crucial impact on disease pathogenesis and 
immunogen design. Epigenetic studies may help understand how environmental change 
influence complex immuno diseases such as allergy. High-throughput technologies enable 
the measurements and catalogue of genes, proteins, interactions, and behaviour. Such 
perception may contribute to the understanding of the interaction network among humans, 
vaccines and drug, to enable new insights of diseases and therapeutic responses. 
Bioinformatics plays an indispensable role in designing experiments, so as high-throughput 
studies, and helping to establish and test hypothesis trough data analyses. This essential 
task in drug discovery and in development cannot be accomplished with traditional 
approaches alone (Yang, 2010). 
System biology studies the interactions among biological elements toward the 
understanding of diseases at the system level (Yang, 2005). The combination of 
bioinformatics and systems biology approach can lead to a better understanding of immune-
related diseases (Rapin et al., 2006). 
With the comprehensive examination of structures, functions, and relationships between 
them at the molecular level, we can scale at the higher level to gain a more complete view of 
how the immune system work and interact with other systems. 
The understanding of changes in molecular and cellular pathways and interactions can be 
useful for finding new drug, target and designing effective drugs. These pathways are 
potential targets for developing novel therapeutics. 
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On the other hand, the structure-function analysis includes the examination of how 
sequence variants such as polymorphisms may have functional influences. Studies of 
transcription factors, functional motifs, 2D and 3D structure may help with the identification 
of epitopes and design of vaccines. These studies may shed light on the mechanisms of 
cellular pathways and protein-protein interactions. Advances in high-throughput analysis 
may greatly enhance such investigations. 
The perception at these points may contribute to the understanding of the interaction 
networks among humans, vaccines, drugs, and the environment and enable new insights of 
disease mechanisms and therapeutic responses. The integration of all of the information at 
various systems levels may ultimately lead to the development of optimized vaccines and 
drugs tailored to individualized prevention and treatment. 
3. Omics approach in allergy diseases 
Our knowledge of how genetic variation between subjects determines susceptibility, 
severity and response to treatment has expanded considerably, providing intriguing 
insights into the pathophysiology of these multifactorial disorders. The picture is complex 
but our understanding is exponentially increasing in the last years thanks to new 
technologies and bioinformatics tools.  
3.1 Genetic and genomic studies in allergy 
During the last 20 years many efforts were realized in order to identify protective factors 
that could increase the tolerance against allergens. The main objective of multiple 
investigations was to identify potential risk factors in the environment and to identify 
“allergy genes”.  
Classically there were two main approaches for searching genes related with 
asthma/allergy diseases: analysis of candidate genes or genome-wide screening, looking for 
new disease loci or genes (Ober & Hofman., 2006, Risk et al., 1996, Cárdaba et al., 1993, 
Carlson et al., 2004, Vercelli, 2008, Holloway et al., 2010). Population genetic studies like 
association studies and linkage analysis have played major roles in identification of several 
causative genes. Population genetic studies could be either hypothesis driven, which is the 
case in candidate gene studies, or with no prior hypothesis such as linkage studies. In 
candidate gene studies, genes are selected from the pathways shown or expected to play 
role in allergy disease pathogenesis. The advantage of this approach is that candidate genes 
have biological plausibility and often display known functional consequences that have 
potentially implications for the disease. Disadvantage is the limitations to discovery novel 
genes. Candidate gene studies could be based on allele frequency differences between 
affected and non-affected individuals (case-control studies) or based on transmission 
distortion or disequilibrium of allele(s) as in family based association studies (Cárdaba et al., 
2000, Cárdaba et al., 2002). Candidate genes are supposed to have high sensitivity to detect 
alleles or variants playing minor role in disease pathogenesis (Risk et al., 1996). Numerous 
association studies have been published (Vercelli, 2008, Ober &Hofman, 2006, Llanes et al., 
2009.), there are almost 1,000 studies that examine polymorphisms in several hundred genes 
including those involved an innate immunity (TLRs, CD14, CARD15, etc,), inflammation 
(e.g. various cytokines, chemokines, etc.), lung function, growth and development (TGFB1, 
ADRB2, NOS1 and SPINK5, etc.) and genes implicated as modifiers of responses to 
environmental exposures (GSTM1, GSTP1, GSTT1). Few candidate genes have been 
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consistently replicated: 54 genes in 2-5 independent samples, 15 genes in 6-10 independent 
samples and 10 genes in >10 independent samples (Ober &Hofman, 2006). 
Linkage studies are usually carried out to identify novel disease loci/genes by genotyping 
evenly markers in the entire genome, in large extended families. Approximately 20 genome-
wide linkage screens have been reported in different study populations to identify 
chromosomal regions linked to asthma/atopy and one or more allergy-phenotypic feature 
(Sleiman & Hakonarson, 2010). The lack of statistically power, differences in study design, 
and genetic differences in the populations studied could be the reason for low 
reproducibility of results. However, some chromosomal region demonstrated consisted 
linkage and contained genes biologically relevant in allergy, such as the cytokine cluster on 
chromosome 5q, FcεRI-β on 11q, IFN-γ and STAT6 on 12q, and IL4R-α on 16p. Linkage 
studies followed by positional cloning have identified novel genes which may influence 
susceptibility to asthma, including ADAM33, DPP10, PHF11 and GPRA (Sleiman 
&Hakonarson, 2010). 
Up to now, despite significant findings regarding susceptibility regions and genes in some 
cases, these studies have still resulted in only a very limited understanding of asthma and 
allergic diseases. Some of the reasons for the failure to replicate the detection of particular 
loci across studies and for the modest contribution of each of these susceptibility loci might 
relate to heterogeneity factors between studies that might be difficult to detect and take into 
account in small-scale studies (Von Mutius, 2004). However, there are some essential points 
that are well established by scientific community, as to recognize that few genes might have 
independent effects, as is typical for Mendelian diseases. It has become clear that the 
pathogenesis of complex polygenic disorders is dependent on multilayered gene-
environment interactions over time, in a model well described by Hersey (2004). 
Nonetheless, the approaches that have been used to find susceptibility genes, either through 
linkage or association studies, have for the most part considered one gene at a time. Despite 
this overly simplistic modelling of asthma and atopy genetics, many important discoveries 
have been made (Ober, 2005, Blumenthal, 2005).  
However, most recently, this kind of studies has been revolutionized by array-based SNP 
genotyping technologies and the characterization of millions of SNP variants in the human 
genome. This has made possible the simultaneous determination of the genotype of 
>500,000 SNPs throughout the genome of a subject. This has allowed the use of genome-
wide, hyphotesis-independent association studies that do not require the recruitment and 
phenotyping of large family-based samples and achieve greater statistically power for the 
same number of subjects. Genome wide association studies (GWASs) have become feasible 
in large cohorts of patients and controls. Using this approach, there are many evidences for 
genetic variants involved in different diseases (Sleiman &Hakonarson, 2010). 
GWAS approaches are based on the ability to rapidly analyze genetic variants (mainly 
single nucleotide polymorphisms (SNPs), usually with a high degree of heterozygosity) 
across the whole genome to determine which genetic variants are associated with disease 
susceptibility (case-control studies) or which are associated with measures of disease 
severity or response to treatment (ie, pharmacogenetics; case-only studies). GWASs are also 
performed in families, especially trios, which are defined as an affected child with 
genotyping from both parents but it is generally easier to ascertain and characterize a large 
number of unrelated cases and control subjects than to study multiple family members 
(Meyers, 2010). GWASs allows the identification of disease genes with only modest 
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increases in risk, a severe limitation in linkage studies and the very type of genes one 
expects for common disorders. 
To date, several GWASs have been performed with great success in allergic diseases, such as 
asthma, eczema, and allergic sensitization (Holloway et al., 2010). In mid-2007 the first 
application of GWA to bronchial asthma was the description of a novel asthma 
susceptibility locus contains the ORM1-like 3 (ORMDL3) and Gasdermin like (GSDML) 
genes on chromosome 17q12-21.1 (Moffatt et al., 2007). Importantly, subsequent studies 
have replicated the association between variation in the chromosome 17q21 region and 
asthma in ethnically diverse populations (Leung et al., 2009, Bisgaard et al., 2009, Wu et al., 
2010, Galanter et al., 2008, Tavendale et al., 2008). Further allergy-related phenotypes 
susceptibility genes have been discovered by GWAS as chromosome 5q12 at the region of 
the phosphodiesterase 4D (PDE4D) (Himes et al., 2009) involved in way smooth muscle 
concentration, an association with asthma and chromosome 1, at the region of DENND1B 
(gene that encodes for a protein that interact s with the TNF-α receptor) (Sleiman & 
Hakonarson , 2010). Using GWASs significant evidences were observed for asthma association 
and several genes as DPP10 (Mathias et al., 2010), TGFB1, IL1RL1 and CYFIP2 (Wu et al., 2010). 
In addition six studies have been reported (Sleiman & Hakonarson, 2010) using quantitative 
triat loci as intermediate phenotypes. A promoter SNP in the CHI3L1gene that encodes the 
chitinase-like protein (YKL-40) was shown to be a major determinant of elevated serum 
protein, being associated with asthma, bronchial responsiveness and pulmonary function 
(Ober et al., 2008), FCERA1A and RAD50 genes were associated with IgE levels and increased 
risk of asthma and atopic eczema (Weidinger et al., 2008), blood eosinophil counts was 
associated with five loci reached significance, one of which, IL1RL1 was also associated with 
asthma in a collection of different populations (Gudbjartsson et al., 2009). 
Finally, two large meta-analysis of lung function identified 11 candidate genes/regions. The 
first (Hancock et al., 2010) found that genes in the INTS12-GSTCD-NPNT region were 
associated with FEV1, and 8 genes (HHIP, GPR126, ADAM19, AGER-PPT2, FAM13A, 
PTCH1, P1D1 and HTR4) were associated with FEV1/forced vital capacity ratios. The second 
(Repapi et al., 2010) identified 4 genes (HHIP, GSTCD, TNS1 and HTR4) associated with 
FEV1 and 3 loci (HHIP, NOTCH4-AGER-PPT2, and THSD4) associated with FEV1/forced 
vital capacity ratios. The important question is to research the relationship among these 
regions and allergy-related phenotypes. 
In conclusion, with the recent advances in genotyping technology and the information 
provided by Human Genome and International HapMap projects, our ability to locate the 
genes underlying complex diseases has been dramatically improved. The results from 
GWASs are the first step. Replication studies are necessary, and meta-analyses are useful to 
determine the importance of these variants in multiple populations. However, in allergic 
diseases, environmental factors influence gene regulation/expression for that, gene-
environment interactions could be critical in these diseases (Cárdaba et al., 2007). In fact, in 
the last four years there has been an increase in the research of this field (review in Vercelli, 
2010b) and although the gene-environment interactions known to date have been identified 
through hypothesis-driven research and candidate gene approaches, several efforts are 
doing in order to develop novel analytical methods at allowing efficient testing for gene-
environment interactions in GWASs (Murcray et al., 2009, Chatterjee et al., 2009, Vineis et 
al., 2008). These studies could be a new era of gene-environment-wide interaction studies 
(GEWIS) (Khoury &Wacholder, 2009) that may change our understanding of gene-
environment interactions and their impact on complex disease susceptibility (Vercelli, 2010). 
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It is possible to group the genes identified until now as contributing to allergic disease into 4 
broad groups (Holloway et al., 2010): First, there is a group of genes that are identified are 
involved directly modulating response to environmental exposures. The second major 
group includes many of the genes identified by hypothesis-independent genome-wide 
approaches and is a group of genes involved in maintaining the integrity of the epithelial 
barrier at the mucosal surface and signalling to the immune system after environmental 
exposure. The third group are those that regulate the immune response, the TH1/TH2 
differentiation and effector functions, and others that might regulate the level of 
inflammation that occurs at the end organ for allergic disease. 
Finally, given the large amount of GWAS data available for many diseases, the results can 
be interrogated across studies to determine whether the same genes are being observed in 
different diseases, even if there is not known relationship between the diseases. After 
analysis of GWAS results from across 118 studies (Johnson & O´Donnell, 2009) evidence for 
the MHC region on chromosome 6 was observed across many studies, and genes involved 
in cell adhesion, signal transduction, and protein phosporilation were the most likely to be 
observed in different diseases entities. This bioinformatics approach can be useful for 
identifying potential similarities between disease processes that can be investigated further 
(Meyers, 2010). 
Anyway, functional biologic studies to understand the role of the identified genes, genetic 
variants and interactions are crucial to further our understanding of disease pathogenesis. 
3.2 Analysis of gene-expression or transcriptomic in allergic diseases 
Because microarray analysis is a more mature technique than the other approaches and 
because of the relative ease of working with nucleic acids, microarray remain the -omics 
technique that is most likely to have early applications in diagnosis or prognosis. 
One of the most popular omic-approach for disease gene identification has been the analysis 
of gene-expression by microarrays, which take advantage of the fact that transcript of 
various genes (until all the genome) can be assayed at large scale simultaneously (Rolph et 
al., 2006). Using both human subjects and animal models a number of studies have 
identified novel genes/pathways or validated others that play important role in asthma 
pathogenesis and may have therapeutic potentials (Rolph et al., 2006).  Combined with 
animal models this technology has played pivotal role in identification of genes/molecules 
involved in complex diseases. Animal models are suitable as confounding factors can be 
better controlled and tissue samples can be harvested sufficiently with easy. Also, identical 
genetic background of the inbred animal strains allow for dissection of environmental 
factors in influencing gene regulation in different pathological conditions (Kumar & Ghosh, 
2009).  
DNA microarrays can be used to compare differential gene-expression between control and 
case or patients before and after treatment, in order to find new genes and disease 
mechanisms and to define molecular signatures that can be useful in the diagnosis or 
classification of the disease and specific treatments. Major applications of this methodology 
have been related with cancer disease or single-genes disorders but in complex disorders, as 
allergic diseases, the number of studies is lower and only in the last years, this field is giving 
some interesting results.  
The first review of microarray technology in allergic diseases (Benson et al., 2004), described 
how some pioneers works identified differentially expressed genes between patient and 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
14
increases in risk, a severe limitation in linkage studies and the very type of genes one 
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controls in allergic rhinitis or atopic dermatitis and how in a study of asthma, a combination 
of genes was showed to more accurately discriminate between the asthmatics and healthy 
controls than IgE (Brutsche et al., 2002). But most importantly, the authors remarked the 
distinctive characteristic of microarrays to identify whole groups of functionally related 
genes, rather than individuals, and the effects of specific cytokines relevant to allergy, as for 
example, the finding that a TH2 cytokine as IL-13, induce distinct transcriptional programs 
in different kind of cells (Lee et al., 2001), as well as pathways (Benson et al., 2002, 
Zimmermann et al., 2003). 
Most recently, interesting advances in allergic diseases has been associated with microarray 
studies. I would like to emphasis three major kinds of advances: Firstly the finding and 
verification of differentially expressed genes, with the description of many potential 
biomarkers and/or therapeutic targets that are still being validated, evaluated and explored 
with no clinical diagnostic or therapeutic benefit to date (Hansel et al., 2008,  Sääf AM et al., 
2008, Izuhara & Saito, 2006, Kuperman et al., 2005, Rolph et al., 2006, Tyner et al., 2006, 
Ricciardolo et al., 2005, Hansel & Diette, 2007, Woodruff et al., 2007, Hakonarson et al., 2005, 
Jones et al., 2009) but with a high potential. Secondly, the possibility to find molecular 
signatures associated with clinical subphenotypes, as has been demonstrated in asthma 
where at least two distinct molecular phenotypes defined by degree of TH2 inflammation 
were described (Woodruff et al., 2009). Interestingly, non-Th2–driven asthma represents a 
significant proportion of patients and responds poorly to current therapies. Most recently, 
gene expression patterns of TH2 inflammation and intercellular communication have been 
described in asthmatic airways (Choy et al., 2011). These results suggest that a predominant 
pattern of differential gene expression in asthma is related to TH2-driven airway 
inflammation; however, this pathway is linked to a large number of other factors associated 
with aspects of airway pathophysiology. An unsolved question is whether TH2 
inflammation is a cause or a consequence of the extended network of inflammatory and 
regulatory factors described as implicated. And finally, and interesting field is the 
possibility to discover dysregulated pathways by the analysis of modules that include 
tightly interacting genes, usually functional related genes. This approach was recently used 
to identify an inhibitory role for IL7R in allergic inflammation (Mobini et al., 2009). The gene 
expression profiles can be used to identify key regulatory networks, to identify novel 
potential candidate genes, and to define phenotypes, which can then serve as quantitative 
traits for genetic studies (Baye et al., 2010). An integrated genetic/genomic approach allows 
the mapping of the genetic factors that underpin individual differences in quantitative levels 
of expression. ArrayExpress and Gene Expression Omnibus are the two major public data 
repository for experimental microarray data with multiple gene annotations, including gene 
symbol, GO terms and disease associations. Integration of molecular and functional 
information it is necessary and the bioiformatic is an area essential for advancing in this 
field. With this integration, using publicly available gene expression datasets from multiple 
sources and tools a functional and regulatory map of asthma (Novershther et al., 2008) was 
described.  
An entire field of biology (Systems Biology) has emerged, with the goal of unravelling the 
complex networks of cells and signals underlying all biological processes. This ongoing 
exploration should lead to better tools to help us interpret gene expression microarray data 
and will ultimately allow us to leverage this technology in the diagnosis and treatment of 
diseases. 
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3.3 Use of protein microarrays in allergy  
DNA microarrays are limited to provide information on the identity or amount or RNA or 
DNA present in a sample. Translational products of genes can not be analyzed on such 
arrays and, therefore, require the use of polypeptide-based array. Most drug targets are 
proteins, therefore, protein and peptides microarrays are set to have an important impact on 
drug discovery. An important challenge when producing protein microarrays is 
maintaining functionality, such as post-transcriptional modifications and phosporylation.  
Due to the improvement in proteomics methodologies, several important proteomic 
applications have been used in allergy diseases (revised by Lucas, 2010). Basic research 
microarray technology has been used for the study of interactions among allergenic 
proteins, immunoglobulins and T cell receptors, with a view to developing genetic 
modifications which can yield hypoallergenic variants of plant proteins (Singh et al., 1999). 
Microarrays have been applied in the investigation of clonal diversity (Pinilla et al., 1999) 
and immune response heterogeneity among patients (Sheffler et al., 2005) and to establish 
the clinical correlations between antibody diversity and the allergic manifestations (Beyer et 
al., 2003, Chatschatee et al., 2001,). Microarray technology has been shown to be very useful 
for mapping and characterising allergenic epitopes (Lin et al., 2009). An example is 
represented by cow’s milk allergens with differentiation between IgE and IgG4 patterns for 
sequential epitopes of alpha (s1)-, alpha (s2)-, beta-and kappa-caseins and beta-lactoglobulin 
in reactive patients and tolerant individuals (Cerecedo et al., 2008).  
But one of the most important applications of proteomic in the allergy field is the microarray 
of allergic components that offer the possibility to study hundreds of allergenic components 
(recombinant or purified) in a single test, and using a very small amount of serum sample. 
This kind of studies or allergenic component-resolved diagnosis (CDR) microarrays, afford an 
image of patient sensitisation at molecular level, allowing the identification of the potential 
disease-eliciting molecules. This analysis led to the development of a new concept in allergy 
diagnosis: molecular diagnosis (Ferrer et al., 2009, Lindholm et al., 2006). Performance 
characteristics for allergens so far tested are comparable with the diagnostic tests currently 
used (Janh-Smith et al., 2003, Wohrl et al., 2006, Ott et al., 2008, Ebo et al., 2010). 
One of the most important utility of molecular diagnosis in allergy is its ability to reveal the 
allergens to which patients are sensitized, including primary or species-specific allergens 
and markers of cross-reactivity to proteins with similar protein structures may help to 
evaluate the risk of reaction on exposure to different allergen sources (Sastre, 2010). 
Using microarray-based testing makes it possible to determine the IgE reactivity profile of a 
patient and assess their clinical pattern. The whole profile can give complementary 
information to the results achieved by single allergen components or extract-based testing. 
In vitro test results should always be evaluated together with the clinical history, because 
allergen sensitization does not necessarily imply a clinical reaction.  The use of a predefined 
large number of allergen components in microarray systems can facilitate this task, although 
such an approach puts greater demands on interpretation. 
The use of IgE epitope mapping of allergens using microarray-based immunoassay will 
probably be the next step in development (Lin et al., 2009). 
Another area of research looks to establish whether information from molecular medicine 
can provide an indication as to the chances of tolerance development or if the allergy will be 
persistent. Molecular medicine can also be a support tool for adapting treatment strategy to 
the particularities of each patient in a timely manner, open the possibility of personalizing 
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the actions to be taken, as include targeted allergen exposure reduction advice, selection of 
suitable allergens for specific immunotherapy (SIT) or the need to perform food challenges. 
Although the fundamental role of two-dimensional gel electrophoresis combined with other 
proteomics techniques in the characterization of allergens, other proteomic approach as 
SELDI-TOF-MS has been useful for discovering biomarkers in asthma-related inflammation 
and remodelling, in a mice model (Calvo et al., 2009) and recently, the use of LC-MS/MS 
analysis combined with genomic expression analyses has been described for identifying 
novel potential markers of glucocorticoids treatment in intermittent allergic rhinitis (Wang 
et al., 2011). 
4. Conclusions 
In the last few years, our knowledge about of the human genome improved considerable. 
Still we are very far from the total understanding of the genomic background of complex 
diseases, but the news high-throughput technologies together with other complementary 
tools, as bioinfomatic, have contributed to highly increase our understanding of these 
complex disorders, and most importantly, have produced a change in the focusing of 
biological studies. The concept of biological systems open a broader, integrated view of 
biological system will yield a more complete understanding of disease, providing improved 
tools for identifying prognostic, diagnostic, biomarkers and treatment. 
However, we need many efforts before to design effective intervention in these diseases. 
New approaches and access to high quality, well-annotated datasets that will allow us to 
gain insight into novel process that we can associate with biological outcomes such as 
disease are needed. Microarray themselves provide only testable hypotheses, not firm 
conclusions, and validating is necessary. This complexity is reflect of the large number of 
new genes (and new splice variants and the expanding classes of noncoding RNAs) 
discovered by the ongoing sequencing of genomes and transcripts. Complicating this is the 
lack of information on molecular interactions; genes expression can only measure gene 
transcription, not translation, and certainly not the complex regulatory pathways and 
interactions leading to the array result, a snapshot of one sample at one moment. This leads 
to the current state of gene expression microarray data in asthma/allergy, where although 
many differentially expressed genes have been found and verify potential biomarkers 
and/or therapeutic targets are still being validated, evaluated and explored with no clinical 
diagnostic or therapeutic benefit to date. Molecular phenotyping of diseases, using 
technologies such as gene expression microarrays, has the potential to provide insights into 
the phenotypic heterogeneity of disease and the identification of associated biomarkers as 
well as strategies to select patients with an increased potential to respond to molecularly 
targeted therapies. However, the efficacy of molecularly targeted therapies in a clinical 
setting depends on both appropriate patient selection and appropriate outcome selection.  
We need to understand individual gene-gene, gene-protein, and protein-protein network 
interactions in human health and disease. An understanding of these networks should 
enable the opportunity to diagnose disease before it is clinically manifest or to define the 
targeted to be regulated. 
However, some areas have been considerable improvement with the high-throughput 
methodologies. Some microarray applications, as allergenic component microarrays offer an 
elegant way to avoid the problem of allergen standardisation and false polysensitisation. 
The possibility of determining specific IgE antibodies against multiple recombinants and 
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purified natural allergen components has allowed for the development of Molecular 
Diagnosis. This novel diagnostic technology is minimally invasive, makes use of small 
sample volumes, offers quantitative results, and constitutes a multianalytic test, thus 
facilitating its incorporation to clinical use. This technology opens the door to personalised 
medical practice, by allowing diagnosis and planning at molecular level, specific for each 
patient, with a known and balanced dosing of standardised allergens for immunotherapy. 
Molecular Diagnosis can be a support tool for reaching appropriate and timely clinical 
decisions on patients, which afford clinicians the possibility of individualizing the actions 
taken. 
In conclusion, although the advances in the understanding of molecular basis of allergic 
diseases have been highly improved by new “omics-approaches” and the potential it is 
undoubted, due to the complexity of this kind of diseases, many efforts before to design 
effective intervention are needed. These kinds of studies highlight the importance of 
understanding the underlying basis of heterogeneity in disease and the relationships 
between targeted pathways and in vivo patophysiology for developing strategies to identify 
patient populations with maximal potential benefit from molecularly targeted therapies. 
Besides, many other concepts as well as missing heritability (study of rare variants or minor 
allele frequency) gene-environment interactions, epigenetic effects, and well-defined 
consistent phenotypes across large population sets should be analyzed. Although the future 
is very promising and we have made great advances, still there is a long way to walk. 
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the actions to be taken, as include targeted allergen exposure reduction advice, selection of 
suitable allergens for specific immunotherapy (SIT) or the need to perform food challenges. 
Although the fundamental role of two-dimensional gel electrophoresis combined with other 
proteomics techniques in the characterization of allergens, other proteomic approach as 
SELDI-TOF-MS has been useful for discovering biomarkers in asthma-related inflammation 
and remodelling, in a mice model (Calvo et al., 2009) and recently, the use of LC-MS/MS 
analysis combined with genomic expression analyses has been described for identifying 
novel potential markers of glucocorticoids treatment in intermittent allergic rhinitis (Wang 
et al., 2011). 
4. Conclusions 
In the last few years, our knowledge about of the human genome improved considerable. 
Still we are very far from the total understanding of the genomic background of complex 
diseases, but the news high-throughput technologies together with other complementary 
tools, as bioinfomatic, have contributed to highly increase our understanding of these 
complex disorders, and most importantly, have produced a change in the focusing of 
biological studies. The concept of biological systems open a broader, integrated view of 
biological system will yield a more complete understanding of disease, providing improved 
tools for identifying prognostic, diagnostic, biomarkers and treatment. 
However, we need many efforts before to design effective intervention in these diseases. 
New approaches and access to high quality, well-annotated datasets that will allow us to 
gain insight into novel process that we can associate with biological outcomes such as 
disease are needed. Microarray themselves provide only testable hypotheses, not firm 
conclusions, and validating is necessary. This complexity is reflect of the large number of 
new genes (and new splice variants and the expanding classes of noncoding RNAs) 
discovered by the ongoing sequencing of genomes and transcripts. Complicating this is the 
lack of information on molecular interactions; genes expression can only measure gene 
transcription, not translation, and certainly not the complex regulatory pathways and 
interactions leading to the array result, a snapshot of one sample at one moment. This leads 
to the current state of gene expression microarray data in asthma/allergy, where although 
many differentially expressed genes have been found and verify potential biomarkers 
and/or therapeutic targets are still being validated, evaluated and explored with no clinical 
diagnostic or therapeutic benefit to date. Molecular phenotyping of diseases, using 
technologies such as gene expression microarrays, has the potential to provide insights into 
the phenotypic heterogeneity of disease and the identification of associated biomarkers as 
well as strategies to select patients with an increased potential to respond to molecularly 
targeted therapies. However, the efficacy of molecularly targeted therapies in a clinical 
setting depends on both appropriate patient selection and appropriate outcome selection.  
We need to understand individual gene-gene, gene-protein, and protein-protein network 
interactions in human health and disease. An understanding of these networks should 
enable the opportunity to diagnose disease before it is clinically manifest or to define the 
targeted to be regulated. 
However, some areas have been considerable improvement with the high-throughput 
methodologies. Some microarray applications, as allergenic component microarrays offer an 
elegant way to avoid the problem of allergen standardisation and false polysensitisation. 
The possibility of determining specific IgE antibodies against multiple recombinants and 
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purified natural allergen components has allowed for the development of Molecular 
Diagnosis. This novel diagnostic technology is minimally invasive, makes use of small 
sample volumes, offers quantitative results, and constitutes a multianalytic test, thus 
facilitating its incorporation to clinical use. This technology opens the door to personalised 
medical practice, by allowing diagnosis and planning at molecular level, specific for each 
patient, with a known and balanced dosing of standardised allergens for immunotherapy. 
Molecular Diagnosis can be a support tool for reaching appropriate and timely clinical 
decisions on patients, which afford clinicians the possibility of individualizing the actions 
taken. 
In conclusion, although the advances in the understanding of molecular basis of allergic 
diseases have been highly improved by new “omics-approaches” and the potential it is 
undoubted, due to the complexity of this kind of diseases, many efforts before to design 
effective intervention are needed. These kinds of studies highlight the importance of 
understanding the underlying basis of heterogeneity in disease and the relationships 
between targeted pathways and in vivo patophysiology for developing strategies to identify 
patient populations with maximal potential benefit from molecularly targeted therapies. 
Besides, many other concepts as well as missing heritability (study of rare variants or minor 
allele frequency) gene-environment interactions, epigenetic effects, and well-defined 
consistent phenotypes across large population sets should be analyzed. Although the future 
is very promising and we have made great advances, still there is a long way to walk. 
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1. Introduction  
The histamine H4 receptor (H4R) is the most recently identified of the four histamine 
receptors (H1R–H4R), and belongs to the same G-protein-coupled receptor (GPCR) family. 
The amino acid sequence of H4R shares approximately 26%, 27%, and 58% homology with 
H1R, H2R, and H3R, respectively, in the transmembrane regions (Nguyen et al., 2001). 
Furthermore, H4R couples to Gi/o proteins and shows 103- to 104-fold higher ligand affinity 
than H1R and H2R (Thurmond et al., 2008). 
Several organs express H4R, and immune tissues such as the spleen, thymus, bone marrow, 
and leukocytes have a wide range of expression levels (Oda et al., 2000). It has been reported 
that chemotaxis of mast cells and eosinophils is stimulated by histamine via H4R; the receptor 
is therefore attractive as a new target of research into allergic diseases (de Esch et al., 2005). 
2. Expression of H4R in synovial tissue in rheumatoid arthritis  
A role for histamine has been implicated in rheumatoid arthritis (RA). RA consists mainly of 
synovial tissue inflammation that may be dispersed throughout the body, but its molecular 
etiology remains unclear. Macrophage infiltration and excessive formation of fibroblasts 
cause a variety of cytokines to be secreted from synovial membranes in patients with RA, 
and this in turn stimulates osteolytic activity (Sweeney & Firestein, 2004). There is evidence 
of a significant increase in histamine concentration in synovial samples from patients with 
RA (Frewin et al., 1986). These observations suggest a potentially significant role of H4R in 
the cause, progression, and treatment of RA. 
The presence of H1R and H2R in human synovial cell culture (HSCC) has been clearly shown 
by ligand-binding experiments (Nagata, 1991). However, there has been no definitive 
evidence or conclusive reports of the similar presence of H3R or H4R. Therefore, utilizing 
our expertise in reverse transcription polymerase chain reaction (RT-PCR) techniques, we 
examined the H4R-specific mRNA expression in HSCC obtained from 11 RA patients who 
underwent artificial knee-replacement surgery (Ikawa et al., 2005). 
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etiology remains unclear. Macrophage infiltration and excessive formation of fibroblasts 
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and this in turn stimulates osteolytic activity (Sweeney & Firestein, 2004). There is evidence 
of a significant increase in histamine concentration in synovial samples from patients with 
RA (Frewin et al., 1986). These observations suggest a potentially significant role of H4R in 
the cause, progression, and treatment of RA. 
The presence of H1R and H2R in human synovial cell culture (HSCC) has been clearly shown 
by ligand-binding experiments (Nagata, 1991). However, there has been no definitive 
evidence or conclusive reports of the similar presence of H3R or H4R. Therefore, utilizing 
our expertise in reverse transcription polymerase chain reaction (RT-PCR) techniques, we 
examined the H4R-specific mRNA expression in HSCC obtained from 11 RA patients who 
underwent artificial knee-replacement surgery (Ikawa et al., 2005). 
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After excising the synovial membrane specimen under aseptic conditions, the sample was 
treated with collagenase and trypsin solution to separate it into single cells. The cells were 
cultured for 2 weeks in medium containing fetal bovine serum. When the culture reached 
confluence, the cells were harvested and all RNA extracted. Analysis of the expression of the 
4 subtypes of histamine receptor-specific mRNA in 2 patients with RA (RA1 and RA2) by 
RT-PCR showed that, under the experimental conditions, H1R-, H2R-, and H4R-specific 
mRNAs were expressed, but H3R-specific mRNA was not (Fig. 1). Expression of H4R-
specific mRNA was confirmed in all 11 samples (RA1–RA11; Fig. 2). Notably, the intensity 
of the separated H4R-specific mRNA bands varied considerably from one sample to another, 
suggesting differences in cellular concentrations of H4R between patients. 
 
 
Fig. 1. Expression of mRNAs specific to 4 subtypes of histamine receptor (H1R, H2R, H3R, 
and H4R) in HSCC from 2 patients with RA. The gel was loaded with 5 μL of amplified 
products. A 100-bp DNA ladder was used as a molecular weight marker. S: standard; C: 
control; samples from 2 RA patients, RA1 and RA2. Figure reprinted with permission from 
the Pharmaceutical Society of Japan. 
Inflamed synoviocytes consist of 3 cell types: (1) macrophage-like cells; (2) fibroblast-like 
cells; and (3) dendritic cells (Tanaka, 2005). High levels of lymphocyte infiltration have been 
observed in RA compared to other types of arthritis (Fonseca et al., 2005). A variety of cell 
types such as macrophage-like cells, dendritic cells, and granulocytes have also been 
identified in the human RA synovium. As H4R has been reported to be present in immune 
cells, expression of H4R mRNA seems most likely to occur in cells derived from the 
hematopoietic system, such as macrophage-like or dendritic cells from synovial sites. 
Consequently, we examined the protein expression levels of H4R in RA HSCC, and used 
fluorescence immunoassays (Ohki et al., 2007) to determine the types of the cells in which 
expression occurred by identifying co-expression of cell type-specific human proteins: PH 
and CD55 for fibroblast-like cells; CD68 and CD163 for macrophage-like cells; and CD1a 
and CD208 for dendritic cells. 
First, we examined the expression patterns of prolyl-4-hydroxylase (PH) (red) and CD68 
(green) using 2 morphologically distinct cell types we identified in our HSCC: fibroblast-like 
and macrophage-like cells. In similar experiments, no expression of human dendritic cell 
markers (either CD1a or CD208) was detectable. Subsequent assays for fibroblast and 
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macrophage markers showed that human H4R protein is expressed in both fibroblast-like 
and macrophage-like cells in RA synovial tissues (Fig. 3 and Fig. 4). Others have also 
reported identification of H4R in synovial tissue of patients with RA (Grzybowska-
Kowalczyk et al., 2007).  
 
Fig. 2. Expression of H4R-specific mRNA in HSCC from 11 RA patients. The gel was loaded 
with 5 μL of amplified products. A 100-bp DNA ladder was used as a molecular weight 
marker. S: standard; C: control; RE: relative expression; sample from 11 different RA 
patients, RA1 to RA11. RE of mRNA was calculated by normalizing the separated sample 
intensity value, taking that of the corresponding internal control (GAPDH) as 100%. 
Intensity values were measured using an image analyzer (IX81, OLYMPUS). Figure 
reprinted with permission from the Pharmaceutical Society of Japan. 
Next, we focused attention on the expression of H4R mRNA in synovial tissues, and serum 
matrix metalloproteinase-3 (MMP-3) concentration in RA. We found a significant negative 
correlation between H4R expression in synovial tissues and serum MMP-3 concentration, 
but no correlation between MMP-3 and H1R or H2R (Yamaura et al., 2011). These 
observations suggest that H4R is a potential target of novel pharmacotherapeutic agents for 
RA, and H4R functional analysis may be useful in developing such treatments. 
In addition, we detected H4R expression in human cartilage chondrocytes and in a murine 
chondrocytic cell line, ATDC5 (Yamaura et al., in press). Further work is needed to 
determine the expression mechanism and function of H4R on chondrocytes. 
3. Expression of H4R in human skin 
Following detection of H4R expression in synovial tissue, we also analyzed H4R expression 
in human epidermal tissue (Yamaura et al., 2009) and fibroblast cell cultures (Ikawa et al., 
2008). Our immunoassays revealed that H4R is expressed in both human epidermal tissues 
and dermal fibroblasts.  
Keratinocytes are the major constituent of the epidermis. We found that 
immunohistochemical staining showed strong H4R expression in keratin (K)10-positive 
differentiated keratinocytes in the prickle cell and granular layers of the epidermis (Fig. 5a). 
By contrast, H4R was weakly expressed in K14-positive proliferating keratinocytes in the 
basal layer (Fig. 5b).  
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After excising the synovial membrane specimen under aseptic conditions, the sample was 
treated with collagenase and trypsin solution to separate it into single cells. The cells were 
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confluence, the cells were harvested and all RNA extracted. Analysis of the expression of the 
4 subtypes of histamine receptor-specific mRNA in 2 patients with RA (RA1 and RA2) by 
RT-PCR showed that, under the experimental conditions, H1R-, H2R-, and H4R-specific 
mRNAs were expressed, but H3R-specific mRNA was not (Fig. 1). Expression of H4R-
specific mRNA was confirmed in all 11 samples (RA1–RA11; Fig. 2). Notably, the intensity 
of the separated H4R-specific mRNA bands varied considerably from one sample to another, 
suggesting differences in cellular concentrations of H4R between patients. 
 
 
Fig. 1. Expression of mRNAs specific to 4 subtypes of histamine receptor (H1R, H2R, H3R, 
and H4R) in HSCC from 2 patients with RA. The gel was loaded with 5 μL of amplified 
products. A 100-bp DNA ladder was used as a molecular weight marker. S: standard; C: 
control; samples from 2 RA patients, RA1 and RA2. Figure reprinted with permission from 
the Pharmaceutical Society of Japan. 
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markers (either CD1a or CD208) was detectable. Subsequent assays for fibroblast and 
 
Expression of the Histamine H4 Receptor in Human Tissue 
 
33 
macrophage markers showed that human H4R protein is expressed in both fibroblast-like 
and macrophage-like cells in RA synovial tissues (Fig. 3 and Fig. 4). Others have also 
reported identification of H4R in synovial tissue of patients with RA (Grzybowska-
Kowalczyk et al., 2007).  
 
Fig. 2. Expression of H4R-specific mRNA in HSCC from 11 RA patients. The gel was loaded 
with 5 μL of amplified products. A 100-bp DNA ladder was used as a molecular weight 
marker. S: standard; C: control; RE: relative expression; sample from 11 different RA 
patients, RA1 to RA11. RE of mRNA was calculated by normalizing the separated sample 
intensity value, taking that of the corresponding internal control (GAPDH) as 100%. 
Intensity values were measured using an image analyzer (IX81, OLYMPUS). Figure 
reprinted with permission from the Pharmaceutical Society of Japan. 
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2008). Our immunoassays revealed that H4R is expressed in both human epidermal tissues 
and dermal fibroblasts.  
Keratinocytes are the major constituent of the epidermis. We found that 
immunohistochemical staining showed strong H4R expression in keratin (K)10-positive 
differentiated keratinocytes in the prickle cell and granular layers of the epidermis (Fig. 5a). 
By contrast, H4R was weakly expressed in K14-positive proliferating keratinocytes in the 
basal layer (Fig. 5b).  
 




Fig. 3. Co-expression of H4R protein with fibroblast-specific marker proteins. (a) Mouse anti-
PH followed by Cy2-conjugated anti-mouse (green); (b) rabbit anti-H4R followed by Cy3-
conjugated anti-rabbit (red); (c) superposition of a on b; (d) Nomarski phase contrast 
microscopy image (NPCMI); (e) rabbit anti-H4R followed by Cy2-conjugated anti-rabbit 
(green); (f) mouse anti-CD55 followed by Cy3-conjugated anti-mouse (red); (g) 
superposition of e on f; (h) NPCMI. Scale bar: 50 μm. Figure reproduced with permission 
from the Pharmaceutical Society of Japan. 
 
 
Fig. 4. Co-expression of H4R protein with macrophage-specific marker proteins.(a) Mouse 
anti-CD68 followed by Cy2-conjugated anti-mouse (green); (b) rabbit anti-H4R followed by 
Cy3-conjugated anti-rabbit (red); (c) superposition of a on b; (d) NPCMI; (e) mouse anti-
CD163 followed by Cy2-conjugated anti-mouse (green); (f) rabbit anti-H4R followed by Cy3-
conjugated anti-rabbit (red); (g) superposition of e on f; (h) NPCMI. Scale bar: 50 μm. Figure 
reproduced with permission from the Pharmaceutical Society of Japan. 
 




Fig. 5. H4R expression in human epidermal tissues. Double immunofluorescence staining of 
human epidermal tissues with anti-human H4R antibody followed by Cy2-conjugated anti-
rabbit secondary antibody (red), and anti-K10 (a) or anti-K14 (b) antibody followed by Cy2-
conjugated anti-mouse secondary antibody (green). (c) For the negative control, tissues were 
only exposed to the secondary antibody. Figure reprinted with permission from the 
Japanese Society of Toxicology. 
Keratinization is the result of keratinocytes dividing in the basal lamina and moving to the 
upper layer as they mature. K10 is expressed in keratinocytes in the early stages following 
differentiation, whereas K14 is expressed in undifferentiated keratinocytes. Accordingly, our 
results suggest that keratinocytes increase expression of H4R following differentiation; 
however, further work is necessary to determine the expression mechanism and the 
physiological role of the receptors.  
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Increased H4R expression has been reported in CD4+ T cells of patients with atopic 
dermatitis (Gutzmer et al., 2009), and skin mast cells have been shown to express H4R 
(Lippert et al., 2004). These findings suggest that dermal cells may play an important role, 
via H4R, in skin disorders. Dermal fibroblasts are a major component of the dermis. When 
the skin is damaged, they perform important roles including production of extracellular 
matrix molecules such as collagens. We have demonstrated the expression of H4R in human 
dermal fibroblast cells using immunohistochemical staining (Fig. 6). Furthermore, Western 
blot analysis showed enhancement of the expression level of H4R in dermal fibroblasts by 
stimulation with dexamethasone (Fig. 7). 
 
 
Fig. 6. Expression of H4R on human dermal fibroblasts.Double immunofluorescence staining 
of dermal fibroblast cells treated with anti-human PH antibody followed by Cy2-conjugated 
anti-mouse secondary antibody (green), and anti-human H4R antibody followed by Cy3-
conjugated anti-rabbit secondary antibody (red). Magnification x 400. Figure reprinted with 
permission from the Japanese Society of Toxicology. 
Ohnishi et al. (2008) reported that the levels of leukotriene B4 receptor 1, which belongs to 
the GPCR family, were up-regulated by dexamethasone. This suggests that H4R, which is 
part of the same family, may be up-regulated by dexamethasone too. This up-regulation of 
H4R expression might be associated with itching that occurs as a rebound phenomenon after 
withdrawal of high-dose topical glucocorticoids. We confirmed that significant 
enhancement of pruritus occurred after chronic topical application of dexamethasone in 
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mice (Yamaura et al., 2011). However, further study is needed to investigate the relationship 




Fig. 7. Effects of dexamethasone on H4R protein expression in human dermal fibroblast cell 
cultures. Expression of H4R was analyzed by Western blot analysis. Protein levels of H4R 
were normalized to the corresponding β-actin protein levels. The mean value of the non-
treatment group was set to 1.0. Data are expressed as means (n=2–3). Figure reprinted with 
permission from the Japanese Society of Toxicology. 
4. Effect of H4R antagonists on pruritus model 
Chronic pruritus, associated with chronic conditions such as skin, liver, and kidney diseases 
and metabolic disorders, is a major diagnostic and therapeutic problem and can have a 
profound impact on the quality of life of patients. Recent studies have raised the possibility 
that H4R, in addition to the H1R, may contribute to histamine-mediated pruritic responses in 
mice (Bell et al., 2004). Both specific H4R agonists and histamine were shown to induce 
pruritic responses which could be blocked by pretreatment with H4R antagonists; the 
response was also found to be markedly attenuated in H4R-deficient mice. We thus 
examined the effectiveness of selective H4R antagonists as antipruritic drugs by their effect 
on histamine H1R antagonist-resistant acute pruritus induced by substance P in mice. 
We investigated the effect of the H1R antagonist fexofenadine and the H4R antagonist 
JNJ7777120 on histamine-induced acute pruritus (Yamaura et al., 2009). Oral administration of 
fexofenadine caused a slight reduction in scratching, whereas JNJ7777120 showed a significant 
reduction (Fig. 8). We then examined the effect of these antagonists in substance P-mediated 
acute pruritus. Fexofenadine showed no reduction in substance P-induced scratching. By 
contrast, JNJ7777120 at 10 and 30 mg/kg doses reduced substance P-induced scratching in a 
dose-dependent manner (Fig. 9). Although JNJ7777120 crosses the blood–brain barrier, it does 
not cause sedation in rodents (Dunford et al., 2007); hence its antipruritic action is not a 
secondary effect of sedation. The results suggest that H1R has only limited involvement in 
histamine-induced pruritus. By contrast, the significant effect of JNJ7777120 suggests that H4R 
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profound impact on the quality of life of patients. Recent studies have raised the possibility 
that H4R, in addition to the H1R, may contribute to histamine-mediated pruritic responses in 
mice (Bell et al., 2004). Both specific H4R agonists and histamine were shown to induce 
pruritic responses which could be blocked by pretreatment with H4R antagonists; the 
response was also found to be markedly attenuated in H4R-deficient mice. We thus 
examined the effectiveness of selective H4R antagonists as antipruritic drugs by their effect 
on histamine H1R antagonist-resistant acute pruritus induced by substance P in mice. 
We investigated the effect of the H1R antagonist fexofenadine and the H4R antagonist 
JNJ7777120 on histamine-induced acute pruritus (Yamaura et al., 2009). Oral administration of 
fexofenadine caused a slight reduction in scratching, whereas JNJ7777120 showed a significant 
reduction (Fig. 8). We then examined the effect of these antagonists in substance P-mediated 
acute pruritus. Fexofenadine showed no reduction in substance P-induced scratching. By 
contrast, JNJ7777120 at 10 and 30 mg/kg doses reduced substance P-induced scratching in a 
dose-dependent manner (Fig. 9). Although JNJ7777120 crosses the blood–brain barrier, it does 
not cause sedation in rodents (Dunford et al., 2007); hence its antipruritic action is not a 
secondary effect of sedation. The results suggest that H1R has only limited involvement in 
histamine-induced pruritus. By contrast, the significant effect of JNJ7777120 suggests that H4R 
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has a much greater role. Substance P-induced pruritus is resistant to H1R antagonists (Togashi 
et al., 2002); given its occurrence in mast cell-deficient mice (Andoh et al., 2001), histamine 
from mast cells is unlikely to be involved. The role of H1R is also thought to be minor, with 
fexofenadine having no observable effect. However, the suppression of the pruritic response 
by JNJ7777120 suggests that histamine may act via H4R rather than H1R. 
 
Fig. 8. Effect of H4R on scratching behavior induced by histamine.Histamine (300 nmol) was 
injected intradermally into shaved skin on the back of each mouse. Immediately after the 
injection of pruritogen, scratching events were counted for 30 min using the MicroAct 
apparatus (Neuroscience Inc., Tokyo, Japan). Fexofenadine (a) or JNJ7777120 (b) was 
administered orally 20 min before the injection of pruritogen. Values represent the mean ± 
SEM of four mice. *p<0.05 vs. control (Dunnett’s multiple comparisons). Figure reprinted 
with permission from the Japanese Society of Toxicology. 
 




Fig. 9. Effect of H4R on scratching behavior induced by substance P. Substance P (100 nmol) 
was injected intradermally into shaved skin on the back of each mouse. Immediately after 
the injection of pruritogen, scratching events were counted for 30 min using MicroAct. 
Fexofenadine (a) or JNJ7777120 (b) was administered orally 20 min before the injection of 
pruritogen. Values represent the mean ± SEM of four mice. *p<0.05 vs. control (Dunnett’s 
multiple comparisons). Figure reprinted with permission from the Japanese Society of 
Toxicology. 
Further, we created a chronic itch model in which repeated application of 2,4,6-
trinitrochlorobenzene to the back skin of HR-1 mice was seen to elicit frequent scratching 
behavior at 24 h after challenge. JNJ7777120 at 10 and 30 mg/kg doses reduced this 
scratching behavior, whereas fexofenadine had no such effect (Suwa et al., 2011). These 
results suggest that H4R antagonists may be useful for treatment of H1R antagonist-resistant 
chronic pruritus such as atopic dermatitis. 
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We have demonstrated the expression of H4R in human synovial cells from patients with 
RA and found a significant negative correlation between H4R expression in RA synovial 
tissues and serum MMP-3 concentration. Furthermore, we have shown expression of H4R in 
human skin and demonstrated that an H4R antagonist ameliorates both H1R antagonist-
resistant acute and chronic pruritus. Taken together, these results suggest that histamine 
H4R could be a new drug target for therapeutic use in RA or pruritic skin disorders such as 
atopic dermatitis. 
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1. Introduction 
Approximately 300 million (M) people worldwide currently suffer from asthma; this number 
is projected to reach 400M by 2025 (Bahadori, et al., 2009). During the allergic immune 
response, inhaled allergens first stimulate epithelial cells, basophils, mast cells, and 
macrophages. This priming leads to the generation of allergen specific T-cells. Atopic asthma is 
strongly correlated with a robust CD4+ Th2 effector response, which results in elevated levels 
of the cytokines IL-4, 5, and 13. These cytokines act on multiple cells types to initiate and 
propagate the hallmark features of asthma such as pulmonary inflammation, periodic 
narrowing of airways, and mucus hypersecretion. Two of these cytokines, IL-4 and IL-13, 
share receptor chains and signaling proteins. In this chapter we discuss the cells that produce 
IL-4 and IL-13 including CD4+ T-cells and cells of the innate immune system, the structure of 
their receptors, their binding potency and kinetics, and their signal transduction. Furthermore, 
we present evidence for the differential effects of IL-4 and IL-13 acting via these receptor 
complexes on features of allergic lung inflammation. Finally, we discuss their contribution to 
the control of negative regulatory mechanisms that act to suppress allergic inflammation. 
2. Cells that produce IL-4 and IL-13 
Interleukin-4 and Interleukin-13 are closely related cytokines (Chomarat & Banchereau, 
1998) critical to the development of T cell-mediated humoral immune responses, which are 
associated with allergy and asthma. Both cytokines display many overlapping functions 
(Chomarat & Banchereau, 1998). However, studies in cytokine-knockout mice and the use of 
blocking antibodies in vivo have shown that IL-4 is a critical cytokine for Th2 development 
whereas IL-13 plays critical roles in allergic asthmatic response (Grunig, et al., 1998, Wills-
Karp, et al., 1998). Both cytokines can be secreted by many cell types but Th2 cells are 
considered to be the major producers. In this section, we will focus on cells capable of 
producing either IL-4, or IL-13, or both.  
2.1 T cells 
Upon antigen receptor stimulation, naive CD4+ T cells can differentiate into several 
different types, including T helper type 2 cells (Th2) depending on the cytokine milieu 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
42
Yamaura K., Doi R., Suwa E., & Ueno K. (2011). A novel animal model of pruritus induced 
by successive application of glucocorticoid to mouse skin. J. Toxicol. Sci. 36: 395-401, 
ISSN 0388-1350. 
Yamaura K., Oda M., Suzuki M., & Ueno K. (2011). Lower expression of histamine H(4) 
receptor in synovial tissues from patients with rheumatoid arthritis compared to 
those with osteoarthritis. Rheumatol Int. Sep 1 (Epub ahead of print), ISSN: 0172-
8172 
Yamaura K., Akiyama S., & Ueno K. (2011). Increased expression of the histamine H4 
receptor subtype in hypertrophic differentiation of chondrogenic ATDC5 cells. J 
Cell Biochem. In press, ISSN 1097-4644. 
3 
The Type I and Type II Receptor 
Complexes for IL-4 and IL-13 Differentially 
Regulate Allergic Lung Inflammation 
Nicola M. Heller, Preeta Dasgupta, Nicolas J. Dorsey, 
Svetlana P. Chapoval and Achsah D. Keegan 
University of Maryland School of Medicine, Baltimore, MD, 
USA 
1. Introduction 
Approximately 300 million (M) people worldwide currently suffer from asthma; this number 
is projected to reach 400M by 2025 (Bahadori, et al., 2009). During the allergic immune 
response, inhaled allergens first stimulate epithelial cells, basophils, mast cells, and 
macrophages. This priming leads to the generation of allergen specific T-cells. Atopic asthma is 
strongly correlated with a robust CD4+ Th2 effector response, which results in elevated levels 
of the cytokines IL-4, 5, and 13. These cytokines act on multiple cells types to initiate and 
propagate the hallmark features of asthma such as pulmonary inflammation, periodic 
narrowing of airways, and mucus hypersecretion. Two of these cytokines, IL-4 and IL-13, 
share receptor chains and signaling proteins. In this chapter we discuss the cells that produce 
IL-4 and IL-13 including CD4+ T-cells and cells of the innate immune system, the structure of 
their receptors, their binding potency and kinetics, and their signal transduction. Furthermore, 
we present evidence for the differential effects of IL-4 and IL-13 acting via these receptor 
complexes on features of allergic lung inflammation. Finally, we discuss their contribution to 
the control of negative regulatory mechanisms that act to suppress allergic inflammation. 
2. Cells that produce IL-4 and IL-13 
Interleukin-4 and Interleukin-13 are closely related cytokines (Chomarat & Banchereau, 
1998) critical to the development of T cell-mediated humoral immune responses, which are 
associated with allergy and asthma. Both cytokines display many overlapping functions 
(Chomarat & Banchereau, 1998). However, studies in cytokine-knockout mice and the use of 
blocking antibodies in vivo have shown that IL-4 is a critical cytokine for Th2 development 
whereas IL-13 plays critical roles in allergic asthmatic response (Grunig, et al., 1998, Wills-
Karp, et al., 1998). Both cytokines can be secreted by many cell types but Th2 cells are 
considered to be the major producers. In this section, we will focus on cells capable of 
producing either IL-4, or IL-13, or both.  
2.1 T cells 
Upon antigen receptor stimulation, naive CD4+ T cells can differentiate into several 
different types, including T helper type 2 cells (Th2) depending on the cytokine milieu 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
44
present during the priming. IL-4 itself is important for the differentiation of naïve CD4+ T 
cells into Th2 cells capable of producing large amounts of IL-4, IL-13, and IL-5 (Zhu&Paul, 
2008). Recent evidence points to basophils (van Panhuys, et al., 2011), mast cells (Plaut, et al., 
1989), natural killer (NK) T cells (Akbari, et al., 2003), and  T cells (Ferrick, et al., 1995) as 
early producers of IL-4 in the innate immune response necessary for the optimal priming of 
the Th2 adaptive response. Therefore, in addition to CD4+ T cells, other T cell 
subpopulations such as NKT cells and  T cells are capable of making IL-4.  
IL-4 and IL-13 producing NKT cells have been shown to be essential for the development 
and progression of allergic airway inflammation (Akbari, et al., 2003). NKT cell-deficient 
(Cd1d1-/-) mice showed reduced Th2 responses after allergen challenge including allergic 
airway inflammation and airway hyperreactivity. The abrogated Th2 response in these mice 
could be restored by the adoptive transfer of purified NKT cells producing IL-4 and IL-13, 
but not by IL-4-deficient and IL-13-deficient NKT cells. IL-13 instillation to the mice could 
restore allergic airway responses. This led the authors to conclude that IL-4 and IL-13 
produced by NKT cells potentiate the development of Th2 response in the lung. However, 
other studies suggest that NKT cells do not play an important role in allergic lung 
inflammation models (Das, et al., 2006).  
Gamma/delta T cells also can differentiate into cells producing Th2 cytokines (Wen, et al., 
1998). When WT mice were infected with Nippostrongylus brasiliensis, an extracellular 
parasite known to induce Th2 responses,  T cells from these mice produced IL-4 (Ferrick, 
et al., 1995). The ability of human  T cells to differentiate into Th2 cytokine producing 
cells was tested using stimulation of peripheral blood-derived  T cells with 
phosphoantigen isopretenyl pyrophosphate (Wesch, et al., 2001). When these cells were 
stimulated with Ag under Th2 priming conditions, they developed into cells producing IL-4. 
CD8+ T cells have been shown to produce IL-4 under specific in vitro stimulation (Seder, et 
al., 1992). When mouse CD8+ T cells were stimulated with immobilized CD3 in the presence 
of IL-2 and IL-4, they became high IL-4 producers. Moreover, both CD4+ T cells and CD8+ T 
cells separated from bulk lymph node T cell cultures with anti-CD3 plus IL-2 and IL-4 
where equally effective in secretion of IL-4 after restimulation with anti-CD3 plus IL-2. The 
authors suggested that in certain in vivo conditions, CD8+ T cells could be major IL-4 
producers. Human CD8+ T cell clones capable of IL-4 secretion were identified previously 
(Paliard, et al., 1988). 
2.2 Granulocytes (Mast cells, basophils, and eosinophils) 
Mouse non-T, non-B cells derived from spleen produce IL-4 and IL-13 in response to FcR 
crosslinkage (Ben-Sasson, et al., 1990). The same phenomenon was described for human 
bone marrow non-B and non-T cells in response to stimulation through either Fc or Fc 
receptors (Piccinni, et al., 1991). It has been suggested then that those IL-4-secreting cells 
could be either mast cells or basophils, or both. Indeed, the ability of mast cells to secrete 
both cytokines has been reported utilizing human cord blood derived mast cells (Toru, et al., 
1998). These cells can generate both cytokines after stimulation with PMA or FcR 
crosslinking. However, these cells do not produce Th2 cytokines spontaneously. Similarly, 
the ability of mouse mast cells to secrete IL-4 and IL-13 in response to specific 
immunological stimulation has been reported for fetal liver derived mast cell lines, bone 
marrow derived mast cells, and the mast cell line C1.MC/C57.1 (Brown, et al., 1987, Burd, et 
al., 1995). Of note, mast cells secrete relatively high IL-13 but low IL-4 levels. 
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As noted above, basophils were among three major cell populations of IL-4 producers in the 
lung under inflammatory conditions (Voehringer, et al., 2004). The ability of basophils to 
secrete both cytokines and other mediators of inflammatory response was extensively 
reviewed by Min and Paul in 2008 (Min & Paul, 2008). Importantly, it has been shown that 
peripheral blood basophils in asthmatic patients are the main producers of IL-4 and IL-13 
(Schroeder, et al., 1995), suggesting a role in asthma exacerbation. IL-4 was detected in 
cultures of human basophils treated with diesel exhaust particles (Devouassoux, et al., 2002) 
suggesting that environmental exposure can predispose basophils to initiate Th2 responses. 
Eosinophils can also make IL-4 under certain circumstances. When mice were injected with 
Schistosoma mansoni eggs intraperitoneally, there were high levels of IL-4 in the peritoneal 
exudate cell cultures (Sabin, et al., 1996). IL-5 and eosinophils were necessary for the 
observed IL-4 production as suggested from similar experiments using egg-immunized IL-5-
/- mice or anti-IL-5 treated mice (Kopf, et al., 1996). Interestingly, these eosinophils were 
found to produce IL-4 early after immunization. The authors suggested that Schistosoma 
mansoni induced an early IL-5 production by mast cells that attracted eosinophils which, in 
their turn, produced IL-4 thus stimulating the development of antigen-specific Th2 cells. The 
ability of eosinophils to make Th2 cytokines was also tested in a more recent study 
(Voehringer, et al., 2004). The authors characterized IL-4 producing cells in the inflamed 
lungs by immunohistochemistry, flow cytometry, and microarray in mice with a bicistronic 
knock-in IL-4 gene linked via internal ribosomal entry site (IRES) with enhanced green 
fluorescent protein (eGFP). Eosinophils, basophils, and Th2 cells were reported as three cell 
populations producing IL-4 in these mice.  
2.3 Myeloid cells 
Macrophages have been shown to produce IL-4 or IL-13 in response to certain stimuli. A 
strong expression of IL-13 in the lung was observed in the experimental model of particle 
inhalation-induced inflammation (Kang, et al., 2005). Immunostaining of lung tissues of 
TiO2-exposed mice demonstrated that alveolar macrophages are major producers of IL-13 
and IL-25 in the inflamed lungs (Kang, et al., 2005). It has also been shown that human 
alveolar macrophages can produce IL-4 (Pouliot, et al., 2005). It has been shown that 
infectious pathogens including Francisella tularensis and respiratory syncitial virus (RSV) 
induce lung and peritoneal macrophages to produce IL-4 and IL-13 (Shirey, et al. 2008, 
Shirey, et al., 2010).  
3. Receptor structure, ligand binding properties, and signal transduction 
3.1 The structure of the IL-4 and IL-13 receptors 
IL-4 and IL-13 elicit a wide variety of cellular responses by binding to high affinity receptor 
complexes expressed on the surface of cells. The IL-4/IL-13 receptor system is complex 
(Figure 1). The IL-4 specific receptor is composed of the IL-4R chain paired with the 
common  chain, or C, forming the Type I IL-4 receptor complex. The IL-4R chain can also 
pair with the IL-13R1 chain, forming the Type II receptor (Figure 1). Type I receptors are 
activated by the binding of IL-4 to the ligand-binding IL-4R chain and Type II receptors 
can be activated by either IL-4 or IL-13, with the IL-4R or IL-13R1 acting as the initial 
ligand-binding chain, respectively. IL-13 can also engage another kind of IL-13 receptor, the 
IL-13R2 chain. 
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Fig. 1. The IL-4 and IL-13 Receptor System. A functional IL-4 receptor is composed of two 
transmembrane proteins. IL-4R chain binds IL-4 with high affinity, leading to dimerization 
with either common gamma chain (C) or IL-13R1, forming the Type I or Type II receptor 
complex, respectively. IL-13 binds to IL-13R1 with lower affinity, followed by 
heterodimerization with IL-4R to form a high affinity complex. IL-13 also binds to IL-
13R2 (the so-called “decoy receptor”) at the cell surface, or in soluble form, but this 
interaction fails to activate the JAK/STAT pathway and generally it is thought to be 
inhibitory. Soluble forms of IL-4R (sIL-4R), IL-13R1 and IL-13R2 exist that can also 
bind ligand. Following ligand binding and heterodimerization, receptor-associated Janus 
Kinases (JAKs) are activated. 
3.1.1 IL-4R 
The IL-4R chain (CD124) is a 140 kDa protein. Human and mouse IL-4 receptors show a 
broad distribution on hematopoietic and non-hematopoietic cells (Park, et al., 1987, 
Lowenthal, et al., 1988), generally expressed at low levels (20-4000 receptors per cell).The IL-
4R cDNAwas cloned from the mouse cytotoxic T-lymphocytic (CTLL-2) cell line (Mosley, 
et al., 1989) and from the human myeloid cell line, TF-1 (Galizzi, et al., 1990).  Sequence 
analysis demonstrated that the IL-4R belongs to the hematopoeitin receptor superfamily. 
There are two extracellular structural features that characterize this family: type III 
fibronectin (FN) repeats and a membrane-proximal WSXWS motif.  
The 2.3 Å resolution crystal structure of human IL-4 complexed to the extracellular domain 
of the human IL-4R determined the overall shape of the two, linked type III FN-like 
domains, D1 and D2 (Hage, et al., 1999). Five IL-4R peptide loops protrude from these two 
D domains and interact with IL-4. Binding of IL-4 to IL-4R occurs through interaction of 
IL-4 with two clusters or sites (I and II) within the receptor, with Y183 and D72 at the center, 
surrounded by a shell of hydrophobic residues.  
3.1.2 C 
The involvement of the IL-2R subunit, or common  chain, in forming heterodimeric IL-4 
receptors was recognized by three groups in the early 90’s (Kondo, et al., 1993, Leonard, et 
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al., 1994, Russell, et al., 1993). The C chain (CD132), which dimerizes with the IL-4R chain 
to form a functional type I IL-4 receptor, is a 60 kDa protein. The extracellular domain of C 
possesses the tandem FN-III domains with four Cys residues and membrane-proximal 
WSXWS motif creating the classical CHR. Mouse C chain was cloned in 1993 (Kumaki, et 
al., 1993) and human C in 1992 (Takeshita, et al., 1992). Both human and mouse C genes 
map to the X-chromosome in humans (Noguchi, et al., 1993) and mouse (Cao, et al., 1993). 
The C subunit participates in the formation of many other cytokine receptor complexes 
including the IL-2, IL-7, IL-9, IL-15 , and IL-21 receptors. Thus, mutations that either 
diminish or eliminate C expression or prevent association of the JAK3 kinase with C 
impair activity of these cytokines important for the development and proliferation of many 
different cells of the immune system, resulting in X-linked severe combined 
immunodeficiency (XSCID) in humans (Leonard, et al., 1994). C-deficient mice have no NK 
cells and severely diminished T- and B-cells, virtually absent lymph nodes and 
spontaneously develop inflammatory bowel lesions (Cao, et al., 1995). 
3.1.3 IL-13 receptor 1 (IL-13R1) 
The IL-13R1 chain (CD213a1) is a 65-70 kDa glycosylated protein, encoded on the X 
chromosome in mice and humans. The mouse IL-13R1 cDNA was cloned in 1996 (Hilton, 
et al., 1996), followed by characterization of the human gene (Aman, et al., 1996), revealing 
the characteristic WSXWS motif and four conserved Cys residues. IL-13R1 can act either as 
a ligand-binding chain for IL-13 or as a dimerization partner to the type II receptor’s IL-4-IL-
4R ternary complex (Zurawski, et al., 1993). The IL-13R1 chain is widely expressed on the 
surface of many hematopoietic and non-hematopoietic cells. It is through this Type II 
receptor complex that IL-4 and IL-13 mediate their effects on non-hematopoietic cells, which 
generally lack C, and therefore Type I receptor expression. IL-13R1 surface expression is 
absent on resting mouse and human T-cells and on mouse B-cells (Ogata, et al., 1998, 
Umeshita-Suyama, et al., 2000), although recent studies suggested inducible expression on 
mouse and human CD4+ T-cells (Newcomb, et al., 2009, Newcomb, et al., 2011). Related 
evolutionarily to C, IL-13R1 has acquired a third extra Ig-like domain, D1, allowing extra 
contacts with IL-13 in Type II receptor complexes (LaPorte, et al., 2008). This D1 domain is 
required for IL-13 binding and the formation of a functional Type II receptor, while it is not 
required for IL-4 binding or its activation of the Type II receptor (Ito, et al., 2009). 
3.1.4 IL-13 receptor 2 (IL-132) 
IL-13 binds to a second IL-13 receptor, IL-13R2 (CD213a2, IL13BP) that was cloned in 
humans (Caput, et al., 1996) and from mice (Donaldson, et al., 1998). The gene is also found 
on the X-chromosome. IL-13R2 (~65 kDa) is inducibly expressed on fibroblasts, 
keratinocytes, epithelial cells, macrophages, and certain tumor cells and requires STAT6 for 
its expression (David, et al., 2003). The soluble form can be generated by proteolytic 
cleavage of the membrane-bound form by matrix metalloproteinases (MMPS) (Matsumura, 
et al., 2007) or by alternative splicing (Tabata, et al., 2006). Interestingly, sIL-13R2 is 
detected in serum from mice but not humans (Chen, et al., 2009). Treatment of cells with IL-
4 or IL-13 in combination with TNF- upregulated IL-13R2 cell surface expression (Zheng, 
et al., 2003). In contrast to IL-13R1, IL-13R2 binds to IL-13 with very high affinity 10-11 M 
(Andrews, et al., 2002) one of the highest measured protein-protein interactions, possibly 
 




Fig. 1. The IL-4 and IL-13 Receptor System. A functional IL-4 receptor is composed of two 
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13R2 (the so-called “decoy receptor”) at the cell surface, or in soluble form, but this 
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inhibitory. Soluble forms of IL-4R (sIL-4R), IL-13R1 and IL-13R2 exist that can also 
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4R cDNAwas cloned from the mouse cytotoxic T-lymphocytic (CTLL-2) cell line (Mosley, 
et al., 1989) and from the human myeloid cell line, TF-1 (Galizzi, et al., 1990).  Sequence 
analysis demonstrated that the IL-4R belongs to the hematopoeitin receptor superfamily. 
There are two extracellular structural features that characterize this family: type III 
fibronectin (FN) repeats and a membrane-proximal WSXWS motif.  
The 2.3 Å resolution crystal structure of human IL-4 complexed to the extracellular domain 
of the human IL-4R determined the overall shape of the two, linked type III FN-like 
domains, D1 and D2 (Hage, et al., 1999). Five IL-4R peptide loops protrude from these two 
D domains and interact with IL-4. Binding of IL-4 to IL-4R occurs through interaction of 
IL-4 with two clusters or sites (I and II) within the receptor, with Y183 and D72 at the center, 
surrounded by a shell of hydrophobic residues.  
3.1.2 C 
The involvement of the IL-2R subunit, or common  chain, in forming heterodimeric IL-4 
receptors was recognized by three groups in the early 90’s (Kondo, et al., 1993, Leonard, et 
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al., 1994, Russell, et al., 1993). The C chain (CD132), which dimerizes with the IL-4R chain 
to form a functional type I IL-4 receptor, is a 60 kDa protein. The extracellular domain of C 
possesses the tandem FN-III domains with four Cys residues and membrane-proximal 
WSXWS motif creating the classical CHR. Mouse C chain was cloned in 1993 (Kumaki, et 
al., 1993) and human C in 1992 (Takeshita, et al., 1992). Both human and mouse C genes 
map to the X-chromosome in humans (Noguchi, et al., 1993) and mouse (Cao, et al., 1993). 
The C subunit participates in the formation of many other cytokine receptor complexes 
including the IL-2, IL-7, IL-9, IL-15 , and IL-21 receptors. Thus, mutations that either 
diminish or eliminate C expression or prevent association of the JAK3 kinase with C 
impair activity of these cytokines important for the development and proliferation of many 
different cells of the immune system, resulting in X-linked severe combined 
immunodeficiency (XSCID) in humans (Leonard, et al., 1994). C-deficient mice have no NK 
cells and severely diminished T- and B-cells, virtually absent lymph nodes and 
spontaneously develop inflammatory bowel lesions (Cao, et al., 1995). 
3.1.3 IL-13 receptor 1 (IL-13R1) 
The IL-13R1 chain (CD213a1) is a 65-70 kDa glycosylated protein, encoded on the X 
chromosome in mice and humans. The mouse IL-13R1 cDNA was cloned in 1996 (Hilton, 
et al., 1996), followed by characterization of the human gene (Aman, et al., 1996), revealing 
the characteristic WSXWS motif and four conserved Cys residues. IL-13R1 can act either as 
a ligand-binding chain for IL-13 or as a dimerization partner to the type II receptor’s IL-4-IL-
4R ternary complex (Zurawski, et al., 1993). The IL-13R1 chain is widely expressed on the 
surface of many hematopoietic and non-hematopoietic cells. It is through this Type II 
receptor complex that IL-4 and IL-13 mediate their effects on non-hematopoietic cells, which 
generally lack C, and therefore Type I receptor expression. IL-13R1 surface expression is 
absent on resting mouse and human T-cells and on mouse B-cells (Ogata, et al., 1998, 
Umeshita-Suyama, et al., 2000), although recent studies suggested inducible expression on 
mouse and human CD4+ T-cells (Newcomb, et al., 2009, Newcomb, et al., 2011). Related 
evolutionarily to C, IL-13R1 has acquired a third extra Ig-like domain, D1, allowing extra 
contacts with IL-13 in Type II receptor complexes (LaPorte, et al., 2008). This D1 domain is 
required for IL-13 binding and the formation of a functional Type II receptor, while it is not 
required for IL-4 binding or its activation of the Type II receptor (Ito, et al., 2009). 
3.1.4 IL-13 receptor 2 (IL-132) 
IL-13 binds to a second IL-13 receptor, IL-13R2 (CD213a2, IL13BP) that was cloned in 
humans (Caput, et al., 1996) and from mice (Donaldson, et al., 1998). The gene is also found 
on the X-chromosome. IL-13R2 (~65 kDa) is inducibly expressed on fibroblasts, 
keratinocytes, epithelial cells, macrophages, and certain tumor cells and requires STAT6 for 
its expression (David, et al., 2003). The soluble form can be generated by proteolytic 
cleavage of the membrane-bound form by matrix metalloproteinases (MMPS) (Matsumura, 
et al., 2007) or by alternative splicing (Tabata, et al., 2006). Interestingly, sIL-13R2 is 
detected in serum from mice but not humans (Chen, et al., 2009). Treatment of cells with IL-
4 or IL-13 in combination with TNF- upregulated IL-13R2 cell surface expression (Zheng, 
et al., 2003). In contrast to IL-13R1, IL-13R2 binds to IL-13 with very high affinity 10-11 M 
(Andrews, et al., 2002) one of the highest measured protein-protein interactions, possibly 
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due to an interlocking IL-13-binding interface (Lupardus, et al., 2010). The IL-13R2 is 
proposed to act as a “decoy receptor” for IL-13 (Yoshikawa, et al., 2003) and, more recently, 
for IL-4 signaling (Rahaman, et al., 2002,). Consistent with this model, mice deficient in IL-
13R2 have exaggerated IL-13 responses, such as severe liver fibrosis following S. mansonii 
infection (Chiaramonte, et al., 2003, Mentink-Kane, et al., 2004), reversible by soluble IL-
13R2-Fc. A signaling role was hypothesized, however, in TNBS-induced colitis, tumor 
surveillance, and cancer (Strober, et al., 2009) and in monocytic cell lines through AP-1 
(Fichtner-Feigl, et al., 2006).  
3.2 Ligand binding properties 
IL-4 binds to the IL-4 receptor  chain with high affinity with a Kd ranging between 20 - 300 
pM (Lowenthal, et al., 1988), allowing ligand binding at low IL-4 concentrations, as would 
be present in the initiating phase of an allergic inflammatory response. There is species 
specificity for the IL-4:IL-4R interaction (Park, et al., 1987), yet dimerization of the binary 
IL-4:IL-4R complex with the C chain is not species specific (Idzerda, et al., 1990). 
Dimerization with the C chain forming Type I IL-4 receptors increases the affinity of IL-4 
binding approximately three-fold (Russell, et al., 1993). The affinity of interaction of the 
binary IL-4:IL-4R complex with either of its dimerization partners, C or IL-13R1, is low 
(559 nM for C with IL-4:IL-4R (Andrews, et al., 2006, LaPorte, et al., 2008, Zhang, et al., 
2002) and 487 nM for IL-13R1 (LaPorte, et al., 2008)). In contrast, IL-13 binding to IL-13R1 
is a relatively low affinity interaction (Kd ~ 30 nM (Andrews, et al., 2002, LaPorte, et al., 
2008)) that is not species-specific (Andrews, et al., 2001). Dimerization of IL-13:IL-13R1 
with IL-4R to form the ternary Type II complex is a high affinity, species-specific 
interaction (Andrews, et al., 2001, LaPorte, et al., 2008).  
The crystal structures of the three ternary complexes were solved in 2008 (LaPorte, et al., 
2008) revealing that the IL-4/IL-13 receptor system was unique in that when forming a Type 
II receptor the “binder” (i.e. ligand-binding) and “trigger” (i.e. dimerizing partner) chains 
were switched depending on whether IL-4 or IL-13 is the ligand. Furthermore, there was a ~ 
8° angle difference in the position of the IL-4R chain relative to the IL-13R1 chain between 
the two Type II structures. The impact of these subtle differences in initial binding affinities, 
order of chain assembly, and 3-dimensional structure of the extracellular domains of the 
ternary complexes on responsiveness to IL-4 and IL-13 is not clear. A recent study suggests 
that the relative abundance of the two receptor types and ratio of the ligand-binding chain 
to the trigger chain can fine-tune sensitivity to these cytokines (Junttila et al., 2008).  
3.3 Signal transduction pathways activated by Type I and Type II receptor 
engagement 
3.3.1 Janus kinases 
Ligand-induced dimerization of the Type I or Type II IL-4 receptor activates receptor-
associated kinases of the Janus kinase (JAK) family. JAK1 was activated by IL-4 and IL-13 
(Welham, et al., 1995). IL-13 did not induce JAK3 activation, as the IL-13R1 does not recruit 
JAK3 (Keegan, et al., 1995, Welham, et al., 1995). JAK2 appeared to be constitutively 
associated with the IL-4R chain in human monocytes and stimulation of the Type II 
receptor complex with IL-13 enhanced the interaction (Roy, et al., 2002). IL-13 
predominantly activates TYK2 (Murata & Puri, 1997), as well as JAK2 (Murata, et al., 1996). 
JAK1 is a substrate for other non-JAK kinases that can affect the activation of IL-4-induced 
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signaling. PKC is required for full IL-4-induced JAK1 activation (Martin, et al., 2005). 
Mutational studies on cytoplasmic domain of IL-4R have revealed the presence of a 
membrane-proximal, proline-rich “box 1” motif (aa262 – 267 for hIL-4R and 263 – 271 for 
mIL-4R) to which JAK1 can bind (Fujiwara, et al., 1997, Russell, et al., 1994). The 
cytoplasmic domain of the C also has a “box 1” motif :Pro-X-Pro and a preceding cluster of 
hydrophobic amino acids (aa286 – 294 that binds JAK3, Murakami, et al., 1991)).  
The proline-rich region in the IL-13R1 (aa 373 – 378 in mouse and aa 376 – 381 in human) 
and the next six amino acids downstream mediate the interaction between IL-13R1 and the 
associated JAKs (TYK2, JAK1 in a transfected FDCP-1 cell line (Orchansky, et al., 1999)). The 
cytoplasmic domain of the IL-13R1 chain is shorter than that of the IL-4Ror C. It 
contains the box 1 motif and two tyrosines, Y402 and Y405, which act as STAT3 binding 
motifs (Orchansky, et al., 1999, Umeshita-Suyama, et al., 2000). Engagement of the receptor 
chain by IL-13 activates JAK1 and TYK2 and triggers a variety of signaling cascades which 
will be discussed below. 
Tyrosine residues within the cytoplasmic domains of the Type I and Type II receptor subunits 
are targets for rapid phosphorylation by the JAKs (Figure 2). Both IL-4 and IL-13 induce 
tyrosine phosphorylation of IL-4R (Wang, et al., 1992). Tyrosine phosphorylation of IL-13R1 
was not detected in immunoprecipitated lysates from IL-13-stimulated FD-5 cells transfected 
with the IL-13R1 subunit (Orchansky, et al., 1999) although mutational studies suggested that 
IL-13R1 tyrosines would indeed become phosphorylated (Umeshita-Suyama, et al., 2000). 
Studies using deletion, Y-to-F mutants, and chimeric forms of the IL-4R (Deutsch, et al., 1995, 
Keegan, et al., 1994, Koettnitz & Kalthoff, 1993, Seldin & Leder, 1994) have characterized 
distinct regions of the IL-4R cytoplasmic domain containing five essential tyrosine residues 
(Y1-Y5). These phosphotyrosines become docking sites for SH2- and PTB-containing proteins: 
Y1 (Y497) recruits IRS proteins, Y2-Y4 (Y575, Y603, Y631) recruit STAT6 and Y5 (Y713) is 
bound by the phosphatases, SHP-1, -2 and SHIP (Hanson, et al., 2003, Kashiwada, et al, 2001). 
3.3.2 IRS proteins 
IL-4 strongly induced the tyrosine phosphorylation of a ~170 kDa protein in the mouse IL-3-
dependent hematopoietic cell line, FDCP-2 (Wang, et al., 1992), named IL-4-induced 
phosphotyrosine substrate (4PS) and it associated with PI3-K and PI3-K activity. This 
protein was identical to that tyrosine phosphorylated in response insulin and IGF-I in FDC 
cells (Wang, et al., 1993). 4PS was cloned from myeloid progenitor cells and renamed IRS-2 
due to similarity to IRS-1 (Sun, et al., 1995). IRS-1 is also tyrosine phosphorylated in 
response to IL-4 stimulation and whether IRS-1 or IRS-2 or both are tyrosine phosphorylated 
after IL-4 stimulation depends on cellular expression of each protein and the surface 
expression of Type I or II receptors (Sun, et al., 1997). IRS-2 is predominantly found in 
hematopoietic cells and IRS-1 in non-hematopoietic cells: studies in 32D cells, which express 
neither IRS protein, revealed the role of both IRS-1 and IRS-2 in IL-4-induced cellular 
proliferation (Wang, et al., 1993). 
The sequence of amino acids important for IRS binding to the IL-4 receptor was determined 
by truncation mutational analysis (between aa437 and 557). Within this interval, there is a 
homologous sequence that binds IRS proteins in the insulin and IGF-I receptor, known as 
the insulin and IL-4 receptor (I4R) motif, whose sequence is 488PL-(X)4-NPXYXSXSD502. The 
central tyrosine when phosphorylated is critical for association of the PTB domain of IRS 
proteins with the I4R motif of the IL-4R (Keegan, et al., 1994, Zhou, et al., 1996).  
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due to an interlocking IL-13-binding interface (Lupardus, et al., 2010). The IL-13R2 is 
proposed to act as a “decoy receptor” for IL-13 (Yoshikawa, et al., 2003) and, more recently, 
for IL-4 signaling (Rahaman, et al., 2002,). Consistent with this model, mice deficient in IL-
13R2 have exaggerated IL-13 responses, such as severe liver fibrosis following S. mansonii 
infection (Chiaramonte, et al., 2003, Mentink-Kane, et al., 2004), reversible by soluble IL-
13R2-Fc. A signaling role was hypothesized, however, in TNBS-induced colitis, tumor 
surveillance, and cancer (Strober, et al., 2009) and in monocytic cell lines through AP-1 
(Fichtner-Feigl, et al., 2006).  
3.2 Ligand binding properties 
IL-4 binds to the IL-4 receptor  chain with high affinity with a Kd ranging between 20 - 300 
pM (Lowenthal, et al., 1988), allowing ligand binding at low IL-4 concentrations, as would 
be present in the initiating phase of an allergic inflammatory response. There is species 
specificity for the IL-4:IL-4R interaction (Park, et al., 1987), yet dimerization of the binary 
IL-4:IL-4R complex with the C chain is not species specific (Idzerda, et al., 1990). 
Dimerization with the C chain forming Type I IL-4 receptors increases the affinity of IL-4 
binding approximately three-fold (Russell, et al., 1993). The affinity of interaction of the 
binary IL-4:IL-4R complex with either of its dimerization partners, C or IL-13R1, is low 
(559 nM for C with IL-4:IL-4R (Andrews, et al., 2006, LaPorte, et al., 2008, Zhang, et al., 
2002) and 487 nM for IL-13R1 (LaPorte, et al., 2008)). In contrast, IL-13 binding to IL-13R1 
is a relatively low affinity interaction (Kd ~ 30 nM (Andrews, et al., 2002, LaPorte, et al., 
2008)) that is not species-specific (Andrews, et al., 2001). Dimerization of IL-13:IL-13R1 
with IL-4R to form the ternary Type II complex is a high affinity, species-specific 
interaction (Andrews, et al., 2001, LaPorte, et al., 2008).  
The crystal structures of the three ternary complexes were solved in 2008 (LaPorte, et al., 
2008) revealing that the IL-4/IL-13 receptor system was unique in that when forming a Type 
II receptor the “binder” (i.e. ligand-binding) and “trigger” (i.e. dimerizing partner) chains 
were switched depending on whether IL-4 or IL-13 is the ligand. Furthermore, there was a ~ 
8° angle difference in the position of the IL-4R chain relative to the IL-13R1 chain between 
the two Type II structures. The impact of these subtle differences in initial binding affinities, 
order of chain assembly, and 3-dimensional structure of the extracellular domains of the 
ternary complexes on responsiveness to IL-4 and IL-13 is not clear. A recent study suggests 
that the relative abundance of the two receptor types and ratio of the ligand-binding chain 
to the trigger chain can fine-tune sensitivity to these cytokines (Junttila et al., 2008).  
3.3 Signal transduction pathways activated by Type I and Type II receptor 
engagement 
3.3.1 Janus kinases 
Ligand-induced dimerization of the Type I or Type II IL-4 receptor activates receptor-
associated kinases of the Janus kinase (JAK) family. JAK1 was activated by IL-4 and IL-13 
(Welham, et al., 1995). IL-13 did not induce JAK3 activation, as the IL-13R1 does not recruit 
JAK3 (Keegan, et al., 1995, Welham, et al., 1995). JAK2 appeared to be constitutively 
associated with the IL-4R chain in human monocytes and stimulation of the Type II 
receptor complex with IL-13 enhanced the interaction (Roy, et al., 2002). IL-13 
predominantly activates TYK2 (Murata & Puri, 1997), as well as JAK2 (Murata, et al., 1996). 
JAK1 is a substrate for other non-JAK kinases that can affect the activation of IL-4-induced 
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signaling. PKC is required for full IL-4-induced JAK1 activation (Martin, et al., 2005). 
Mutational studies on cytoplasmic domain of IL-4R have revealed the presence of a 
membrane-proximal, proline-rich “box 1” motif (aa262 – 267 for hIL-4R and 263 – 271 for 
mIL-4R) to which JAK1 can bind (Fujiwara, et al., 1997, Russell, et al., 1994). The 
cytoplasmic domain of the C also has a “box 1” motif :Pro-X-Pro and a preceding cluster of 
hydrophobic amino acids (aa286 – 294 that binds JAK3, Murakami, et al., 1991)).  
The proline-rich region in the IL-13R1 (aa 373 – 378 in mouse and aa 376 – 381 in human) 
and the next six amino acids downstream mediate the interaction between IL-13R1 and the 
associated JAKs (TYK2, JAK1 in a transfected FDCP-1 cell line (Orchansky, et al., 1999)). The 
cytoplasmic domain of the IL-13R1 chain is shorter than that of the IL-4Ror C. It 
contains the box 1 motif and two tyrosines, Y402 and Y405, which act as STAT3 binding 
motifs (Orchansky, et al., 1999, Umeshita-Suyama, et al., 2000). Engagement of the receptor 
chain by IL-13 activates JAK1 and TYK2 and triggers a variety of signaling cascades which 
will be discussed below. 
Tyrosine residues within the cytoplasmic domains of the Type I and Type II receptor subunits 
are targets for rapid phosphorylation by the JAKs (Figure 2). Both IL-4 and IL-13 induce 
tyrosine phosphorylation of IL-4R (Wang, et al., 1992). Tyrosine phosphorylation of IL-13R1 
was not detected in immunoprecipitated lysates from IL-13-stimulated FD-5 cells transfected 
with the IL-13R1 subunit (Orchansky, et al., 1999) although mutational studies suggested that 
IL-13R1 tyrosines would indeed become phosphorylated (Umeshita-Suyama, et al., 2000). 
Studies using deletion, Y-to-F mutants, and chimeric forms of the IL-4R (Deutsch, et al., 1995, 
Keegan, et al., 1994, Koettnitz & Kalthoff, 1993, Seldin & Leder, 1994) have characterized 
distinct regions of the IL-4R cytoplasmic domain containing five essential tyrosine residues 
(Y1-Y5). These phosphotyrosines become docking sites for SH2- and PTB-containing proteins: 
Y1 (Y497) recruits IRS proteins, Y2-Y4 (Y575, Y603, Y631) recruit STAT6 and Y5 (Y713) is 
bound by the phosphatases, SHP-1, -2 and SHIP (Hanson, et al., 2003, Kashiwada, et al, 2001). 
3.3.2 IRS proteins 
IL-4 strongly induced the tyrosine phosphorylation of a ~170 kDa protein in the mouse IL-3-
dependent hematopoietic cell line, FDCP-2 (Wang, et al., 1992), named IL-4-induced 
phosphotyrosine substrate (4PS) and it associated with PI3-K and PI3-K activity. This 
protein was identical to that tyrosine phosphorylated in response insulin and IGF-I in FDC 
cells (Wang, et al., 1993). 4PS was cloned from myeloid progenitor cells and renamed IRS-2 
due to similarity to IRS-1 (Sun, et al., 1995). IRS-1 is also tyrosine phosphorylated in 
response to IL-4 stimulation and whether IRS-1 or IRS-2 or both are tyrosine phosphorylated 
after IL-4 stimulation depends on cellular expression of each protein and the surface 
expression of Type I or II receptors (Sun, et al., 1997). IRS-2 is predominantly found in 
hematopoietic cells and IRS-1 in non-hematopoietic cells: studies in 32D cells, which express 
neither IRS protein, revealed the role of both IRS-1 and IRS-2 in IL-4-induced cellular 
proliferation (Wang, et al., 1993). 
The sequence of amino acids important for IRS binding to the IL-4 receptor was determined 
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Fig. 2. Signaling by the Type I and Type II receptors. The signaling pathways activated by 
the Type I and Type II receptor complexes are shown in cartoon form. The font size is an 
indication of the relative strength of activation of IRS-2, STAT6, and SHP1 by the IL-4 or IL-13 
receptor complexes. Differences in signaling by the receptor complexes are highlighted. A. 
Type I Receptor. IL-4 (yellow), IL-4R (blue) and c (red). IL-4R binds JAK1 (pink) while c 
binds JAK3 (rust). c associates with Nedd4. B. Type II Receptor bound to IL-4. IL-4 
(yellow), IL-4R (blue), and IL-13R1 (green). The D1 domain of IL-13R1 is shown. IL-
13R1 binds to TYK2 (green). IL-13R1 recruits STAT3 (orange). C. Type II Receptor bound 
to IL-13. IL-13 (orange), IL-13R1 (green), IL-4R (blue). The relative ability of these 
receptor complexes to activate Shc or the MAP kinase pathways is unclear.  
The IRS proteins are tyrosine phosphorylated in response to engagement of the IL-4 
receptors. JAK1 is required for this to occur (Wang, et al., 1997). Once phosphorylated, 
tyrosines that are part of typical SH2-binding motifs (Sun, et al., 1991) provide docking sites 
for a variety of different SH2-domain-containing downstream molecules, such as the p85 
subunit of PI3-K and Grb2 (Pruett, et al., 1995). There are three tyrosines, part of classical 
YXXM motifs, that act as p85 binding sites in IRS-1 and two in IRS-2 (White, 2002). Binding 
of p85 can activate PI3-K thus allowing IL-4 to initiate a large number of downstream 
signaling cascades. The IRS proteins can also bind SHP-2 following IL-4 stimulation and 
IRS-2 can recruit PLC- in response to IL-13 (Sozzani, et al., 1998). The IRS proteins also 
interact with the SOCS proteins that are negative regulators of IL-4 signaling and will be 
discussed in more detail in a later section.  
The contribution of IRS-2 to allergy and asthma is not well understood. Transgenic 
overexpression of IRS-2 enhanced IgE production in vivo, and increased IL-5 secretion from 
in vitro differentiated CD4+ Th2 cells (Kelly-Welch, et al., 2004). Early studies of T-cells 
isolated from IRS2-/- mice found reduced T-cell proliferation and IL-5 production by Th2 
cells compared to wildtype T-cells (Wurster, et al., 2002). Surprisingly, mice with a mutation 
in the IRS-2 docking site of the IL-4R (Y500F) demonstrated enhanced allergic 
inflammation, suggesting a significant contribution of this region of the IL-4R to 
inflammation control in vivo (Blaeser, et al., 2003). Activation of the IRS-2 pathway was 
abrogated but this Y500 region of the IL-4R also recruits a number of other signaling 
molecules including Shc, FRIP1, p62DOK, and p85 (Nelms, et al., 1998) that may negatively 
regulate the pathway (described below). 
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3.3.3 Activation of PI3-K 
The p85 or regulatory subunit of PI3-K binds phosphotyrosines on the IRS protein via SH2-
domains and the resulting conformational change releases inhibition of the enzymatic 
activity of the p110 (catalytic) subunit and allows it to translocate to the plasma membrane. 
Activation of PI3K activity in response to IL-4 was first demonstrated in hematopoietic 
FDCP cells inducing mitogenic signals (Wang, et al., 1992). The kinase transfers a phosphate 
group from ATP to phosphoinositol (PI) to rapidly form PIP3, activating a myriad of 
downstream pathways. PIP3 has the potential to activate protein kinase C (PKC) and 
protein kinase B (PKB)/Akt. Activation of Akt in response to IL-4 has been shown in human 
eosinophils (Coffer, et al., 1998), although we found no induction of phosphorylation on 
AktSer473 in mouse eosinophils by IL-4 or IL-13 (Heller et al, under review).  
3.3.4 Signal Transducers and Activators of Transcription (STATs) 
IL-4 receptor engagement can activate a number of members of the STAT family. STAT6 is 
the predominantly activated STAT but other members of the STAT family can also be 
activated to a lesser degree. The human STAT6 gene was cloned in 1994 and the same group 
determined that STAT6 (IL-4 Stat) directly interacted with the IL-4 receptor cytoplasmic 
domain, homodimerized via its SH2-domain and characterized the DNA binding motif 
recognized by STAT6 (Hou, et al., 1994). STAT6 docks via its highly conserved SH2-domain 
to the “gene regulation domain” (aa 557 – 657) encompassing three of the five conserved 
tyrosines of human IL-4R (Ryan, et al., 1996). STAT6 becomes tyrosine phosphorylated on 
Y641 and forms homodimers through pY641-SH2 interactions (Mikita et al., 1996). The C-
terminus of STAT6 contains the transcriptional activation domain (Goenka, et al., 1999). In 
addition to tyrosine phosphorylation, the STAT6 protein can be post-translationally 
modified in other ways to affect its function: methylation (Chen, et al., 2003), serine 
phosphorylation (Pesu, et al., 2000) on S756 (Wang, et al., 2004) and S707 (Shirakawa, et al., 
2011) and acetylation (Shankaranarayanan, et al., 2001). 
Once in the nucleus, STAT6 homodimers bind to consensus DNA motifs in STAT6-
responsive genes (reviewed in Goenka & Kaplan, 2011). The preferred DNA binding motif 
recognized by STAT6 is a dyad symmetric recognition element TTC-GAA separated by four 
nucleotides although STAT6 can also bind the dyad element separated by three nucleotides. 
STAT6 often co-operates with other transcription factors and co-activators to activate 
transcription including NK-B, CEBP CBP and p300 and p160 steroid receptor nuclear 
coactivator (NCoA-1).  
STAT6 deficiency (Takeda, et al., 1996) is protective in many different in vivo models of 
allergy including allergic airway disease, food allergy, eosinophilic esophagitis and atopic 
dermatitis. In contrast, mice expressing constitutively active STAT6 are predisposed to an 
allergic phenotype (Sehra, et al., 2008, Sehra, et al., 2010). Hyperactive STAT6 can lead to 
cellular transformation and various cancers, due to dysregulated p27Kip/cell cycle 
progression (Bruns, et al., 2003). Mice deficient in STAT6 have compromised expulsion of 
helminth parasites: they cannot produce Th2-cells, mount an effective IgE response, produce 
mucus or chemokines (Kaplan, et al., 1998).  
While STAT6 is clearly the dominant STAT family member activated by IL-4 and IL-13, 
there are reports of activation of several other STATs to varying degrees. Some STAT1a 
activation was documented in the mouse T-helper cell line, HT-2, in response to IL-4 (Brunn, 
et al., 1995) and by IL-4 and IL-13 in five primary human cell types generally to a lesser 
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3.3.3 Activation of PI3-K 
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degree than STAT6 (Wang, et al., 2004). Primary human monocytes respond to IL-13 with 
tyrosine phosphorylation of STAT1a (Roy, et al., 2002). Furthermore, STAT5 
phosphorylation was detected in human B-cells in response to IL-4 and IL-13 (Rolling, et al., 
1996) and in primary human monocytes by IL-13 (Roy, et al., 2002). The role of STAT1 and 
STAT5 in IL-4- or IL-13-induced responses is unknown. 
The cytoplasmic domain of IL-13R1 contains two STAT3 binding motifs (Y402 andY405, 
(Orchansky, et al., 1999)). STAT3 activation by IL-4 and IL-13 is dependent upon expression of 
the IL-13R1 (Orchansky, et al., 1999) and occurs in response to IL-4 and IL-13 in human B-
cells (Rolling, et al., 1996) and weakly in HMVEC-L and NHLF cells (Wang, et al., 2004). 
STAT3 phosphorylation was induced by IL-13 in primary human monocytes (Roy, et al., 2002) 
and by IL-4 in keratinocytes (Wery-Zennaro, et al., 1999). We have observed the relatively 
weak induction of STAT3 phosphorylation by IL-4 and IL-13 in murine bone-marrow-derived 
macrophages and the human lung adenocarcinoma cell line A549 (LaPorte, et al., 2008). The 
specific function of STAT3 in mediating responses to IL-4 and IL-13 is unclear. A recent report 
demonstrated that STAT3 played a role in Th2 differentiation, however the cytokines 
responsible for STAT3 activation in that setting were thought to be IL-6 or IL-21 (Stritesky, et 
al., 2011). 
3.3.5 Other pathways activated by IL-4R (Ras/MAPK, Shc, Dok) 
Activation of the Ras/MAPK pathway is not generally observed in response to IL-4 despite 
IRS activation leading to interaction with the adapter molecule, Grb2 (Pruett, et al., 1995, 
Wang, et al., 1995). Since Grb2 is constitutively associated with the guanine nucleotide 
exchange protein, SOS, that catalyzes exchange of GDP bound to Ras for GTP, it is often 
assumed that IL-4 will trigger the phosphorylation cascade of Raf/MEK/ERK-1/-2. 
However, IL-4 does not activate p21ras (Duronio, et al., 1992, Satoh, et al., 1991, Welham, et 
al., 1994), Raf1 or ERK1/2 (Welham, et al., 1992, Welham, et al., 1994). We too have been 
unable to detect ERK-1/2 activation in response to IL-4 or IL-13 in primary mouse bone 
marrow-derived macrophages (Heller, et al., 2008) or peripheral blood eosinophils. 
Activation of the Ras/MAPK pathway was demonstrated to enhance IL-4 signaling, 
possibly through MEK phosphorylation of JAK1 and STAT6 (Yamashita, et al., 1999).  
Activation of Shc can be linked to Ras activation, via the Grb2 adapter-Sos interaction. There 
are three widely-expressed Shc proteins (~46, 52 and 66 kDa) containing a C-terminal SH2 
domain, regions homologous to the a1 chain of collagen (Pelicci, et al., 1992) and an N-
terminal PTB domain, similar in structure to IRS protein PTB domain (Zhou, et al., 1996). 
Shc moves to the plasma membrane and docks to the phosphorylated I4R motifs on 
activated IL-4 receptors via its SH2 and PTB domains (Wolf, et al., 1995). Phospho-Shc is 
then bound by the SH2/3 motifs of the Grb2 adaptor and bound Sos is activated. Shc 
activation in response to IL-4 appears to be dependent on cell type (Crowley, et al., 1996, 
Wery, et al., 1996, Welham, et al., 1994). 
Two hematopoietically-expressed members of the Dok proteins play a role in IL-4R-induced 
responses. The N-terminal PH and PTB domains of the Dok proteins suggest that they could 
bind phosphotyrosines in membrane-localized receptors (Mashima, et al., 2009). Indeed, 
Dok-2 (also known as FRIP, Dok-R or p56dok) has been shown to interact with the I4R motif 
of the IL-4R (Nelms, et al., 1998). T-cells from Dok-2-deficient mice (the hairless allele, 
hr/hr) have an increased proliferative response to IL-2 and IL-4 (Nelms, et al., 1998). Studies 
of Dok-1 (p62dok)-deficient cells suggest this protein plays a positive role in sustaining IL-4 
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signaling responses (IL-4-induced T-cell proliferation and CD23 expression and IgE class 
switching in B-cells (Inoue, et al., 2007)). The Dok proteins have multiple docking sites for 
SH2-containing proteins in their C-terminus and thus act as adaptor proteins. Because both 
Dok proteins bind RasGAP, which inactivates Ras by hydrolysis of GTP, it is thought that 
they might be negative regulators of the Ras/MAPK pathway. Recruitment of the Dok 
proteins to the IL-4R may explain the lack of Ras activation by IL-4 in some cell types. 
3.4 Negative regulation of receptor signaling 
3.4.1 SHP-1 and SHP-2 
Protein tyrosine phosphatases (PTP) that remove phosphate groups from phosphotyrosine 
residues that are activating signals can downregulate the signaling cascades initiated by IL-
4. SHP-1 and SHP-2 are PTP molecules containing two N-terminal SH2-domains, a single 
central phophatase domain and C-termini with two potential tyrosine phosphorylation sites 
that affect activity. The SH2-domain targets the phosphatase to a particular cellular location 
and binds to and inhibits the catalytic domain when the phosphatase is not bound to 
substrate. The expression of SHP-1 is restricted to hematopoietic cells (Yi, et al., 1992) and 
low expression is also found in epithelial cells. SHP-2, on the other hand, is widely 
expressed including in cells that express SHP-1.  
SHP-1 may positively (White, et al., 2001) or negatively (Imani, et al., 1997) regulate IL-4 
responses , depending upon the cell type (Huang, et al., 2005). Interestingly, SHP-1 
constitutively associates with the IL-4R chain even in resting lymphocytes(Huang & 
Paul, 2000). Subsequent studies have indicated that SHP-1 also negatively regulates 
signaling responses to IL-13 by downregulating the phosphorylation of STAT6 (Haque, et 
al., 1998). 
SHP SH2-domains bind to ITIM sequences [I/V/L]xY(p)xx[I/V/L] in activated receptors 
(Ravetch & Lanier, 2000). The cytoplasmic domain of the IL-4R possesses a putative ITIM 
surrounding the fifth tyrosine, Y713 (Figure 2) and a variety of studies have indicated this 
motif may interact with SHP-1, SHP-2, Shc and SHIP (Kashiwada, et al., 2001,Hershey, et al., 
1997, Kruse, et al., 2002). Our group showed that Y713 in human IL-4R mediated 
recruitment of SHP-1 (Hanson, et al., 2003) and SHIP (Zamorano & Keegan, 1998) to the IL-4 
receptor complex. Knock-in of a Y713F mutant of IL-4R in mice resulted in enhanced 
STAT6 phosphorylation, IgE production, and allergic lung inflammation (Tachdjian, et al., 
2010). Loss of Y713 had a more dramatic effect on the magnitude of responses to IL-13 vs. IL-
4. Taken together these results suggest that IL-4 and IL-13 signaling is modulated by SHP1 
or other phosphatases capable of binding to Y713, and that this modulation may be more 
profound for the Type II receptor complex (Figure 2).  
While tyrosine phosphorylation of SHP-1 increases its phosphatase activity, tyrosine 
phosphorylation of SHP-2 has been proposed to allow this molecule to function as an 
adaptor protein by providing docking sites for other SH2-domain-containing proteins 
(Lorenz, 2009). Conflicting data describe that SHP-2 was (Kruse, et al., 2002, Wang, et al., 
1999) or was not (Gadina, et al., 1999) tyrosine phosphorylated in response to IL-4 
stimulation. IL-13 stimulation of PBMC also induced tyrosine phosphorylation of SHP-2 
(Kruse, et al., 2002). SHP-2 interacts with IRS-1 (Xiao, et al., 2002), JAK1, JAK3 and 
coprecipitates with Grb-2 and p85 after cytokine stimulation (Gadina, et al., 1998, Kuhne, et 
al., 1993). Peptides derived from the IL-4R (aa 545–558) were able to pull down SHP-2 from 
lysates of IL-13-stimulated PBMC (Kruse, et al., 2002).  
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activation in response to IL-4 appears to be dependent on cell type (Crowley, et al., 1996, 
Wery, et al., 1996, Welham, et al., 1994). 
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signaling responses (IL-4-induced T-cell proliferation and CD23 expression and IgE class 
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proteins to the IL-4R may explain the lack of Ras activation by IL-4 in some cell types. 
3.4 Negative regulation of receptor signaling 
3.4.1 SHP-1 and SHP-2 
Protein tyrosine phosphatases (PTP) that remove phosphate groups from phosphotyrosine 
residues that are activating signals can downregulate the signaling cascades initiated by IL-
4. SHP-1 and SHP-2 are PTP molecules containing two N-terminal SH2-domains, a single 
central phophatase domain and C-termini with two potential tyrosine phosphorylation sites 
that affect activity. The SH2-domain targets the phosphatase to a particular cellular location 
and binds to and inhibits the catalytic domain when the phosphatase is not bound to 
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surrounding the fifth tyrosine, Y713 (Figure 2) and a variety of studies have indicated this 
motif may interact with SHP-1, SHP-2, Shc and SHIP (Kashiwada, et al., 2001,Hershey, et al., 
1997, Kruse, et al., 2002). Our group showed that Y713 in human IL-4R mediated 
recruitment of SHP-1 (Hanson, et al., 2003) and SHIP (Zamorano & Keegan, 1998) to the IL-4 
receptor complex. Knock-in of a Y713F mutant of IL-4R in mice resulted in enhanced 
STAT6 phosphorylation, IgE production, and allergic lung inflammation (Tachdjian, et al., 
2010). Loss of Y713 had a more dramatic effect on the magnitude of responses to IL-13 vs. IL-
4. Taken together these results suggest that IL-4 and IL-13 signaling is modulated by SHP1 
or other phosphatases capable of binding to Y713, and that this modulation may be more 
profound for the Type II receptor complex (Figure 2).  
While tyrosine phosphorylation of SHP-1 increases its phosphatase activity, tyrosine 
phosphorylation of SHP-2 has been proposed to allow this molecule to function as an 
adaptor protein by providing docking sites for other SH2-domain-containing proteins 
(Lorenz, 2009). Conflicting data describe that SHP-2 was (Kruse, et al., 2002, Wang, et al., 
1999) or was not (Gadina, et al., 1999) tyrosine phosphorylated in response to IL-4 
stimulation. IL-13 stimulation of PBMC also induced tyrosine phosphorylation of SHP-2 
(Kruse, et al., 2002). SHP-2 interacts with IRS-1 (Xiao, et al., 2002), JAK1, JAK3 and 
coprecipitates with Grb-2 and p85 after cytokine stimulation (Gadina, et al., 1998, Kuhne, et 
al., 1993). Peptides derived from the IL-4R (aa 545–558) were able to pull down SHP-2 from 
lysates of IL-13-stimulated PBMC (Kruse, et al., 2002).  
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Hematopoietically-expressed SH2-domain-containing inositol 5'-phosphatase (SHIP) 
dephosphorylates PIP3, the product of the PI3-K enzyme, to form PIP2. IL-4 stimulation can 
induce tyrosine phosphorylation of SHIP, suggesting that SHIP can dock to multiple sites in 
the IL-4R(Zamorano & Keegan, 1998). SHIP-1-deficient mice spontaneously developed 
allergic lung inflammation, have increased mast cells that spontaneously released histamine 
indicating a potential homeostatic role for SHIP-1 in regulating Th2-responses in vivo (Oh, et 
al., 2007).  Recent exciting data have defined a role for SHIP-1 in the skewing of macrophage 
phenotype (Rauh, et al., 2005).  
3.4.2 Suppressors of Cytokine Signaling (SOCS) 
The suppressor of cytokine signaling (SOCS) proteins are a family of cytokine-induced 
negative regulators of cytokine signaling (Starr, et al., 1997, Yoshimura, et al., 2003). The 
general structure of the SOCS protein includes a central SH2-domain, critical for binding to 
their tyrosine phosphorylated substrates, and a C-terminal SOCS box that mediates 
ubiquitin-dependent proteolysis. SOCS-1), -3 and CIS are induced by IL-4 and SOCS-1 and -
3 were shown to inhibit IL-4 signaling transduction (Haque, et al., 2000, Losman, et al., 
1999). SOCS-1 and SOCS-3, both of which are induced by IL-4, have an additional kinase 
inhibitory region that functions as a pseudosubstrate to inhibit JAK activity (Yasukawa, et 
al., 1999). Another mechanism of action is by SOCS interaction with the phosphorylated 
tyrosines within the cytoplasmic domains of the receptor. SOCS-3 directly interacted with 
IL-4 (O'Connor, et al., 2007). SOCS proteins can also target activated signaling 
intermediates to the proteasome. SOCS-1 is able to regulate the half-life of JAKs and 
insulin/IGF-I-induced IRS-2 (Rui, et al., 2001) in this manner.  
4. Differential roles for IL-4 and IL-13 acting via the Type I or Type II receptors 
on features of allergic lung inflammation 
Recent evidence suggests that even though IL-4 and IL-13 share receptor components and 
signaling proteins, and elicit overlapping responses in vitro, they can elicit different 
functional responses in vivo. IL-4 is primarily responsible for regulating Th2 development 
and inflammation while IL-13 is responsible for effector activities such as airway 
hypersensitivity, collagen production, and mucus hypersecretion (Gavett, et al., 1994, Pernis 
& Rothman, 2002, Wills-Karp, et al., 1998). The molecular basis for this variation is not 
understood clearly, since both IL-4 and IL-13 use the Type II receptor complex. It has been 
postulated that differences in the relative abundance of the Type I or Type II receptor 
subunits in different cell types may be responsible for the differences in responses elicited 
by IL-4 versus IL-13. Certainly the presence or absence of individual receptor subunits and 
appropriate Janus kinases in each cell determines whether a cell can respond to IL-4 or IL-
13. However, many of the cell types involved in the effector activities express the Type II 
receptor that is activated by both IL-4 and IL-13. 
4.1 Different receptor signaling pathways utilized by IL-4 and IL-13 via the Type I and 
Type II receptors  
One reason proposed for differential functions of these cytokines is the observed differences 
in the amounts of IL-4 and IL-13 produced in tissues during Type II inflammation. Various 
reports have shown that IL-13 is secreted by large number of cell types and in much greater 
quantities than IL-4 during Th2 responses in both asthma patients (Huang, et al., 1995) as 
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well as mouse models of this disease (Munitz, et al., 2008). However, analysis of the binding 
affinities of the Type I and Type II receptors with their respective ligands have shown that 
the relative amounts of each cytokine does not necessarily explain the functional differences 
between IL-4 and IL-13.  
As discussed above, LaPorte and colleagues have shown that although IL-4 binding to the 
IL-4Rchain occurs with high affinity, complex formation of IL-4: IL-4R with γC or IL-
13R1 is quite unstable and inefficient (LaPorte, et al., 2008). On the other hand, IL-13 binds 
to IL-13R1 with low affinity, but the interaction of IL-13: IL-13R1 with IL-4R is more 
favorable and stable. As a result even at very low concentrations, IL-4 is able to mediate 
efficient and rapid STAT6 phosphorylation via Type I and Type II receptors, while cells 
have to be stimulated with much higher concentrations of IL-13 and for a longer time to 
obtain similar responses via the Type II receptor. Since the IL-4 bound complexes are less 
stable, LaPorte et. al. proposed that when expression of receptor chains in cells become 
limiting, IL-4 responses would be limited, while IL-13 responses would take over.  
However, experiments using transgenic overexpression of large quantities of IL-4 or IL-13 
still showed differences in the pathophysiology elicted by these two cytokines (Rankin, et 
al., 1996, Zhu, et al., 1999). These results suggest that there are real signaling differences 
between IL-4 and IL-13. To analyze potential signaling differences, we undertook a careful, 
side-by-side comparison of primary cells and cell lines that expressed either both Type I and 
II receptors or Type II receptors only. IL-4 stimulated tyrosine phosphorylation of STAT6 in 
the human airway epithelial cell line, A549, and the human B-cell line, Ramos, at 
significantly lower doses than IL-13. We demonstrated that IL-4 signaling through the Type 
I receptor induced robust tyrosine phosphorylation of the downstream adaptor protein IRS-
2 and greater expression of the mRNAs for a subset of alternatively activated macrophage 
genes in primary mouse bone marrow-derived macrophages (BMM) (Heller, et al., 2008). 
This was in contrast to IL-4/IL-13 signaling through the Type II receptor which resulted in 
weaker tyrosine phosphorylation of IRS-2 and less mRNA for the AAM genes studied. This 
marked difference in IRS-2 phosphorylation and AAM gene expression induced by IL-4 was 
dependent upon expression of the C subunit.  
4.2 Differential functions of IL-4 and IL-13 in allergic lung inflammation  
In both humans and mice, IL-4 and IL-13 signaling through the Type I and Type II receptors 
play a critical role in inducing asthma. The hallmark features of this disease include 
excessive pulmonary inflammation, periodic narrowing of airways, airway 
hyperesponsiveness (AHR) and enhanced mucus secretion. IL-4 and IL-13 have differential 
roles in asthma pathogenesis. Studies using IL-4R-/- and STAT6-/- mice in our lab and by 
other investigators have suggested that many of the asthma symptoms mentioned above are 
regulated by IL-4R and STAT6 (Cohn, et al., 1997, Corry, et al., 1998, Grunig, et al., 1998, 
Kelly-Welch, et al., 2004, Kuperman, et al., 1998, Mathew, et al., 2001, Wills-Karp, et al., 
1998). However, since IL-4/IL-13 binding to either the Type I or Type II receptor activates 
STAT6, the contributions of these individual pathways in inducing the pathophysiology 
associated with this disease was unclear, until recently.  
It is known that IL-4 is predominantly required for Th2 cell differentiation and proliferation 
(Kaplan, et al., 1996). Since most naive T cells lack the Type II receptor, they are 
unresponsive to IL-13. IL-4 signaling through the Type I IL-4R/STAT6 axis upregulates 
GATA3, the Th2 master transcription factor (reviewed in (Zhu & Paul, 2008)). STAT6-
deficient T cells cannot differentiate into Th2 cells in vitro (Kaplan, et al., 1996). Recent 
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Hematopoietically-expressed SH2-domain-containing inositol 5'-phosphatase (SHIP) 
dephosphorylates PIP3, the product of the PI3-K enzyme, to form PIP2. IL-4 stimulation can 
induce tyrosine phosphorylation of SHIP, suggesting that SHIP can dock to multiple sites in 
the IL-4R(Zamorano & Keegan, 1998). SHIP-1-deficient mice spontaneously developed 
allergic lung inflammation, have increased mast cells that spontaneously released histamine 
indicating a potential homeostatic role for SHIP-1 in regulating Th2-responses in vivo (Oh, et 
al., 2007).  Recent exciting data have defined a role for SHIP-1 in the skewing of macrophage 
phenotype (Rauh, et al., 2005).  
3.4.2 Suppressors of Cytokine Signaling (SOCS) 
The suppressor of cytokine signaling (SOCS) proteins are a family of cytokine-induced 
negative regulators of cytokine signaling (Starr, et al., 1997, Yoshimura, et al., 2003). The 
general structure of the SOCS protein includes a central SH2-domain, critical for binding to 
their tyrosine phosphorylated substrates, and a C-terminal SOCS box that mediates 
ubiquitin-dependent proteolysis. SOCS-1), -3 and CIS are induced by IL-4 and SOCS-1 and -
3 were shown to inhibit IL-4 signaling transduction (Haque, et al., 2000, Losman, et al., 
1999). SOCS-1 and SOCS-3, both of which are induced by IL-4, have an additional kinase 
inhibitory region that functions as a pseudosubstrate to inhibit JAK activity (Yasukawa, et 
al., 1999). Another mechanism of action is by SOCS interaction with the phosphorylated 
tyrosines within the cytoplasmic domains of the receptor. SOCS-3 directly interacted with 
IL-4 (O'Connor, et al., 2007). SOCS proteins can also target activated signaling 
intermediates to the proteasome. SOCS-1 is able to regulate the half-life of JAKs and 
insulin/IGF-I-induced IRS-2 (Rui, et al., 2001) in this manner.  
4. Differential roles for IL-4 and IL-13 acting via the Type I or Type II receptors 
on features of allergic lung inflammation 
Recent evidence suggests that even though IL-4 and IL-13 share receptor components and 
signaling proteins, and elicit overlapping responses in vitro, they can elicit different 
functional responses in vivo. IL-4 is primarily responsible for regulating Th2 development 
and inflammation while IL-13 is responsible for effector activities such as airway 
hypersensitivity, collagen production, and mucus hypersecretion (Gavett, et al., 1994, Pernis 
& Rothman, 2002, Wills-Karp, et al., 1998). The molecular basis for this variation is not 
understood clearly, since both IL-4 and IL-13 use the Type II receptor complex. It has been 
postulated that differences in the relative abundance of the Type I or Type II receptor 
subunits in different cell types may be responsible for the differences in responses elicited 
by IL-4 versus IL-13. Certainly the presence or absence of individual receptor subunits and 
appropriate Janus kinases in each cell determines whether a cell can respond to IL-4 or IL-
13. However, many of the cell types involved in the effector activities express the Type II 
receptor that is activated by both IL-4 and IL-13. 
4.1 Different receptor signaling pathways utilized by IL-4 and IL-13 via the Type I and 
Type II receptors  
One reason proposed for differential functions of these cytokines is the observed differences 
in the amounts of IL-4 and IL-13 produced in tissues during Type II inflammation. Various 
reports have shown that IL-13 is secreted by large number of cell types and in much greater 
quantities than IL-4 during Th2 responses in both asthma patients (Huang, et al., 1995) as 
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well as mouse models of this disease (Munitz, et al., 2008). However, analysis of the binding 
affinities of the Type I and Type II receptors with their respective ligands have shown that 
the relative amounts of each cytokine does not necessarily explain the functional differences 
between IL-4 and IL-13.  
As discussed above, LaPorte and colleagues have shown that although IL-4 binding to the 
IL-4Rchain occurs with high affinity, complex formation of IL-4: IL-4R with γC or IL-
13R1 is quite unstable and inefficient (LaPorte, et al., 2008). On the other hand, IL-13 binds 
to IL-13R1 with low affinity, but the interaction of IL-13: IL-13R1 with IL-4R is more 
favorable and stable. As a result even at very low concentrations, IL-4 is able to mediate 
efficient and rapid STAT6 phosphorylation via Type I and Type II receptors, while cells 
have to be stimulated with much higher concentrations of IL-13 and for a longer time to 
obtain similar responses via the Type II receptor. Since the IL-4 bound complexes are less 
stable, LaPorte et. al. proposed that when expression of receptor chains in cells become 
limiting, IL-4 responses would be limited, while IL-13 responses would take over.  
However, experiments using transgenic overexpression of large quantities of IL-4 or IL-13 
still showed differences in the pathophysiology elicted by these two cytokines (Rankin, et 
al., 1996, Zhu, et al., 1999). These results suggest that there are real signaling differences 
between IL-4 and IL-13. To analyze potential signaling differences, we undertook a careful, 
side-by-side comparison of primary cells and cell lines that expressed either both Type I and 
II receptors or Type II receptors only. IL-4 stimulated tyrosine phosphorylation of STAT6 in 
the human airway epithelial cell line, A549, and the human B-cell line, Ramos, at 
significantly lower doses than IL-13. We demonstrated that IL-4 signaling through the Type 
I receptor induced robust tyrosine phosphorylation of the downstream adaptor protein IRS-
2 and greater expression of the mRNAs for a subset of alternatively activated macrophage 
genes in primary mouse bone marrow-derived macrophages (BMM) (Heller, et al., 2008). 
This was in contrast to IL-4/IL-13 signaling through the Type II receptor which resulted in 
weaker tyrosine phosphorylation of IRS-2 and less mRNA for the AAM genes studied. This 
marked difference in IRS-2 phosphorylation and AAM gene expression induced by IL-4 was 
dependent upon expression of the C subunit.  
4.2 Differential functions of IL-4 and IL-13 in allergic lung inflammation  
In both humans and mice, IL-4 and IL-13 signaling through the Type I and Type II receptors 
play a critical role in inducing asthma. The hallmark features of this disease include 
excessive pulmonary inflammation, periodic narrowing of airways, airway 
hyperesponsiveness (AHR) and enhanced mucus secretion. IL-4 and IL-13 have differential 
roles in asthma pathogenesis. Studies using IL-4R-/- and STAT6-/- mice in our lab and by 
other investigators have suggested that many of the asthma symptoms mentioned above are 
regulated by IL-4R and STAT6 (Cohn, et al., 1997, Corry, et al., 1998, Grunig, et al., 1998, 
Kelly-Welch, et al., 2004, Kuperman, et al., 1998, Mathew, et al., 2001, Wills-Karp, et al., 
1998). However, since IL-4/IL-13 binding to either the Type I or Type II receptor activates 
STAT6, the contributions of these individual pathways in inducing the pathophysiology 
associated with this disease was unclear, until recently.  
It is known that IL-4 is predominantly required for Th2 cell differentiation and proliferation 
(Kaplan, et al., 1996). Since most naive T cells lack the Type II receptor, they are 
unresponsive to IL-13. IL-4 signaling through the Type I IL-4R/STAT6 axis upregulates 
GATA3, the Th2 master transcription factor (reviewed in (Zhu & Paul, 2008)). STAT6-
deficient T cells cannot differentiate into Th2 cells in vitro (Kaplan, et al., 1996). Recent 
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studies have shown that STAT6 is not required for in vivo differentiation, although it is 
required for stabilization of Th2 cells and generating memory responses (reviewed in 
(Chapoval, et al., 2010)). Activated Th2 cells then secrete large quantities of IL-4, IL-5 and IL-
13 which can act on many different cell types. IL-4 induces expression of MHC Class II in 
resting B cells and also causes antibody class switching from IgM to IgE and IgG1 (reviewed 
in Nelms, et al., 1999). Treatment with anti-IL-4 antibody blocks both primary and 
secondary IgE responses in vivo, when administered at the time of antigenic challenge 
(Finkelman, et al., 1988). IL-13 on the other hand is thought to be responsible for causing 
AHR, excessive mucus production and lung fibrosis. Neutralization of IL-13 was able to 
completely reverse allergen induced airway resistance and abolished mucus production by 
airway epithelial cells seen in control mice (Grunig, et al., 1998, Wills-Karp, et al., 1998).  
Apart from its action on lymphocytes, IL-4 also activates mast cells. This cytokine enhances 
surface expression of FcRI, the high affinity receptor for IgE (Toru, et al., 1996). Binding of 
IgE to FcRI causes crosslinking of the cytoplasmic Fc domain of this receptor and triggers 
degranulation (release of mast cell granules). This process causes rapid release of many 
inflammatory mediators such as histamine, leukotrienes and prostaglandins (reviewed in 
(Weller, et al., 2011)). Histamine increases blood circulation and permeability of blood 
vessels, causing increased recruitment of inflammatory cells, including eosionophils, T cells, 
dendritic cells and monocytes. Leukotrienes and prostaglandins promote 
bronchoconstriction and stimulate epithelial cell induced mucus production. The 
importance of FcRI in allergic responses has been demonstrated in studies using a soluble 
form of FcRI and mice lacking the  chain of this receptor (Dombrowicz, et al., 1993, Ra, et 
al., 1993). In both cases IgE-mediated allergic responses were abrogated. 
In addition to mast cells, eosinophils are closely associated with asthma pathogenesis. 
Increased numbers of eosinophils in the lung and other tissues in asthmatic patients usually 
correlate with disease severity and it is thought to be the central effector cell involved in 
airway inflammation (reviewed in (Hogan, et al., 2008)). IL-5 plays an important role in 
eosinophil development, proliferation and survival in the bone marrow. It is also required 
for migration of eosinophils into the blood and subsequently the lung. Recruitment of 
eosinophils to the peribronchial regions of the lung is thought to be mediated by secretion of 
various eotaxins (eotaxin 1, 2 and 3) by airway epithelial cells. Moreover, IL-5 and the 
eotaxins cooperate to induce tissue eosinophilia. Various eosinophilic granule components 
such as major basic protein (MBP) and eosinophilic cationic protein (ECP) have been 
implicated in initiating and propagating many features of asthma including pulmonary 
inflammation, airway hyperresponsiveness and bronchoconstriction. Eosinophils express 
both the Type I and Type II receptors. We have shown that IL-4, but not IL-13, can enhance 
chemotaxis of eosinophils to eotaxin 1 in vitro through the Type I receptor (Heller and 
Keegan, unpublished). Studies using IL-13R1-/- mice have shown that while eotaxin 
production and secretion by epithelial cells was completely dependent on IL-13 signaling 
through the Type II receptor, recruitment of eosinophils into the lungs was not (Munitz, et 
al., 2008, Ramalingam, et al., 2008). Therefore, it is possible that the Type I receptor is 
compensating for the absence of the Type II receptor. Alternatively, IL-5 may be playing a 
role in this response. Unlike hematopoietic cells, epithelial, endothelial and smooth muscle 
cells contain only the Type II receptor. Although both IL-4 and IL-13 can bind to this 
receptor complex, IL-13 is considered to be the main effector cytokine responsible for AHR, 
excessive mucus production and lung fibrosis.  
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The unique contributions of the Type II receptor in allergic lung inflammation have been 
studied using IL-13R1-/- mice. Mucus secretion, airway resistance, eotaxin production and 
induction of pro-fibrotic mediators such as TGF were completely dependent on the IL-
13R1 chain, and thus the Type II receptor (Munitz, et al., 2008, Ramalingam, et al., 2008). 
However, the authors showed that Th2 cell differentiation, IgE secretion in response to T cell 
dependent antigens (such as ovalbumin) and recruitment of eosinophils and other 
inflammatory cells into the lungs could occur independently of IL-13R1 . In addition, DNA 
microarray analysis of cells isolated from allergen or IL-4 treated WT or IL-13R1-/- mice 
indicated that several AAM genes were differentially regulated. Munitz et.al. showed that 
allergen and IL-4 induced Retnla expression levels were similar in both WT and IL-13R1-/- 
mice, but induction of chitinase (Chia) was completely dependent on IL-13R1 (Munitz, et 
al., 2008). Interestingly enough, allergen induced arginase 1 expression required the Type II 
receptor, but IL-4 induced arginase 1 expression did not. Thus, it appears that IL-4 utilizes 
both the Type I and Type II receptors to stimulate AAM development in the lung.  
Studies conducted by us as well as other groups have shown that IL-4 preferentially induces 
robust AAM gene expression, while IL-13 does so only weakly (Heller, et al., 2008, Munitz, 
et al., 2008, Ramalingam, et al., 2008). Intriguingly, mutation of the ITIM motif in the IL-4R 
chain resulted in increased sensitivity of macrophages to IL-13 mediated AAM activation. 
As demonstrated earlier, the Y709 (WT) BMMs treated with IL-4 led to significantly higher 
expression of AAM genes (Arginase1, Chi3l3) and also Ccl11 in contrast to IL-13. Mutation of 
Y709 residue to F709 resulted in dramatic amplification of Arginase1, Chi3l3 and Ccl11 genes 
in response to IL-13, while leaving the IL-4 induced responses intact or slightly enhanced 
(Tachdjian, et al., 2010). IL-13 but not IL-4 induced similar responses in primary lung 
fibroblasts. These results suggest that there is a disproportionate increase in AAM activation 
induced by IL-13 signaling via the Type II receptor. The authors hinted that differential 
recruitment of SHP-1 by the Type I and Type II receptors may be the reason behind these 
observations (Figure 2). Although much progress has been made in understanding the 
mechanisms by which IL-4 and IL-13 may elicit different responses in different cell types 
and in the lung during allergic diseases and asthma, many more questions remain 
unanswered. Future research in this area will shed light on the molecular basis of the 
separation of functions of IL-4 and IL-13 and their consequences in vivo.  
4.3 Single nucleotide polymorphisms leading to amino acid changes are commonly 
found in the IL-4R 
Commonly occurring genetic polymorphisms leading to amino acid changes in the IL-4R 
have been linked to susceptibility to asthma and/or to asthma severity (Hershey, et al., 1997, 
Ober, et al., 2000, Risma, et al., 2002, Shirakawa, et al., 2000). The E400A, Q576R and the 
S503P polymorphisms reside in the cytoplasmic domain while the I50V resides in the 
extracellular domain of the IL-4R chain. Two of the polymorphisms located in the 
cytoplasmic domain, S503 to P and the Q576 to R, are frequently linked (Kruse, et al., 1999). 
This double mutation (S503P/Q576R) was associated with lower total IgE concentrations, 
similar to the single S503P polymorphism, and an increase in the phosphorylation of IRS2. 
E400A is especially prevalent in African-American populations and was associated with 
severe asthma exacerbations (Wenzel, et al., 2007). An I50 in the extracellular domain of the 
IL-4R chain was linked with enhanced signal transduction culminating in an increase in 
the production of IgE (Mitsuyasu, et al., 1998, Mitsuyasu, et al., 1999). On the other hand, 
several other studies reported no correlation of this polymorphism with enhanced IgE levels 
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studies have shown that STAT6 is not required for in vivo differentiation, although it is 
required for stabilization of Th2 cells and generating memory responses (reviewed in 
(Chapoval, et al., 2010)). Activated Th2 cells then secrete large quantities of IL-4, IL-5 and IL-
13 which can act on many different cell types. IL-4 induces expression of MHC Class II in 
resting B cells and also causes antibody class switching from IgM to IgE and IgG1 (reviewed 
in Nelms, et al., 1999). Treatment with anti-IL-4 antibody blocks both primary and 
secondary IgE responses in vivo, when administered at the time of antigenic challenge 
(Finkelman, et al., 1988). IL-13 on the other hand is thought to be responsible for causing 
AHR, excessive mucus production and lung fibrosis. Neutralization of IL-13 was able to 
completely reverse allergen induced airway resistance and abolished mucus production by 
airway epithelial cells seen in control mice (Grunig, et al., 1998, Wills-Karp, et al., 1998).  
Apart from its action on lymphocytes, IL-4 also activates mast cells. This cytokine enhances 
surface expression of FcRI, the high affinity receptor for IgE (Toru, et al., 1996). Binding of 
IgE to FcRI causes crosslinking of the cytoplasmic Fc domain of this receptor and triggers 
degranulation (release of mast cell granules). This process causes rapid release of many 
inflammatory mediators such as histamine, leukotrienes and prostaglandins (reviewed in 
(Weller, et al., 2011)). Histamine increases blood circulation and permeability of blood 
vessels, causing increased recruitment of inflammatory cells, including eosionophils, T cells, 
dendritic cells and monocytes. Leukotrienes and prostaglandins promote 
bronchoconstriction and stimulate epithelial cell induced mucus production. The 
importance of FcRI in allergic responses has been demonstrated in studies using a soluble 
form of FcRI and mice lacking the  chain of this receptor (Dombrowicz, et al., 1993, Ra, et 
al., 1993). In both cases IgE-mediated allergic responses were abrogated. 
In addition to mast cells, eosinophils are closely associated with asthma pathogenesis. 
Increased numbers of eosinophils in the lung and other tissues in asthmatic patients usually 
correlate with disease severity and it is thought to be the central effector cell involved in 
airway inflammation (reviewed in (Hogan, et al., 2008)). IL-5 plays an important role in 
eosinophil development, proliferation and survival in the bone marrow. It is also required 
for migration of eosinophils into the blood and subsequently the lung. Recruitment of 
eosinophils to the peribronchial regions of the lung is thought to be mediated by secretion of 
various eotaxins (eotaxin 1, 2 and 3) by airway epithelial cells. Moreover, IL-5 and the 
eotaxins cooperate to induce tissue eosinophilia. Various eosinophilic granule components 
such as major basic protein (MBP) and eosinophilic cationic protein (ECP) have been 
implicated in initiating and propagating many features of asthma including pulmonary 
inflammation, airway hyperresponsiveness and bronchoconstriction. Eosinophils express 
both the Type I and Type II receptors. We have shown that IL-4, but not IL-13, can enhance 
chemotaxis of eosinophils to eotaxin 1 in vitro through the Type I receptor (Heller and 
Keegan, unpublished). Studies using IL-13R1-/- mice have shown that while eotaxin 
production and secretion by epithelial cells was completely dependent on IL-13 signaling 
through the Type II receptor, recruitment of eosinophils into the lungs was not (Munitz, et 
al., 2008, Ramalingam, et al., 2008). Therefore, it is possible that the Type I receptor is 
compensating for the absence of the Type II receptor. Alternatively, IL-5 may be playing a 
role in this response. Unlike hematopoietic cells, epithelial, endothelial and smooth muscle 
cells contain only the Type II receptor. Although both IL-4 and IL-13 can bind to this 
receptor complex, IL-13 is considered to be the main effector cytokine responsible for AHR, 
excessive mucus production and lung fibrosis.  
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The unique contributions of the Type II receptor in allergic lung inflammation have been 
studied using IL-13R1-/- mice. Mucus secretion, airway resistance, eotaxin production and 
induction of pro-fibrotic mediators such as TGF were completely dependent on the IL-
13R1 chain, and thus the Type II receptor (Munitz, et al., 2008, Ramalingam, et al., 2008). 
However, the authors showed that Th2 cell differentiation, IgE secretion in response to T cell 
dependent antigens (such as ovalbumin) and recruitment of eosinophils and other 
inflammatory cells into the lungs could occur independently of IL-13R1 . In addition, DNA 
microarray analysis of cells isolated from allergen or IL-4 treated WT or IL-13R1-/- mice 
indicated that several AAM genes were differentially regulated. Munitz et.al. showed that 
allergen and IL-4 induced Retnla expression levels were similar in both WT and IL-13R1-/- 
mice, but induction of chitinase (Chia) was completely dependent on IL-13R1 (Munitz, et 
al., 2008). Interestingly enough, allergen induced arginase 1 expression required the Type II 
receptor, but IL-4 induced arginase 1 expression did not. Thus, it appears that IL-4 utilizes 
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several other studies reported no correlation of this polymorphism with enhanced IgE levels 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
58
in patients (Khoo, et al., 2006, Noguchi, et al., 1999). Furthermore, the V50 polymorphism has 
been linked with enhanced CD23 expression, an increase in atopic asthma, and an increase 
in allergic bronchopulmonary aspergillosis (Knutsen, et al., 2006, Risma, et al., 2002). More 
recently the V50 polymorphism reduced the ability of IL-4 to suppress IL-17 production by 
human peripheral mononuclear cells (Wallis, et al., 2011). Because many of these 
polymorphisms are located in the cytoplasmic domain of the IL-4R, many investigators 
have hypothesized that they modulate signal transduction. However, experiments designed 
to analyze the direct effects of these polymorphisms on receptor signaling have lead to 
contradictory reports (Franjkovic, et al., 2005, Kruse, et al., 1999, Mitsuyasu, et al., 1998, 
Mitsuyasu, et al., 1999, Prots, et al., 2006, Risma, et al., 2002, Stephenson, et al., 2004). 
We analyzed the impact of the Q576R, S503P, and I50V polymorphisms on signal 
transduction by the Type I receptor complex in vitro. While the R576 and P503 polymorphisms 
had no effect on STAT6 or IRS2 activation induced by IL-4 (Wang, et al., 1999), we found 
that the V50 polymorphism located in the extracellular domain of the IL-4R mediated a 
prolonged STAT6 signaling induced by IL-4 through the Type I receptor (Ford, et al., 2009). 
This was associated with a prolonged expression of the SOCS family member Cis. The effect 
of this polymorphism on signaling by the Type II receptor is unknown.  
Using mouse knock-in strategies, the murine IL-4R-Q576 was replaced with IL-4R 
expressing the R576 polymorphism (Tachdjian, et al., 2009). This change was shown to 
enhance allergic asthma in vivo. The IL-4R-R576 enhanced Th2 differentiation and IgE 
production; both of these responses are Type I receptor dependent in the mouse model. 
Furthermore, it enhanced the production of CCL11 by BMM, fibroblasts, and tracheal 
epithelial cells (TEC) in response to IL-4 or IL-13. These results suggest the R576 
polymorphism affects STAT6-dependent responses down stream of both the Type I and 
Type II receptors. However, there was no apparent effect of the R576 on the tyrosine 
phosphorylation of STAT6 (Tachdjian, et al., 2009), consistent with our study in cell lines 
(Wang, et al., 1999). Furthermore, there was no effect on the tyrosine phosphorylation of 
Shc. The effect of the R576 on IRS2 phosphorylation was not reported. Interestingly, the 
longevity of Erk1,2 phosphorylation in TEC was dramatically enhanced by R576, however 
the mechanism by which R576 leads to Erk phosphorylation is still unclear. It will be 
important to understand the effects of the polymorphisms and their interactions on both IL-
4 and IL-13 signaling since they are linked to different clinical phenotypes in human 
populations (Wenzel, et al., 2007).  
5. Contribution of Type I and Type II receptor complexes to the control of 
regulatory mechanisms that act to modulate allergic inflammation 
During Th2-driven allergic lung inflammation, a number of effector and regulatory 
mechanisms are orchestrated by IL-4 and IL-13 through Type I and Type II receptors. 
Several of these regulatory mechanisms allow for the amplification of Th2 differentiation 
and function, while others function as part of a negative feed-back loop to limit Th2-
driven inflammation (Figure 3). Just as IL-4 and IL-13 are differentially involved in 
promoting various features of allergic lung disease, these cytokines utilize separate 
mechanisms to negatively regulate the signaling pathways activated by each other. These 
regulatory mechanisms will need to be considered in the design of inhibitors of the IL-
4/IL-13 system. 
The Type I and Type II Receptor 




Fig. 3. Differential control of regulatory mechanisms by the Type I and II Receptors. IL-4 
signaling through the Type I receptor on Th2 cell surfaces renders them resistant to control 
by T regulatory cells. Furthermore, IL-4 signaling STAT6 activation through the Type I 
receptor on naive CD4+ T-cells inhibits the differentiation of iTregs and Th1 cells. These 
responses lead to enhanced allergic inflammation. On the other hand, IL-4 signals through 
the Type I receptor on NK cell surfaces to induce IFN production. IFN in turn suppresses 
Th2 differentiation and inhibits signaling by both Type I and Type II receptors by inducing 
SOCS family members. IL-13 signals through the Type II receptor that is induced on the 
surface of Th17 cells and decreases IL-17 production. This suppression of IL-17 production 
by Th17 cells would limit the influx of neutrophils that are present in steroid resistant 
asthma.  
5.1 Type I IL-4 receptor modulation of regulatory T-cells 
Signaling through the Type I IL-4 receptor antagonizes the differentiation and function of 
regulatory T cells (Tregs). Tregs are a subset of T lymphocytes that regulate immune 
responses and prevent excessive immune system activation (Sakaguchi, et al., 2008, Shevach, 
2009). The most studied Tregs are CD4+CD25+FoxP3+, which have been found to play a role 
in allergic disease. FoxP3 is a transcription factor important for Treg development and 
function. Mice lacking FoxP3 expression (Scurfy mice) or humans with mutations in their 
foxP3 gene (X-linked autoimmunity-allergic dysregulation syndrome) develop widespread 
autoimmune disease with a Th2-mediated allergic component (Khattri, et al., 2003). There 
are many mechanisms elicited by Tregs to suppress effector T cells, such as: (1) cell-
mediated presentation of TGF- or galectin-1 (Shevach, 2009), (2) secretion of the 
immunosuppressive cytokines IL-10 or TGF- (Bettini & Vignali, 2009), or (3) consumption 
of IL-2, a limiting growth factor for T cells (Scheffold, et al., 2007). Th2 cells utilize several 
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methods to inhibit immunosuppression by Tregs. Gata3 is the master transcriptional regulator 
of Th2 cells and is activated by signal transduction through the Type I IL-4 receptor. Using co-
immunoprecipitation assays, Dardalhon and colleagues have shown physical interaction 
between Gata3 and FoxP3 in transiently transfected human embryo kidney 293 cells. The 
authors also observed IL-4 inhibition of FoxP3 induction in Ag-specific adaptive (inducible) 
Tregs, which was dependent on STAT6 expression (Dardalhon, et al., 2008). Our recent 
findings are in support of this antagonistic relationship between STAT6 and Tregs and IL-4-
induced, STAT6-dependent inhibition of FoxP3. We have found that STAT6-/- mice have 
higher numbers of Tregs than wildtype mice (Chapoval, et al., 2011). This observation has also 
been confirmed by Takaki and colleagues who identified a STAT6-binding site in the silencer 
region in the FoxP3 mRNA transcript. STAT6 binding to this site reduced TGF-1 induction of 
FoxP3 transcriptional activation (Takaki, et al., 2008).  
Additionally, IL-4 was found to serve as a survival factor for CD4+CD25(-) T helper (Th) cells 
and to aid in their protection from immunosuppression by CD4+CD25+ Tregs (Pace, et al., 
2005). IL-13 failed to have this same effect. Therefore, this phenomenon was found to be 
dependent on Th cell surface expression of IL-4R chain and a functional Type I IL-4 
receptor complex, as IL-4R-/- Th cells were not protected by IL-4 from Treg 
immunosuppression. IL-4 activation of the Type I IL-4 receptor, but not the Type II receptor, 
maintains anti-apoptotic and pro-proliferative processes in Th cells and protects them from 
Treg-induced perturbed cell growth and proliferation. Surprisingly, CSFE-labeled 
cocultures of IL-4R-/- Th cells and IL-4R+/+ Tregs revealed that although IL-4 has on effect 
on Treg immunosuppression of IL-4R-/- Th cells, it promoted proliferation of Tregs in-vitro 
(Pace, et al., 2006). This could be a direct effect of IL-4 that would further complicate the role 
of this Th2 cytokine in modulating Treg immunosuppression.  
5.2 Role of Type I receptors in control of Th1 responses that act to suppress allergic 
inflammation 
Th1 cell programming antagonizes Th2 cell differentiation and could serve as a regulatory 
mechanism to suppress Th2-mediated allergic response. Gavett and colleagues showed that 
IL-12 can inhibit antigen induced-airway hyperreactivity and inflammation and to also 
reduce Th2 cytokine production (Gavett, et al., 1995). Th2 cells inhibit Th1 cell induction 
during the allergic response. Gata3 is activated downstream of STAT6 phosphorylation, 
which is induced by signaling through the Type I receptor (Kurata, et al., 1999, Nelms, et al., 
1999). Not only does it serve as the master regulator transcription factor (TF) for Th2 cells, 
but Gata3 has also been shown to inhibit Th1 cell-specific factors. Gata3-deficient cell clones 
produced high levels of the Th1 cytokine, IFN, and had enhanced expression of T-bet (the 
Th1 cell master regulator TF) (Zhu, et al., 2006). Therefore, activation of the Type I IL-4 
receptor could lead to activation of Gata3, which in turn inhibits Th1-inducing factors 
during the Th2-mediated allergic response. Th1 cells have also been shown to play a 
potentially stimulatory role in airway inflammation. Hansen et al. found that Th1 cells 
decreased airway eosinophilia, but failed to reduce airway hyperreactivity in ovalbumin-
immunized Balb/c mice (Hansen, et al., 1999). But this may be a late phenomenon in airway 
inflammation during which additional non-Th2 inflammatory cells aid in amplifying 
chronic lung inflammation. This would be in direct contrast to the initiation of allergic 
airway inflammation which is characterized by strong Th2 immune responses and can be 
inhibited by non-Th2-promoting immune cells.  
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5.3 Modulation of NK cells 
Although IL-4 and IFN are antagonistic towards each other during T cell differentiation, IL-
4 can increase IL-2 and IL-12 induced IFN secretion by Natural Killer (NK) cells. Bream and 
co-authors also found that the increase in IFN production caused by IL-4 in conjunction 
with IL-2 was STAT6 dependent, while IL-4 synergy with IL-12 was independent of STAT6 
activation (Bream, et al., 2003, Morris, et al., 2006). Further studies have shown that IL-13 
was unable to cause a similar increase in NK cell derived IFN release (Morris, et al., 2006). 
This result is in agreement with the fact that IL-13 signals through the Type II receptor, and 
this receptor complex is absent in NK cells. IL-4 stimulated IFN production by NK cells has 
significant implications in the context for allergic lung inflammation. One group has shown 
that Sendai virus infection of mice suppressed NK cell derived IFN secretion. This led to 
enhanced Th2 responses and subsequent development of exacerbated allergic lung disease 
(Kaiko, et al., 2010). IFN production would suppress Th2 differentiation and inhibit 
signaling by both Type I and Type II receptors by inducing SOCS family members.  
The role of NK cells in human allergic disease has been extensively examined; because of 
their ability to produce cytokines, NK cells have the potential to heavily influence the 
adaptive allergic immune response. Based on cytokine production, NK cells can be divided 
into 2 classes: (1) NK1 cells produce Th1 cytokines, such as IFN (Romagnani, 1992) and (2) 
NK2 cells produce Th2 cytokines IL-4, 5, and 13 (Hoshino, et al., 1999, Peritt, et al., 1998, 
Warren, et al., 1995). In a recent study analyzing NK cell populations in healthy and allergic 
patients, the authors found a predominance of NK2 cells in the peripheral blood of allergic 
patients. These NK2 cells produced high amounts of Th2 cytokines that could promote 
allergic inflammation (Timonen & Stenius-Aarniala, 1985, Wei, et al., 2005).  
5.4 IL-13 inhibition of Th17 cells via the Type II receptor in severe asthma 
It has long been thought that naïve T cells do not express the IL-13R1 chain of the Type II 
receptor complex and therefore cannot be regulated by IL-13. Due to restricted expression of 
IL-13R1 on non-hematopoetic cells, Type II receptor signaling has been limited to those 
cells and not seen in T cells. But this central dogma has been recently challenged by 
observations that Th17 cells are able to induce surface expression of IL-13R1 chain 
(Newcomb, et al., 2009, Newcomb, et al., 2011).  
Th17 cells are a distinct population of CD4+ T cells, whose differentiation is induced by IL-6 
or IL-21 and TGF (McGeachy, et al., 2007). Th17 cells produce IL-17, IL-6, and tumor 
necrosis factor. They have been shown to play a role in autoimmune diseases including the 
experimental autoimmune encephalitis (EAE) model of multiple sclerosis (Langrish, et al., 
2005). Th17 cells also provide protection from some extracellular pathogens, such as 
Klebsiella pneumoniae infection of the lung (Happel, et al., 2005).  
A statistically higher number of IL-17 + cells can be found in the sputum and BAL of 
asthmatic patients compared to controls and the greater expression of IL-17A in the lungs 
was associated with increased asthma severity. (Jatakanon, et al., 1999, Molet, et al., 2001). 
IL-17A induces neutrophil recruitment to the airway and augments the pathogenesis of 
steroid-resistant, severe asthma (McKinley, et al., 2008). Th17 cells alone cannot induce 
eosinophillic infiltration into the airway following immunization and challenge, but in the 
presence of Th2 cells, antigen-specific Th17 cells can enhance the eosinophil-activating 
properties of Th2 cells (Wakashin, et al., 2008). 
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Th17 polarized cells from mouse spleens were shown to have increased mRNA and protein 
levels of IL-13R1 after stimulation in vitro. When added to Th17 cell cultures, IL-13 reduced 
IL-17A production by Th17 cells and decreased the percentage of CD4+ Th17 cells. 
Additionally, IL-13 caused a reduction in the expression of ROR, the master regulator 
transcription factor for Th17 cells (Newcomb, et al., 2009). This phenomenon of IL-13 
suppression of IL-17A production by Th17 cells was also observed in vitro using human CD4+ 
T cells (Newcomb, et al., 2011). Therefore, activated Th17 cells upregulate their surface 
expression of IL-13R1 chain and this allows for IL-13 to signal through a functional Type II 
receptor complex to decrease IL-17 production by Th17 cells. Thus, paradoxically, IL-13, a 
major effector cytokine of atopic asthma, inhibits the Th17 component of severe asthma. This 
concept could also explain the observation that IL-25-induced production of IL-13 inhibited 
Th17-mediated EAE disease progression (Kleinschek, et al., 2007). This is a unique mechanism 
whereby a Th2 immune-mediated illness is prevented from becoming more severe by IL-13, a 
Th2 cytokine. Consequently, efforts to suppress IL-13 function to treat allergic asthma may 
lead to Th17 induction and severe and persistent asthma in susceptible individuals.  
6. Conclusion 
The importance of the Type I IL-4 receptor in regulating T cells to become Th2 cells has been 
well documented. Furthermore, numerous studies have indicated the IL-4R expressed on 
lung epithelium is necessary for goblet cell differentiation and mucus hypersecretion. In 
addition, the IL-4R is expressed on many cell types that could contribute to the overall 
pathology and severity of asthma. The relative role of the Type I and Type II receptors on these 
cells has not yet been fully delineated. Using mice lacking one or the other complex (i.e. C-/- or 
IL-13R1-/-) several groups have recently delineated interesting differences in their 
contributions to lung pathology. The Type I receptor is the major regulator of eosinophilic 
inflammation and the alternative activation of macrophages while the Type II receptor controls 
mucus hypersecretion and airway hyperresponsiveness. These receptors differentially regulate 
potential regulatory pathways including the control of T regulatory cells and the production of 
cytokines by NK cells; both of these responses are controlled by the Type I receptor complex. 
The Type II receptor complex can be induced on Th17 cells and allows IL-13 to down regulate 
Th17 differentiation. This could be of clinical importance for severe, steroid resistant forms of 
human asthma that may be mediated by Th17 cells. In this scenario, inhibiting IL-13 could be 
detrimental to the patient and illustrates the need to stratify patients prior to treatment. 
As mentioned above, the intricate differences between the Type I and Type II receptor 
complexes could impact the therapeutic effectiveness of agents designed to target these 
receptors in asthma. Indeed initial trials to inhibit IL-4 using the soluble IL-4R in asthmatic 
patients were largely unsuccessful and possibly detrimental (Borish, et al., 2001, Wenzel, et 
al., 2007). The ability of IL-4 to suppress TNF production, a highly pro-inflammatory 
cytokine, was suggested to be part of a negative regulatory mechanism that was 
unintentionally blocked by the therapy (Borish, 2010). Studies using soluble IL-13R2 to 
inhibit IL-13 signaling are ongoing. However, blocking one cytokine at a time may not prove 
beneficial. Since both cytokines can elicit effector functions, blocking only one could actually 
exacerbate disease because of the loss of a negative regulatory pathway. The most promising 
approach thus far has been to use a mutant IL-4 (Pitrakinra) that binds to the IL-4R, and 
blocks dimerization with either the C or the IL-13R1 (Wenzel, et al., 2007). Thus, this 
single agent can prevent the formation of both the Type I and the Type II receptor 
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complexes. Further understanding of the complex IL-4/IL-13 receptor system and its 
contribution to various features of allergic asthma will be essential to fine-tune therapeutic 
strategies for the treatment of asthma. 
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1. Introduction  
Food allergy is defined as an abnormal immunological reaction to food proteins, which 
causes an adverse clinical reaction. Today 4–6% of children and 1–3% of adults are affected 
with food allergy in Europe (Mills et al., 2007), while in the USA 6– 8% of children and 4% of 
adults are affected (Gupta et al., 2008). The incidence of food allergy has been increasing 
over the years, and to date, no effective treatment of food allergies is available. Therapies 
involving drugs (antihistamines, decongestants, or steroids) only combat the symptoms of 
an allergic reaction and do not prevent allergenic reactions due to future exposures to the 
allergen. Specific immunotherapy (SIT) is the only prophylactic desensitizing therapy for 
allergy (Bousquet et al., 1998; Durham et al., 1999). However, for food allergies 
immunotherapy safety-profile is extremely poor because allergic reactions are associated 
with a significant risk of anaphylactic side-effects (Nelson et al., 1997; Skripak et al., 2008), 
even with fatal outcome. Therefore, allergen modification resulting in almost complete 
reduction of IgE-binding, while retaining its immunogenicity, could improve formulations 
for immunotherapy of food allergies.  
The best way to prevent unintended exposure to a food allergen is the strict avoidance of 
foodstuffs containing allergens. Such avoidance may not always be possible, and in certain 
instances impossible. Furthermore, complete elimination of foodstuffs causing allergy also 
has negative impact on healthy diet as about 90 % of allergens are present in food of high 
nutrition value (milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, and soybeans) 
(Thompson et al., 2006). Therefore production of hypoallergenic food become increasingly 
indispensable part of food industry with growing demand for methods aimed to reduce 
allergenic potential of food products. There is increasing number of publications describing 
successful attempts to reduce allergenicity of food allergens. A number of studies of food 
processing on allergen reactivity are largely focused on thermal treatments. Although 
thermal treatments can be used on many products to alter food allergen reactivity, thermal 
processing has also been known to modify organoleptic properties, including flavor, color, 
and nutrient content (Holdsworth, 1985). Therefore, novel non-thermal food processing 
techniques are being explored in order to create hypoallergenic products (Shriver & Yang, 
2011). Variable success of methods for allergenicity reduction, due to limited knowledge of 
allergen and epitope structures and the factors governing their stability, imposes need for an 
empirical approach (Soler-Rivas & Wichers, 2001). Chemical or enzymatic modification of 
allergen molecule may alter its structure or physically obstruct binding of IgE antibodies to 
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conformational or linear epitopes. The objective of this review is to thoroughly explore 
chemical and enzymatic processing techniques utilized to modify food allergens, 
highlighting the efficacy of these methods in their ability to alter food allergen reactivity. As 
there are comprehensive reviews on food allergen treatment with digestive enzymes and the 
effects of fermentation on food reactivity, this review is focused on chemical and enzymatic 
modification of food allergen in the narrow sense.  
2. Methods for assessing allergenicity of food products  
The efficacy of chemical and enzymatic methods used to alter food allergen reactivity must 
be verified by analyzing the treated allergen’s (or treated allergenic food) ability to trigger 
an immune response. As the reactivity of an allergen is often described by its ability to bind 
IgE antibodies, reduced IgE activity may indicate a modification or removal of food 
allergen(s). A variety of rapid assay methods are in use as analytical tools in research of 
molecular structure, integrity and biological activity of food allergens and their epitopes. 
Allergen reactivity can be determined by in vitro, ex vivo and in vivo testing. In vitro tests are 
often inexpensive, quick and without a threat to human or animal subjects. On the other 
hand in vivo assays provide a more accurate representation of the research. Ex vivo tests are 
advantageous because they are measuring allergenic response on effector cell level, using 
human subject blood without exposing them to risk. Animal models may also be used, 
though these models are not always analogous to the human. However, animal models may 
be a useful tool for predicting sensitizing potential of proteins introduced into diet by 
genetic manipulation or modified allergens which may carry higher allergenic risk. 
In vivo tests. In vivo detection includes skin prick tests (SPT) and oral food challenges 
(OFC). SPT is simple and inexpensive, but the wheal sizes can vary by allergen and subject 
(Sampson, 1999), subjective results can differ between evaluators (Poulsen, 2001) and 
patients with atopic dermatitis may develop false-positive wheals (Fleischer et al., 2010). 
OFC is considered the ‘‘gold standard’’ in diagnosing food allergy as it can provide more 
accurate information regarding food allergy. However, these tests are complex, expensive 
and time consuming. As subject may experience severe adverse reactions patients who are 
susceptible to anaphylaxis should not be included in this type of study (Fleischer et al., 
2010). However, final proof of improved safety of potentially less allergenic foods must be 
provided through human test studies, via double-blind placebo-controlled food challenge 
(DBPCFC)-tests.  
Animal models. Rodent animal models are the most often exploited animal models of food 
allergy. Though the dosage of the allergen, route of exposure and duration of the build-in 
phase of allergy may differ depending on the allergen used and animal strain, many food 
allergy models have been described in the literature providing generation of IgE in the 
serum upon immunization and/or anaphylaxis reaction upon challenge with allergen. 
Animal models are useful in elucidation of mechanisms involved in reduction of 
allerenicity, especially on B cell and T cell level (Hattori et al., 2000; Kobayashi et al., 2001; 
Kobayashi et al., 2003).  
Ex vivo tests. Ex vivo tests include histamine release or up regulation of surface molecules 
CD63 or CD203c on basophile granulocytes, known as the basophile activation test, BAT. By 
measuring specific IgE we only measure one interaction, between IgE and an allergen, 
whilst an allergic response requires two simultaneous interactions of allergen with IgE on 
the same effector cell. This is simulated in the ex vivo tests based on basophile granulocytes.  
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In vitro tests. In vitro studies for determining allergen reactivity include the measurement of 
serum IgE using radio-allergosorbent tests (RAST), enzyme-allergosorbent tests (EAST), 
enzyme linked immunosorbent assay (ELISA), ImmunoCAP assays (Phadia, Uppsala, 
Sweden); and immunobloting. By RAST, EAST and ELISA (competitive inhibition and 
indirect) multiple samples can be tested at once. However, due to differences with solid 
phase and sample preparation among analysts standardization is the main problem. 
Furthermore, IgG antibodies can compete with IgE antibodies for similar epitopes. Although 
expensive, an ImmunoCAP tests have increased sensitivity compared to RAST, EAST and 
ELISA with minimized nonspecific binding by non-IgE binding antibodies. Immunoblotting 
includes Western blot and dot blot allergen analysis. In Western blotting proteins are most 
often tested in their linear conformation so that conformational epitopes may not be 
represented and new IgE binding epitopes, in native conformation hidden within the 
protein, may be uncovered. Immunobloting is frequently used since protein bands can be 
individually analyzed to determine the changes in a specific allergen. In dot blot 
conformational epitopes may be preserved due to non-denaturing conditions, but in the case 
of protein mixture immunogenicity of the entire sample is analyzed.  
Digestibility assays for food protein allergenicity assessment. The observation that many 
food allergens exhibit proteolytic stability led to allergy assessment strategy that use of 
digestion stability as a criterion for protein allergenicity assessment (Becker, 1997; Besler er 
al., 2001; Taylor & Lehrer, 1996). Although the relationship between the stability of proteins 
in simulated gastric fluid (SGF) and allergenicity has been inconsistent among studies, many 
recent reports proved increased incidence of food allergies in relation to impaired gastric 
digestion in human and animal studies. (Untersmayr & Jensen-Jarolim, 2008). Thomas et al. 
(Thomas et al., 2008) demonstrated that common protocol for evaluating the in vitro 
digestibility of proteins is reproducible and yields consistent results when performed using 
the same proteins at different laboratories. However, digestibility assays of pure proteins 
may not be always relevant in assessing allergenicity potential as they do not account for the 
effects of food matrices (Ofori-Anti et al., 2008). Therefore, in vitro gastrointestinal digestion 
protocols should be preferably combined with immunological assays in order to elucidate 
the role of large digestion-resistant fragments and the influence of the food matrix (Moreno, 
2007). For a comprehensive review on digestibility of food allergens refer to Cirkovic 
Velickovic et al. (Cirkovic Velickovic et al., 2009). Anyway, comparison of unmodified and 
modified food allergen in digestibility studies can give valuable information about allergic 
potential of modified food protein and efficiency of modifying method used. As enzymatic 
and chemical methods change allergen structure digestibility of modified allergen can be 
increased or decreased thus directly influencing allergen availability to gut immune system.  
3. Chemical modifications  
The aim of chemical modifications of proteins used for nutritional purposes, in addition to 
reduction of allergenic properties, is obtaining of proteins with required techno-functional 
properties (solubility, emulsification, foaming, gelling, etc.) and preserved nutritional value. 
Chemical modifications of food proteins can lead to a change in the charge and 
hydrophobicity of proteins, which in turn can diminish or eliminate allergenicity of food 
allergens. However, regardless the application of non-toxic reagents, chemical modifications 
are not so often applied in the food industry regarding complex procedures of removing 
remaining chemical agents. 
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conformational or linear epitopes. The objective of this review is to thoroughly explore 
chemical and enzymatic processing techniques utilized to modify food allergens, 
highlighting the efficacy of these methods in their ability to alter food allergen reactivity. As 
there are comprehensive reviews on food allergen treatment with digestive enzymes and the 
effects of fermentation on food reactivity, this review is focused on chemical and enzymatic 
modification of food allergen in the narrow sense.  
2. Methods for assessing allergenicity of food products  
The efficacy of chemical and enzymatic methods used to alter food allergen reactivity must 
be verified by analyzing the treated allergen’s (or treated allergenic food) ability to trigger 
an immune response. As the reactivity of an allergen is often described by its ability to bind 
IgE antibodies, reduced IgE activity may indicate a modification or removal of food 
allergen(s). A variety of rapid assay methods are in use as analytical tools in research of 
molecular structure, integrity and biological activity of food allergens and their epitopes. 
Allergen reactivity can be determined by in vitro, ex vivo and in vivo testing. In vitro tests are 
often inexpensive, quick and without a threat to human or animal subjects. On the other 
hand in vivo assays provide a more accurate representation of the research. Ex vivo tests are 
advantageous because they are measuring allergenic response on effector cell level, using 
human subject blood without exposing them to risk. Animal models may also be used, 
though these models are not always analogous to the human. However, animal models may 
be a useful tool for predicting sensitizing potential of proteins introduced into diet by 
genetic manipulation or modified allergens which may carry higher allergenic risk. 
In vivo tests. In vivo detection includes skin prick tests (SPT) and oral food challenges 
(OFC). SPT is simple and inexpensive, but the wheal sizes can vary by allergen and subject 
(Sampson, 1999), subjective results can differ between evaluators (Poulsen, 2001) and 
patients with atopic dermatitis may develop false-positive wheals (Fleischer et al., 2010). 
OFC is considered the ‘‘gold standard’’ in diagnosing food allergy as it can provide more 
accurate information regarding food allergy. However, these tests are complex, expensive 
and time consuming. As subject may experience severe adverse reactions patients who are 
susceptible to anaphylaxis should not be included in this type of study (Fleischer et al., 
2010). However, final proof of improved safety of potentially less allergenic foods must be 
provided through human test studies, via double-blind placebo-controlled food challenge 
(DBPCFC)-tests.  
Animal models. Rodent animal models are the most often exploited animal models of food 
allergy. Though the dosage of the allergen, route of exposure and duration of the build-in 
phase of allergy may differ depending on the allergen used and animal strain, many food 
allergy models have been described in the literature providing generation of IgE in the 
serum upon immunization and/or anaphylaxis reaction upon challenge with allergen. 
Animal models are useful in elucidation of mechanisms involved in reduction of 
allerenicity, especially on B cell and T cell level (Hattori et al., 2000; Kobayashi et al., 2001; 
Kobayashi et al., 2003).  
Ex vivo tests. Ex vivo tests include histamine release or up regulation of surface molecules 
CD63 or CD203c on basophile granulocytes, known as the basophile activation test, BAT. By 
measuring specific IgE we only measure one interaction, between IgE and an allergen, 
whilst an allergic response requires two simultaneous interactions of allergen with IgE on 
the same effector cell. This is simulated in the ex vivo tests based on basophile granulocytes.  
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In vitro tests. In vitro studies for determining allergen reactivity include the measurement of 
serum IgE using radio-allergosorbent tests (RAST), enzyme-allergosorbent tests (EAST), 
enzyme linked immunosorbent assay (ELISA), ImmunoCAP assays (Phadia, Uppsala, 
Sweden); and immunobloting. By RAST, EAST and ELISA (competitive inhibition and 
indirect) multiple samples can be tested at once. However, due to differences with solid 
phase and sample preparation among analysts standardization is the main problem. 
Furthermore, IgG antibodies can compete with IgE antibodies for similar epitopes. Although 
expensive, an ImmunoCAP tests have increased sensitivity compared to RAST, EAST and 
ELISA with minimized nonspecific binding by non-IgE binding antibodies. Immunoblotting 
includes Western blot and dot blot allergen analysis. In Western blotting proteins are most 
often tested in their linear conformation so that conformational epitopes may not be 
represented and new IgE binding epitopes, in native conformation hidden within the 
protein, may be uncovered. Immunobloting is frequently used since protein bands can be 
individually analyzed to determine the changes in a specific allergen. In dot blot 
conformational epitopes may be preserved due to non-denaturing conditions, but in the case 
of protein mixture immunogenicity of the entire sample is analyzed.  
Digestibility assays for food protein allergenicity assessment. The observation that many 
food allergens exhibit proteolytic stability led to allergy assessment strategy that use of 
digestion stability as a criterion for protein allergenicity assessment (Becker, 1997; Besler er 
al., 2001; Taylor & Lehrer, 1996). Although the relationship between the stability of proteins 
in simulated gastric fluid (SGF) and allergenicity has been inconsistent among studies, many 
recent reports proved increased incidence of food allergies in relation to impaired gastric 
digestion in human and animal studies. (Untersmayr & Jensen-Jarolim, 2008). Thomas et al. 
(Thomas et al., 2008) demonstrated that common protocol for evaluating the in vitro 
digestibility of proteins is reproducible and yields consistent results when performed using 
the same proteins at different laboratories. However, digestibility assays of pure proteins 
may not be always relevant in assessing allergenicity potential as they do not account for the 
effects of food matrices (Ofori-Anti et al., 2008). Therefore, in vitro gastrointestinal digestion 
protocols should be preferably combined with immunological assays in order to elucidate 
the role of large digestion-resistant fragments and the influence of the food matrix (Moreno, 
2007). For a comprehensive review on digestibility of food allergens refer to Cirkovic 
Velickovic et al. (Cirkovic Velickovic et al., 2009). Anyway, comparison of unmodified and 
modified food allergen in digestibility studies can give valuable information about allergic 
potential of modified food protein and efficiency of modifying method used. As enzymatic 
and chemical methods change allergen structure digestibility of modified allergen can be 
increased or decreased thus directly influencing allergen availability to gut immune system.  
3. Chemical modifications  
The aim of chemical modifications of proteins used for nutritional purposes, in addition to 
reduction of allergenic properties, is obtaining of proteins with required techno-functional 
properties (solubility, emulsification, foaming, gelling, etc.) and preserved nutritional value. 
Chemical modifications of food proteins can lead to a change in the charge and 
hydrophobicity of proteins, which in turn can diminish or eliminate allergenicity of food 
allergens. However, regardless the application of non-toxic reagents, chemical modifications 
are not so often applied in the food industry regarding complex procedures of removing 
remaining chemical agents. 
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3.1 Covalent modifications  
Acylation. Acylation of allergens by treatment with anhydrides, such as acetic or succinic, 
blocks positively charged amino groups on the protein molecule and the remaining free 
carboxyl groups of aspartic and glutamic acid residues make the net charge of the modified 
protein more negative. Szymkiewicz & Jędrychowski (Szymkiewicz & Jedrychowski, 2009) 
modified pea proteins with acetic or succinic anhydride. Immunoreactivity of albumins and 
legumin, as estimated by ELISA with rabbit polyclonal antibodies, was reduced by 91-99% 
and 78-97% after succinylation and acetylation, respectively, while immunoreactivity of 
vicilin fraction was reduced down to 12% and 17%, respectively. In their other study 
(Szymkiewicz & Jędrychowski, 2008) the authors combined enzymatic hydrolysis by 
Alcalase with chemical modification by acylation of pea proteins. The enzyme hydrolysis of 
acylation-modified pea proteins caused significant reduction in the immunoreactivity of pea 
proteins, especially vicilin, whose epitopes were the most resistant to the modifications, 
both chemical (Szymkiewicz & Jedrychowski, 2009) and enzymatic one (Szymkiewicz & 
Jędrychowski, 2005), applied separately. The application of Alcalase lowered the 
immunoreactivity of vicilin to 2-2.5%, while immunoreactivity of legumin and albumin 
decreased by nearly 100%. Thus, combining various methods of protein modification is 
more efficient and can be a promising approach for preparing products with reduced 
allergenicity. However, in ELISA tests with individual sera of patients allergic to 
leguminous seeds, IgE binging of pea proteins were reduced only by 40-75%, indicating that 
considerable decrease in the antigenicity of proteins not always guarantees their lower 
allergenicity and also shows differences in individual patients. 
Carbamoylation. Mistrello et al. (Mistrello et al., 1996) chemically modified ovalbumin by 
reaction with potassium cyanate (KCNO), which transforms the ε-amino group of the lysine 
of proteinaceous allergens into ureido groups. KCNO-modified (carbamylated) allergens 
have low allergenic potency, as demonstrated in vitro (RAST inhibition) and in vivo (passive 
cutaneous anaphylaxis). When used to immunize rabbits, carbamylated allergens still 
induce IgG antibodies able to cross-react with native allergens (immunoblotting 
experiments). Although potentially useful for immunotherapy formulations preparation this 
method is not suitable for hypoallergic food preparation. 
Nitration. In study of Untersmayr et al. (Untersmayr et al., 2010) BALB/c mice were 
immunized intragastrically by feeding untreated ovalbumin (OA) and nitrated ovalbumin 
(nOA) with or without acid-suppression. While oral immunizations of nOA under anti-acid 
treatment did not result in IgG and IgE formation, intraperitoneal immunization induced 
high levels of OA specific IgE, which were significantly increased in the group that received 
nOA by injection. Furthermore, nOA triggered significantly enhanced mediator release of 
effector cells of sensitized allergic animals. In gastric digestion experiments nOA was 
degraded within few minutes, whereas OA remained stable up to 120 min. Additionally, 
one tyrosine residue being very efficiently nitrated is part of an ovalbumin epitope 
recognized exclusively after oral sensitization. These data indicated that despite the 
enhanced triggering capacity in existing allergy, nitration of OVA may be associated with a 
reduced de novo sensitizing capability via the oral route due to enhanced protein 
digestibility and/or changes in antibody epitopes. Although the authors considered effects 
of endogenously nitrated allergen, these results imply that nitration of food allergen as 
method have no potential for reducing its allergenic potential. 
Conjugation with synthetic copolymer. Conjugates of ovalbumin (OA) and the copolymer 
of N-vinyl pyrrolidone and maleic anhydride (VMA) modified with epsilon-aminocaproic 
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acid (Acp) were prepared by Babakhin et al. (Babakhin et al., 1995). Of all conjugates 
injected intraperitoneally into mice only the conjugate containing 20%OA (OA-Acp-VMA) 
did induce anti-OA IgG antibodies without significant quantities of anti-OA IgE. In passive 
cutaneous anaphylaxis, RAST inhibition and leukocyte histamine release, OA-Acp-VMA 
have shown significant reduction of allergenicity and stimulated activation of the OA-
specific T-cell comparable to that of unconjugated OA. During experimental allergen-
specific hyposensitization with OA-Acp-VMA, suppression of anti-OA IgE response and 
elevation of anti-OA IgG responses were noted. By using the carrier Acp-VMA to reduce 
allergenicity there is selective blockage of B-cell epitopes of allergen without affecting T-cell 
epitopes, thereby preserving immunogenicity, which enable creation of preparations for 
allergen-specific immunotherapy. 
Polymerization by glutaraldehyde. By treatment with glutaraldehyde aldehyde groups of 
glutaraldehyde react with the amino groups of protein resulting in cross-linked allergen 
proteins with altered immunological characteristics (Patterson et al., 1979). Recently the 
ability of glutaraldehyde-treated allergens to stimulate T-cells has been disputed (Wurtzen 
et al., 2007). XiYang et al. (Yang et al., 1993) demonstrated that whereas in vivo 
administration of ovalbumin (OA) induces cytokine synthesis that is neither Thl nor Th2 
dominated, administration of glutaraldehyde polymerized, high relative molecular weight 
OA (OA-POL) leads to 20-fold increase in the ratio of interferon γ (IFN-γ)/IL-4 and IFN-
γ/IL-10 synthesis observed after short-term, antigen-mediated restimulation directly ex vivo. 
In contrast, concurrent in vivo administration of anti-IFN-γ/mAb and OA or OA-POL 
results in marked increases in IL-4 and IL-10, and decreased IFN-γ production, reflecting a 
polarization of the response towards a Th2-1ike pattern of cytokine synthesis. This is 
approach that allows selective activation of strongly Thl-dominated immune responses to 
protein antigens and it may be useful in clinical settings where the ability to actively select 
specific patterns of cytokine gene expression would be advantageous. Koppelman et al. 
(Koppelman et al., 2010) demonstrated that modification of peanut conglutin with 
glutaraldehyde (GA) does not result nor in a change of secondary structure nether in 
substantial decrease of IgE binding (only 2-3 fold). Reduction/alkylation treatment (RA) 
change secondary structures, whereas RA treatment followed by GA modification (RA-GA) 
results in a tertiary structure that differs from that of conglutin treated only with RA, due to 
modification of Cys and Lys residues. As demonstrated by IgE-ELISA and IgE blot 
treatment with RA-GA decreases IgE-binding up to a hundred fold and also induce a strong 
T cell response in T cell proliferation tests. These data demonstrate that all three 
modifications lead to a reduction in IgE binding, with the strongest reduction observed after 
both reduction/alkylation and glutaraldehyde treatment.  
3.1.1 Covalent hydrophilisation - conjugation with polysaccharides  
The shielding of epitopes by materials having low-antigenicity and immunogenicity may be 
efficient way of reducing allergenicity of the protein, especially with the use of a high 
molecular weight modifier to achieve effective shielding of epitopes. 
Carboxymethyldextran. Hattori et al. (Hattori et al., 2000) prepared BLG-carboxymethyl 
dextran conjugates (BLG-CMD), by using a water-soluble carbodiimide. The anti-BLG 
antibody response was markedly reduced after immunization with the BLG-CMD 
conjugates in mice. Linear epitope profiles of the BLG-CMD conjugates were similar to those 
of BLG, while the antibody response for each epitope was dramatically reduced. Reduction 
of immunogenicity of BLG depend on CMD content indicating that masking of epitopes by 
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acid (Acp) were prepared by Babakhin et al. (Babakhin et al., 1995). Of all conjugates 
injected intraperitoneally into mice only the conjugate containing 20%OA (OA-Acp-VMA) 
did induce anti-OA IgG antibodies without significant quantities of anti-OA IgE. In passive 
cutaneous anaphylaxis, RAST inhibition and leukocyte histamine release, OA-Acp-VMA 
have shown significant reduction of allergenicity and stimulated activation of the OA-
specific T-cell comparable to that of unconjugated OA. During experimental allergen-
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ability of glutaraldehyde-treated allergens to stimulate T-cells has been disputed (Wurtzen 
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results in marked increases in IL-4 and IL-10, and decreased IFN-γ production, reflecting a 
polarization of the response towards a Th2-1ike pattern of cytokine synthesis. This is 
approach that allows selective activation of strongly Thl-dominated immune responses to 
protein antigens and it may be useful in clinical settings where the ability to actively select 
specific patterns of cytokine gene expression would be advantageous. Koppelman et al. 
(Koppelman et al., 2010) demonstrated that modification of peanut conglutin with 
glutaraldehyde (GA) does not result nor in a change of secondary structure nether in 
substantial decrease of IgE binding (only 2-3 fold). Reduction/alkylation treatment (RA) 
change secondary structures, whereas RA treatment followed by GA modification (RA-GA) 
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treatment with RA-GA decreases IgE-binding up to a hundred fold and also induce a strong 
T cell response in T cell proliferation tests. These data demonstrate that all three 
modifications lead to a reduction in IgE binding, with the strongest reduction observed after 
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3.1.1 Covalent hydrophilisation - conjugation with polysaccharides  
The shielding of epitopes by materials having low-antigenicity and immunogenicity may be 
efficient way of reducing allergenicity of the protein, especially with the use of a high 
molecular weight modifier to achieve effective shielding of epitopes. 
Carboxymethyldextran. Hattori et al. (Hattori et al., 2000) prepared BLG-carboxymethyl 
dextran conjugates (BLG-CMD), by using a water-soluble carbodiimide. The anti-BLG 
antibody response was markedly reduced after immunization with the BLG-CMD 
conjugates in mice. Linear epitope profiles of the BLG-CMD conjugates were similar to those 
of BLG, while the antibody response for each epitope was dramatically reduced. Reduction 
of immunogenicity of BLG depend on CMD content indicating that masking of epitopes by 
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CMD is responsible for the decreased immunogenicity of the BLG conjugates due to 
effective shielding by CMD. Similar result were obtained by Kobayashi et al. (Kobayashi et 
al., 2001) who prepared BLG-CMD with different molar ratios. Results of both studies show 
that conjugation with CMD of higher molecular weight is effective in reducing the 
immunogenicity of BLG by masking of B cell epitopes by CMD. In their further study 
Kobayashi et al. (Kobayashi et al., 2003), investigated changes in the T cell response to BLG 
after conjugation with CMDs. When lymph node cells from mice immunized with BLG or 
the conjugates were stimulated with BLG, T cells from the conjugate-immunized mice 
showed a lower proliferative response comparing to BLG-immunized mice (Fig.1). T cell 
epitope profiles of the conjugates were similar to those of BLG, whereas the proliferative 
response to each epitope was reduced, indicating that the lower in vivo T cell response with 
the conjugates was not due to induction of conjugate-specific T cells, but due to a decrease in 
the number of BLG-specific T cells. In addition, conjugation with CMD enhanced the 
resistance of BLG to cathepsin B and cathepsin D, suggesting that conjugation with CMD 
inhibited the degradation of BLG by proteases in antigen presenting cells (APC) and led to 
suppression of the generation of antigenic peptides including T cell epitopes from BLG. 
Therefore, the authors considered that the suppressive effect on the generation of T cell 
epitopes reduced the antigen presentation of the conjugates and this reduction led to a 
decrease in the number of BLG-specific T cells in vivo. As a result, the decreased help to B 
cells by T cells would have reduced the antibody response to BLG leading to conclusion that 
suppression of the generation of T cell epitopes by conjugation with CMD is important to 
the mechanism for the reduced immunogenicity of BLG. 
 
 
Fig. 1. Proliferative response to BLG of lymph node cells from mice immunized with BLG 
(circles) or the BLG-CMD conjugates (triangles) and stimulated with BLG at various 
concentrations. The magnitude of the in vivo T cell response was evaluated as the ex vivo 
proliferative response by BrdU ELISA. Each value is expressed as the mean absorbance at 
450 nm and standard deviation of triplicate cultures after subtracting the background values 
(stimulated with PBS). Significant differences (p < 0.05) between BLG and each conjugate 
were determined by Student’s t-test and are indicated by asterisks. Reprinted with 
permission from (Kobayashi et al., 2003). Copyright (2003) American Chemical Society. 
Acidic polysaccharides. Hattori et al. (Hattori et al., 2004) conjugated BLG with the acidic 
oligosaccharides, alginic acid oligosaccharide (ALGO) and phosphoryl oligosaccharides 
(Pos), by the Maillard reaction. Fluorescence studies indicated surface of each conjugate was 
covered with a saccharide chain. The anti-BLG antibody response was markedly reduced 
after immunization with both conjugates in mice. Linear epitope profiles of the conjugates 
were found to be similar to those of BLG, whereas the antibody response to each epitope 
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was dramatically reduced. In particular, effective reduction of the antibody response was 
observed in the vicinity of the carbohydrate-binding sites. Obtained conjugates are edible, 
have higher thermal stability and improved emulsifying properties than those of native 
BLG, thus being very useful for food application. Yoshida et al. (Yoshida et al., 2005) 
demonstrate that the T cell response was reduced when mice were immunized with BLG-
ALGO conjugates and that novel epitopes were not generated by conjugation. The authors 
clarified that the BLG-ALGO conjugate modulated the immune response to Th1 dominance 
and considered that this property of the BLG-ALGO conjugate would be effective for 
preventing food allergy as well as by its reduced immunogenicity. Therefore, conjugation 
with acidic oligosaccharides could be applied to various food allergens to achieve reduced 
allergenicity with multiple improvements in their properties. 
Galactomannan. Babiker et al. (Babiker et al., 1998) prepared soy protein-galactomannan 
conjugate by the Maillard reaction. Conjugation removed the allergenicity of the 34 kDa 
protein which is frequently recognized by the IgE antibody in the sera of soybean-sensitive 
patients as a major allergen. Monitoring of polyclonal antibody titers by an indirect enzyme-
linked immunosorbent assay and immunoblotting of rabbit sera, monoclonal antibody, and 
human allergic sera showed that soy protein-galactomannan conjugation was more effective 
in reducing the allergenicity of the soy protein than transglutaminase treatments and/or 
chymotrypsin. Additionally, heat stability, solubility and emulsifying properties were 
greatly improved by conjugation with galactomannan. 
Chitosan. Aoki et al. (Aoki et al., 2006) conjugated BLG with chitosan (CHS) by means of a 
water-soluble carbodiimide to reduce its immunogenicity. The antigenicity of the BLG-CHS 
conjugates was similar to that of BLG in C3H/He mice, while immunogemicity of BLG was 
reduced by conjugation. The linear epitope profiles of the conjugates were found to be 
similar to those of BLG, while the antibody response to each epitope was dramatically 
reduced. The researchers suggested masking of B cell epitopes as one of the mechanisms in 
reduction of immunogenicity. 
Dextran-glycylglycine and amylose-glycylglycine. Nodake et al. (Nodake et al., 2010) 
conjugated BLG with the N-hydroxysuccinimide ester of the dextran-glycylglycine adduct 
(DG-ONSu) to reduce the immunogenicity of BLG. Conjugation with DG-ONSu greatly 
decreased the reactivity of BLG with anti-BLG antibodies and suppressed their production 
in vivo due to its shielding action for epitope(s) on the protein's molecular surface. Beside, 
DG-BLG was resistant to proteolytic enzymes. In the other study (Nodake et al., 2011) these 
authors demonstrated that conjugation BLG with the N-hydroxysuccinimide ester of the 
amylose-glycylglycine adduct (AG-ONSu) also greatly decreased the reactivity of BLG. The 
authors proposed usage of DG-ONSu and AG-ONSu to suppress the hypersensitivity 
mediated by IgE antibodies in milk allergy. 
3.1.2 Covalent lipophilization  
Stearic acid. In the study of Akita and Nakai (Akita & Nakai, 1990) BLG was chemically 
modified by covalent attachment of different levels of stearic acid. A decreased in vitro 
digestibility was observed with extent of stearic acid incorporation (lipophilization). At low 
lipophilization increased ability to elicit IgE antibodies, determined by heterologous passive 
cutaneous anaphylaxis, was observed. Medium level of lipophilization decreased this 
ability, while high lipophilization almost destroyed the ability to elicit IgE antibodies. The 
researchers also found that low- and medium-lipophilization increased while high 
lipophilization decreased the IgG binding ability, measured by ELISA. 
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were found to be similar to those of BLG, whereas the antibody response to each epitope 
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was dramatically reduced. In particular, effective reduction of the antibody response was 
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3.1.2 Covalent lipophilization  
Stearic acid. In the study of Akita and Nakai (Akita & Nakai, 1990) BLG was chemically 
modified by covalent attachment of different levels of stearic acid. A decreased in vitro 
digestibility was observed with extent of stearic acid incorporation (lipophilization). At low 
lipophilization increased ability to elicit IgE antibodies, determined by heterologous passive 
cutaneous anaphylaxis, was observed. Medium level of lipophilization decreased this 
ability, while high lipophilization almost destroyed the ability to elicit IgE antibodies. The 
researchers also found that low- and medium-lipophilization increased while high 
lipophilization decreased the IgG binding ability, measured by ELISA. 
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3.2 Noncovalent modifications 
Components of food matrix can interact noncovalentlly with food allergens resulting 
insoluble complexes thus lowering the level of soluble allergens and reducing their 
allergenic properties. Also they can reduce digestibility of food allergens and consequently 
their allergenicity by hindering access of digestive enzymes. Phenolic compounds and 
phytic acid are known to form soluble and insoluble complexes with proteins. For instance, 
it was shown that multivalent hydrophobic interactions cause compaction of cow’s milk 
caseins with the polyphenol epigallocatechin in way that individual casein molecules “wrap 
around” polyphenol (Jobstl et al., 2006). 
Phytic acid. Chung et al. (Chung & Champagne, 2007) treated peanut extract with phytic acid 
and demonstrated that phytic acid formed complexes with the major peanut allergens (Ara h 1 
and Ara h 2), reducing their solubility in acidic and neutral conditions. Also, 6-fold reduction 
in IgE binding of the extract was observed after treatment with phytic acid, observed by 
competitive inhibition ELISA using a pooled serum from peanut-allergic individuals. Similar 
result obtained with peanut butter slurry led to the suggestion that phytic acid treatment 
might reduce the allergenicity of peanut-based products due to reducing their solubility (Fig 
2). In another study by the same group of authors, a facilitated IgE binding in vitro was 
observed was peanut allergens and phytic acid. Apparently, phytic acid was able to stabilize 
allergen-antibody interactions (Chung & Champagne, 2006) However, usage of phytic acid 
might be limited considering its anti-nutritive properties due to ability to chelate iron.  
 
 
Fig. 2. a) SDS-PAGE and b) competitive inhibition ELISA of natural peanut butter slurry 
treated and centrifugated with and without phytic acid. Values are means ± SD (n=3). 
Values of the treated samples at 0.01–100 µg/mL are signicantly different from those of the 
control (P < 0.05, n=3). Reprinted with permission from (Chung & Champagne, 2007). 
Copyright (2003) American Chemical Society. 
Phenolic compounds: Adding of phenolics such as caffeic, chlorogenic and ferulic acids to 
peanut extracts, liquid peanut butter and peanut butter slurries, precipitated most of the 
major peanut allergens, Ara h 1 and Ara h 2, and complexation was irreversible (Chung & 
Champagne, 2008; Chung & Champagne, 2009). Of the three phenolics, caffeic acid formed 
the most precipitates with peanut extracts. IgE binding was reduced approximately 10- to 
16-fold as determined by inhibition ELISA (Fig. 3). Assuming that the insoluble complexes 
are not absorbed by the body the researchers concluded that reducing IgE binding by 
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phenolics is feasible and have a great potential in development of less allergenic liquid 
peanut-based products.  
 
 
Fig. 3. IgE binding of phenolic-treated and untreated peanut extracts in competitive 
inhibition ELISA using pooled human plasma from peanut-allergic individuals. Values (on 
semi-log scale) are mean of three determinations. Values between treatments (caffeic, 
chlorogenic, and ferulic) are not signicantly different from each other but from the 
untreated (P < 0.05). Reprinted from (Chung & Champagne, 2009 ), Copyright (2009), with 
permission from Elsevier. 
Polysaccharides. Mouecoucou et al. (Mouecoucou et al., 2004) examined the influence of 
polysaccharides, i.e., gum arabic, low methylated pectin (LMP) and xylan, on the in vitro 
hydrolysis of peanut protein isolate (PPI) and the in vitro allergenicity of the digestion 
products. PPI was hydrolyzed in vitro by pepsin, followed by a trypsin/ chymotrypsin 
(T/C) mixture in dialysis bags. Hydrolysis by all of the digestive enzymes showed retention 
of some proteins in the dialysis bags in the presence of gum arabic and xylan. The retentates 
were recognized by IgG and IgE, but IgE binding of retentate containing xylan was reduced. 
The immunoreactivity of hydrolysis products in dialysates was considerably reduced by 
polysaccharides. Polovic et al. (Polovic et al., 2007) demonstrated that addition of apple fruit 
pectin (1.5% and 3%) to the purified kiwi allergen Act c 2 was able to protect it from pepsin 
digestion in vitro. In vivo experiments on healthy non-atopic volunteers have shown that 1 h 
after ingestion of kiwi fruit in gastric content intact Act c 2 was still present. In their further 
work Polovic et al. (Polovic et al., 2010) discovered that after in vivo digestion of Act c 2 with 
pure pectin in rats both gastric acidity, as well as specific and total pepsin activity declined 
and thus protected 23% of the ingested allergen from digestion for 90 minutes. These results 
show that although presence of polysaccharides can be effective in masking of IgE epitopes, 
thus reducing allergenicity, it also reduces allergen digestibility, enabling higher dosages of 
the allergen to reach the immune system. 
Oxidized lipids. In study of Doke et al. (Doke et al., 1989) though oxidized soybean oil did 
not show any allergenicity, the IgE titer of sera from soybean-sensitive patients (in ELISA) 
was greatly increased when oxidized soybean oil was incubated with soybean 2S-globulin. 
The IgE titer became higher when greater amounts of oxidized soybean oil were used, but 
little difference was noted when soybean 2S-globulin was replaced by other food proteins. A 
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similar tendency was noted when soybean oil was replaced by other vegetable oils or fatty 
acids. The authors speculated that proteins interacted with oxidized lipid are allergenic to 
soybean-sensitive patients probably due to creation of new epitopes.  
3.3 Modifications by oxidation/reduction 
Oxidation. Heavy metal ions (Cu2+, Fe 2+, etc.) with hydrogen peroxide can cross-link 
proteins through oxidation of their tyrosine residues and forming dityrosine and 
isodityrosine, as well as by oxidation of sulfhydriles resulting in disulfides. In study of 
Chung et al. (Chung, 2005) extracts from raw and roasted peanuts were treated with 
Cu2+/H2O2 and only roasted peanuts were affected by Cu2+/H2O2 . In this case cross-links 
were formed and levels of Ara h 1 and Ara h 2 were reduced as shown in competitive 
inhibition ELISA with pooled serum of peanut-allergic individuals. IgE binding, overall, 
was lower despite some binding of IgE to cross-links leading to conclusion that Cu2+/H2O2 
reduced peanut allergenicity by inducing the decrease and cross-linking of peanut allergens.  
Reduction. The proteins are allergenically active and less digestible in the oxidized (S--S) 
state. When reduced (SH state), they lose their allergenicity and/or become more digestible. 
Allergen reduction can be performed by using a reducing agent such as 2-mercaptoethanol, 
dithiothreitol, cysteine, glutathione, etc., or by using proteins glutaredoxin or thioredoxin. In 
study of Buchanan et al. (Buchanan et al., 1997) thioredoxin mitigated the allergenicity of 
whey flour proteins, gliadins and glutenins, as determined by skin tests with a canine model 
for food allergy, but gave less consistent results with albumins and globulins. In the study of 
de Val et al. (del Val et al., 1999) after reduction of one or both of its disulfide bonds by 
thioredoxin, BLG became strikingly sensitive to pepsin in simulated gastric fluid and lost its 
allergenicity as determined by skin test responses and gastrointestinal symptoms in inbred 
colony of high IgE–producing dogs sensitized to milk. Koppelman et al. (Koppelnan et al., 
2007) modified 2S albumins by reduction by thioredoxin, resulting in breakage of disulfide 
bonds, followed by alkylation for prevention of reformation of disulfide bonds. Oral 
administration of native 2S albumin resulted in the development of Th-1 mediated IgG1- 
and Th-2 mediated IgG2a and IgE responses in the rat, as determined by ELISA. Oral 
exposure to RA-2S albumin did not result in the development of specific IgE against RA-2S, 
but IgGl and IgG2a antibodies against RA-2S albumin were formed in a lower level 
compared to native 2S albumin. Dosing of the animals with the low dose RA-2S albumin 
(0.1 mg protein/rat/day) did not result in an antibody response at all in the rats whereas the 
same dose of native 2S albumin induced specific IgGI, IgG2a and IgE responses, again 
indicating a lesser immunogenicity. Taken together, these data show that reduction of the 
disulphide bonds of 2S albumin results in loss of allergenicity and an increased sensitivity to 
digestion. All these results provide evidence that thioredoxin can be applied to enhance 
digestibility and lower allergenicity of food proteins. However, thioredoxins represent a 
novel family of cross-reactive allergens involved in the pathogenesis of atopic eczema and 
asthma. Also, cross-reactivity to human thioredoxin can contribute to the exacerbation of 
severe atopic diseases by involvement of IgE-mediated autoreactivity (Glaser et al., 2008). 
Considering these facts usage of thioredoxin in food allergen modification might be limited.  
4. Enzymatic modifications 
Beside proteolytic enzymes, enzymes able to cross-link proteins have shown to be promising 
tools for reduction of allergenicity of food proteins. Enzymatic cross-linking of proteins, by 
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transglutaminases, peroxisases and phenol oxidases (such as tyrosinases and laccases), is 
currently exploited in the food processing industry (Buchert et al., 2007). 
4.1 Transglutaminases  
Transglutaminases (TG) catalyze formation of a covalent bond between a primary amines 
(including ε-amino group of lysine residues) and the γ-carboxamid group of protein-bound 
glutamine leading to protein cross-linking.  
Villas-Boas et al. (Villas-Boas et al., 2010) polymerized heat treated BLG and TG (BLG-TG) 
and untreated BLG in the presence of cysteine and TG (BLG-Cys-TG). BALB/c mice 
sensitized with BLG-Cys-TG showed lower levels of IgG1 and IgE than those immunized 
with native BLG or BLG-TG, suggesting that polymerization in the presence of Cys 
modified or hid epitopes, reducing the potential antigenicity of BLG. Clare et al. (Clare et al., 
2007) cross-linked peanut flour dispersions with transglutaminase in the presence and 
absence of the dithiothreitol. Transglutaminase treatment did not diminish IgE binding 
responses in ELISA implying only that transglutaminase cross-linking do not enhance 
potential for allergic responses. In their further study Clare et al. (Clare et al., 2008) cross-
linked light roasted peanut flour (PF) with transglutaminase with casein (CN) as co-
substrate. In immunoblotting, in some patient sera IgE binding to TGase-treated PF-CN 
fractions appeared less compared to equivalent polymeric PF dispersions lacking 
supplemental CN and non-cross-linked PF-CN samples. The researchers assumed that 
covalent modification masked IgE peanut protein binding epitopes, at least to some degree, 
on an individual patient basis.  
In study of Wroblewska et al. (Wroblewska et al., 2008) whey protein concentrate (WPC) 
was modified by two enzymes: proteinase Alcalase and transglutaminase. The new 
products were characterized by 2D electrophoresis, immunoblotting, and ELISA methods. 
The WPC hydrolysate obtained with Alcalase contained proteins and peptides showing 
strong immunoreactive properties, as revealed by immunoblotting with α-la and β-lg 
polyclonal rabbit antibodies. However, the immunoblot analysis demonstrated that WPC 
showed a stronger reactivity towards IgE of allergic patients then WPC treated with 
transglutaminase. ELISA assay with human sera showed that two-step modification with 
Alcalase followed by TG significantly reduced the immunoreactive properties of whey 
proteins. Patients with wheat-dependent, exercise-induced anaphylaxis (WDEIA) 
experience recurrent anaphylactic reactions when exercising after ingestion of wheat 
products.  
Palosuo et al. (Palosuo et al., 2003) digested purified ω-5 gliadin, major allergen in WDEIA, 
with pepsin or with pepsin/trypsin and treated with tissue transglutaminase (tTG). The IgE-
binding ability of ω-5 gliadin was retained after pepsin and pepsin-trypsin digestion, as 
shown in IgE ELISA test. tTG treatment of the whole peptic digest resulted in cross-linked 
aggregates which bound IgE antibodies in immunoblotting more intensely than untreated, 
pepsin-digested, or pepsin-trypsin–digested ω-5 gliadin. In the 20 WDEIA patients the mean 
skin prick test wheal elicited by tTG treated peptic fraction was 77% larger than that elicited 
by the untreated peptic fraction and 56% larger than that elicited by intact ω-5 gliadin. These 
results suggest that activation of tTG during exercise in the intestinal mucosa of patients 
with WDEIA could lead to the formation of large allergen complexes capable of eliciting 
anaphylactic reactions. Leszczynska et al. (Leszczynska et al., 2006) modified wheat flour by 
the treatment with transglutaminase and demonstrated, in indirect non-competitive ELISA 
with human sera, reduction of glutenin immunoreactivity to below 30%.  
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Watanabe et al. (Watanabe, 2004) have made hypoallergenic flour by flour treatment with 
actinase, collagenase, and transglutaminase and that TG is the least effective of tested 
enzymes in reducing flour allergenicity. Soy protein-galactomannan conjugation was more 
effective in reducing the allergenicity of the soy protein than transglutaminase treatments 
(Babiker et al., 1998) (Fig. 4). In the study of Monogioudi et al. (Monogioudi et al., 2011) β-
casein was cross-linked of by transglutaminase and demonstrated that enzymatically cross-
linked β-casein was stable under acidic conditions and was more resistant to pepsin 
digestion when compared to non cross-linked β-casein. In the study of Stanic et al (Stanic et 
al., 2010) TG-treated casein showed no mitigated IgE binding reactivity compared with the 
untreated CN in BAT.  
 
 
Fig. 4. Determination of antibody titers by indirect ELISA of acid precipitated soy protein 
(APP), chymotrypsin digest (APPC), transglutaminase treated APP and galactomannan 
conjugate dry heated for 7 days. Error bars indicate the standard deviations (n=6). Reprinted 
with permission from (Babiker et al., 1998). Copyright (1998) American Chemical Society. 
As a microbial TG is included in many food technological processes, safety of the TG itself, 
as well as safety of the deamidated/cross-linked proteins generated by this enzyme should 
be checked (Malandain, 2005). In their study, Pedersen et al. (Pedersen et al., 2004) 
investigated the allergenicity of TG from Streptoverticillium mobaraens by evaluation of amino 
acid sequence similarity to known allergens, pepsin resistance, and detection of protein 
binding to specific serum immunoglobulin E (IgE) (RAST) evaluated as recommended by 
2001 FAO/WHO Decision Tree, recommended for evaluation of proteins from genetically 
modified organisms (GMOs). All tests demonstrated that there is no safety concerns with 
regard to the allergenic potential of tested TG. 
4.2 Peroxidases 
Peroxidases (POD) are a heme-containing enzymes catalyzing the oxidation of a variety of 
organic compounds by hydrogen peroxide or hydroperoxides. Acting on phenolic 
compounds POD generate o-quinones, which further react with other phenolics, amino, or 
sulfhydryl compounds in proteins to form cross-linked products. 
In their study Chung et al. (Chung et al., 2004) have treated protein extracts from raw and 
roasted defatted peanut meals with POD in the presence of hydrogen. While POD treatment 
had no effect on raw peanuts, a significant cross-linking and decrease in the levels of the 
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major allergens, Ara h 1 and Ara h 2, in roasted peanuts (Fig.7) was observed in imunoblots 
and IgE ELISA. The authors suppose that POD induced the cross-linking of mainly Ara h 1 
and Ara h 2 from roasted peanuts and that, due to POD treatment, IgE binding was 
reduced.  
Garcia et al. (Garcia et al., 2007) investigated effect of peroxidase and antioxidant 
diethyldithiocarbamic acid (DIECA) on IgE-binding by Mal d 1, the major apple allergen. In 
competitive ELISA IgE-binding by Mal d 1 decreased by adding peroxidase with more 
pronounced effect in presence of catechin. DIECA protected the IgE-binding by the allergen, 
protection being less strong in the presence of exogenous peroxidase (Fig 5).  
Weangsripanaval et al. (Weangsripanaval et al., 2003) purified and characterized new 
allergenic protein from the tomato identified as suberization-associated anionic peroxidase 
1. Furthermore, SanchezMonge et al. (SanchezMonge et al., 1997) purified and characterized 
allergenic protein from wheat flour identified as seed-specific peroxidase. These facts imply 
that peroxidases themselves can be allergens and safety for use them must be assessed. 
 
 
Fig. 5. Influence of the treatments performed on apple peel samples on Mal d 1 
concentration determined by competitive ELISA using a pool of sera. The treatments 
consisted of: additional peroxidase (POD), additional substarte catechin, additional catechin 
combined with POD, additional diethyldithiocarbamic acid (DIECA) and additional DIECA 
combined with POD.T he incubation times were 0, 1, 2, 5, and 24 h at room temperature. 
Reprinted from (Garcia et al., 2007), Copyright (2007), with permission from Elsevier.  
4.3 Phenol oxidases 
4.3.1 Polyphenoloxidases (tyrosinases)  
Polyphenol oxidases (PPO) or tyrosinases are bifunctional enzymes catalyzing o-
hydroxylation of monophenols (including protein-bound tyrosine residues) to o-diphenols 
and subsequent oxidation of o-diphenols to o-quinones (Lerch, 1983). Reactive o-quinones 
can further undergo non-enzymatic polymerization or can react with amino acid residues in 
proteins. 
In the study of Gruber et al. (Gruber et al., 2004) incubation of recombinant Pru av 1, major 
cherry allergen, with phenol compounds in the presence of tyrosinase led to decrease in IgE-
binding activity of the protein as revealed by EAST and inhibition assays. Caffeic acid and 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
94
Watanabe et al. (Watanabe, 2004) have made hypoallergenic flour by flour treatment with 
actinase, collagenase, and transglutaminase and that TG is the least effective of tested 
enzymes in reducing flour allergenicity. Soy protein-galactomannan conjugation was more 
effective in reducing the allergenicity of the soy protein than transglutaminase treatments 
(Babiker et al., 1998) (Fig. 4). In the study of Monogioudi et al. (Monogioudi et al., 2011) β-
casein was cross-linked of by transglutaminase and demonstrated that enzymatically cross-
linked β-casein was stable under acidic conditions and was more resistant to pepsin 
digestion when compared to non cross-linked β-casein. In the study of Stanic et al (Stanic et 
al., 2010) TG-treated casein showed no mitigated IgE binding reactivity compared with the 
untreated CN in BAT.  
 
 
Fig. 4. Determination of antibody titers by indirect ELISA of acid precipitated soy protein 
(APP), chymotrypsin digest (APPC), transglutaminase treated APP and galactomannan 
conjugate dry heated for 7 days. Error bars indicate the standard deviations (n=6). Reprinted 
with permission from (Babiker et al., 1998). Copyright (1998) American Chemical Society. 
As a microbial TG is included in many food technological processes, safety of the TG itself, 
as well as safety of the deamidated/cross-linked proteins generated by this enzyme should 
be checked (Malandain, 2005). In their study, Pedersen et al. (Pedersen et al., 2004) 
investigated the allergenicity of TG from Streptoverticillium mobaraens by evaluation of amino 
acid sequence similarity to known allergens, pepsin resistance, and detection of protein 
binding to specific serum immunoglobulin E (IgE) (RAST) evaluated as recommended by 
2001 FAO/WHO Decision Tree, recommended for evaluation of proteins from genetically 
modified organisms (GMOs). All tests demonstrated that there is no safety concerns with 
regard to the allergenic potential of tested TG. 
4.2 Peroxidases 
Peroxidases (POD) are a heme-containing enzymes catalyzing the oxidation of a variety of 
organic compounds by hydrogen peroxide or hydroperoxides. Acting on phenolic 
compounds POD generate o-quinones, which further react with other phenolics, amino, or 
sulfhydryl compounds in proteins to form cross-linked products. 
In their study Chung et al. (Chung et al., 2004) have treated protein extracts from raw and 
roasted defatted peanut meals with POD in the presence of hydrogen. While POD treatment 
had no effect on raw peanuts, a significant cross-linking and decrease in the levels of the 
 
Enzymatic and Chemical Modifications of Food Allergens 
 
95 
major allergens, Ara h 1 and Ara h 2, in roasted peanuts (Fig.7) was observed in imunoblots 
and IgE ELISA. The authors suppose that POD induced the cross-linking of mainly Ara h 1 
and Ara h 2 from roasted peanuts and that, due to POD treatment, IgE binding was 
reduced.  
Garcia et al. (Garcia et al., 2007) investigated effect of peroxidase and antioxidant 
diethyldithiocarbamic acid (DIECA) on IgE-binding by Mal d 1, the major apple allergen. In 
competitive ELISA IgE-binding by Mal d 1 decreased by adding peroxidase with more 
pronounced effect in presence of catechin. DIECA protected the IgE-binding by the allergen, 
protection being less strong in the presence of exogenous peroxidase (Fig 5).  
Weangsripanaval et al. (Weangsripanaval et al., 2003) purified and characterized new 
allergenic protein from the tomato identified as suberization-associated anionic peroxidase 
1. Furthermore, SanchezMonge et al. (SanchezMonge et al., 1997) purified and characterized 
allergenic protein from wheat flour identified as seed-specific peroxidase. These facts imply 
that peroxidases themselves can be allergens and safety for use them must be assessed. 
 
 
Fig. 5. Influence of the treatments performed on apple peel samples on Mal d 1 
concentration determined by competitive ELISA using a pool of sera. The treatments 
consisted of: additional peroxidase (POD), additional substarte catechin, additional catechin 
combined with POD, additional diethyldithiocarbamic acid (DIECA) and additional DIECA 
combined with POD.T he incubation times were 0, 1, 2, 5, and 24 h at room temperature. 
Reprinted from (Garcia et al., 2007), Copyright (2007), with permission from Elsevier.  
4.3 Phenol oxidases 
4.3.1 Polyphenoloxidases (tyrosinases)  
Polyphenol oxidases (PPO) or tyrosinases are bifunctional enzymes catalyzing o-
hydroxylation of monophenols (including protein-bound tyrosine residues) to o-diphenols 
and subsequent oxidation of o-diphenols to o-quinones (Lerch, 1983). Reactive o-quinones 
can further undergo non-enzymatic polymerization or can react with amino acid residues in 
proteins. 
In the study of Gruber et al. (Gruber et al., 2004) incubation of recombinant Pru av 1, major 
cherry allergen, with phenol compounds in the presence of tyrosinase led to decrease in IgE-
binding activity of the protein as revealed by EAST and inhibition assays. Caffeic acid and 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
96
epicatechin showed to be the most efficient in decreasing of rPru av 1 IgE-binding activity, 
followed by catechin and gallic acid, while quercetin and rutin were the least efficient. 
However, PPO without the addition of a phenolic compound did not display a reduction in 
IgE binding. The researchers speculated that, reactive intermediates formed during 
enzymatic polyphenol oxidation are responsible for modifying nucleophilic amino acid side 
chains of proteins, thus inducing an irreversible change in the tertiary structure of the 
protein and resulting in a loss of conformational epitopes of the allergen. In study of Chung 
et al. (Chung et al., 2005) peanut extracts were treated with and without PPO, PPO/caffeic 
and caffeic acid. All treatments resulted in cross-linking and decreased the levels and IgE 
binding (competitive inhibition ELISA) of two peanut major allergens, Ara h 1 and Ara h 2, 
with PPO/caffeic as the most effective (Fig.6).  
 
 
Fig. 6. Inhibition of IgE antibodies in a competitive inhibition ELISA by (a) PPO- and 
PPO/caffeic-treated extracts, pH 8, and (b) caffeic-treated extract, pH 10.5. Extracts, diluted 
at the concentration indicated, were each mixed with a pooled serum from peanut allergic 
individuals, and then added to an allergen-coated microtiter plate. Values are means ± SD (n 
= 3). Values of the treated samples at 1–100 μg mL−1 are significantly different from those of 
the control (P < 0.05, n = 3).Reprinted from (Chung et al., 2005), Copyright (2005), with 
permission from John Wiley and Sons.  
In their further study Chung et al. (Chung & Champagne, 2008) treated peanut butter 
slurries with phenolic compounds/PPO and obtained reduction in IgE-binding, despite the 
formation of soluble allergen complexes or cross-links, for which authors assume that are 
less allergenic. Novotna et al. (Novotna et al., 2011) investigated effects of celery juice by 
oxidation by utilising its natural polyphenol oxidase (PPO) content on the reduction of the 
content of the Api g1, the main celery allergen. Oxidation failed to eliminate the 
allergenicity of pure celery juice, but oxidation in apple-celery juices reduced the 
allergenicity of the mixture. However, the basophil activation test showed no reduction in 
the allergic response to the oxidised juice mixture. Skin testing showed that the prolonged 
oxidation of juice mixture showed significantly lower reaction, while apple juice stabilised 
with ascorbic acid did not have effect. Due to the contradictory results in different tests, the 
method cannot be declared successful or safe, even for mixtures of apple-celery juices. In 
competitive ELISA Garcia et al. (Garcia et al., 2007) demonstrated decreased IgE binding of 
Mal d 1 after enrichment of apple extract with PPO, with the strongest effect in presence of 
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catechin. Antioxidant DIECA protected the IgE-binding by the allergen, protection being less 
strong in the presence of exogenous PPO. Schmitz et al. (Schmitz-Eiberger & Matthes, 2011) 
evaluated relationship between Mal d 1, the main apple allergen, content and PPO, total 
phenol content and antioxidative capacity in different apple varietie. Whereas higher PPO 
activities and polyphenols contents result in less extractable Mal d 1, higher antioxidative 
activity can inhibit the interaction between oxidised phenols and Mal d 1, resulting in higher 
allergenicity (extractable Mal d 1). In the study of Monogioudi et al. (Monogioudi et al., 2011) 
β-casein was cross-linked of by tyrosinase and demonstrated that enzymatically cross-linked 
b-casein was stable under acidic conditions and was more resistant to pepsin digestion when 
compared to non cross-linked b-casein. In the study of Stanic et al. (Stanic et al., 2010) 
tyrosinase treated casein showed mitigated IgE binding reactivity, compared with the 
untreated CN, only in the presence of caffeic acid as mediator in BAT.  
4.3.2 Laccases 
Laccases catalyse oxidation of various phenolic compounds with one electron mechanism 
generating free radical species. Reactive free radicals can further undergo non-enzymatic 
polymerization or can react with high redox potential substrate targets, such as amino acid 
residues in proteins (Canfora et al., 2008). 
 
 
Fig. 7. Basophil activation to casein and crosslinked caseins in seven patients with CMA. 
p<0.05 was statistically significant difference in a Wilcoxon-maitched pairs test. Reprinted 
from (Stanic et al., 2009), Copyright (2009), with permission from John Wiley and Sons.  
Tantoush et al. (Tantoush et al., 2011) cross-linked BLG by laccase in the presence of an sour 
cherry phenolics. In a BAT assay, the allergenicity of the cross-linked protein was shown to 
decrease in all nine cow’s milk-allergic patients, while digestibility of the remaining 
monomeric BLG in simulated conditions of the gastrointestinal tract increased. In the further 
study of Tantoush et al. (Tantoush et al., 2011) cross-linking BLG by laccase in the presence 
of apple phenolics (APE) rendered the protein insoluble in the reaction mixture consisting of 
cross-linked BLG, with a fraction of the BLG remaining monomeric. Enzymatic processing 
of BLG decrease the bi-phasal pepsin–pancreatin digestibility of the monomeric and cross-
linked protein, thus decreasing its nutritional value. Stanic et al. (Stanic et al., 2010) 
crosslinked β-casein (CN) by laccase and caffeic acid and demonstrated that crosslinking 
was not very efficient, leaving mostly monomeric CN modified by caffeic acid. Regardless to 
that ability of crosslinked CNs to activate basophils was significantly reduced in seven 
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patients and reduced inhibition potential is possibly due to hindering of epitopes by 
monomer modification. Also, digestion of crosslinked CN by pepsin was hampered.  
As enzyme preparations used in food technology are food grade, but often not of the highest 
purity, they can contain contaminating enzyme activities. These so-called ‘‘side activities’’ 
even if present only in trace quantities, can have unpredictable influence on functional 
properties, nutritional quality and safety of food implying that effects of contaminating 
enzymes in used enzyme preparations should be carefully monitored. Stanic et al. (Stanic et 
al., 2009) found out that in the presence of high purity commercial laccase and tyrosinase 
preparations, both variants of BLG (A and B) underwent removal of a peptide from the N-
terminus. The truncated forms were more susceptible to digestion by pepsin and thus with 
lower allergenic potential. 
5. Conclusion 
In development of new methods for food allergen modification there are two main 
applications. First one, and the most frequent, is creation of hypoallergic food and food 
additives, and the second one is preparation of formulations for safe immunotherapy of 
food allergies. In addition to the main aim, reduction of allergenicity, there are several other 
requirements that must be satisfied for certain application. For both applications safety is 
obligatory, implicating usage of minimal toxic and nonalleregnic agents, including the main 
and auxiliary one. Preferred reagents used for allergen modification are those acceptable for 
the production of foodstuffs or pharmaceuticals. In that sense, recent researches are more 
focused on usage of enzymes as modification agents, as well as compounds naturally 
occurring in food. Also, all products of modification reaction, not only modified allergen, 
must be safe or successfully eliminated/degraded in further processing and expenses of 
method have to be reasonable. For food industry desirable physico-chemical properties of 
modified proteins are important as they determine technological properties such as 
solubility, pH stability, gelling, foaming, emulsifying properties etc., as well as nutritional 
value and impact on taste and flavor. Allergen modifications, although efficient in reducing 
allergenicity, do not bare potential for application in food industry if mentioned properties 
are significantly disturbed, as for food industry the most important is consumer`s 
acceptance of certain food (texture, taste, stability, natural origin, etc.). Typical example are 
extensive protein hydrolysates, although highly hypoallergenic, having bitter taste, which is 
difficult to mask, and high osmolarity. For immunotherapy preparations, in addition to 
reduced/eliminated allergenicity and preserved immunogenicity, immunomodulatory 
properties are highly desirable for increasing immunotherapy efficiency. Also, physico-
chemical properties of modified proteins define their stability, such as susceptibility for 
proteolysis and heat denaturation. 
There is numerous studies focusing on modification of food protein as new properties 
enable design of more different food products and exploitation of cheap high nutritional 
food sources. Many of methods for reducing food protein allergenicity emerged from these 
studies, as evidenced by in parallel investigation of techno-functional properties and 
allergenicity testing in some publications. Reducing of allergenic properties by chemical or 
enzymatic methods was demonstrated on full extract, raw or pretreated, or on isolated 
allergens from peanut, wheat, whey, soy, pea and cherry. The most frequently modified 
food allergens are BLG and ovalbumin. BLG was interesting due to its high nutritional 
value, important functional properties and its availability as by-product cheese industry. 
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Ovalbumin was the most frequently used as a model allergen in studies using animal 
models. 
As reducing of alleregenicity can be achieved by removal of epitopes, destruction of 
epitopes, and by their masking, knowledge of the structural aspects of allergenicity and of 
the factors that determine epitope integrity will lead to novel and more specific approaches 
to decrease allergenicity. By treatment with chemical or enzyme agent only few amino acid 
residues of allergen react, such as residues of lysine, arginine, cystein, tyrosine. Therefore, 
epitope containing these residues are expected to be changed/masked in significant extent 
and knowing the epitope structure can help in prediction which method would be the most 
successful. In addition to B cell epitope changes, changes in T cell eptopes can significantly 
contribute reduction of allergic response as well. T cells provide help to B cells, by direct 
interaction and secretion of cytokines, and promote their proliferation and differentiation 
into antibody producing cells (Kaminogava, 1996). Therefore, during allergen modification 
formation of bonds non-hydrolisabile by processing machinery in APC, can change T cell 
epitope profiles of allergens and have influence on direction of immune response, 
potentiating allergy or tolerance. 
It seems that the most effective approach for allergen modification is combination of two or 
more methods acting by different mechanisms, such as combination of acylation and 
proteolysis (Szymkiewicz & Jedrychowski, 2008), reduction, alkylation and cross-linking 
(Koppelman et al., 2010), cross-linking and reduction (Villas-Boas et al., 2010), proteolysis 
and cross-linking (Wroblewska et al., 2008). Covalent modification of allergens by edible 
high molecular mass polysaccharides is effective and acceptable way for designing 
hypoallergic food formulatios offering also improved techno-functional properties. 
However, low immugenicity of modifications limits this method for creation of effective 
immunotherapy preparations.  
Of all applied cross-linking enzymes it seems that transglutaminase is the least efficient in 
reducing protein allergenicity, and only when it is combined with allergen reduction or in 
the presence of co-substrate or with proteolysis. Although for the efficiency of peroxidase 
there are only sparse data, food allergen cross-linking with phenol oxidases (tyrosinases, 
laccases) with assistance of small phenolic compounds have great potential. It looks like that 
protein cross-linking itself is not enough for significant masking IgE epitopes and that 
phenolic mediators contribute by modification of the nucleophilic surface residues in the 
protein and the hindering of the epitopes by their covalent attachment in a highly 
aggregated product, as well as to monomer allergen. Also, it seems that cross-linked 
allergens are more resistant to digestion then their monomeric form. It is well known that 
proteins resistant to both gastric and intestinal digestion are not allergenic. The data from 
animal models show that both gastric and intestinal-resistant allergens do not carry strong 
food-allergy risk or induce oral tolerance, simply because both food-allergy and oral-
tolerance are MHC class II-dependent processes and require antigen presentation to the 
immune system i.e. readily available peptides in intestinal fluids (Bowman & Selgrade, 
2008).  
For the most methods mentioned in this review exhaustive studies on human subjects, 
including DBPCFC tests, are needed in order to design food with label hypoallergenic. As 
substantial part of the population reacts to very low amounts of allergens, residual 
unmodified allergen that remain after modification can still bind IgE and elicit symptoms in 
highly sensitive patients (Wensing et al., 2002). Also some modifications may be clinically 
relevant for some allergic individuals but not for others. The method for allergen 
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epitopes, and by their masking, knowledge of the structural aspects of allergenicity and of 
the factors that determine epitope integrity will lead to novel and more specific approaches 
to decrease allergenicity. By treatment with chemical or enzyme agent only few amino acid 
residues of allergen react, such as residues of lysine, arginine, cystein, tyrosine. Therefore, 
epitope containing these residues are expected to be changed/masked in significant extent 
and knowing the epitope structure can help in prediction which method would be the most 
successful. In addition to B cell epitope changes, changes in T cell eptopes can significantly 
contribute reduction of allergic response as well. T cells provide help to B cells, by direct 
interaction and secretion of cytokines, and promote their proliferation and differentiation 
into antibody producing cells (Kaminogava, 1996). Therefore, during allergen modification 
formation of bonds non-hydrolisabile by processing machinery in APC, can change T cell 
epitope profiles of allergens and have influence on direction of immune response, 
potentiating allergy or tolerance. 
It seems that the most effective approach for allergen modification is combination of two or 
more methods acting by different mechanisms, such as combination of acylation and 
proteolysis (Szymkiewicz & Jedrychowski, 2008), reduction, alkylation and cross-linking 
(Koppelman et al., 2010), cross-linking and reduction (Villas-Boas et al., 2010), proteolysis 
and cross-linking (Wroblewska et al., 2008). Covalent modification of allergens by edible 
high molecular mass polysaccharides is effective and acceptable way for designing 
hypoallergic food formulatios offering also improved techno-functional properties. 
However, low immugenicity of modifications limits this method for creation of effective 
immunotherapy preparations.  
Of all applied cross-linking enzymes it seems that transglutaminase is the least efficient in 
reducing protein allergenicity, and only when it is combined with allergen reduction or in 
the presence of co-substrate or with proteolysis. Although for the efficiency of peroxidase 
there are only sparse data, food allergen cross-linking with phenol oxidases (tyrosinases, 
laccases) with assistance of small phenolic compounds have great potential. It looks like that 
protein cross-linking itself is not enough for significant masking IgE epitopes and that 
phenolic mediators contribute by modification of the nucleophilic surface residues in the 
protein and the hindering of the epitopes by their covalent attachment in a highly 
aggregated product, as well as to monomer allergen. Also, it seems that cross-linked 
allergens are more resistant to digestion then their monomeric form. It is well known that 
proteins resistant to both gastric and intestinal digestion are not allergenic. The data from 
animal models show that both gastric and intestinal-resistant allergens do not carry strong 
food-allergy risk or induce oral tolerance, simply because both food-allergy and oral-
tolerance are MHC class II-dependent processes and require antigen presentation to the 
immune system i.e. readily available peptides in intestinal fluids (Bowman & Selgrade, 
2008).  
For the most methods mentioned in this review exhaustive studies on human subjects, 
including DBPCFC tests, are needed in order to design food with label hypoallergenic. As 
substantial part of the population reacts to very low amounts of allergens, residual 
unmodified allergen that remain after modification can still bind IgE and elicit symptoms in 
highly sensitive patients (Wensing et al., 2002). Also some modifications may be clinically 
relevant for some allergic individuals but not for others. The method for allergen 
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modification applied to food source, such as wheat, peanut, soy flour or WPI, may change 
different allergens to a different extent. Therefore, methods enabling a reduction of 
allergenicity of all proteins should be used or different types of modification should be 
applied simultaneously.  
In the future further and more fundamental researches in this multidisciplinary field is 
necessary in order to develop novel hypoallergenic foods and food additives on one hand, 
and to obtain suitable preparations enabling safe and efficient food allergen-specific 
immunotherapy in clinical practice on the other hand.  
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1. Introduction
Food allergy is increasing at a faster rate than any other allergic disorder (Gupta et al., 2007).
In the last few decades, a large movement toward healthier eating makes seafood one of the
major foods consumed worldwide (Wild & Lehrer, 2005). Consequently, the international
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Salmon, plaice, tuna, hake, cod,
herring, pilchard, anchovy,
trout, swordfish, sole, pomfret,
yellowfin, fishmeal (flour)
Chondrichthyes




Red soft coral, Daphnia, Marine
sponge, Algae
Table 1. Seafood species causing occupational allergy and asthma [Reproduced with
permission from (Jeebhay et al., 2001)].
1.1 Shellfish allergens
In shellfish, crustaceans and mollusks, the protein tropomyosin (TM) seems to be the major
allergen responsible for ingestion-related allergic reactions (Table1). Tropomyosin belongs to
the family of actin filament-binding proteins with different isoforms that can be expressed
in muscle, and non-muscle tissues. A complex of TM and troponin regulates the calcium
sensitive interaction of actin and myosin. Tropomyosin in crustaceans was first identified
in shrimp in 1981 by Hoffman et al (Hoffman et al., 1981). Shanti et al. reported an 86%
amino acid sequence homology between the Penaeus indicus shrimp allergen Pen i 1 and fruit
fly (Drosophila melanogaster) TM (Shanti et al., 1993). The open reading frame of the cloned
TM in invertebrates was reported to be 281-amino acids with a monomeric molecular weight
ranging from 38-41 kDa. The highly conserved amino acid sequence of TM is responsible for
its identification as a panallergen for cross-reactivity between crustaceans, insects, arachnids,
and different classes of mollusks (Rodriguez et al., 1997; Wild & Lehrer, 2005). In addition, the
allergenicity of TM was confirmed in six species of crustaceans: black tiger prawn, kuruma
prawn, pink shrimp, king crab, snow crab, and horsehair crab by immunoblotting and the
overall sequence identity showed more than 90% homology (Motoyama et al., 2007).
Many other allergens have been identified in crustaceans. Yu’s group identified arginine
kinase (AK) (40 kDa) as a novel shrimp allergen (Yu et al., 2003). The amino acid sequence of
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Fig. 1. Mechanisms of allergic and non-allergic inflammation in seafood exposed individuals
(Modified and adapted from (Lehrer et al., 1996).
this protein showed 60% similarity to AK of the crustacean, kuruma prawn (Penaeus japonicas)
(Yu et al., 2003). AK was recently reported as an allergen in different crustacean species
which was identified in white shrimp (Litopenaeus vannamei) (García-Orozco et al., 2007), gulf
shrimp (Penaeus aztecus) (France et al., 1997), chinese shrimp (Fenneropenaeus chinensis) (Yao
et al., 2005), black tiger prawn (Penaeus monodon) and other shrimp species using a proteomics
approach (Abdel Rahman et al., 2010a; Yu et al., 2003). Moreover, AK has been identified in
other crab species: mud crab (Scylla serrata) (Shen et al., 2011), and by our group in snow
crab (Chionoecetes opilio) (Abdel Rahman et al., 2011), where 49% of the participant patient’s
sera have a reactivity with AK. Arginine kinase also has been reported is allergen in some
other invertebrates, such as the house dust mite (Dermatophagoides farinae) (Bi & Chew, 2004),
Indian-meal moth (Plodia interpunctella) (Binder et al., 2001), and silkworm larvae (Bombyx
mori) (Liu et al., 2009).
Recent studies have reported other novel crustacean allergens. In 2008, Shiomi et al. identified
the immunoreactive band (20 kDa) as sarcoplasmic reticulum Ca-binding protein, which
was consequently extracted from black tiger shrimp (Penaeus monodon) (Shiomi et al., 2008).
Recently, this allergen was also identified in white shrimp (Litopenaeus vannamei) (Ayuso et al.,
2009), and in snow crab (Chionoecetes opilio) (Abdel Rahman et al., 2011). Sarcoplasmic calcium
binding protein (SCP) is an invertebrate EF-hand calcium buffering protein that fulfills a
similar function in muscle relaxation as vertebrate major allergen parvalbumin (White et al.,
2011).
In 2008, myosin light chain was identified as an allergen in white shrimp (Litopenaeus
vannamei) (Ayuso et al., 2008; 2010), and our group also identified in black tiger prawn (Penaeus
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monodon) (Abdel Rahman et al., 2010a). Since TM is a common allergen in both crustaceans
and mollusks (Ishikawa et al., 1998a;b; Lopata et al., 1997; Miyazawa et al., 1996; Suma et al.,
2007), other potent allergens such as myosin heavy chain (Martins et al., 2004), troponin,
actine, hemocyanin (Juji et al., 1990; Koshte et al., 1989; Maeda et al., 1991), and amylase
(Azofra & Lombardero, 2003) are reported also in molluscan shellfish. These allergens were
identified and characterized in different species such as mussel, oyster, and could exist alone
in crustaceans (Table 2) (Taylor, 2008). Some of these allergenic proteins are rapidly degraded
within a short period of digestion time, while TM seems to be relatively resistant to acidic
digestion (Huang et al., 2010; Liu et al., 2010; 2011).
1.2 Fish allergens
The Atlantic cod was the first model for studying fish allergens, Gad c 1(12 kDa) (Aas &
Elsayed, 1969; Aas & Lundkvist, 1973; Elsayed & Aas, 1970). This glycoprotein is identified
later as parvalbumin, which buffers calcium during muscle relaxation. Parvalbumin has a
higher natural abundance in the lower invertebrates than the fast twitch muscles of higher
vertebrates (Lehky et al., 1974). Parvalbumin represents the major clinical cross-reactive fish
allergen with sequence homology ranging from 60-80%. This feature was comprehensively
applied to exploit the closeness between fish allergens and their human homologs (Jenkins
et al., 2007). Parvalbumin, with allergen molecular mass ranges from 10-13 kDa, contains
heat-resistant linear epitopes that are stabilized by the interaction of metal-binding domains
(Lopata & Lehrer, 2009). The allergenicity of the parvalbumin was studied in purified forms
from different types of fish along with two other high molecular weight allergens: 29 and
54 kDa (Beale et al., 2009; Lim et al., 2008; Rehbein & Lopata, 2011). The polymeric form
of the parvalbumin is also reported as a high molecular weight allergen (Besler et al., 2000;
Rosmilah et al., 2005). In addition, other fish allergens are characterized such as collagen and
gelatin isolated from skin (Sakaguchi et al., 2000) and muscle tissues (Taylor et al., 2004), fish
hormones like vitellogenin in caviar (Escudero et al., 2007; Perez-Gordo et al., 2008), and many
other allergens reviewed in detail by Lopata and Lehrer 2009. The literature reports that there
is no cross-reactivity between fish allergens and shellfish (Lopata & Lehrer, 2009).
2. Allergen discovery platforms
Raw and cooked seafood extracts are used to diagnose allergic sensitization in individuals by
skin prick test (Jeebhay et al., 2008). These in-vivo assays lack the molecular information
needed for component resolved diagnostics and initiated the development of various
biomolecular and chemical approaches.
The seafood allergens discovery platform is reviewed as described in Fig. 2, which starts
with the allergenic protein separation, western blotting, and amino acid sequencing. This
developed strategy for allergen identification has expedited the discovery of the seafood
allergens in two dimensions: among the same species (different allergens) and between
other species (cross-reactivity). The cross-reactivity between the novel allergen and the
equivalent protein in other species can be investigated by applying the same strategy that
is used for the investigation but using the same antibody. The idea for this strategy is based
mainly on the high level of homology between the same functional proteins, which makes
the extensive characterization using molecular biology techniques more feasible. The most
common seafood allergens and the used method(s) for the characterization and quantification
are summarized in Table 2.
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Techniques
Species Allergen/code Characterization Quantification Reference
Tropomyosin Cra c1,
Lit v1, Met e1, Pan
b1, Pen a1, Pen i1,
Pen m1
RAST, MG, MS ELISA, MS
(Abdel Rahman et al.,
2010a; Leung et al., 1994;







c2, Lit v2, Pen m2,
Met e 2, Met j 2
MG, MS MS
(Abdel Rahman et al.,
2010a; García-Orozco
et al., 2007; Yoon et al.,











protein/ Cra c4, Pen




N/A (Ayuso et al., 2009;Shiomi et al., 2008)
Myosin, light chain










et al., 2008; 2010)
Troponin C/ Pen m6,
Cra c6 MG N/A WHO-IUIS Allergen DB
Triosephosphate
isomerase/Cra c8 MG N/A WHO-IUIS Allergen DB
Table 2. The most common known seafood allergens and the method of their characterization
and quantification. [MG: Molecular genetics, WB: western blotting, MS: Mass spectrometry,
ELISA: Enzyme-linked immunosorbent assay]
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Species Allergen/code Characterization Quantification Reference
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Table 2. The most common known seafood allergens ..... continued from previous page
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Fig. 2. The allergen discovery platform: starting from the seafood meat and ending by the
characterization and quantification approaches
2.1 protein profiling and the allergenicity evaluation
2.1.1 Protein separation using gel electrophoresis
To characterize seafood allergens, it is necessary to profile the complex crude extracts by
separating the protein content by gel electrophoresis. This technique plays a central role in
seafood allergen research, wherein it provides a powerful separation and semi-quantification
information. The principle of separation by gel electrophoretic techniques is mainly based
on the ability of molecules to move through the pores of the gel media under the influence
of an electric field. In this experiment, proteins carry charges from either a uniform coating
by sodium dodecyl sulphate (SDS) or its natural net charge state isoelectric point (pI). The
rate of protein mobility is based on the protein size and pI in both sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and isoelectric focusing (IEF), respectively,
where the larger difference in mobility gives better resolutions (Kinter & Sherman, 2000).
Combining both electrophoresis separation behaviors, SDS-PAGE and IEF, gives better
resolution and sensitive detection of allergen profile. In two dimensional gel electrophoresis
(2-DE), the first dimension separates proteins based on their pI and consequently, the IPGstrip
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of isoelectric focusing gel is saturated in SDS buffer and then applied to the SDS-PAGE, as the
second dimension. The resulting gel profile shows pI values on the abscissa and the molecular
weight along the ordinate. These two sources of information are very important in identifying
proteins and comparing different profiles originating from different species. In addition, the
2-DE profile gives a relative amount of the allergens in each single spot (Rabilloud, 2000).
2.1.2 Western blotting
After separating the complex of proteins that might contain allergens by gel electrophoresis,
the separation profile should be applied to the immunoblotting experiment using allergic
patients’ sera. Immunoblotting is a powerful, selective, and sensitive technique, used to
detect a small amount of protein or to study antibody-antigen reactivity. The protein
profile in gel electrophoresis is electrophoretically transferred to a membrane which is
usually nitrocellulose or polyvinylidene fluoride (PVDF). The membranes are soaked with
a blocking reagent, either bovine serum albumin or skim milk in tris-buffered saline (TBS),
to prevent any non-specific binding of the primary antibody on the membrane (Habsah
et al., 2000). Consequently, the blot is incubated with sera collected from individuals
who have tested positive in the skin test (Abdel Rahman et al., 2011; 2010b). After that,
the peroxidase-conjugated antihuman IgE secondary antibody is added for the purpose
of visualization (Towbin et al., 1979). Then the color development substrate is added in
solution to visualize the immuno-reacted bands. Once the allergen is identified, the antibody
against this protein can be produced in animals such as rats, rabbits, or goats.These allergen
specific antibodies can subsequently be used for cross-reactivity studies and for developing
quantitative approaches that will be discussed later.
This basic profile is very important to determine the target allergenic protein, which
can subsequently be further analyzed with different techniques for further molecular
characterization using molecular cloning or MS techniques. The allergen bands could be cut
and introduced to Edman sequencing to identify the amino acid sequence of the N-terminal
protein region. This information is very important to develop the primers that will be used
for producing a recombinant protein from the related gene. The Edman sequencing can be
omitted if the allergen is identified as being related to other known allergens.
2.2 Edman sequencing
Edman sequencing was in the past the only technique to identify the amino acid sequence
of the N-terminus of seafood allergens, which is necessary to design the appropriate
primers for isolating the relevant gene and deoxyribonucleic acid (DNA) sequencing (Ayuso
et al., 2008; Hamada et al., 2004; Ma et al., 2008). The Edman reaction is performed on
the protein N-terminus, where the amine side of the N-terminal amino acid reacts with
phenylisothiocyanate (PITC) to form a phenylthiocarbamyl (PTC) protein. Consequently,
trifluoroacetic acid is used to cleave the PTC, which then gives phenylthiohydantoin (PTH)
amino acid derivatives as final products. These final products have different chemical
structures, depending on the side chain of the N-terminal amino acid, and can subsequently be
separated by high-performance liquid chromatography (HPLC) and compared to a standard
to identify the N-terminal amino acid. Through this reaction, the N-terminal amino acid is
removed from the protein, and produces a cleaved derivative of that amino acid along with a
protein that is shortened by one amino acid and has a new N-terminus. This shortened protein
is re-exposed to the same procedure for removing the next amino acid (Findlay et al., 1989).
Edman degradation is a part of modern protein analysis because of its ability to sequence a
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protein in its intact form as well as the proteolytic peptides. Furthermore, Edman sequencing
has many other advantages, making it the main technique used worldwide in the last few
decades before the use of mass spectrometry (MS) took over this kind of analysis. Advantages
include its sensitivity, which is sufficient for analyzing proteins detected by Coomassie
staining, the ease of operation, and the clarity of the data. However, this technique has a
number of serious drawbacks compared to tandem MS, which will be discussed later, to be
used in a proteomics platform. The time required to accomplish each cycle is very long ( 45
min/amino acid) and it cannot be used with proteins having blocked N-termini (Kinter &
Sherman, 2000). However, Edman sequencing was the only technique to identify the amino
acid sequence of the N-terminus of seafood allergens, which are necessary to design the
proper primer for isolating the relevant gene and DNA sequencing.
2.3 Sequencing of proteins by cDNA analysis
After collecting the N-terminus amino acid sequence of the target protein, specific DNA
primers are designed for amplifying the equivalent gene using polymerase chain reaction
(PCR). The complete amino acid sequence of the target allergen is deduced from the DNA
sequence of its equivalent gene(s) for the isolated genome. A recombinant protein from
the target gene can be produced inside bacteria. After the gene amplification, a restriction
enzyme is used to produce staggered cuts on the specific sequence of one of the gene strands.
The same enzyme is also used to have a complementary cut on the bacteria plasmid. The
gene is incorporated in the plasmid sequence by insertion, where the cohesive ends are
bound and form a full plasmid. While the bacteria are cultured, the gene is transcripted,
translated, and then produces the target protein. The recombinant allergen is isolated from
the bacteria-media complex using some affinity techniques such as affinity chromatography
or immuno-precipitation (Reese et al., 1997; Swoboda et al., 2002). This protein should have
the same allergenicity and identity as seen in the native protein that was extracted from the
seafood meat.
2.4 Characterization of seafood allergen using molecular genetics approach
The molecular genetics based-method is followed by the allergen discovery, which is based
on the charcterization of its primary structure. The first shellfish allergen characterized was
from the shrimp (Hoffman et al., 1981), where the target allergen was applied to a crossed
immunoelectrophoresis technique against rabbit and pig antisera. In that time, the identity
of the allergen was limited to its reactivity with the patient sera, native and reduction size,
the molecular contents, such as carbohydrates and amino acids, and the isoelectric point
(Hoffman et al., 1981). Using the same molecular information, cross-reactivity studies between
shrimp extracts with other species were commenced with homology ranging from 60-80%
among the sequenced peptides (Halmepuro et al., 1987; Lehrer et al., 1985; Lin et al., 1993).
The 36-kDa allergen was identified as TM by comparing the molecular characterization of Pen
a 1 with the fruit fly (Drosophila melanogaster) (Daul et al., 1994). This study gave a remarkable
movement in allergen characterization by comparing experimentally the known allergen’s
structural features with other species’ known proteins (Table 2). Among different fish
species, another cross-reactivity study was commenced with more molecular identification
(Van der Ventel et al., 2010). The Atlantic cod major allergen Gad m 1 (Aas & Elsayed, 1969)
was identified as parvalbumin, by profiling the protein in isolectric focusing, SDS-PAGE,
immunoblotting, and later identified using a recombinant form in Atlantic salmon (Do et al.,
1999; ONeil et al., 1993; Pascual et al., 1992). The primary structure of the major shrimp
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or immuno-precipitation (Reese et al., 1997; Swoboda et al., 2002). This protein should have
the same allergenicity and identity as seen in the native protein that was extracted from the
seafood meat.
2.4 Characterization of seafood allergen using molecular genetics approach
The molecular genetics based-method is followed by the allergen discovery, which is based
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movement in allergen characterization by comparing experimentally the known allergen’s
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species, another cross-reactivity study was commenced with more molecular identification
(Van der Ventel et al., 2010). The Atlantic cod major allergen Gad m 1 (Aas & Elsayed, 1969)
was identified as parvalbumin, by profiling the protein in isolectric focusing, SDS-PAGE,
immunoblotting, and later identified using a recombinant form in Atlantic salmon (Do et al.,
1999; ONeil et al., 1993; Pascual et al., 1992). The primary structure of the major shrimp
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allergen Met e 1, was also identified for the first time by a cloning technique, nucleotide
sequencing, and translation to the amino acid sequence (Leung et al., 1994). Allergenicity
of the recombinant protein was subsequently examined using the same protocol that has been
used for the fish allergen discovery. After applying this informative strategy, the seafood
allergen characterization, a new era in the field of seafood allergy research has begun. Other
research groups started to focus on other novel allergens from mollusks, such as 49 kDa
which is known as Hal m 1 (Lopata et al., 1997), and to study the cross-reactivity among
different species: lobster (Zhang et al., 2006), crab (Leung & Chu, 1998) and among shellfish;
crustaceans and mollusks, such as squid (Miyazawa et al., 1996). Motoyama et al., used the
gene cloning technique to identify the reactive TM protein in six species of crustaceans using
immunoblotting against sensitized patient sera and also a specific monoclonal antibody (Mabe
et al., 2009; Motoyama et al., 2007).
2.5 Protein mass spectrometry
Mass spectrometry is a technique used to characterize the gas-phase chemical structure of
compounds after having them ionized. Based on the ion source, the ions in mass spectrometer
can be formed in either of five different mechanisms: protonation, deprotonation, electron
capturing, electron ejection, and adduct formation. The molecular ions, positive or negative,
are electrically attracted and focused to get them in the mass analyzer, where the ions are
separated based on their mass-to-charge ratio (m/z). This experiment usually gives the
molecular weight of the target compound. For further structural analysis, tandem MS is
performed by separating the target ions in the first mass analyzer, and then exposed to the
collision cell. The produced fragment ions are separated in the second mass analyzer based
on their mass-to-charge ratio to give a chemical structure.
Analyzing large molecules using tandem MS was only possible for the energetic stable
molecules, such as polymers. Proteins were analyzed by MS after the invention of the
matrix-based laser desorption techniques, like fast atom bombardment (FAB) and matrix
assisted laser desorption ionization (MALDI), where the laser energy transferred indirectly
and softely to the protein via the matrices. Although, MALDI and time-of-flight (TOF) is a
good combination between an ion source and mass analyzer for protein MW determination,
generating a fragmentation pattern for the protein’s ion is a challenge. This dilemma is limited
to the fact that the MALDI mainly forms mono-charged ions, which requires higher energy
in acceleration voltage for the effective fragmentation process, as well as the difficulties of
coupling a TOF MS to another analyzer for tandem process. The electrospray ionization
(ESI) invention offered a historical shift for protein characterization using MS, where this ion
source produces the multiply charged ions with lower demand on fragmentation energy. The
primary structure of the allergenic proteins can now be identified using MS, where it helps
to understand the other proteins’ structural features and functional activity. In addition, the
amino acid sequence directly corresponds to the DNA sequence of the corresponding gene
(s), which helps to study the activity of proteins by detecting the common mutations at the
molecular level.
Amino acid sequencing is performed by determining the structure and the position of each
amino acid residue within the protein. This target demands a method sensitive and specific
enough to analyze native proteins in highly throughput manner. In addition, it must
provide reliable information with sufficient mass accuracy (Kinter & Sherman, 2000). The
ESI generates multiply-charged ions, which are easily accelerated and fragmented in tandem
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MS experiments. Allergen analysis can be performed in MS by peptide mass fingerprinting
(PMF) as an identification technique or by tandem MS for de novo sequencing.
2.5.1 Peptide mass fingerprinting.
Mass spectrometry has become a major analytical tool for protein structural analyses.
Generating the gas phase ions of protein molecule was a challenge before MALDI and ESI
along with accurate mass analyzers, which offered a valuable tool for protein identification.
Following the completion of the early genome sequencing projects, several search engines
(i.e. Mascot and Sequest) were developed for the genome databases with MS interface.
The enzymatic digested protein generates a highly unique peptide profile which is further
analyzed by MS. These peptides are introduced to a mass spectrometer to give fingerprint
profiles. The so called PMF technique is important for protein identification that already has
genetic information in the databases. There are several factors that control the precision of the
database search such as the resolving power of the MS, type of protease, availability of the
gene data in data bank, and the purity of the target proteins (Aebersold & Mann, 2003).
2.5.2 Tandem mass spectrometry
Selected gas-phase ions of peptides and proteins are fragmented in the tandem MS mode,
which gives a series of ions related to the amino acid sequence. This development in protein
MS was extended to give high throughput protein identification, de novo sequencing, and
identification of post-translational modifications (Aebersold & Mann, 2003). Protein tandem
MS-based techniques are mainly divided into two major types; bottom-up or top-down. These
terminologies are assigned for the point of sample handling before MS analysis and from the
data processing and sequencing manipulation (Kinter & Sherman, 2000).
2.5.2.1 Bottom-up approach
In the bottom-up approach, the enzymatically-digested proteins are subjected to LC-MS/MS
analyses. The precursor ions of the peptides are separated in the first mass event, and then
fragmented to produce a series of informative product ions. These ions are separated and
analyzed in the second mass event.
A distinctive series of product ions are directly related to the amino acid sequence, which
then compared with ’in-silico’ ions that are generated theoretically from the DNA databases
by computers. The sequence will be assigned when both series of ions, experimental
and theoretical, are matched perfectly as shown in peptide number 3 in Fig.3. This
technique usually provides useful information about the post-translational modifications (i.e.
phosphorylated, acetylated). Some of these post-translational modified residues are difficult
to be identified due to poor chromatographic resolution or detector sensitivity (Chait, 2004;
Scherperel & Reid, 2007), as seen for the two peptides number 2 and 5 in Fig. 3. On the
other hand, introducing the whole protein to the mass spectrometer without any digestion,
top-down (discussed below), is a very useful technique to identify most of the labile post
translation modification groups with high amino acid sequencing coverage (Siuti & Kelleher,
2007).
Enzymatic digestion of the intact protein followed by purification and electrophoretic
separation prior to MS analyses is routine but tedious work for bottom-up approach. The
enzymatic peptides are normally separated by reversed phase chromatography and subjected
ESI or MALDI with analysis by tandem MS. The sequence of each peptide is deduced from the
product ion spectra after gas phase collision induced dissociation (CID) (Kinter & Sherman,
2000).
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Following the completion of the early genome sequencing projects, several search engines
(i.e. Mascot and Sequest) were developed for the genome databases with MS interface.
The enzymatic digested protein generates a highly unique peptide profile which is further
analyzed by MS. These peptides are introduced to a mass spectrometer to give fingerprint
profiles. The so called PMF technique is important for protein identification that already has
genetic information in the databases. There are several factors that control the precision of the
database search such as the resolving power of the MS, type of protease, availability of the
gene data in data bank, and the purity of the target proteins (Aebersold & Mann, 2003).
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Selected gas-phase ions of peptides and proteins are fragmented in the tandem MS mode,
which gives a series of ions related to the amino acid sequence. This development in protein
MS was extended to give high throughput protein identification, de novo sequencing, and
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MS-based techniques are mainly divided into two major types; bottom-up or top-down. These
terminologies are assigned for the point of sample handling before MS analysis and from the
data processing and sequencing manipulation (Kinter & Sherman, 2000).
2.5.2.1 Bottom-up approach
In the bottom-up approach, the enzymatically-digested proteins are subjected to LC-MS/MS
analyses. The precursor ions of the peptides are separated in the first mass event, and then
fragmented to produce a series of informative product ions. These ions are separated and
analyzed in the second mass event.
A distinctive series of product ions are directly related to the amino acid sequence, which
then compared with ’in-silico’ ions that are generated theoretically from the DNA databases
by computers. The sequence will be assigned when both series of ions, experimental
and theoretical, are matched perfectly as shown in peptide number 3 in Fig.3. This
technique usually provides useful information about the post-translational modifications (i.e.
phosphorylated, acetylated). Some of these post-translational modified residues are difficult
to be identified due to poor chromatographic resolution or detector sensitivity (Chait, 2004;
Scherperel & Reid, 2007), as seen for the two peptides number 2 and 5 in Fig. 3. On the
other hand, introducing the whole protein to the mass spectrometer without any digestion,
top-down (discussed below), is a very useful technique to identify most of the labile post
translation modification groups with high amino acid sequencing coverage (Siuti & Kelleher,
2007).
Enzymatic digestion of the intact protein followed by purification and electrophoretic
separation prior to MS analyses is routine but tedious work for bottom-up approach. The
enzymatic peptides are normally separated by reversed phase chromatography and subjected
ESI or MALDI with analysis by tandem MS. The sequence of each peptide is deduced from the
product ion spectra after gas phase collision induced dissociation (CID) (Kinter & Sherman,
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Generating a good sequencing coverage for the intact protein requires producing peptides that
are readily soluble for chromatography. The chromatographic separation of peptides prior to
MS ionization is very important. Generating ion of highly energetic gas-phase ions inside
the field free region is required for facile fragmentation or dissociation. Sequencing the intact
protein using a regular tandem mass spectrometer is limited to the energy of the dissociation
and the resolving power of the mass analyzer, which leads to erroneously manipulation from
the algorithms of the database. The labile post-translational and environmental modifications
of proteins are difficult to be identified using energetic dissociation bottom-up method. As
well the modified peptides are more sensitive to be detected by MS than the large hydrophobic
proteins (Eidhammer et al., 2007). The bottom-up approach can usually deal with most types
of proteins regardless of their size or function. This approach is still the most common, but
the sequence coverage is limited (Eidhammer et al., 2007).
Fig. 3. Schematic overview of bottom-up and top-down approaches employed for tandem
MS-based protein identification and characterization. The shaded circles represent the amino
acids of a protein, while the shaded triangle and rectangle represents post-translational
modifications. (Reproduced by permission of The Royal Society of Chemistry; (Scherperel &
Reid, 2007)
2.5.2.2 Top-down approach
Manipulating the bottom-up approach data requires data availability in the gene bank.
Thus, the top-down approach was found to improve protein identification even in case of
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the lack of genetic information in the databases. Understanding the chemical composition,
molecular weight, and stability/solubility of the target protein(s) is paramount for achieving
proper ionization and gas phase dissociation in the mass spectrometer. Kelleher and group
introduced the top-down approach by analyzing an intact protein using an ESI ion source
(Kelleher et al., 1999). This type of analysis requires high resolution mass analyzers as well
as a high energy collision cell. The amino acid sequence, and post-translation modification
structures were determined in this approach using in-time tandem MS experiments. The
mass difference between the generated precursor ions and their equivalent predicted ions
in the DNA databases were considered for amino acid sequencing of the intact protein (Reid
& McLuckey, 2002).
The top-down approach was further developed for the analysis of a mixture of proteins
without classical separation (chromatography or electrophoresis). The precursor ion of
the target protein is selected and isolated in the first mass analysis event for amino
acid sequencing (Reid & McLuckey, 2002). This approach still offers a comprehensive
post-translation modification mapping. Several bioinformatic tools can be implemented to
map the post-translation modification information in protein, which are mainly defined by the
mass differences between the experimental and theoretical spectral data (Kelleher et al., 1999).
The MS resolution is high enough to identify a disulfide bond, which increases the molecular
weight of the protein by 2 Da after reduction. The top-down method has clearly been
shown to identity even the labile post-translation modification groups (Scherperel & Reid,
2007). Two-dimensional correlation between MS/MS and MS/MS/MS was also developed
to confirm the amino acid sequence in Fourier-transform ion cyclotron resonance (FTICR)
instruments (Zhang & McElvain, 2000).
The top-down approach affords another valuable and powerful tool for proteomic analyses.
Post-translation modification mapping can become a reliable tool for determining chemistry,
location, and quantity of these modifications along with the primary structure of a protein.
Using this method as the sequencing approach for an intact protein can provide close to 100%
coverage. Moreover proteins can be part of a mixture, or have unusually large molecular
weight. Analysis of these types of samples will still give the same accuracy and with less
complexity compared to the bottom-up approach. Simple algorithm databases with more
sophisticated data processing are readily available for top-down approaches. Including
powerful and advanced MS instruments such as FTICR allowing for maximum mass accuracy
and resolution reinforces the strength behind this approach
2.6 Characterization of seafood allergen using mass spectrometry
Mass spectrometry serves as a characterization technique of seafood allergens by determining
the molecular weight, the primary structure, and the quantity of the intact allergenic protein.
Unfortunately, a number of seafood allergen research articles that used MS is quite low
compared with other protein-based food allergen research. The shortage of genomic data for
many of the seafood species in GenBank and lack of expertise in facilitating the MS techniques
in this research area are also the main reasons for this literature shortage. Officially, MS was
recommended as a replacement technique for allergen detection in inspection labs back in
2005 (Hungerford, 2006; Hungerford & Trucksess, 2005).
Allergen analysis by MS started by determining the molecular weight of small allergens such
as parvalbumin (12 kDa) in fish (Bugajska-Schretter et al., 2000; Cai et al., 2010; Swoboda
et al., 2002). After completing the genome sequence and developing the MS-interface
databases, some studies use the PMF approach to identify the seafood allergens evaluated
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by immunoblotting (Ayuso et al., 2009; García-Orozco et al., 2007; Mazzeo et al., 2008; Shen
et al., 2011; Yamasaki et al., 2010; Yu et al., 2003). The best example of this kind of research
was in 2003, when Pen m 2 shrimp allergen was identified using PMF, where the recognized
spot proteins by a pool of patients’ sera were tryptic digested and analyzed by MALDI-ToF
(Yu et al., 2003). Consequently, the purified AK of white shrimp that was partially sequenced
using the shot-gun MS method (García-Orozco et al., 2007) was also identified by comparing
the MS data with the sequence of Pen m 2 in the MASCOT search engine. Instrumentally,
most of this unambiguous characteristic information was generated by coupling MALDI ion
source to the TOF mass analyzer, which can give the molecular weight of the purified intact
protein with a margin of error of 0.1% (DeHoffmann & Stroobant, 2007) and perform the PMF
experiments. The precision of MALDI-TOF is poorer with larger proteins, which provoked
to use more advanced ion sources like ESI coupled with FTICR (Ma et al., 2008). The high
resolution of MS analyzers are used to study seafood authentication by measuring the exact
molecular weight of a marker protein (Mazzeo et al., 2008).
The seafood allergenic proteins can be also sequenced using tandem MS (Abdel Rahman
et al., 2010a; 2011; 2010b; Misnan et al., 2010). This method was used in the seafood allergen
studies as a confirmatory technique to study some biochemical and biophysical properties
by collecting the amino acid sequence of a few peptides (Perez-Gordo et al., 2011). Ma et al.
(2008) validated the using of high resolution MS profiles to evaluate the cross-reactivity of the
allergens based on their structural similarities. The cross-reactivity between both the natural
and recombinant forms of cod and carp parvalbumin was evaluated using patients’ sera and
the structure was also evaluated using both circular dichroism (CD) and nuclear magnetic
resonance (NMR) (Ma et al., 2008).
In Helleur’s group, the tandem MS technique was the method for de novo sequencing of
seafood allergens. Tropomyosin, the major snow crab and black tiger prawn allergens, was
used as a reference protein to develop a tandem MS strategy for the protein sequencing
(Abdel Rahman et al., 2010a;b). Since the amino acid sequences of both allergens are
available in the databases, it was an advantage to optimize the full sequence strategy. The
multi-enzymatic digestions, multi-ion sources, and multi-derivatization reactions were used
for obtaining the full amino acid coverage. This strategy was later applied for other allergens
characterization (Abdel Rahman et al., 2011; Carrera et al., 2010; Liu et al., 2011). The high
resolution tandem MS is also capable to study the heterogeneity of allergen isoforms in
micro scale. Permyakov et al. studied the microheterogeneity of Pike α-parvalbumin, where
precisely the MS output shows the presence of both amino acid sequences for α1 and α2
isoforms (Permyakov et al., 2009). Extensively, 25 new parvalbumin isoforms were identified
and de novo sequenced from different 11 species using some bioinformtic tools (e.g. PEAK).
The high mass accuracy of the FTICR (0.05-4.47 ppm) allowed for the amino acid sequence of
the species which their genomes remain unsequenced (Carrera et al., 2010).
3. Allergen quantification
3.1 Immunological-based techniques
There are several techniques that can be used for the quantification of potential allergens.
These techniques target either the allergenic protein itself or biomarker that indicates its
presence. However, the allergen detection itself is a challenge, as their chemical properties
are not be well characterized. In addition, many allergenic seafood species contain multiple
allergenic proteins that can vary in their concentration. Once the allergenic protein is
characterized and a specific antibody produced, this allergen can be routinely detected in
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one of the immunochemical detection protocols such as radio-allergosorbent test (RAST),
enzyme allergosorbent test (Dearnaley et al., 2010), rocket Immuno-electrophoresis (RIE),
immunoblotting, and enzyme-linked immunosorbent assay (ELISA). Whereas, RIE is only
used for qualitative or semi-quantitative the same as immunoblotting, however, RAST,
EAST, and ELISA are absolute quantitative methods. The choice of method depends on the
availability of the antibody, the target of the analysis, and the method characteristic merits
such as detection limit and precision.
3.1.1 Radio-allergosorbent inhibition
Radio-allergosorbent is a technique that can be used for the determination of allergen-specific
IgE antibodies generated by the sensitized individuals, which is commonly used in the clinical
diagnosis of most allergies. In addition, this technique has been used for the qualitative
detection and determination of allergenicity of different seafood species. Basically, the target
allergen in the RAST test is bound to a solid polymer. The specific IgE in the patient
sera binds to the allergen. After removing non-specific IgE, antigens in a sample solution
inhibit IgE binding to the antigen immobilized on the solid phase. Radio-labeled anti-human
IgE antibody is added to form a complex, and then the unbound secondary antibody is
washed away after incubation. The amount of radioactivity, detected in gamma counter, is
proportional to the amount of the bound IgE (Malo et al., 1997). These methods have several
drawbacks to be the major technique for allergen quantification, one of them is its reliance on
human sera from allergic individual (Nordlee & S.L.Taylor, 1995)
3.1.2 Enzyme-linked immunosorbent assay.
Currently, ELISA is the main immunological reaction-based technique used for determination
levels of allergens in different matrices. In principle, a calibration curve of a serial dilution
from the allergen extracts is developed and the antigen/antibody reaction is optimized. There
are two main approaches for allergen quantification using ELISA: competitive and sandwich.
The sandwich ELISA is more specific and precise than the competitive, where the primary
antibody is bound to the solid phase like the microtiter plate. The specific protein is
captured and the non-bound species will be removed. The captured protein is detected by
the enzyme-labeled secondary antibody. The complex is visualized by a reaction between a
particular substrate with the conjugated enzyme on the secondary antibody and developing
a colored product. The analyte concentration is proportional directly with the measured
absorption. The relatively small proteins are preferably measured by the competitive ELISA.
The patients’ sera and the allergen extracts are pre-incubated, and then this mixture is added
to the microtiter wells that have an antigen bound to the solid phase. The maximum binding
between the solid phase-bound antigen and the enzyme-labeled antibody is performed when
there is no antigen presence in the inhibitor sample. Antigens in the sample inhibit the
binding of enzyme-labeled antibody to the immobilized antigen, where the concentration of
the allergen is inversely proportional to the color absorption.
3.1.3 Detection and quantification of selected allergens in seafood
The RAST technique was used as a diagnosis method, where the positive skin test patient sera
were evaluated using a crude extract of the potential allergenic seafood, such as in crustaceans,
prawn, shrimp, crawfish, and lobster (Daul et al., 1988; Halmepuro et al., 1987; Nagano et al.,
1984). This technique was used to study the cross-reactivity between the oyster and crustacean
(Lehrer & McCants, 1987) and caddis fly with arthropoda and mollusca (Koshte et al., 1989),
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which indicated to the non-specificity of RAST to be a diagnostic assay. However, the RAST
inhibition technique was used to evaluate the species-specific shrimp allergen (Morgan et al.,
1989). Shrimp allergy is estimated to be about 2% of the general population (Besler et al.,
2001; Lopata et al., 2010). The threshold doses for shrimp allergic individual were evaluated
to be 16g (Daul et al., 1988) and for fish ranging from 5-600 mg (Taylor et al., 2002) using
the double-blind placebo controlled food challenges (DBPCFC). Cod fish allergen, the first
reported allergen, was also evaluated by RAST to study the physico-chemical properties and
the cross-reactivity with other fish species (Aas & Elsayed, 1975; Aas & Lundkvist, 1973;
Aukrust et al., 1978).
The absolute quantification for the seafood allergen was initiated in 1997 by Lehrer’s group
(Jeoung et al., 1997). A sandwich ELISA method was developed using TM extracted and
purified from brown shrimp. The detection limit was 4 ng/ml and the assay detected the
TM-like allergen in different crustacean species such as crab and lobster. Recently, the method
was optimized to evaluate the level of crustacean major allergen, TM, in processed food
(Motoyama et al., 2008; Seiki et al., 2007) with a limit of detection of about 2.5 mg/kg (Rejeb
et al., 2002). This assay demonstrated cross-reactivity between other crustaceans like crab and
lobster. Although the TM sequence homology between the shrimp and pork or chicken was
around 55%, this study showed no cross-reactivity between them (Reese et al., 1997). The
fish major allergen, parvalbumin, was quantified for the first time by Lopata et al (2005) in its
aerosolized form (Lopata et al., 2005). Recently, this method was applied for the evaluation of
fish allergen levels in foodstuff (Faeste & Plassen, 2008), and for comparing the parvalbumin
levels in different species (Kuehn et al., 2010). Commercially, there is only one ELISA kit
available for detection of crustacean’ allergens in foodstuff: however there is none available
for the fish allergens.
3.2 Allergen quantification using mass spectrometry
Studying the large variety of proteins belonging to a certain biological system is known
as proteomics. In recent decades, high throughput MS-based proteomics techniques have
been developed for protein analysis and identification. The tandem MS tools have been
very influential in the field of protein science as the genome sequence projects were
being completed. The discovery and development of ESI and MALDI sources has given
protein MS a huge push to become one of the dominating fields in proteomics. At its
inception, MS proteomics research was mainly a qualitative discipline, where the outputs
were limited to a list of identified proteins without any further information about abundances,
distributions, or stoichiometry (Schulze & Usadel, 2010). In contrast, quantitative strategies
were developed by analyzing the gene expression by microarray technology, real-time PCR,
or evaluating the enzymes’ activity that directly represent theirae quantity. Several MS-based
tools are being developed for proteomics quantification, which help in characterizing the
proteome complexities. For example, quantitative data can assist in the study the true
protein interactions (interactoms) of a given bait protein over the background. These
proteomics strategies are used to differentiate between stressed and normal samples or
between knock-out and wild types for certain biological systems.
3.2.1 Proteomics quantification
Quantitative proteomics approaches are used as part of the larger framework of the available
techniques for studying regulatory processes in the living cell. Choosing the quantification
method is less important than the method’s practical aspects which include good technical
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reproducibility. By the same token, the biological system variations must be considered in
the experimental design, along with financial costs. Since there is no amplification step at the
protein level, the sample size is the most important limiting factor affecting the strategy of
quantitative differential proteomics. Accordingly, enrichments and purification of protein are
carried out to meet the sensitivity of the quantification technique. In this way, the sample size
will influence the choice of analytical method (Schulze & Usadel, 2010).
The differences in the physical and chemical properties of different peptides, directly affect
the proton affinity and the MS signal intensity. These peptide variables are their charge
state, peptide length, amino acid composition, and any post-translational modification. These
structural variations contribute to the peptides’ ion intensities even if they belong to the
same protein. Because of this, many MS-based quantitative methods produce only relatively
quantitative data, which is based mainly on the MS response in contest with its sample matrix.
Accordingly, careful experimental design and suitable data analysis are needed to obtain the
desired analytical information.
3.2.2 Relative quantification MS-based techniques
The relative quantification MS-based techniques are categorized into two major groups:
stable-isotope-labeling and the label-free approach. The relative standard deviation for most
stable-isotope-labeling techniques is below 10% and the accuracy is approximately 30%, based
on peak intensities or extracted ion chromatograms. However, the precision obtainable from
label-free approaches, based on spectral counting or derived indices, is as high as 50% RSD
(Schulze & Usadel, 2010).
The label-free quantification methods are based mainly on precursor signal intensity, which
requires a high precision mass spectrometer. The label-free approaches are inexpensive (no
labeled material to purchase) and can be applied to any biological material. The proteome
coverage for quantified proteins can be very high, because any protein with one or more
identified peptides can be quantified. Thus the sample complexity does not normally increase
by mixing different proteomes together. Hence the protein expression can be quantified
between different biological samples from different treatments. These samples can be
analyzed by the free-label MS approach due to its analytical power and flexible dynamic range
(Old et al., 2005). There are two main label-free approaches; protein-based methods (spectral
count or derived indices) and peptide-based methods (ion intensities and protein correlation
profile). The protein-based method looks to the protein expression levels among proteins of
the same sample and compares them with another sample. In contrast, the peptide-based
method utilizes the averaged and normalized ion intensities of the identified peptides (of
specific proteins) for quantification.
The isotopic-labeling methods are classified with respect to the labeling strategy; metabolic
labeling and isobaric mass tags. The metabolic labeling approach introduces the whole cell
or organism to a labeled culture media (e.g. stable-isotope labeling by amino acid (SILAC) in
cultured cells). On the other hand, chemical labeling (isobaric mass tags) can be attached to
the protein or proteolytic peptides by a chemical reaction. Equivalent quantities of the labeled
and unlabeled samples are mixed and treated in the same manner prior to the MS analysis.
The differences between the labeled peptides’ intensities and those of unlabeled represent
the levels of that specific protein in the original sample. The drawback in this method is
interference by co-eluting isobaric compounds when tandem MS is not used.
The isobaric mass tags method can overcome any co-eluting interferences by developing
reagents that co-elute with the target peptide ion, then they will have a significant resolution
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3.2 Allergen quantification using mass spectrometry
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very influential in the field of protein science as the genome sequence projects were
being completed. The discovery and development of ESI and MALDI sources has given
protein MS a huge push to become one of the dominating fields in proteomics. At its
inception, MS proteomics research was mainly a qualitative discipline, where the outputs
were limited to a list of identified proteins without any further information about abundances,
distributions, or stoichiometry (Schulze & Usadel, 2010). In contrast, quantitative strategies
were developed by analyzing the gene expression by microarray technology, real-time PCR,
or evaluating the enzymes’ activity that directly represent theirae quantity. Several MS-based
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proteome complexities. For example, quantitative data can assist in the study the true
protein interactions (interactoms) of a given bait protein over the background. These
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reproducibility. By the same token, the biological system variations must be considered in
the experimental design, along with financial costs. Since there is no amplification step at the
protein level, the sample size is the most important limiting factor affecting the strategy of
quantitative differential proteomics. Accordingly, enrichments and purification of protein are
carried out to meet the sensitivity of the quantification technique. In this way, the sample size
will influence the choice of analytical method (Schulze & Usadel, 2010).
The differences in the physical and chemical properties of different peptides, directly affect
the proton affinity and the MS signal intensity. These peptide variables are their charge
state, peptide length, amino acid composition, and any post-translational modification. These
structural variations contribute to the peptides’ ion intensities even if they belong to the
same protein. Because of this, many MS-based quantitative methods produce only relatively
quantitative data, which is based mainly on the MS response in contest with its sample matrix.
Accordingly, careful experimental design and suitable data analysis are needed to obtain the
desired analytical information.
3.2.2 Relative quantification MS-based techniques
The relative quantification MS-based techniques are categorized into two major groups:
stable-isotope-labeling and the label-free approach. The relative standard deviation for most
stable-isotope-labeling techniques is below 10% and the accuracy is approximately 30%, based
on peak intensities or extracted ion chromatograms. However, the precision obtainable from
label-free approaches, based on spectral counting or derived indices, is as high as 50% RSD
(Schulze & Usadel, 2010).
The label-free quantification methods are based mainly on precursor signal intensity, which
requires a high precision mass spectrometer. The label-free approaches are inexpensive (no
labeled material to purchase) and can be applied to any biological material. The proteome
coverage for quantified proteins can be very high, because any protein with one or more
identified peptides can be quantified. Thus the sample complexity does not normally increase
by mixing different proteomes together. Hence the protein expression can be quantified
between different biological samples from different treatments. These samples can be
analyzed by the free-label MS approach due to its analytical power and flexible dynamic range
(Old et al., 2005). There are two main label-free approaches; protein-based methods (spectral
count or derived indices) and peptide-based methods (ion intensities and protein correlation
profile). The protein-based method looks to the protein expression levels among proteins of
the same sample and compares them with another sample. In contrast, the peptide-based
method utilizes the averaged and normalized ion intensities of the identified peptides (of
specific proteins) for quantification.
The isotopic-labeling methods are classified with respect to the labeling strategy; metabolic
labeling and isobaric mass tags. The metabolic labeling approach introduces the whole cell
or organism to a labeled culture media (e.g. stable-isotope labeling by amino acid (SILAC) in
cultured cells). On the other hand, chemical labeling (isobaric mass tags) can be attached to
the protein or proteolytic peptides by a chemical reaction. Equivalent quantities of the labeled
and unlabeled samples are mixed and treated in the same manner prior to the MS analysis.
The differences between the labeled peptides’ intensities and those of unlabeled represent
the levels of that specific protein in the original sample. The drawback in this method is
interference by co-eluting isobaric compounds when tandem MS is not used.
The isobaric mass tags method can overcome any co-eluting interferences by developing
reagents that co-elute with the target peptide ion, then they will have a significant resolution
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after fragmentation in the product ion spectra. Each product ion spectrum is the result of a
different chemical tag with its intensity equivalent to the level of protein expression in the
original sample. These fragments (tags) are in the low mass range, which make interferences
from other peptides’ fragments difficult. There are some commercial isobaric reagents that
offer this type of quantification strategy such as the isobaric tag for relative and absolute
quantification (iTRAQ) and the tandem mass tag (TMT).
3.2.3 Absolute quantification and isotopic dilution mass spectrometric techniques
A technique called absolute quantification (AQUA) using the stable-isotopic-labeled
technique was reported for the first time by Desiderio and Kai (1983) (Desiderio & Kai, 1983).
By using selected reaction monitoring (SRM) in triple quadruple tandem mass spectrometer,
the AQUA became a standard protocol in protein quantification. The informatics combination
between the retention time, peptide precursor ion, and the fragmentation profile gives this
method high specificity toward the particular target peptide. The signal-to-noise ratio in SRM
is very high, which gives an extended linear dynamic range up to 5 orders of magnitude.
By spiking a protein sample with a known amount of the stable-isotopic-labeled peptide, the
concentration of the native protein can be calculated. However, this may not cover all levels
of the expressed protein in the tissue, because sample preparation steps may lead to loss or
enrichment of the target peptide that are not addressed by the AQUA method. The absolute
quantification of large proteins (MW>15kDa) by MS can be performed using the bottom-up
approach. The intact protein is digested and the signature peptide is selected to represent the
target protein. The stable-isotopic-labeled and natural (light) forms of the signature peptide
are chemically synthesized, where the heavy form is used as an internal standard. Before
MS analysis, the heavy form of the signature peptide is added to the sample in a deliberate
manner; hence the method is called ’isotope dilution’ MS. Small proteins (<15kDa) can also
be quantified using the top-down approach, whereby the internal standard is prepared as a
metabolic labeling strategy using labeled culture media (Brun et al., 2009).
3.2.4 Validation of bioanalytical methods
Once the AQUA method for the target protein is developed, the validity of the method
is studied and evaluated to meet successfully the minimum standards of the Food and
Drug Administration (Marko-Varga et al., 2005) guidelines for accuracy, precision, selectivity,
sensitivity, reproducibility, and stability (Food and Drug Administration, 2001). This
guideline was specifically developed for studying the bioanalytical method validation of small
molecules or drugs, however, Helleur’s group has modified this protocol to be developed for
studying the AQUA method for allergen quantification using multiple reaction monitoring
(MRM) tandem MS (Abdel Rahman et al., 2010c).
3.2.5 Insight of using mass spectrometry for seafood allergen quantification
The seafood allergen discovery platform, starting from the seafood species and ending by
allergens absolute quantification, can be expedited efficiently by applying the allergenomics
approach as discriped in Fig 4. Allergenomics is one of the functional proteomics strategies
that focus on potential allergen discovery of such species. Whereas the primary structure and
the relative and absolute quantification of the target allergen are determined. This strategy
gives a reliable tool for monitoring the immuno-reactivity proteins in various conditions
such as heating or adding food additives. Helleur’s group commenced this strategy in
seafood allergen, where the snow crab and black tiger prawn were the species of choice
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(Abdel Rahman et al., 2010a;b). The real seafood allergen quantification by MS was performed
for measuring the level of aerosolized snow crab major allergens in the workplaces. The TM
and AK were simultaneously measured using MRM-MS/MS in air samples collected from
crab processing plants (Abdel Rahman et al., 2012; 2010c) and from fishing vessels as joint
project between SafteyNet and Rural Center at Memorial University of Newfound land and
Dalhousie University, respectively (in preparation).
For developing allergenomics quantification method for any species, the crude extract
samples should be profiled in 2D-gel electrophoresis (Fig. 4). The allergenicity of the
protein profile is evaluated by immunoblotting the 2D-gels with a pool of patients’ sera.
The reactive proteins would then be cut, tryptic digested, and characterized using MS. The
relative abundances of the discovered allergens can be evaluated using either the label-free
or the isobaric mass tags methods such as iTRAQ. It is highly recommended to have
an allergenomics profile and absolute multi-allergens quantification method. Therefore,
proteomics quantification methods such as iTRAQ or TMT can be used to give a relative
quantification profile for all detected allergens in a very specific and sensitive manner. All
candidate allergens that have been shown up in the iTRAQ profile will be considered for
developing an absolute quantification method. An artificial polypeptide is designed to
produce all the signature peptides of all target allergens as soon as digested by trypsin. The
heavy form standard of this polypeptide is added to the target sample (e.g. food or air filters),
as an internal standard right before the extraction and digestion. Stoichiometrically, this
process will control completeness of the digestion and sample loss as well as give an absolute
quantification for each single allergen in the sample in a single run. This approach can be
performed in air samples as well as for monitoring the levels of allergens in food as a quality
control test (food grades) for the sake of reporting the nutritional facts.
4. Occupational/inhalant allergy and asthma associated with seafood
The increasing growth of the seafood market in the past two decades has led to an increasing
number of workers engaged in various harvesting and aquaculture activities. Aside from
increased consumption worldwide, more than 45 million workers are also involved in seafood
production and are therefore exposed to seafood allergens in various contexts (Food and
Agriculture Organisation, 2010). Adverse reactions have increasingly been reported in
individuals consuming, handling or processing seafood in various settings. Aside from the
ingestion route, seafood proteins can also enter the body through inhalation of aerosols or
vapours containing allergens.
In domestic settings, a Spanish study reported 11% of children from a group of 197 children
with fish allergy/hypersensitivity, placed on a strict fish avoidance diet, who experienced
repeated allergic reactions upon incidental inhalation of fish odors or vapors. In most cases,
these episodes occurred at home when other people were eating fish (James & Crespo, 2007).
A similar observation in a South African study of 105 individuals with self-reported seafood
allergy, reported 30% of individuals with allergic symptoms after handling or inhaling seafood
in the domestic home environment (Lopata & Jeebhay, 2001).
In the workplace setting, occupational asthma was first reported in 1937 by De Besche
in a fisherman who developed allergic symptoms when handling codfish. Since then
various other seafood has been reported to cause occupational allergy and asthma including
crustaceans as summarized in Table 1 (shrimp and shrimpmeal, prawn, lobsters), mollusc’s
(mussels, octopus, scallops, abalone) and other bony fish (trout, salmon, pilchard, anchovy,
plaice, hake, tuna, haddock, cod, pollack). These incidents have been reported on board
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MS analysis, the heavy form of the signature peptide is added to the sample in a deliberate
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is studied and evaluated to meet successfully the minimum standards of the Food and
Drug Administration (Marko-Varga et al., 2005) guidelines for accuracy, precision, selectivity,
sensitivity, reproducibility, and stability (Food and Drug Administration, 2001). This
guideline was specifically developed for studying the bioanalytical method validation of small
molecules or drugs, however, Helleur’s group has modified this protocol to be developed for
studying the AQUA method for allergen quantification using multiple reaction monitoring
(MRM) tandem MS (Abdel Rahman et al., 2010c).
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The seafood allergen discovery platform, starting from the seafood species and ending by
allergens absolute quantification, can be expedited efficiently by applying the allergenomics
approach as discriped in Fig 4. Allergenomics is one of the functional proteomics strategies
that focus on potential allergen discovery of such species. Whereas the primary structure and
the relative and absolute quantification of the target allergen are determined. This strategy
gives a reliable tool for monitoring the immuno-reactivity proteins in various conditions
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quantification for each single allergen in the sample in a single run. This approach can be
performed in air samples as well as for monitoring the levels of allergens in food as a quality
control test (food grades) for the sake of reporting the nutritional facts.
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The increasing growth of the seafood market in the past two decades has led to an increasing
number of workers engaged in various harvesting and aquaculture activities. Aside from
increased consumption worldwide, more than 45 million workers are also involved in seafood
production and are therefore exposed to seafood allergens in various contexts (Food and
Agriculture Organisation, 2010). Adverse reactions have increasingly been reported in
individuals consuming, handling or processing seafood in various settings. Aside from the
ingestion route, seafood proteins can also enter the body through inhalation of aerosols or
vapours containing allergens.
In domestic settings, a Spanish study reported 11% of children from a group of 197 children
with fish allergy/hypersensitivity, placed on a strict fish avoidance diet, who experienced
repeated allergic reactions upon incidental inhalation of fish odors or vapors. In most cases,
these episodes occurred at home when other people were eating fish (James & Crespo, 2007).
A similar observation in a South African study of 105 individuals with self-reported seafood
allergy, reported 30% of individuals with allergic symptoms after handling or inhaling seafood
in the domestic home environment (Lopata & Jeebhay, 2001).
In the workplace setting, occupational asthma was first reported in 1937 by De Besche
in a fisherman who developed allergic symptoms when handling codfish. Since then
various other seafood has been reported to cause occupational allergy and asthma including
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Fig. 4. The allergenomics strategy for allergen discovery, which uses the seafood crude
extracts and the proteomics-MS based approach for characterization
fishing vessels and among workers involved with land-based seafood processing factories.
Various epidemiological studies among seafood processors indicate that the prevalence of
occupational asthma is between 2% and 36%. These differences in prevalence are partly due
to varying definitions of occupational asthma used by investigators; the allergenic potential
of the seafood proteins involved; and the type of work process resulting in excessive exposure
such as steam, organic dust, air blowing and water jets. What is notable, however, is that these
studies show that occupational asthma is more commonly associated with shellfish (4-36%)
than with bony fish (2-8%) (Jeebhay & Cartier, 2010; Jeebhay et al., 2001).
Various studies show that the common work processes causing bioaerosol production include
butchering or grinding; degilling, ’cracking’ and boiling of crabs; cleaning and brushing of
crab; ’tailing’ of lobster; ’blowing’ of prawn meat through shells; washing or scrubbing of
shellfish; degutting, heading, and cooking/boiling of fish; mincing of seafood; and cleaning
of the processing line or storage tanks with high pressured water hoses (Jeebhay et al., 2001).
Processes that generate dry aerosol particulates such as prawn blowing operations using
compressed air and fishmeal loading/bagging appear to generate higher levels of particulate
than wet processes (prawn blowing with water jets). It is these aerosolized wet or dry
particulates produced from seafood during processing operations that are inhaled by workers
in the occupational setting. In domestic environments, it is highly probable that similar
conditions prevail, although on a much smaller scale, resulting in allergic symptoms in highly
exposed or allergic individuals.
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Experimental studies in crab processing plants demonstrate that the aerosols generated in
these factories contain mainly crab exoskeleton containing chitin, meat primarily muscle
protein, gills and kanimiso/internal organs (Jeebhay et al., 2001). Fish juice produced in fish
filleting and canning plants has various biogenic amines, degradation compounds associated
with postmortem changes, digestive enzymes, skin slime/mucin, collagen and fish muscle
proteins.
4.1 Aeroallergen quantification in seafood workplaces
There are several quantification approaches utilized to measure the levels of aeroallergens
in workplace environments. These techniques are based mainly on the immunoreactivity of
allergenic proteins with the specific IgE of sensitized patients’ sera. Inhibition RIA, RAST,
and ELISA are the most common techniques that have been used historically. Taylor et al.
measured the level of raw fish aeroallergens in open-air fish markets using the inhibition RIA
(Taylor et al., 2000). In 1997 Malo et al. applied the RAST test for the first time to measure
seafood aeroallergens, where the air samples were collected from snow crab processing plants
(Malo et al., 1997). In this study, total allergen extracts were prepared as a standard and the
activity of these extracts was evaluated by skin test in patients known to have occupational
asthma. The amount of the allergenic protein was estimated by percent inhibition of the
RAST profile. A comprehensive study with four snow crab plants was accomplished in
Newfoundland and Labrador, where air samples were analyzed using a similar process
(Howse et al., 2006).
Inhibition ELISA techniques have also been used to study seafood aeroallergens. The water or
meat protein extract and a pool of patients’ sera were used as standard and primary antibody,
respectively. Weytjens et al. measured the levels of snow crab allergen in workplaces and
studied the gradient profile of the aeroallergens inside a processing plant using the ELISA
technique with an 125I-radiolabel (Weytjens et al., 1999). Using the same approach, Beaudet’s
group studied aerosolized crab levels aboard crab processing vessels in Alaska, where the
concentration of crab allergen was reported to be similar across all job categories (Beaudet
et al., 2002). ELISA techniques with a colorimetric detection system were developed for
measuring the fish aeroallergen in processing plants (Lopata et al., 2005). In 2005, Jeebhay
et al. quantified the level of aeroallergens to study the correlation between the levels of the
aerosolized allergens and other major determinants of variability in an attempt to establish
dose-response relationships for asthma due to fish antigen exposure (Jeebhay et al., 2008;
2005). Another comprehensive study was performed for examining the levels of bioaerosols
in the seafood industry using the ELISA reader for quantification purposes (Bang et al., 2005).
Recently, the aeroallergen levels of snow crab and northern shrimp in harvesting vessels and
processing plants were measured directly using tandem MS techniques. The TM and the AK
were detected in their aerosolized form in the processing plants; however, TM was the only
allergen detected aboard the vessels holds and decks (Abdel Rahman et al., 2012; 2011; 2010c).
Table 3 summarizes the results of the various exposure characterization studies conducted
and demonstrates the wide range of total inhalable airborne particulate (0.001-11.293 mg/m3),
protein (0.001-6.4 mg/m3) and allergen (0.001-75.748 mg/m3) levels (Jeebhay & Cartier, 2010).
Particulate and allergen levels reach very high levels in the processing operations aboard
vessels at sea in the case of crab processing and during fishmeal operations.
In conclusion, the development of novel methods to characterize airborne seafood allergens
have the potential to introduce accurate, sensitive, and specific advanced monitoring
approaches that will contribute towards strategies to minimize allergen exposures among
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Fig. 4. The allergenomics strategy for allergen discovery, which uses the seafood crude
extracts and the proteomics-MS based approach for characterization
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common, King) total inhalable 0.001-0.680 0.001-6.400 0.001-5.061
crabs (snow)* total inhalable ND ND 0.001-5.061
crabs (snow, Tanner,
common, King) total inhalable ND ND 0.079-21.093
prawns total inhalable 0.100-3.300 ND ND
shrimp total inhalable ND ND 1.500-6.260
rock lobster thoracic LOD-0.661 LOD-0.002 ND




salmon respirable 0.040-3.570 ND 0.100-1.00
pollock total inhalable 0.004 ND ND
whiff megrim/hake total inhalable ND ND 0.002-0.025
pilchard thoracic LOD-2.954 LOD-0.006 0.010-0.898
cod total inhalable ND ND 3.800-5.100
salmon total inhalable ND ND LOD-1.600
herring total inhalable ND ND 0.300-1.900
fishmeal (anchovy) thoracic LOD-11.293 LOD-0.004 0.069-75.748
shark cartilage** Respirable 0.920 - 5.140 ND ND
total inhalable 26.400 - 44.700 ND ND
ND: Not done, LOD: Limit of detection,
* processing aboard vessels; and
** non-food-handling environment
Table 3. Exposure assessment studies of seafood processing workers on land and aboard
vessels (Reproduced with permission from (Jeebhay & Cartier, 2010)
seafood processing workers in the seafood industry(Lopata & Jeebhay, 2007). Monitoring
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1. Introduction 
According to the position paper from the European Academy for Allergy and Clinical 
Immunology (EAACI) “food allergy” summarizes immune-mediated, non-toxic adverse 
reactions to foods (Figure 1)(Bruijnzeel-Koomen et al., 1995). The most common form of 
food allergy is mediated by immunoglobulin (Ig)E antibodies and reflects an immediate-
type ("Type 1 hypersensitivity") reaction, i.e. acute onset of symptoms after ingestion or 
inhalation of foods. IgE-mediated food allergy is further classified into primary (class 1) and 
secondary (class 2) food allergy. This distinction is based on clinical appearance, the 
predominantly affected group of patients (children or adults), disease-eliciting food 
allergens and the underlying immune mechanisms. Primary (class 1) or “true” food allergy 
starts in early life and often represents the first manifestation of the atopic syndrome. The 
most common foods involved are cow´s milk, hen´s egg, legumes (peanuts and soybean), 
fish, shellfish and wheat. Of note, allergens contained in these foods do not only elicit 
allergic reactions in the gastrointestinal tract but often cause or influence urticaria, atopic 
dermatitis as well as bronchial obstruction. With a few exceptions (peanut and fish) most 
children outgrow class 1 food allergy within the first 3 to 6 years of life. 
Secondary (class 2) food allergy describes allergic reactions to foods in mainly adolescent 
and adult individuals with established respiratory allergy, for example to pollen of birch, 
mugwort or ragweed. This form of food allergy is believed to be a consequence of 
immunological cross-reactivity between respiratory allergens and structurally related 
proteins in the respective foods. In principle, the recognition of homologous proteins in 
foods by IgE-antibodies specific for respiratory allergens can induce clinical symptoms. 
Foods inducing allergic reactions in the different groups of patients vary according to the 
manifested respiratory allergy. Different syndromes have been defined, such as the birch-
fruit-hazelnut-vegetable syndrome, the mugwort-celery-spice syndrome or the latex-shrimp 
syndrome. 
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Adverse reactions to foods
Non-toxic Toxic
Non-immune-mediated (food intolerance) Immune-mediated (food allergy)
Pharmacological Enzymatic Irritant Psychosomatic IgE-mediated Non-IgE-mediated
Class 1 Class 2  
Fig. 1. Classification of adverse reactions to foods according to the pathophysiology 
(Bruijnzeel-Koomen et al., 1995). Adverse reactions to foods comprise toxic and non-toxic 
reactions. The latter reactions are either non-immune-mediated or immune-mediated. IgE-
mediated reactions constitute type I hypersensitivity while non-IgE-mediated reactions are 
suspected to be mediated by IgG or IgM immune complex reactions (type III 
hypersensitivity) or cell-mediated delayed-type reactions (type IV hypersensitivity). 
2. Immune mechanisms underlying IgE-mediated allergy 
IgE-mediated allergy develops upon contact with an allergenic protein leading to 
sensitisation. The allergen is absorbed through the mucosal membrane of the respiratory or 
the gastrointestinal tract or the skin and can enter tissues through disrupted epithelium and 
gain access to antigen-presenting cells (APC), most importantly dendritic cells, which takes 
up allergen and migrate to lymph nodes. There they present small peptide fragments 
resulting from allergen processing bound to major histocompatibility complex (MHC) class 
II molecules to naïve CD4+ Th lymphocytes. Depending on key cytokines present during the 
initial interaction with APC naïve CD4+ cells differentiate into five different (and maybe 
more) “classical” effector cell subsets, Th2, Th1, Th17, Th22 cells and induced regulatory T 
(Treg) cells (Figure 2). The presence of interleukin (IL)-4 promotes T cell differentiation 
towards allergen-specific Th2 cells that produce high amounts of the signature cytokines IL-
4, IL-5, IL-9 and IL-13 but little or no interferon-γ (IFN-γ). IL-4 is the major switch factor for 
IgE synthesis in B cells. The presence of IL-12 and IL-27 during T cell priming fosters the 
differentiation of Th1 cells that produce high amounts of the signature cytokine IFN-γ, 
which is a potent antagonist of IL-4 and inhibits the differentiation of Th2 cells. Human 
Th17 cells differentiate in the presence of IL-1β and IL-23. This subset synthesizes the 
signature cytokines IL-17a, IL-17f, IL-22 and IL-21. Th17 cells are important for the defence 
against extracellular bacteria and fungi and play a role in inflamed skin in atopic dermatitis. 
Moreover, Th17 cells have been shown to be involved in initiation and augmentation of 
inflammation in the airways and in the gut mucosa. Th22 cells produce IL-22 but not IL-17 
and differentiate in the presence of IL-6 and TNF-α (Duhen et al., 2009). IL-22 is a growth 
factor for keratinocytes and Th22 cells have been considered to have a role in protective and 
regenerative epithelial cell responses (Eyerich et al., 2009). Induced Treg cells suppress the 
differentiation and effector phases of other T cell subsets either by cell-cell contact and/or 
by IL-10 and/or TGF-β. Different subsets of Treg cells have been described. So-called Th3 
cells producing high amounts of TGF-β have been implicated as mediators of oral tolerance. 
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The term “Tr1 cells” was proposed for all IL-10-producing regulatory T cell populations that 
are induced by IL-10. Additional subsets of Treg cells may exist as well as additional subsets 
of effector cells, e.g. the more recently described Th9 (Veldhoen et al., 2008, Wong et al., 
2010). In addition, evidence accumulates that there is a significant degree of overlap and 
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Fig. 2. Classical CD4+ T cell subsets and their role in IgE-mediated allergy. Naïve CD4+ T 
lymphocytes differentiate into different subsets directed by cytokines in the 
microenvironment during their activation via the T cell receptor. The presence of high 
concentrations of IL-4 promotes the induction of Th2 cells, IL-12 of Th1 cells, TGF-β Treg 
cells, TGF-β and IL-6 and/or IL-1 Th17 cells and IL-6 and TNF-α Th22 cells. The different 
subsets are characterized by the expression of different transcription factors (GATA-3, T-bet, 
Foxp3, RORγt). The transcription factor of Th22 cells has not yet been identified. Upon 
activation the different subsets of CD4+ effector cells produce different signature cytokines 
and thereby exert different effector functions. 
IgE-mediated disorders result from an aberrant Th2-dominated response to allergens due to 
ineffective counter-regulation by allergen-specific Th1 and Treg cells. The overshooting 
allergen-specific Th2 response promotes the production of allergen-specific IgE antibodies 
which subsequently are bound to the high affinity receptor (FcεRI) on the surface of effector 
cells such as mast cells and basophils (Figure 3). Cross-linking of IgE by allergen induces 
effector cell activation and the release of preformed mediators, most importantly histamine, 
which cause immediate allergic symptoms. After 6-48 hours late phase reactions occur 
which are mediated by eosinophils and allergen-specific T cells that have migrated to the 
site of inflammation. Allergen-IgE-complexes bind to low affinity IgE receptors (FcεRII, 
CD23) expressed on lymphocytes, monocytes, macrophages and platelets. Receptor-
mediated endocytosis of allergens via FcεRII is an important way of allergen uptake by B 
lymphocytes which is thought to increase allergic responses by promoting Th2 responses. 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
142 
Adverse reactions to foods
Non-toxic Toxic
Non-immune-mediated (food intolerance) Immune-mediated (food allergy)
Pharmacological Enzymatic Irritant Psychosomatic IgE-mediated Non-IgE-mediated
Class 1 Class 2  
Fig. 1. Classification of adverse reactions to foods according to the pathophysiology 
(Bruijnzeel-Koomen et al., 1995). Adverse reactions to foods comprise toxic and non-toxic 
reactions. The latter reactions are either non-immune-mediated or immune-mediated. IgE-
mediated reactions constitute type I hypersensitivity while non-IgE-mediated reactions are 
suspected to be mediated by IgG or IgM immune complex reactions (type III 
hypersensitivity) or cell-mediated delayed-type reactions (type IV hypersensitivity). 
2. Immune mechanisms underlying IgE-mediated allergy 
IgE-mediated allergy develops upon contact with an allergenic protein leading to 
sensitisation. The allergen is absorbed through the mucosal membrane of the respiratory or 
the gastrointestinal tract or the skin and can enter tissues through disrupted epithelium and 
gain access to antigen-presenting cells (APC), most importantly dendritic cells, which takes 
up allergen and migrate to lymph nodes. There they present small peptide fragments 
resulting from allergen processing bound to major histocompatibility complex (MHC) class 
II molecules to naïve CD4+ Th lymphocytes. Depending on key cytokines present during the 
initial interaction with APC naïve CD4+ cells differentiate into five different (and maybe 
more) “classical” effector cell subsets, Th2, Th1, Th17, Th22 cells and induced regulatory T 
(Treg) cells (Figure 2). The presence of interleukin (IL)-4 promotes T cell differentiation 
towards allergen-specific Th2 cells that produce high amounts of the signature cytokines IL-
4, IL-5, IL-9 and IL-13 but little or no interferon-γ (IFN-γ). IL-4 is the major switch factor for 
IgE synthesis in B cells. The presence of IL-12 and IL-27 during T cell priming fosters the 
differentiation of Th1 cells that produce high amounts of the signature cytokine IFN-γ, 
which is a potent antagonist of IL-4 and inhibits the differentiation of Th2 cells. Human 
Th17 cells differentiate in the presence of IL-1β and IL-23. This subset synthesizes the 
signature cytokines IL-17a, IL-17f, IL-22 and IL-21. Th17 cells are important for the defence 
against extracellular bacteria and fungi and play a role in inflamed skin in atopic dermatitis. 
Moreover, Th17 cells have been shown to be involved in initiation and augmentation of 
inflammation in the airways and in the gut mucosa. Th22 cells produce IL-22 but not IL-17 
and differentiate in the presence of IL-6 and TNF-α (Duhen et al., 2009). IL-22 is a growth 
factor for keratinocytes and Th22 cells have been considered to have a role in protective and 
regenerative epithelial cell responses (Eyerich et al., 2009). Induced Treg cells suppress the 
differentiation and effector phases of other T cell subsets either by cell-cell contact and/or 
by IL-10 and/or TGF-β. Different subsets of Treg cells have been described. So-called Th3 
cells producing high amounts of TGF-β have been implicated as mediators of oral tolerance. 
Birch Pollen-Related Food Allergy: An Excellent Disease 
Model to Understand the Relevance of Immunological Cross-Reactivity for Allergy 
 
143 
The term “Tr1 cells” was proposed for all IL-10-producing regulatory T cell populations that 
are induced by IL-10. Additional subsets of Treg cells may exist as well as additional subsets 
of effector cells, e.g. the more recently described Th9 (Veldhoen et al., 2008, Wong et al., 
2010). In addition, evidence accumulates that there is a significant degree of overlap and 












IL-4, IL-5, IL-9, IL-13

























Fig. 2. Classical CD4+ T cell subsets and their role in IgE-mediated allergy. Naïve CD4+ T 
lymphocytes differentiate into different subsets directed by cytokines in the 
microenvironment during their activation via the T cell receptor. The presence of high 
concentrations of IL-4 promotes the induction of Th2 cells, IL-12 of Th1 cells, TGF-β Treg 
cells, TGF-β and IL-6 and/or IL-1 Th17 cells and IL-6 and TNF-α Th22 cells. The different 
subsets are characterized by the expression of different transcription factors (GATA-3, T-bet, 
Foxp3, RORγt). The transcription factor of Th22 cells has not yet been identified. Upon 
activation the different subsets of CD4+ effector cells produce different signature cytokines 
and thereby exert different effector functions. 
IgE-mediated disorders result from an aberrant Th2-dominated response to allergens due to 
ineffective counter-regulation by allergen-specific Th1 and Treg cells. The overshooting 
allergen-specific Th2 response promotes the production of allergen-specific IgE antibodies 
which subsequently are bound to the high affinity receptor (FcεRI) on the surface of effector 
cells such as mast cells and basophils (Figure 3). Cross-linking of IgE by allergen induces 
effector cell activation and the release of preformed mediators, most importantly histamine, 
which cause immediate allergic symptoms. After 6-48 hours late phase reactions occur 
which are mediated by eosinophils and allergen-specific T cells that have migrated to the 
site of inflammation. Allergen-IgE-complexes bind to low affinity IgE receptors (FcεRII, 
CD23) expressed on lymphocytes, monocytes, macrophages and platelets. Receptor-
mediated endocytosis of allergens via FcεRII is an important way of allergen uptake by B 
lymphocytes which is thought to increase allergic responses by promoting Th2 responses. 
 






















primes naive T cells
T-B cell interaction
results in IgE production
Activation of effector cells
and immediate reaction
Cell-mediated
late phase reactions  
Fig. 3. The pathophysiology of IgE-mediated allergy. Allergens enter the human body 
through mucosal sites, e.g. in the respiratory or gastrointestinal tract, or via the skin. 
Antigen-presenting cells, most importantly dendritic cells (DC), take up allergens and 
migrate to lymph nodes where they present allergens to naïve CD4+ T helper (Th) cells. In 
atopic individuals, the majority of allergen-specific T cells differentiate into Th2 cells 
producing high amounts of the signature cytokine IL-4. Interaction of Th2 cells and B cells 
leads to the production of IgE antibodies which are bound on the surface of effector cells. 
Upon repeated allergen encounter, these effector cells are activated and release preformed 
mediators, most importantly histamine, causing immediate allergic symptoms. After 6-48 
hours cell-mediated late phase reactions in target organs can occur because different types 
of granulocytes and allergen-specific T cells have migrated to inflammatory sites. 
3. Birch pollen-related food allergy: Clinical appearance 
Birch pollen is one of the most common causes of rhinoconjunctivitis and allergic asthma in 
Northern and Central Europe and North America (Lin et al., 2002, Stevens et al., 2003). 
Already in 1948 it has been recognized that birch pollen-allergic patients tend to develop 
allergic reactions to fruits and vegetables in addition to seasonal respiratory symptoms 
(Juhlin-Dannfelt, 1948). An association between birch pollinosis and allergic reactions to 
diverse foods was first demonstrated in the late seventies (Hannuksela and Lahti, 1977). In 
this report, more than 380 Finish patients with various atopic disorders were tested for 
allergic reactivity to common fruits and vegetables. Of the patients with hypersensitivity to 
birch pollen, 36% showed immediate positive responses to fresh fruits and vegetables 
whereas such reactions were rare among patients without allergy to birch pollen. One year 
later a correlation between birch pollen allergy and allergic symptoms to nuts, apple, peach, 
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cherry, pear, plum, carrot and new potato was reported in 1120 adult Swedish patients 
(Eriksson, 1978). A subsequent interrogation of 600 patients with pollen allergy again 
confirmed that hypersensitivity to various nuts, fruits and roots was reported more often by 
patients with (70%) than by patients without birch pollen allergy (19%) and that grass pollen 
allergy negatively correlated with food hypersensitivity (Eriksson et al., 1982). 
Approximately, 100 million people suffer from birch pollen allergy worldwide and 
approximately 70% of these individuals develop birch pollen-related food allergy. 
Therefore, this secondary food allergy has to be regarded as one of the most common plant 
food allergies in adolescent and adult individuals today. Interestingly, birch pollen-related 
food allergy is perennial in more than 80% of the affected individuals, i.e. affecting the 
patients also outside of the birch pollen season (Geroldinger-Simic et al., 2011). Around 40% 
of the patients suffer from more severe symptoms during the pollen season as compared to 
the pollen-free time period. The most frequent triggers of birch pollen-related food allergy 
are stone-fruits (apple, peach) and hazelnuts. In addition, particular vegetables (celery, 
carrot), peanuts and soy products can also induce allergic reactions in birch pollen-allergic 
patients (Asero et al., 1996, Eriksson et al., 1982, Geroldinger-Simic et al., 2011, Ghunaim et 
al., 2005, Osterballe et al., 2005). In the majority of patients allergic reactions to these foods 
manifest as contact urticaria of the oral mucosa (oral allergy syndrome, OAS). Typical 
symptoms comprise itching of the lips, tongue and throat, sometimes accompanied by 
oedema of the lips and tongue and occur within minutes after contact with the food 
(Ortolani et al., 1988). Many patients also describe itching in their ears. Usually, these 
reactions disappear within 20-30 minutes. In addition to OAS which is confined to the site of 
allergen exposure, systemic and more severe IgE-mediated reactions such as urticaria, 
asthma or anaphylactic shock may occur occasionally. In particular, the consumption of soy-
containing food products which contain the Bet v 1-homologous protein Gly m 4 have been 
described to trigger anaphylactic reactions such as swollen tongue, angioedema, urticaria, 
rhino-conjunctivitis and/or hypotension within 15-30 min after consumption (Kleine-Tebbe 
et al., 2002, van Zuuren et al., 2010). However, several patients experiencing severe systemic 
reactions to soy-products were found to show IgE-reactivity to seed storage proteins in soy 
which are primary food allergens and also likely candidates to cause the observed severe 
soy allergy (van Zuuren et al., 2010). 
4. Birch pollen-related food allergy: Involved allergens 
Birch pollen contains one major allergen, Bet v 1, which is recognized by IgE antibodies 
from more than 90% of birch pollen-allergic patients (Geroldinger-Simic et al., 2011). Bet v 1 
belongs to the pathogenesis-related (PR) 10 protein family. Other members of this protein 
family have been identified in different foods, such Mal d 1 in apple, Pru p 1 in peach, Pru 
av 1 in cherry, Pyr c 1 in pear, Cor a 1 in hazelnut, Api g 1 in celery, Dau c 1 in carrot, Gly m 
4 in soybean, (all summarized in (Bohle, 2006), Vig r 1 in mungbean (Mittag et al., 2005), Ara 
h 8 in peanut (Mittag et al., 2004), Act d 8 in kiwi (Oberhuber et al., 2008) and jackfruit 
(Bolhaar et al., 2004). Although birch pollen contains additional minor allergens, e.g. Bet v 2 
(birch profilin), that have homologous proteins in various foods, IgE antibodies specific for 
Bet v 1 seem to be most relevant for clinical reactions against birch pollen-related foods since 
a large number of birch pollen-allergic patients with food allergy is exclusively sensitized to 
the major birch pollen allergen (Geroldinger-Simic et al., 2011). 
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The identification of the genes encoding various different Bet v 1-homologs in a great 
variety of food (Table 1) allowed their production as recombinant proteins (Table 1) which 
were employed to analyse structural and immunological characteristics. 
 
Food Bet v 1-homolog GeneBank Acct. No. Sequence identity (%) 
Apple Mal d 1 AJ417551 56 
Hazelnut Cor a 1 AF136945 67 
Nectarine/Peach Pru p 1 DQ251187 73 
Kiwi Act d 8 AM489568 53 
Carrot Dau c 1 AF456481 37 
Apricot Pru ar 1 U93165 56 
Cherry Pru av 1 U66076 59 
Pear Pyr c 1 AF057030 57 
Peanut Ara h 8 AY328088 46 
Celery Api g 1 Z48967 41 
Soybean Gly m 4 X60043 45 
Strawberry Fra a 1 Q256S2 53 
Raspberry Rub I 1 Q0Z8U9 55 
Table 1. Bet v 1-homologs in birch pollen-related foods 
Bet v 1-related food proteins display the typical Bet v 1-fold due to their high amino acid 
sequence similarity with Bet v 1 (Radauer et al., 2008). The highly similar tertiary structure 
explains why IgE-antibodies specific for conformational epitopes of Bet v 1 can cross-react 
with its food homologs. In addition to Bet v 1-specific IgE antibodies, Bet v 1-specific T 
lymphocytes cross-react with related food allergens. This fact has been demonstrated in in 
vitro experiments by employing Bet v 1-specific T cell clones that had been isolated from the 
blood of birch pollen-allergic patients. The clones were stimulated with recombinant Bet v 1-
related food allergens and proliferative and cytokine responses were assessed (Bohle et al., 
2003, Bohle et al., 2005, Fritsch et al., 1998). Several Bet v 1-specific clones proliferated in 
response to different food allergens and produced similar cytokine patterns as compared to 
stimulation with Bet v 1. In particular, T cells specific for the immunodominant T cell-
activating region Bet v 1142-156 which is located in a highly conserved amino acid region of 
the major birch pollen allergen responded to several Bet v 1-related food allergens (Jahn-
Schmid et al., 2005). The cellular cross-reactivity is due to the high amino acid sequence 
similarity between Bet v 1 and its food homologs in this region. In addition to the C-terminal 
T cell epitope located within Bet v 1142-156 (Figure 4), the major birch pollen allergen contains 
other relevant T cell activating regions spreading its entire amino acid sequence (Jahn-
Schmid et al., 2005). Most T cell-activating regions that have been identified in Mal d 1, Cor 
a 1 and Api g 1 match the amino acid sequences of these epitopes (Bohle et al., 2003, Bohle et 
al., 2005, Fritsch et al., 1998). Thereby, the receptor of a Bet v 1-specific T cell can cross-react 
with a peptide derived from antigen-processing of Bet v 1-related food allergens. 
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Fig. 4. Sequence alignment of Bet v 1-related food proteins and Bet v 1. Similar amino acid 
residues are indicated by +. The immunodominant T cell epitope in the C-terminus of Bet v 
1 is underlined. 
Resistance to gastrointestinal degradation and to heat treatment is considered to be an 
important characteristic of food allergens and was investigated by employing recombinant 
Bet v 1-related food allergens. Simulated gastrointestinal degradation of Mal d 1, Api g 1 
and Cor a 1 revealed that these proteins were completely fragmented within a few minutes 
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of exposure to pepsin, the most prominent gastric protease (Kopper et al., 2004, Schimek et 
al., 2005, Schulten et al., 2011). Proteolytic degradation of Bet v 1-homologous food allergens 
into small fragments leads to the loss of their IgE-binding capacity because most IgE-
epitopes of Bet v 1 are conformational epitopes depending on the tertiary protein structure 
(Mittag et al., 2006, Neudecker et al., 2003, Scheurer et al., 1999). The rapid and complete 
degradation of Bet v 1-homologous food allergens explains why systemic IgE-mediated 
reactions rarely occur after consumption of birch pollen-related foods. At the site of contact 
with fresh foods, i.e. the oral mucosa, local IgE-mediated immediate allergic reactions are 
induced by intact food allergens. After swallowing Bet v 1-related food allergens are rapidly 
degraded in the stomach and cannot be absorbed into the blood stream in a form capable of 
inducing IgE-mediated effector cell activation. As a consequence, systemic allergic reactions 
to birch pollen-related foods are rare. However, there are exceptions to this process, for 
example, the so-called “bio-bar syndrome”. This syndrome describes occasional 
anaphylactic reactions in patients with birch pollen allergy that occur after the consumption 
of fruit and vegetable smoothies. These drinks are usually prepared from fresh apple 
and/or raw carrot and drunk very rapidly at so-called bio-bars. We recently found a 
possible explanation for this phenomenon by performing  in vivo absorption assays in an 
animal model (Schulten et al., 2011). We observed that the pH value in the stomach of rats 
rises to 5 after allergen administration. Similarly, administration of a peanut-based meal 
initially neutralized the gastric pH value of piglets to approximately 7, which was 
subsequently acidified by HCl secretion (Kopper et al., 2006). The high pH value renders 
pepsin inactive. Consequently, Bet v 1-homologous food allergens were not degraded by the 
protease and could be detected in the rat serum after a time period of 2 hours (Schulten et 
al., 2011). Deduced from these in vivo results from animal models we propose that rapid 
drinking of freshly prepared smoothies on an relatively empty stomach of birch pollen-
allergic individuals will rise the gastric pH value and prevent immediate pepsinolysis of 
food allergens. Thereby, a dose of IgE-reactive Bet v 1-related food allergens can be 
absorbed which is sufficient to subsequently cause systemic anaphylaxis. The same cascade 
of events may also explain the severe anaphylactic reactions observed in birch pollen-
allergic patients after ingestion of soy-based foods, in particular soy milk, containing the Bet 
v 1-homolog Gly m 4 (Kleine-Tebbe et al., 2002). 
Recombinant Bet v 1-related food allergens were also employed to investigate the effects of 
heat treatment on these proteins. Exposure to high temperatures demolishes their 3-
dimensional structure, thereby reducing their capacity to bind IgE and consequently, to 
induce IgE-mediated effector cell activation (Bohle et al., 2006). This biochemical behaviour 
explained why typically, only fresh fruits and vegetables induce immediate allergic 
symptoms whereas cooked birch pollen-related foods are usually tolerated by birch pollen-
allergic patients. 
In summary, Bet v 1-related food allergens lack typical features of primary food allergens, 
i.e. resistance to gastrointestinal degradation and heat treatment. Therefore, they are 
considered to be secondary or incomplete food allergens, i.e. incapable of initiating an 
allergic sensitization in an individual by themselves. However, due to their structural 
similarity with Bet v 1 and to the high amino acid sequence identity between the major birch 
pollen allergen and its dietary homologs these proteins can induce allergic symptoms when 
cross-reactive Bet v 1-specific IgE antibodies and T cells are present in allergic patients. IgE-
mediated symptoms appear as OAS immediately after contact with the respective fresh 
foods in the majority of patients. The activation of Bet v 1-specific T cells by Bet v 1-related 
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food allergens may induce late phase responses in target organs in a minority of birch 
pollen-allergic patients, for example a worsening of atopic eczema occurring 12-48 hours 
after consumption of birch pollen-related foods (Bohle et al., 2006, Werfel et al., 1999). In 
biopsies of such flare ups Bet v 1-specific T cells have been detected (Reekers et al., 1999). 
This finding indicated that after ingestion and gastrointestinal proteolysis of Bet v 1-related 
food allergens fragments thereof were absorbed into the blood and induced the activation of 
Bet v 1-specific T cells. Indeed, several fragments of Bet v 1-homologous food allergens were 
identified after simulated gastrointestinal degradation that contained T cell activating 
regions and induced the proliferation and cytokine synthesis of Bet v 1-specific T cell clones 
in vitro (Schimek et al., 2005). In vivo, Bet v 1-specific T lymphocytes activated by such cross-
reactive peptides may migrate into target organs such as the skin and exert local effector 
functions, e.g. a worsening of atopic eczema. 
Of note, T cell-mediated symptoms induced by Bet v 1-related food allergens can occur 
independently from IgE-mediated reactions. This means that patients who do not 
experience an OAS when consuming birch pollen-related foods may still suffer from flare-
ups of their atopic eczema several hours after ingestion. For example, when birch pollen-
allergic patients were challenged with cooked birch pollen-related foods, these individuals 
did not experience immediate symptoms but T cell-mediated late phase reactions  (Bohle et 
al., 2006). Together, biochemical and immunological data gained with recombinant Bet v 1-
homologous food allergens provide an explanation for this clinical observation. Allergen-
recognition differs between IgE antibodies and allergen-specific T cells. In contrast to IgE 
antibodies which often recognize conformational epitopes depending on the tertiary 
structure of an allergen T cells recognize small linear peptides generated during antigen 
processing of proteins (Figure 5). Cooking of Bet v 1-homologs leads to their loss of IgE-
binding. Nevertheless, heat-denatured Bet v 1-related food allergens are taken up and 
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Fig. 5. Antigen-recognition by B and T lymphocytes. Antibodies (indicated as Y) produced 
by plasma cells often recognize conformational epitopes that depend on the tertiary 
structure of proteins. The amino acid residues forming the epitope are not neighbouring 
residues in the primary sequence. In contrast, linear T cell epitopes highlighted as black 
lines within the amino acid sequence consist of neighbouring amino acid residues. 
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considered to be secondary or incomplete food allergens, i.e. incapable of initiating an 
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food allergens may induce late phase responses in target organs in a minority of birch 
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in vitro (Schimek et al., 2005). In vivo, Bet v 1-specific T lymphocytes activated by such cross-
reactive peptides may migrate into target organs such as the skin and exert local effector 
functions, e.g. a worsening of atopic eczema. 
Of note, T cell-mediated symptoms induced by Bet v 1-related food allergens can occur 
independently from IgE-mediated reactions. This means that patients who do not 
experience an OAS when consuming birch pollen-related foods may still suffer from flare-
ups of their atopic eczema several hours after ingestion. For example, when birch pollen-
allergic patients were challenged with cooked birch pollen-related foods, these individuals 
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recognition differs between IgE antibodies and allergen-specific T cells. In contrast to IgE 
antibodies which often recognize conformational epitopes depending on the tertiary 
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What may be the consequence of T cell activation by ingested Bet v 1-related food allergens? In 
allergic individuals, allergen-specific T cells were shown be long-lived and to exist for several 
years (Bohle et al., 1998, Wedderburn et al., 1993). In order to survive, specific memory T cells 
seem to require repeated contact with antigen. The ingestion of pollen-related food proteins 
capable of activating pollen-specific T lymphocytes may represent one way to stimulate these 
cells, in particular outside of the tree pollen season. In our studies the majority of the food 
allergen-reactive Bet v 1-specific TCC were Th2-like and synthesized high levels of IL-4 in 
response to the food allergens (Bohle et al., 2003, Bohle et al., 2005, Fritsch et al., 1998). 
Therefore, the perennial uptake of pollen-related food could stimulate the survival of T cells 
and ongoing IL-4 synthesis and thereby contribute to the typical maintenance of high levels of 
pollen-specific IgE also outside of the tree pollen season. A summary of the consequences of 
consumption of Bet v 1-related food allergens is provided in Figure 6. 
5. Bet v 1 is the primary sensitizer in birch pollen-related food allergy 
Clinical, immunological and biochemical data support that birch pollen-related food allergy 
is a secondary food allergy and results from primary respiratory sensitization to the major 
birch pollen allergen and subsequent immunological cross-reactivity. From the clinical point 
of view, the majority of patients develop food-induced allergic symptoms after the onset of 
respiratory allergy (Geroldinger-Simic et al., 2011). Furthermore, a high number of birch 
pollen-allergic patients shows IgE-reactivity to Bet v 1-related food allergens without 
developing clinical reactions to the respective foods whereas only very few food-allergic 
individuals display IgE-reactivity to Bet v 1-homologous food allergens in the absence of Bet 
v 1-specific IgE antibodies (Flinterman et al., 2006, Moneo et al., 1999). Finally, patients 
suffering from allergic reactions to stone-fruits and hazelnuts in birch-free areas are not 
sensitized to Bet v 1-homologous food allergens but to other plant food allergens, e.g. non-
specific lipid transfer proteins (Fernandez-Rivas et al., 2008, Fernandez-Rivas et al., 2006). 
Immunologically, Bet v 1 not only cross-reacts with its related dietary proteins but the major 
birch pollen allergen dominates the IgE and T cell reactivity to its homologs. For example, 
pre-incubation of patients´ sera with Bet v 1 totally abolishes their IgE-binding to Mal d 1 
and Api g 1 whereas pre-incubation of the same sera with Bet v 1-related food allergens 
reduces IgE-binding to the major birch pollen allergen to only around 50% (Bohle et al., 
2003, Kinaciyan et al., 2007). These experimental findings indicate that Bet v 1 contains most 
IgE-epitopes of its food homologues and binds IgE with higher affinity. Thus, it may be 
concluded that Bet v 1 initiated the production of specific IgE antibodies in vivo. Similar to 
the IgE level, experimental in vitro approaches revealed that Bet v 1 dominates the T cell 
response to its food-homologs. When T cells reactive with Bet v 1-related food allergens 
were isolated from the peripheral blood of allergic patients and re-stimulated with either the 
food allergen or Bet v 1, most cultures responded stronger to the major birch pollen allergen 
(Bohle et al., 2003, Bohle et al., 2005, Fritsch et al., 1998). This finding indicates that T cells 
which respond to stimulation with Bet v 1-related food allergens are cross-reactive, Bet v 1-
specific clonotypes. Again, these observations support that Bet v 1 was the initial stimulus 
for an allergic response in birch pollen-related food allergy. 
Biochemically, the high susceptibility of Bet v 1-homologous dietary allergens to proteolytic 
degradation in the stomach and small intestine prevents them from reaching the gut-
associated lymphoid tissue (GALT) in an intact form. Therefore, Bet v 1-homologous food 
allergens are considered to be incapable of sensitizing an individual by themselves after 
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being taken up through their natural route of exposure. In contrast, the major birch pollen 
allergen is inhaled and thereby not exposed to the harsh conditions of the gastrointestinal 
tract. Bet v 1 reaches the respiratory tract in an immunological active form where it can 
induce IgE-production. Together, clinical and experimental observations support that the 
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Fig. 6. Proposed pathophysiology of pollen-related food allergy. Bet v 1 initiates respiratory 
sensitization. Bet v 1-specific IgE antibodies recognize structurally related dietary proteins in 
various foods which may cause clinical reactions, often directly at the site of allergen contact, 
e.g. the oral mucosa. After ingestion Bet v 1-related food homologs are degraded when passing 
through the intestinal tract. Cooking of the respective foods also denatures Bet v 1-related food 
allergens. The destruction of their 3-dimensional structure leads to the loss of IgE-binding 
capacity of Bet v 1-homologous food proteins. Nevertheless, allergenic fragments after 
gastrointestinal degradation as well as heat-denatured Bet v 1-related allergens are still 
capable of activating Bet v 1-specific T lymphocytes. Upon activation, Bet v 1-specific T cells 
proliferate and produce cytokines. They also migrate to different target organs where they 
may exert clinical late-phase reactions, e.g. the worsening of atopic eczema in the skin. 
Possibly, activation of pollen-specific Th2 cells by ingested food proteins also contributes to 
their survival and longevity in allergic patients. 
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Interestingly, a few food-allergic patients have been identified to bear IgE antibodies specific 
for Bet v 1-related food allergens, e.g. Cor a 1 in hazelnut, without being sensitized to the 
major birch pollen allergen (Flinterman et al., 2006). This finding suggested that a non-pollen-
related route of sensitization to the Bet v 1-homologous hazelnut allergen may be possible. 
Along these lines, we previously found evidence for a potential sensitizing capacity of Cor a 1 
based on the identification of T cell clones that did not cross-react with Bet v 1 (Bohle et al., 
2005). However, in simulated gastrointestinal degradation assays pure Cor a 1 lost its IgE-
binding ability within a few seconds of incubation with pepsin (Schimek et al., 2005). This 
discrepancy tempted us to investigate whether the natural matrix embedding Cor a 1 may 
contribute to its sensitizing capacity. Actually, in simulated gastrointestinal degradation 
assays, we found that the presence of hazelnut extract protected Bet v 1-related food allergens 
from gastric proteolysis (Schulten et al., 2011). Since Cor a 1 has been demonstrated to be 
relatively resistant to simulated degradation by the intestinal protease trypsin (Schimek et al., 
2005) we conclude that hazelnuts which provide a food matrix rich in carbohydrates and 
proteins under certain circumstances may contribute to a sensitizing capacity of the major 
hazelnut allergen independently from respiratory sensitization to Bet v 1. Most patients 
showing IgE-reactivity to Cor a 1 but not to Bet v 1 were children (Flinterman et al., 2006). 
Therefore, the still immature gastrointestinal tract of children may be such an additional 
precondition for a possible sensitization to Cor a 1. 
6. Treatment strategies for birch pollen-related food allergy 
6.1 Specific immunotherapy with birch pollen 
Together, clinical and immunological observations provide strong evidence that birch 
pollen-related food allergy is a consequence of cross-reactivity between Bet v 1 and its 
dietary homologs. Thus, one would assume that successful allergen-specific 
immunotherapy (SIT) of birch pollen allergy might concomitantly cure birch pollen-related 
food allergy. SIT consists of a series of continuous administration of increasing doses of 
allergen extracts to the allergic patient in order to induce clinical tolerance (1993) and is 
currently the only causative treatment for IgE-mediated allergy that results in long-term 
clinical tolerance to allergens. Various studies have shown that successful SIT alters the 
allergen-specific immune response (Larche et al., 2006). In general, SIT induces high levels of 
allergen-specific IgG antibodies, in particular IgG4, which are considered as “blocking” 
antibodies because they compete with IgE for allergen-binding and thereby impair IgE-
mediated reactions, e.g. allergen-induced activation of basophils and mast cells or IgE-
facilitated allergen uptake and presentation to T cells (James et al., 2011, Nouri-Aria et al., 
2004, van Neerven et al., 1999, Wachholz et al., 2003). At the T cell level it has been 
demonstrated that SIT induces a shift from the disease-eliciting T helper (Th) 2- towards a 
Th1-like response and regulatory CD4+ T (Treg) cells that actively suppress proliferation 
and cytokine production of allergen-specific effector T cells (Akdis et al., 1998, 
Bellinghausen et al., 1997, Ebner et al., 1997, Jutel et al., 2003). In addition to the modulation 
of the adaptive immune response to allergens, SIT also modulates the function of APC and 
effectors cells (Larche et al., 2006), e.g. reduction of the number of mast cells and their ability 
to release mediators. The recruitment of eosinophils and neutrophils to sites of allergen 
exposure is also reduced during SIT. 
An overview on the immune mechanisms operative during successful SIT is given in Figure 
7. However, it is still not clear which of these immune mechanisms actually translate(s) into 
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clinical tolerance of patients, i.e. improvement of symptoms, and whether one or more of 
these mechanisms fail those individuals who are not cured by SIT. 
SIT with birch pollen has been proven efficient for the treatment of birch pollinosis (Bodtger 
et al., 2002, Cirla et al., 1996, Winther et al., 2000). However, the clinical benefit of SIT with 
birch pollen on birch pollen-related food allergy is still debated. Whereas a few studies have 
described that patients improved their clinical symptoms to birch pollen-related foods after 
birch pollen-SIT (Asero, 1998, 2003, 2004) others have reported limited curative effects of 
birch pollen-SIT on birch pollen-related food allergy and some patients even developed 
allergic reactions to foods during the course of therapy (Bucher et al., 2004, Herrmann et al., 
1995, Modrzynski et al., 2002, van Hoffen et al., 2011). It has to be stressed that at present a 
prospective study investigating food allergic reactions in a sufficient number of birch 
pollen-allergic patients before and during birch pollen-SIT by means of double-blind 
placebo controlled food challenges (DBPCFC) is lacking. Nevertheless, the majority of 
clinicians observe that only approximately one third of birch pollen-allergic patients 
undergoing birch pollen-SIT concomitantly improve birch pollen-related food allergy. Thus, 
no effective treatment for this secondary food allergy exists at present. However, because of 
its high prevalence and the impaired quality of life of the affected individuals, there is a 


















Fig. 7. Immune mechanisms operative during allergen-specific immunotherapy (SIT). An 
overshooting allergen-specific Th2 response causes allergic diseases. Th2 cells produce IL-4 
that triggers B cells to produce allergen-specific IgE antibodies. Th2 cells also synthesize IL-
5, which activates eosinophils. IgE and eosinophils mediate the immediate allergic response. 
SIT induces immune deviation, i.e. the switch from Th2 towards Th1-like cells which 
produce high levels of IFN-γ,  a potent antagonist of IL-4. SIT also promotes the induction of 
regulatory T (Treg) cells which produce IL-10 and/or TGF-β. These immunosuppressive 
cytokines induce the production of allergen-specific IgG4 and IgA antibodies which may 
compete with IgE for allergen-binding (“blocking antibodies”. IL-10 promotes further 
induction of regulatory T cells. 
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An overview on the immune mechanisms operative during successful SIT is given in Figure 
7. However, it is still not clear which of these immune mechanisms actually translate(s) into 
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clinical tolerance of patients, i.e. improvement of symptoms, and whether one or more of 
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its high prevalence and the impaired quality of life of the affected individuals, there is a 


















Fig. 7. Immune mechanisms operative during allergen-specific immunotherapy (SIT). An 
overshooting allergen-specific Th2 response causes allergic diseases. Th2 cells produce IL-4 
that triggers B cells to produce allergen-specific IgE antibodies. Th2 cells also synthesize IL-
5, which activates eosinophils. IgE and eosinophils mediate the immediate allergic response. 
SIT induces immune deviation, i.e. the switch from Th2 towards Th1-like cells which 
produce high levels of IFN-γ,  a potent antagonist of IL-4. SIT also promotes the induction of 
regulatory T (Treg) cells which produce IL-10 and/or TGF-β. These immunosuppressive 
cytokines induce the production of allergen-specific IgG4 and IgA antibodies which may 
compete with IgE for allergen-binding (“blocking antibodies”. IL-10 promotes further 
induction of regulatory T cells. 
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Sublingual immunotherapy (SLIT) has been demonstrated to be an effective and safe 
alternative for conventional subcutaneous SIT of birch pollen allergy (Horak et al., 1998, 
Khinchi et al., 2004, Mauro et al., 2007). Similar to subcutaneous immunotherapy SLIT 
induces allergen-specific IgG1 and IgG4 antibodies and a modulation of the allergen-specific 
T cell response (O'Hehir et al., 2009, Scadding et al., 2010). Moreover, SLIT induced 
increased Foxp3+  cells - presumably regulatory T cells - in the sublingual epithelium 
(Scadding et al., 2010). Speculating that sublingual administration, directly at the site of 
food-induced allergic symptoms, instead of subcutaneous injections might improve the 
therapeutic benefit on birch pollen-related food allergy, we have evaluated the effects of 
SLIT with birch pollen extract on apple allergy in birch pollen-allergic individuals 
(Kinaciyan et al., 2007). The clinical efficacy of birch pollen SLIT was assessed by means of 
nasal provocation tests with birch pollen extract and double-blind placebo-controlled food 
challenges with Golden Delicious apples before and after 1 year of treatment. Nine patients 
improved in nasal provocation tests to birch pollen and were therefore considered as 
successfully treated. However, only very few of the nine patients concomitantly improved 
allergic reactions to apple in double-blind placebo-controlled food challenges. To 
understand this limited curative effect of birch pollen-SLIT on associated apple allergy, Bet 
v 1- and Mal d 1-specific antibody and T cell responses were analysed in the successfully 
treated individuals. All patients developed significantly increased Bet v 1-specific IgG4 
antibody levels after 1 year of SLIT. Interestingly, Mal d 1-specific IgG4 antibody levels did 
not increase significantly in parallel (Kinaciyan et al., 2007). At the T cell level, a significant 
reduction of Bet v 1-specific T cell proliferation after 4 and 52 weeks of SLIT was found 
(Bohle et al., 2007). This reduced allergen-specific T cell response could be referred to the 
induction of IL-10-producing regulatory T cells in the early phase and the switch from Bet v 
1-specific Th2 cells towards more Th1 cells in the late phase of SLIT. However, no similar 
modulation of the Mal d 1-specific T cell response was observed. Together, these findings 
suggested that birch pollen SLIT induced the characteristic immune mechanisms operative 
during SIT, such as blocking antibodies, peripheral tolerance, regulatory T cells and immune 
deviation, specific for Bet v 1 but not for its highly cross-reactive homologue in apple. Along 
these lines, a more recent study demonstrated that conventional subcutaneous SIT with 
birch pollen also failed to induce food-reactive IgG4 antibodies (van Hoffen et al., 2011). The 
sera from 10 birch pollen-allergic patients with associated allergy to hazelnut were 
investigated for Bet v 1- and Cor a 1-specific IgG4 antibodies before, after 3, 6, 9 and 12 
months of birch pollen-SIT. Again, the significant increase of Bet v 1-specific IgG4 antibody 
titers was not paralleled by a significant increase of Cor a 1-reactive IgG4 antibody levels. 
Nevertheless, after three months of treatment the sera contained significantly enhanced Cor 
a 1-reactive IgG levels and the sera obtained after 1 year of treatment showed IgE-blocking 
capacity in facilitated antigen-binding (FAB) assays (Shamji et al., 2006). Still, SIT with birch 
pollen extract did not result in clinical improvement of hazelnut allergy in these patients as 
analyzed by means of double-blind placebo-controlled food challenges at inclusion and after 
1 year of treatment (van Hoffen et al., 2011). 
Together, these studies imply that the limited clinical effect of SIT with birch pollen may be 
due to a failure of the induction of cross-reactive IgG and T cell responses. However, it 
needs to be pointed out that so far in relatively low numbers of birch pollen-allergic 
individuals were assessed for their antibody and T cell responses to Bet v 1-homologous 
food allergens during birch pollen-SIT or SLIT. Therefore, we analysed IgG responses 
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specific for Bet v 1, Mal d 1 and Cor a 1 in sera from 49 patients who received birch pollen 
SIT for 1-3 years and developed Bet v 1-specific IgG4 antibodies. Interestingly, only around 
33% of these individuals developed food-reactive IgG4 antibodies. Food-reactive antibodies 
in general increased later during the course of therapy as compared to Bet v 1-specific IgG4 
antibodies and blocked IgE binding to Bet v 1-related food allergens. Similarly, only a 
limited number of birch pollen-allergic patients developed food-reactive IgG1 antibodies 
after subcutaneous administration of a recombinant hypoallergenic variant of Bet v 1 
(Niederberger et al., 2007). In a recent study including more than 200 birch pollen-allergic 
individuals we observed that patients tolerating birch pollen-related foods showed higher 
ratios of serum allergen-specific IgG4/IgE antibody levels than patients with food allergy 
(Geroldinger-Simic et al., 2011). These naturally occurring allergen-specific IgG4 antibodies 
were capable of blocking IgE-binding to Bet v 1-related food allergens. These data indicate 
that the presence of allergen-specific IgG4 antibodies which compete with IgE for allergen-
binding may be important for the development of food tolerance. Therefore, SIT or SLIT 
should induce such antibodies. However, treatment with birch pollen does not effectively 
induce food-reactive IgG4 antibodies in every patient. Therefore, we propose that vaccines 
for the treatment of birch pollen-related food allergy should contain the disease-eliciting 
food allergens. Previously, a randomized, double-blind, placebo-controlled study has 
demonstrated significant increases in tolerance to hazelnut after sublingual administration 
of hazelnut extract (Enrique et al., 2005). Tolerance induction was accompanied by increased 
IgG4 antibody and IL-10 levels after immunotherapy in only the active group. Thus, SLIT 
with Bet v 1-associated food allergens may be a promising approach for treatment of birch 
pollen-related food allergy. 
Finally, it is an interesting immunological finding that a high number of birch pollen-allergic 
patients show food-reactive Bet v 1-specific IgE antibodies but fail to develop cross-reactive 
IgG antibodies during treatment with birch pollen despite developing high levels of Bet v 1-
specific IgG antibodies. Therefore, birch pollen-related food allergy is an interesting model 
to study the question how cross-reactivity of structurally related allergens can cause allergy 
whereas the immunomodulation of the allergen-specific response in SIT-treated patients 
who improve their pollinosis does not concomitantly translate into clinical tolerance to 
associated foods. 
6.2 Future concepts for treatment of birch pollen-related food allergy 
Although rarely life-threatening birch pollen-related food allergy is highly prevalent and 
often causes perennial discomfort. Furthermore, this secondary food allergy prevents birch 
pollen-allergic patients from consuming a great variety of fresh fruits and vegetables which 
contain vitamins and are considered to be healthy. This situation demands for effective 
treatment which at present does not exist. Recent developments in the treatment of food 
allergy suggest oral immunotherapy (OIT) with the disease-eliciting food as an interesting 
option (Nowak-Wegrzyn and Sampson, 2011). Indeed, results from a double-blind placebo 
controlled study in peanut-allergic children demonstrated that OIT with peanut induced 
desensitization and concurrent immune modulation (Varshney et al., 2011). In contrast to 
the placebo group, the actively treated OIT group showed significant reductions in skin 
prick reactivity to peanut and significant increases in peanut-specific IgG4 antibodies. 
Furthermore, the ratio of FoxP3hi: FoxP3intermediate CD4+CD25+ T cells increased in peanut 
OIT subjects suggesting the induction of regulatory T cells. Similar approaches might be 
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feasible for the treatment of birch pollen-related food allergy. Recently, it was observed that 
continuous consumption of small amounts of apple induces clinical tolerance in birch 
pollen-allergic patients with apple allergy (Kopac et al., 2010). In this study, 21 patients daily 
consumed small amounts of apple, doubling the dose every two weeks. After a regular 
exposure of in average 22 weeks, 16/21 patients tolerated a complete apple without 
developing any signs of an OAS. This desensitization was paralleled by a decrease of 
intradermal reactivity to Mal d 1. This preliminary study indicates that OIT may be a 
possible approach to treat birch pollen-related apple allergy. 
Novel concepts for allergy vaccines for SIT include the use of recombinant allergens instead 
of crude extracts containing a mixture of allergenic and non-allergenic proteins of an 
allergen source (Valenta et al., 2011). Although progress has been made to improve the 
quality and standardization of protein extracts the use of allergen extracts for SIT still bears 
some disadvantages. The complex protein mixture makes it difficult to determine the exact 
content of single allergens. Due to the production process the concentration of individual 
allergens may vary between different batches. Highly labile allergens might even be totally 
lost during the production process and not be present in the extract. The availability of 
recombinant allergens with the same immunological characteristics as their natural 
counterparts can overcome several of these disadvantages. Briefly, recombinant allergens 
can be produced as molecules with known molecular, immunologic and biological 
characteristics in consistent quality and unlimited amounts. Thus, the content of individual 
allergens in a vaccine can precisely be formulated and the potential loss of allergens 
destroyed during the production process of allergen extracts can be excluded. Regarding the 
treatment of birch pollinosis, recombinant Bet v 1 has been demonstrated to be as effective 
as birch pollen extract (Pauli et al., 2008). As discussed above, we propose that vaccines for 
the treatment of birch pollen-related food allergy should contain the disease-eliciting dietary 
allergens. Bet v 1-related proteins are known to be easily degraded during the procedures 
applied for the production of protein extracts. Since the most important and frequently 
recognized Bet v 1-related food allergens are available as recombinant proteins (Table 1), 
these proteins should be employed as active component in future vaccines for SIT or SLIT of 
birch pollen-related food allergy. 
In addition to producing well-defined batches of recombinant wild-type allergens with 
identical features to their natural counterparts, the recombinant DNA technology also offers 
the possibility to selectively modify certain properties and functions of allergenic proteins 
(Mutschlechner et al., 2009). Diverse modifications of allergens can be genetically 
engineered, e.g. variants with reduced IgE-binding capacity, multi-mers of single allergens 
or hybrids consisting of different allergens. Furthermore, allergens can be genetically fused 
with proteins that promote immune responses which counter regulate the disease-eliciting 
Th2-dominated immune response in allergic individuals and may therefore, improve the 
efficacy of SIT (Bohle et al., 2004, Gerstmayr et al., 2007). All these approaches may also be 
employed to develop an effective treatment strategy for birch pollen-related food allergy. 
We have recently sublingually administered recombinant Mal d 1 to 18 birch pollen-allergic 
patients with associated apple allergy. The recombinant apple allergen was well tolerated by 
the individuals and no severe side-effects were observed. This approach may be regarded as 
a first proof-of-concept for the applicability of recombinant Bet v 1-related food allergens for 
SLIT.  Certainly, several questions regarding the optimum content of a vaccine to treat birch 
pollen-related food allergy remain open. Most patients react to more than one food and it 
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remains to be determined whether all individual food allergens should be employed for 
treatment. Moreover, it remains to be investigated whether the vaccine should contain food 
allergens with or without Bet v 1. 
7. Conclusion 
Birch pollen-related food allergy is a relevant allergic disease that affects the vast majority of 
birch pollen-allergic patients and strongly impairs their quality of life. Currently, no 
effective therapy for this form of food allergy is available. The detailed investigation of the 
allergic response to Bet v 1-homologous food allergens has provided evidence that birch 
pollen-related food allergy results from immunological cross-reactivity of the major birch 
pollen allergen and structurally related dietary proteins. However, it is somehow 
astonishing that successful SIT or SLIT of birch pollinosis accompanied by the modulation of 
the Bet v 1-specific immune response does not effectively cure birch pollen-associated food 
allergy in parallel. Primary sensitization to the major birch pollen allergen and subsequent 
cross-reactivity can cause food allergy. However, the immunomodulation of Bet v 1-specific 
antibody and T cell responses during SIT with birch pollen does not concomitantly 
modulate reactivity to the respective food allergens. Thus, birch pollen-related food allergy 
is an interesting model to learn more about the consequence of immunological cross-
reactivity between related allergens in different sources. The detailed analysis of the 
immune mechanisms failing in patients who do not improve pollen-associated food allergy 
during SIT with birch pollen will help to improve the treatment and to develop an efficient 
therapy for birch pollen-related food allergy. 
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pollen-related food allergy remain open. Most patients react to more than one food and it 
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remains to be determined whether all individual food allergens should be employed for 
treatment. Moreover, it remains to be investigated whether the vaccine should contain food 
allergens with or without Bet v 1. 
7. Conclusion 
Birch pollen-related food allergy is a relevant allergic disease that affects the vast majority of 
birch pollen-allergic patients and strongly impairs their quality of life. Currently, no 
effective therapy for this form of food allergy is available. The detailed investigation of the 
allergic response to Bet v 1-homologous food allergens has provided evidence that birch 
pollen-related food allergy results from immunological cross-reactivity of the major birch 
pollen allergen and structurally related dietary proteins. However, it is somehow 
astonishing that successful SIT or SLIT of birch pollinosis accompanied by the modulation of 
the Bet v 1-specific immune response does not effectively cure birch pollen-associated food 
allergy in parallel. Primary sensitization to the major birch pollen allergen and subsequent 
cross-reactivity can cause food allergy. However, the immunomodulation of Bet v 1-specific 
antibody and T cell responses during SIT with birch pollen does not concomitantly 
modulate reactivity to the respective food allergens. Thus, birch pollen-related food allergy 
is an interesting model to learn more about the consequence of immunological cross-
reactivity between related allergens in different sources. The detailed analysis of the 
immune mechanisms failing in patients who do not improve pollen-associated food allergy 
during SIT with birch pollen will help to improve the treatment and to develop an efficient 
therapy for birch pollen-related food allergy. 
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1. Introduction  
Anaphylaxis is an acute systemic allergic reaction that can potentially be life-threatening. 
Therefore it has to be diagnosed and treated promptly. It can occur after exposure to various 
triggers or spontaneously and can potentially affect multiple organ systems and prompt and 
definite treatment may be life saving. In this chapter, possible triggers of anaphylaxis, 
clinical manifestations, diagnosis and management will be discussed. 
2. Epidemiology  
Anaphylaxis is defined as a “severe, potentially fatal, systemic allergic reaction that occurs 
suddenly after contact with an allergy-causing substance” (Sampson et al., 2006). As there is 
no unified method of obtaining data about anaphylaxis, its incidence is very difficult to 
evaluate clearly. A substantial portion of the existing data on the epidemiology of 
anaphylaxis has come from investigations that have limited scope population sources, such 
as surveys and volunteer registries (Harduar-Morano et al., 2011). Lifetime prevalence is 
estimated as 0.05% to 2% (Simons, 2008). Recent studies confirm that the incidence of 
anaphylaxis, particularly food-induced anaphylaxis, is increasing world-wide (Chiu & 
Kelly, 2005). A very recent study investigated a large diverse population with anaphylaxis 
diagnosed in emergency departments using rigorous descriptive and analytic evaluation of 
risk factors, such as sex, race, ethnicity, and age (Harduar-Morano et al., 2011). In this study 
the highest observed rates were among the youngest male subjects (8.2/100,000 aged  
0-4 years) and among adult female subjects (15-54 years) grouped in 10-year age categories 
(9,9-10.9/100,000). Previous epidemiologic studies also suggested that until age 15 years, 
there is a predilection for males, but after age 15 years, there is a predilection for females. 
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middle-aged and older adults (Simons, 2008). Atopy is an associated risk factor for 
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of 142 patients with anaphylaxis who presented to an emergency department from 1998 to 
1999 (Brown et al., 2001). 
 7 
Anaphylaxis: Etiology, Clinical 
Manifestations, Diagnosis and Management 
Asl Gelincik and Suna Büyüköztürk 
Istanbul University, Istanbul Faculty of Medicine, 
Turkey 
1. Introduction  
Anaphylaxis is an acute systemic allergic reaction that can potentially be life-threatening. 
Therefore it has to be diagnosed and treated promptly. It can occur after exposure to various 
triggers or spontaneously and can potentially affect multiple organ systems and prompt and 
definite treatment may be life saving. In this chapter, possible triggers of anaphylaxis, 
clinical manifestations, diagnosis and management will be discussed. 
2. Epidemiology  
Anaphylaxis is defined as a “severe, potentially fatal, systemic allergic reaction that occurs 
suddenly after contact with an allergy-causing substance” (Sampson et al., 2006). As there is 
no unified method of obtaining data about anaphylaxis, its incidence is very difficult to 
evaluate clearly. A substantial portion of the existing data on the epidemiology of 
anaphylaxis has come from investigations that have limited scope population sources, such 
as surveys and volunteer registries (Harduar-Morano et al., 2011). Lifetime prevalence is 
estimated as 0.05% to 2% (Simons, 2008). Recent studies confirm that the incidence of 
anaphylaxis, particularly food-induced anaphylaxis, is increasing world-wide (Chiu & 
Kelly, 2005). A very recent study investigated a large diverse population with anaphylaxis 
diagnosed in emergency departments using rigorous descriptive and analytic evaluation of 
risk factors, such as sex, race, ethnicity, and age (Harduar-Morano et al., 2011). In this study 
the highest observed rates were among the youngest male subjects (8.2/100,000 aged  
0-4 years) and among adult female subjects (15-54 years) grouped in 10-year age categories 
(9,9-10.9/100,000). Previous epidemiologic studies also suggested that until age 15 years, 
there is a predilection for males, but after age 15 years, there is a predilection for females. 
Different trigger factors predominate in different age groups; for example, fatalities from 
food-induced anaphylaxis peak in adolescents and young adults, and fatalities from 
anaphylaxis triggered by insect stings, diagnostic agents, and medications predominate in 
middle-aged and older adults (Simons, 2008). Atopy is an associated risk factor for 
anaphylaxis triggered by food, exercise, and latex but not for anaphylaxis triggered by insect 
stings, β-lactam antibiotics (Chiu and Kelly, 2005). In addition, asthma was reported in 23% 
of 142 patients with anaphylaxis who presented to an emergency department from 1998 to 
1999 (Brown et al., 2001). 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
168 
3. Pathogenesis  
The underlying pathogenesis of human anaphylaxis commonly involves an immunologic 
mechanism in which IgE is synthesized in response to allergen exposure and becomes fixed 
to high affinity receptors for IgE (FcεRI receptors) on the surface membranes of mast cells 
and basophils (Simons, 2010). Other potential immunologic mechanisms in anaphylaxis 
include involvement of immune aggregates, IgG, IgM, platelets, and T cells; shift in 
eicosanoid metabolism toward leukotriene formation; and activation of the complement or 
coagulation systems (Simons, 2008).  
The mast cells and basophils are central players in allergic reaction (Rivera & Gilfillan, 2006). 
Activation of these cells induces the release of preformed inflammatory mediators localized 
in specialized granules and the de novo synthesis and secretion of cytokines, chemokines, 
and eicosanoids. Appropriate activation of mast cells is mediated by a number of factors, 
including the cells’ ability to distinguish activating or inhibiting stimuli and the strength 
and duration of stimulus. FcεRI on mast cells is comprised of an IgE- binding α chain, a 4-
transmembrane spanning β chain and a monodimer of γ chains. The β chain functions as an 
amplifying modul for this receptor. The γ chain monodimer imports signaling competence 
to this receptor. It has been demonstrated that both the β and γ chains function to generate 
positive signals that are key in initiating and amplifying the mast cells’ effector responses. 
However, recent evidence suggests that these two chains can also function to negatively 
regulate cell activation and effector responses (Rivera & Gilfillan, 2006).  
Current knowledge suggests that mast cell’s response to a stimulus is very complex. A 
number of molecules play role in the coordination and control of degranulation. FcεRI- 
mediated activation of mast cells requires both Lyn and the related Src PTK Fyn as receptor-
proximal kinases. Fyn-deficient and Lyn/Fyn double deficient mice showed defective 
passive systemic anaphylaxis responses indicating a positive role for Fyn in promoting mast 
cell degranulation in vivo (Rivera & Gilfillan, 2006). 
Recent investigations showed that stem cell factor and its receptor Kit are fundamentally 
important in IgE/antigen-induced mast cell activation, and concurrent inhibition of Kit- and 
FcεRI-mediated signaling achieves coordinated suppression of human mast cell activation 
(Jensen et al., 2007). Inhibitory sialic acid-binding immunoglobulin-like lectins are expressed 
on human mast cells, on which Siglec-8 engagement results in inhibition of FcεRI-dependent 
mediator release without apoptosis (Yokoi et al., 2006). Sphingosine kinases are reported to 
be determinants of mast cell responsiveness (Olivera et al., 2007).  
In some individuals described as having idiopathic anaphylaxis, FcεRI receptors may be 
aggregated through autoimmune mechanisms (Simons, 2010). Nonimmunological factors, 
which activate mast cells by mechanisms not yet fully understood, include exercise, cold air 
or water exposure, radiation, ethanol, insect venom, constituents, radiocontrast media and 
medications such as opioids and vancomycin (Simons, 2010). Regardless of the immunologic 
or nonimmunologic triggering mechanism, and regardless of whether FcεRI or other 
receptors such as G protein-coupled receptors or Toll-like receptors are activated, mast cells 
and basophils play an important role in initiating and amplifying the acute allergic 
response. They release mediators of inflammation including histamine, proteases such as 
tryptase, mast cell carboxypeptidase A3 and chymase, lipids such as platelet activating 
factor (PAF), prostaglandines (PGD2) and leukotrienes (LTC4) as well as chemokines and 
cytokines (Simons, 2008). 
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3.1 Animal models 
Studies with murine models demonstrate 2 pathways of systemic anaphylaxis: one 
mediated by IgE, FcεRI, mast cells, histamine, and platelet-activating factor (PAF), and the 
other mediated by IgG, FcγRIII, macrophages, and PAF. The former pathway requires much 
less antibody and antigen than the latter. As a result, IgG antibody can block IgE-mediated 
anaphylaxis induced by small quantities of antigen without mediating FcγRIII-dependent 
anaphylaxis (Finkelman et al., 2005).  
The IgE pathway is most likely responsible for most human anaphylaxis, which generally 
involves small amounts of antibody and antigen; similarities in the murine and human 
immune systems suggest that the IgG pathway might mediate disease in persons repeatedly 
exposed to large quantities of antigen. Antigen cross-linking of antigen specific IgE bound to 
mast cell FcεRI stimulates mast cell degranulation, with the rapid release of histamine and 
serotonin and the synthesis and secretion of platelet activation factor (PAF) and leukotrienes. 
These mediators act on target cells to increase vascular permeability which cause depletion of 
intravascular volume. The resulting decrease in vital organ perfusion is the primary cause of 
the symptoms that characterize murine anaphylaxis (Finkelman et al., 2005). 
The other pathway in mouse is Ig-E independent pathway. As contrary of clasical pathway, at 
first immunized and antigen challenged mice had anaphylaxis despite the absence of mast 
cells, FcεRI and IgE. This pathway is also complement independent but requires IgG antibody, 
macrophages, FcγRIII and PAF. Regardless which pathway takes place, mouse anaphylaxis 
occurs in very short time and displays similar symptoms. Potentially important differences 
between mouse and human anaphylaxis are proposed as follows: 1. Mouse IgG has some 
ability to activate mast cells, an effect that is not shared by any human IgG isotype, 2. IgE binds 
weakly to murine, but not human low-affinity FcγRs, 3. Human but not mouse macrophages, 
Langerhans cells and dendritic cells can express FcεRI, and 4. Human platelets, B cells and 
natural killer cells, and neutrophils express low affinity IgG receptor (FcγRIIA, FcγRIIC, and 
FcγRIIIB, respectively) that are not expressed in mouse (Finkelman et al., 2005). 
Less antibody and antigen are required to trigger IgE dependent anaphylaxis then IgG 
mediated anaphylaxis. IgG and IgA blocking antibodies inhibit the ability of small quantities 
of antigen to induce IgE dependent anaphylaxis by neutralizing antigen before it can cross link 
mast cell associated IgE. IgG antibodies also inhibit IgE-dependent anaphylaxis by mediating 
an interaction between FcεRI and FcγRIIb on mast cells. In mice the predominant determinants 
that influence whether IgE dependent anaphylaxis is induced appear to be the quantity of 
antigen specific IgG antibody produced and the quantity of antigen used to challenge 
immunized mice. This suggests that IgG antibodies, in addition to mediating IgE- independent 
anaphylaxis, can block IgE-dependent anaphylaxis and provide the rationale for investigating 
the function of blocking antibody. Gastrointestinal anaphylaxis is induced by IgE/ FcεRI/mast 
cell/PAF plus serotonin pathway and can cause systemic symptoms if levels of blocking 
antibodies are low (Finkelman et al., 2005).  
3.2 Cytokines  
The development and severity of anaphylaxis depend not only on the presence of the 
required IgE or IgG antibodies, inflammatory cells that express receptor for these antibodies 
and mediators that are released by these cells but also on the responsiveness of cells that are 
targeted by these mediators. This last factor is influenced by IL-4 and IL-13, cytokines that 
are also important in the initial generation of the antibody and inflammatory cell responses 
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that mediate anaphylaxis to a considerable extent. These effects depend on IL-4Rα-
dependent IL4/IL13 activation of transcription factor signal transducer and activator of 
transcription 6 and thus likely depend on new gene expression and protein synthesis even 
though they develop within 1-2 hours after mice are treated with either cytokine. The most 
dramatic and rapid effect of IL-4 on anaphylaxis is a 3-to-6 fold enhancement of 
responsiveness of targeted cells to vasoactive mediators, including histamine, serotonin, 
PAF and cysteinyl lekotrienes (Finkelman et al., 2005). 
4. Clinical aspects  
Currently, there is no universally accepted clinical definition of anaphylaxis. Because of 
large variability in presenting clinical signs and symptoms, a clear definition of anaphylaxis 
is difficult. It is likely that anaphylaxis is under diagnosed, especially if it is a patient’s first 
episode, if there is a hidden or previously unrecognized trigger, or if symptoms are mild, 
transient, or skin signs are absent. Patients might not be able to describe their symptoms if 
awareness, recognition, and judgment are impaired or if they are dyspneic or becoming 
unconscious. Symptoms may be suppressed by other medications such as first-generation 
H1- antihistamines. Health care providers may fail to recognize symptoms of anaphylaxis 
without obtaining a detailed history and full physical examination. Even after a detailed 
history and examination, the diagnosis may be overlooked when hives or other skin 
manifestations are absent. The guidelines published in 2006 by the National Institute of 
Allergy and Infectious Disease (NIAID) and the Food Allergy and Anaphylaxis Network 
(FAAN) have partially responded to this difficulty (Sampson et al., 2006) (Table 1). 
However, new large studies are necessary to evaluate current situation. 
For the diagnosis of anaphylaxis, a detailed and comprehensive clinical history is essential. 
Such a history may disclose exposure to potential triggering agents or events, time elapsed 
between exposure and symptom onset, and evolution of the episode over minutes or hours. 
5. Anaphylaxis triggers 
The triggering factors of anaphylaxis are listed on Table 2. Foods, medications, and venom 
continue to be leading causes of anaphylaxis (Boden & Burks, 2011). 
5.1 Foods 
Food allergy is the most common trigger of children presenting with anaphylaxis (Boden & 
Burks, 2011). Although most episodes of food-induced anaphylaxis occur within minutes of 
ingestion, anaphylaxis triggered by mammalian meat may be delayed by several hours. 
Although, the most common food triggers are reported to be peanut, tree nuts, shellfish, 
fish, milk, egg, and sesame; there are important variations between the populations from 
different geographic regions (Sicherer & Sampson, 2006). Any food can potentially trigger 
anaphylaxis, including previously unrecognized triggers, or some fresh red meats 
containing carbohydrates. Food triggers can be hidden (eg, substituted foods, cross-reacting 
foods, and cross-contacting foods). Food triggers also include additives, such as spices, 
vegetable gums, and colorants (eg, carmine [cochineal]); contaminants, such as dust mites; 
and parasites, such as the live sea fish nematode Anisakis simplex. Although some food 
allergies resolve with age others persist. An estimated 80% of children with anaphylaxis to 
milk or egg are able to tolerate ingestion by age 16 years (Sampson & Burks, 2009).  
 
Anaphylaxis: Etiology, Clinical Manifestations, Diagnosis and Management 
 
171 
Anaphylaxis is highly likely when any 1 of the following 3 criteria is fulfilled: 
1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal 
tissue, or both (eg, generalized hives, pruritus or flushing, and swollen lips-tongue-uvula) 
AND at least 1 of the following: 
A. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF, 
hypoxemia) 
B. Reduced blood pressure or associated symptoms of end-organ dysfunction (eg, 
hypotonia [collapse], syncope, incontinence) 
2. Two or more of the following that occur rapidly after exposure to a likely allergen for that 
patient (minutes to several hours): 
A. Involvement of the skin–mucosal tissue (eg, generalized hives, itch-flush, swollen lips-
tongue-uvula) 
B. Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF, 
hypoxemia) 
C. Reduced blood pressure or associated symptoms (eg, hypotonia [collapse], syncope, 
incontinence) 
D. Persistent gastrointestinal symptoms (eg, cramping abdominal pain, vomiting) 
3. Reduced blood pressure after exposure to a known allergen for that patient (minutes to 
several hours): 
A. Infants and children: low systolic blood pressure (age-specific) or greater than 30% 
decrease in systolic blood pressure 
B. Adults: systolic blood pressure of less than 90 mm Hg or greater than 30% decrease from 
that person’s baseline 
Table 1. Clinical criteria for diagnosing anaphylaxis (Sampson et al., 2006 with permission) 
 
Immunologic mechanisms (IgE dependent) 
Foods and food additives 
Medications 
Venoms, such as stinging insects (Hymenoptera) 
Natural rubber latex 
Occupational allergens 
Seminal fluid (prostate-specific antigen) 
Inhalants, such as horse, hamster, and other animal danders and grass pollen (rare) 
Radiocontrast media 
Immunologic mechanisms (IgE independent, formerly classified as anaphylactoid reactions) 
Dextran, such as high-molecular-weight iron dextran 
Infliximab 
Nonimmunologic mechanisms 
Physical factors, such as exercise, cold, heat, and sunlight/UV radiation 
Ethanol 
Medications, such as opioids 
Idiopathic anaphylaxis 
Consider the possibility of hidden or previously unrecognized allergens 
Consider the possibility of mastocytosis/clonal mast cell disorder 
Table 2. Mechanisms and triggers of anaphylaxis in the community (Simons, 2010 with 
permission) 
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Many drugs may induce anaphylaxis as a consequence of drug allergy/hypersensitivity. 
The parenteral use of drugs increases the risk and severity of anaphylactic reactions, and 
most fatal reactions have occurred with intramuscular or intravenous administration (Chiu 
& Kelly, 2005). Although drug related anaphylaxis may occur at any age , it is particularly 
common in middle-aged and older adults. Atopy appears to be associated with a 
substantially increased risk of serious allergic reactions (including anaphylaxis) once an IgE 
antibody response to any drug has developed (Lieberman et al., 2010). Antibiotics, 
especially β-lactam antibiotics including penicillin, semi-synthetic penicillins (eg, 
amoxicillin), cephalosporins, carbapenems (eg, imipenem), monobactams (eg, aztreonam), 
and carbecephems, and nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, 
ibuprofen, and other agents, are the most often implicated drugs. In the retrospective review 
of pediatric cases of anaphylaxis, the incidence of drug-induced anaphylaxis was 11%, with 
nonsteroidal anti-inflammatory drugs causing 50%, antibiotics 40%, and muscle relaxants 
10% of reactions (Novembre et al., 1998). In another study, the incidence of medications 
inducing anaphylaxis was 16%, with antibiotics causing 9%, and other drugs causing 7% of 
reactions (Dibs & Baker, 1997). In a review of fatal reactions, over four fifths of victims of 
fatal drug anaphylaxis had no previous awareness or indication of their drug allergy (Chiu 
and Kelly, 2005). Other common drugs that cause such reactions are insulin, enzymes 
(streptokinase and chymopapain), heterologous antisera (equine antitoxins and, 
antilymphocyte globulin), monoclonal antibodies (such as cetuximab, infliximab, and 
omalizumab), protamine, and heparin. However a great number of medications are known 
to cause anaphylactic reactions including chemotherapeutic agents, anesthetic agents, 
radioconrast media etc. Vaccines to prevent infectious diseases seldom trigger anaphylaxis 
(Simons, 2010). Allergic Type 1 reactions also have been reported after exposure to 
excipients such as eugenol, carmine, vegetable gums, paraben, thiomerosal, sodium 
metabisulfite, formaldehyde, and sulfonechloramide. 
5.3 Venom 
Hymenoptera stings can cause systemic and occasionally fatal anaphylaxis (Bilo & Bonifazi, 
2009). Epidemiological population-based studies over the last decade show a prevalence of 
systemic reaction from hymenoptera stings ranging from 0.3% to 8.9%, with the lowest 
occurrence in children (Chiu & Kelly, 2005). Order Hymenoptera, family Apidae 
[honeybees]; family Vespidae [eg, yellow jackets, yellow hornets, white-faced hornets, and 
paper wasps]; and family Formicidae [eg, ants]) are well known causes. Factors determining 
the severity of reaction to hymenoptera sting include history of previous severe systemic 
reaction, insect type, older age, pre-existing cardiovascular and respiratory disease, and use 
of some medications. Mastocytosis and monoclonal mast cell activation syndrome are a risk 
factor for severe systemic reactions in allergic patients (Brockow & Ring, 2011). 
5.4 Latex 
Latex-induced anaphylaxis is due to IgE-mediated mechanisms and may occur in latex 
sensitive individuals due to direct contact with latex, usually gloves, or instruments, or with 
aerosolization of latex antigen adherent to the cornstarch powder of latex gloves (Lieberman 
et al., 2010). Anaphylaxis to natural rubber latex (NRL) became one of the most pervasive 
problems in medical and surgical care in the early 1990s in children with spina bifida (Chiu 
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& Kelly, 2005). Latex reactions may occur immediately with latex contact or may be delayed 
from 30 to 60 minutes. Latex has been reported to account for up to 17% of intraoperative 
anaphylaxis (Lieberman et al., 2010). Intraoperative latex anaphylaxis may be related to the 
administration of drug through a latex port prior to surgery, or during the surgical 
procedure itself. Latex reactions have also been reported to occur during dental procedures 
from latex gloves or dams, during obstetrical or gynecologic examinations and during latex 
condom use. Spina bifida patients are potentially at risk during each surgical procedure 
because of the number of procedures they undergo. Latex sensitization is due to IgE-
mediated reactivity to any number of antigens from Hevea brasiliensis, the source of latex. 
Sensitization occurs in up to 12 percent of health care workers, up to 75 percent of patients 
with spina bifida and in patients undergoing multiple surgical procedures (Lieberman et al., 
2010).  
5.5 Perioperative anaphylaxis 
The incidence of anaphylaxis during anesthesia has been reported to range from 1 in 4000 to 
1 in 25,000 (Lieberman et al., 2005). The causes of anaphylaxis in this setting are varied, as 
are the mechanisms responsible for the reaction. The most common cause of anaphylaxis 
during general anesthesia or postoperatively is neuromuscular blocking agents (muscle 
relaxants), which are responsible for sixty to seventy percent of episodes of anaphylaxis 
occurring during this period. Most of the muscle relaxants cause direct release of mast cell 
histamine without the requirement for specific antibody. However, life-threatening 
reactions usually are IgE- mediated. The tertiary or quaternary ammonium group, common 
to all muscle relaxants, is likely the immunodominant determinant recognized by IgE. The 
antigenicity of the shared ammonium structures may be responsible for cross-reactivity 
among the muscle relaxants. Cross-reactivity occurs most consistently between 
pancuronium and vecuronium. Cross-reactions also may occur between muscle relaxants 
and other classes of pharmaceuticals, based upon in vitro inhibition of specific-IgE binding 
to the muscle relaxants. Agents that potentially cross-react with muscle relaxants include: 
acetylcholine, choline, morphine, neostigmine, and pentolinium. Cross-inhibition suggests 
that previous exposure to these non-anesthetic drugs may sensitize individuals to muscle-
relaxing agents, resulting in reactions among patients without prior anesthesia (Lieberman 
et al., 2005). 
5.6 Exercise anaphylaxis 
In some individuals anaphylaxis can be triggered by exercise (exercise-induced anaphylaxis 
EIA); this phenomenon usually preceded by a causative food ingestion (food-dependent, 
exercise-induced anaphylaxis (FDEIA) (Barg et al., 2011) . Both are rare but potentially life-
threatening clinical syndromes. The symptoms of FDEIA may vary in severity but, 
reassuringly, fatalities are rare. EIA occurs in all ages, in both sexes, and is more common in 
atopic individuals. Typical early signs and symptoms begin a few minutes into exercise, and 
include diffuse warmth, flushing, pruritus, urticaria, and fatigue. If exercise continues, there 
may be progression to angioedema of the face and extremities, gastrointestinal symptoms, 
laryngeal edema, hypotension, or collapse. Wheezing can occur, although it is less common 
than other symptoms. Some patients experience disabling headache that persists for several 
days after an episode. Attacks occur sporadically and unpredictably, even though most 
patients with this disorder exercise regularly. Vigorous exercises, such as jogging, racquet 
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sports, dancing, and aerobics, are most often implicated, although lower levels of exertion, 
such as brisk walking or yard work, are capable of triggering attacks in some patients. 
Cessation of exercise usually results in improvement or resolution of symptoms, although, 
patients often do not instinctively stop exercising when they first experience symptoms. 
Instead, many try to run for help or sprint home, and this precipitates a dramatic worsening 
of symptoms. Although wheat is the most commonly reported food allergen associated with 
FDEIA many other food allergens such as grains, nuts, and seafood, have also been reported 
(Barg et al., 2011). 
5.7 Idiopathic anaphylaxis 
Idiopathic anaphylaxis is diagnosed when no triggers can be identified based on history, 
skin tests are negative, and serum specific IgE levels are absent or undetectable 
(Greenberger, 2007). Before this diagnosis is made, however, the possibility of a hidden or 
previously unrecognized trigger should be ruled out and the patients should be evaluated 
for mastocytosis and clonal mast cell disorders. Idiopathic anaphylaxis has been classified 
into two categories. When there is a sudden episode that includes urticaria and angioedema 
associated with acute bronchoconstriction, voice change or stridor, syncope or proven 
hypotension with or without abdominal pain and diarrrhea, it is then considered as 
idiopathic anaphylaxis generalized (IA-G). Anaphylaxis that is characterized by marked 
upper airway obstruction attributable to massive tongue enlargement or a severely 
edematous larynx or pharynx is categorized as anaphylaxis angioedema (IA-A) 
(Greenberger, 2007).  
5.8 Mastocytocic and anaphylaxis  
In adults with mastocytosis, the cumulative prevalence of anaphylaxis has been reported to 
be 22% to 49%, and in children 6% to 9%. Those with systemic disease have an increased risk 
of anaphylaxis as compared with patients with cutaneous disease only. As in patients 
without mastocytosis, the most frequently reported elicitors of anaphylaxis are insect 
venoms, drugs, and food. Severe and fatal reactions to hymenoptera venom have been 
described in patients with mastocytosis (Brockow & Ring, 2011). 
A variety of drugs have been reported to elicit anaphylaxis in patients with mastocytosis. 
Every year, reports have been published regarding patients with mastocytosis in whom the 
diagnosis of systemic mastocytosis was made following anaphylaxis to muscle relaxants or 
other drugs used during general anesthesia. Other medications leading to reactions in 
patients with mastocytosis are opiates (including morphine and codeine), acetylsalicylic 
acid, other NSAIDs, antibiotics, and radiocontrast media. In some patients with 
mastocytosis, anaphylaxis remains idiopathic despite an extensive search for elicitors 
(Brockow & Ring, 2011). 
The intensity of anaphylaxis in patients with mastocytosis has been described to be 
particularly severe. Among 55 patients with insect sting allergy and confirmed mastocytosis, 
81% experienced severe anaphylaxis with shock or cardiopulmonary arrest (Brockow & 
Metcalfe, 2010). In another study in which the severity of anaphylaxis was rated, 60% of 
patients reported severe symptoms and 43% experienced loss of consciousness. Fatal 
reactions may occur. This is in agreement with the observation that baseline serum tryptase 
levels are the best known predictor of the severity of anaphylaxis in insect sting–allergic 
patients (Brockow & Ring, 2011) . 
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5.9 Rare causes of anaphylaxis 
Although rare, anaphylaxis due to coital exposure to human seminal fluid is a known 
occurrence. Since the initial report in 1958, approximately 30 cases of seminal fluid induced 
anaphylaxis have been described. All reactions have occurred in female patients during or 
after sexual intercourse. The vast majority of such reactions are caused by IgE-mediated 
sensitization to human seminal plasma proteins with molecular weights ranging from 12-75 
kD (Lieberman et al., 2010).  
Subcutaneous allergen immunotherapy (AIT) injections may rarely cause systemic reactions. 
Its rate has been estimated at 0.25-1.3%. Fatal anaphylaxis to AIT injections occurs at an 
estimated rate of 1 in 2.5 million injections and near-fatal anaphylactic reactions at a rate of 1 
in every 1 million injections. Patients with asthma, particularly poorly controlled asthma are 
at higher risk for serious systemic reactions to AIT injections (Lieberman et al., 2005). 
In the patients having anaphylaxis attacks without any apparent trigger hydatid cyst 
ruptures must be kept in mind. Hydatid cysts can rupture as a result of trauma or 
sometimes spontaneously, and anaphylaxis can be a complication. However, several case 
reports indicate that anaphylaxis can also occur without macroscopic hydatid cyst rupture 
(Gelincik et al., 2007). 
6. Clinical presentation  
Although most definitions specify the need for more than one organ system involvement in 
the syndrome, it is more important to understand the systemic nature of the clinical 
symptoms. The first symptoms and signs of anaphylaxis often appear within seconds to 
minutes after exposure to an offending trigger, however sometimes they may develop later. 
Late phase or biphasic reactions could also arise 8-12 hours after the initial attack 
(Lieberman et al., 2010). Each exposure to antigen is unique, and past episodes of 
anaphylaxis do not predict future events (Boden & Burks, 2011). Among individuals 
recognized as having anaphylaxis, typical initial symptoms are palmar and/or plantar itch 
with or without urticaria and/or angioedema. Target organs include skin (90% of episodes), 
respiratory tract (70%), gastrointestinal tract (30% to 45%), cardiovascular system (10% to 
45%), and central nervous system (CNS; 10% to 15%) (Simons, 2008). Accordingly, there 
may be nausea, abdominal pain, vomiting, or diarrhea. There may also be 
rhinoconjunctivitis, obstructive respiratory symptoms, tachycardia, arrhythmia, altered 
mental state, and fainting. Severe respiratory and cardiovascular signs and symptoms such 
as arterial hypotension and cardiovascular collapse may be the primary manifestations, 
particularly in perioperative reactions (Schnyder, 2009). 
Urticaria and angioedema are the most common and usually the first manifestations of 
anaphylaxis (Greenberger, 2006). Angioedema was found in 40% and urticaria in 49.3% of 
142 patients presenting to an ER with anaphylaxis (Brown et al., 2001). Laryngeal edema 
was present in 25% of such patients. In 67 patients referred to an outpatient service for 
evaluation of anaphylaxis, 44.8% of patients had experienced angioedema compared with 
58.2% for urticaria. Dyspnea, which may have included oropharyngeal or laryngeal 
swelling, was noted in 59.7% of patients (Thong et al., 2005). In patients with idiopathic 
anaphylaxis, 335 patients, ages 5 to 83, were categorized based on whether the acute episode 
was generalized (urticaria or angioedema with bronchospasm, hypotension, syncope, or 
gastrointestinal symptoms with or without upper airway obstruction) or angioedema 
(urticaria or angioedema with upper airway compromise without other systemic symptoms 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
174 
sports, dancing, and aerobics, are most often implicated, although lower levels of exertion, 
such as brisk walking or yard work, are capable of triggering attacks in some patients. 
Cessation of exercise usually results in improvement or resolution of symptoms, although, 
patients often do not instinctively stop exercising when they first experience symptoms. 
Instead, many try to run for help or sprint home, and this precipitates a dramatic worsening 
of symptoms. Although wheat is the most commonly reported food allergen associated with 
FDEIA many other food allergens such as grains, nuts, and seafood, have also been reported 
(Barg et al., 2011). 
5.7 Idiopathic anaphylaxis 
Idiopathic anaphylaxis is diagnosed when no triggers can be identified based on history, 
skin tests are negative, and serum specific IgE levels are absent or undetectable 
(Greenberger, 2007). Before this diagnosis is made, however, the possibility of a hidden or 
previously unrecognized trigger should be ruled out and the patients should be evaluated 
for mastocytosis and clonal mast cell disorders. Idiopathic anaphylaxis has been classified 
into two categories. When there is a sudden episode that includes urticaria and angioedema 
associated with acute bronchoconstriction, voice change or stridor, syncope or proven 
hypotension with or without abdominal pain and diarrrhea, it is then considered as 
idiopathic anaphylaxis generalized (IA-G). Anaphylaxis that is characterized by marked 
upper airway obstruction attributable to massive tongue enlargement or a severely 
edematous larynx or pharynx is categorized as anaphylaxis angioedema (IA-A) 
(Greenberger, 2007).  
5.8 Mastocytocic and anaphylaxis  
In adults with mastocytosis, the cumulative prevalence of anaphylaxis has been reported to 
be 22% to 49%, and in children 6% to 9%. Those with systemic disease have an increased risk 
of anaphylaxis as compared with patients with cutaneous disease only. As in patients 
without mastocytosis, the most frequently reported elicitors of anaphylaxis are insect 
venoms, drugs, and food. Severe and fatal reactions to hymenoptera venom have been 
described in patients with mastocytosis (Brockow & Ring, 2011). 
A variety of drugs have been reported to elicit anaphylaxis in patients with mastocytosis. 
Every year, reports have been published regarding patients with mastocytosis in whom the 
diagnosis of systemic mastocytosis was made following anaphylaxis to muscle relaxants or 
other drugs used during general anesthesia. Other medications leading to reactions in 
patients with mastocytosis are opiates (including morphine and codeine), acetylsalicylic 
acid, other NSAIDs, antibiotics, and radiocontrast media. In some patients with 
mastocytosis, anaphylaxis remains idiopathic despite an extensive search for elicitors 
(Brockow & Ring, 2011). 
The intensity of anaphylaxis in patients with mastocytosis has been described to be 
particularly severe. Among 55 patients with insect sting allergy and confirmed mastocytosis, 
81% experienced severe anaphylaxis with shock or cardiopulmonary arrest (Brockow & 
Metcalfe, 2010). In another study in which the severity of anaphylaxis was rated, 60% of 
patients reported severe symptoms and 43% experienced loss of consciousness. Fatal 
reactions may occur. This is in agreement with the observation that baseline serum tryptase 
levels are the best known predictor of the severity of anaphylaxis in insect sting–allergic 
patients (Brockow & Ring, 2011) . 
 
Anaphylaxis: Etiology, Clinical Manifestations, Diagnosis and Management 
 
175 
5.9 Rare causes of anaphylaxis 
Although rare, anaphylaxis due to coital exposure to human seminal fluid is a known 
occurrence. Since the initial report in 1958, approximately 30 cases of seminal fluid induced 
anaphylaxis have been described. All reactions have occurred in female patients during or 
after sexual intercourse. The vast majority of such reactions are caused by IgE-mediated 
sensitization to human seminal plasma proteins with molecular weights ranging from 12-75 
kD (Lieberman et al., 2010).  
Subcutaneous allergen immunotherapy (AIT) injections may rarely cause systemic reactions. 
Its rate has been estimated at 0.25-1.3%. Fatal anaphylaxis to AIT injections occurs at an 
estimated rate of 1 in 2.5 million injections and near-fatal anaphylactic reactions at a rate of 1 
in every 1 million injections. Patients with asthma, particularly poorly controlled asthma are 
at higher risk for serious systemic reactions to AIT injections (Lieberman et al., 2005). 
In the patients having anaphylaxis attacks without any apparent trigger hydatid cyst 
ruptures must be kept in mind. Hydatid cysts can rupture as a result of trauma or 
sometimes spontaneously, and anaphylaxis can be a complication. However, several case 
reports indicate that anaphylaxis can also occur without macroscopic hydatid cyst rupture 
(Gelincik et al., 2007). 
6. Clinical presentation  
Although most definitions specify the need for more than one organ system involvement in 
the syndrome, it is more important to understand the systemic nature of the clinical 
symptoms. The first symptoms and signs of anaphylaxis often appear within seconds to 
minutes after exposure to an offending trigger, however sometimes they may develop later. 
Late phase or biphasic reactions could also arise 8-12 hours after the initial attack 
(Lieberman et al., 2010). Each exposure to antigen is unique, and past episodes of 
anaphylaxis do not predict future events (Boden & Burks, 2011). Among individuals 
recognized as having anaphylaxis, typical initial symptoms are palmar and/or plantar itch 
with or without urticaria and/or angioedema. Target organs include skin (90% of episodes), 
respiratory tract (70%), gastrointestinal tract (30% to 45%), cardiovascular system (10% to 
45%), and central nervous system (CNS; 10% to 15%) (Simons, 2008). Accordingly, there 
may be nausea, abdominal pain, vomiting, or diarrhea. There may also be 
rhinoconjunctivitis, obstructive respiratory symptoms, tachycardia, arrhythmia, altered 
mental state, and fainting. Severe respiratory and cardiovascular signs and symptoms such 
as arterial hypotension and cardiovascular collapse may be the primary manifestations, 
particularly in perioperative reactions (Schnyder, 2009). 
Urticaria and angioedema are the most common and usually the first manifestations of 
anaphylaxis (Greenberger, 2006). Angioedema was found in 40% and urticaria in 49.3% of 
142 patients presenting to an ER with anaphylaxis (Brown et al., 2001). Laryngeal edema 
was present in 25% of such patients. In 67 patients referred to an outpatient service for 
evaluation of anaphylaxis, 44.8% of patients had experienced angioedema compared with 
58.2% for urticaria. Dyspnea, which may have included oropharyngeal or laryngeal 
swelling, was noted in 59.7% of patients (Thong et al., 2005). In patients with idiopathic 
anaphylaxis, 335 patients, ages 5 to 83, were categorized based on whether the acute episode 
was generalized (urticaria or angioedema with bronchospasm, hypotension, syncope, or 
gastrointestinal symptoms with or without upper airway obstruction) or angioedema 
(urticaria or angioedema with upper airway compromise without other systemic symptoms 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
176 
such as shock) (Ditto et al., 1996). From the 335 patients, 201 (60%) were classified as IA-G 
and 119 (35.5%) were designated as IA-A. In this series, urticaria or angioedema occurred in 
all 335 patients, but anaphylaxis, implying a life-threatening emergency, involved 
angioedema of the upper airway in over a third of patients. Indeed, these patients had 
experienced laryngeal or pharyngeal edema or ‘‘massive tongue edema’’. Perhaps, most 
persuasively, in this series of 335 patients, upper airway obstruction occurred in 210 (63%) 
patients (Ditto et al., 1996).  
However, skin and mucosal symptoms and signs are absent or unrecognized in 10% to 20% of 
all anaphylactic episodes (Simons, 2010). These are rather more severe forms of anaphylaxis 
arising suddenly with either respiratory compromises or cardiovascular collapse. The lack of 
cutaneous signs reflects that anaphylaxis episode is likely to become fatal.  
There are some differences in the presentation of anaphylaxis in the pediatric population 
compared with the adult population, including smaller numbers having cardiovascular 
signs and symptoms (21% compared with 41%). Other features noted in pediatric 
anaphylaxis include skin and respiratory signs appearing with an earlier onset compared 
with gastrointestinal and cardiovascular signs. Most children had a personal history of 
atopy (Dibbs & Baker, 1997). 
The symptoms and signs of anaphylaxis are shown in Table 3. 
 
Cutaneous/subcutaneous/mucosal tissue 
Flushing, pruritus, hives (urticaria), swelling, morbilliform rash, pilor erection 
Periorbital pruritus, erythema and swelling, conjunctival erythema, tearing 
Pruritus and swelling of lips, tongue, uvula/palate 
Pruritus in the external auditory canals 
Pruritus of genitalia, palms, soles 
Respiratory 
Nose: pruritus, congestion, rhinorrhea, sneezing 
Larynx: pruritus and tightness in the throat, dysphonia and hoarseness, dry staccato cough, 
stridor, dysphagia 
Lung: shortness of breath, chest tightness, deep cough, wheezing/bronchospasm 
(decreased peak expiratory flow) 
Cyanosis 
Gastrointestinal 
Nausea, cramping abdominal pain, vomiting (stringy mucus), diarrhea 
Cardiovascular 
Chest pain, palpitations, tachycardia, bradycardia, or other dysrhythmia 
Feeling faint, altered mental status, hypotension, loss of sphincter control, shock, cardiac arrest 
CNS 
Aura of impending doom, uneasiness, throbbing headache, dizziness, confusion, tunnel vision; 
in infants and children, sudden behavioral changes, such as irritability, cessation of play, and 
clinging to parent 
Other 
Metallic taste in the mouth 
Dysphagia 
Uterine contractions in postpubertal female patients 
Table 3. Symptoms and signs of anaphylaxis (Simons, 2010 with permission) 
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7. Laboratory tests 
No optimal and readily available laboratory test can confirm the clinical diagnosis of an 
anaphylactic episode. Nevertheless, in some patients the clinical diagnosis of anaphylaxis can 
be confirmed by means of a blood test; for example, an increased plasma histamine level or 
serum total tryptase level (Simons, 2010). These tests are not specific for anaphylaxis. Plasma 
histamine levels should optimally be measured 15 to 60 minutes after onset of symptoms of 
anaphylaxis. Special handling of the blood sample is required. Histamine and its metabolite, 
N-methylhistamine, can also be measured in a 24-hour urine sample. Because tryptase is 
selectively and abundantly produced by mast cells, tryptase levels in biologic fluids should 
provide a more precise measure of local or systemic involvement of these cells than is possible 
to ascertain by clinical presentation or documentation of antigen-specific IgE. Basophils, the 
only other cell type that normally expresses tryptase, contain approximately 1/500th the 
amount mature β tryptase levels generally reflect the magnitude of mast cell activation and are 
elevated during most cases of systemic anaphylaxis, particularly with parenteral exposure to 
the inciting agent (Schwartz, 2006). Not all hypotensive reactions that clinically seem to be 
anaphylactic are associated with elevated levels of mature tryptase, however. For example, 
victims of fatal and near-fatal food-induced anaphylaxis often show no mature tryptase 
elevation, raising the possibility that some of these events may not be dependent on mast cell 
activation. Basophils have been suggested as an alternative effector cell, but direct evidence for 
this has not yet emerged. Other considerations might include overproduction through non-
mast cell pathways of vasoactive mediators, such as complement anaphylatoxins, kinins, or 
lipids (Schwartz, 2006). 
Serum total tryptase levels should optimally be measured from 15 minutes to 3 hours after 
onset of symptoms. No special handling of the blood sample is required. The total tryptase 
level is typically increased in patients with anaphylaxis triggered by an injected medication 
or an insect sting and in those with hypotension and shock but is less likely to be increased 
in those with anaphylaxis triggered by food or in those who are normotensive. Serial 
measurements of serum total tryptase and comparison with baseline levels obtained after 
the acute episode or available in stored serum might be more helpful than measurement at a 
single point in time. Other biomarkers reported to be useful in confirming an acute episode 
of anaphylaxis include serum mature β-tryptase; mast cell carboxypeptidase A3; chymase; 
platelet-activating factor; bradykinin; C-reactive protein; cytokines, such as IL-2, IL-6, IL-10, 
IL-33, and TNF-receptor I; and urinary cysteinyl leukotriene E4 and 9-a-11-b prostaglandin 
F2 (Simons, 2010).  
It was shown that serum PAF levels were directly correlated and serum PAF 
acetylhydrolase activity was inversely correlated with the severity of anaphylaxis. PAF 
acetylhydrolase activity was significantly lower in patients with fatal anaphylactic reactions 
to peanuts than in patients in any of the control groups. Failure of PAF acetylhydrolase to 
inactivate PAF may contribute to the severity of anaphylaxis (Vadas et al., 2008). 
8. Diagnosis 
All individuals who have had a known or suspected anaphylactic episode require a careful 
and complete review of their clinical history. This history may elicit manifestations such as 
urticaria, angioedema, flushing, pruritus, upper airway obstruction, gastrointestinal 
symptoms, syncope, hypotension, lower airway obstruction, and/or other less common 
manifestations (Lieberman et al., 2010). 
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such as shock) (Ditto et al., 1996). From the 335 patients, 201 (60%) were classified as IA-G 
and 119 (35.5%) were designated as IA-A. In this series, urticaria or angioedema occurred in 
all 335 patients, but anaphylaxis, implying a life-threatening emergency, involved 
angioedema of the upper airway in over a third of patients. Indeed, these patients had 
experienced laryngeal or pharyngeal edema or ‘‘massive tongue edema’’. Perhaps, most 
persuasively, in this series of 335 patients, upper airway obstruction occurred in 210 (63%) 
patients (Ditto et al., 1996).  
However, skin and mucosal symptoms and signs are absent or unrecognized in 10% to 20% of 
all anaphylactic episodes (Simons, 2010). These are rather more severe forms of anaphylaxis 
arising suddenly with either respiratory compromises or cardiovascular collapse. The lack of 
cutaneous signs reflects that anaphylaxis episode is likely to become fatal.  
There are some differences in the presentation of anaphylaxis in the pediatric population 
compared with the adult population, including smaller numbers having cardiovascular 
signs and symptoms (21% compared with 41%). Other features noted in pediatric 
anaphylaxis include skin and respiratory signs appearing with an earlier onset compared 
with gastrointestinal and cardiovascular signs. Most children had a personal history of 
atopy (Dibbs & Baker, 1997). 
The symptoms and signs of anaphylaxis are shown in Table 3. 
 
Cutaneous/subcutaneous/mucosal tissue 
Flushing, pruritus, hives (urticaria), swelling, morbilliform rash, pilor erection 
Periorbital pruritus, erythema and swelling, conjunctival erythema, tearing 
Pruritus and swelling of lips, tongue, uvula/palate 
Pruritus in the external auditory canals 
Pruritus of genitalia, palms, soles 
Respiratory 
Nose: pruritus, congestion, rhinorrhea, sneezing 
Larynx: pruritus and tightness in the throat, dysphonia and hoarseness, dry staccato cough, 
stridor, dysphagia 
Lung: shortness of breath, chest tightness, deep cough, wheezing/bronchospasm 
(decreased peak expiratory flow) 
Cyanosis 
Gastrointestinal 
Nausea, cramping abdominal pain, vomiting (stringy mucus), diarrhea 
Cardiovascular 
Chest pain, palpitations, tachycardia, bradycardia, or other dysrhythmia 
Feeling faint, altered mental status, hypotension, loss of sphincter control, shock, cardiac arrest 
CNS 
Aura of impending doom, uneasiness, throbbing headache, dizziness, confusion, tunnel vision; 
in infants and children, sudden behavioral changes, such as irritability, cessation of play, and 
clinging to parent 
Other 
Metallic taste in the mouth 
Dysphagia 
Uterine contractions in postpubertal female patients 
Table 3. Symptoms and signs of anaphylaxis (Simons, 2010 with permission) 
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7. Laboratory tests 
No optimal and readily available laboratory test can confirm the clinical diagnosis of an 
anaphylactic episode. Nevertheless, in some patients the clinical diagnosis of anaphylaxis can 
be confirmed by means of a blood test; for example, an increased plasma histamine level or 
serum total tryptase level (Simons, 2010). These tests are not specific for anaphylaxis. Plasma 
histamine levels should optimally be measured 15 to 60 minutes after onset of symptoms of 
anaphylaxis. Special handling of the blood sample is required. Histamine and its metabolite, 
N-methylhistamine, can also be measured in a 24-hour urine sample. Because tryptase is 
selectively and abundantly produced by mast cells, tryptase levels in biologic fluids should 
provide a more precise measure of local or systemic involvement of these cells than is possible 
to ascertain by clinical presentation or documentation of antigen-specific IgE. Basophils, the 
only other cell type that normally expresses tryptase, contain approximately 1/500th the 
amount mature β tryptase levels generally reflect the magnitude of mast cell activation and are 
elevated during most cases of systemic anaphylaxis, particularly with parenteral exposure to 
the inciting agent (Schwartz, 2006). Not all hypotensive reactions that clinically seem to be 
anaphylactic are associated with elevated levels of mature tryptase, however. For example, 
victims of fatal and near-fatal food-induced anaphylaxis often show no mature tryptase 
elevation, raising the possibility that some of these events may not be dependent on mast cell 
activation. Basophils have been suggested as an alternative effector cell, but direct evidence for 
this has not yet emerged. Other considerations might include overproduction through non-
mast cell pathways of vasoactive mediators, such as complement anaphylatoxins, kinins, or 
lipids (Schwartz, 2006). 
Serum total tryptase levels should optimally be measured from 15 minutes to 3 hours after 
onset of symptoms. No special handling of the blood sample is required. The total tryptase 
level is typically increased in patients with anaphylaxis triggered by an injected medication 
or an insect sting and in those with hypotension and shock but is less likely to be increased 
in those with anaphylaxis triggered by food or in those who are normotensive. Serial 
measurements of serum total tryptase and comparison with baseline levels obtained after 
the acute episode or available in stored serum might be more helpful than measurement at a 
single point in time. Other biomarkers reported to be useful in confirming an acute episode 
of anaphylaxis include serum mature β-tryptase; mast cell carboxypeptidase A3; chymase; 
platelet-activating factor; bradykinin; C-reactive protein; cytokines, such as IL-2, IL-6, IL-10, 
IL-33, and TNF-receptor I; and urinary cysteinyl leukotriene E4 and 9-a-11-b prostaglandin 
F2 (Simons, 2010).  
It was shown that serum PAF levels were directly correlated and serum PAF 
acetylhydrolase activity was inversely correlated with the severity of anaphylaxis. PAF 
acetylhydrolase activity was significantly lower in patients with fatal anaphylactic reactions 
to peanuts than in patients in any of the control groups. Failure of PAF acetylhydrolase to 
inactivate PAF may contribute to the severity of anaphylaxis (Vadas et al., 2008). 
8. Diagnosis 
All individuals who have had a known or suspected anaphylactic episode require a careful 
and complete review of their clinical history. This history may elicit manifestations such as 
urticaria, angioedema, flushing, pruritus, upper airway obstruction, gastrointestinal 
symptoms, syncope, hypotension, lower airway obstruction, and/or other less common 
manifestations (Lieberman et al., 2010). 
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Other conditions that should be considered in the differential diagnosis include: (1) 
vasodepressor (vasovagal/neuro-cardiogenic) syncope; (2) syndromes that can be 
associated with flushing (e.g., metastatic carcinoid); (3) postprandial syndromes (e.g., 
scombroid poisoning); (4) systemic mastocytosis; (5) psychiatric disorders that can mimic 
anaphylaxis such as panic attacks or vocal cord dysfunction syndrome; (6) angioedema (e.g., 
hereditary angioedema); (7) other causes of shock (e.g., cardiogenic); and (8) other 
cardiovascular or respiratory events (Lieberman et al., 2005). 
The history is the most important tool to establish the cause of anaphylaxis and takes 
precedence over diagnostic tests. A detailed history of all food consumed and drugs taken 
over the four to six hours prior to the episode should be obtained. In addition, the labels for 
all packaged foods ingested by the patient in this period of time should be reviewed since a 
substance added to the food could be responsible. A history of any preceding bite or sting 
should be obtained. The patient’s activities (e.g., exercise, sexual activity) preceding the 
event should be reviewed. Patient diaries may be a useful adjunct in confirming or 
identifying the cause of anaphylaxis (Lieberman et al., 2010).  
A detailed history of all potential causes should be obtained. This includes a list of 
ingestants consumed and/or medications taken within six hours of the event, any sting or 
bite occurring prior to the event, if the event occurred during exercise, location of the event 
(e.g., work versus home), and whether or not the event was related to exposure to heat, cold, 
or occurred during sexual activity. The patient’s atopic status should be noted since food-
induced, seminal fluid and idiopathic anaphylaxis are more common in atopic than non-
atopic individuals. In women, the history should include any relationship between the 
attack and their menstrual cycle. A return of symptoms following a remission should be 
noted since this may indicate a late phase reaction, which might require a prolonged period 
of observation if subsequent events occur (Lieberman et al., 2010).  
8.1 Confirmation of the triggers of anaphylaxis 
The next step in the evaluation of a patient experienced anaphylaxis is confirmation of the 
trigger or triggers identified or suspected through the history (Simons, 2010). So that the 
relevant specific trigger or triggers can be avoided and recurrences of anaphylaxis can be 
prevented. Skin tests should be performed with validated instruments, techniques, and 
recording systems, preferably at least 3 to 4 weeks after the anaphylactic episode, to allow 
time for rearming of skin mast cells and recovery of mast cell releasability. When possible, 
standardized extracts for skin testing should be used, although occasionally fresh food 
extracts will be superior to available standardized extracts. If the skin testing extract has not 
been standardized (e.g., latex, protamine, or antibiotics other than penicillin), the clinical 
relevance of the results may be uncertain. Skin tests or in vitro tests can determine the 
presence of specific IgE antibodies to foods, medications (e.g., penicillin and insulin), and 
stinging insects as a cause of anaphylaxis (Lieberman et al., 2010). Measurement of allergen-
specific IgE levels by using a quantitative method can be performed at any time during or 
after the acute anaphylactic episode; however, if the blood sample is obtained during or 
shortly after the episode from patients who have received intravenous fluid resuscitation, 
levels can be falsely undetectable or low because of the dilutional effect on circulating IgE. 
Negative tests for sensitization to a trigger in a patient with a convincing history of 
anaphylaxis from that trigger should be repeated weeks or months later. It is important to 
note that both positive skin tests and increased specific IgE levels indicate sensitization to 
the allergens tested but are not diagnostic of anaphylaxis or any other disease (Lieberman et 
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al., 2010). The clinical significance of skin testing or in vitro test depends on the ability to 
correlate the results of such testing with the patient’s history. If tests for specific IgE 
antibodies (i.e., skin tests, in vitro tests, or both) do not provide conclusive evidence of the 
cause of anaphylaxis, challenge with the suspected agent can be considered. If indicated, 
incremental challenge/provocation tests should be conducted in appropriately equipped 
health care facilities by professionals trained and experienced in patient selection, timing of 
the challenge, use of challenge protocols, and diagnosing and treating anaphylaxis. Before a 
challenge is performed, the potential risks and benefits should be discussed with the patient 
(or, for children, the caregivers) and documented in the medical record. Challenge 
procedures may also be appropriate in patients who develop non-IgE-mediated reactions 
(e.g., reactions to aspirin (ASA) or other nonsteroidal anti-inflammatory drugs. Challenge 
with suspected agents must be done carefully by individuals knowledgeable in the 
challenge procedure and with expertise in managing reactions to the challenge agent if they 
should occur (Lieberman et al., 2010). 
8.2 Assessment of patients with food-triggered anaphylaxis  
Skin prick tests with foods that elicit a wheal of 3 mm larger than that caused by the negative 
control (eg. saline) are considered positive (Simons, 2010). Commercially available food 
allergen extracts do not contain standardized allergens. Some food allergens, such as fruits and 
vegetables, are labile and degrade in glycerinated extracts during manufacture and storage; 
therefore skin prick tests with these allergens are often performed with fresh foods. 
Intradermal tests to foods are contraindicated because of lack of specificity (false-positive 
tests) and their potential for triggering anaphylaxis (Lieberman et al., 2010). An exception to 
this might be use of intradermal tests to assess sensitization to fresh meat containing the 
carbohydrate galactose-alpha-1,3-galactose. In food-sensitized patients specific IgE levels 
have predictive values for positive (failed) or negative (passed) food challenge tests. 
Allergen-specific IgE levels with greater than 95% predictive risk values of a positive (failed) 
food challenge result have been identified by using the ImmunoCAP (Phadia, Uppsala, 
Sweden). These levels are defined for cow’s milk (15 kU/L), egg (7 kU/L), peanut (14 
kU/L), tree nuts (15 kU/L), and fish (20 kU/L); in infants lower values have been 
established for milk (5 kU/L) and egg (2 kU/L) (Boden & Burks, 2011). Predictive values for 
allergen-specific IgE levels potentially differ from one immunoassay to another, and this can 
affect management decisions. 
A positive skin test, an increased serum IgE level, or both to a specific food document 
sensitization to that food. Such tests are not diagnostic of anaphylaxis because sensitization 
to 1 or more food allergens is common in the general population of healthy people who 
have no history of anaphylaxis. For example, 60% of young people have a positive skin prick 
test to 1 or more foods, yet most of those with positive tests have never experienced 
anaphylaxis from a food. In addition, although positive skin tests and increased allergen-
specific IgE levels correlate with an increased probability of clinical reactivity to specific 
foods, the results of these tests do not necessarily correlate with the risk of future 
anaphylactic episodes or with the severity of such episodes (Simons, 2010). 
Oral food challenge testing is accepted as a gold standard for detection of a food 
allergy/hypersensitivity (Sampson & Burks, 2009). Patients with a convincing history of 
anaphylaxis to a specific food and evidence of sensitization to that food should not undergo 
oral food challenge tests because of their high risk of anaphylaxis from such tests. Others, 
such as those with an equivocal history, low or moderate evidence of sensitization, or both, 
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Other conditions that should be considered in the differential diagnosis include: (1) 
vasodepressor (vasovagal/neuro-cardiogenic) syncope; (2) syndromes that can be 
associated with flushing (e.g., metastatic carcinoid); (3) postprandial syndromes (e.g., 
scombroid poisoning); (4) systemic mastocytosis; (5) psychiatric disorders that can mimic 
anaphylaxis such as panic attacks or vocal cord dysfunction syndrome; (6) angioedema (e.g., 
hereditary angioedema); (7) other causes of shock (e.g., cardiogenic); and (8) other 
cardiovascular or respiratory events (Lieberman et al., 2005). 
The history is the most important tool to establish the cause of anaphylaxis and takes 
precedence over diagnostic tests. A detailed history of all food consumed and drugs taken 
over the four to six hours prior to the episode should be obtained. In addition, the labels for 
all packaged foods ingested by the patient in this period of time should be reviewed since a 
substance added to the food could be responsible. A history of any preceding bite or sting 
should be obtained. The patient’s activities (e.g., exercise, sexual activity) preceding the 
event should be reviewed. Patient diaries may be a useful adjunct in confirming or 
identifying the cause of anaphylaxis (Lieberman et al., 2010).  
A detailed history of all potential causes should be obtained. This includes a list of 
ingestants consumed and/or medications taken within six hours of the event, any sting or 
bite occurring prior to the event, if the event occurred during exercise, location of the event 
(e.g., work versus home), and whether or not the event was related to exposure to heat, cold, 
or occurred during sexual activity. The patient’s atopic status should be noted since food-
induced, seminal fluid and idiopathic anaphylaxis are more common in atopic than non-
atopic individuals. In women, the history should include any relationship between the 
attack and their menstrual cycle. A return of symptoms following a remission should be 
noted since this may indicate a late phase reaction, which might require a prolonged period 
of observation if subsequent events occur (Lieberman et al., 2010).  
8.1 Confirmation of the triggers of anaphylaxis 
The next step in the evaluation of a patient experienced anaphylaxis is confirmation of the 
trigger or triggers identified or suspected through the history (Simons, 2010). So that the 
relevant specific trigger or triggers can be avoided and recurrences of anaphylaxis can be 
prevented. Skin tests should be performed with validated instruments, techniques, and 
recording systems, preferably at least 3 to 4 weeks after the anaphylactic episode, to allow 
time for rearming of skin mast cells and recovery of mast cell releasability. When possible, 
standardized extracts for skin testing should be used, although occasionally fresh food 
extracts will be superior to available standardized extracts. If the skin testing extract has not 
been standardized (e.g., latex, protamine, or antibiotics other than penicillin), the clinical 
relevance of the results may be uncertain. Skin tests or in vitro tests can determine the 
presence of specific IgE antibodies to foods, medications (e.g., penicillin and insulin), and 
stinging insects as a cause of anaphylaxis (Lieberman et al., 2010). Measurement of allergen-
specific IgE levels by using a quantitative method can be performed at any time during or 
after the acute anaphylactic episode; however, if the blood sample is obtained during or 
shortly after the episode from patients who have received intravenous fluid resuscitation, 
levels can be falsely undetectable or low because of the dilutional effect on circulating IgE. 
Negative tests for sensitization to a trigger in a patient with a convincing history of 
anaphylaxis from that trigger should be repeated weeks or months later. It is important to 
note that both positive skin tests and increased specific IgE levels indicate sensitization to 
the allergens tested but are not diagnostic of anaphylaxis or any other disease (Lieberman et 
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al., 2010). The clinical significance of skin testing or in vitro test depends on the ability to 
correlate the results of such testing with the patient’s history. If tests for specific IgE 
antibodies (i.e., skin tests, in vitro tests, or both) do not provide conclusive evidence of the 
cause of anaphylaxis, challenge with the suspected agent can be considered. If indicated, 
incremental challenge/provocation tests should be conducted in appropriately equipped 
health care facilities by professionals trained and experienced in patient selection, timing of 
the challenge, use of challenge protocols, and diagnosing and treating anaphylaxis. Before a 
challenge is performed, the potential risks and benefits should be discussed with the patient 
(or, for children, the caregivers) and documented in the medical record. Challenge 
procedures may also be appropriate in patients who develop non-IgE-mediated reactions 
(e.g., reactions to aspirin (ASA) or other nonsteroidal anti-inflammatory drugs. Challenge 
with suspected agents must be done carefully by individuals knowledgeable in the 
challenge procedure and with expertise in managing reactions to the challenge agent if they 
should occur (Lieberman et al., 2010). 
8.2 Assessment of patients with food-triggered anaphylaxis  
Skin prick tests with foods that elicit a wheal of 3 mm larger than that caused by the negative 
control (eg. saline) are considered positive (Simons, 2010). Commercially available food 
allergen extracts do not contain standardized allergens. Some food allergens, such as fruits and 
vegetables, are labile and degrade in glycerinated extracts during manufacture and storage; 
therefore skin prick tests with these allergens are often performed with fresh foods. 
Intradermal tests to foods are contraindicated because of lack of specificity (false-positive 
tests) and their potential for triggering anaphylaxis (Lieberman et al., 2010). An exception to 
this might be use of intradermal tests to assess sensitization to fresh meat containing the 
carbohydrate galactose-alpha-1,3-galactose. In food-sensitized patients specific IgE levels 
have predictive values for positive (failed) or negative (passed) food challenge tests. 
Allergen-specific IgE levels with greater than 95% predictive risk values of a positive (failed) 
food challenge result have been identified by using the ImmunoCAP (Phadia, Uppsala, 
Sweden). These levels are defined for cow’s milk (15 kU/L), egg (7 kU/L), peanut (14 
kU/L), tree nuts (15 kU/L), and fish (20 kU/L); in infants lower values have been 
established for milk (5 kU/L) and egg (2 kU/L) (Boden & Burks, 2011). Predictive values for 
allergen-specific IgE levels potentially differ from one immunoassay to another, and this can 
affect management decisions. 
A positive skin test, an increased serum IgE level, or both to a specific food document 
sensitization to that food. Such tests are not diagnostic of anaphylaxis because sensitization 
to 1 or more food allergens is common in the general population of healthy people who 
have no history of anaphylaxis. For example, 60% of young people have a positive skin prick 
test to 1 or more foods, yet most of those with positive tests have never experienced 
anaphylaxis from a food. In addition, although positive skin tests and increased allergen-
specific IgE levels correlate with an increased probability of clinical reactivity to specific 
foods, the results of these tests do not necessarily correlate with the risk of future 
anaphylactic episodes or with the severity of such episodes (Simons, 2010). 
Oral food challenge testing is accepted as a gold standard for detection of a food 
allergy/hypersensitivity (Sampson & Burks, 2009). Patients with a convincing history of 
anaphylaxis to a specific food and evidence of sensitization to that food should not undergo 
oral food challenge tests because of their high risk of anaphylaxis from such tests. Others, 
such as those with an equivocal history, low or moderate evidence of sensitization, or both, 
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might benefit from a physician-monitored incremental oral food challenge. A positive 
(failed) challenge provides a basis for continued avoidance of the food. A negative (passed) 
challenge allows introduction or reintroduction of the specific food into the patient’s diet.  
8.3 Assessment of medication- or biological agent –triggered anaphylaxis  
Any medication or biological agent can potentially trigger anaphylaxis. In cases with severe  
anaphylactic reactions, it is advisable to first perform skin tests with the presumably 
causative drugs only by prick (Schnyder & Pichler, 2009). If responses are negative and the 
involved drug is available as a parenteral formulation, negative skin tests do not have 
sufficient sensitivity to exclude an immune-mediated hypersensitivity in the case of a 
suggestive history. For most agents, the antigenic determinants have not been characterized 
or validated; indeed, the relevant immunogenic prodrugs, haptens, metabolites, and 
unidentified degradation products or contaminants are often unknown. For most 
medications, with the exception of some β-lactam antibiotics, appropriate reagents are not 
commercially available for use in skin tests, measurement of medication-specific IgE levels, 
or other in vitro tests. In penicillin allergies, standardized preparations with 
penicilloylpolylysine and minor determinant mixture may be used (Lieberman et al., 2010). 
Penicillin allergy may also be evaluated by in vitro tests for specific IgEs; however, these 
tests have a low sensitivity. Additionally, assays for a few drugs such as suxamethonium, 
rocuronium, morphine, sulfamethoxazole, and chlorhexidine, are offered, some with 
potentially higher sensitivity (Schnyder, 2009). A further in vitro test to identify the relevant 
drug may be the basophil activation test. This test is based on flow cytometric quantification 
of drug-induced CD63 expression or CD203c up-regulation or measurement of sulfo-
leukotriene release by ELISA. The sensitivity in IgE-mediated reactions appears to be 
superior to CAP-based IgE determinations and comparable with skin tests. Customized tests 
and physician-monitored challenge/provocation tests performed in specialized centers 
therefore play a central role in assessment of patients with a history of anaphylaxis triggered 
by a medication. A drug provocation test (DPT) is defined as controlled administration of a 
drug to diagnose immune-mediated and non–immune-mediated drug hypersensitivity. Its 
advantage is that it permits testing of a patient with his or her individual metabolism and 
immunogenetic background. A DPT reproduces not only symptoms of allergy but other 
adverse clinical manifestations, irrespective of their mechanism. A DPT is currently the 
‘‘gold standard,’’ but its use is limited by the possibility of severe and uncontrollable relapse 
of the reaction (Aberer et al., 2010). Therefore, a DPT should be reserved for specific 
situations when a significant drug is suspected to have provoked an intolerance reaction 
and alternative test methods have failed to yield conclusive results. The patient being tested 
has to be in stable condition, and an anticipated positive reaction must be controllable by 
adequate measures. Because of these restrictions, only physicians experienced in drug 
allergy should perform this test. The two main indications for a DPT with the suspected 
drug are the following: to exclude hypersensitivity in the presence of unconvincing histories 
of drug hypersensitivity or in patients with nonspecific conditions, such as subjective 
symptoms under local anesthesia, or to establish a distinct diagnosis in suggestive histories 
of drug hypersensitivity with inconclusive, negative, or nonavailable allergy test results. A 
positive DPT result optimizes the avoidance of certain drugs, whereas a negative one 
permits the clinician to rule out a false diagnosis of drug hypersensitivity. 
For assessment of anaphylaxis triggered by vaccines to prevent allergic diseases, skin prick 
tests should be performed not only with the immunizing agent but also with the relevant 
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excipients in the culprit vaccine, such as gelatin in measles vaccines or egg in some influenza 
vaccines and in yellow fever vaccine (Simons, 2010). 
8.4 Assessment of stinging insect-triggered anaphylaxis  
Standardized Hymenoptera venoms, such as honeybee, yellow jacket, yellow hornet, white-
faced hornet, and Paper wasp, are available for skin testing. Skin prick tests, if negative, 
should be followed by intradermal tests (Bilo & Bonifazi, 2009). Use of dialyzed venoms in 
skin tests is reported to improve the identification of venom-sensitized patients (Golden et 
al., 2009). For fire ant-triggered anaphylaxis, whole-body extracts are used as skin test 
reagents. Measurements of venom-specific IgE levels are commercially available (Freeman, 
2004). Some patients with a history of Hymenoptera sting–triggered anaphylaxis have 
negative skin test responses to insect venoms but increased specific IgE levels to venoms 
and vice versa (Simons, 2010). Positive intradermal tests to stinging insect venoms, 
increased venom-specific IgE levels, or both occur in up to 28.5% of the general adult 
population, most of whom do not have systemic symptoms after an insect sting (Simons, 
2010). It is therefore critically important that the test results be interpreted in the context of 
the clinical history. In some centers additional tests used to assist in interpretation of 
positive test results include consideration of total IgE levels as well as venom-specific IgE 
levels, and measurement of basophil activation markers, such as CD63 or CD203c after 
incubation with different concentrations of venom (Simons, 2010). Conversely, venom skin 
tests might be negative and venom specific IgE levels might be absent or undetectable in 
patients with a convincing history of insect sting–triggered anaphylaxis (Simons, 2010).  
8.5 Perioperative anaphylaxis  
Skin testing may be useful to determine the safest alternative for subsequent anesthesia 
following a suspected reaction. Skin testing with neuromuscular blocking agents, hypnotics 
and opioids is used. Antibiotics frequently are administered before, during, or immediately 
after anesthesia and surgery. Allergic reactions to antibiotics, particularly anaphylaxis, may 
occur during the perioperative period. For this reason, following a suspected reaction 
during anesthesia, skin tests with antibiotics should also be done. It should be noted that 
nonimmunologic reactions are not identified by this diagnostic method. Skin testing is not 
recommended for preanesthetic screening of subjects without a history of suspected 
reactions (Lobera et al., 2008).  
8.6 Assessment of anaphylaxis triggered by natural rubber latex 
Skin prick tests should be performed with commercial latex allergens, where available, or 
with extracts of rubber products, such as natural rubber latex gloves, where commercial 
allergens are not available. In vitro tests have highly variable sensitivity and specificity 
characteristics (Lieberman et al., 2010). Consideration should be given to testing with foods 
that cross-react with latex, such as banana, kiwi, papaya, avocado, potato, and tomato. 
Latex-specific IgE antibodies can also be measured. 
8.7 Assessment of exercise-triggered anaphylaxis  
These should be done: meticulous clinical history, skin or in vitro testing for potential food 
allergen co triggers, and occasionally, documenting mast cell activation if this can be 
determined in the minutes or hours following an attack (Lieberman et al., 2010). The 
diagnosis of EIA can be confirmed by eliciting symptoms with treadmill testing. However, 
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might benefit from a physician-monitored incremental oral food challenge. A positive 
(failed) challenge provides a basis for continued avoidance of the food. A negative (passed) 
challenge allows introduction or reintroduction of the specific food into the patient’s diet.  
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Any medication or biological agent can potentially trigger anaphylaxis. In cases with severe  
anaphylactic reactions, it is advisable to first perform skin tests with the presumably 
causative drugs only by prick (Schnyder & Pichler, 2009). If responses are negative and the 
involved drug is available as a parenteral formulation, negative skin tests do not have 
sufficient sensitivity to exclude an immune-mediated hypersensitivity in the case of a 
suggestive history. For most agents, the antigenic determinants have not been characterized 
or validated; indeed, the relevant immunogenic prodrugs, haptens, metabolites, and 
unidentified degradation products or contaminants are often unknown. For most 
medications, with the exception of some β-lactam antibiotics, appropriate reagents are not 
commercially available for use in skin tests, measurement of medication-specific IgE levels, 
or other in vitro tests. In penicillin allergies, standardized preparations with 
penicilloylpolylysine and minor determinant mixture may be used (Lieberman et al., 2010). 
Penicillin allergy may also be evaluated by in vitro tests for specific IgEs; however, these 
tests have a low sensitivity. Additionally, assays for a few drugs such as suxamethonium, 
rocuronium, morphine, sulfamethoxazole, and chlorhexidine, are offered, some with 
potentially higher sensitivity (Schnyder, 2009). A further in vitro test to identify the relevant 
drug may be the basophil activation test. This test is based on flow cytometric quantification 
of drug-induced CD63 expression or CD203c up-regulation or measurement of sulfo-
leukotriene release by ELISA. The sensitivity in IgE-mediated reactions appears to be 
superior to CAP-based IgE determinations and comparable with skin tests. Customized tests 
and physician-monitored challenge/provocation tests performed in specialized centers 
therefore play a central role in assessment of patients with a history of anaphylaxis triggered 
by a medication. A drug provocation test (DPT) is defined as controlled administration of a 
drug to diagnose immune-mediated and non–immune-mediated drug hypersensitivity. Its 
advantage is that it permits testing of a patient with his or her individual metabolism and 
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excipients in the culprit vaccine, such as gelatin in measles vaccines or egg in some influenza 
vaccines and in yellow fever vaccine (Simons, 2010). 
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should be followed by intradermal tests (Bilo & Bonifazi, 2009). Use of dialyzed venoms in 
skin tests is reported to improve the identification of venom-sensitized patients (Golden et 
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8.6 Assessment of anaphylaxis triggered by natural rubber latex 
Skin prick tests should be performed with commercial latex allergens, where available, or 
with extracts of rubber products, such as natural rubber latex gloves, where commercial 
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8.7 Assessment of exercise-triggered anaphylaxis  
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symptoms are difficult to reproduce. The differential diagnosis includes arrhythmias and 
other cardiovascular events, but such events do not include pruritus, urticaria, angioedema, 
or upper airway obstruction. Exercise induced bronchoconstriction presents with symptoms 
that are limited to the airways. Exercise-associated gastroesophageal reflux could mimic 
mild symptoms of EIA, although, urticaria and/or pruritus are not observed (Feldweg & 
Sheffer, 2011). 
8.8 Assessment of idiopathic anaphylaxis  
When a meticulous history of antecedent exposures and events does not yield any clues 
about potential triggers and when allergen skin tests are negative and specific IgE 
measurements are absent or undetectable to selected common allergens, patients are said to 
have idiopathic anaphylaxis (Greenberger, 2007). The diagnosis of idiopathic anaphylaxis is 
based on exclusion. Before making this diagnosis, physicians should consider the possibility 
of a hidden or previously unrecognized trigger. Sensitization to a novel trigger for which 
there is no commercially available test material, can be identified through a history of the 
event and confirmed by objective tests.  
Patients with idiopathic anaphylaxis should receive careful evaluation for possible causes, 
with emphasis on the history of events in the 3 hours prior to an episode. Selective skin 
testing with foods (and if indicated to fresh food extracts) may be of value. Indolent 
systemic mastocytosis must be excluded. Consistently elevated serum tryptase levels 
suggest the presence of indolent systemic mastocytosis since the serum tryptase will be 
elevated in the absence of episodes of anaphylaxis. In contrast, serum tryptase levels will be 
normal in quiescent idiopathic anaphylaxis. A bone marrow examination may be indicated 
in patients with a diagnosis of idiopathic anaphylaxis even in the absence or elevated 
tryptase levels if salmon colored, hyperpigmented macules and papules consistent with 
urticaria pigmentosa are found (Akn et al., 2007). The differential diagnosis of idiopathic 
anaphylaxis includes hereditary angioedema or acquired C1 inhibitor deficiency. Some 
patients with idiopathic anaphylaxis present with massive enlargement of the tongue 
and/or life-threatening upper airway obstruction due to pharyngeal or laryngeal 
angioedema, but their C4 concentration is not reduced.  
9. Management  
Anaphylaxis, as a potentially life-threatening condition must be diagnosed and managed 
promptly. Although the etiology may be various or indefinite and there is lack of rapid 
diagnostic tests, the diagnosis relies mostly on clinical symptoms, therefore requires a high 
index of suspicion. Irrespective of the trigger or mechanism of anaphylaxis, the initial 
management is the same and is based on basic therapeutic agents that all healthcare 
professionals should be able to provide, even in a low resource environment (Lee & Vadas, 
2011; Simons et al., 2011). Prompt and definitive management can be life saving whereas the 
delay in the management may result in a fatal outcome (Lieberman et al., 2010). 
Anaphylaxis can potentially affect cardiovascular and respiratory systems and be presented 
as a multisystem emergency. The trigger has to be removed, if possible and the patient’s 
circulation, airway, breathing, level of consciousness, and skin should be rapidly assessed 
(Simons et al., 2011). According to the consensus of experts, in general the treatment in order 
of importance includes epinephrine (adrenaline), patient position, oxygen, intravenous 
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fluids, nebulized therapy, vasopressors, antihistamines, corticosteroids, and other agents 
(Lieberman et al., 2010). 
In a series of over 200 anaphylaxis deaths the median time from onset of symptoms to fatal 
cardiopulmonary arrest was reported as <30 minutes (Pumphrey, 2000). In the same paper 
the median times to cardiopulmonary arrest were 5 minutes after administration of a 
diagnostic or therapeutic intervention, 15 minutes after an insect sting, and 30 minutes after 
food ingestion. As soon as the need is recognized, supplemental oxygen at a flow rate of 6-8 
L/min, intravenous fluid resuscitation must be administered and the cardiopulmonary 
resuscitation with continuous chest compressions before giving rescue breathing must be 
initiated (Simons et al., 2011). Patients should be kept supine with legs raised to prevent 
death due to ‘empty vena cava/ empty ventricle syndrome’ with pulseless electrical activity 
(Pumphrey, 2003). In this syndrome patients in shock suddenly sit, stand, or are placed 
upright, the vena cava empties within seconds, and epinephrine is prevented from 
circulating the body (Pumphrey & Gowland, 2007). The patient must be kept in a 
comfortable position if vomiting or respiratory distress is present (Simons et al., 2011).  
Supplemental oxygen should be given by face mask or oropharyngeal airway to all patients 
with concomitant asthma, other chronic respiratory disease, or cardiovascular disease and 
those having prolonged reactions or those who are receiving inhaled β-agonists as part of 
the treatment for anaphylaxis or repeated doses of epinephrine (Lieberman et al., 2010; 
Simons et al., 2011). Oxygen supplementation should be guided with continuous pulse 
oximetry and/or arterial blood gas determination (Lieberman et al., 2010). 
The fluid management is critical as massive fluid shifts can occur due to increased vascular 
permeability within minutes (Brown et al., 2004). Saline stays in the intravascular space 
longer than dextrose and contains no lactate which may exacerbate metabolic acidosis. 
Therefore one to 2 L of 0.9% isotonic saline as a preferred solution should be commenced as 
5-10 mL/kg in the first 5-10 minutes to an adult or 10 mL/kg to a child as soon as the need 
for it is recognized (Lieberman et al., 2010; Simons et al., 2011). The rate of administration 
should be titrated according to the blood pressure, cardiac rate and function and urine 
output. Caution should be undertaken for volume overload (Simons et al., 2011). In some 
cases fluid replacement may not be so effective when considered with other indications. It is 
possible that the replaced fluid during management can also shift from the vasculature to 
tissues. Therefore the cornerstone of management is a non-selective adrenergic agonist 
agent, epinephrine which acts on α-1, β-1 and β-2 adrenergic receptors and is highly 
effective to reverse the clinical symptoms mainly with vasoconstriction, cardiac stimulation 
and bronchodilatation (Lee & Vadas, 2011; Simons et al., 2009a). The World Health 
Organization (WHO) classifies epinephrine as an essential medication for the treatment of 
anaphylaxis (Simons et al., 2011). The evidence base for prompt epinephrine injection in the 
initial treatment of anaphylaxis is stronger than the evidence base for the use of 
antihistamines and glucocorticoids in anaphylaxis (Simons et al., 2011). Therefore overt 
signs of distributive shock or cardiovascular compromise should not be waited to 
administer epinephrine. It is recommended that epinephrine be given as soon as possible 
(Lee & Vadas, 2011). Although there is any doubt in recognition of the clinical situation as 
anaphylaxis, it is generally better to administer epinephrine (Lieberman et al., 2010). 
Pharmacokinetic studies have shown that the intramuscular route of administration into the 
mid-anterolateral thigh (the vastus lateralis muscle) is preferable with a faster onset of 
action and more sustained levels as compared with the subcutaneous route (Lee & Vadas, 
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possible that the replaced fluid during management can also shift from the vasculature to 
tissues. Therefore the cornerstone of management is a non-selective adrenergic agonist 
agent, epinephrine which acts on α-1, β-1 and β-2 adrenergic receptors and is highly 
effective to reverse the clinical symptoms mainly with vasoconstriction, cardiac stimulation 
and bronchodilatation (Lee & Vadas, 2011; Simons et al., 2009a). The World Health 
Organization (WHO) classifies epinephrine as an essential medication for the treatment of 
anaphylaxis (Simons et al., 2011). The evidence base for prompt epinephrine injection in the 
initial treatment of anaphylaxis is stronger than the evidence base for the use of 
antihistamines and glucocorticoids in anaphylaxis (Simons et al., 2011). Therefore overt 
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action and more sustained levels as compared with the subcutaneous route (Lee & Vadas, 
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2011; Simons, 2009b). The rationale for intramuscular injection is that the striated muscle is 
well vascularized, facilitating rapid systemic absorption and prompt achievement of peak 
epinephrine pharmacologic effects. In contrast subcutaneous tissue consisting mostly of 
poorly vascularized adipose tissue provides the slow absorption of epinephrine with 
variable time intervals for peak pharmacologic effects (Simons, 2009b). Significantly faster 
peak plasma concentrations are achieved via the intramuscular route (8 ± 2 min) than the 
subcutaneous route of administration (34 ± 14 min) in children, and in adults (Frew, 2010). 
Intramuscular epinephrine injections into the thigh have been reported to provide more 
rapid absorption and higher plasma epinephrine levels in both children and adults than 
intramuscular or subcutaneous injections administered in the arm (Lieberman et al., 2010). 
Alternative routes of administration have been anecdotally tried. For example sublingual 
delivery of 40 mg epinephrine has been shown to lead to plasma concentrations that are not 
significantly different to those following intramuscular administration of 0.3 mg 
epinephrine (Frew, 2010). 
The recommended dose of epinephrine for children is 0.01 mg/kg body weight of a 1:1,000 
(1 mg/mL) solution, to a maximum initial dose of 0.3 mg in a 30 kg child (Simons, 2009b). In 
the recent guideline of World Allergy Organization (WAO) the same dose of epinephrine in 
adults with a maximum initial dose of 0.5 mg is recommended (Simons et al., 2011). In the 
recent Practice Parameter on the Diagnosis and Management of Anaphylaxis, the dose is 
defined as 0.2-0.5 ml of aqueous epinephrine of a 1:1,000 dilution in adults and as 
0.01mg/kg of the same dilution in children (Lieberman et al., 2010). The dose can be 
repeated every 5-15 minutes, as needed depending on the severity of the episode and the 
response to the initial injection (Lieberman et al., 2010; Simons et al., 2011). Approximately 
20% of cases in the community require a second dose because of lack of response to the first 
dose, or development of a biphasic reaction (Simons, 2009b).  
The patient has to be monitored with blood pressure, cardiac rate and function, respiratory 
status at regular intervals and oxygenation continuously, if possible (Simons et al., 2011). 
The duration of monitoring should be individualized. Patients with moderate respiratory or 
cardiovascular compromise should be monitored in a medically supervised setting for at 
least 4 hours and if indicated 8-10 hours or longer, and patients with severe or protracted 
anaphylaxis might require monitoring and interventions for days (Simons et al., 2011). 
In patients who remain hypotensive and unresponsive to intramuscular epinephrine and 
fluid resuscitation, the ones who have progressed to shock or cardiac arrest intravenous 
epinephrine is recommended (Lee & Vadas, 2011; Simons et al., 2011). Ideally, this route 
should be administered only by trained, experienced physicians who are equipped to give 
vasopressors through an infusion pump and titrate the dose frequently according to 
noninvasive continuous monitoring of cardiac rate and function. A controlled infusion is 
safer than bolus administration (Soar et al., 2008). If cardiac arrest is imminent or has 
already occurred, an intravenous bolus dose of epinephrine is indicated according to 
Resuscitation Guidelines (Simons et al., 2011). An intravenous epinephrine infusion is 
prepared by adding 1 mg (1 mL) of 1:1,000 dilution of epinephrine to 250 mL of 5% dextrose 
to yield a concentration of 4.0 µg/mL. This 1:250,000 solution is infused at a rate of 1µg/mL, 
titrated to a maximum of 10.0µg/min for adults. In children, a dosage of 0.01 mg/kg (0.1 
mL/kg of a 10,000 solution up to 10µg/min; maximum dose, 0.3 mg is administered 
(Lieberman et al., 2010). Other protocols for intravenous administration are also suggested 
(Lieberman et al., 2010). 
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Dopamine as a vasopressor agent is recommended when epinephrine and fluid 
resuscitation fail to alleviate hypotension in a dose of 2-20µg/kg/min, titrated to maintain 
systolic blood pressure greater than 90 mmHg. During cardiopulmonary resuscitation 
intravenous high-dose epinephrine is recommended. A common sequence is 1 to 3 mg 
(1:10,000 dilution) intravenous slowly administered over 3 min, 3 to 5 mg intravenous over 3 
min, and then 4-10 µg/min infusion. For children, the recommended initial resuscitation 
dosage is 0.01 mg/kg (0.1 ml/kg of a 1:10,000 solution up to 10 µg/min rate of infusion), 
repeated every 3 to 5 min for ongoing arrest. Higher subsequent dosages (0.1-0.2 mg/kg: 0.1 
ml/kg of a 1:1,000 solution) may be considered for unresponsive asystole or pulseless 
electrical activity (Lieberman et al., 2010). 
The common adverse effects of epinephrine include anxiety, dizziness, restlessness, 
headache, palpitations, tremor, and pallor and indicate that a therapeutic dose has been 
given (Lee & Vadas, 2011; Simons, 2009b). Rare side effects of epinephrine more commonly 
related with high or rapid doses of intravenous administration include ventricular 
arrhythmias, angina, myocardial infarction, pulmonary edema, hypertensive emergency, 
and intracranial haemorrhage (Lee & Vadas, 2011; Simons et al., 2011). It was demonstrated 
that the heart is the target organ of anaphylaxis and acute coronary syndrome can occur in 
anaphylaxis in the absence of epinephrine administration in patients with known coronary 
artery disease, and those in whom subclinical coronary artery disease is unmasked by the 
anaphylactic episode (Simons et al., 2011). Concerns about adverse effects, especially 
potential myocardial infarction and cardiac arrhythmias, need to be weighed against the 
cardiac risks of untreated anaphylaxis (Simons, 2009b; Simons et al., 2011). As there is no 
controlled trials mainly because of ethical concerns, there is no way to estimate the risk in 
relation to benefit of epinephrine, but on the basis of current evidence, the benefit of using 
appropriate doses of intramuscular epinephrine is likely to far exceed the risk (Sheikh et al., 
2009). According to the recent WAO guidelines epinephrine is not contraindicated in the 
treatment of anaphylaxis in patients with known or suspected cardiovascular disease, or in 
elderly patients without known coronary artery disease who are at risk of acute coronary 
syndrome only because of their age (Simons et al., 2011). However, careful monitoring and 
avoidance of an adrenaline overdose are necessary in these patients (Sheikh et al., 2009). 
In a recent systematic Cochrane review, it was emphasized that there are no absolute 
contraindications to epinephrine use in anaphylaxis and in the absence of appropriate trials, 
and suboptimal evidence, epinephrine administration is recommended to be regarded as the 
first-line treatment for the management of anaphylaxis (Sheikh et al., 2009). Some relative 
contraindications include patients using mono-amine oxidase inhibitors, tricyclic anti-
depressants, or stimulant medications or illicit substances, all of which are possibly 
increasing the risk of adverse effects of epinephrine (Lee & Vadas, 2011). Caution is needed 
in patients with recent intracranial surgery, aortic or cerebral aneurism(s), uncontrolled 
hyperthyroidism, or hypertensive emergencies (Lee & Vadas, 2011).  
H1-antihistamines are frequently used in anaphylaxis, but they cannot be substituted for 
epinephrine as first line treatment (Sheikh et al., 2007). A Cochrane systematic review of the 
literature has found no high quality evidence either for or against the use of H1-
antihistamines in anaphylaxis; therefore randomized controlled trials are needed (Sheikh et 
al., 2007). These agents do not prevent or reverse life-threatening upper and lower 
respiratory tract obstruction, hypotension or shock (Simons et al., 2009a), but they relieve 
itching, flushing, urticaria, angioedema and nasal and eye symptoms (Simons, 2009b; 
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Simons et al., 2011). As a second line medication, for example diphenhydramine 1 mg/kg, 
approximately 25-50 mg in adults, maximum 50 mg in children is recommended by slow 
intravenous infusion over 10-15 minutes. The route of administration depends on the 
severity of the attack. Only the first generation H1-antihistamines are available for 
intravenous use and they potentially increase vasodilation and hypotension if given rapidly 
(Simons et al., 2011). H2-antihistamines in combination with H1-antihistamines are 
sometimes used for anaphylaxis treatment in the US and Canada (Lieberman et al., 2010; 
Simons et al., 2011). When an oral H1-antihistamine is indicated, a low sedating medication 
such as cetirizine is preferable to a sedating H1-antihistamine (Simons et al., 2011). 
Glucagon is preferred in patients who are already using β- blockers therefore experiencing a 
relative bradycardia and refractory hypotension and are not fully responding to epinephrine 
(Gallagher et al., 2011; Thomas & Crawford, 2005). It shows its effects independent of β-
receptors by directly activating adenyl cyclase. The recommended dose is 1 to 5 mg in adults 
and 20-30 µg/kg (maximum of 1 mg) administered intravenously over 5 min as a bolus. The 
bolus dose can be repeated or followed by an infusion of 5-15µg/min, titrated to clinical 
response (Lieberman et al., 2010). The common side effect is emesis, particularly related 
with rapid infusion and therefore protection of the airways to prevent aspiration in severely 
drowsy patients is important (Lee & Vadas, 2011; Lieberman et al., 2010). 
A recent Cochrane systematic review concluded that there is insufficient high-quality 
evidence to either support or not to support the use of glucocorticosteroids in the 
management of anaphylaxis (Choo et al., 2010). The existing evidence consists mainly of 
retrospective studies, case reports, and other descriptive literature. The recent WAO 
anaphylaxis guideline recommends glucocorticosteroid use in anaphylaxis management as a 
second line medication. It is used to prevent biphasic or protracted symptoms, although 
there is weak evidence for it (Simons et al., 2011). It doesn’t provide rapid relief of upper or 
lower airway obstruction, shock, or other symptoms of anaphylaxis (Simons, 2009b). The 
route of administration depends on the severity of the attack (Simons et al., 2011). The 
recommended dose of methylprednisolone by WAO anaphylaxis guideline is 1-
2mg/kg/day, approximately 50-100 mg or equivalent for 3-4 days in adults, at a maximum 
dose of 50 mg in children (Lee & Vadas, 2011; Simons et al., 2011). Other guidelines 
recommend hydrocortisone, triamcinolone, prednisone by intravenous, intramuscular, or 
oral routes using different doses and dose regimens (Soar, 2005, Brown et al., 2006, Alrasbi 
& Sheikh, 2007, Muraro et al., 2007, as cited in Choo et al., 2010). Short term glucocorticoid 
treatment is seldom associated with adverse effects (Choo et al., 2010). 
Additionally short and rapid acting β2-adrenergic agonist, salbutamol is recommended in 
nebulised form in doses of 2.5 mg/3 mL in children or 5 mg/3 mL in adults to treat 
bronchoconstriction with combination of oxygen supplementation (Simons et al., 2011). 
Tremor, tachycardia dizziness are potential side effects in usual doses, where as headache, 
hypokalemia, vasodilation can be seen in overdoses (Simons et al., 2011). Vasopressors such 
as dopamine can be used to correct hypotension despite other interventions.  
It should be pointed out that the time taken by draw up and administration of a second-line 
medication such as H1- antihistamines, corticosteroids, β2-adrenergic agonists should not 
cause a delay in the administration of the first line treatment of epinephrine, 
supplementation of oxygen or intravenous fluid resuscitation (Simons et al., 2011). 
In refractory anaphylaxis methylene blue is used in a number of case reports. In 
anaphylactic shock endothelial nitric oxide synthase-derived NO appears to be the principal 
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vasodilator. Therefore methylene blue by inhibiting nitric oxide synthesis inhibition blocks 
nitric oxide (NO)-mediated vascular smooth muscle relaxation and seems to be effective in 
these cases (Lieberman et al., 2010). Tranexamic acid was used to treat anaphylactic episodes 
associated with disseminated intravascular coagulation (Lieberman et al., 2010). 
The management of anaphylaxis in pregnancy is similar to the management of non-
pregnant patients. The correct posture of the patient is also important. She has to be placed 
semi recumbent on her left side with the lower extremities elevated, to prevent positional 
hypotension resulting from compression of the inferior vena cava by gravid uterus (Simons 
et al., 2011).  
10. Prevention  
Long-term preventive measures to reduce the risk of fatality of anaphylaxis include 
avoidance of triggers, optimal management of relevant comorbidities such as asthma, 
cardiovascular diseases, mastocytosis and immunomodulation (Simons, 2009b).  
When anaphylaxis has occurred because of exposure to a specific trigger, patients should be 
educated about agents or exposures that would place them at risk for future reactions and 
be counseled on avoidance measures that may be used to reduce risk for such exposures 
(Lieberman et al., 2010). Triggers should be identified with a detailed history, and the 
sensitization to the triggers should be confirmed by using allergen skin tests and/or 
measurement of allergen-specific IgE levels in serum or challenge tests especially for 
therapeutic agents or foods. Optimally the patients can be tested for IgE sensitizations 
approximately 3-4 weeks after an acute anaphylactic episode. The time interval has not been 
definitely identified for most of the allergens, preferably patients with a convincing history 
of anaphylaxis and a negative test result should be retested afterwards. Challenge tests 
should be conducted in an appropriately equipped healthcare setting staffed by trained and 
experienced healthcare professionals as a supervised, graded test in order to diagnose and 
to assess risk of future anaphylactic episodes further. Before a challenge is performed the 
potential risk versus the potential benefit should be discussed with the patient and 
documented in the medical record (Simons et al., 2011).  
Absolute avoidance of triggers such as allergens like latex, foods, or a medication is life 
saving, but as an example lifelong avoidance of a food may disrupt daily life and may lead 
to anxiety or decrease the quality of life of the patients and their families or may lead to 
nutritional deficiencies, especially in children (Simons, 2009b). Additionally avoidance is 
difficult to perform in some situations. For example hidden, substituted, and cross-reacting 
foods, or foods that are contaminated and mislabeling or confusing labels on packaged 
foods are some of the reasons of difficulties in avoidance of triggers. So patients with food 
anaphylaxis should be informed about all of these possibilities, regularly provided 
personalized written instructions for avoidance of the confirmed specific triggers (Simons et 
al., 2011). Biphasic reactions appear to be more common in food-induced anaphylaxis when 
compared to other reasons of anaphylaxis and it is reported in up to 25% of fatal or near 
fatal reactions (Lieberman, 2005, as cited in Lieberman et al., 2010). Although it is rare for 
patients with oral allergy syndrome to develop anaphylaxis, they may be at increased risk. 
Therefore these patients may be prescribed epinephrine auto-injectors (Kleine-Tebbe et al., 
2002, as cited in Lieberman et al., 2010). Another important trigger to which avoidance is 
difficult is the stinging insects. Beekeepers, gardeners, others with occupational exposure 
may find it difficult to follow this advice (Lieberman et al., 2010; Simons et al., 2011). In 
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patients with a history of anaphylaxis triggered by a medication should not be given the 
offending drug, and if available a safe, non-reacting alternative medication should be 
substituted. Patients should be informed about the offending drug, related and cross-
reactive drug with written documents (Simons et al., 2011). During anesthesia patients are 
under drapes and are unconscious, so early cutaneous signs are often unrecognized (Brock-
Utne, 2003). Therefore the staff has to be prepared and ready for unexpected anaphylaxis. 
Patients who experience anaphylaxis during the peri-operative period should be carefully 
evaluated to elucidate the responsible agent and be examined by an allergist prior future 
procedure. In the case of anaphylaxis due to radiocontrast agents, non-ionic radiocontrast 
agents should be considered as alternatives (Lieberman et al., 2010; Simons et al., 2011). 
In exercise-induced anaphylaxis avoidance of relevant co-triggers such as foods, 
medications, cold or hot air exposure, or other concomitant factors should be considered 
(Simons, 2009b). Exercise under ambient conditions of high humidity, extreme heat or cold 
or high pollen counts should be avoided (Simons et al., 2011). These patients should never 
exercise alone, should stop exercise immediately with the first symptom of anaphylaxis, and 
should carry a mobile phone and an epinephrine auto-injector during every exercise 
(Lieberman et al., 2010; Simons et al., 2011).  
In latex induced anaphylaxis avoidance of latex and if relevant, also the avoidance of cross-
reactive fruits, vegetables is extremely important (Lieberman et al., 2010; Simons et al., 
2011). Latex can enter the body through different routes including, mucous membranes, 
contact with the skin, parenteral exposure, and contact with internal organs as in surgery 
and with inhalation of latex powder. Therefore avoidance measures for latex allergy should 
be intensively applied to establish a latex-safe environment for the patients. Both latex-
sensitive healthcare workers and their co-workers should wear non-latex or non-powdered 
gloves and all non-glove latex devices should be replaced by non-latex devices. The most 
important procedures during which latex avoidance should be instituted in latex-sensitive 
patients include surgical procedures, obstetrical or gynecologic examinations or dental care 
(Lieberman et al., 2010). The problem can also manifest itself when latex sensitive patients 
experience anaphylaxis with related foods. These patients should be informed about the 
possible foods known to be cross-reactive latex. For anaphylaxis induced by some 
nonimmune triggers such as cold, heat, sunlight or ethanol, avoidance of the trigger is the 
key to prevention of recurrence (Simons et al., 2011). 
Anaphylaxis due to allergen specific immunotherapy is another important cause of 
anaphylaxis which can be strongly avoided when this treatment is administered by 
healthcare professionals trained in the recognition and treatment of anaphylaxis. In patients 
using β-blockers the beneficial therapeutic effects of epinephrine may be diminished. 
Therefore a cautious attitude should be adopted in patients receiving concomitant β-
blockers and allergen specific immunotherapy (Lieberman et al., 2010).  
Seminal fluid anaphylaxis is a rare condition, which can not be generally prevented with 
antihistamines or intravaginal cromolyn sodium taken as precoital medications, where as 
barrier condoms are successful options for prevention. When these therapies are not 
effective or unacceptable, immunotherapy with seminal plasma fractions can be instituted in 
specialized centers (Lieberman et al., 2010). 
The accompanying medications which can interfere with anaphylaxis and management such 
as β-blockers, angiotensin-converting enzyme inhibitors, NSAIDs, aspirin should be given 
weighing the risks and benefits of each medication (Lee & Vadas, 2011).  
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Oral desensitization to a specific food, subcutaneous anti-IgE injections, Food Allergy 
Herbal Formula-2, a well-characterized Chinese herbal formulation are investigational 
immunomodulator interventions being studied in humans for the prevention of anaphylaxis 
(Simons, 2009b). Desensitization strategies with the offending drug, where an alternative 
drug is not available are safe and effective immunomodulatory approaches particularly in 
patients with anaphylaxis due to β-lactam or other antibiotics, aspirin, or other nonsteroidal 
anti-inflammatory drugs, and chemotherapy agents. This procedure should be conducted by 
trained and experienced healthcare professionals in healthcare settings where all facilities 
for the management of anaphylaxis are available. This method provides protection only 
during the procedure as a temporary state of tolerance (Simons et al., 2011). Where as long-
lasting protection against anaphylaxis can only be achieved with successful allergen specific 
immunotherapy which is mostly seen in subcutaneous venom immunotherapy (Simons, 
2009b). It protects up to 80-90% of adults and 98% of children, in whom it lasts for decades 
(Simons et al., 2011). Latex sublingual immunotherapy has been shown to be an effective 
treatment in double blind placebo controlled studies both in children and adults, but 
according to our experience in the dose incremental phase precautions should be taken 
(Bernardini et al., 2008; Buyukozturk et al. , 2010). 
In patients with frequent recurrent episodes of idiopathic anaphylaxis, empiric use of 
prednisone in a daily dose of 60-100 mg in combination with H1-antihistamines for 1-2 
weeks followed by decreasing alternate day prednisone over 3 months as prophylaxis is 
recommended by the experts and has been demonstrated to reduce the frequency or 
severity of episodes (Lieberman et al., 2010). This treatment is considered in patients 
experiencing 6 or more episodes per year or 2 episodes in 2 months (Lieberman et al., 2010). 
Anti-IgE treatment is also promising (Simons, 2009b; Simons et al., 2011). These patients 
should carry their epinephrine auto-injectors at all times. Pretreatment strategies with 
antihistamines and corticosteroids have been used successfully to prevent anaphylaxis due 
to radiocontrast agents, cold-induced anaphylaxis and fluorescein (Lee & Vadas, 2011; 
Simons, et al., 2011). 
Despite these preventive measures anaphylaxis sometimes recurs. Therefore, those at risk, 
should be prepared to recognize and treat unexpected episodes and be educated. 
Anaphylaxis education should begin before patients are discharged from the emergency 
department or other healthcare facility where the anaphylaxis was treated (Simons et al., 
2011). Patients should be informed about the importance of the reactions that they have 
experienced. For this purpose, patients should carry medical identification prepared as a 
bracelet or a wallet card listing their diagnosis of anaphylaxis, confirmed trigger factors, 
relevant comorbidities, and concurrent medications (Simons, 2009b; Simons et al., 2011). 
They should be also advised that they are at increased risk for future episodes of 
anaphylaxis and therefore need follow-up, preferably by an allergy/immunology specialist 
(Simons et al., 2011) and prescribed for epinephrine auto-injectors and have their 
personalized written anaphylaxis emergency action plans (Simons 2009b; Liebermann et al., 
2010). If epinephrine auto-injectors are not available or affordable, a substitute epinephrine 
formulation should be recommended, such as an ampoule of epinephrine, a 1 ml syringe, 
and written instructions about drawing up the correct dose. In emergency action plans, 
patients should be briefly informed about how to recognize anaphylaxis symptoms, 
instructed to inject epinephrine promptly and then admit to emergency to seek medical 
assistance (Simons et al., 2011).  
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2011). Patients should be informed about the importance of the reactions that they have 
experienced. For this purpose, patients should carry medical identification prepared as a 
bracelet or a wallet card listing their diagnosis of anaphylaxis, confirmed trigger factors, 
relevant comorbidities, and concurrent medications (Simons, 2009b; Simons et al., 2011). 
They should be also advised that they are at increased risk for future episodes of 
anaphylaxis and therefore need follow-up, preferably by an allergy/immunology specialist 
(Simons et al., 2011) and prescribed for epinephrine auto-injectors and have their 
personalized written anaphylaxis emergency action plans (Simons 2009b; Liebermann et al., 
2010). If epinephrine auto-injectors are not available or affordable, a substitute epinephrine 
formulation should be recommended, such as an ampoule of epinephrine, a 1 ml syringe, 
and written instructions about drawing up the correct dose. In emergency action plans, 
patients should be briefly informed about how to recognize anaphylaxis symptoms, 
instructed to inject epinephrine promptly and then admit to emergency to seek medical 
assistance (Simons et al., 2011).  
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Delayed injection or non-injection of epinephrine has been shown to be a risk factor for 
severe and biphasic reactions and fatal outcome (Gallagher et al., 2011; Lee & Vadas, 2011; 
Simons et al., 2010). Therefore patients are commonly prescribed at least two auto-injector 
devices for the administration of epinephrine in the community settings for this sudden, 
rapid, and usually unexpected clinical situation (Gallagher et al., 2011; Kemp et al., 2007). 
There is clear consensus in the research literature that these auto-injectors are under-used by 
patients of all-ages (Gallagher et al., 2011; Simons, 2009b, Simons et al., 2011). A recent paper 
suggested that auto-injector under-use is commonly due to patients preferring to take other 
medications most commonly antihistamines, not having auto-injector prescriptions, lack of 
severity of previous episodes or spontaneous recovery from previous episodes (Simons et 
al., 2009a). A recent study demonstrated that in addition to demonstrating injection 
technique, several other points must also be elucidated to the patients (Gallagher et al., 
2011). They should be informed that auto-injectors should be used swiftly rather than 
waiting. They should be trained in recognizing anaphylaxis, taking into account the wide 
variability of symptoms and the side effects of epinephrine, offering reassurance about its 
safety if used unnecessarily (Gallagher et al., 2011). It should also be pointed out that an 
anaphylactic episode doesn’t possess a predictive value for the severity of future episodes 
because of variable target organ involvement and the influence of comorbid illness and 
concurrently medications (Simons et al., 2009a).  
The currently available epinephrine auto-injectors have some structural limitations (Frew, 
2010). There are two types of delivery systems either as cartridge-based or a syringe delivery 
system used in the currently available auto-injectors (Frew, 2010). Evidence suggests there 
are several clear advantages of auto-injectors that utilize a cartridge system compared with a 
syringe system, but they are found in only 2 fixed doses as 0.15 mg which may be too high 
for infants and young children weighing less than 15 kg and 0.3 mg which can be a low dose 
for some children and adults, especially those who are overweight or obese (Frew, 2010; 
Simons, 2009b). Additionally the needle is 1.43 cm, not allowing optimal intramuscular 
injection in especially obese patients. New compact, lightweight, auto-injectors providing a 
0.5 mg dose per injection, with a needle length of 2.54 cm are being designed and 
noninjectable epinephrine preparations for sublingual or transdermal administrations are 
also in development (Frew, 2010; Simons, 2009b). 
The reasons for lack of response to epinephrine can be summarized as the error in the 
diagnosis, the wrong position of the patient after the injection, the rapid progression of 
anaphylaxis, the presence of a beta-adrenergic blocker or interfering drugs in the patient’s 
medications, the low dose or the delayed injection of epinephrine, and the suboptimal route 
or injection site (Simons et al., 2011). Therefore the aim of every physician should be to teach 
their patients when and how to inject epinephrine and to educate them about anaphylaxis 
and save their lives. 
11. Conclusion  
Anaphylaxis is a serious acute allergic reaction and has to be recognized with signs and 
symptoms involving various organ systems and treated promptly. To diminish the risk for 
further attacks detailed history has to be taken carefully from the patients including the 
potential triggers or events, the clinical signs and symptoms. Laboratory tests most 
importantly an elevated serum tryptase level sometimes but not always support the 
diagnosis. The trigger has to be removed, if possible and the patient’s circulation, airway, 
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breathing, level of consciousness, and skin should be rapidly assessed. Epinephrine is the 
cornerstone of the treatment. Patients should be kept in the correct position, oxygen and 
fluid supplementation should be given. Antihistamines, corticosteroids, and other agents 
are the second-line treatment agents. Patients should be informed about the potential risk 
for the future attacks and be educated and prepared. For this purpose, patients should carry 
medical identification and be prescribed for epinephrine auto-injectors and have their 
personalized written anaphylaxis emergency action plans. 
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1. Introduction  
Allergic airway inflammation is one characteristic feature of asthma disease, with additional 
pathology including a reversible airway obstruction, airway hyperresponsiveness (AHR), 
infiltration of eosinophils and T-helper type 2 (Th2) cells into the airway submucosa, mucus 
hypersecretion, and airway remodeling (Agrawal & Shao 2010). Allergic airway diseases are 
inflammatory disorders in which aberrant immune regulation occurs and susceptible 
individuals mount allergen specific responses. Inflammatory cells are recruited to the 
asthmatic airways or are activated in situ. The inflammatory cells include mast cells, 
macrophages, eosinophils, T lymphocytes, dendritic cells, basophils, neutrophils, and 
platelets (Barnes et al. 1998). Structural cells may also be important sources of inflammatory 
mediators in asthma. Airway epithelial cells, smooth muscle cells, endothelial cells, and 
fibroblasts are all capable of synthesizing and releasing inflammatory mediators (Levine, 
1995; Saunders et al. 1997; John et al. 1997). Moreover, these cells may become the major 
source of inflammatory mediators in the airway, which may explain how asthmatic 
inflammation persists even in the absence of activating stimuli. A majority of patients with 
asthma have an atopic, allergic background (Robinson 2000). The prevailing consensus in 
regards to these patients is that the immunological basis of atopic sensitization and allergic 
disease results from inappropriate Th2 cell responses to common environmental proteins 
termed allergens (Robinson 2009). 
Here, we summarize recent findings regarding how immune response and inflammatory 
cells contribute to allergic airway inflammation and discuss recent progress in the regulation 
of these cells. 
2. Immune mechanism 
In general, airway inflammation involves the activation of pathogenic-specific inflammatory 
cells, modulation of transcription factors and release of inflammatory mediators (Barnes et 
al. 1998). Allergic asthma, classified as a type 1 hypersensitivity reaction, involves allergen-
specific immunoglobulins of the IgE class bound to high-affinity Fcε receptors (FceR) on the 
surface of basophils and mast cells present in the subepithelial layer of the airways. Cross-
linking of the receptor initiates a coordinated sequence of biochemical and morphological 
events that results in exocytosis (figure 1) of secretory granules containing histamine or 
other pre-formed inflammatory mediators; synthesis and secretion of newly formed lipid 
mediators, such as prostaglandins and leukotrienes; and synthesis and secretion of 
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In general, airway inflammation involves the activation of pathogenic-specific inflammatory 
cells, modulation of transcription factors and release of inflammatory mediators (Barnes et 
al. 1998). Allergic asthma, classified as a type 1 hypersensitivity reaction, involves allergen-
specific immunoglobulins of the IgE class bound to high-affinity Fcε receptors (FceR) on the 
surface of basophils and mast cells present in the subepithelial layer of the airways. Cross-
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mediators, such as prostaglandins and leukotrienes; and synthesis and secretion of 
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cytokines (Will-Karp et al. 1999). Many mediators are released in asthma, and it is clear that 
these mediators interact with each other in some way. Mediators may act synergistically to 
enhance each other’s effects, or one mediator may modify the release or action of another 
mediator. Although the involved signaling pathways have been extensively studied, the 
precise sequence of events is still not well understood (Turner et al. 1999; Kim et al. 1997; 
Ali., et al. 2001; Ching et al., 2001; Siraganian 2003; Galli et al. 2008; Kim et al. 2008; Saini et 
al. 2009; Moran et al. 2010a,b; Colgan & Hankel 2010). The inflammatory mediators are 
capable of contracting airway smooth muscle cells, inducing edema and mucus secretion, 
which leads to narrowed, constricted airways. Furthermore, locally produced chemokines 



































Fig. 1. Products of Mast Cells. PGD2, prostaglandin D2; LTC4, leukotriene C4; PAF, platelet-
activating factor; FGP, fibroblast growth factor; VEGF, vascular endothelial growth factor, 
MIP; macrophage inflammatory protein; RANTES, regulated on activation, normal T-cell 
expressed and secreted MCP-1, monocyte chemotactic protein-1. 
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2.1 Role of T cells in airways allergy disease 
T cells play an important role in the modulation of the immune response and are critical 
during allergy airway pathogenesis. Since 1986, the Th1/Th2 paradigm has dominated the 
understanding of the pathophysiology of asthma and allergic disease (Akbari et al. 2003). It 
is generally accepted that allergic respiratory disease in adults is associated with active T-
cell immune responses to inhaled allergens that are skewed toward the Th2 phenotype, 
which is in contrast to a Th1-skewed immunity in healthy individuals (Agrawal and Shao 
2010). Experimental animals model have been useful in the immunological delineation of 
the role of T cells and T cell-derived cytokines in the pathogenesis of airway allergy disease. 
In these animal models, sensitization with various allergens, such as ovalbumin, house dust 
mite, and aspergillus, induce a phenotype closely resembling that observed in human 
asthma (Hausding et al. 2008; Humar et al. 2008; Allen 2009; Bates et al. 2009; Qarcoo et al. 
2009; Moran & Folch 2011).  
Th2-associated cytokines such as IL-4 are important in driving IgE production to allergens 
and are essential in the initiation of an allergic airway response (Coyle et al. 1995). IL-5 
contributes to the development, recruitment and activation of eosinophils at the site of the 
Th2 inflammatory response, which characterizes allergic disease. IL-9 is an important 
regulator of mast-cell activation.  Studies suggest that IL-13 has an important role in the 
effector phase of the allergy response, specifically airway inflammation, bronchial 
hyperresponsiveness and mucus cell hypersecretion (Wills-Karps et al. 1998; Wills-Karps et 
al. 1999 ). The involvement of each the specific Th2 cytokines in atopic airway response has 
been demonstrated in studies in which IL-4, IL-5, IL-9 and IL-13 have been manipulated 
through either antibody blockade (Kung et al. 1995; Gavet et al. 1997) or gene targeting 
(Brusselle et al. 1995; Foster et al. 1996; Spergel et al. 1999). Additionally, IL-21 has been 
shown to be important in the development of Th2 immune response (Frohlich et al. 2007). 
Frohlich and colleagues (2007) suggest that although the mechanisms by which IL-21 
regulates allergy inflammation are unknown, IL-21 may be important for Th2-cell survival 
or migration to peripheral tissues. On the other hand, Th1 cells are also pro-inflammatory, 
and the development of a Th1-associated inflammatory response can exacerbate asthma and 
allergic disease. IFN-γ is often present at sites of allergic inflammation and is thought to 
contribute to the disease. Th1 cells cross-regulate Th2 cells in some systems, and it was 
thought that Th1 cells downmodulated the effects of Th2 cells. However, recent advances in 
immunology have raised the possibility that other mechanisms may drive or co-exist with 
pathology in some patients with Th2-type allergy airway inflammation. New effector T-cell 
lineages have recently been identified. Th17 cells, which differentiate from naïve CD4+ T 
cells under the influence of IL-6/IL-21/IL-23 and transforming growth factor (TGF)-β via 
the signal transducer and activator of transcription 3 (STAT3)-RORγt pathway, are mainly 
responsible for neutrophilia in allergic severe asthma (Louten et al. 2009). Moreover, a 
variety of cytokines derived from epithelium, fibroblasts and other airway structural cells 
have recently been shown to have an important potential for interaction with Th1, Th2, 
Th17, eosinophil and mast cells.  These cytokines include the following: proinflammatory 
cytokines [IL-1β, IL-6, IL-11, tumor necrosis factor (TNF)-α, and granulocyte/macrophage 
colony–stimulating factor (GMCSF)], which are involved in innate host defense; anti-
inflammatory cytokines [IL-10, IFN-γ, IL-12, and IL-18]; growth factors [platelet derived 
growth factor (PDGF), TGF-β, fibroblast growth factor (FGF), and epidermal growth factor 
(EGF)]; and chemotactic cytokines or chemokines [RANTES, monocyte chemoattractant 
protein (MCP)-1–MCP-5, eotaxin, and IL-8] (Hamid and Tulic 2009). 
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Conversely, investigations into the contribution of cytotoxic CD8+ T cells towards the 
development of allergic airway inflammation are not well understood. The depletion of 
CD8+ T cells does not affect airway response to allergen challenge in mice (Gonzalo et al. 
1996).  However, a subset of CD8+ T cells, named Tc2 cells, can produce Th2 cytokines such 
as IL-4, IL-5, and IL-13, which are increased in the bronchoalveolar lavage fluids (BALF) of 
allergic asthmatic patients in studies. This rise of cytokine production suggests that the 
immune responses to virus infections are characterized by an increase in the frequency of 
type 2 cytokine-producing T cells when they take place in an allergic environment in animal 
models (Coyle et al. 1995; Makela et al. 2003). Human studies show that CD8+ T cells from 
both normal and asthmatic subjects have the capacity to produce type 2 cytokines (Stanciu 
et al. 1996; Stanciu et al. 1997). In addition, the stimulation of CD8+ T cells from normal, 
healthy subjects in an IL-4 rich milieu significantly increased the number of IL-5-positive 
CD8+ T cells (Stanciu et al. 2001). Additionally, studies suggest that during a respiratory 
virus infection activated CD8+ T cells from asthmatic subjects may produce excess type 2 
cytokines and may contribute to asthma exacerbation by augmenting allergic inflammation 
(Stanciu et al. 2005). These studies thus demonstrate that the frequency of airway CD8+ T 
cells producing type 2 cytokines are as great as those of airway CD4+ T cells are and that 
both are increased in asthma and are related to disease severity (Cho et al. 2005).  
2.1.1 Transcription factors responsible for the Th1/Th2/Th17 cells and inflammatory 
mediators 
Transcription factors are DNA-binding proteins that regulate the expression of inflammatory 
genes, including enzymes involved in the synthesis of inflammatory mediators as well as 
protein and peptide mediators (Barnes et al. 1998). Inflammation associated with 
hypersensitivity results from an exaggerated expression of inflammatory genes, and a number 
of researchers have explored the mechanisms implicated in inflammatory gene induction 
(Barnes and Karin, 1997; Barnes and Adcock, 1998). Many transcription factors are cell-specific 
and are crucial in cell differentiation and the regulation of specific cellular processes such as 
proliferation, enzymes, and cytokine expression. In animal models of airway diseases, such as 
atopic asthma, nuclear factor NF-(kB), activator protein-1 (AP-1), GATA-3, JunB and c-Maf 
play a central role in the control of airway inflammation (Finotto et al. 2001; Nguyen et al. 
2003; Yamashita et al. 2007). In humans, there is evidence that NF-kB, AP-1 and GATA-3 
expression is increased in asthmatic airways (Hart et al., 1998; Taha et al. 2003). Furthermore, 
these transcription factors are key downstream regulators of Th1/Th2/Th17 cytokine function 
and are phosphorylated/dephosphorylated in the asthmatic airway (Pernis and Rothman, 
2002). The Th1 master regulator, T-box transcription factor (T-bet), is extensively expressed 
in polarized Th1 cells, and its expression and activity are induced by IL-12 via STAT4 or by 
IFN-γ via STAT1.  IL-4 drives differentiation of IL-4-producing Th2 cells through STAT6, 
which is necessary and sufficient for the induction of the Th2 master regulator, GATA-3. 
Moreover, transcription factor c-Maf is selectively expressed in Th2 cells as a downstream 
effector of the IL-4/IL-4R/STAT6 signal transduction pathway, primarily regulating IL-4 
expression in Th2 cells (Agrawal & Shao 2010). 
2.1.2 Role of regulatory T cells in allergy airway diseases 
As mentioned previously, allergic airway diseases show complex genetic associations and 
have a hereditary component (Cookson & Moffat 2004). However, the rapid and 
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geographically localized nature of the increase in the incidence of allergic diseases indicates 
compounding effects of recent changes in environment and lifestyle in the Western world. 
How these factors impact disease by promoting immune responses to allergens is a subject 
of considerable debate, which has led to the “hygiene hypothesis” (Wills-Karp et al. 2001; 
Liu & Murphy 2003). According to the theory, in its simplest iteration, the increase in 
hygienic living conditions and in the use of antibiotic and sterile food preparations resulted 
in the separation of the immune system from positive microbial exposure early in life 
(Martinez and Holt, 1999). The immunoregulatory mechanisms remain underdeveloped, 
and an imbalance in immune homeostasis predisposes to the development of T helper type 
2-biased immune responses and, consequently, allergic disease (Feleszko et al. 2005). 
Recent studies indicate that Th2 responses that are characteristic of allergic manifestations 
can be regulated by naturally occurring CD4+CD25+ regulatory T (nTreg) cells. These cells 
are a functionally mature T-cell subpopulation, which play key roles in the maintenance of 
immunologic self-tolerance and negative control of a variety of physiological and 
pathological immune responses (Sakagushi et al. 2006). They also constitutively express 
transcription factor forkhead box P3 (FoxP3), which prevents the deviation of Tregs into 
effector T cells (Burchill et al. 2007). These cells originate in the thymus, but inducible Treg 
(iTreg) cells, which have similar properties and characteristics, can also be induced in the 
periphery. Regulatory T cells appear to control the development of autoimmune disease and 
transplant rejection and may play a critical role in controlling asthma and allergy (Akdis et 
al. 2005).  Several studies indicate that the function of naturally occurring Treg cells is 
impaired or altered in patients with allergies compared with normal healthy individuals. 
The adoptive transfer of antigen-specific CD4+CD25+ T-regs attenuates acute allergic 
airway inflammation, AHR, and airway remodeling. The capacity of Treg cells to inhibit the 
proliferation of naive T cells in vitro requires cell–cell contact (induction of an inhibitory 
signals on CD4+ and CD8+ T cells); however, in vivo, these cells can also function through 
induction of inhibitory cytokines (such as TGF-β and IL-10) and inhibition of antigen-
presenting capacity (Zheng et al. 2006; Kearly et al. 2008). These data suggest that one 
potential treatment option would be to enhance CD4+CD25+ Tregs in addition to targeting 
decreased Th2 populations. An example of this therapeutic strategy would be allergen 
desensitization immunotherapy, which has been in use for almost a century and is one of 
the few specific immunomodulatory treatments that are commonly used for allergic asthma 
(Akbari et al. 2003; Kearly et al. 2008). Understanding the immune mechanisms that underlie 
successful allergen immunotherapy offers the potential to improve current allergen-
immunotherapy regimens. Some authors suggest that this therapy might function, at least in 
part, to promote the generation of IL-10 and TGF-β-secreting regulatory T cells 
(Hawrylowicz & Garra 2005; Shevach et al. 2008). 
3. Apoptosis regulation in allergy airway disease 
Apoptosis is defined as a genetic program that eliminates unneeded, senescent, or damaged 
cells (Thompson 1995). Moreover, apoptosis is an important regulatory mechanism in the 
selection and containment of an immunocompetent T cell population, in T cell development 
and during immune responses. Dysregulation of apoptosis has been implicated in a range of 
diseases including tumors, neurodegenerative disorders, autoimmunity (Cohen 1999) and, 
perhaps, allergic asthma (Vignola et al. 1999; Woolley et al. 1996). Studies in human patients 
have demonstrated that reduced T cell apoptosis plays an important role in the pathogenesis 
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of allergic bronchial asthma (Cormican et al. 2001; Vignola et al. 1999; De Rose et al. 2004). 
These findings are also consistent in murine models of asthma (Jayaraman et al. 1999; Tong 
et al. 2006; Finotto et al. 2007). In addition, increasing lines of evidence suggest that changes 
in programmed cell death mechanisms in both mobile and resident cells of the airway may 
directly contribute to the development and clinical severity of allergy airway inflammation 
(Vignola et al. 2000). 
Apoptosis has emerged as a major mechanism in the clearance of activated T cells during 
the resolution of an inflammatory response (Akbar and Salmon 1997). Inadequate T cell 
apoptosis in asthma patients appears to interfere with normal T cell elimination, resulting in 
T cell accumulation, which contributes to chronic inflammation and may be the major 
underlying cause for tissue damage, remodeling and repair (Müller et al. 2006; Vignola et al. 
2000). Spinozzi et al. (1998) reported that pulmonary T cells isolated from the BALF of atopic 
asthma patients showed hypoexpression of Fas and FasL; this result may explain the low 
frequency of apoptosis in this group of patients. In contrast, horses with acute airway 
allergy have increased apoptosis of airway lymphocytes, which may partially explain the 
rapid resolution of the pathology once the allergen is removed in this allergy model (Moran 
et al. 2011). However, these authors suggest additional studies to examine apoptosis and 
cytokine profiles in other stages of the disease. In addition, basal levels of apoptotic activity 
were significantly lower in BALF lymphocytes from asthmatic subjects compared with 
peripheral blood lymphocytes from the same subjects. These data indicate that airway 
inflammation in asthma is associated with a reduced susceptibility to apoptosis, which may 
lead to enhanced survival of lymphocytes in the bronchial mucosa and prolonged 
inflammation (Müller et al. 2006). Other molecules are involved in the programmed cell 
death process, including members of the Bcl-2 gene family, which are known to inhibit 
apoptosis. Studies have shown that Bcl-2 expression is increased in lymphoid cells obtained 
from the airways of asthmatic patients and that neutralization of IL-10, an important 
inducer of Bcl-2, decreases Bcl-2 expression and apoptosis of cells from the respiratory tract 
of asthmatic patients (Hamzaoui et al. 1999a; Hamzaoui et al. 1999b). 
4. Airway remodeling 
Recently, airway remodeling has become a field of special interest in chronic asthma, 
chronic bronchitis, chronic obstructive pulmonary disease (COPD) and cystic fibrosis 
research as the process that causes patients to become largely resistant to medication and is 
an important factor in the development of irreversible airflow limitation (James et al., 1989; 
Lange et al., 1998; Jeffery et al., 2000; Kranenburg et al., 2002 Wegmann, 2008). In tissues 
from human with these diseases, remodeling changes include goblet cell and mucous gland 
hyperplasia, subepithelial fibrosis, neovascularization, airway smooth muscle (ASM) 
growth as well as increased deposition of extracellular matrix (ECM) proteins such as 
collagens, elastin, laminin, and  proteoglycans around  the smooth muscle and an overall 
thickening of the airway wall (Roche et al 1989; Laitinen et al., 1997; Davies et al., 2003). The 
molecular mechanisms that drive remodeling remain undefined, but many growth factors 
and cytokines, including fibroblast growth factor (FGF)-1, FGF-2, and transforming growth 
factor (TGF)-β1, that are released from  the airway wall have the potential to contribute to 
airway remodeling, revealed by enhanced ASM proliferation and increased ECM protein 
deposition (Parameswaran et al., 2006; Kariyawasam and Robinson 2007).  TGF-β1 is an 
important fibroblast chemotactic factor. Fibroblast numbers have been shown to correlate 
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with TGF-β1 expression. TGF-β1 also induces the differentiation of fibroblasts to 
myofibroblasts (Postlethwaite and Seyer, 1995; Vignola et al., 1997; Thannickal et al., 2003). 
Morover, TGF-β1 and FGF-1 stimulate mRNA expression of collagen I and III in ASM cells, 
suggesting their role in the deposition of extracellular matrix proteins by ASM cells in the 
airways of patients with chronic lung diseases. Furthermore, ECM proteins promote the 
survival, proliferation, cytokine synthesis, migration, and contraction of human ASM cells 
contributing to airway wall remodeling (Parameswaran et al., 2006) 
5. Conclusion  
Asthma allergy disease is multifactorial, characterized by allergy airway inflammation and 
increased bronchoconstrictory response to nonspecific stimuli. The current body of 
knowledge suggests that the inflammatory component of asthma results from a combination 
of elements from both the innate and adaptive immune responses. Expression of cytokine 
patterns consistent with Th1, Th2 and Th17 cell activation has been identified and 
determined to vary based on the chronic condition of the disease. Activation of transcription 
factors plays a pivotal role in regulating cellular signaling pathways through dynamic 
modulation of cytokines, chemokines, and similar molecules. The regulation of the 
apoptosis of inflammatory cells, fibroblasts, and myocytes through Bcl-2 expression 
contributes to the establishment of chronic disease and remodeling. Tregs seem to play a 
pivotal role in balancing tolerance versus immunologic response to allergens. Therapy with 
immunomodulators that enhance tolerance to allergens and increase Tregs would be most 
effective in the treatment of allergy airway disease.  
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The prevalence of specific sensitization and its clinical relevance for the development of 
allergic diseases and asthma is one of the subjects currently being in the focus of scientific 
studies. In the field of asthma we find additionally several studies of occupational asthma 
with specific sensitization and of treatment efficacy and duration of omalizumab in asthma 
patients with high IgE levels, which will not be discussed in this chapter. Several other 
studies focus on general aspects of sensitization pattern or classification of specific 
sensitization corresponding to type or severity of asthma or globally the development of 
asthma in different populations. Based on a short literature review of such studies we will 
finally present own representative data of our German Health Interview and Examination 
Survey for Children and Adolescents (KiGGS).  
In this presentation we will describe specific IgE levels to several common aeroallergens in 
asthmatic and nonasthmatic children, search for a possible correlation between the number 
of sensitizations and the development of asthma and correlations between age, gender, 
social and migration status and rural or urban residency of the children and their 
sensitization status. Finally we will try to identify high risk mono- and polysensitization for 
asthma and will compare typical combinations of sensitizations in children with and 
without asthma. 
2. Asthma and specific sensitization in the literature 
During the last years the scientific community seemed to feel more and more that asthma is 
a disease showing very different phenotypes with different courses of the disease and 
therapeutic outcomes and a different prognosis. So the disease has been described not only – 
as in former times – as eosinophilic or neutrophilic type asthma or intrinsic, extrinsic and 
mix type asthma but increasingly also as early onset and late onset asthma, childhood and 
adult onset asthma and several special asthma forms are subject of clinical studies as 
exercise induced asthma, seasonal asthma, variant asthma and so on. Together with this 
history also dependencies between specific allergic sensitization and asthma became a target 
of several studies. 
The fact that asthma without any signs of allergy may occur is well known. Additionally, it 
has become clear that being measurably sensitized does not automatically mean to suffer 
from any allergic disease. Ten years ago in a population of nearly 800 school children in 
Italy, using a skin prick test, it was monitored (Crimi et al., 2001) that “about one third of the 
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sensitized children were without symptoms” – meaning symptoms of asthma and/or 
rhinitis. So the question arose, how sensitization or special sensitization patterns may 
influence the development of allergic and atopic diseases like asthma.  
Beforehand endeavour has been made to describe frequency and patterns of sensitization 
itself, for example in a population of more than 700 school children in Germany (Hader et 
al., 1990). 34.4 % of the studied children had been sensitized to one or more of the tested 
aeroallergens, 39.6 % of these monosensitized. The most common sensitization was that to 
grasspollen, followed by birch, than house-dust mite, cat and hazelpollen. Several patterns 
of mono- and polysensitization have been described. 
Nowadays we have a wide overview of demographic distribution of sensitizations and its 
correlation to asthma. As one could expect, “residence of rural area is associated with a 
significant lower prevalence of allergic sensitization” seen in more than 400 school children 
12-16 years old (Majkowska-Wojciechowska et al., 2007) and boys are significantly more 
often than girls sensitized to a wide range of allergens (Soto-Quiros et al., 1998) as they are 
more often affected by asthma. However, in Italy, polysensitization of children living in a 
rural area especially against pollen and mould led to comparable asthma prevalence as 
house dust mite sensitization in those living in urban regions (Verini et al., 2005). We will 
report about the special role of dust mite sensitization in asthma in the course of this review. 
Reviewing studies using skin tests for defining sensitization, it has been clearly shown that 
“aeroallergen sensitization occurs in most patients with asthma” (Craig, 2010). It was 
concluded that in mild to moderate asthma about 95 % of patients show sensitization and in 
severe asthma still up to 90 %. Remembering the fact that up to 5 % of asthma patients show 
a neutrophilic asthma and nearly all of those patients develop a severe form of asthma and 
subtracting those patients from the selected patient groups this may mean that with the 
exception of neutrophilic asthma forms all other patients show a similar high percentage of 
sensitization independant from asthma severity grade. This review also showed that 
sensitization “pattern varies with ethnicity, location of residance, and onset of asthma, but 
not age”. 
The same author described two years earlier in a population of mild-to-moderate athma 
patients 14 % of these showing a sensitization only to 1 or 2 aeroallergens but 81 % showing 
a polysensitization to at least 3 aeroallergens (Craig et al., 2008). He was also able to 
demonstrate a correlation between sensitization and factors characterising asthma as 
exhaled nitric oxide measures as a sign of inflammation activity and lung function values. 
Not only asthma severity grade correlates with sensitization but also the chance of asthma 
remission during childhood. In the data of ISAAC, the internatioal study of asthma and 
allergies in childhood and one of the most important international studies in this field, a 
cohort comparison of 7 - 8 year versus 11 - 12 year old school children showed that the 
“remission of asthma was 10 % yearly and inversely related to allergic sensitization” (Bjerg-
Bäcklund et al., 2006). 
The number of sensitizations against aeroallergens clearly correlates with the risk for 
asthma, as shown in a total of more than 3000 patients aged 10 to 50 years in Spain and 
Portugal (Valero Santiago et al. 2009). 
Very interesting in this relation is the fact that asthma prevalence in children is enhanced by 
very different specific sensitizations. A study in a random population of more than 6000 
children in New South Wales was able to show that high sensitization to house dust mites in 
coastal regions as well as high sensitization to alternaria in other regions correlated 
significantly with higher asthma prevalence compared with regions where sensitization 
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levels are lower (Peat et al., 1995).  Sensitization to house dust mite seems to be one of the 
most common sensitizations linked to asthma over the world, as for example also shown in 
children living in Florida, where 89.6 % of the asthmatic children showed a positive RAST 
result to Dermatophagoides pteronyssinus (Nelson et al., 1996). A similar prevalence was 
seen in Chinese asthmatic children by skin prick testing. 81.9 % showed a positive test to 
house dust mite (Leung et al., 2001). And also in Zimbabwe sensitization in RAST test to 
dust mites was the most common sensitization in atopic children (Kambarami et al., 1999). 
Astonishingly another study in children living in high altitude (7200 feet) “in a mite-free 
environment with low levels of outdoor air pollution” saw a comparably high asthma 
prevalence rate of 6.3 % and high total IgE levels in asthmatic children (Sporik et al. 1995). 
The explanation of this finding was that 77 % of the studied households had a pet (cat or 
dog) and the predominant sensitization in children therefore was a sensitization to cat. That 
sensitization to cat allergen generally is a risk for childhood asthma was confirmed in a 
prospective birth cohort study in Germany (MAS 90), the German Multicenter Allergy 
Study (Lau et al., 2005). 
In summary, indoor allergen sensitization seems to be closer connected to asthma than 
outdoor allergen sensitization. This was confirmed for two different ethnic groups living in 
the same environment of New York City (Rastogi et al. 2006). Similar environment led in 
both groups to similar sensitization and only indoor allergen sensitization was significantly 
associated not only with asthma prevalence but also with its severity. In contrary, different 
environmental circumstances lead not only to different sensitization prevalences and 
patterns, but also to different association levels with and different attributable fractions of 
asthma and other atopic diseases (Rona et al. 2008). 
When the close correlation between childhood asthma and sensitization had become known, 
also efforts had been made to define correlations between adult onset asthma and 
sensitization. The result of a case-control study in Finland including only cases of adult 
onset asthma in patients 21 - 63 years of age was that specific “IgE antibodies to house dust 
mite and storage mite were significantly related to an incresased risk of asthma.” The same 
correlation was found with IgE antibodies to aspergillus fumigatus and cladosporium 
herbarum (Jaakkola et al., 2006). 
Nevertheless, one has to keep in mind sensitization being only one of several possible 
triggers for allergic asthma and these triggers probably showing dependencies among each 
other. An example was shown in children at high atopic risk, where the prevalence of 
asthma was higher for those children having suffered more from severe viral lower 
respiratory tract infections but only when they had also an early sensitization at the age 2 
years or lower (Kusel et al., 2007).  
From another perspective, specific sensitization only enhanced the risk of being asthmatic 
significantly for children with “a positive parental history of asthma or atopy” (Illi et al., 
2001). 
Also – as another example - the socioeconomic status influences sensitization in general, 
indoor sensitization and together with the latter the risk of asthma in the direction that 
sensitization is increased with lower socioeconomic status (Lewis et al., 2001). May 
anyone think sensitization against cockroach and animal to be understandable by social 
differences in residency environment and pet ownership, the significant increase in 
ragweed sensitization also will stay unexplainable by such obvious status dependant 
circumstances. 
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On the other hand, as we know as another result of the ISAAC study, the correlation 
between asthma and sensitization seems to be closer in developed countries with higher 
income (Weinmayr, 2006 2007). 
Looking somewhat deeper into the description of sensitization in asthmatic patients, in 
asthmatic children prevalence rates of sensitization to cat were 40 %, to dog 34 %, to horse 
28 %, to birch 23 % and to timothy 16 % and somewhat different to sensitization shown in 
other atopic diseases like rhinitis or eczema (Rönmark et al., 2003). 
An association between different mono-sensitizations against pollen was seen in Sweden in 
a birth-cohort study with more than 2500 children, where especially birch pollen 
sensitization was closely correlated to allergic symptoms (Ghunaim et al., 2006). 
Already several years ago the knowledge of correlations between sensitization and asthma 
had led to establishing a new asthma classification based on specific IgE antibodies among 
other parameters (Kumura 1994). In our time quite ambitious efforts have been made to 
redefine atopic phenotype and correlate the resultant patterns of sensitization with asthma 
and asthma outcome parameters even in a population-based birth cohort study (Simpson et 
al. 2010). 
3. Asthma and sensitization pattern in a population-based study in German 
children and adolescents 
Having performed the first population-based interview and examination survey in children 
and adolescents in Germany, we will seize the opportunity to look for correlations between 
sensitization and asthma in this population. As we will continue the study, later on we will 
have the chance to look for changes of sensitization in individuals over time and asthma 
development also. 
For now we want to learn something about sensitization prevalence in German children and 
adolescents – as well in those with asthma as in nonasthmatic children – RAST classes of 
indentified sensitizations, demographically based differences in sensitizations and 
correlations of specific sensitizations with asthma. 
3.1 The German health interview and examination survey for children and adolescents 
(KiGGS) 
A total of 17641 children and adolescents from birth up to 17 years of age have been 
included in this survey, being studied in 167 study points throughout Germany between 
May 2003 and May 2006. The survey was composed of questionnaires filled in by the 
parents and parallel by children aged 11 years or older, a computer assisted personal 
interview (CAPI) performed by study physicians and physical examination and (laboratory) 
test parts. 
A publication describing the study design and methods, patient enrollment and 
randomisation, response and representativeness can be found in BMC Public Health (Kurth 
et al., 2008). The response rate was 66.6 % and a non-response analysis based on “key socio-
demographic and health-related characteristics for children and parents” was performed for 
about two thirds of the non-responders. The non-response analysis did not provide an 
indication of relevant differences in four health related variables compared to responders. 
Therefore the survey will provide us with as far as possible representative information 
about the health status of German children and adolescents. 
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3.2 Methods of assessing asthma and defining specific sensitization in KiGGS 
During a Computer-assisted Personal Interview (CAPI) conducted by the studyteam 
physician parents had been asked wether their children ever had had a positive physicians 
diagnosis of asthma. Though the study results presented with some evidence that possibly 
more children suffered from asthma as being told to the parents – seen for example 
analysing the drug anamnesis regarding children having had specific asthma medication on 
prescription base without their parents having reported a physicians diagnosis of asthma as 
allready publicized (Langen & Knopf, 2007) – we think the accuracy of reported physicians 
diagnosis to be more reliable. So we will operate in this analysis with a positive answer to 
the question of physician diagnosed asthma as the decisive indicator for grouping 
participants in asthmatic and nonasthmatic children and adolescents. 
In laboratory blood tests only the blood of children more than 2 years old and adolescents, 
had been tested for specific IgE-antibodies to 20 common allergens including 11 frequent 
inhalative indoor and outdoor allergens. The test system used was the ImmunoCAP® test of 
Phadia. The allergens involved included food allergens and the following groups and 
substances of inhalative allergens: 
House dust mites: Dermatophagoides pteronyssinus and dermatophagoides farinae 
Animal epithelia:  Cat, horse and dog 
Pollen:   Birch, mugwort, rye and timothy grass 
Mould fungi:  Cladosporium herbarum and aspergillus fumigatus 
In summary we will be able to present the data of 12911 children and adolescents from 3 
years to 17 years of age having had a blood test for specific IgE antibodies and having their 
parents had answered the CAPI. 
3.3 Statistical analysis of the KiGGS data 
For this analysis SPSS (Statistical Package of the Social Sciences) Version 17 was used. The 
data have been weighted in the intention to adjust them for deviations between the sample 
group and German population statistics especially regarding “age structure and 
disproportionately higher sample size in Eastern vs. Western Germany” (Kurth, 2008). All 
analyses are based on “complex samples” procedures, so that estimated variations of the 
results became more realistic having in mind the complex sampling procedure of the study 
as in detail described in the above mentioned article. 
3.4 Results and interpretation 
In the entire study population, 4.7 % of the participants had a positive lifetime prevalence of 
asthma. At least one sensitization was identified in 40.8 % of the children aged 3 years or 
older and the adolescents. 
As asthma and sensitization prevalence rise with increasing age, asthma prevalence in our 
population aged 3 years and older is measurably higher as in the entire population from birth 
to age 17. Also the prevalence in sensitization shows differences to the complete study 
population while we only analyzed the above described subgroup of children and adolescents. 
3.4.1 Demographic data 
In Table 1 we show demographic characteristics for asthmatic and nonasthmatic 
participants as well as for those without sensitization, being monosensitized or 
polysensitized. Statistically significant differences are shown in bold numbers. 
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As asthma and sensitization prevalence rise with increasing age, asthma prevalence in our 
population aged 3 years and older is measurably higher as in the entire population from birth 
to age 17. Also the prevalence in sensitization shows differences to the complete study 
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3.4.1 Demographic data 
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 Asthmatic Non-asthmatic Not sensitized Mono-
sensitized 
Polysensitized 
Overall n=12911 5.5 %  
(5.0-6.0  %) 
94.5 % 
(94.0-95.0  %) 
62.8 % 























































































































































































































Table 1. Demographic characteristics of study population 
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We also analysed the population for differences regarding eastern or western region of 
Germany, rural or urban region, prematurity or underweight at birth, pets in household, 
preschool children’s care outside the family (kindergarten etc.), sleeping behaviour, breast 
feeding and smoking behaviour and social status of the family. We have not been able to 
detect any additional statistically significant differences neither concerning asthma nor 
sensitization prevalence. 
What we can clearly perceive is that sensitizations and asthma show a parallel continued 
rise from 3 years of age up to the age group of 11 – 13 years. Especially the 
polysensitizations make a major contribution to the increase in sensitization prevalence, 
whereas the rise in monosensitizations is significant between the agegroup of 3 – 6 and the 
agegroup of 14 – 17 years but numerically quite small.  
Male children and adolescents suffer more often from asthma and sensitizations, both 
mono- and polysensitizations, than female. Such relationship between asthma and sex in 
children is described by the GINA (Global Initiative for Asthma) Report (GINA, 2009), while 
the causes for this difference are pictured as unknown. Nevertheless, the lung size, being 
smaller in male children and larger in male adults is mentioned as a possible reason for the 
different asthma prevalence. The importance of this argument may be supported by our 
data, as sensitizations to inhalative allergens remain more common in male adults than in 
female while asthma prevalence is decreasing. The fact that boys are more often sensitized 
than girls has been described in the literature – as mentioned in the review above – but the 
reasons for this gender based difference remain unclear. 
Very well known in contrary is that children of atopic parents tend to more sensitizations 
and atopic diseases than those of healthy parents as is supported by our data. 
Also living in the northern or southern part of Germany produces a significant difference 
regarding sensitizations. Significantly more study participants living in southern Germany 
suffer from polysensitizations. This finding may be caused by climatic differences as 
Germany borders in the North on the North and the Baltic Sea or by differences in the flora. 
Differences in asthma prevalence show descriptively the converse direction but did not 
reach significance.  
Children belonging to a family with positive migration background show less 
polysensitizations than others, what may be explained by the known sensitization 
differences in differently developed countries with a more or less “westernized” lifestyle. 
Nevertheless, differences in asthma prevalence are barely detectable. 
In the same way fitting into the so called hygiene hypothesis are the data showing children 
without older siblings suffering more from polysensitizations than children with two or 
more older siblings. This can be explained by the children with older siblings having had 
more contact with bacteria during early childhood leading in the maturing immune system 
to a decision more in favour of Th1 lymphocyte answer development which is needed for 
fighting infections than Th2 lymphocytes which contribute to allergic diseases. 
Nevertheless, the difference in asthma prevalence was not able to reach statistical 
significance although descriptively the correlation was similar. 
3.4.2 Asthma and specific sensitizations to inhalative allergens 
We have been able to scan the blood of nearly 13000 children and adolescents for specific 
IgE levels to certain common inhalative allergens. IgE is not detectable beneath a margin of 
0.35 kU/l with the method used in this study and children not showing detectable IgE levels 
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are defined as not sensitized as it is common in sensitization analyses. Also common 
understanding is to value a result between 0.35 and 0.69 kU/l as marginally positive and all 
results 0.7 or higher as positive. A clear correlation between the level of sensitization and 
clinical severity of symptoms has not been described. 
Table 2 presents the results for the IgE levels in nonasthmatic and asthmatic study 
participants. It clearly shows up that sensitization prevalence for each single inhalative 
allergen shows statistically significant differences between the two groups. For better 
readability, variation has not been presented in the table. Significantly different prevalence 
rates between asthmatic and nonasthmatic subjects are presented in bold letters. 
Additionally detectable is the fact that with the exemption of house dust mites and rye all 
other allergens show significantly different prevalence also regarding the lowest class 
between 0.35 and 0.69 kU/l. Our interpretation is that the relevance of such “marginally” 
positive results may be higher than estimated up to now. 
Though we already knew that sensitization does not have to present automatically with 
clinical symptoms it remains interesting that we found also subjects sensitized with IgE 





































































































































































































Table 2. Specific IgE to several inhalative allergens in asthmatic and nonasthmatic subjects 
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Nevertheless, the most subjects showing very high IgE levels equal or higher than 50 kU/l 
also suffered from asthma. Nearly 20 % of the asthmatic children and adolescents showed 
sensitizations to house dust mite in these both classes. 
3.4.3 Number of sensitizations and asthma 
When we saw the clear correlation between sensitizations to each of the tested inhalative 
allergens and asthma, the question arose, whether the development of asthma may also 
show a correlation with the number of sensitizations persons have developed during their 
life. 
Figure 1 presents the correlation between asthma and the number of sensitizations we found 
in our study. We see that there seems to be a quite clear exponential relationship between 
the mentioned circumstances. 
Only 2.1 % of the study participants without any sensitization suffered from asthma 
whereas 49.8 % of the participants showing sensitizations to each of the tested 11 inhalative 
allergens also have had an asthma anamnesis. 
For those children and adolescents suffering from asthma but not showing sensitization to 
any of the inhalative allergens we made an additional analyses with the intention to 
indentify possible sensitizations to food allergens (egg white, milk protein, rice flour, 
peanut, soybean, carrot, potato, wheat flour or green apple) but were not able to find any 
correlation. Only a few single cases showed sensitizations to egg, milk or peanut, all other 
test results where negative. 
 
 
Fig. 1. Number of sensitizations to inhalative allergens and asthma 
We also performed the same analyses for different age groups, sex, migration and social 
status as well as groups living in rural or urban regions of Germany. In each case we have 
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a positive correlation between the number of sensitizations and asthma. Additionally those 
curves are located very closely together so that the shown relationship seems to be 
somewhat like a constitutional or natural correlation. 
3.4.4 Course of sensitizations with increasing age 
With increasing age the prevalence of sensitizations is rising as well in children with as in 
those without asthma but in the former the rise starts on much higher values. 
Table 3 shows in bold numbers statistically significant increases (those will be marked in all 
other tables in the same manner) of specific sensitizations with age in comparison with the 
youngest group or the last group having displayed significant differences already. 
Variations are presented, those in asthmatic children being much wider than the others as 
this group is much smaller as that of nonasthmatic children. 
The first fact to detect is that in each case with only one exemption sensitization prevalence 
in asthmatic participants is statistically significant higher than that in nonasthmatic 
participants. Only in the age group 3 - 6 years sensitization to cladosporium herbarum does 
not reach significance between those two groups and this circumstance is explainable by the 
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2.4 % (1.9-3.1) 
14.6 % (10.5-20.0) 
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Another fact we have to notice is the high prevalence of sensitizations in asthmatic 
children of very young age (3 – 6 years) to dermatophagoides pteronyssinus, 
dermatophagoides farinae, rye and timothy. The prevalence lies between more than 30 up 
to nearly 43 %. For the same allergens we see in the highest age group nearly two thirds of 
the asthmatic adolescents being sensitized. These findings support what was referred in 
the literature review – the most important role of house dust mite sensitization in asthma 
development.  
A much minor role play sensitizations to moulds as shown in sensitizations to cladosporium 
herbarum and aspergillus fumigatus. The prevalence of sensitizations to pets and the not 
already mentioned pollen varies in between those described groups. 
Sensitization rates in asthmatic children and adolescents rise significantly over time for each 
allergen with two exemptions: sensitizations to horse epithelia do not reach statistical 
significance although descriptively the rise seems quite clear, probably explained by the 
high variation of these results and the same holds true for sensitizations to aspergillus 
fumigatus where numbers may have become too small for showing significance in this 
somewhat less steep increase of sensitizations over time. 
In nonasthmatic children as well as in asthmatic children we find the highest prevalence rate 
of sensitizations in the highest age group to the same allergens, both house dust mites, rye 
and timothy. So, from this point of view the kind of sensitization does not seem to influence 
the development of asthma in contrary to the number of sensitizations and – to some extent 
- the specific IgE level.  
In the group of nonasthmatic children, increase over time did reach statistical significance 
for each tested inhalative allergen. 
3.4.5 Demographic differences in sensitizations to inhalative allergens 
Having learned boys to suffer more often from asthma as girls (in our study 5.5 % of the 
male children and adolescents have ever had a physician diagnosed asthma versus 3.9   of 
the female) and to be more often sensitized, as shown in table 1, we wanted to know 
whether sensitizations in boys and girls occur to different allergens. 
The results are shown in table 4. All statistically significant differences between boys and 
girls did show up only in the group of nonasthmatic children and adolescents. Here we see 
differences in favour for the girls being less often sensitized for both house dust mites, cat 
and dog (but not horse), and all tested pollen but not to moulds. 
Regarding the tested moulds, even here boys are descriptively more often sensitized but 
numbers all together are very small. Looking to the result for sensitization to horse epithelia 
girls are nearly as often sensitized as boys. This does not seem to be remarkable as horse 
riding in Germany has to be reckoned as a typical girl’s hobby and only a small number of 
boys have horse contacts. So the greater sensitivity of boys for developing sensitizations 
seems to be counteracted by girls dealing more often with horses. 
Again, the group of asthmatic children is clearly too small for differences in sensitizations 
between boys and girls becoming significant. With the exemption of horse epithelia 
sensitization, to all other allergens boys are descriptively more often sensitized than girls.  
As mentioned above, with the development of polysensitization, the risk for asthma is 
increasing exponentially for boys and girls as well. Unfortunately not identifiable in the data 
is a sensitization pattern difference between boys and girls which could have explained the 
higher asthma prevalence in boys. 
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a positive correlation between the number of sensitizations and asthma. Additionally those 
curves are located very closely together so that the shown relationship seems to be 
somewhat like a constitutional or natural correlation. 
3.4.4 Course of sensitizations with increasing age 
With increasing age the prevalence of sensitizations is rising as well in children with as in 
those without asthma but in the former the rise starts on much higher values. 
Table 3 shows in bold numbers statistically significant increases (those will be marked in all 
other tables in the same manner) of specific sensitizations with age in comparison with the 
youngest group or the last group having displayed significant differences already. 
Variations are presented, those in asthmatic children being much wider than the others as 
this group is much smaller as that of nonasthmatic children. 
The first fact to detect is that in each case with only one exemption sensitization prevalence 
in asthmatic participants is statistically significant higher than that in nonasthmatic 
participants. Only in the age group 3 - 6 years sensitization to cladosporium herbarum does 
not reach significance between those two groups and this circumstance is explainable by the 
















10.7 % (9.3-12.2) 





26.2 % (24.4-28.0) 
65.4 % (58.5-71.7) 
Derm. 
farinae 
10.7 % (9.4-12.1) 





25.5 % (23.8-27.3) 
64.0 % (56.8-70.5) 
Cat 
 
3.1 % (2.5-3.8) 
16.9 % (9.6-28.1) 
6.7 % (5.8-7.6) 
30.7 % (24.0-38.2)
7.3 % (6.0-8.8) 
38.8 % (31.4-46.7)
9.4 % (8.4-10.5) 
34.6 % (28.0-41.9) 
Horse 
 
1.4 % (1.0-1.9) 
15.4 % (8.5-26.1) 
3.1 % (2.5-3.8) 
20.8 % (14.4-29.0)
4.1 % (3.1-5.4) 
24.4 % (18.1-32.0)
4.3 % (3.7-5.1) 
28.9 % (22.9-35.7) 
Dog 
 
3.1 % (2.5-3.9) 
23.5 % (15.2-34.6) 
7.5 % (6.6-8.6) 
31.1 % (23.4-40.0)
9.2 % (7.8-10.8) 
45.4 % (37.4-53.6)
11.3 %(10.2-12.4) 
48.4 % (41.1-55.7) 
Birch 
 
6.2 % (5.3-7.2) 





16.5 % (14.9-18.1) 
46.0 % (39.2-52.9) 
Mugwort 
 
3.4 % (2.7-4.3) 
12.6 % (6.4-23.4) 




13.1 % (11.7-14.7) 
36.6 % (30.5-43.1) 
Rye 
 
9.5 % (8.2-11.0) 





24.0 % (22.1-26.1) 
62.2 % (54.5-69.3) 
Timothy 
 
11.3 % (9.9-12.9) 





25.5 % (23.7-27.6) 
65.0 % (57.4-72.0) 
Cladosporium 
herbarum 
0.7 % (0.4-1.1) 
2.4 % (0.7-7.8) 
1.3 % (1.0-1.8) 
6.3 % (3.3-12.0) 
1.2 % (0.8-1.7) 
11.9 % (7.7-18.0) 
1.8 % (1.3-2.4) 
13.1 % (9.1-18.7) 
Aspergillus 
fumigatus 
0.8 % (0.6-1.3) 
6.3 % (2.5-15.1) 
1.6 % (1.2-2.1) 
9.0 % (5.3-14.9) 
1.8 % (1.4-2.4) 
17.3 % (12.0-24.3)
2.4 % (1.9-3.1) 
14.6 % (10.5-20.0) 
Table 3. Percentage of nonasthmatic and asthmatic participants of different age being 
specifically sensitized  
 
Asthma and Sensitization Pattern in Children 
 
219 
Another fact we have to notice is the high prevalence of sensitizations in asthmatic 
children of very young age (3 – 6 years) to dermatophagoides pteronyssinus, 
dermatophagoides farinae, rye and timothy. The prevalence lies between more than 30 up 
to nearly 43 %. For the same allergens we see in the highest age group nearly two thirds of 
the asthmatic adolescents being sensitized. These findings support what was referred in 
the literature review – the most important role of house dust mite sensitization in asthma 
development.  
A much minor role play sensitizations to moulds as shown in sensitizations to cladosporium 
herbarum and aspergillus fumigatus. The prevalence of sensitizations to pets and the not 
already mentioned pollen varies in between those described groups. 
Sensitization rates in asthmatic children and adolescents rise significantly over time for each 
allergen with two exemptions: sensitizations to horse epithelia do not reach statistical 
significance although descriptively the rise seems quite clear, probably explained by the 
high variation of these results and the same holds true for sensitizations to aspergillus 
fumigatus where numbers may have become too small for showing significance in this 
somewhat less steep increase of sensitizations over time. 
In nonasthmatic children as well as in asthmatic children we find the highest prevalence rate 
of sensitizations in the highest age group to the same allergens, both house dust mites, rye 
and timothy. So, from this point of view the kind of sensitization does not seem to influence 
the development of asthma in contrary to the number of sensitizations and – to some extent 
- the specific IgE level.  
In the group of nonasthmatic children, increase over time did reach statistical significance 
for each tested inhalative allergen. 
3.4.5 Demographic differences in sensitizations to inhalative allergens 
Having learned boys to suffer more often from asthma as girls (in our study 5.5 % of the 
male children and adolescents have ever had a physician diagnosed asthma versus 3.9   of 
the female) and to be more often sensitized, as shown in table 1, we wanted to know 
whether sensitizations in boys and girls occur to different allergens. 
The results are shown in table 4. All statistically significant differences between boys and 
girls did show up only in the group of nonasthmatic children and adolescents. Here we see 
differences in favour for the girls being less often sensitized for both house dust mites, cat 
and dog (but not horse), and all tested pollen but not to moulds. 
Regarding the tested moulds, even here boys are descriptively more often sensitized but 
numbers all together are very small. Looking to the result for sensitization to horse epithelia 
girls are nearly as often sensitized as boys. This does not seem to be remarkable as horse 
riding in Germany has to be reckoned as a typical girl’s hobby and only a small number of 
boys have horse contacts. So the greater sensitivity of boys for developing sensitizations 
seems to be counteracted by girls dealing more often with horses. 
Again, the group of asthmatic children is clearly too small for differences in sensitizations 
between boys and girls becoming significant. With the exemption of horse epithelia 
sensitization, to all other allergens boys are descriptively more often sensitized than girls.  
As mentioned above, with the development of polysensitization, the risk for asthma is 
increasing exponentially for boys and girls as well. Unfortunately not identifiable in the data 
is a sensitization pattern difference between boys and girls which could have explained the 
higher asthma prevalence in boys. 
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17.4 % (16.0-18.8) 
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Cladosporium herbarum 1.6 % (1.3-2.0) 
11.3 % (8.1-15.5) 
1.0 % (0.7-1.3) 
8.5 % (5.4-13.3) 
Aspergillus fumigatus 2.4 % (2.0-3.0) 
15.4 % (11.8-19.9) 
1.0 % (0.8-1.4) 
10.2 % (6.7-15.1) 
Table 4. Percentage of participants sensitized to inhalative allergens by sex 
Regarding the social status of the families our participants live with, not many significant 
differences in sensitization status can be observed, as shown in table 5. 
In nonasthmatic children with medium social status sensitizations to both house dust mites 
are significantly more common than in those with low social status. This may possibly be 
explainable by hygiene measures as vacuum cleaning, which may be – as other hygiene 
measures – more often practised in families with higher social status. In the literature, it has 
been shown that vacuum cleaning can enhance air levels of specific house dust allergens 
(Kalra et al., 1990, online 2003). In contrary, in asthmatic children that difference should not 
be able to play a major role as parents of those children should have been taught to use 
vacuum cleaners with small particle filters and especially parents with high social status are 
thought to follow those instructions closely. 
Nonasthmatic children with medium social status are more often sensitized to horse 
epithelia than both, children with lower as well as those with higher social status, 
significantly more often compared to the children living in families with high social status. 
The reason of this difference seems to remain unclear. Horse riding may be a somewhat 
more expensive hobby so that children with low social status may not have as often contact 
to horses as other children, but this does not explain why children with high social status 
show significantly less often sensitizations to horse epithelia then those with medium social 
status. 
 

















17.5 % (15.9-19.2) 
54.3 % (46.9-61.6) 
20.5 % (19.4-21.8) 
55.9 % (49.6-62.0) 
19.0 % (17.3-20.9) 
57.7 % (49.6-65.3) 
Dermatophagoides 
farinae 
16.8 % (15.3-18.4) 
51.4 % (43.5-59.2) 
20.2 % (19.0-21.5) 
53.8 % (47.7-59.8) 
20.0 % (18.2-21.9) 
57.7 % (49.5-65.5) 
Cat 
 
6.3 % (5.3-7.4) 
25.9 % (20.1-32.8) 
7.6 % (6.9-8.4) 
36.0 % (30.2-42.3) 
6.6 % (5.6-7.6) 
34.7 % (28.2-41.9) 
Horse 
 
2.8 % (2.2-3.5) 
19.5 % (14.3-26.0) 
4.1 % (3.5-4.8) 
25.6 % (20.4-31.7) 
2.6 % (2.0-3.4) 
28.7 % (22.2-36.3) 
Dog 
 
7.6 % (6.6-8.7) 
35.4 % (28.7-42.8) 
9.0 % (8.1-9.9) 
39.3 % (32.7-46.2) 
7.3 % (6.3-8.4) 
50.8 % (43.8-57.7) 
Birch 
 
11.1 % (9.8-12.6) 
31.7 % (24.7-39.6) 
13.6 % (12.3-15.0) 
44.2 % (38.1-50.4) 
14.0 % (12.3-15.8) 
47.4 % (38.8-56.1) 
Mugwort 
 
8.7 % (7.5-10.1) 
25.0 % (18.6-32.7) 
10.8 % (9.7-12.0) 
29.8 % (24.9-35.3) 
10.7 % (9.3-12.3) 
34.4 % (27.1-42.4) 
Rye 
 
17.8 % (16.1-19.7) 
46.2 % (37.8-54.9) 
20.9 % (19.3-22.6) 
55.4 % (49.2-61.5) 
20.8 % (18.8-22.9) 
56.4 % (48.4-64.2) 
Timothy 
 
19.6 % (17.8-21.5) 
47.5 % (38.8-56.4) 
22.3 % (20.7-24.1) 
59.6 % (53.7-65.2) 
22.0 % (20.1-24.2) 
60.3 % (52.1-67.9) 
Cladosporium 
herbarum 
1.0 % (0.7-1.5) 
14.1 % (9.3-20.9) 
1.6 % (1.3-2.0) 
8.3 % (5.2-12.9) 
1.0 % (0.7-1.4) 
8.9 % (5.4-14.2) 
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Table 5. Percentage of participants sensitized to inhalative allergens by social status 
The only significant difference we can observe in asthmatic children is the very high degree 
of sensitizations to dog epithelia in children with high social status compared to those with 
low social status. Pet ownership and the development of asthma and other atopic diseases 
are very controversially discussed. Time point of pet contact, cat / dog ownership and other 
circumstances may be puzzle pieces of a picture not yet completely visible. Some studies 
seem to direct to early dog contacts being protective regarding a development of atopy 
(Gern et al., 2004). Having in mind, that dog ownership in Germany is more common in 
families with high social status (high income and house owner), as was shown in a situation 
bulletin to dog ownership in Germany by the German University of Göttingen (Ohr & 
Zeddies, 2006), we have to query a protective effect of dog ownership on asthma 
development. Cross-sectional studies showing a protective effect of dog ownership could be 
biased by atopic parents avoiding dog ownership leading to children more in danger of 
atopy development more often growing up in a household without dogs. 
Descriptively but not statistically significant for all tested pollen sensitizations numbers rise 
from low over medium to high social status, what, if confirmed by other studies, could be 
explained by different free time behaviour. Children with lower social status are known to 
spend more time indoor than others, as confirmed by other analyses of the KiGGS study 
(Robert Koch Institut, 2008). 
Independent of social status, in all three groups, again, number of asthma cases rises with 
rising number of sensitizations in an exponential manner. 
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Table 4. Percentage of participants sensitized to inhalative allergens by sex 
Regarding the social status of the families our participants live with, not many significant 
differences in sensitization status can be observed, as shown in table 5. 
In nonasthmatic children with medium social status sensitizations to both house dust mites 
are significantly more common than in those with low social status. This may possibly be 
explainable by hygiene measures as vacuum cleaning, which may be – as other hygiene 
measures – more often practised in families with higher social status. In the literature, it has 
been shown that vacuum cleaning can enhance air levels of specific house dust allergens 
(Kalra et al., 1990, online 2003). In contrary, in asthmatic children that difference should not 
be able to play a major role as parents of those children should have been taught to use 
vacuum cleaners with small particle filters and especially parents with high social status are 
thought to follow those instructions closely. 
Nonasthmatic children with medium social status are more often sensitized to horse 
epithelia than both, children with lower as well as those with higher social status, 
significantly more often compared to the children living in families with high social status. 
The reason of this difference seems to remain unclear. Horse riding may be a somewhat 
more expensive hobby so that children with low social status may not have as often contact 
to horses as other children, but this does not explain why children with high social status 
show significantly less often sensitizations to horse epithelia then those with medium social 
status. 
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Table 5. Percentage of participants sensitized to inhalative allergens by social status 
The only significant difference we can observe in asthmatic children is the very high degree 
of sensitizations to dog epithelia in children with high social status compared to those with 
low social status. Pet ownership and the development of asthma and other atopic diseases 
are very controversially discussed. Time point of pet contact, cat / dog ownership and other 
circumstances may be puzzle pieces of a picture not yet completely visible. Some studies 
seem to direct to early dog contacts being protective regarding a development of atopy 
(Gern et al., 2004). Having in mind, that dog ownership in Germany is more common in 
families with high social status (high income and house owner), as was shown in a situation 
bulletin to dog ownership in Germany by the German University of Göttingen (Ohr & 
Zeddies, 2006), we have to query a protective effect of dog ownership on asthma 
development. Cross-sectional studies showing a protective effect of dog ownership could be 
biased by atopic parents avoiding dog ownership leading to children more in danger of 
atopy development more often growing up in a household without dogs. 
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from low over medium to high social status, what, if confirmed by other studies, could be 
explained by different free time behaviour. Children with lower social status are known to 
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Looking for children with or without migration background (table 6), we can observe more 
significant differences in sensitizations than in the above mentioned groups with different 
social status but only in nonasthmatic children. 
To cat and horse but not dog children without migration background show more 
sensitizations. Unfortunately, we did not find data showing pet ownership behaviour in 
people living in Germany with migration background. Therefore we can not discuss pet 
ownership in relation to sensitization status. Sensitizations to horse epithelia nevertheless 
could be higher in children without migration background more due to income differences 
than cultural disparity. 
Children without migration background are more often sensitized to all tested pollen than 
the other group of children. As it was previously shown in the KiGGS data, children with 
migration background spend much more time with indoor activities than children without 
such a background. Sensitization to pollen may be a consequence of outdoor activities. 
No differences were seen regarding house dust mite and mould allergies. In children with 














19,1 % (17.2-21.0) 
67,2 % (56.6-76.2) 
19,4 % (18.5-20.4) 
54,0 % (49.3-58.6) 
Dermatophagoides 
farinae 
17,9 % (16.0-20.0) 
64,7 % (54.5-73.6) 
19,5 % (18.6-20.5) 
52,4 % (47.8-56.9) 
Cat 5,0 % (4.0-6.3) 
30,6 % (22.0-40.8) 
7,3 % (6.7-7.9) 
33,5 % (29.6-37.6) 
Horse 2,0 % (1.4-2.7) 
16,2 % (9.9-25.0) 
3,6 % (3.2-4.1) 
26,0 % (22.1-30.3) 
Dog 6,4 % (5.1-8.0) 
38,8 % (28.9-49.6) 
8,5 % (7.8-9.1) 
41,6 % (37.4-45.9) 
Birch 8,7 % (7.2-10.3) 
36,0 % (27.2-46.0) 
13,8 % (12.7-14.9) 
42,4 % (38.3-46.6) 
Mugwort 7,5 % (6.0-9.2) 
22,5 % (15.0-32.4) 
10,7 % (9.8-11.7) 
30,9 % (27.1-35.0) 
Rye 15,9 % (13.9-18.0) 
57,8 % (47.4-67.5) 
20,8 % (19.4-22.2) 
52,0 % (47.2-56.7) 
Timothy 17,9 % (15.9-20.0) 
60,2 % (50.6-69.2) 
22,1 % (20.8-23.5) 
55,7 % (50.7-60.5) 
Cladosporium herbarum 1,0 % (0.6-1.7) 
7,3 % (2.9-17.3) 
1,3 % (1.1-1.6) 
10,7 % (8.1-14.0) 
Aspergillus fumigatus 1,9 % (1.3-2.7) 
13,6 % (6.9-24.9) 
1,7 % (1.4-2.1) 
13,2 % (10.4-16.4) 
Table 6. Percentage of participants sensitized to inhalative allergens by migration status 
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Additionally we searched for differences in sensitizations between children living in more 
rural or urban regions of Germany. We have been able to identify only one single significant 
difference: in rural regions 12.7 % of the children without asthma where sensitized to 
mugwort, in small towns 10.4 % in medium towns 9.6 % and in large cities 8.5 %. The 
difference between the smallest and the biggest region class reaches significance. As, 
according to the hygiene hypothesis, sensitization occurs more easy in urban regions, these 
data in our view back up the hypothesis of outdoor activities leading to more sensitizations 
to outdoor allergens – independent of residence. 
Descriptively, children with asthma show the same slope in sensitization prevalence to 
mugwort as children without asthma. Again, children in all regions show the above 
described exponential coherency between asthma and number of sensitizations.  
3.4.6 Sensitization patterns in asthmatic children 
In the intention to look for patterns of sensitizations we grouped sensitizations to house 
dust mites, animals, pollen and moulds respectively. In table 7 we demonstrate groups of 
children showing sensitizations to at least one allergen of one of the mentioned groups alone 
or to at least one allergen of the mentioned group and any other allergens and the 
prevalence of asthma in those groups compared to the overall prevalence. 
If sensitizations to allergens of only one of the four groups show up, asthma prevalence is 
not enhanced with the exemption of sensitizations to animals. These more than double the 
asthma prevalence. In the underneath mentioned groups with combined sensitizations, 
asthma prevalence is enhanced in each group, what may result from the above described 
effect of multiple sensitizations exponentially leading to an increase of asthma. 
 
Sensitization type Asthma prevalence (%) n=690, 5.5 % (5.0-6.0) 
only to house dust mites 5.9 % (4.5-7.7) 
only to animals 12.5 % (7.7-19.8) 
only to pollen 4.5 % (3.4-5.9) 
only to moulds 5.4 % (0.7-30.4) 
  
to house dust mites and other allergen(s) 13.6 % (12.1-15.3) 
to animals and other allergen(s) 19.8 % (17.7-22.2) 
to pollen and other allergen(s) 12.7 % (11.4-14.1) 
to moulds an other allergen(s) 27,2 % (22.3-32.8) 
Table 7. Percentage of sensitization types having asthma 
Nevertheless, noticeably asthma prevalence is much higher in children with animal epithelia 
and other sensitizations as with house dust mite or pollen and other sensitizations and 
highest in the group of children and adolescents with mould and other sensitizations. So, in 
monosensitized children, sensitization to animals plays the major role and in 
polysensitizations animals and even more moulds. 
After these insights we wanted to know exactly the sequence of mono- and 
polysensitizations regarding asthma prevalence and present the data in figure 2. 
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Additionally we searched for differences in sensitizations between children living in more 
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difference: in rural regions 12.7 % of the children without asthma where sensitized to 
mugwort, in small towns 10.4 % in medium towns 9.6 % and in large cities 8.5 %. The 
difference between the smallest and the biggest region class reaches significance. As, 
according to the hygiene hypothesis, sensitization occurs more easy in urban regions, these 
data in our view back up the hypothesis of outdoor activities leading to more sensitizations 
to outdoor allergens – independent of residence. 
Descriptively, children with asthma show the same slope in sensitization prevalence to 
mugwort as children without asthma. Again, children in all regions show the above 
described exponential coherency between asthma and number of sensitizations.  
3.4.6 Sensitization patterns in asthmatic children 
In the intention to look for patterns of sensitizations we grouped sensitizations to house 
dust mites, animals, pollen and moulds respectively. In table 7 we demonstrate groups of 
children showing sensitizations to at least one allergen of one of the mentioned groups alone 
or to at least one allergen of the mentioned group and any other allergens and the 
prevalence of asthma in those groups compared to the overall prevalence. 
If sensitizations to allergens of only one of the four groups show up, asthma prevalence is 
not enhanced with the exemption of sensitizations to animals. These more than double the 
asthma prevalence. In the underneath mentioned groups with combined sensitizations, 
asthma prevalence is enhanced in each group, what may result from the above described 
effect of multiple sensitizations exponentially leading to an increase of asthma. 
 
Sensitization type Asthma prevalence (%) n=690, 5.5 % (5.0-6.0) 
only to house dust mites 5.9 % (4.5-7.7) 
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Table 7. Percentage of sensitization types having asthma 
Nevertheless, noticeably asthma prevalence is much higher in children with animal epithelia 
and other sensitizations as with house dust mite or pollen and other sensitizations and 
highest in the group of children and adolescents with mould and other sensitizations. So, in 
monosensitized children, sensitization to animals plays the major role and in 
polysensitizations animals and even more moulds. 
After these insights we wanted to know exactly the sequence of mono- and 
polysensitizations regarding asthma prevalence and present the data in figure 2. 
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Fig. 2. Sensitization pattern and asthma prevalence 
Combinations we did not find were that of animal and mould sensitizations and house dust 
mite and mould sensitizations. 
Again, we have to keep in mind that increasing number of sensitizations lead to 
exponentially increasing asthma prevalence so that the shown figure must be strained by 
that effect. But – as an example – the combination of sensitizations to pollen and moulds 
seems to result in much higher asthma prevalence than the combination of sensitizations to 
pollen and animal epithelia, whereas the addition of a sensitization to animals to pollen and 
mould sensitizations does nearly not further enhance asthma prevalence. 
Having a look into these data from another perspective we find that nearly a quarter of our 
asthmatic children and adolescents did not show any sensitization to the tested inhalative 
allergens (23.7 %). Never or infrequently (< 5 %) seen in the asthmatic children were 
sensitizations to mould only, pollen and mould, animals only, animals and mould, animals, 
pollen and mould, house dust mite and mould, house dust mite, pollen and mould, mould 
and animals as well as house dust mite, animals and mould. More frequently (5 - 10 %) we 
saw sensitizations to pollen only, animals and pollen and house dust mite only. 
Sensitizations to at least one allergen of each group were more frequent with 10.4 % of the 
asthmatic children concerned, sensitizations to house dust mite and pollen occurred in 
10.9 % of the asthma cases and most frequent were sensitizations to house dust mites, pollen 
and animals in 22 % of asthmatic children. 
In a cross-sectional study we are not able to detect the time sequence of acquired 
sensitizations. Alternatively we looked for dual combinations of sensitizations. Taking the 
assumption that sensitizations are livelong conditions, a dual combination could indirectly 
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light the way of the beginning of multisensitizations and may show us, how sensitizations 
usually combine or start to build cluster. 
In our data we found 1420 nonasthmatic and 86 asthmatic children with exactly two 
sensitizations (not grouped) as shown in figures 3 and 4 in absolute numbers.  
 
Non-
asthmatic DermPt DermFA Cat Horse Dog Birch 
Mug-
wort Rye Timothy Clado Asperg 
DermPt                       
DermFa 810                     
Cat 4 2                   
Horse 3  6                 
Dog 1 3 24 2               
Birch 5 1 5  5             
Mugwort 3 4 1 1 2 10           
Rye 1 1    4 1         
Timothy 2 5 3 1 2 11 6 474       
Clado  1    1 1       
Asperg  4   1  1 1  7   
n=1420 829 21 39 4 10 26 9 475 0 7  
Fig. 3. Combinations of exactly two sensitizations in nonasthmatic children 
 
Asthmatic DermPt DermFA Cat Horse Dog Birch 
Mug-
wort Rye Timothy Clado Asperg 
DermPt                       
DermFa 53                     
Cat                     
Horse   1                 
Dog   3 1               
Birch                  
Mugwort      1           
Rye                
Timothy   1   3  21       
Clado              
Asperg        1  1   
n=86 53 0 5 1 0 4 0 22 0 1  
Fig. 4. Combinations of exactly two sensitizations in asthmatic children 
In the group of the nonasthmatic children we can observe that combinations of the two 
house dust mites are very common and also the combination between rye and timothy, two 
kinds of weed, so that these combinations are likely produced by cross reactivity. The same 
applies to the rarer combination of cat and dog sensitizations. The pattern in asthmatic 
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In the group of the nonasthmatic children we can observe that combinations of the two 
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children is exactly the same, only the numbers are too small to show a peak at cat and dog 
sensitizations. 
As a last step we then looked into the data of exactly two sensitizations in the above 






Animals Pollen Moulds Asthmatic House 
dust mite 
Animals Pollen Moulds 
House 
dust mite 
        House 
dust mite 
        
Animals 125 (11.6 %)       Animals 23  
(16.3 %) 
      
Pollen 607 (56.4 %) 292  
(27.1 %) 




    
Moulds 19 (1.8 %) 2  
(0.2 %) 
32 (3.0 %)   Moulds 0 0 7 (5.0 %)   
n=1077         N=141         
Fig. 5. Combinations of exactly two group sensitizations in children and adolescents 
Again, it becomes clearly visible, that sensitization patterns of dual group sensitizations in 
our study do not differ between asthmatic and nonasthmatic children. The number of 
sensitizations influences asthma prevalence very much but patterns of sensitization to a 
much lesser degree – although the most differentiated analysis of the data shown in figure 2 
seems to indicate some coherence between sensitization pattern and asthma. 
3.5 Discussion and perspectives 
We have been able to confirm data known from the literature on the grounds of a database 
as far as possible representative for German children and adolescents. 
There is no mandatory coherency between sensitizations to inhalative allergens and asthma 
looking into individual developments. While in adults non allergic asthma forms concern a 
high percentage of asthmatic persons, in children it was thought that a broad majority 
suffers from allergic asthma. We identifyed 23.7 % of the asthmatic children not showing a 
sensitization to any of the tested inhalative allergens and additionally only a few of them 
showing sensitizations to food allergens. Though sensitizations to allergens not being 
included in our test are theoretically possible (included were the most common allergens 
being content of standard test series), possibly non allergic asthma forms in children may 
still be somewhat underestimated. 
We also saw that sensitizations confirmed in the range of 0.35 - 0.69 kU/l and up to now 
regarded only as marginally positive are allready statistically significant more frequent in 
asthmatic children for all tested allergens with the exemption of the two house dust mites. 
Potentially such low sensitization results for animals, pollen and moulds should be noticed 
more attentively in clinical practise at least in children with a higher risk for the 
development of atopy.  
In contrary, very high levels of sensitizations from 50.0 kU/l on have been seen nearly only 
in asthmatic children and only some single nonasthmatic individuals. Such high levels seem 
to be nearly an indicator for asthma development. 
In contrast to the literatur identifying significantly less sensitizations in rural compared to 
urban regions, in Germany we were able to identify differences in sensitization patterns 
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between those regions but no overall differences regarding sensitization prevalence. 
Possibly life style differences between rural and urban regions in Germany are very low as 
we are a country with a pronounced “westernized lifestyle”. A higher prevalence of 
sensitizations to pollen in rural regions already had been described for Italian children. We 
identified significantly higher sensitization prevalence in rural regions only for mugwort. 
Sensitization prevalence being higher for boys compared to girls was already depicted. In 
connection with asthma it was an interesting fact that with increasing age sensitization 
prevalence in boys remains still higher than that in girls while asthma prevalence in boys 
declines. This could possibly back up the theory of lung size being an important factor in 
asthma prevalence differences in men and women being contrary to those in boys and girls. 
Living in families with a lower social status was said to enhance the chance for having 
sensitizations. In our study, for most tested allergens the contrary held true. Especially 
regarding house dust mites, one of the most important factors for the development of 
asthma, higher social status was a risk factor for sensitizations. As far as causes are known, 
disproportionate hygiene behaviour could be one of the factors, what would fit in the 
widely respected hygiene hypothesis. We think that social habits like the use of 
desinfectants and odors in the househould and in public have to be questioned and that 
activities for prevention of allergies should be also directed to such behavioural factors. 
The findings of polysensitization more often to cohere with asthma than monosensitization 
and the number of sensitizations to correlate with the risk for asthma were substanciated by 
our data. We have been able to show a clear exponential correlation between the number of 
sensitizations and asthma. This may be considered as an impulse to reconsider 
hyposensitization therapy in children at high risk for atopy. Maybe those children should 
undergo therapy the minute a second or third sensitization occurs regardless of symptoms 
of hayfever to prevent asthma development. As in the literature it was also shown that 
asthma remission relates inversely to sensitizations, this may make hyposensitization 
therapy also more fundamental in asthmatic children as it already is. 
The special importance of house dust mite sensitizations was confirmed by our study, as 
was to be expected. Presumably based on cross reactivity sensitization to both tested house 
dust mites showed an overlap of nearly 100 % so that testing sensitizations to only one of 
the house dust mites would be in nearly every case able to confirm house dust mite allergy. 
All in all we learned that the number of sensitizations was a much stronger element in 
asthma development than sensitization patterns. Nevertheless, it became clear that 
sensitizations to only animal epithelia more than double asthma prevalence compared to 
house dust mite, pollen or mould sensitizations only. In combined sensitization patterns 
containing animal sensitizations and by far more mould sensitizations are linked with 
enhanced asthma prevalence. 
The KiGGS study will be carried forward and partly transformed into a longitudinal study. 
So we are looking forward to being better able to identify sensitizations or sensitization 
patterns really leading to asthma development. Additionally – as we will include in our 
study questions for hyposensitization therapy – we should be able to show whether early 
specific immunotherapy will be capable to prevent the development of polysensitizations 
and/or the development of asthma or influence asthma remission during adolescence. 
Also the effectiveness of social measures such as proposed for example by the ABAP (an 
alliance for prevention of allergies initiated by the German Ministry for Health) could be 
followed up by this study. 
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children is exactly the same, only the numbers are too small to show a peak at cat and dog 
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identified significantly higher sensitization prevalence in rural regions only for mugwort. 
Sensitization prevalence being higher for boys compared to girls was already depicted. In 
connection with asthma it was an interesting fact that with increasing age sensitization 
prevalence in boys remains still higher than that in girls while asthma prevalence in boys 
declines. This could possibly back up the theory of lung size being an important factor in 
asthma prevalence differences in men and women being contrary to those in boys and girls. 
Living in families with a lower social status was said to enhance the chance for having 
sensitizations. In our study, for most tested allergens the contrary held true. Especially 
regarding house dust mites, one of the most important factors for the development of 
asthma, higher social status was a risk factor for sensitizations. As far as causes are known, 
disproportionate hygiene behaviour could be one of the factors, what would fit in the 
widely respected hygiene hypothesis. We think that social habits like the use of 
desinfectants and odors in the househould and in public have to be questioned and that 
activities for prevention of allergies should be also directed to such behavioural factors. 
The findings of polysensitization more often to cohere with asthma than monosensitization 
and the number of sensitizations to correlate with the risk for asthma were substanciated by 
our data. We have been able to show a clear exponential correlation between the number of 
sensitizations and asthma. This may be considered as an impulse to reconsider 
hyposensitization therapy in children at high risk for atopy. Maybe those children should 
undergo therapy the minute a second or third sensitization occurs regardless of symptoms 
of hayfever to prevent asthma development. As in the literature it was also shown that 
asthma remission relates inversely to sensitizations, this may make hyposensitization 
therapy also more fundamental in asthmatic children as it already is. 
The special importance of house dust mite sensitizations was confirmed by our study, as 
was to be expected. Presumably based on cross reactivity sensitization to both tested house 
dust mites showed an overlap of nearly 100 % so that testing sensitizations to only one of 
the house dust mites would be in nearly every case able to confirm house dust mite allergy. 
All in all we learned that the number of sensitizations was a much stronger element in 
asthma development than sensitization patterns. Nevertheless, it became clear that 
sensitizations to only animal epithelia more than double asthma prevalence compared to 
house dust mite, pollen or mould sensitizations only. In combined sensitization patterns 
containing animal sensitizations and by far more mould sensitizations are linked with 
enhanced asthma prevalence. 
The KiGGS study will be carried forward and partly transformed into a longitudinal study. 
So we are looking forward to being better able to identify sensitizations or sensitization 
patterns really leading to asthma development. Additionally – as we will include in our 
study questions for hyposensitization therapy – we should be able to show whether early 
specific immunotherapy will be capable to prevent the development of polysensitizations 
and/or the development of asthma or influence asthma remission during adolescence. 
Also the effectiveness of social measures such as proposed for example by the ABAP (an 
alliance for prevention of allergies initiated by the German Ministry for Health) could be 
followed up by this study. 
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Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, 
Japan 
1. Introduction 
Symptoms of Gastroesophageal Reflux Disease (GERD) are both esophageal and 
extraesophageal symptoms. The consensus statements on the definition of GERD in the 
pediatric population were reported that respiratory symptoms might be occurred by 
gastroesophageal acid reflux (Sherman et al.,2009). But, the definition of GERD used by 
gastroenterologists are much different from that used by allergists (Colombo, 2004).  
Usually, the diagnosis of GERD is based on the reflux index (percentage of total recording 
time with a pH below 4) during 24-hour pH monitoring (pH monitoring) (Working group of 
the European society of pediatric gastroenterology and nutrition, 1992). But, this baseline of 
the reflux index was defined by gastroenterologists.In our previous study in asthmatic 
children with GERD, we showed that respiratory symptoms tended to worse not only at 
night but also in the daytime, and the index of the mean hourly number of acid refluxes (the 
mean number of acid reflux/h) which we defined parameters as the frequency of acid 
refluxes during upright position during pH monitoring was important for the diagnosis of 
GERD when associated with asthma (Yoshida et al., 2009).  
In some previous reports, the frequency of GERD in children with respiratory symptoms 
was comparatively high (Saglani et al., 2006). But, at the present situation, it has not been 
cleared sufficiently when GERD should be considered in children with episodes of recurrent 
wheezing. In clinically, when episodes of recurrent wheezing are intractable regardless of 
doing medications, we suspect that GERD is associated with episodes of recurrent 
wheezing. So, in the present study, we investigated the difference of characteristics for 
diagnosis and treatment of GERD more appropriately in children with episodes of recurrent 
wheezing associated with GERD. 
Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are widely 
used as acid suppression therapy of GERD (Scarupa et al.,2005). In recent years, not only 
H2RAs but also PPIs were reported for treatment of GERD (Gustafsson et al.,1992; Harper et 
al., 1987; Khoshoo et al.,2003; Sopo et al.,2009; Stordal et al.,2005; The American lung 
association asthma clinical research center,2009). However, in Japan, we can only use the 
enteric-coated tablet-type PPIs. Therefore, PPIs are difficult to use for preschool children 
especially those under 5 years of age. So, we have no choice but to use the powdered-type 
H2RAs in children under 5 years of age. In our country, the powdered-type H2RAs we can 
use is famotidine. So, in the present study, we used famotidine as acid suppression therapy. 
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1. Introduction 
Symptoms of Gastroesophageal Reflux Disease (GERD) are both esophageal and 
extraesophageal symptoms. The consensus statements on the definition of GERD in the 
pediatric population were reported that respiratory symptoms might be occurred by 
gastroesophageal acid reflux (Sherman et al.,2009). But, the definition of GERD used by 
gastroenterologists are much different from that used by allergists (Colombo, 2004).  
Usually, the diagnosis of GERD is based on the reflux index (percentage of total recording 
time with a pH below 4) during 24-hour pH monitoring (pH monitoring) (Working group of 
the European society of pediatric gastroenterology and nutrition, 1992). But, this baseline of 
the reflux index was defined by gastroenterologists.In our previous study in asthmatic 
children with GERD, we showed that respiratory symptoms tended to worse not only at 
night but also in the daytime, and the index of the mean hourly number of acid refluxes (the 
mean number of acid reflux/h) which we defined parameters as the frequency of acid 
refluxes during upright position during pH monitoring was important for the diagnosis of 
GERD when associated with asthma (Yoshida et al., 2009).  
In some previous reports, the frequency of GERD in children with respiratory symptoms 
was comparatively high (Saglani et al., 2006). But, at the present situation, it has not been 
cleared sufficiently when GERD should be considered in children with episodes of recurrent 
wheezing. In clinically, when episodes of recurrent wheezing are intractable regardless of 
doing medications, we suspect that GERD is associated with episodes of recurrent 
wheezing. So, in the present study, we investigated the difference of characteristics for 
diagnosis and treatment of GERD more appropriately in children with episodes of recurrent 
wheezing associated with GERD. 
Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are widely 
used as acid suppression therapy of GERD (Scarupa et al.,2005). In recent years, not only 
H2RAs but also PPIs were reported for treatment of GERD (Gustafsson et al.,1992; Harper et 
al., 1987; Khoshoo et al.,2003; Sopo et al.,2009; Stordal et al.,2005; The American lung 
association asthma clinical research center,2009). However, in Japan, we can only use the 
enteric-coated tablet-type PPIs. Therefore, PPIs are difficult to use for preschool children 
especially those under 5 years of age. So, we have no choice but to use the powdered-type 
H2RAs in children under 5 years of age. In our country, the powdered-type H2RAs we can 
use is famotidine. So, in the present study, we used famotidine as acid suppression therapy. 
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And, in our previous study, the mean number of acid reflux/h during the upright position 
exceeded 7 in all the children with GERD associated asthma (Yoshida, et al., 2009). So, in the 
present study, we diagnosed of GERD by the mean number of acid reflux/h which baseline 
was defined as exceeded 7 and response of acid suppression therapy.  
2. Materials and methods 
We performed pH monitoring between June 2007 and December 2008 in 52 preschool 
children with episodes of recurrent wheezing. All participant’s chest radiograph were 
normal. They had no other respiratory disorders, for example, bronchiectasis, recurrent 
pneumonia, aspiration, intestinal lung disease and airway abnormality. And they had no 
neurological disorders, cardiac disease and  gastrointestinal symptoms. 
All patients received inhaled corticosteroid (ICS) for more than 3 months. The ICS used was 
fluticasone or hydrofluoroalkane-beclomethasone dipropionate more than 200 μg/day. But, 
their respiratory symptomatic days during one month were more than 5 days. Their 
respiratory symptoms were uncontrolled. So, we suspected that GERD was associated with 
their respiratory symptoms, and we performed the pH monitoring.  
When the mean number of acid refluxes/h during upright position exceeded 7, by the result 
of pH monitoring, we started famotidine therapy (0.5mg/kg twice daily). And, we followed 
up the children who started famotidine therapy for one month. So, we counted respiratory 
symptomatic days for one month before and after starting the famotidine therapy. And we 
compared them before and after starting the famotidine therapy. 
So, in the case that symptomatic days were decreased less than half days, we defined that 
framotidine therapy was effective. When famotidine therapy was effective, children formed 
the effective group. On the other hand, in the case that symptomatic days were not 
decreased less than half days, we defined that framotidine therapy was not effective. When 
famotidine therapy was not effective, children formed the no effective group. Then, we 
compared the patient’s characteristics between the two groups. We investigated the 
patient’s age, onset age of wheezing episodes, level of serum IgE, amount of ICS and results 
of pH monitoring as patient’s characteristics. And we investigated modified asthma 
predictive index (mAPI) as the risk factors for the development of asthma (Panettieri et al., 
2008). 
The pH monitoring was performed using a Synectics Digitrapper MKⅢ (Synetics Medical 
Stockholm Sweden). The catheter had 4 probes that sensed acid reflux. The most upper 
probe (the first probe) was 20 cm above the bottom probe. The third probe of the catheter 
was placed 3-4 cm above the gastroesophageal junction, and its position was checked by 
chest radiography. We examined the mean number of acid refluxes/h during upright 
position and the reflux index at the third probe. The asthma medication was continued as 
usual during pH monitoring. 
In our hospital, respiratory symptoms are recorded in a diary in order to acquire the precise 
clinical manifestation. At every patient’s visit, each physician checked the diary. 
3. Data analysis 
Normal distributed data were presented as mean ± SD. Nonparametric data were expressed 
as median. The differences were assessed by the Mann-Whitney U-test. A p-vale <0.05 was 






Patient profiles were summarized in Table 1. 27 children showed the results that the mean 
number of acid reflux/h during upright position exceeded 7. In 18 of the 27 children, the 
reflux index exceeded 4%. In the remaining 25 children with the mean number of acid 
reflux/h during upright position being below 7, the reflux index was below 4%.  
 
Gender  
- Male,n 35 
- Female,n 17 
Age,years* 3.1 (1.8) 
Amount of ICS, μg/day* 219 (59.4) 
Results of 24-hour pH monitoring 
- Reflux index,%* 
 
6.2 (9.5) 
- The mean number of acid reflux/h during 
upright position, times* 
12.4 (13.6) 
- The number of children with reflux index 
over 4 %, n 
18 
- The number of children with the mean 
number of acid reflux/h  
during upright position over seven, n 
27 
*Data are presented as mean (SD). n:number.  ICS; inhaled corticosteroid 
Table 1. Patient profiles (n=52) 
19 of the 27 children profiles with the mean number of acid reflux/h during upright position 
being over 7 were summarized in Table 2. The remaining 8 children did not record 
respiratory symptoms in the diary or did not visit our hospital. Among the 19 children, 8 
were included in the effective group and 11 were included in the no effective group. 
 
Gender  
- Male,n 12 
- Female,n 7 
Age,year* 3.1 (1.33) 
Amount of ICS, μg/day* 235 (236) 
Results of 24-hour pH monitoring  
- The mean number of acid reflux/h during upright 
position, times* 19.5 (19.9) 
- Reflux index,%* 9.0 (9.3) 
The effective group 8 
The no effective group 11 
*Data are presented as mean (SD). n:number.  ICS; inhaled corticosteroid 
Table 2. Patient profiles with the mean number of acid reflux/h during upright position 
over 7 (n=19) 
A comparison of patient’s characteristics between the effective group and the no effective 
group was summarized in Table 3. The mean (SD) age was 2.4 (1.0) years old in the effective 
group, and 3.5 (1.3) years old in the no effective group (p<0.05). And, the mean (SD) onset 
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 Effective group 
n=8 
No effective group 
n=11 p vale 
Age,year 2.4(1.0) 3.5(1.3) p<0.05 
Onset age of episodes of  wheezing, year 1.0(1.1) 3.0(1.0) p<0.05 
Serum IgE, IU/ml 209(201) 150(237) n.s. 
Amount of ICS, μg/day 237(106) 236(80) n.s. 
Results of 24-hour pH monitoring    
- reflux index,% 11.4(10.8) 7.6(9.8) n.s. 
- The mean number of acid reflux/h 
during upright position, times 20.9(9.5) 19.0(19.6) n.s. 
Respiratory symptomatic days    
- Before famotidine 16.0(7.2) 14.1(5.8) n.s. 
- After famotidine 5.6(5.4) 13.9(4.5) p<0.05 
Data are presented as mean(SD). 
Table 3. Comparison of the effective group and the no effective group 
age of wheezing was 1.0 (1.1) years old in the effective group, and 3.0 (1.0) years old in the 
no effective group (p<0.05). The mean (SD) respiratory symptomatic days before famotidine 
were 16.0 (7.2) in the effective group, and 14.1 (5.8) in the no effective group. The mean (SD) 
respiratory symptomatic days were 5.6 (5.4) in the effective group, and 13.9(4.5) in the no 
effective group (p<0.05). There was no significant difference between the two groups before 
famotidine tehapy. But, there was difference between the two groups after famotidine 
therapy. The changes of the respiratory symptomatic days between before and after 
famotidine therapy in each group were showed in figure 1. In the effective group, there was 
singinficant difference (p<0.05). There was no singinficant difference between the two 
groups about level of serum IgE, amount of ICS and the results of pH monitoring in Table 3.  
A comparison of modified asthma predictive index between the effective group the no 
effective group was summarized in Table 4. There was no singinficant difference about each 
index between the two groups. 
 
Modified Asthma Prediction Index Effective group (n=8) 




• Major criteria, n     
Parental history of asthma 3 5 n.s. 
Physician-diagnosed atopic dermatitis 2 3 n.s. 
Allergic sensitization to ≧ 1 aeroallergen 5 6 n.s. 
• Minor criteria,n    
Allergic sensitization to milk, egg, or 
peanuts 3 3 n.s. 
Wheezing unrelated to colds 8 11 n.s. 
Blood eosinophils ≧ 4% 5 5 n.s. 
The presence of 1 of the major criteria  






Table 4. Comparison of Modified Asthma Prediction Index between the effective group and 






Fig. 1. The difference of the effective group and the no effective group of respiratory 
symptomatic days between before and after famotidine therapy 
5. Discussion 
The incidence of GERD was comparatively high in children with episodes of recurrent 
wheezing. The previous report had shown that the incidence of asthma in children with 
episodes of recurrent wheezing was 40.4%, and that of GERD was 23.4%. In particular, 57% 
children with asthma also had GERD (Saglani et al., 2006). But, the efficacy of acid 
suppression therapy was not cleared sufficiently for children with episodes of recurrent 
wheezing (Brand et al., 2008). For example, in the treatment of asthma, there was a report 
that PPIs did not improve asthma control (The American lung association asthma clinical 
research center, 2009). So, in the present study, we prescribed for famotidine based on result 
of pH monitoring in the lower age preschool children with episodes of recurrent wheezing, 
and compared between children with effective and ineffective of famotidine therapy. And, 
we showed that famotidine therapy could be more effective in the lower age preschool 
children with episodes of recurrent wheezing with associated GERD. 
In the present study, 8 out of 19 (42%) children who received the famotidine therapy were 
included the effective group. And, in the effective group, the mean age and the onset age of 
first wheezing episode were significantly lower than that of the no effective group. Namely, 
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age of and the lower onset age of first wheezing episodes were, the more effective 
famotidine therapy was. In clinically, a diagnosis of GERD is made by the efficacy of acid 
suppression therapy in addition to the results of pH monitoring. So, in the effective group, 
their respiratory symptoms could be defined that GERD was associated with episodes of 
recurrent wheezing. About relationship of gastroesophageal acid reflux (GER) and age, the 
other previous report had shown that GER occurs easily below one year of age (Nelson et 
al., 1997). From the present results and previous reports, we suggested that respiratory 
symptoms of lower age could be much associated with GERD witch symptoms were 
improved by famotidine in children with episodes of recurrent wheezing.  
Some previous reports had shown the efficacy of PPIs for children with episodes of 
recurrent wheezing (Sopo et al., 2009; Stordal et al., 2005). PPIs were more effective than 
H2RAs such as famotidine. But, PPIs available in Japan are difficult to use for preschool 
children. So, in the no effective group in the present study, there might be improved 
respiratory symptoms if PPIs were used. But, unfortunately, this problem could not be 
cleared in the present situation in Japan. 
But, there are two treatment regimens of GERD. One treatment regimen witch is called the 
no effective therapy is to begin with H2RAs. When symptoms are not improved by H2RAs, 
then PPIs are used. The other medication witch is called step-down therapy is to begin with 
PPIs. But, in treatment of GERD, cost-effectiveness considerations must be needed when 
which medication is used (Hassall, 2008). In general, PPIs are superior to H2RAs for erosive 
esophagitis (Vandenplas et al., 2009). So, PPIs were capable of being a cost-effective 
diagnostic test in adult (Ofman et al., 1999). But, in children, there was no study comparing 
these two medications (Hassall, 2008). In pediatric gastroesophageal reflux clinical practice 
guidelines, there needs special concern to prescription of PPIs in infants(Vandenplas et al., 
2009). In previous report, PPIs were used over the age of 2 years old or those with moderate 
symptoms of GERD. But, under the age of 12 month, H2RAs were better starting medication 
(Hassall, 2008; Vandenplas et al., 2009). So, in clinical cases, the medication is selected by 
considering age and severity of symptoms.  
About symptoms of GERD, the presence of esophageal erosions or ulcers is one of the 
factors that determine the severity of GERD (Armstrong et al., 2005). But, the previous study 
showed that the presence of esophagitis did not always exist in children with refractory 
respiratory symptoms of GERD (Ravelli et al., 2006). So, the severity of GERD with episodes 
of recurrent wheezing could be defined “mild”  
Another previous report showed that H2RAs were safe and effective for the management of 
mild GERD symptoms (Vandenplas et al., 2009). So, we suggested that H2RAs might be 
prescribed first for children with episodes of recurrent wheezing. H2RAs include cimetidine, 
famotidine and ranitidine. There was no previous study about the effective of famotidine for 
respiratory symptoms. So, our present study is valuable. 
Asthma is the most common cause in diseases with episodes of recurrent wheezing 
(Weinberger & Abu-Hasan, 2007). Recurrent wheezing during first 3 years is one of the 
established risk factor for the development of asthma in childhood (Panettieri et al., 2008). 
But, we must take careful of asthma like symptoms caused by other causes (Weinberger & 
Abu-Hasan, 2007). Diagnosis of asthma in preschool children with episodes of recurrent 
wheezing is difficult (Brand et al., 2008). The previous report had shown that the incidence 
of asthma in children with episodes of recurrent wheezing was 41%, and that of GERD was 
23%, and that of predominantly infection was 13% ( Saglani et al., 2006). One of the common 
diagnosis in the diseases of predominantly infection is protracted bacterial bronchitis 





labeled as having severe asthma (Chang et al., 2008). So, the other previous report had 
shown that the differential diagnosis should be considered when young children with 
recurrent respiratory symptoms had a negative mAPI (Chipps, 2010). 
The mAPI is a clinical index of asthma for 2 years of age and older (Panettieri et al., 2008). 
When the child has the presence of 1 the major criteria or 2 minor criteria in the mAPI, the 
recurrent respiratory symptoms of child might be developed persistent asthma (Chipps, 
2010). So, we investigated mAPI whether there were differences about risk factor for asthma 
development between the effective group and the no effective group. As a result, there was 
no significant difference on each subject. And all children of each groups had the presence of 
1 of the major criteria or 2 minor criteria. So, there was no significant difference about risk 
factor for asthma development according to the mAPI. But, in the no effective group, 
amount of ICS was increased within 3 months after famotidine therapy for controlling of 
respiratory symptoms. The mean (SD) amount of ICS was 308 (78) μg/day. (data not 
shown). We speculated that children in the no effective group had more progressive airway 
inflammation and had more risk for asthma development than children in the effective 
group. But, it is not cleared sufficiently in the present study.  
6. Conclusion 
It is not cleared sufficiently that we must consider what kind of preschool children with 
episodes of recurrent wheezing are prescribed for the acid suppression therapy. In our 
present study, in preschool children with episodes of recurrent wheezing associated with 
GERD, the lower age of and the lower onset age of first wheezing episodes were, the more 
effective famotidine therapy was. We suggest that lower age preschool children with 
episodes of recurrent wheezing whose symptoms are suspected associating with GERD 
from the result of pH monitoring might be prescribed acid suppression therapy actively.  
And, famotidien is inferior to PPIs as the acid suppression therapy. But, we suggest that 
famotidine might be useful as primary medication for “mild” GERD which main symptom 
is recurrent wheezing. 
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1. Introduction 
Allergic rhinitis (AR) is a symptomatic nose disorder induced after exposure to allergens via 
IgE-mediated hypersensitivity reactions, which are characterized by 4 cardinal symptoms: 
nasal obstruction, watery rhinorrhea, nasal itching and sneezing. For both children and 
adults, AR is more than just sneezing and nose itching. Complications of this disease are 
numerous and can have a significant impact, both physically and psychosocially. Major 
comorbidities in patients with AR include asthma, rhinosinusitis (RS), otitis media with 
effusion (OME), and sleep disturbance. The symptoms of AR can cause not only physical 
problems to the nose and lower airway, but also psychosocial problems including those in 
learning and cognitive processes and in missing work or school (Fig. 1). Thus, it is very 
important to understand other conditions caused by AR when managing this disorder. 
 
 
Fig. 1. Physical and psychological comorbidities of AR (Adapted from Spector, 1997) 
The ongoing efforts of physicians to identify comorbidities of AR in the fields of allergy can 
be put to practical use in caring and protecting the community from the burden of disease as 
well as saving costs and offering preventive education. Moreover, providing information to 
the patients with AR is expected to have a direct and positive effect on their well being. 
In this chapter, we will provide an overview of the comorbidities of AR that could cause 
both physical and psychosocial complications. 
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important to understand other conditions caused by AR when managing this disorder. 
 
 
Fig. 1. Physical and psychological comorbidities of AR (Adapted from Spector, 1997) 
The ongoing efforts of physicians to identify comorbidities of AR in the fields of allergy can 
be put to practical use in caring and protecting the community from the burden of disease as 
well as saving costs and offering preventive education. Moreover, providing information to 
the patients with AR is expected to have a direct and positive effect on their well being. 
In this chapter, we will provide an overview of the comorbidities of AR that could cause 
both physical and psychosocial complications. 
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2. Physical comorbidities 
2.1 AR and asthma 
AR and asthma affect the upper and lower respiratory tract, respectively. Both are 
characterized by inflammation of the respiratory mucosa and involve similar inflammatory 
cells and mediators. Moreover AR and asthma have a considerable impact on quality of life, 
work and school productive, absenteeism, and individual and socioeconomic burden 
(Gaugris et al., 2006; Bachert et al., 2002; Bousquet et al., 2001). The socioeconomic burden 
via annual costs of treating AR and asthma, both direct costs such as hospitalization, 
medication and indirect costs such as time lost from work are substantial, and represent 
heavier burden in modern societies. 
2.1.1 Association between AR and asthma 
AR and asthma commonly coexist. Among asthmatic patients, approximately 85% also have 
AR. Conversely, up to 40% of AR patients have or will develop asthma (Bousquet et al., 
2001; Guerra et al., 2002). There are many common anatomical and pathophysiological 
features between upper and lower airway disorders, primarily in histology and 
immunology. Examples of common anatomical features include ciliated columnar epithelial 
cells, mucinous glands, vasculature, and innervation (Baraniuk, 1997). Both AR and asthma 
are chronic inflammatory diseases of the upper and lower airways and their inflammatory 
mechanisms are characterized by inflammatory infiltrates made up of eosinophils, T cells, 
and mast cells that release several mediators, chemokines and cytokines, inducing local and 
systemic IgE synthesis, and activate a systemic link via the bone marrow. 
AR has been shown to be a risk factor for asthma in children and adults (Leynaert et al., 
2000). A longitudinal, population-based study confirmed an association between AR and 
adult-onset asthma (Shaaban et al., 2008). In another study, among 1,836 college freshman, 
those with AR were significantly more likely to have asthma by the 23-year follow-up than 
those without (Settipane et al., 1994). 
In AR, one distinction is heavy vascularization of the nasal passages, which may lead to 
severe nasal obstruction. In asthma, the presence of smooth muscle from the trachea to the 
bronchioles can result in characteristic bronchoconstriction. Despite these differences, 
similarities exist. Notably, the anatomical structure and physiology of the airway mucosa 
are similar in both upper and lower airway (Bousquet et al., 2003). 
Inflammation is a central component of both conditions. In AR, the inflammatory cascade is 
initiated by allergen deposition on the nasal mucosa and comprises early-phase and often 
late-phase responses. The antigen cross-links and activates IgE receptors, resulting in the 
degranulation of mast cells and the release of several mediators of inflammation, including 
histamine, prostaglandins, leukotrienes, and proteases, leading to sneezing, itching, 
rhinorrhea and congestion symptoms of AR. In asthma, antigen cross-linking and activation 
of IgE receptors may precipitate acute airway constriction.  
AR may promote or exacerbate asthma through several physiological mechanisms that link 
2 disorders. An early study investigating the integrated airway hypothesis suggested a 
nasobronchial reflex arc as a potential mechanism linking upper and lower airway disorders 
(Kaufman et al., 1970). Based on this hypothesis, nasal allergen challenge affects bronchial 
hyperresponsiveness through a reflex arc that involves trigeminal afferents and vagal 
efferents. In addition, other mechanisms include systemic release of mediators and 
cytokines, postnasal drip resulting irritation and oral breathing caused by nasal obstruction, 
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which causes dry, cold air to penetrate into the bronchi and promote bronchial 
hyperresponsiveness (Meltzer, 2005) (Fig. 2). 
 
 
Fig. 2. Mechanisms of pathologic relationships between upper and lower airways (Adapted 
from Meltzer, 2005). 
2.1.2 Asthma evaluation in AR 
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines recommend that asthma 
patients be evaluated for AR and, conversely, that AR patients be evaluated for asthma 
(Bousquet et al., 2001). In a prospective study evaluating 375 adults with persistent 
moderate to severe AR and 115 controls, the authors concluded that patients with persistent 
moderate to severe AR without an asthma diagnosis should be evaluated for the lower 
airway with pulmonary function testing (Ciprandi et al., 2008). Similarly, ARIA 2008 
updates recommend that persistent AR patients should be evaluated for asthma (Bousquet 
et al., 2008). In our previous study, 173 AR patients were evaluated for the lower airway 
with the methacholine bronchoprovocation test and we recommend lower airway 
evaluation for the selected patients with nasal polyps, moderate to severe symptoms, and 
high blood eosinophil count (>320 cells/µL) instead of a routine lower airway evaluation 
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(Ahn et al., 2010). In another study, persistent type of rhinitis and parental history of asthma 
were significant and independent risk factors for bronchial hyperresponsiveness in AR 
children (Choi et al., 2007).  
2.1.3 Treatment of AR 
Early, active treatment of AR may be appropriate to decrease the incidence and morbidity 
associated with asthma. In a retrospective US cohort study of medical records covering 1 
year for 4,944 asthmatic patients, approximately 73% were treated for AR. Asthma-related 
events occurred more often in untreated patients than in treated patients (6.6% vs. 1.3%) 
(Crystal-Peters et al., 2002). 
Controlling nasal symptoms with intranasal steroids improves asthma symptoms and 
nonspecific bronchial hyperresponsiveness (Watson et al., 1993). The authors reported that 
bronchial hyperresponsiveness to methacholine was significantly reduced in patients with 
perennial AR and asthma following treatment with intranasal steroids but not following 
intranasal placebo. More importantly, they also performed a radiolabeled deposition study 
of intranasal steroid administration and found that less than 2% was deposited in the chest 
area. These results suggest that treatment of inflammation in the upper airways indirectly 
improves asthma symptoms and decreases bronchial hyperresponsiveness, which is not a 
direct effect of the intranasally administered corticosteroid on the lower airways (Watson et 
al., 1993).  
A 3-year retrospective cohort study conducted in 14 US centers evaluated whether treatment 
with intranasal corticosteroid (INS) in patients of 5 years or older with asthma was 
associated with a reduced risk of emergency room visits for asthma (Adams et al., 2002). 
Treatment of nasal conditions, particularly with INSs, appeared to prevent asthma 
exacerbations leading to emergency room visits.  
2.2 AR and RS 
AR and RS are increasingly being regarded as interrelated and part of a spectrum of upper 
airway inflammatory disease. AR also may be a contributing factor in 25% to 30% of patients 
with acute maxillary sinusitis and in as many as 60% to 80% of patients with chronic 
sinusitis (Spector, 1997). At the least, AR is associated with and probably a predisposing 
factor in the development of RS (Slavin, 1998). Both conditions are characterized by an 
inflammatory response leading to an altered milieu within the nose and paranasal sinuses, 
thus rendering normal host defenses weakened and susceptible to further inflammatory 
insult. 
However, the role of allergy in the pathogenesis of RS has been under debate and 
controversy over the past several years.  
2.2.1 Association between AR and RS 
RS is an inflammation of the nose and paranasal sinuses, attributed to many potential 
factors. The term “rhinosinusitis” rather than “sinusitis” reflects more accurately close 
anatomical and pathophysiological relationship between rhinitis and chronic sinusitis, 
which are commonly comorbid. The typical pathophysiological scheme leading to the 
development of RS starts with some inciting agents (viral, bacterial, fungal, allergen) or 
predisposing factor (anatomical, immunological) leading to generalized mucosal edema and 
inflammation. In the development of RS, mucosal inflammation leads to ciliary dysfunction 
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and mucus stasis, as well as edema of the sinus ostia. The stasis of secretions within the 
sinuses serves as a nidus for bacterial colonization and growth. These events coupled with 
the impairment of host defenses as a result of the inflammatory mediators released in 
response to the inciting agent, create a cycle of sustained inflammation that can chronically 
damage the nasal and paranasal sinus linings (Ahmad and Zacharek, 2008; Gwaltney et al., 
1995) (Fig. 3).  
 
 
Fig. 3. Sinus cycle leading to RS (Adapted from Ahmad and Zacharek, 2008) 
Adult chronic RS was defined as a group of disorders characterized by inflammation of the 
mucosa of the nose and paranasal sinuses of at least 12 weeks duration. In the past, chronic 
RS was characterized as a disease process caused by an anatomical obstruction of the sinus 
ostia, specifically ostiomeatal complex occlusion. The factors leading to this obstruction 
included viral infection aided by anatomical factors, leading to mucosal inflammation and 
edema, with thickening of mucus secretions and secondary bacterial infection. It has become 
clear that the pathogenic mechanisms are more complex than would be explained by a 
simple model and that there are other chronic inflammatory processes that contribute to the 
development of chronic RS. However, the exact mechanism by which allergy predisposes to 
the development of chronic RS has not been fully elucidated. 
According to another model of the pathogenesis of RS, chronic RS is characterized by 
basement membrane thickening, subepithelial fibrosis and edema, goblet cell hyperplasia, 
and persistent inflammation (Christodoulopoulos et al., 2000). Like in asthma, remodeling of 
the mucosa occurs in response to this chronic and progressive inflammation. This model of 
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and mucus stasis, as well as edema of the sinus ostia. The stasis of secretions within the 
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the impairment of host defenses as a result of the inflammatory mediators released in 
response to the inciting agent, create a cycle of sustained inflammation that can chronically 
damage the nasal and paranasal sinus linings (Ahmad and Zacharek, 2008; Gwaltney et al., 
1995) (Fig. 3).  
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edema, with thickening of mucus secretions and secondary bacterial infection. It has become 
clear that the pathogenic mechanisms are more complex than would be explained by a 
simple model and that there are other chronic inflammatory processes that contribute to the 
development of chronic RS. However, the exact mechanism by which allergy predisposes to 
the development of chronic RS has not been fully elucidated. 
According to another model of the pathogenesis of RS, chronic RS is characterized by 
basement membrane thickening, subepithelial fibrosis and edema, goblet cell hyperplasia, 
and persistent inflammation (Christodoulopoulos et al., 2000). Like in asthma, remodeling of 
the mucosa occurs in response to this chronic and progressive inflammation. This model of 
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pathogenesis also supports the notion of a unified airway with similar histopathological 
changes and immunological mechanism occurring as a result of inflammatory insult. 
In a 1989 study, skin testing in 2 groups of young adults, one with acute maxillary sinusitis, 
and a matched group without sinusitis, revealed that the prevalence of positive allergen 
testing was greater in the group with RS (45% vs. 33%) (Savolainen, 1989). The author thus 
concluded that allergy did play a role in the development of acute RS, and that it was more 
common among atopic individuals. In another study, positive inhalant allergy testing was 
present in over 50% of the 120 patients undergoing endoscopic sinus surgery, which led him 
to conclude that allergy may be a predisposing cause of chronic sinusitis (Kennedy, 1992). 
The contribution of allergy in the pathophysiology of both acute and chronic RS has been 
supported by studies examining the role of the ethmoid sinuses in terms of immunological, 
histopathological and postsurgical changes. The ethmoid mucosa affected by RS 
demonstrates an increased CD4/CD8 ratio and increase in the number of eosinophils and 
mast cells as well as extracellular matrix deposition, basement membrane disruption, and 
denudation of the epithelium (Christodoulopoulos et al., 2000). These findings are similar to 
the effect of allergy on other parts of the respiratory tract. In another study attempting to 
correlate tissue histopathology in chronic RS with immune mechanisms in allergic disease, 
the conclusions were that the proposed method for quantifying tissue eosinophilia in sinus 
mucosa was reliable and valid and that a relatively strong correlation existed between CT 
scan stage and tissue eosinophilia in chronic RS (Bhattacharyya et al., 2001).  
Several studies examining the relationship between allergen exposure or provocation and 
RS exacerbation have also suggested a common mechanism in AR and RS (Pelikan and 
Pelikan-Filipek, 1990; Conner et al., 1989; Slavin, 1998). The investigators demonstrated an 
increase in metabolic activity of the maxillary sinus mucosa in chronic RS patients during 
ragweed season, using single-photon emission CT scanning (Slavin, 1998).  
Evidence of a common pathophysiological mechanism between AR and RS is convincing. 
Although a clear causal mechanism leading from AR to the development of RS remains to 
be elucidated, an increasing number of studies have found the possibility and evidence of 
this link. 
2.3 AR and OME 
OME is one of the most commonly encountered diseases in children, affecting 
approximately 90% of children at some time before school age (Tos, 1984). OME is 
characterized by an accumulation of fluid in the middle ear behind an intact tympanic 
membrane in the absence of signs and symptoms of acute infection. If we look at the natural 
history of OME, many cases are self-limited and resolve spontaneously (Williamson et al., 
1994). But, OME is the most frequent cause of hearing loss in children (Thomas et al., 2006; 
Shekelle et al., 2002). 
An epidemiologic link between OME and AR has been demonstrated in many trials (Alles et 
al., 2001; Tomonaga et al., 1988). Prevalence of AR among patients with chronic or recurrent 
OME is higher than that seen in the same age group in the general population. 
2.3.1 Pathophysiology of OME and AR 
The etiology of OME is multifactorial. It may be related to bacterial infection, poor clearance 
due to Eustachian tube (E-tube) dysfunction, local inflammatory reactions and possibly 
atopy (Thomas et al., 2006; Luong and Roland, 2008). 
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Data from several animal studies have suggested a link between nasal allergic inflammation 
and E-tube dysfunction. For example, an intranasal pollen antigen challenge significantly 
compromised E-tube function in 23 passively sensitized juvenile rhesus monkeys (Doyle et 
al., 1984). A nasal allergen challenge in rats resulted in E-tube inflammation, negative 
pressure and hindrance of mucociliary clearance (Ebert et al., 2007). Another previous study 
showed negative middle ear pressure following nasal allergen challenge in subjects with AR 
and hypothesized the involvement of both immunological and mechanical mechanisms 
(O'Connor et al., 1984). E-tube dysfunction developed during allergy season in 60% of 
children with seasonal AR and correlated with AR symptom severity (Osur et al., 1989).  
Because the E-tube lining is contiguous with the nasopharynx, allergic disorders such as AR 
may cause inflammation and swelling in this region resulting in E-tube obstruction in the 
same manner as in the nasal mucosa (Alles et al., 2001; Luong and Roland, 2008; Fireman, 
1988) (Fig. 4). Furthermore, it has been found that a reduction in the size of the lumen in an 
inflamed E-tube could impede mucociliary function, thus delaying clearance of acute 
infective middle ear effusion, leading to recurrent OME (Alles et al., 2001). 
Several studies analyzing middle ear mucosa and effusions in atopic patients with OME 
have demonstrated that the composition of the inflammatory substrate in acute otitis media 
is similar to the type I late-phase allergic response seen in other areas of the respiratory tract, 
such as in AR, chronic RS, and asthma (Nguyen et al., 2004; Sobol et al., 2002; Hurst, 1996). 
The middle ear effusions of atopic patients with OME showed significantly higher levels of 
eosinophils, T lymphocytes, and IL-4 mRNA+ cells (p<0.01) and significantly lower levels of 
neutrophils and IFN-γ mRNA+ cells (p<0.01) compared to non-atopic patients with OME 
(Nguyen et al., 2004). Similarly, in another study, a higher percentage of eosinophils and T 
lymphocytes, and a higher percentage of cells expressing IL-4 and IL-5 were found among 
atopic patients with OME (Sobol et al., 2002). 
 
 
Fig. 4. Schematic diagram showing anatomical relationship of E-tube between the 
nasopharynx and middle ear (Adapted from Fireman, 1988) 
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pathogenesis also supports the notion of a unified airway with similar histopathological 
changes and immunological mechanism occurring as a result of inflammatory insult. 
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and a matched group without sinusitis, revealed that the prevalence of positive allergen 
testing was greater in the group with RS (45% vs. 33%) (Savolainen, 1989). The author thus 
concluded that allergy did play a role in the development of acute RS, and that it was more 
common among atopic individuals. In another study, positive inhalant allergy testing was 
present in over 50% of the 120 patients undergoing endoscopic sinus surgery, which led him 
to conclude that allergy may be a predisposing cause of chronic sinusitis (Kennedy, 1992). 
The contribution of allergy in the pathophysiology of both acute and chronic RS has been 
supported by studies examining the role of the ethmoid sinuses in terms of immunological, 
histopathological and postsurgical changes. The ethmoid mucosa affected by RS 
demonstrates an increased CD4/CD8 ratio and increase in the number of eosinophils and 
mast cells as well as extracellular matrix deposition, basement membrane disruption, and 
denudation of the epithelium (Christodoulopoulos et al., 2000). These findings are similar to 
the effect of allergy on other parts of the respiratory tract. In another study attempting to 
correlate tissue histopathology in chronic RS with immune mechanisms in allergic disease, 
the conclusions were that the proposed method for quantifying tissue eosinophilia in sinus 
mucosa was reliable and valid and that a relatively strong correlation existed between CT 
scan stage and tissue eosinophilia in chronic RS (Bhattacharyya et al., 2001).  
Several studies examining the relationship between allergen exposure or provocation and 
RS exacerbation have also suggested a common mechanism in AR and RS (Pelikan and 
Pelikan-Filipek, 1990; Conner et al., 1989; Slavin, 1998). The investigators demonstrated an 
increase in metabolic activity of the maxillary sinus mucosa in chronic RS patients during 
ragweed season, using single-photon emission CT scanning (Slavin, 1998).  
Evidence of a common pathophysiological mechanism between AR and RS is convincing. 
Although a clear causal mechanism leading from AR to the development of RS remains to 
be elucidated, an increasing number of studies have found the possibility and evidence of 
this link. 
2.3 AR and OME 
OME is one of the most commonly encountered diseases in children, affecting 
approximately 90% of children at some time before school age (Tos, 1984). OME is 
characterized by an accumulation of fluid in the middle ear behind an intact tympanic 
membrane in the absence of signs and symptoms of acute infection. If we look at the natural 
history of OME, many cases are self-limited and resolve spontaneously (Williamson et al., 
1994). But, OME is the most frequent cause of hearing loss in children (Thomas et al., 2006; 
Shekelle et al., 2002). 
An epidemiologic link between OME and AR has been demonstrated in many trials (Alles et 
al., 2001; Tomonaga et al., 1988). Prevalence of AR among patients with chronic or recurrent 
OME is higher than that seen in the same age group in the general population. 
2.3.1 Pathophysiology of OME and AR 
The etiology of OME is multifactorial. It may be related to bacterial infection, poor clearance 
due to Eustachian tube (E-tube) dysfunction, local inflammatory reactions and possibly 
atopy (Thomas et al., 2006; Luong and Roland, 2008). 
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Data from several animal studies have suggested a link between nasal allergic inflammation 
and E-tube dysfunction. For example, an intranasal pollen antigen challenge significantly 
compromised E-tube function in 23 passively sensitized juvenile rhesus monkeys (Doyle et 
al., 1984). A nasal allergen challenge in rats resulted in E-tube inflammation, negative 
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showed negative middle ear pressure following nasal allergen challenge in subjects with AR 
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Because the E-tube lining is contiguous with the nasopharynx, allergic disorders such as AR 
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2.3.2 Treatment of OME 
Because of the pathophysiological associations of AR with OME, treatments focusing on 
allergic inflammation may be helpful in the management of OME (Caffarelli et al., 1998; 
Fireman, 1988).  
A meta-analysis of 16 randomized controlled trials demonstrated no significant benefit from 
antihistamines, decongestants, or combined antihistamines and decongestants versus 
placebo for treatment of OME (Griffin et al., 2006). However, in a meta-analysis of 6 
randomized clinical trials, oral steroids administered for 7-14 days increased the rate of 
complete effusion resolution versus no steroid (Rosenfeld et al., 1991). A Cochrane database 
review yielded very similar results, demonstrating a quicker resolution of OME in the short 
term (≤2 wk) with oral steroids alone or in combination with antibiotics (Thomas et al., 
2006). However, there are likely to be safety concerns surrounding oral corticosteroids, such 
as behavioral changes, increased appetite, weight gain, and adrenal and growth 
suppression. On the contrary, INS has limited systemic absorption, these drugs offer safety 
advantages over oral corticosteroids and would be expected to exert their anti-inflammatory 
effects more locally in the nose, nasopharynx, and E-tube (Tracy et al., 1998). In this study, 
the authors compared the effects of prophylactic antibiotic alone or in combination with 
either intranasal beclomethasone or placebo on middle ear pressure, otoscopic examination, 
and symptom scores in 61 children with persistent middle ear effusion greater than 3 
months. Subjects with the beclomethasone plus antibiotic group improved more rapidly in 
middle ear pressure and otoscopic examination than those with the antibiotic alone or 
placebo groups during the initial 8 wk. At 12 wk, only the combination treatment showed 
significant improvement in bilateral ear pressures. In addition, symptom resolution was 
significantly greater at 12 wk with antibiotic plus beclomethasone group than with the 
antibiotic alone group. However, there were no differences in outcomes between atopic and 
nonatopic subjects (Tracy et al., 1998). In another previous study, patients with OME treated 
with mometasone furoate nasal spray experienced significantly higher rates of resolution of 
OME at 6 wk compared with untreated controls (42.2% vs. 14.5%; p<0.001) (Cengel and 
Akyol, 2006). 
In conclusion, atopic status should be evaluated in recurrent or chronic OME patients who 
had no response to antibiotic therapy and INS could be used as an adjunct to treatment of 
OME patients with AR. However, further studies are needed to elucidate whether atopic 
status or rhinitis itself may influence the development of OME. 
2.4 AR and sleep disturbance 
The effect of AR on sleep can impair a patient’s quality of life (Canonica et al., 2007; Schatz, 
2007). A nationwide controlled cross-sectional study showed that patients with AR have 
more difficulties in falling asleep, take more sleeping drugs, suffer from nocturnal 
awakenings, and feel that they do not get sufficient sleep when compared to healthy 
controls (Leger et al., 2006). Children with AR can experience micro-arousal during their 
sleep and irregular breathing. 
A prospective study of 39 children with habitual snoring revealed that 14 subjects (36%) 
showed sensitivity to allergens (McColley et al., 1997), which is higher than expected for the 
general pediatric population. Based on subjective criteria, sleep apnea syndrome has also 
been found to be more prevalent in AR than in controls (Leger et al., 2006). The reasons for 
poor sleep in AR are not clearly understood, but may be related, at least in part, to nasal 
congestion (Meltzer, 2004). Several studies have shown the relationships between AR and 
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nasal obstruction and abnormal breathing during sleep, snoring and sleep apnea (Scharf and 
Cohen, 1998; Young et al., 1997).  
The impact of the severity of rhinitis on quality of life including sleep, daily activities, and 
work performance was shown to be stronger than the duration of rhinitis (Bousquet et al., 
2006). Another study showed that the severity of rhinitis, but not its frequency, was significant 
factors for severe insomnia, hypersomnia, respiratory arrest, apnea, sleepiness, and regular use 
of sedatives (Leger et al., 2006). Recently, we are conducting multi-center cohort study on the 
complication of rhinitis in Korean children. All patients were classified into 4 categories 
(intermittent mild, intermittent moderate to severe, persistent mild and persistent moderate to 
severe) using ARIA classification, and Korean version of Obstructive Sleep Apnea 18 (KOSA-
18) questionnaire were performed. High KOSA-18 scores mean more sleep disturbance. In our 
cohort study, the preliminary results (n=999) showed that sleep disturbance was more 
frequent according to the ARIA classification (Fig. 5) and there were no differences between 
atopic and nonatopic patients (48.7±17.5 vs. 51.1±19.7, p=0.120) (unpublished data). 
In these groups, after the treatment of rhinitis, KOSA-18 scores at 6 months were lower than 
those of baseline; sleep disturbance were improved after the 6-month follow-up (Fig. 6). 
AR appears to increase the risk of obstructive sleep apnea syndrome (OSAS) in children. 
Adequate treatment of AR can reduce the severity of OSAS and prevent the emergence of an 
elongated face, which predisposes patients to OSAS. It may also reduce the severity of 
coexisting OSAS. 
3. Psychosocial comorbidities 
3.1 AR and cognitive disorder 
AR leads to psychosocial complications such as cognitive impairment and learning 
problems as well as physical complications. Young people, with and without treatment, 
were given the task, during the ongoing pollen season, to learn about agriculture in desert 
environments. The results showed that individuals receiving placebo or sedative 
antihistamines performed significantly worse than healthy controls (Vuurman et al., 1993). 
In another study, patients allergic to ragweed have impaired cognitive learning during the 
pollen season and some also had memory impairment (Marshall et al., 2000). It was also 
shown that patients with AR symptoms take a longer time to make decisions and have a 
slower psychomotor rate than healthy control subjects. 
However, it is under debate whether AR itself does or does not lead to learning problems 
among allergic students. Resultant symptoms, such as sleep deprivation and general 
malaise can affect concentration and learning. Consequently, this theory argues that 
cognitive difficulties are a secondary result of sleep problems. 
The consequences of AR effect on learning and other cognitive functions in relation to 
school performance have been established. A case–control study was conducted on 1,834 
students sitting for the national examinations in mathematics, English and science (Walker 
et al., 2007). Those who had allergic symptoms during the examination period had a 40% 
higher risk of achieving lower grades than students who did not have symptoms.  
Children with AR may fall behind in classes. Sniffling, rubbing and blowing the nose are 
more common among children with AR than those without. These behaviors make children 
self-conscious and peers may be annoyed by them, leading to teasing and a further increase 
in their stress levels (Meltzer, 2001) and may cause behavioral disorders. Thus, adequate 
treatment of AR should be needed, especially in school children. 
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Because of the pathophysiological associations of AR with OME, treatments focusing on 
allergic inflammation may be helpful in the management of OME (Caffarelli et al., 1998; 
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A meta-analysis of 16 randomized controlled trials demonstrated no significant benefit from 
antihistamines, decongestants, or combined antihistamines and decongestants versus 
placebo for treatment of OME (Griffin et al., 2006). However, in a meta-analysis of 6 
randomized clinical trials, oral steroids administered for 7-14 days increased the rate of 
complete effusion resolution versus no steroid (Rosenfeld et al., 1991). A Cochrane database 
review yielded very similar results, demonstrating a quicker resolution of OME in the short 
term (≤2 wk) with oral steroids alone or in combination with antibiotics (Thomas et al., 
2006). However, there are likely to be safety concerns surrounding oral corticosteroids, such 
as behavioral changes, increased appetite, weight gain, and adrenal and growth 
suppression. On the contrary, INS has limited systemic absorption, these drugs offer safety 
advantages over oral corticosteroids and would be expected to exert their anti-inflammatory 
effects more locally in the nose, nasopharynx, and E-tube (Tracy et al., 1998). In this study, 
the authors compared the effects of prophylactic antibiotic alone or in combination with 
either intranasal beclomethasone or placebo on middle ear pressure, otoscopic examination, 
and symptom scores in 61 children with persistent middle ear effusion greater than 3 
months. Subjects with the beclomethasone plus antibiotic group improved more rapidly in 
middle ear pressure and otoscopic examination than those with the antibiotic alone or 
placebo groups during the initial 8 wk. At 12 wk, only the combination treatment showed 
significant improvement in bilateral ear pressures. In addition, symptom resolution was 
significantly greater at 12 wk with antibiotic plus beclomethasone group than with the 
antibiotic alone group. However, there were no differences in outcomes between atopic and 
nonatopic subjects (Tracy et al., 1998). In another previous study, patients with OME treated 
with mometasone furoate nasal spray experienced significantly higher rates of resolution of 
OME at 6 wk compared with untreated controls (42.2% vs. 14.5%; p<0.001) (Cengel and 
Akyol, 2006). 
In conclusion, atopic status should be evaluated in recurrent or chronic OME patients who 
had no response to antibiotic therapy and INS could be used as an adjunct to treatment of 
OME patients with AR. However, further studies are needed to elucidate whether atopic 
status or rhinitis itself may influence the development of OME. 
2.4 AR and sleep disturbance 
The effect of AR on sleep can impair a patient’s quality of life (Canonica et al., 2007; Schatz, 
2007). A nationwide controlled cross-sectional study showed that patients with AR have 
more difficulties in falling asleep, take more sleeping drugs, suffer from nocturnal 
awakenings, and feel that they do not get sufficient sleep when compared to healthy 
controls (Leger et al., 2006). Children with AR can experience micro-arousal during their 
sleep and irregular breathing. 
A prospective study of 39 children with habitual snoring revealed that 14 subjects (36%) 
showed sensitivity to allergens (McColley et al., 1997), which is higher than expected for the 
general pediatric population. Based on subjective criteria, sleep apnea syndrome has also 
been found to be more prevalent in AR than in controls (Leger et al., 2006). The reasons for 
poor sleep in AR are not clearly understood, but may be related, at least in part, to nasal 
congestion (Meltzer, 2004). Several studies have shown the relationships between AR and 
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nasal obstruction and abnormal breathing during sleep, snoring and sleep apnea (Scharf and 
Cohen, 1998; Young et al., 1997).  
The impact of the severity of rhinitis on quality of life including sleep, daily activities, and 
work performance was shown to be stronger than the duration of rhinitis (Bousquet et al., 
2006). Another study showed that the severity of rhinitis, but not its frequency, was significant 
factors for severe insomnia, hypersomnia, respiratory arrest, apnea, sleepiness, and regular use 
of sedatives (Leger et al., 2006). Recently, we are conducting multi-center cohort study on the 
complication of rhinitis in Korean children. All patients were classified into 4 categories 
(intermittent mild, intermittent moderate to severe, persistent mild and persistent moderate to 
severe) using ARIA classification, and Korean version of Obstructive Sleep Apnea 18 (KOSA-
18) questionnaire were performed. High KOSA-18 scores mean more sleep disturbance. In our 
cohort study, the preliminary results (n=999) showed that sleep disturbance was more 
frequent according to the ARIA classification (Fig. 5) and there were no differences between 
atopic and nonatopic patients (48.7±17.5 vs. 51.1±19.7, p=0.120) (unpublished data). 
In these groups, after the treatment of rhinitis, KOSA-18 scores at 6 months were lower than 
those of baseline; sleep disturbance were improved after the 6-month follow-up (Fig. 6). 
AR appears to increase the risk of obstructive sleep apnea syndrome (OSAS) in children. 
Adequate treatment of AR can reduce the severity of OSAS and prevent the emergence of an 
elongated face, which predisposes patients to OSAS. It may also reduce the severity of 
coexisting OSAS. 
3. Psychosocial comorbidities 
3.1 AR and cognitive disorder 
AR leads to psychosocial complications such as cognitive impairment and learning 
problems as well as physical complications. Young people, with and without treatment, 
were given the task, during the ongoing pollen season, to learn about agriculture in desert 
environments. The results showed that individuals receiving placebo or sedative 
antihistamines performed significantly worse than healthy controls (Vuurman et al., 1993). 
In another study, patients allergic to ragweed have impaired cognitive learning during the 
pollen season and some also had memory impairment (Marshall et al., 2000). It was also 
shown that patients with AR symptoms take a longer time to make decisions and have a 
slower psychomotor rate than healthy control subjects. 
However, it is under debate whether AR itself does or does not lead to learning problems 
among allergic students. Resultant symptoms, such as sleep deprivation and general 
malaise can affect concentration and learning. Consequently, this theory argues that 
cognitive difficulties are a secondary result of sleep problems. 
The consequences of AR effect on learning and other cognitive functions in relation to 
school performance have been established. A case–control study was conducted on 1,834 
students sitting for the national examinations in mathematics, English and science (Walker 
et al., 2007). Those who had allergic symptoms during the examination period had a 40% 
higher risk of achieving lower grades than students who did not have symptoms.  
Children with AR may fall behind in classes. Sniffling, rubbing and blowing the nose are 
more common among children with AR than those without. These behaviors make children 
self-conscious and peers may be annoyed by them, leading to teasing and a further increase 
in their stress levels (Meltzer, 2001) and may cause behavioral disorders. Thus, adequate 
treatment of AR should be needed, especially in school children. 
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Fig. 5. Mean differences of KOSA-18 scores according to ARIA classification among (a) total 
patients and (b) allergic rhinitis (AR)/non allergic rhinitis (NAR) patients. All the data 
showed statistical significances (p<0.001, adjusted to age). Group A: intermittent mild, 
Group B: intermittent moderate to severe, Group C: persistent mild, Group D: persistent 
moderate to severe. □: AR patients, ■: NAR patients 
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Fig. 6. Mean differences of KOSA-18 scores after the treatment of rhinitis (a) between 
AR/NAR patients and (b) according to ARIA classification. Group A: intermittent mild, 
Group B: intermittent moderate to severe, Group C: persistent mild, Group D: persistent 
moderate to severe. 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 248 
Total patients
















(a) Total patients 
AR/NAR patients
















(b) AR/NAR patients 
Fig. 5. Mean differences of KOSA-18 scores according to ARIA classification among (a) total 
patients and (b) allergic rhinitis (AR)/non allergic rhinitis (NAR) patients. All the data 
showed statistical significances (p<0.001, adjusted to age). Group A: intermittent mild, 
Group B: intermittent moderate to severe, Group C: persistent mild, Group D: persistent 
moderate to severe. □: AR patients, ■: NAR patients 
 





















(a) KOSA-18 scores changes between AR/NAR patients 
 
 





















Fig. 6. Mean differences of KOSA-18 scores after the treatment of rhinitis (a) between 
AR/NAR patients and (b) according to ARIA classification. Group A: intermittent mild, 
Group B: intermittent moderate to severe, Group C: persistent mild, Group D: persistent 
moderate to severe. 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 250 
3.2 AR and missing school or work 
AR has considerable negative effects on both school-aged children and adult workers. 
Especially in school-aged children, it can not only affect sleep and cognitive function, but 
also cause school absenteeism and presenteeism. Untreated AR in childhood could cause 
sleep disturbances and daytime sleepiness, absenteeism and presenteeism (inattention, 
distraction, lack of concentration), irritability and mood disorders (Jauregui et al., 2009). In 
terms of adult workers, a previous study in the US evaluated economic impact of workplace 
productivity losses due to AR (Lamb et al., 2006). A total of 8,267 US employees at 47 
employer locations volunteered to participate in health/wellness screenings. AR was the 
most prevalent; 55% of employees reported AR symptoms for an average of 52.5 days, were 
absent 3.6 days per year. The mean total productivity losses (absenteeism+presenteeism) 
were 593 US dollars for AR, 518 dollars for high stress, 277 dollars for migraine, 273 dollars 
for depression, 269 dollars for arthritis/rheumatism, 248 dollars for anxiety disorder, 181 
dollars for respiratory infections, 105 dollars for hypertension, 95 dollars for diabetes, 85 
dollars for asthma, and 40 dollars for coronary heart disease. Thus, the authors suggested 
that allergies are major contributors to the total cost of health-related absenteeism and 
presenteeism. 
4. Conclusion 
AR has a considerable effect on one’s quality of life and can have significant consequences if 
left untreated. The consequences are more far-reaching than expected. Because all the 
possible comorbidities of AR have significant consequences to the community, it is fair to 
say that physicians and patients should pay close attention to prevent the occurrence of 
comorbidities. Furthermore, the adequate treatment of AR could prevent physical and 
psychosocial complications. 
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1. Introduction 
Hoarseness is a result of the vocal cords not working properly and it can be detected by 
hearing. Basic and higher harmonic tones are associated with severe hoarseness, as well as 
noises replacing the harmonic noise. Hoarseness can also appear as a result of organic 
changes of the vocal cords (also caused by allergic mucosal changes) or functional 
disorders.  
The most common organic changes of the vocal cords are polyps, nodules and Reinke's 
oedema (1). Under a microscope they share many common characteristics of mucosal 
changes and indicate pathological changes in the superficial layer of the lamina propria, in 
the so-called Reinke’s space (2). The main changes include: fluid oedema, elevated 
interstitial and exudative proteins, dilated or hypertrophic vein walls. The aetiology of the 
benign changes is, however, slightly different although the changes in the lamina propria 
are quite similar. The most common cause is trauma (phonotrauma), exposure to 
unfavourable microclimate conditions, smoking, voice overuse or incorrect vocal technique, 
hormonal changes, and allergy (3).  
Reinke's oedema is a swelling of vocal cords that mostly occurs bilaterally. It is a chronic 
benign condition. On examination a transparent, sometimes a pink swelling is seen along 
the length and on the upper side of the vocal cord. As long as the swelling remains small, 
the vocal cords can vibrate normally. However, as the oedema grows and therefore 
changes the biomechanics of the larynx, the functional impairment of the phonation 
appears, vocal cords do not vibrate appropriately and the voice becomes low-pitched and 
hoarse.  
Histologically, the mucosa is covered by a layer of normal and hyperplastic epithelium. By 
enlargement of the swelling, it may become atrophic. Persisting etiologic factors can cause 
the epithelium to thicken or become hypetrophic. Simple hyperplasia is the most common 
form of the epithelial changes due to hypertrophy (1).  
A polyp is a mucosal thickness usually found at the front midpoint of the vocal cord. It is 
most commonly thought to be caused by vocal overuse or incorrect vocal technique. It is 
very similar to the Reinke's oedema, except that the polyp is localised.  
Of all the benign oedematous vocal cord lesions, nodules are the smallest and by aetiology 
similar to polyps. The oedema is modified as in Reinke's oedema or polyps.  
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2. Allergy and Reinke’s edema 
There is a lack of research on aetiologic factors such as allergies, allergic inflammation, and 
hormonal changes. We became suspicious of their influence over oedematous changes of the 
mucosa only on the basis of our clinical experience. Pathohistological examination did not 
reveal any pathognomonic changes of the mucosa neither during an allergy nor during 
hormonal changes. The changes of the lamina propria in Reinke's oedema, polyps and 
nodules are nearly the same: oedema with interstitial proteins (collagen, elastane), 
fibroblasts, intercellular substance (glycoproteins and proteoglycans), dilated vessels, 
thickened basal membrane. The number of inflammatory cells in the lamina propria in the 
tissue samples of patients with and without allergy was the same: individual monocytes are 
visible (4).  
Reinke's oedema patients are not more allergy-prone compared to normal population. A 
study carried out among ENT outpatient clinic patients with Reinke's oedema showed that 
the frequency of allergy was 20%, which complies with the number of allergies among 
normal population (5).  
3. Hypersensitivity skin tests and Reinke’s edema 
On the basis of history we determined how many patients with Reinke’s edema (N=80) 
suspected on possible hypersensitiveness. Only in five cases patients noticed changes in 
their voice in contact with a certain substance or in certain circumstances. In the study group 
there were 16 patients with clinical signs of allergy and positive allergy skin tests, and in the 
control group (N=80) there were 19 subjects with proven allergy type I.; this did not present 
a statistically significant difference (χ = 0,59 ; p = 0,57). 16 subjects were hypersensitive to 
inhalatory allergens, three among them also to food allergens (flour, eggs, fruit). 
Hypersensitivity to mite was the most frequently established. 
4. Allergic rhinitis ena Reinke’s edema 
Among the patients with Reinke’s edema on vocal folds (N=80) there were 28 subjects with 
chronic hyperplastic rhinitis (35,0%). In 11 patients with Reinke’s edema and hyperplastic 
rhinitis allergy was proven by skin tests. In the control group there were 9 such patients 
with allergic rhinitis and positive skin tests. The difference in the prevalence of allergic 
hyperplastic rhinitis between the groups was not statistically significant (χ=0,06, p= 0,863). 
We also compared the prevalence of allergy between the patients with RE and rhinitis, and 
the patients with Reinke’s edema without rhinitis. Allergy skin tests were positive in the 
group with rhinitis and RE in 11 cases, and in the group with Reinke’s edema without 
rhinitis in 5 subjects, what presented a statistically significant difference  (χ= 13,29, 
p=0,001). 
5. Thyroid disease and Reinke’s edema 
In the study group there were 13 patients who claimed thyroid diseases in the history: 9 
subjects had enlarged thyroid gland in euthyroid state, and 4 subjects had hypothyroidism. 
In the control group two subjects had difficulties with the thyroid gland (one 
hypothyroidism, the other hyperthyroidism). 
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The prevalence of other risk factors for the occurrence of Reinke’s edema in the study and 
control groups is represented in Table 1.  
 
Etiological factor Study group n=80 
Control group 
n=80 P 
Smoking 69 10 0.001 
Thyroid diseases 13 2 0.003 
Gastroesophageal reflux 38 20 0.003 
Microclimate conditions 25 12 0.015 
Unsuitable speaking and 
voice technique 21 7 0.04 
Table 1. Prevalence of some risk factors for the occurrence of RE on vocal folds in the study 
and control groups 
6. Discussion 
According to the results of our study we suppose that allergy is one of the factors 
contributing to the occurrence of RE on vocal cords, but it is by no means a crucial one. We 
have established that other risk factors (smoking, unsuitable speaking habits and vocal load 
at work, gastroesophageal reflux, thyroid diseases) are much more frequent (5).  
Allergy type I was confirmed on the basis of history, clinical examination and skin tests in 
20% of patients from the study group with RE and in 23.8% of subjects from the control 
group; this is similar to the prevalence of allergy in general. Among general population the 
prevalence of allergy type I is about 20% (6). In the case that allergy type I is an important 
factor in the etiology of RE, an infiltration of eosinophils in the vocal cord mucosa is 
expected. Actually, there were no eosinophils found in the removed vocal fold mucosa in 
any of 10 patients who had previous surgery on vocal folds because of RE. Similar data were 
also reported by Hočevar-Boltežar et al. who on the basis of history and clinical data 
presumed the allergy as an etiologic factor in the patients with RE and other epithelial 
hyperplastic lesions on vocal cords, however histopathological picture of vocal cord mucosa 
did not confirm it (7). 
In studying allergy as an etiological factor for the occurrence of epithelial hyperplastic 
lesions on vocal cords, we suppose that immediate hypersensitivity type I, according to Gel 
and Coombs, does not play a significant role, because there are other types of 
hypersensitivity that are much more important. Immediate hypersensitivity is easier to 
study because the tests are fast, easy and reliable tests for determining it. However, medical 
literature describes that the most notable type of allergy causing laryngeal mucosa lesions is 
allergy type III but this one is difficult to prove. Sometimes we can rely only on anamnestic 
data which present the basis for the performance of a tolerance test – a patient is exposed to 
a particular allergen. 
It is possible that allergy type I is relevant for the occurrence of RE only in connection with 
the other risk factors. Despite the fact that allergy is not more frequent in the patients with 
RE than in the population in general, we have to consider it and decide for allergy skin tests 
if there is anamnestically and clinically set suspicion to allergy. This is important primarily 
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in the patients with RE and hyperplastic rhinitis. Regarding the results of our study, allergy 
was the cause of rhinitis almost in 40% of patients with RE and hyperplastic rhinitis. On the 
basis of test results the patient will find out which allergens should be avoided. 
In the patients with RE, we have found a relatively frequent occurrence of hyperplastic 
rhinitis (35% of the study group). It is possible that apart from allergy type I there are also 
other factors – above all unfavourable microclimate conditions in workplace – affecting the 
occurrence of rhinitis. 
All authors investigating the etiology of RE agree that smoking is the main risk factor for the 
occurrence of RE (3). In our study, there were significantly more smokers in the study group 
than in the control group. Smoking was the only risk factor merely in 8 patients with RE on 
vocal folds, in all the others it was one of two or more simultaneously acting factors. There 
were also some previous researches emphasizing the importance of simultaneous acting of 
several risk factors (8). 
In the study group we expected a greater percentage of those who incorrectly of excessively 
strain vocal folds while speaking. This factor was only on the fourth place among the most 
important etiologic causes for RE. Voice strain or incorrect speaking technique is performed 
by abnormal activity of the muscles participating in speaking. The fluid accumulates in the 
RS because of microtraumas of vocal folds' vessels, caused by greater mechanical forces 
during vocal folds' vibration. The mechanical stress makes the vessels more permeable 
because their walls degenerate faster. At indirect laryngoscopy, adduction of ventricular 
folds during phonation is often noticed. Their contraction pushes intersticial fluid down into 
the vocal fold and enlarges the edema in RS (9). Learning correct speaking and voice 
technique is the most important step in the treatment of RE, besides giving up smoking. It is 
especially important after the vocal folds' surgery for RE.. 
Due to limited technical possibilities in our study, we determined GER on the basis of 
history, and estimation of typical changes in the larynx and pharynx at indirect 
laryngoscopy performed with the rigid laryngoscope. The findings of the 
esophagogastroscopy which was carried out in less than one quarter of the patients before 
the inclusion in the study confirmed the diagnosis. In our study GER was significantly more 
often present in the study group than in the control group. Therefore, we presume that GER 
is an important factor in the etiology of RE on vocal folds but not the only one and not a 
crucial one. GER has never occurred as the only etiologic factor. It was always accompanied 
by at least one more risk factor for the occurrence of RE. GER causes inflammation of 
laryngeal mucosa, so the vessels become more fragile. Thick mucus accumulated in the 
posterior part of the larynx forces patients to clear their throats. Coughing represents a huge 
mechanical strain of vocal folds and results in their damage. 
Until now, not much has been determined about the role of thyroid hormones in the 
occurrence of RE. The main cause for RE is most probably hypotyroidism. In 1992, Benfary 
performed a thorough study on assessing the thyroid function by measuring seven different 
parameters after indirectly stimulating the thyroid gland with TRH (thyrotropin-releasing 
hormone). As much as 78% of patients had pathological tests which indicated subclinical 
hypothyroidism (10). In our study we stated statistically significant difference between the 
study group and the control group regarding thyroid gland problems. The majority of 
subjects with thyroid gland problems had normal serum levels of TSH and thyroid 
hormones. During the research period only 3 subjects had increased level of TSH. According 
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to the findings of the endocrinologist two subjects needed treatment. Our scarce experience 
with the relation between hypotyroidism and RE indicate that a wider spectrum of tests (for 
example, thyroid stimulation test, determination of thyroid antibodies) is necessary in the 
estimation of thyroid function.  
Laryngeal lesions in subjects working in unfavourable microclimate conditions in chemical 
industry were studied. Some chronic inflammatory changes on laryngeal mucosa were 
found also in the workers without any subjective laryngeal problems. It was supposed that 
the damages of the laryngeal mucosa occurred because of the irritation of chemicals or 
harmful concentration of inhaled dust (11). More recent studies presumed that the possible 
cause of laryngeal inflammation could also be an allergic reaction to chemicals and dust (12). 
Therefore, the laryngeal inflammation can be the consequence of immunological and non-
immunological reaction to the unfavourable microclimate at work. In our study we 
determined only how unpleasant microclimate in workplace influences the occurrence of 
vocal fold swelling without getting in details. The results have shown that the subjects from 
the study group were significantly more often exposed to unfavourable microclimate 
conditions than the subjects from  the control group. Patients stated constant flow of cold air 
in workplace as the most frequent unpleasant factor. This factor has not been stated by 
studies already mentioned; they even very rarely mentioned temperature changes in 
workplace. According to the frequency of appearance, the unpleasant microclimate factors 
are arranged in the following order: dust, industrial chemicals, detergents, cold air due to 
refrigerating chamber or air-conditioning systems, welding gases, lathe dust, cement dust, 
hair-dressing chemicals, and hot water steam. On the basis of our researche we claim that 
microclimate conditions in workplace have a significant influence on the occurrence of the 
vocal fold swelling. The inflammation that occurs as a consequence of their irritating effect, 
changes vessel walls in vocal folds. The changed vessels get more permeable after the action 
of mechanical forces occurring during phonation. Because almost one third of the patients 
with RE from our study was exposed to harmful substances or abnormal temperature in 
workplace, it would be useful to expand the research with the cooperation of other experts 
from this field. Patients with the recurrence of RE on vocal folds were also significantly 
more frequently exposed to unfavourable microclimate than the patients who had the first 
occurrence of RE. 
7. Conclusion 
On the basis of the results of the study we have found out that in the majority of patients 
with RE at least two risk factors were present simultaneously, sometimes even more. Every 
otorhinolaryngologist treating a patient with RE has to be aware of the interconnectedness 
of all the factors. He/she should think about all six factors described and exclude or confirm 
them with selected diagnostic procedures. The treatment has to be etiological, otherwise 
vocal fold swelling can also reoccur after the surgical treatment. We wish to stress that in all 
patients with the recurrence of RE we found at least two risk factors which undoubtedly 
brought up the recurrence of the disease. 
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1. Introduction 
The in vitro diagnosis of allergic reactions to drugs is of particular interest to clinicians, as 
neither the clinical history nor the in vivo tests are fully conclusive. In addition, these tests 
may often be associated with risk, as occurs with the drug provocation test. Various 
different in vitro tests are available for the evaluation of drug hypersensitivity depending on 
the immunological mechanism involved, either IgE mediated or T cell mediated.  
For IgE-mediated reactions, the determination of serum-specific IgE, antigen-specific 
histamine release and sulphidoleukotriene production after in vitro stimulation of effector 
cells, as well as analysis of the activation markers of these cells (the basophil activation test), 
provide greater diagnostic precision. 
Serum-specific IgE assays are still the most common in vitro method for evaluating 
immediate reactions. However, either there is no great commercial availability of fixed drugs 
for this study, with the exception of antibiotics (penicillin G and V, ampicillin, amoxicillin and 
cefaclor), a few muscle relaxants and certain substances, like insulins and ACTH. The most 
validated immunoassay, ImmunoCAP (Phadia, Uppsala, Sweden), has been widely used to 
evaluate immediate reactions to beta-lactams, mainly penicillins, with a specificity 
approaching 90% and a sensitivity of up to 50% (Blanca et al., 2001; Sanz et al., 2002a) 
The in vitro study of the cell response in non-immediate reactions mainly assesses the T-cell 
response. A cellular response involving drug-related T-cell activity may be assessed in vitro 
by means of both the lymphocyte transformation test (LTT) (Pichler & Tilch, 2004) and the 
flow cytometric lymphocyte activation test, based on upregulation of the activation marker 
CD69 (Beeler et al., 2008). The combination of these tests with an assay of the production of 
drug-specific cytokines (e.g., IFN-g, IL-2, IL-5, IL-8 and IL-12) can increase the sensitivity 
and specificity to 48% and 82%, respectively (Romano et al., 2011; Rozieres et al., 2009a). 
2. Cellular tests for the diagnosis of immediate type drug hypersensitivity 
reactions 
2.1 The Basophil activation test 
The in vitro diagnosis of drug allergies has advanced much over recent years, mainly due to 
the incorporation of new technologies, such as flow cytometry, which permits the analysis 
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of various types of cells, even when they are poorly represented in peripheral blood, as is 
the case with basophils. These cells are a useful model for the study of IgE-mediated 
reactions, as they are effectors of the reactions (Schleimer et al., 1985). 
Basophils are able to release the content of their granules (either preformed mediators, like 
histamine, or formed de novo, like sulphidoleukotrienes) after antigen-specific activation. In 
addition, after this process they express, or overexpress, activation molecules on their 
membranes (Fig. 1). 
 
 
Fig. 1. Immune response in Immediate drug allergic reaction. 
The basophil activation test (BAT) is based on the identification of basophils by labelling 
with monoclonal antibodies against different molecules, such as the IgE receptor, anti-CD 
123 (IL-3 receptor) and fluorochrome-labelled anti-HLA-DR or anti-CCR3. This strategy, 
coupled with the identification of cell activation markers, such as CD63 or CD 203c, enables 
the comparison of cell activation before and after in vitro antigen-specific stimulation (Sanz 
et al., 2002b). Parallel to this process there is production of mediators, such as 
sulphidoleukotrienes that can be quantified simultaneously. 
The CD63 molecule is a tetraspan, 53 kDa granular protein that is expressed not only on 
basophil granules but also on monocytes, macrophages and platelets. The expression of this 
marker correlates with degranulation and histamine release, which makes it an ideal marker 
of basophil activation (De Weck et al., 2008). 
For in vitro stimulation with allergen, the peripheral blood cells are incubated with the 
suspected allergen for 15-40 minutes at 37ºC (Fig. 2).  
After stopping the reaction, the cells are labelled with anti-CD63-PE and anti-IgE-FITC 
monoclonal antibodies. Two controls are used: a negative control in which the cells are 
incubated with the stimulation buffer used in the assay and that often contains IL-3 
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(negative control alias basal stimulation); as a positive control, an anti-IgE or an anti-IgE 
receptor antibody can be used (Sanz et al., 2008) (Fig. 3). The results are analised through 
flow cytometry (Fig. 4). 
 
 
Fig. 2. Basophil activation test. Stimulation phase. 
 
Fig. 3. Basophil activation test. Labelling phase. 
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Fig. 4. Flow cytometry analysis. 
Numerous studies over recent years have shown the usefulness of this technique for the in 
vitro diagnosis of allergic diseases (Ebo et al., 2006a, 2004a; Kleine-Tebbe et al., 2006) 
involving different allergens, such as inhalants (Paris-Köhler et al., 2000; Sanz et al., 2001; 
Saporta et al., 2001), hymenoptera venoms (Sabbah et al., 1998; Sainte-Laudy et al., 2000), or 
latex (Ebo et al., 2002; Sanz et al., 2003). For the diagnosis of allergy to drugs like muscle 
relaxants (Abuaf et al., 1999; Monneret et al., 2002), betalactam antibiotics (Sanz et al., 2001b, 
2002a; Torres et al., 2004), pyrazolones (Sabbah et al., 1997; Sanz et al., 2005) and non 
steroidal anti-inflammatory drugs (NSAIDs) (Gamboa et al., 2004) BAT has opened up an 
important diagnostic pathway, either on its own or combined with other techniques (de 
Weck et al., 2008b; Gamboa et al., 2003a), allowing avoidance of challenge tests in an 
important number of cases (Hausmann et al., 2009; Romano et al., 2011; Sanz et al., 2009). 
2.1.1 Basophil activation test and sulphidoleukotriene production in immediate type 
allergic reactions to beta-lactams 
We studied the reliability of BAT, the determination of specific IgE by CAP (CAP-FEIA, 
Phadia, Uppsala, Sweden) and the production of leukotrienes after antigen-specific 
stimulation using the Cellular Antigen Stimulation Test (CAST ELISA (Bühlmann 
Laboratories, Allschwill, Switzerland) for the in vitro diagnosis of immediate allergy to 
betalactams in a series of 81 patients (58 patients with positive and 23 with negative skin 
tests) and in 30 healthy controls (Gamboa et al., 2004b; Sanz et al., 2001b, 2002a). Our results, 
as well as those found by Torres et al (Torres et al., 2004), showed that the sensitivity of BAT 
in the diagnosis of immediate hypersensitivity reactions to beta-lactams was 50%, and the 
specificity 93.3%, although there were certain differences depending on the technique 
applied (e.g., use of total blood or isolated cells) (de Weck et al., 2008a). 
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In our study (Sanz et al., 2002a) the best predictive values were obtained with BAT, in 
comparison with immunoassay or CAST. The positive predictive value of BAT was 18.9% 
and the negative predictive value 97.7%, with amoxicillin being the antibiotic with the 
highest predictive values. The joint use of CAP (Phadia) and BAT allowed identification of 
65.2% of the betalactam allergic patients, with a specificity of 83.3% (Sanz et al., 2008).  
In betalactam allergic patients with negative skin tests BAT was positive in 39.1%, CAST 
was positive in 22.7% with a specificity of 83.3%, and CAP showed a sensitivity of 21.7% 
with a specificity of 83.3%. The association of all three techniques allowed diagnosis in 
60.9% of the patients of this group, with a specificity of 70% (Gamboa et al., 2004b). 
Torres et al (Torres et al., 2004) studied the reliability of BAT in 70 patients with immediate 
allergic reactions. Like us, these authors found a greater positivity to amoxicillin (28.6%), 
followed by benzylpenicillin (BP) (21.7%), penicilloyl polylysine (PPL) (20%), ampicillin 
(12.5%) and MDM (2.2%).  
They, too, reported a BAT sensitivity for cephalosporins of 77.7%. These results have since 
been confirmed in a multicentre study involving 181 betalactam allergic patients and 80 
controls. This study concluded that the association of this technique with the determination 
of the production of antigen-specific sulphidoleukotrienes increases the sensitivity to 62% 
(de Weck et al., 2008b). 
A certain lack of association exists between clinical and BAT cross-reactivity, which restricts 
the usefulness of this method for predicting cross-reactive responses in beta-lactam 
reactions. With BAT it is possible to find positive results when BP is used as the hapten in 
patients who are selective responders to amoxicillin (Torres et al., 2004).  
2.1.2 BAT in IgE-mediated hypersensitivity reactions to quinolones 
IgE-mediated hypersensitivity reactions to quinolones are a particularly difficult situation 
for the clinician as skin testing may induce false positive results. A recent report confirms 
that BAT is a useful method for diagnosing patients with confirmed immediate allergic 
reactions to quinolones (Aranda et al., 2011). In this study, involving 38 patients, the 
Sepharose-RIA technique was positive in 12 cases (31.57%), BAT in 27 (71.05%) and the 
combination of both tests showed positive results in 28 (73.68%). The drug most frequently 
involved in the reaction was moxifloxacin (63.2%), followed by ciprofloxacin (28.9%). The 
authors conclude that the BAT is a useful method for diagnosing patients, especially in 
those with severe reactions where drug provocation testing may increase the risk. 
2.1.3 Basophil activation test in muscle relaxant allergic reactions 
Muscle relaxants are an important group of drugs involved in 60% of adverse reactions 
during anaesthesia. Relevant studies have found that BAT sensitivity and specificity for 
muscle relaxants varied from 36% to 92% and 93% to 100%, respectively (Sudheer et al., 
2005). Most of these studies reported a high specificity and a sensitivity above 50%, reaching 
91% (Abuaf et al., 1999; Kvedariene et al., 2006; Laxenaire et al., 1999; Monneret et al., 2002; 
Moss, 1995; Stellato et al., 1991). 
This sensitivity is lower (36%) when the marker CD203c is used (Sudheer et al., 2005). 
However, results are discordant; Kvedarine et al. (Kvedariene et al., 2006) observed in 47 
patients a sensitivity of 36% and a specificity of 93% performing BAT (CD63 in whole 
blood). On the other hand, Ebo et al. (Ebo et al., 2006b) reported the sensitivity of a similar 
BAT technique to be 91.7% and the specificity 100% for rocuronium in a study including 14 
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patients with an anaphylactic reaction to drugs and with a positive skin test to rocuronium. 
However, the sensitivity apparently increases up to 80% when BAT is performed shortly 
after the clinical reaction (Kvedariene et al., 2006); this technique allows evaluation of the 
cross-reactivity between different muscle relaxants (Ebo et al., 2006b).  
Leysen et al (Leysen et al., 2011) recently reported that BAT is complementary to skin testing 
in the assessment of cross-reactivity between rocuronium and vecuronium. In patients with 
negative skin tests and positive sIgE results, BAT helps in interpreting the clinical 
significance of a positive sIgE result. 
These authors found a cross-reactivity with vecuronium in 69% of 104 curarized patients 
with a history of profound hypotension and severe bronchospasm immediately after 
induction of anaesthesia 
2.1.4 Basophil activation test as a diagnostic tool for immediate radiocontrast media 
(RCM) hypersensitivity 
A study involving 26 patients with immediate RCM reactions and 43 specimens from healthy 
volunteers found that the specificity of BAT ranged from 88.4% to 100%, with a sensitivity 
around 50% (most of the patients in this study experienced only mild skin symptoms) 
(Pinnobphun et al., 2011). The authors demonstrated the potential of BAT as a diagnostic tool 
for immediate RCM hypersensitivity, particularly as a confirmation test, with significantly 
higher activated basophil percentages in BAT in patients with a history of immediate RCM 
reactions than in normal controls. The time between the RCM reaction and the BAT in their 
study was rather long (1–4 years), and this time lag may have lowered BAT reactivity. 
2.1.5 Basophil activation test in IgE-mediated selective reactions to NSAIDs 
Until now only two articles have been published on selective NSAID reactors, patients 
reacting exclusively to only one NSAID family through an IgE-mediated mechanism and 
tolerating other NSAID groups (Gamboa et al., 2003a; Gómez et al., 2009). The first study 
comprised 26 patients with exclusive IgE-mediated allergy to methamizole. BAT sensitivity 
was 42.3% and specificity 100%. Upon adding the leukotriene release test, the sensitivity 
increased to 52% in the overall patient group, with a specificity of 92% (Gamboa et al., 
2003a). In the second study, involving 51 patients with immediate reactions also to 
methamizole, the sensitivity was 54.9% but with a lower specificity, 85.71% (Gómez et al., 
2009). The differences in the sensitivities and specificities may have been due to differences 
in the time interval between the in vitro test being performed and the reaction (16.9 versus 8 
months, respectively), and the number of cases with anaphylaxis (57.5% versus 74.5%). 
Importantly, the BAT was positive in 38.5% of patients with negative skin tests but even 
more importantly, the BAT was positive in 75% of patients with anaphylaxis and negative 
skin tests. (Gómez et al., 2009). 
BAT is the only in vitro technique currently available which allows the evaluation, with 
sufficiently high sensitivity and specificity values, of patients with selective IgE-mediated 
reactions to methamizole without the use of drug provocation tests and their associated 
dangers for patients. Negative BAT testing is associated with the delay to the test after the 
occurrence of the reaction. 
2.1.6 Basophil activation test in NSAID hypersensitivity reactions 
The mechanism involved in these type of reactions is not well known although it is clear 
that it is a non immunological mechanism.  
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In this first  study (Gamboa et al., 2004a) in 60 patients with this syndrome the use of only 2 
drugs (aspirin and diclofenac) allowed a diagnosis to be reached in 58% of these patients, with 
a specificity of 90%. In similar studies carried out in 43 patients with NSAID hypersensitivity 
(Rodríguez-Trabado et al., 2008), BAT achieved a sensitivity of 43% with a specificity of 100%.  
Subsequently, the European Network for Drug Allergy began a multi-centre study to validate 
the real usefulness of this technique (de Weck et al., 2010). However, a notable heterogeneous 
response in the results from each participating group in both sensitivity and specificity was 
observed that can be attributed to two main factors: different clinical characteristics in the 
study patients and technical variation between the different groups. The specificity value was 
notably better in those groups that used buffy coat than in those using plasma leukocytes. The 
lower values in sensitivity and specificity found by others increase the need for further studies. 
In this paper (de Weck et al., 2010), we further analyzed basophil activation in vitro in 
apparently normal individuals tolerating the administration of NSAIDs, in particular the 
specificity of these reactions and the role of technical conditions, such as the cell isolation 
technique. Different clinical and technical conditions may give rise to discordant results 
relating to NSAID hypersensitivity reactions (de Weck et al., 2009). 
2.1.7 Basophil activation test in various drug-allergic reactions  
Other drugs are also of interest since evaluation of allergy to drugs that cannot be studied 
by other in vitro techniques is interesting. BAT has proven useful for the in vitro diagnosis 
of such allergy-causing drugs as corticosteroids (Lehmann Ott, 2008), heparins (Caballero & 
Fernández-Benítez, 2003; Ebo et al., 2004b), omeprazole (Gamboa et al., 2003b), cyclosporine 
(Ebo et al., 2001), Gelofusine (Apostolou et al., 2006), dexchlorpheniramine (Caceres Calle & 
Fernández-Benítez, 2004), chlorhexidine (Ebo et al., 2006c), iodinated povidone (Le Pabic et 
al., 2003), hyaluronidase (Ebo et al., 2005), or bovine serum albumin (Orta et al., 2003).  
2.1.8 The sensitivity of BAT for evaluating immediate allergic reactions to drugs may 
decrease over time 
The diagnostic capacity of BAT has been shown to fall as the time increases between the 
clinical reaction and the test, both for allergic reactions to betalactams (where the sensitivity 
of BAT decreases to 12.5% one year after the reaction) (Blanca et al., 1999), and for reactions 
to muscle relaxants, where the sensitivity fell from 85.7% to 47.6% 4-8 years after the 
reaction (Abuaf et al., 1999) as well as for allergy to dipyrone, where 60% of the patients had 
a negative BAT 6 months after the reaction (Gómez et al., 2009), or expressed another way, if 
the tests are carried out within 6 months from the initial drug reaction, the efficacy of the 
BAT increases to 56% (Gamboa et al., 2003a). Thus, it is generally recommended to perform 
BAT at least two weeks after the allergic reaction but within no more than 6 months 
(Rodríguez Trabado et al., 2006), given that negativization of BAT does not correlate with 
tolerance to the drug (Antúnez et al, 2006).  
In summary, BAT is a useful technique for the diagnosis of allergy to drugs, though 
additional validation studies are warranted. 
3. Cellular tests in the diagnosis of non-immediate type drug hypersensitivity 
reactions  
Although it has been shown that delayed reactions to drugs are mediated by effector T 
lymphocytes (Fernández et al, 2010) with a Th1 profile, based on the transcription factors 
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patients with an anaphylactic reaction to drugs and with a positive skin test to rocuronium. 
However, the sensitivity apparently increases up to 80% when BAT is performed shortly 
after the clinical reaction (Kvedariene et al., 2006); this technique allows evaluation of the 
cross-reactivity between different muscle relaxants (Ebo et al., 2006b).  
Leysen et al (Leysen et al., 2011) recently reported that BAT is complementary to skin testing 
in the assessment of cross-reactivity between rocuronium and vecuronium. In patients with 
negative skin tests and positive sIgE results, BAT helps in interpreting the clinical 
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methamizole, the sensitivity was 54.9% but with a lower specificity, 85.71% (Gómez et al., 
2009). The differences in the sensitivities and specificities may have been due to differences 
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skin tests. (Gómez et al., 2009). 
BAT is the only in vitro technique currently available which allows the evaluation, with 
sufficiently high sensitivity and specificity values, of patients with selective IgE-mediated 
reactions to methamizole without the use of drug provocation tests and their associated 
dangers for patients. Negative BAT testing is associated with the delay to the test after the 
occurrence of the reaction. 
2.1.6 Basophil activation test in NSAID hypersensitivity reactions 
The mechanism involved in these type of reactions is not well known although it is clear 
that it is a non immunological mechanism.  
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involved and with cytokine and chemokine production (Cornejo-Garcia et al., 2007; 
Fernández et al., 2009; Mullen et al., 2001; Rengarajan et al., 2000), an important number of 
heterogeneous clinical manifestations nevertheless indicate that different mechanisms with 
different cell subsets and mediators may be involved (Posadas et al., 2002) (Fig. 5). 
3.1 Lymphocyte transformation test 
Among the in vitro tests proposed for delayed hypersensitivity reactions to drugs, the 
lymphocyte transformation test (LTT) was one of the earliest. However, for some years now 
its role in the evaluation of these reactions has been questioned. This is owing to the 
existence of studies reporting series with a low number of cases where many drugs were 
involved and the clinical entities experienced by the patients were very heterogeneous 
(Mayorga et al., 2006; Luque et al., 2001). However, promising results together with the need 
for an in vitro test are now revitalizing its use.  
 
 
Fig. 5. Non immediate drug allergic reactions. Different profiles of T response. 
The LTT enables identification of the drug involved and cross-reactivities, but it is important 
to take into account that a negative LTT does not always indicate the absence of a delayed 
reaction to the drug.  
Different studies have shown the good sensitivity and specificity of the LTT, with 
heterogeneity in the drugs and clinical entities (Luque et al., 2001; Naisbitt et al., 2003a, 
2003b; Nyfeler & Pichler, 1997; Schnyder & Pichler 2000). The most frequent drugs studied 
are beta-lactam antibiotics and anti-epileptics, particularly carbamazepine (Hertl et al., 1993; 
Luque et al., 2001; Mauri-Hellweg et al., 1995; Nyfeler & Pichler, 1997; Tapia et al., 2004; 
Yawalkar et al., 2000). These studies have shown an overall sensitivity of 60-70% for LTT 
(Lerch et al., 2007; Luque et al., 2001; Mauri-Hellweg et al., 1995; Pichler & Tilch, 2004). In 
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the case of beta-lactams, for immediate and non immediate reactions, the sensitivity was 
64.5% and 57.9%, respectively and the specificity was 92.8% (Luque et al., 2001; Pichler & 
Tilch, 2004). In a retrospective analysis of patients with adverse drug reactions, the LTT 
sensitivity was seen to depend also on the drug involved in the reaction (Nyfeler & Pichler, 
1997; Roujeau et al., 1985) and the sensitivity might significantly improve when LTT is 
performed at the optimal time (Kano et al., 2007). This timing could vary depending on the 
clinical manifestations, since it has been shown that LTT should be performed within one 
week for patients with MPE and SJS/TEN whereas 5-8 weeks is optimal for patients with 
DRESS (Kano et al., 2007). 
Recently, a modification of the LTT with inclusion of monocyte derived dendritic cells as 
antigen presenting cells has shown promising results, with higher sensitivity and specificity 
in delayed reactions to amoxicillin, heparins, glucocorticosteroids and contrast media, as 
well as providing the possibility of detecting a response over a longer period of time, 
preserving sensitivity to the culprit drug (Lopez S et al., 2009, 2010; Nyfeler & Pichler, 1997; 
Rodríguez-Pena et al., 2006).  
3.2 ELISPOT 
The Elispot assay is based on the detection of a cytokine caught by an immobilized antibody 
and revealed by a secondary antibody (Czerkinsky et al., 1988). With this method it is 
possible to detect different cytokines as well as cytotoxic markers released by antigen or 
drug stimulated cells (Beeler et al., 2006, 2008; Rozieres et al., 2009a; Zawodniak et al., 2010). 
This test has a high sensitivity, and is able to detect fewer than 25 secreting cells per million 
PBMC (Schmittel et al., 1997, 2001). The results are expressed as spot forming cells obtained 
from the rate between the cytokine secretion produced in the presence of the drug compared 
to the absence of stimulus. The Elispot assay has detected lymphocytes secreting cytokines 
such as IFN-, IL-5, IL-13 from allergic patients in the presence of the culprit drug. Recently, 
this test has been used to determine the release of the granule content (granzymes and 
perforin) by cytotoxic cells after activation with the culprit drug (Zawodniak et al, 2010). 
The test showed a high sensitivity and specificity, although in some cases no correlation 
with LTT results was found, probably because cytotoxicity-based tests measure effector cell 
function, which is distinct from proliferative response.  
The secretion of cytokines (IFN-γ) or cytotoxic granules (Granzyme B) has been detected in 
vitro in response to the culprit drug in allergic patients but not in tolerant subjects (Rozieres 
et al., 2009a; Zawodniak et al., 2010), demonstrating that the Elispot can be a complementary 
method to evaluate delayed reactions to drugs. 
3.3 Monitoring delayed reaction to drugs 
Another approach for the in vitro evaluation of delayed reactions to drugs is the follow-up 
of the immunopathological response by performing serial determinations in peripheral 
blood and the affected skin, from the acute phase to basal conditions (Mayorga et al., 2006). 
This enables an idea of the underlying process to be built up, not only in the development 
and progress of the reaction but also related to the degree of response to treatment 
(Mayorga et al., 2003). These reactions involve not only different cell populations but also 
activation markers, signalling molecules, cytokines, chemokines and transcription factors. 
These are all assessed and it is important to determine the changes in the different markers 
rather than their quantification per se.  
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Among the available methods the most widely used are flow cytometry and mRNA gene 
expression by real time PCR. These methodologies provide important information about the 
immunological mechanisms involved, since different clinical manifestations like urticaria, 
MPE, DRESS, AGEP, FDE or TEN are produced by different cell subsets contributing to each 
particular entity. Different authors have shown that CD4+ T lymphocytes are mainly 
involved in MPE, DRESS, and AGEP (Fernandez et al., 2009; 1995; Hertl et al., 1993; Mauri-
Hellweg et al., 1995; Pichler, 2003; Schnyder et al., 2000; Shiora & Muzukawa, 2007; Torres et 
al., 2006, 2009; Whittam et al., 2000; Zedlitz et al., 2002), whereas CD8+ T lymphocytes are 
the effector cells in FDE and TEN (Alanko et al., 1987; Chung et al., 2008; Nassif et al., 2002, 
2004a). Although other studies indicate that both CD4+ and CD8+ T lymphocytes may be 
involved in TEN (Torres et al., 2006) and CD8+ T cells have been found in the epidermis of 
non bullous lesions including MPE (Rozieres et al., 2009b).  
These cells become activated and express high levels of CD25, CD69, CD71 and HLA-DR 
(Leyva et al., 2000; Mayorga et al., 2003; Nishio et al., 2007; Shiohara & Mizukawa, 2007; 
Torres et al., 2008). Apart from activation, different chemokine and chemokine receptors 
involved in cell recruitment to the affected organ, mainly the skin, can also be analyzed. 
Thus, an increase in the expression of cutaneous lymphocyte-associated antigen (CLA), a 
skin homing receptor in delayed reactions to drugs, correlates with disease severity (Blanca 
et al., 2000; Mullen et al., 2001; Torres et al., 2006). In a study in patients with drug-induced 
MPE, an increase in the expression of Th1 chemokines (CXCL9 and CXCL10) and their 
specific receptor CXCR3, as well as in the expression of the cutaneous homing chemokines 
(CCL17, CCL20, and CCL27) and their receptors (CCR4, CCR6, CCR10), with high 
production of TNF-α and IFN-γ, was found at the acute phase of the reaction (Fernandez et 
al., 2008). In MPE or DRESS an increase has also been found in IL-5 and chemokines such as 
RANTES and eotaxins, which explains the involvement of eosinophils expressing CCR3 
(Hertl et al., 1993). In AGEP, another severe delayed drug-induced reaction, lymphocytes 
have a dual role as cytotoxic agents and inducing migration of neutrophils to the skin by 
producing IL-8 (Britschgi & Pichler, 2002; Hertl et al., 1993; Padial et al., 2004; Yawalkar et 
al., 2000). At the acute phase of TEN, T cells are recruited to the skin, producing cytotoxic 
markers such as perforin and granzyme B (Fernandez et al., 2010; Mayorga et al., 2003; 
Pichler, 2003; Posadas et al., 2002; Torres et al., 2006; Zawodniak et al., 2010), and they 
express high levels of CCR10 and their chemokine CCL27 (Tapia et al., 2004).  
As mentioned, this monitoring is useful in order to understand not only the underlying 
mechanisms but also to assess the response to treatment. This latter was analyzed during the 
follow-up of TEN, where the administration of gamma globulin was associated with a rapid 
decrease in the cytotoxic markers (Mayorga et al., 2003). 
A Th1 pattern with expression of IFN-, IL-12, and TNF-α and down-regulation of IL-4 has 
been found in delayed reactions to drugs (Cornejo-Garcia et al., 2007; Posadas et al., 2000). 
The polarizations also extend to the expression of transcription factors, such as T-bet in Th1 
and inhibition of c-maf and GATA3 in Th2 (Cornejo-Garcia et al., 2007). 
3.4 Trafficking between different organs 
Since the skin is the organ most frequently affected in delayed reactions to drugs, it is 
possible to assess the parallel course in the two compartments, the skin (in both biopsies and 
blister fluid cells) and the peripheral blood. At the very early stage of the reaction, there is 
an increase in the blister fluid of CLA+ cells which later appear in peripheral blood, 
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probably due to recirculation from the skin (Leyva et al., 2000; Mayorga et al., 2003). These 
cells also show a Th1 profile, with high production of perforin and granzyme B that 
correlates with the reaction and its severity (Nassif et al., 2004a; 2004b). 
In patients with MPE (Fernandez et al., 2008) an increase in the expression of Th1 
chemokines, including CXCL9 and CXCL10, as well as cutaneous homing chemokines such 
as CCL17, CCL20, and CCL27, was found only in the skin. In this study they also found a 
high production of TNF-α and IFN-γ as well as the presence of Th1 cytotoxic T lymphocytes 
in the skin. However, in the peripheral blood T lymphocytes expressing only the chemokine 
receptors CXCR3, CCR4, CCR6, and CCR10 were found. These data indicate that during the 
reaction there is recruitment of Th1 cytotoxic T lymphocytes to the skin induced by different 
chemokines produced by cutaneous cells (Fernandez et al., 2008). 
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Among the available methods the most widely used are flow cytometry and mRNA gene 
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Thus, an increase in the expression of cutaneous lymphocyte-associated antigen (CLA), a 
skin homing receptor in delayed reactions to drugs, correlates with disease severity (Blanca 
et al., 2000; Mullen et al., 2001; Torres et al., 2006). In a study in patients with drug-induced 
MPE, an increase in the expression of Th1 chemokines (CXCL9 and CXCL10) and their 
specific receptor CXCR3, as well as in the expression of the cutaneous homing chemokines 
(CCL17, CCL20, and CCL27) and their receptors (CCR4, CCR6, CCR10), with high 
production of TNF-α and IFN-γ, was found at the acute phase of the reaction (Fernandez et 
al., 2008). In MPE or DRESS an increase has also been found in IL-5 and chemokines such as 
RANTES and eotaxins, which explains the involvement of eosinophils expressing CCR3 
(Hertl et al., 1993). In AGEP, another severe delayed drug-induced reaction, lymphocytes 
have a dual role as cytotoxic agents and inducing migration of neutrophils to the skin by 
producing IL-8 (Britschgi & Pichler, 2002; Hertl et al., 1993; Padial et al., 2004; Yawalkar et 
al., 2000). At the acute phase of TEN, T cells are recruited to the skin, producing cytotoxic 
markers such as perforin and granzyme B (Fernandez et al., 2010; Mayorga et al., 2003; 
Pichler, 2003; Posadas et al., 2002; Torres et al., 2006; Zawodniak et al., 2010), and they 
express high levels of CCR10 and their chemokine CCL27 (Tapia et al., 2004).  
As mentioned, this monitoring is useful in order to understand not only the underlying 
mechanisms but also to assess the response to treatment. This latter was analyzed during the 
follow-up of TEN, where the administration of gamma globulin was associated with a rapid 
decrease in the cytotoxic markers (Mayorga et al., 2003). 
A Th1 pattern with expression of IFN-, IL-12, and TNF-α and down-regulation of IL-4 has 
been found in delayed reactions to drugs (Cornejo-Garcia et al., 2007; Posadas et al., 2000). 
The polarizations also extend to the expression of transcription factors, such as T-bet in Th1 
and inhibition of c-maf and GATA3 in Th2 (Cornejo-Garcia et al., 2007). 
3.4 Trafficking between different organs 
Since the skin is the organ most frequently affected in delayed reactions to drugs, it is 
possible to assess the parallel course in the two compartments, the skin (in both biopsies and 
blister fluid cells) and the peripheral blood. At the very early stage of the reaction, there is 
an increase in the blister fluid of CLA+ cells which later appear in peripheral blood, 
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probably due to recirculation from the skin (Leyva et al., 2000; Mayorga et al., 2003). These 
cells also show a Th1 profile, with high production of perforin and granzyme B that 
correlates with the reaction and its severity (Nassif et al., 2004a; 2004b). 
In patients with MPE (Fernandez et al., 2008) an increase in the expression of Th1 
chemokines, including CXCL9 and CXCL10, as well as cutaneous homing chemokines such 
as CCL17, CCL20, and CCL27, was found only in the skin. In this study they also found a 
high production of TNF-α and IFN-γ as well as the presence of Th1 cytotoxic T lymphocytes 
in the skin. However, in the peripheral blood T lymphocytes expressing only the chemokine 
receptors CXCR3, CCR4, CCR6, and CCR10 were found. These data indicate that during the 
reaction there is recruitment of Th1 cytotoxic T lymphocytes to the skin induced by different 
chemokines produced by cutaneous cells (Fernandez et al., 2008). 
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1. Introduction 
Cow’s milk protein allergy (CMPA) is defined as an immunological reaction to one or more 
milk proteins(1). A variety of symptoms can be suggestive for CMPA. CMPA is suspected 
clinically in 5-15% of infants (2), while most estimates of prevalence of CMPA vary from 
only 2 to 5 % (1). Confusion regarding CMPA prevalence is often due to differences in study 
population, and a lack of defined diagnostic criteria for CMPA. The importance of defined 
diagnostic criteria needs to be emphasised. It precludes infants from an unnecessary diet (3) 
and avoids delay in diagnosis, which can lead to malnutrition (4). 
The intention of this manuscript is to help diagnose and manage CMPA. Most of the 
recommendations are based on recently published guidelines on CMPA diagnosis and 
management (3, 5-9).  
2. Manifestations  
CMPA may develop in breastfed (BF) and in cow’s milk formula (CMF) fed infants and 
usually occurs within the first weeks after cow’s milk introduction. The presentation is 
variable; no symptom is pathognomonic. Manifestations mainly occur at the level of the 
digestive tract (50-60%), the skin (50-60%) and the respiratory tract (20-30%) (2). They vary 
from mild-moderate to severe (Table 1).  
There are two clinical types of CMPA: the immediate and the delayed type. The immediate 
type presents shortly after ingestion of cow’s milk protein (CMP) (urticaria, angio-oedema, 
vomiting or an acute flare of atopic dermatitis) and is present in slightly more than half of 
the patients with CMPA(10). They are more likely to have positive skin prick test (SPT) 
(wheel size >3 mm) or positive serum specific Immunoglobulin e (IgE ) (10). The amount of 
cow’s milk necessary to elicit an immediate reaction varies from one drop to more than 150 
ml, which shows that some patients tolerate a considerable amount of milk before 
manifestations develop (11). Delayed reactions such as atopic dermatitis or gastrointestinal 
manifestations like proctocolitis or enteropathy, usually present after hours or days.  
Immunologically, CMPA can be IgE or non-IgE mediated (12). IgE mediated reactions are 
clinically more often of the immediate type and can be confirmed with SPT or serum specific 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 278 
metabolites by drug-specific CD4+ T cells from allergic individuals. J Immunol; 
164:6647-6654. 
Schnyder B. & Pichler W.J. (2000). Skin and laboratory tests in amoxicillin- and penicillin-
induced morbilliform skin eruption. Clin Exp Allergy; 30: 590–595. 
Shiohara T. & Mizukawa Y. (2007). Fixed drug eruption: a disease mediated by self-inflicted 
responses of intraepidermal T cells. Eur J Dermatol;17(3):201-8.  
Sudheer P.S., Hall J.E., Read G.F., Rowbottom A.W. & Williams PE. (2005). Flow cytometric 
investigation of peri- anaesthetic anaphylaxis using CD63 and CD203c. Anaesthesia; 
60:251–256. 
Stellato C., de Paulis A., Cirillo R., Mastronardi P., Mazzarella B. & Marone G. (1991). 
Heterogeneity of human mast cells and basophils in response to muscle relaxants. 
Anesthesiology; 74:1078-86. 
Tapia B., Padial A., Sanchez-Sabate E., Alvarez-Ferreira J., Morel E., Blanca M. & Bellon T. 
(2004). Involvement of CCL27- CCR10 interactions in drug-induced cutaneous 
reactions. J Allergy Clin Immunol ;114:335-340. 
Torres M.J., Padial A, Mayorga C., Fernandez T., Sanchez-Sebate E., Cornejo-Garcia J.A., 
Antúnez C. & Blanca M. (2004). The diagnostic interpretation of basophil activation 
test in immediate allergic reactions to betalactams. Clin Exp Allergy; 34: 1768-75. 
Torres M.J., Mayorga C., Fernández T.D., Cornejo-García J.A., Antúnez C., Valenzuela M., 
Del Prado M.F., Rodriguez- Pena R. & Blanca M. (2006). T cell assessment in 
allergic drug reactions during the acute phase according to the time of occurrence. 
Int J Immunopathol Pharmacol; 19(1):119-30.  
Torres M.J., Mayorga C., Cornejo-Garcia J.A., Lopez S., Chaves P., Rondon C., Fernandez T. 
& Blanca M. (2008). Monitoring non-immediate allergic reactions to iodine contrast 
media. Clin Exp Immunol; 152:233-238.  
Torres M.J., Mayorga C. & Blanca M. (2009). Nonimmediate allergic reactions induced by 
drugs: Pathogenesis and diagnostic tests. J Investig Allergol Clin Immunol; 19: 80-90. 
Whittam L.R., Wakelin S.H. & Barker JNWN. (2000). Generalized pustular psoriasis or drug-
induced pustuloderma? The use of patch testing. Clin Exp Dermatol; 25: 122-124. 
Yawalkar N., Shrikhande M., Hari Y., Nievergelt H., Braathen L.R. & Pichler WJ. (2000). 
Evidence for a role of IL-5 and eotaxin in activating and recruitment of eosinophils 
in drug-induced cutaneous eruptions. J Allergy Clin Immunol; 106:1171-6. 
Zawodniak A., Lochmatter P., Yerly D., Kawabata T., Lerch M., Yawalkar N. & Pichler WJ. 
(2010). In vitro detection of cytotoxic T and NK cells in peripheral blood of patients 
with various drug-induced skin diseases. Allergy;65:376- 384. 
Zedlitz S., Linzbach L., Kaufmann R. & Boehncke W.H. (2002). Reproducible identification 
of the causative drug of a fixed drug eruption by oral provocation and lesional 
patch testing. Contact Dermatitis; 46: 352-353. 
14 
Diagnosis and Management of  
Cows’ Milk Protein Allergy in Infants 
Elisabeth De Greef, Gigi Veereman-Wauters, Thierry Devreker,  
Bruno Hauser and Yvan Vandenplas 
Pediatric Gastroenterology, Hepatology and Nutrition, 
University Children’s Hospital Brussels, 
Free University Brussels, 
Belgium 
1. Introduction 
Cow’s milk protein allergy (CMPA) is defined as an immunological reaction to one or more 
milk proteins(1). A variety of symptoms can be suggestive for CMPA. CMPA is suspected 
clinically in 5-15% of infants (2), while most estimates of prevalence of CMPA vary from 
only 2 to 5 % (1). Confusion regarding CMPA prevalence is often due to differences in study 
population, and a lack of defined diagnostic criteria for CMPA. The importance of defined 
diagnostic criteria needs to be emphasised. It precludes infants from an unnecessary diet (3) 
and avoids delay in diagnosis, which can lead to malnutrition (4). 
The intention of this manuscript is to help diagnose and manage CMPA. Most of the 
recommendations are based on recently published guidelines on CMPA diagnosis and 
management (3, 5-9).  
2. Manifestations  
CMPA may develop in breastfed (BF) and in cow’s milk formula (CMF) fed infants and 
usually occurs within the first weeks after cow’s milk introduction. The presentation is 
variable; no symptom is pathognomonic. Manifestations mainly occur at the level of the 
digestive tract (50-60%), the skin (50-60%) and the respiratory tract (20-30%) (2). They vary 
from mild-moderate to severe (Table 1).  
There are two clinical types of CMPA: the immediate and the delayed type. The immediate 
type presents shortly after ingestion of cow’s milk protein (CMP) (urticaria, angio-oedema, 
vomiting or an acute flare of atopic dermatitis) and is present in slightly more than half of 
the patients with CMPA(10). They are more likely to have positive skin prick test (SPT) 
(wheel size >3 mm) or positive serum specific Immunoglobulin e (IgE ) (10). The amount of 
cow’s milk necessary to elicit an immediate reaction varies from one drop to more than 150 
ml, which shows that some patients tolerate a considerable amount of milk before 
manifestations develop (11). Delayed reactions such as atopic dermatitis or gastrointestinal 
manifestations like proctocolitis or enteropathy, usually present after hours or days.  
Immunologically, CMPA can be IgE or non-IgE mediated (12). IgE mediated reactions are 
clinically more often of the immediate type and can be confirmed with SPT or serum specific 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
280 
IgE. Non-IgE mediated reactions are due to a cellular immune response or to a mixed 
immune response in which IgE and immune cells play a role. This type of reaction is more 




Gastro-intestinal tract Failure to thrive
 Iron deficiency anemia
 Enteropathy
Skin Exudative/Severe atopic dermatitis 


















Table 1. Clinical Manifestations suggesting CMPA.  
3. Diagnosis 
None of the diagnostic tests available in routine clinical situations prove or exclude CMPA 
completely (11). A thorough history, including family history of atopy, and a careful clinical 
examination are therefore the key elements in the diagnostic process. Clinicians may 
perform SPT (preferable with fresh cows’ milk or whole CMP extracts), determination of 
specific IgE, or patch tests, but they merely indicate sensitisation to the substrate and are not 
necessarily proof of an allergic reaction. The rate of outgrowing CMPA varies between 30-
79% in IgE mediated CMPA (13); consecutive IgE measurements can be indicative in this 
process (14). If serum specific IgE and/or SPT at time of diagnosis are negative, tolerance is 
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obtained at a younger age and the risk of severe acute reaction is small. On the contrary, 
persistant high IgE titers increase the risk of developing other atopic conditions like asthma, 
rhino-conjunctivitis and atopic dermatitis. Patch testing, still a topic of on-going research, 
can aid in the diagnosis of non-IgE mediated reactions.  
3.1 Diagnostic challenge procedures 
The double-blind placebo-controlled challenge is considered the gold standard in CMPA 
diagnosis, but in practice only an open challenge is often performed.(3) The patient with 
suspected CMPA will follow a cow’s milk free diet for 2-4 weeks. Formula fed infants get an 
extensively hydrolyzed formula (eHF) and breastfeeding mothers follow a cow’s milk free 
diet. If CMPA is present, clinical manifestations will disappear. Cow’s milk protein is 
reintroduced progressively thereafter and clinical symptoms are monitored. The risk of an 
open challenge is an overestimation of the diagnosis.(15) A double-blind placebo-controlled 
challenge will blind the parent and the doctor as for the introduction of cow’s milk protein 
and is the only objective measure to make the diagnosis. Unfortunately, it is expensive, 
requires extensive preparation, is time consuming and is difficult to perform.(16)  
Medical supervision during a challenge is necessary because the severity of symptoms 
cannot be predicted (17, 18). When additional allergy testing (serum specific IgE, SPT) is 
negative, life threatening manifestations are extremely rare and a non-hospital setting with 
medical supervision is often sufficient (19), but in patients with a history of severe reactions 
or high IgE levels, a hospital setting with an established protocol is indicated. In case of an 
unequivocal history of recent anaphylactic reaction to cow's milk, a challenge is debatable.  
When CMPA is confirmed, the infant should be maintained on an elimination diet until the 
infant is between 9-12 months or at least for 6 months, whichever occurs first. A new 
challenge is then performed. Children who do not develop allergy-related manifestations 
during challenge and up to one week thereafter can resume their normal diet. 
If the patient with CMPA is on amino acid formula (AAF) because of ongoing allergic 
manifestations under an eHF, the debate whether to challenge with an eHF or standard 
infant formula is still ongoing. After the initial phase, allergic symptoms may not recur on 
an eHF challenge and the formula can be used as a less expensive and more palatable 
treatment. (20) Whereas in the same patient recurrence of symptoms after a challenge with 
normal cow's milk formula might be more likely. 
3.2 Differential diagnosis 
The list of potential differential diagnoses for CMPA is long including repetitive viral 
infections and transient lactose intolerance. Concurrent conditions can also be present: 
troublesome regurgitation occurs in 20 % of all infants, with or without CMPA. On the other 
hand, gastro-oesophageal reflux has been mentioned as a possible manifestation of CMPA. 
(21) CMPA has also been related to infantile colic; CMPA contributes to colic in about 10% 
of colicky infants (22).  
Although in some young infants, a correlation between atopic dermatitis and CMPA is 
suggested, many cases of atopic dermatitis are not related. The younger the infant and/or 
the more severe the atopic dermatitis, the stronger the association appears to be (23).  
Reactions to other foods - especially egg and soy, wheat, fish and peanut – occur frequently 
and often in combination with CMPA (24). Therefore, complementary feeding and, 
preferentially, all supplementary feeding should be avoided during the diagnostic 
elimination diet.  
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4. Management of CMPA 
The principles for the management of CMPA differ in breastfed and formula fed infants.   
4.1 Management of CMPA in exclusively breastfed infants (Figure 1) 
Breastfeeding is the gold standard feeding in infant nutrition and is recommended 
exclusively at least for the first four months of life.(25) Only about 0.5% of exclusively 
breast-fed infants show a reproducible clinical reaction to CMP, mostly mild to moderate.(2) 
Life-threatening symptoms due to CMPA in breast-fed infants are extremely rare, but severe 
cases with protein losing enteropathy and atopic dermatitis have been described. (24) Any 
other underlying disease should be looked for in severe cases. 
 
 
Fig. 1. Decision tree for the diagnosis and treatment of CMPA in Breastfed infants with mild 
to moderate symptoms 
Due to the many benefits of breastfeeding, clinicians should advise to continue, even if the 
infant has CMPA. A cow's milk elimination diet for the mother is then indicated. The 
maintenance of a strict avoidance of CMP is mandatory if supplementary feeding is being 
given to the infant. (23) The elimination diet for breastfeeding mother and child should be 
continued for a minimum of two (to four) weeks. In cases of atopic dermatitis, symptoms 
may not have disappeared after two to four weeks, in which case, clinical experience 
suggests that other food proteins, such as egg, peanut, fish and wheat may as well sensitise 
an infant through its mother’s milk. If so, elimination diet should be adapted accordingly. 
Advice of a dietician is often required in order to help the mother to keep a nutritionally 
balanced diet; an adequate calcium intake (1000 mg per day) needs special attention. 
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If symptoms disappear, cows’ milk should be reintroduced in the mother’s diet after 2 to 4 
weeks. If symptoms relapse, the milk should be eliminated from the mother’s diet as long as 
she is breastfeeding. When the mother wants to wean, the infant should receive an extensive 
hydrolysed formula (eHF). When the elimination diet fails to improve the symptoms or 
when the patient remains asymptomatic on reintroduction of specific food proteins, the 
mother should resume her normal diet.   
4.2 Management of CMPA in formula-fed infants (Figure 2) 
4.2.1 Mild- moderate manifestations 
In formula-fed infants with mild to moderate symptoms related to CMPA, a "therapeutic 
formula" is the first choice. According to consensus in literature, a therapeutic formula is a 
formula tolerated by at least 90% (with 95% confidence) of CMPA infants (26, 27). Many 
eHF’s based on whey, casein or another protein source comply to those criteria as well as 
amino acid based formulae (AAF). During a diagnostic elimination diet, all other food 
intake should be stopped to avoid misinterpretation of manifestations due to other 
allergens. The CMP-free diet should be maintained for at least 6 months. To maintain a 
balanced therapeutic diet, help of a dietician is often needed. 
 
 
Fig. 2. Decision tree for diagnosis and treatment of formula fed infants with suspected 
CMPA  
Because of high cross-reactivity (up to 80%) and nutritional inadequacy, the use of most 
animal milk is precluded (28-30). Rice based hydrolysates, available in certain countries, 
may offer an alternative approach in the treatment of CMPA. (31-33) However, any protein 
hydrolysate, independent of its origin, has a certain residual allergenicity. Residual 
symptoms on eHF is often due to a non IgE related mechanisms (20). Failure on eHF may be 
up to 10% in CMPA children in tertiary care centres (20). There are no data available from 
primary health care centres.   
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Although eHF is the treatment of choice in formula fed CMPA infants, AAF can sometimes 
be indicated if symptoms persist beyond 2-4 weeks on eHF.  AAF has the advantage of no 
residual protein allergenicity, since AAF is a pure chemically made formula, not derived 
from cow’s milk (or any native protein) containing isolated amino-acids instead of peptides. 
If symptoms persist on an AAF, the CMPA diagnosis should be questioned. 
4.3 Severe manifestations 
Formula-fed infants with severe CMPA should be given AFF, “the most effective” 
elimination diet. There is no specific evidence for the use of AAF in severe symptoms, but 
the risk to aggravate further weight loss and nutritional deficiencies is hereby minimised. 
Patients with life-threatening, particularly respiratory symptoms or anaphylaxis need 
immediate referral to the nearest emergency department.  
4.4 Soy formula in CMPA 
The discussion on the use of soy-based infant formula is difficult, since scientific societies 
have different recommendations. There is a broad consensus on the following statements: 
The incidence of soy allergy in soy formula-fed infants is comparable to that of CMPA in 
cows’ milk formula-fed babies (34). Cross reactivity to soy has been reported in 10 to 35% of 
infants with CMPA, regardless whether they were positive or negative for specific IgE for 
CMP (10) . In particular, infants with multiple food allergies and eosinophilic enterocolitis 
also react to soy protein (35). Therefore, different specialist groups have different 
standpoints on the use of Soy formula for CMPA, but is generally not recommended before 
the age of 6 months (26, 34, 36, 37). Soy could be considered as an alternative, the possible 
cross reactivity in mind, in cultures where the hydrolyzation process with pork-derived 
enzymes is considered a problem and beyond the age of 6 months.  
5. Prevention 
Genetic predisposition, environmental factors and the influence of allergen exposure early 
in life may play a role in the development of allergy (38). There are no data on the 
development of CMPA in atopic versus non-atopic families. A comprehensive history 
(including family history of atopy) and careful physical examination are therefore an 
important part of diagnosis. 
Irrespective of the atopic heredity, exclusive breastfeeding remains the best nutrition for all 
infants up to the age of 4-6 months, even as prevention of CMPA. If breastfeeding is not an 
option, hydrolysed formulas with proven efficacy are recommended in high risk infants (39) 
combined with the avoidance of solid food and cow's milk for the same period. (25) 
6. Conclusion 
CMPA can present in BF and FF infants. The manifestations are non pathognomonic and a 
comprehensive history and thorough clinical examination form the basis of the diagnosis. 
Confirmation with SPT, serum specific IgE or patch testing, unfortunately lack specificity 
and a double blind placebo controlled food challenge, remains the gold standard.  
Although several groups have published recommendations (3, 6, 40), the ongoing debate on 
CMPA management is still dependent on the primary outcome measure chosen: most 
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efficient or cheapest solution. BF remains the best and cheapest option to feed healthy 
infants, even in CMPA. When BF is not an option, eHF in CMPA is recommended as by 
European consensus. 
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1. Introduction 
Natural rubber latex (NRL) is a milky fluid from the Hevea brasiliensis (Hev b) tree, which  
functions as a protective sealant (Ownby, 2002). Because of its excellent elastic properties, it 
is widely used in the manufacture of medical devices and in a variety of everyday articles 
such as gloves, condoms, balloons, baby nipples, syringe plungers, and vial stoppers. As 
many as 40 000 types of consumer products may contain NRL (Perkin et al., 2000). The use 
of rubber for surgical gloves was first made in 1984 by Richard Cook and who popularized 
the use of rubber gloves in surgery was William Hasted (Dyck, 2000).  
NRL allergy is a common occupational disease. The induction of latex allergy commonly 
occurs after exposure of skin or mucous membrane to natural rubber latex. It is usually a 
contact dermatitis or delayed allergy (type IV), and reaction mediated by IgE (type I) or 
immediate hypersensitivity. Latex allergy symptoms can be mild or severe and manifest as 
contact urticaria, rhinoconjunctivitis, asthma, and mucosal swelling; systemic reactions 
consist of generalized urticaria and anaphylactic shock (Hamann et al., 1998; Agarwal & 
Gawkrodger, 2002; Cao et al., 2010; Cleenewerck, 2010). 
It affects people who are frequently exposed to products made of natural rubber latex, such 
as health care workers HCWs (5 to 17%); and groups at high risk included spina bifida 
cystica patients (to almost 65%), latex industry workers, specific food-allergy patients, and 
patients with a history of atopy or multiple surgical procedures (Nettis et al., 2002; 
Turjanmaa et al., 2002; Sullivan, 2005; Sukekava & Sell, 2007; Armentia et al., 2010; Bains et 
al., 2010; Radauer et al., 2011).  
Knowledge about latex allergy is important for three reasons: firstly, it is potentially fatal if 
the patient is not properly managed; secondly, it is common in healthcare workers (HCWs) 
as an occupational disease; and thirdly, its incidence has been increasing due to increased 
use of latex gloves as a barrier against viral infections (Agarwal & Gawkrodger, 2002). Also, 
latex has cross reactivity to banana, avocado, kiwi and other foods. 
Undiagnosed latex allergy is potentially very serious for patients and is increasingly 
recognized as a significant contributor to morbidity and mortality during medical and 
surgical procedures, and anaphylactic shock has been documented (Kosti & Lambrianidis, 
2002; Sonofuchi et al., 2010).  
At present, latex avoidance is the only available treatment and is the key to preventing 
allergic reactions in latex-sensitized individuals.  
This chapter will present the etiology, epidemiology, and pathogenesis of natural rubber 
latex allergy. 
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2. Latex allergens 
Latex products are ubiquitous in our environment and its use and choice is attributed to its 
biomechanical performance characteristics, which include strength, elasticity, tear 
resistance, and superior barriers qualities. 
Raw latex is a milky sap harvested from the rubber tree (Hevea brasiliensis) and it is 
subsequently vulcanized into elastic rubber with which we are all familiar. This milky 
substance is the cytoplasm of the cells of the lactiferous system of the tree. The vast majority 
of Hevea brasiliensis cultivation occurs in Malaysia, Indonesia and Thailand. After harvest by 
sap collection, NRL is ammoniated to prevent bacterial contamination and coagulation, 
resulting in the hydrolysis to latex proteins. Prior to use in manufacturing, the latex is 
formulated by the addition of multiple chemicals: accelerators, antioxidants, and secondary 
preservatives. Thus human exposure is a mixture of residual chemicals and hydrolyzed 
latex peptides. The proteins components have been responsible for type I latex-specific 
allergy and the accelerators and antioxidants are agents of type IV allergic reactions (contact 
dermatitis). Not until Charles Goodyear developed the process of vulcanization to stabilize 
rubber and prevent it from easily melting or freezing, did the rubber industry become 
important (Dyck, 2000). 
The essential structural functional unit in processed latex is an aqueous elastomer emulsion 
containing mainly cis-1,4-polyisoprene (30%-40%) and water (55%-65%), which is coated 
with a layer of protein, lipid, and phospholipids. The protein content of rubber tree sap is 
approximately 15mg/ml and includes more than 240 polypeptides, and 60 of these react to 
latex-specific IgE. Latex proteins can be divided into: water-soluble proteins, starch-bound 
proteins, and latex-bound proteins. Of the multiple proteins found in latex, certain specific 
proteins have been identified as being the major concern in causing IgE-mediated allergic 
reactions. Fourteen proteins have been identified, characterized, and officially accepted as 
allergenic components (Sussman & Beezold, 1994; Lee et al., 2010; Ott et al., 2010).  
The WHO_International Union of Immunological Societies Allergen Nomenclature 
Committee (www.allergens.org) listed 14 NRL Hev b allergens (Hev b 1-14) characterized at 
the molecular level.  It has included Hev b 1, rubber elongation factor (Chen et al., 1997); 
Hev b 2, b-1,3-glucanase (Yagami et al., 2002); Hev b 3, small rubber particle protein - a 24-
kDa protein (Wagner et al., 1999); Hev b 4, a component of the microhelix protein complex – 
lecithinase  homologue; Hev b 6, prohevein/hevein precursor; Hev b 7; patatin-like protein; 
and Hev b 13, esterase (Beirnstein et al., 2003); Hev b 5, acidic protein – proline-rich protein 
(Slater et al., 1996); Hev b 8, profiling (Nieto et al., 2002); Hev b 9, enolase (Wagner et al., 
2000); Hev b 10, manganese superoxide dismutase (Rihs et al., 2001); Hev b 12, non-specific 
lipid transfer protein 1 (Beezhold et al., 2003); and Hev b 11, class I chitinase, and  Hev b 14, 
hevamine, that no allergenicity has been described yet. The epitopes identified as IgE-
binding areas have been defined (Pedraza-Escalona et al., 2009; Rougé et al., 2010). Natural 
rubber latex (NRL) allergenic proteins are listed in Table 1. 
It has been suggested that Hev b 1 and Hev b 3 are major allergens in children with spina 
bifida and urological congenital anomalies (Baur et al., 1995; Yeang et al., 1996; Chen et al., 
1997). Berstein et al. (2003) identified Hev b 2, 5, 6.01 and Hev b 13 as the major in vivo 
allergens among HCWs with allergy to NRL, confirmed by percutaneous sensitivity to 
nonammoniated latex (NAL). These differences of epitopes reactivity can be explained by 
the different allergen profiles on internal and external surfaces of natural rubber latex gloves 
(Peixinho et al., 2008). 
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 Allerginicity  
 reference 
Rubber elongation factor Hev b 1 14 mainly associated with spina 
bifida patients  
Chen et al., 1997 
b-1,3-glucanase  Hev b 2 34 linked more to adult latex-allergy 
patients 
Yagami et al., 2002 
Small rubber particle 
protein 
Hev b 3 24 mainly associated with spina 
bifida patients 
Wagner et al., 1999 
Lecithinase homologue Hev b 4 53-55  Beirnstein et al., 
2003 
Acidic protein  Hev b 5 16 linked more to adult latex-allergy 
patients 
Slater et al., 1996 
Hevein precursor Hev b 6 20 linked more to adult latex-allergy 
patients 
Beirnstein et al., 
2003 
Patatin-like protein Hev b 7 42  Beirnstein et al., 
2003 
Profilin Hev b 8 15  Nieto et al., 2002 
Enolase  Hev b 9 51  Wagner et al., 2000 
Superoxide dismutase 
(Mn)  
Hev b 10 26  Rihs et al., 2001 
Class I chitinase Hev b 11 30 no allergenicity described   
Non-specific lipid 
transfer protein 1  
Hev b 12 9  Beezhold et al., 
2003 
Esterase Hev b 13 42 linked more to adult latex-allergy 
patients 
Beirnstein et al., 
2003 
Hevamine Hev b 14 30 no allergenicity described   
Table 1. Natural rubber latex (NRL) allergenic proteins 
3. Hypersensitivity reactions  
Specific immune responses are normally stimulated when an individual is exposed to a 
foreign antigen and this process is called immunization. Immune responses are specific for 
different structural components of the most complex proteins and polysaccharides antigens. 
The portions of such antigens are specifically recognized by distinct lymphocytes are called 
epitopes. This fine specificity exists because T and B lymphocytes express membrane 
receptors that distinguish subtle difference between distinct antigens. Naïve lymphocytes are 
continually released from the primary lymphoid organs into the periphery (secondary 
lymphoid organs). Antigen-binding can lead to activation of a T or B cell. All of the progeny 
cells derived from any single naïve lymphocytes that constitute a clone. 
Responses to most immunogens can begin only after the immunogen has been captured, 
processed, and presented by an APC (antigen-processing cell) to CD4 T cells (TH0). The 
reason of this is that T cells only recognize immunogens that are bound to major 
histocompatiblity complex (MHC) proteins on the surfaces of other cells. There are two 
different classes of MHC proteins. Class I MHC proteins are expressed virtually by all 
somatic cell types and are used to present substances to CD8 T cells, most of which are 
cytotoxic T cells. Class II MHC proteins, on the other hand, are expressed only by 
macrophages and a few other cells types and are necessary for antigen presentation to CD4 
T cells - the subset that includes most helper cells. Since helper-cell activation is necessary 
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for virtually all responses, the class II-bearing APCs plays a pivotal role in controlling such 
responses.  
Exogenous immunogens can be captured in a variety of ways. After captured by APCs 
become enclosed within membrane-lined vesicles in the cytoplasm and, within these 
vesicles, undergo a series of alterations called antigen processing and a limited number of 
the resulting peptides associated non-covalently with class II MHC proteins and transported 
to APC surface, where they can be detected by CD4 T cells. This process is called antigen 
presentation. At specific antigen recognition the sequences of events induced in 
lymphocytes initiate the activation phase. First, the lymphocyte proliferate, leading to 
expansion of the clones of antigen-specific lymphocytes and amplification of the protective 
response. Second, lymphocytes differentiate to cells that functions are to eliminate foreign 
antigens: thus, B cells transform to plasma cells that secret specific antibody that binds to 
soluble antigen; and some T cells (CD4 or T helper) differentiate into cells that activate 
phagocytes to kill intracellular antigens, and other T cells (CD8) that directly lyses cells that 
are producing foreign antigens such as viral proteins. The effector phase is the stage that 
activated performs the functions that lead to elimination of the antigens: inflammatory 
response is amplified after recruitment of specific and nonspecific effectors cells 
(lymphocytes, macrophages, basophiles, mast cells) and their soluble components 
production (lymphokines, monokines, complement, kinines, arachidonic acid derivates, and 
mast cells- basophile products).  
The immune response serves to protect the individual from foreign antigens with a well-
controlled immune and inflammatory response. However damage to host tissues and 
diseases can result from dysfunction of any component of the host defense system, like 
hypersensitivity or allergy. 
The allergy results when an exposure to the allergens induces an immune response, referred 
to as “sensitization” rather than immunization. Once sensitization occurs, an individual will 
be not symptomatic until there is a new exposure to the same allergen. Then the reaction of 
allergen with specific antibody or sensitized effector T lymphocyte induces an inflammatory 
response, producing the symptoms and signs of the allergic reaction. 
The reactions characteristic of type I hypersensitivity are dependent on the specific 
triggering of IgE-sensitized mast cell by allergen. The sensitization occurs when foreign 
antigens or allergens enter in the host, are processed and presented to APC to the T helper 2 
(TH2) cells. TH2 cells secrete cytokines (interleukins: IL-4, IL-5 and IL-6) that induces B cells 
proliferation and favour to production of an allergens specific-IgE response. IgE binds, via 
Fcε receptors, to mast cells and basophiles thus sensitizing them. When allergen 
subsequently reaches the sensitized mast cells it cross-links surphace-bound IgE and 
increases intracellular calcium that triggers the release of pre-formed mediators, such as 
histamine and proteases, and newly synthesized, lipid-derived mediators such as 
leukotrienes and prostaglandins. These autacoids produce the clinical symptoms of allergy 
(asthma, eczema, and anaphylaxis). 
Type IV (delayed) hypersensitivity reactions involve cell-mediated immune reactions rather 
than humoral response. The sensitization occurs when Langerhans cells process foreign 
antigens and present them to T helper 1 (TH1) cells. The T cells responsibly for the delayed 
response have been specifically sensitized by a previous encounter, and act recruiting other 
cell types to the site of the reaction. Contact hypersensitivity is characterized by an 
eczematous reaction at the point of the contact with an allergen. 
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4. Latex sensitization 
Sensitization and development of latex allergy arise from exposure to products containing 
residual latex proteins and chemical additives in latex products. Latex proteins are potent 
allergens capable of inducing fatal anaphylaxis. 
Sensitization of latex allergy can occur through the skin, by inhalation or by internal 
exposure (mucous membranes of the mouth, vagina or rectum). Medical devices (anesthetic 
masks, condom catheters, ileostomy bags, balloon catheters used for enemas and latex 
gloves) can induce sensitization and then subsequently cause an allergy to develop on re-
exposure. The addiction of cornstarch powder of gloves, in 1947, to prevent sticking and 
give a smoother fit, has been shown to increase the leaching of latex proteins and exposure 
latex proteins on the surface. Powder from latex gloves serves as vector of the dangerous 
proteins that then trigger an allergic response. Cornstarch also promotes aerosolization of 
the latex proteins when gloves are removed, and its release powder into the air and latex 
proteins are inhaled by all individuals in the room. Rubber is extensively distributed in the 
environment and we are in contact with it virtually all the time.  
Latex absorption through the skin is postulated as the major route of sensitization in health 
care workers by the soluble proteins. Friction, pressure, heat, and perspiration are among 
the nonspecific factors that influence the occurrence, severity, and sites of involvement of 
hypersensitivity and cutaneous manifestations. 
5. Pathogenesis and clinical manifestations 
Clinical manifestations include irritant contact dermatitis, allergic contact dermatitis (type 
IV), and immediate hypersensitivity reaction mediated by IgE (type I) (Table 2). It can affect 
the skin, eyes and lungs (Nutter, 1979; Hamann et al., 1998; Mebra & Hunter, 1998; Agarwal 
& Gawkrodger, 2002; Cao et al., 2010; Cleenewerck, 2010).  
5.1 Irritant contact dermatitis 
Irritant contact dermatitis (ICD) is not an allergic reaction. It occurs when an exogenous 
substance without previous sensitization causes direct damage to the skin. Usually it is the 
result of contact with glove additives. Chapped skin from hand washing can be responsible 
for this symptom. Early manifestations of this type of reaction include itchy (most common 
symptoms), but morphological features (dry, crusted lesions) are similar in allergic 
dermatitis, especially on fingers webs and under rings. Greater degrees of irritation result in 
burning, red or swollen tissues. Vesiculation is a late manifestation, but rarely occurs. ICD 
has a diagnosis for exclusion, and patch testing is negative. Management includes careful 
hand washing techniques, use of skin emollients, and an effective routine. 
5.2 Type IV hypersensitivity - Delayed reactions 
Delayed (type IV) allergy or contact dermatitis to rubber gloves is primarily caused by 
accelerators added to speed up rubber vulcanization, including carbamates, thiurams, 2-
mercaptobenzothiszole, and 1,3-diphenylguanidina. It may also cause by antioxidants that 
prevent rubber deterioration, such as black rubber mix chemicals (p-phenylenediamines 
(Cao et al., 2010). It typically manifests within 24 to 48 hours after contact with the allergen. 
It is localized to the skin or mucous membrane. The patient presents a diffuse or patchy 
eczema on the dorsal surface of the hands, wrists, and distal forearms. Latter the reaction 
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can become generalized, and chronic exposure leads to hyperkeratosis and lichenification, 
and at times either hyper- or hypopigmentation. The scalp and palms have a greater 
resistance to contact allergic and irritant reactions than other skin areas. The eyelids, penis, 
and scrotum often show erythema and edema rather than vesiculation. Patch testing is 
positive in these patients. The development of a type IV hypersensitivity allergic response 
may occur after years of contact with the substance. 
5.3 Type I hypersensitivity - Immediate reactions 
Type I reactions to latex involve specific immunoglobulin IgE and mediators of anaphylaxis. 
It is caused by latex proteins that direct sensitize the patients, and reactions occur within 1-
30 minutes. There may be a wide spectrum of clinical presentations. The route of latex 
antigen presentation will usually dictate the clinical manifestations. The skin manifestations 
include itching, swelling, localized pruritus and urticaria (direct contact). Respiratory 
involvement consists of sneezing, wheezing and rhinitis; and the eyes may water, itch and 
conjunctivitis (aerosol exposure or facial contact – latex proteins are adsorbed on gloves 
powder that becomes airborne and can be directly inhaled). A mucosal route of exposure to 
latex allergens is often associated with anaphylactic reactions. The clinical manifestations 
may be serious and give rise to a generalized shock-like reaction: systemic reactions such as 
broncospasm, hypotension, cardiorespiratory collapse, and shock can occur with more 
substantial exposure and in extremely sensitive individuals.  
Contact urticaria is the most common early manifestation of rubber allergy, particularly in 
latex-sensitive health care workers. Symptoms appear within 10-15 min after donning 
gloves. No residual coloration occurs after resolution of the urticaria. 
Anaphylactic shock is potentially fatal and anaphylactic response to latex exposure occurs 
most commonly intraoperatively. However, anaphylactic reactions have been encountered 
during gloving, exposure to dental dams, condom use, and even after indirect exposition by 
contact with individual who use latex gloves. The response appears minutes after the 
administration the allergen, manifesting as a respiratory distress, followed by vascular 
collapse and shock. Cutaneous symptoms, pruritus and urticaria, often occur with or 
without angioedema. Gastrointestinal manifestations involved nausea, vomiting, crampy 
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6. Incidence of latex allergy  
Latex allergy is now an important medical, occupational, medico-legal and financial 
problem, and it is essential that policies are developed to reduce it.  
The diffusion of the "universal precautions", promoted in 1987 by the Center for Disease 
Control and Prevention, dramatically increased the use of latex glove in health care workers 
(HCWs) to reduce the risk of infection, for protection against the HIV and HBV. The 
increased demand caused an increased production of gloves, and a different chemical 
treatment of rubber trees which lowered the glove quality, that means high levels of 
antigens and high powder content. This situation causes an increase of allergic frequency 
(type I and type IV) and irritant reactions to latex gloves in health care workers. 
The prevalence of latex allergy in the general population was estimated at 0.7%-1% in the 
most reports, but some reports now show numbers up to 6%.  A high prevalence of latex 
hypersensitivity is observed in certain occupational and other high-risk groups with 
frequent exposure to NRL products, including health care workers (ranges from 2.8% to 
17%), operating room personal (15-20%), rubber industry workers (near 10%), spina bifida 
cystica patients (to almost 65%), atopic individuals (7%), and those who have had multiple 
surgical operations (6.5%), patients with congenital urologic abnormalities, and those with a 
coexisting food allergy, most often related to certain fruits. The risk is associated with the 
peoples who are frequently exposed to products made of natural rubber latex such as in 
different regions, age, sex and ethnic groups. 
6.1 General population 
Although data is difficult to obtain, estimates now indicate that 1% to 6% of the general 
population has some sensitivity or allergy to latex. In 1994, Ownby et al. measured latex-
specific IgE in the serum from 1000 blood donors and 6.5% were positive. Prevalence of 
positive samples was not associated to race or age.  
6.2 Risk groups 
6.2.1 Health care workers 
The major source of workplace exposure has been powered natural rubber latex gloves used 
mainly by HCW. It has been a problem especially for HCW working in surgical areas or in 
places where  there is more use of latex gloves, in function of the high levels of airbone latex 
particles in these areas. The prevalence of immediate latex allergy increased with increasing 
duration of latex exposure. Studies have reported a prevalence of latex sensitization of from 
2.8 to 17% of the hospital workpopulation. 
The first scientific work describing dermatitis from rubber gloves was published in 1933 
(Downing, 1933). Nutter (1979) was the first investigator to describe contact urticaria to 
rubber gloves: the condition occurred in a house-wife with atopic dermatitis, and during the 
exacerbation of her hand eczema she noted intensive itching for her hands which occurred 5 
min after donning a pair of rubber gloves. The urticaria was confirmed by a patch test using 
a small piece of rubber gloves and with a skin prick test. One year later, Förström described 
the first case of contact urticaria from latex surgical gloves in a nurse with history of atopic 
dermatitis and allergic rhinitis. 
In 1987, Turjanmaa was the first to evaluate the frequency of latex gloves allergy among 
health care workers. A total of 512 hospital employees were screened by using a latex gloves 
scratch-chamber test and subsequent prick test for individuals who are positive in 
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broncospasm, hypotension, cardiorespiratory collapse, and shock can occur with more 
substantial exposure and in extremely sensitive individuals.  
Contact urticaria is the most common early manifestation of rubber allergy, particularly in 
latex-sensitive health care workers. Symptoms appear within 10-15 min after donning 
gloves. No residual coloration occurs after resolution of the urticaria. 
Anaphylactic shock is potentially fatal and anaphylactic response to latex exposure occurs 
most commonly intraoperatively. However, anaphylactic reactions have been encountered 
during gloving, exposure to dental dams, condom use, and even after indirect exposition by 
contact with individual who use latex gloves. The response appears minutes after the 
administration the allergen, manifesting as a respiratory distress, followed by vascular 
collapse and shock. Cutaneous symptoms, pruritus and urticaria, often occur with or 
without angioedema. Gastrointestinal manifestations involved nausea, vomiting, crampy 
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particles in these areas. The prevalence of immediate latex allergy increased with increasing 
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min after donning a pair of rubber gloves. The urticaria was confirmed by a patch test using 
a small piece of rubber gloves and with a skin prick test. One year later, Förström described 
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scratch-chamber test and subsequent prick test for individuals who are positive in 
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screening. Twenty-three (4.5%) had positive scratch-chamber test, and the prick test was 
positive in 15 of these 23 patients. Most of them had a personal history of atopy, asthma, 
allergic rhinitis, and atopic eczema. Latex gloves allergy was significantly more frequent in 
personal of operative room. 
Arellano et al. (1992) were the first to report the prevalence of latex sensitization among 
physicians using latex gloves in a North American Hospital setting. Using a latex skin prick 
test they determined the sensitization in 9.9% of the North American physicians. 
Since 1987, the number of HCW with positive test results for NRL has been increased. In 
1994, Charous et al. reviewed medical histories of symptomatic workers with occupational 
exposure to latex and they evidenced that the number of patients reporting onset of latex-
induced contact dermatitis had remained relatively constant, whereas the number of the 
patients with contact dermatitis and systemic reactions had markedly increased.  
Some reports about prevalence of latex allergy in HCW in different countries are presented. 
At an Italy Hospital, a high prevalence of rubber glove-induced dermatoses among the 
employees were evidenced: about of 24% the health care workers, who used or had used 
latex gloves at work, reported glove-induced symptoms, namely, cutaneous symptoms in all 
the cases. Non-cutaneous symptoms appeared in 8.1%. Positive patch tests to rubber-related 
allergens were exhibited at 10.5% of symptomatic employees (Nettis et al., 2002). 
The prevalence of latex allergy among HCWs in Russia, and adjacent eastern European 
countries was available and considerably less than reported in Western Europe and the 
United States. Skin test to latex was positive in 5.4% of HCWs and 1.9% were classified as 
latex-allergic based on positive skin tests to latex associated with allergy symptoms with 
exposure. Some of them had experienced anaphylactic reactions to latex. The low prevalence 
of latex allergy suggests that lessened exposure to natural latex powdered gloves in HCWs 
in Russia (Nolte et al., 2002). 
To assess the allergic risk induced by latex gloves in HCWs, a meta-analysis was carried out 
under the auspices of the French National Regulatory Authority. Latex allergy was found in 
4.32% (range, 4.01% to 4.63%) of HCWs and in 1.37% (range, 0.43% to 2.31%) of the general 
population. Latex-positive skin prick test responses ranged from 2.1% to 3.7% in the general 
population and from 6.9% to 7.8% for the HCWs (Bousquet et al, 2006). 
To determine the main factors associated with latex allergy and to quantify levels of 
airborne latex particles in different areas of Spanish hospital, a cross-sectional study was 
conducted by Diéguez et al. (2007). More allergic patients were found in the surgery 
department, intensive care unit, and vascular radiology unit.  
In Taiwan, natural rubber latex is the most important occupational allergen among medical 
workers. To evaluate immediate latex allergy and contact dermatitis, 1253 medical workers 
were interviewed using a screening questionnaire and skin prick testing with commercial 
latex extract was performed. The prevalence of contact hand dermatitis from latex gloves 
was 35%. Twelve percent had positive latex skin prick test, suggesting that they had been 
sensitized to latex proteins. Seventy nine subjects (6%) had immediate allergic reactions to 
latex products (Lin et al., 2008).  
The prevalence of hypersensitivity to natural rubber latex and potential food cross reactions 
in operation room personnel in Shiraz hospitals revealed a significant correlation between 
those with positive skin tests to latex with atopia, urticaria, and food hypersensitivity. 
About 18% of operating room personnel showed positive latex skin tests. The prevalence 
did not vary by sex, age, education, surgical and non-surgical gloves users, or history of 
contact dermatitis (Nabavizadeh et al., 2009). 
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Dates from Asia countries with regard to latex allergy are scarce. Amarasekera et al. (2010) 
determined the prevalence and risk factors among healthcare workers in a hospital in Sri 
Lanka. Symptoms suggestive of latex allergy were reported in 16% of the subjects. A 
considerable proportion (11.4%) of workers had been suffering from latex allergy for more 
than 5 years.  
Oral health care professionals have been shown to be at risk for developing a type I allergy 
to natural rubber latex (NRL). The prevalence of this allergy in dental hygienists has been 
evaluated. Hamann et al. (2005) investigated by screened positive for a type I allergy to NRL 
(SPT-positive) 582 participants to 2000-2002 American Dental Hygienists' Association 
(ADHA) national meetings. Risk factors and symptom assessments were questioned and 
were based on a self-reported health history. About 5% screened positive for a type I allergy 
to NRL (SPT-positive). They observed that the NRL allergy was significantly more likely to 
report an allergy to cross-reacting foods, plants, moulds, and pollens, and to report reactions 
to rubber products. Sukekava & Sell (2007) determined the incidence of latex gloves allergy 
among dental care workers. Latex gloves reaction occurred in 19% of them, and 5% reported 
allergic reactions to other latex products; 2.5% reported symptoms suggesting contact 
dermatitis and anaphylaxis hypersensitivities, 1.5% reported contact dermatitis, and 1% 
reported anaphylaxis symptoms when wearing them. 
6.2.2 Latex industry workers 
Latex industry workers have an increased prevalence of chronic respiratory symptoms and 
reduced lung function. In 1988, Bascom et al. described a spectrum of respiratory illness 
associated with eosinophilia that occurred in a group of rubber workers exposed to fumes 
from a synthetic rubber-based curing operation. Two years latter, 81 latex industry workers 
were evaluated, and 7 had spirometric changes consistent with asthma, and two of them 
had positive skin prick test to latex. To known the relation of rubber tree dust exposure to 
respiratory and skin symptoms, asthma and lung function in regard  to wood dust from the 
rubber tree, a cross-sectional study was carried out among 103 workers in a rubber tree 
furniture factory and 76 office workers in four factories in Thailand. Factory workers 
showed increased risk of wheezing, nasal symptoms and asthma compared to office 
workers. There was a dose-dependent increase in wheeze and skin symptoms in regard to 
dust level. Significantly increased risks of nasal symptoms and asthma were detected in the 
low exposure category (Sripaiboonkij et al., 2009). 
6.2.3 Patients with spina bifida cystica 
Patients with spina bifida cystica form a population at highest risk of latex allergy. 
Management of infants with spina bifida cystica involves different procedures that include 
immediate operative skin closure of an open or thin walled defect, ventriculoperitoneal 
shunting of hydrocephalus, bracing of the lower extremities, and other surgical procedures 
to address sensory deficits, bowel and bladder dysfunction, pain elimination, orthopedic 
problems, and minimize or prevent associated neurologic defects. The major risk factors for 
latex sensitization in spina bifida cystica children include atopy, familiarity propensity for 
allergy, and very early exposure with mucosal absorption of allergen related to number of 
surgical procedures. Kelly et al. (1991) pointed out in their studies that spina bifida pediatric 
patients have 500 times greater a risk of latex-related anaphylaxis during operative 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
296 
screening. Twenty-three (4.5%) had positive scratch-chamber test, and the prick test was 
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procedures than of the general pediatric population: eight of the 10 pediatric patients 
experiencing anaphylaxis during surgery. Prevalence of latex sensitivity among the spina 
bifida cystica pediatric population was among 40 to 65%. The recommendation is that 
children with spina bifida avoid contact with NRL products from birth.  
7. Cases reports of latex-induced anaphylactic reactions 
The prevalence of latex allergy is increasing in general population and surgical patient 
individuals. Several anaphylactic events during some surgical procedures are still rare; 
however they are associated with increased morbidity and mortality. Undiagnosed latex 
allergy is potentially very serious for patients. The risk factors for latex skin sensitization 
were: a previous history of atopy and asthma; history of surgery; pre-existing hand 
dermatitis; work-related symptoms; and positive skin tests to common inhalant and certain 
foods. Avoidance of exposure to the allergen is essential to minimizing preoperative 
complications in patients suspect to be at risk. 
In 2003, Verdolin et al. described an accidental diagnosis of latex allergy after urological 
surgery under spinal anesthesia when patient presented clinical manifestation of 
anaphylactic shock: confusion, dyspnea, generalized pruritus and erythema, bronchospasm, 
arterial hypotension, and tachycardia. In Japan, Ueda et al. (2008) reported an anaphylactic 
reaction to latex forty-three minutes subsequent to spinal anesthesia in a 46-year-old man 
with a history of atopic dermatitis and bronchial asthma underwent surgery for an inguinal 
hernia. Sonofuchi et al. (2010) reported anaphylactic shock after introduction of the general 
anesthesia in the patient who had latex allergy. Machado et al. (2011) described a case of 
severe latex induced anaphylactic reaction in a patient with a diagnostic suspicion of 
appendicitis who underwent an emergency surgery under spinal anesthesia. The symptoms 
occurred approximately 30 minutes after beginning the surgery. 
One of the groups that are at risk for anaphylactic reactions to latex during surgical and 
medical procedures is represented by the obstetric and gynecologic population. A case was 
reported when an anaphylactic reaction to latex occurred in a pregnant woman patient who 
underwent a caesarean section that the diagnosis of latex allergy was missed. Following day 
the woman underwent a surgical re-exploration complicated by fatal cardiovascular arrest. 
At post-mortem examination, pulmonary mast cells in the bronchial walls and capillary 
septa were identified, and a great number of degranulating mast cells with tryptase-positive 
material outside the cells was documented and the latex-specific IgE test showed a high title. 
Latex-induced fatal anaphylactic shock was recorded as the cause of death.  This case 
highlights some of the practical difficulties in the initial diagnosis and subsequent 
investigation of fatal anaphylactic reaction during anesthesia. Anaphylaxis is often 
misdiagnosed because many other pathologic conditions may present identical clinical 
manifestations, so anaphylactic shock must be differentiated from other causes of 
circulatory collapse. Although latex allergy usually has a delayed onset after the start of the 
surgery and most often a slow onset too, it should be always suspected if circulatory 
collapse and respiratory failure occur during surgery, even if the patient does not belong to 
a risk group; in the presence of identified risk factors for latex allergy a well-founded 
suspicion must be stronger, leading to an immediate discontinuation of the potential trigger 
(Turillazzi et al., 2008). 
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8. Immunological cross-reactivity between latex and other products 
8.1 Food cross-reactivity 
Latex allergy has been reported to be associated with allergy to certain foods. 
Approximately 30-50% of individuals who are allergic to natural rubber latex (NRL) show 
an associated hypersensitivity to some plant-derived foods, especially freshly consumed 
fruits. This association of latex allergy and allergy to plant-derived foods is called latex-fruit 
syndrome. An increasing number of plant sources have been associated with this syndrome. 
The most frequently involved are banana, avocado, kiwi, and chestnut, although several 
others may also be included as peach, grape, pineapple, nuts, figs, passion fruit, celery, 
citrus fruits, chestnut, peach, tomato, potato and bell pepper. Some studies have found out 
immunological and clinical cross-reactivity.  
The hypothesis is that allergen cross-reactivity is due to IgE antibodies that recognize 
structurally similar epitopes on different proteins that are phylogenetically closely related or 
represent evolutionarily conserved structures. Several types of proteins have been identified 
to be involved in the latex-fruit syndrome. Two of these are higher plant defense proteins. 
Class I chitinases containing an N-terminal hevein-like domain cross-react with hevein (Hev 
b 6.02). A beta-1,3-glucanase was identified as an important latex allergen which shows 
cross-reactivity with proteins of bell pepper and banana. Nine distinct IgE-binding epitopes 
were identified along the entire amino acid sequence of the major latex allergen Hev b 2 
(beta-1,3-glucanase), and a smaller number of IgE-binding epitopic areas was identified on 
the banana beta-1,3- glucanase, which exhibits a very similar overall conformation and 
charge distribution. Plant defense-related proteins are relatively conserved in the course of 
evolution and can supply cross-reactive epitopes. It is important to note that various stresses 
can stimulate the expression of these proteins, which implies that allergens increase in 
plants under stressful conditions like severe growing situations and exposure to some kinds 
of chemicals. Another important NRL allergen, Hev b 7, is a patatin-like protein that shows 
cross-reactivity with its analogous protein in potato (Wagner and Breiteneder, 2002; Barre et 
al., 2009).  
Axelsson e cols. were one of the first researches to described an association between latex 
allergy and fruit. They describe a 12-year-old girl who developed rhinoconjuntivitis and 
itching in the throat after eating stone fruits. Subsequently, she developed angioedema after 
inflating a rubber balloon (Woods et al., 1997). Recently, anaphylactic shock was related in a 
woman underwent a cardiac catheter examination, and a Swan-Ganz catheter was inserted. 
She declared no past history of latex allergy, but did have a banana allergy. Skin prick test 
showed a positive reaction to an extract of latex gloves an extract of the balloon of a Swan-
Ganz catheter (Sekiya et al., 2011). It is necessary to pay attention to not only latex allergy 
but also fruit allergies with cross-reactivity to latex.  
Up to 2 out of 3 spina bifida patients with natural rubber latex (NRL) antibodies have 
crossreacting IgE-antibody against tropical fruit, due to structural homologies between 
several NRL antigens and allergenic fruit proteins. To investigate whether the patients were 
first sensitized against NRL or fruit, Cremer et al. (2011) investigated sera of 96 patients for 
specific IgE antibody against NRL, banana and kiwi as examples for cross reacting fruit. 
Only two patients developed antibody against fruit without being sensitized against NRL. 
In most cases the sensitization against fruit follows the NRL sensitization. There is no need 
to recommend spina bifida patients without NRL sensitization to primarily avoid tropical 
fruit. 
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procedures than of the general pediatric population: eight of the 10 pediatric patients 
experiencing anaphylaxis during surgery. Prevalence of latex sensitivity among the spina 
bifida cystica pediatric population was among 40 to 65%. The recommendation is that 
children with spina bifida avoid contact with NRL products from birth.  
7. Cases reports of latex-induced anaphylactic reactions 
The prevalence of latex allergy is increasing in general population and surgical patient 
individuals. Several anaphylactic events during some surgical procedures are still rare; 
however they are associated with increased morbidity and mortality. Undiagnosed latex 
allergy is potentially very serious for patients. The risk factors for latex skin sensitization 
were: a previous history of atopy and asthma; history of surgery; pre-existing hand 
dermatitis; work-related symptoms; and positive skin tests to common inhalant and certain 
foods. Avoidance of exposure to the allergen is essential to minimizing preoperative 
complications in patients suspect to be at risk. 
In 2003, Verdolin et al. described an accidental diagnosis of latex allergy after urological 
surgery under spinal anesthesia when patient presented clinical manifestation of 
anaphylactic shock: confusion, dyspnea, generalized pruritus and erythema, bronchospasm, 
arterial hypotension, and tachycardia. In Japan, Ueda et al. (2008) reported an anaphylactic 
reaction to latex forty-three minutes subsequent to spinal anesthesia in a 46-year-old man 
with a history of atopic dermatitis and bronchial asthma underwent surgery for an inguinal 
hernia. Sonofuchi et al. (2010) reported anaphylactic shock after introduction of the general 
anesthesia in the patient who had latex allergy. Machado et al. (2011) described a case of 
severe latex induced anaphylactic reaction in a patient with a diagnostic suspicion of 
appendicitis who underwent an emergency surgery under spinal anesthesia. The symptoms 
occurred approximately 30 minutes after beginning the surgery. 
One of the groups that are at risk for anaphylactic reactions to latex during surgical and 
medical procedures is represented by the obstetric and gynecologic population. A case was 
reported when an anaphylactic reaction to latex occurred in a pregnant woman patient who 
underwent a caesarean section that the diagnosis of latex allergy was missed. Following day 
the woman underwent a surgical re-exploration complicated by fatal cardiovascular arrest. 
At post-mortem examination, pulmonary mast cells in the bronchial walls and capillary 
septa were identified, and a great number of degranulating mast cells with tryptase-positive 
material outside the cells was documented and the latex-specific IgE test showed a high title. 
Latex-induced fatal anaphylactic shock was recorded as the cause of death.  This case 
highlights some of the practical difficulties in the initial diagnosis and subsequent 
investigation of fatal anaphylactic reaction during anesthesia. Anaphylaxis is often 
misdiagnosed because many other pathologic conditions may present identical clinical 
manifestations, so anaphylactic shock must be differentiated from other causes of 
circulatory collapse. Although latex allergy usually has a delayed onset after the start of the 
surgery and most often a slow onset too, it should be always suspected if circulatory 
collapse and respiratory failure occur during surgery, even if the patient does not belong to 
a risk group; in the presence of identified risk factors for latex allergy a well-founded 
suspicion must be stronger, leading to an immediate discontinuation of the potential trigger 
(Turillazzi et al., 2008). 
 
Natural Rubber Latex Allergy 
 
299 
8. Immunological cross-reactivity between latex and other products 
8.1 Food cross-reactivity 
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syndrome. An increasing number of plant sources have been associated with this syndrome. 
The most frequently involved are banana, avocado, kiwi, and chestnut, although several 
others may also be included as peach, grape, pineapple, nuts, figs, passion fruit, celery, 
citrus fruits, chestnut, peach, tomato, potato and bell pepper. Some studies have found out 
immunological and clinical cross-reactivity.  
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Allergen cross-reactivity between tobacco and other species of Solanaceae family (tomato, 
potato, aubergine, and egg plant) have been reported. Armentia et al. (2010) have recently 
studied IgE response to tobacco in asthmatic patients sensitized to Lolium perenne 
(Perennial rye grass pollen), and have found that 30% of the tobacco responsive patients also 
have latex sensitization. They concluded that exist cross-reactivity between latex and 
tobacco allergens, and smoker patients with IgE response to tobacco may be a risk 
population for latex sensitization. 
8.2 Gutta-percha and gutta-balata 
In general dental practice, there is over than 30 products containing latex rubber. The 
practitioner should be cautions when threatening patients with a history or allergy to latex 
products. Gutta-percha and gutta-balata, used in endodontic treatment, are derived from 
the Paliquium gutta and Mimusops globsa trees, respectively, that are in the same botanical 
family of the rubber tree Hevea brasiliensis. For this reason immunological cross-reactivity 
between gutta-percha, gutta-balata and NRL were investigated (Costa et al., 2001): no 
detectable cross-reactivity was observed with any of the raw or clinically used gutta-percha 
products. In contrast, gutta-balata released proteins that were cross-reactive with latex. 
Because gutta-balata is sometimes added to commercial gutta percha products, caution 
should be taken if these products are used in endodontic care of latex-allergic individuals.   
Many cases of anaphylaxis reactions occurrence in patient sensitive to latex during 
endodontic treatment has been reported. Boxer et al. (1994) described a latex-allergic dental 
hygienist who experienced immediate lip and gingival swelling and diffuse urticaria after 
the insertion of gutta-percha points into her maxillary molar by a general dentist. 
Immediately after removal of the gutta-percha, relief of the oral discomfort was noted, and 
the urticaria resolved several hours thereafter.  
9. Genetic predisposition 
The intensity of latex exposure, the route of sensitization, the genetically determined 
susceptibility, or the combination of all may have significant influence on pathogenesis of 
type I reaction to latex allergens. Although exposure to NRL products is necessary for 
sensitization, it is not sufficient.  
The field of genome-based medicine, which attempts to identify genetic ffactors some 
individuals have, which may protect them or created problems when they undergo medical 
intervention, is rapidly evolving and affecting all fields of medical practice. Allergic diseases 
are dependent on the specific triggering of IgE-sensitized mast cell and their activation 
resulting in an inflammatory response. Immunological specific mechanism is genetically 
controlled and some individuals are more susceptible to allergic manifestations. Any steps 
of immunological and inflammatory reactions could be involved and are target of 
investigations. Polymorphism in over 30 genes localized on 15 different chromosomes has 
been associated with human allergy. Although the importance of these genetic components 
in the development of allergic diseases, susceptibility genes have been difficult to identify 
given the multigenic nature of this effect. The genetic/ immunologic risk factors of diseases 
susceptibility, that had been most studied, are the classic and non-classic alleles of the Major 
Histocompatibility Complex (MHC), and promoter genes of cytokine polymorphisms. 
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The Major Histocompatibility Complex (MHC), located on chromosome 6p21, is the most 
polymorphic genetic system in mammalians, and has been studied with regard to a wide 
variety of diseases of distinct etiology. The fundamental role of the different molecules 
within the MHC is antigen processing and presentation to the T-cell receptor (TCR), which 
is crucial for the cell interactions in immune response. In humans, while the classic class I 
loci, HLA-A, -B, and -C, bind peptides of intra-cellular origin and present them to CD8 T 
cells, the classic class II loci, HLA-DR, -DQ, and -DP, primarily bind peptides of extra-
cellular origin and present them to CD4 T cells, resulting in cytokine production that drives 
an antibody production. 
Focusing specifically on NRL allergy, Rihs et al. (2002) demonstrated the association 
between the specific IgE response to the major latex allergen hevein (Hev b 6.02) in HCW 
with latex allergy and latex-sensitized patients with spina bifida, and HLA class II alleles of 
DQB1 and DRB1, DRB3, DRB4, and DRB5. The class II HLA-DQB1*03:02 (DQ8) allele and 
HLA-DQB1*03:02 (DQ8)-DRB1*04(DR4) haplotype were significantly involved in the 
hevein-specific IgE immune response in HCW with latex allergy. NRL-sensitized patients 
with spina bifida showed an increase HLA-DQB1*03:02 frequency, but this result was not 
significant. 
Two genes that have been of interest with regard to NRL allergy are IL13 and IL18. IL-13, 
along with IL-4, is critical for the promotion of allergic response. IL-13 plays an important 
role in mediating airway hyperresponsiveness in asthma. Binding of IL-4 and IL-13 to the α 
chain of the IL-4 receptor activates germline transcription of the ε heavy-chain gene locus 
and isotype switching of B cells to IgE production. IL-18 can stimulate interferon production 
or enhance cytokines and IgE production. SNPs in these genes have been postulated to 
influence physiologic functions that are important in development of atopy (Monitto et al., 
2010).  Genetic predisposition to natural rubber latex allergy in the health care workers was 
available, and has been shown to be associated with promoter polymorphisms in IL13 and 
IL18 genes when compared with nonatopic controls (Brown et al., 2005). This association 
was not seen when these patients were genotyped for SNPs in other immunomodulatory 
genes, including IL4, tumor necrosis factor- α and -, CC chemokine receptor 2 and 5, and 
toll-like receptor 4. In patients born with spina bifda and or genitourinary abnormalities the 
association of promoter polymorphisms in IL13 and IL18 genes was not observed (Monitto 
et al., 2010). 
10. Diagnosis of latex allergy  
To manage latex allergy appropriately, prompt and correct diagnosis is essential, and both 
in vivo and in vitro assays have been included. There are two elements to consider in latex 
allergy diagnosis: history and qualitative and quantitative tests. 
10.1 History 
The diagnosis of latex requires a thorough and accurate medical history. Screening patients 
is the first step for minimizing the risk of a latex allergic reaction. It is necessary to have a 
high index of suspicion, especially for patients in high risk occupations or with medical 
histories that induce repeated exposure to latex. Patients at special risk are those individuals 
with frequent or prolonged exposure to latex products. The following points must be 
considered: history of atopy (general allergies); food allergies (especially bananas, kiwi, 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
300 
Allergen cross-reactivity between tobacco and other species of Solanaceae family (tomato, 
potato, aubergine, and egg plant) have been reported. Armentia et al. (2010) have recently 
studied IgE response to tobacco in asthmatic patients sensitized to Lolium perenne 
(Perennial rye grass pollen), and have found that 30% of the tobacco responsive patients also 
have latex sensitization. They concluded that exist cross-reactivity between latex and 
tobacco allergens, and smoker patients with IgE response to tobacco may be a risk 
population for latex sensitization. 
8.2 Gutta-percha and gutta-balata 
In general dental practice, there is over than 30 products containing latex rubber. The 
practitioner should be cautions when threatening patients with a history or allergy to latex 
products. Gutta-percha and gutta-balata, used in endodontic treatment, are derived from 
the Paliquium gutta and Mimusops globsa trees, respectively, that are in the same botanical 
family of the rubber tree Hevea brasiliensis. For this reason immunological cross-reactivity 
between gutta-percha, gutta-balata and NRL were investigated (Costa et al., 2001): no 
detectable cross-reactivity was observed with any of the raw or clinically used gutta-percha 
products. In contrast, gutta-balata released proteins that were cross-reactive with latex. 
Because gutta-balata is sometimes added to commercial gutta percha products, caution 
should be taken if these products are used in endodontic care of latex-allergic individuals.   
Many cases of anaphylaxis reactions occurrence in patient sensitive to latex during 
endodontic treatment has been reported. Boxer et al. (1994) described a latex-allergic dental 
hygienist who experienced immediate lip and gingival swelling and diffuse urticaria after 
the insertion of gutta-percha points into her maxillary molar by a general dentist. 
Immediately after removal of the gutta-percha, relief of the oral discomfort was noted, and 
the urticaria resolved several hours thereafter.  
9. Genetic predisposition 
The intensity of latex exposure, the route of sensitization, the genetically determined 
susceptibility, or the combination of all may have significant influence on pathogenesis of 
type I reaction to latex allergens. Although exposure to NRL products is necessary for 
sensitization, it is not sufficient.  
The field of genome-based medicine, which attempts to identify genetic ffactors some 
individuals have, which may protect them or created problems when they undergo medical 
intervention, is rapidly evolving and affecting all fields of medical practice. Allergic diseases 
are dependent on the specific triggering of IgE-sensitized mast cell and their activation 
resulting in an inflammatory response. Immunological specific mechanism is genetically 
controlled and some individuals are more susceptible to allergic manifestations. Any steps 
of immunological and inflammatory reactions could be involved and are target of 
investigations. Polymorphism in over 30 genes localized on 15 different chromosomes has 
been associated with human allergy. Although the importance of these genetic components 
in the development of allergic diseases, susceptibility genes have been difficult to identify 
given the multigenic nature of this effect. The genetic/ immunologic risk factors of diseases 
susceptibility, that had been most studied, are the classic and non-classic alleles of the Major 
Histocompatibility Complex (MHC), and promoter genes of cytokine polymorphisms. 
 
Natural Rubber Latex Allergy 
 
301 
The Major Histocompatibility Complex (MHC), located on chromosome 6p21, is the most 
polymorphic genetic system in mammalians, and has been studied with regard to a wide 
variety of diseases of distinct etiology. The fundamental role of the different molecules 
within the MHC is antigen processing and presentation to the T-cell receptor (TCR), which 
is crucial for the cell interactions in immune response. In humans, while the classic class I 
loci, HLA-A, -B, and -C, bind peptides of intra-cellular origin and present them to CD8 T 
cells, the classic class II loci, HLA-DR, -DQ, and -DP, primarily bind peptides of extra-
cellular origin and present them to CD4 T cells, resulting in cytokine production that drives 
an antibody production. 
Focusing specifically on NRL allergy, Rihs et al. (2002) demonstrated the association 
between the specific IgE response to the major latex allergen hevein (Hev b 6.02) in HCW 
with latex allergy and latex-sensitized patients with spina bifida, and HLA class II alleles of 
DQB1 and DRB1, DRB3, DRB4, and DRB5. The class II HLA-DQB1*03:02 (DQ8) allele and 
HLA-DQB1*03:02 (DQ8)-DRB1*04(DR4) haplotype were significantly involved in the 
hevein-specific IgE immune response in HCW with latex allergy. NRL-sensitized patients 
with spina bifida showed an increase HLA-DQB1*03:02 frequency, but this result was not 
significant. 
Two genes that have been of interest with regard to NRL allergy are IL13 and IL18. IL-13, 
along with IL-4, is critical for the promotion of allergic response. IL-13 plays an important 
role in mediating airway hyperresponsiveness in asthma. Binding of IL-4 and IL-13 to the α 
chain of the IL-4 receptor activates germline transcription of the ε heavy-chain gene locus 
and isotype switching of B cells to IgE production. IL-18 can stimulate interferon production 
or enhance cytokines and IgE production. SNPs in these genes have been postulated to 
influence physiologic functions that are important in development of atopy (Monitto et al., 
2010).  Genetic predisposition to natural rubber latex allergy in the health care workers was 
available, and has been shown to be associated with promoter polymorphisms in IL13 and 
IL18 genes when compared with nonatopic controls (Brown et al., 2005). This association 
was not seen when these patients were genotyped for SNPs in other immunomodulatory 
genes, including IL4, tumor necrosis factor- α and -, CC chemokine receptor 2 and 5, and 
toll-like receptor 4. In patients born with spina bifda and or genitourinary abnormalities the 
association of promoter polymorphisms in IL13 and IL18 genes was not observed (Monitto 
et al., 2010). 
10. Diagnosis of latex allergy  
To manage latex allergy appropriately, prompt and correct diagnosis is essential, and both 
in vivo and in vitro assays have been included. There are two elements to consider in latex 
allergy diagnosis: history and qualitative and quantitative tests. 
10.1 History 
The diagnosis of latex requires a thorough and accurate medical history. Screening patients 
is the first step for minimizing the risk of a latex allergic reaction. It is necessary to have a 
high index of suspicion, especially for patients in high risk occupations or with medical 
histories that induce repeated exposure to latex. Patients at special risk are those individuals 
with frequent or prolonged exposure to latex products. The following points must be 
considered: history of atopy (general allergies); food allergies (especially bananas, kiwi, 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
302 
avocados, chesnut, fig, tomato); history of allergic reactions to latex (including hives, 
swelling, eye/nose symptoms, asthma, and anaphylaxis); and undiagnosed reactions or 
complications during anesthesia, surgery, or dental work. 
The medical clinical history about manifestations is often similar among individuals affected 
by latex allergy. Onset is often insidious with dermatitis of the hands, which patients 
attribute to frequent hand washing and irritation. After a short period of time (less than a 
year) erythema, papulovesiculation, induration, and pruritis emerge within 1-3 hours after 
onset of gloves use. Among HCW, one may often elicit a history of respiratory symptoms, 
which is pronounced while at work. For patients presenting contact dermatitis or urticaria, 
the physician should ask about localization and time of onset of the eruption, morphology, 
nature of progression, and recurrence or periodicity (Woods et al., 1997). 
10.2 Diagnostic testing 
Latex allergy can be diagnosed by skin prick testing, latex-specific serum immunoglobulin E 
testing, glove provocation testing, and patch testing.  Both in vivo and in vitro testing 
methods have been used to diagnose latex allergy with varying degrees of success. 
10.2.1 Skin prick testing (SPT)  
The cutaneous test or skin prick tests with latex extracts are commonly used in the 
diagnostic approach to natural rubber latex allergy. For this, a minute quantity of the 
allergen is introduced into the dermis to cause a reaction with IgE antibodies fixed to 
cutaneous mast cells for release of mediators, producing a visible wheal and erythema. After 
20 minutes the reactions are graded and recorded. The skin of the back or upper arms can be 
used. It should be done by trained allergists in a hospital setting with adequate resuscitation 
and medical support services. Reports of anaphylaxis during SPT for latex allergy 
emphasize the need to safe testing methods for diagnosis. This test has the advantage of 
being sensitive, rapid, and cost-effective. Reactivity in SPT is related to the potency of the 
SPT solution used: as a rule solutions with higher protein and antigen contents gave better 
results. Commercial extracts are used with good specificity and sensivity. Ammoniated and 
non-ammoniated latex extracts and Hev b 1, 2, 3, 4, 6.01, 7.01, and 13 allergens and 
recombinant Hev b 5 (rHev b 5) allergens are commonly used for this purpose. Serial 
dilutions extracts and NRL allergens were employed in skin testing. It is important to 
consider that sensitivity and specificity of different commercially available skin prick tests 
could vary (Bernardini et al., 2008b; van Kampen et al., 2010).   
10.2.2 In vitro assays for latex-specific IgE 
Quantitative measurement of allergen-specific IgE antibodies in serum requires special 
methods to detect the extremely minute quantities (pictograms per milliliter) found in 
allergic patients. Sensitive and specific commercial in vitro serological assays that have been 
developed for the diagnosis of IgE-mediated latex allergy include a radioallergosorbent 
assay – RAST, and enzyme-immunoassay method - ELISA. These occur in a 2-phase 
(solid/liquid) system using an insolubilized allergen that is incubated first in the test serum 
to react with latex specific IgE and then in radio, fluoro or enzyme- labeled heterologous 
anti-human IgE isotype. These tests require purified preparations of allergens (Hev b 1, Hev 
b 3, Hev b 5 - rHev b 5, Hev b 6.02, Hev b 8, and Hev b 13) and anti-human IgE. The 
differences in preparations of latex allergen and the existence of possible cross-reacting 
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antibodies contribute to variance in accuracy of these tests. In atopic individuals, especially 
in patients with allergies to fruits or vegetables, these serological tests can produce false- 
positive results. The diagnostic sensitivity and specificity of the latex-specific IgE serology 
can be less when compared with skin tests (Smith et al., 2007). 
10.2.3 Microarray technology 
Microarray technology has recently been introduced being a reliable tool for diagnosing 
latex allergy (Ebo et al., 2010; Ott et al., 2010). A positive specific IgE (sIgE) result for latex 
does not always mirror the clinical situation and is frequently found in individuals without 
overt latex allergy. The diagnosis of latex allergy could be established by the combination of 
recombinant latex components present on the microarray (Hev b 1, Hev b 3, Hev b 5 and 
Hev b 6.02).  The reaction can be performed with different platforms, the ImmunoCAP ISAC 
microarray and traditional singleplexed ImmunoCAP. Microarray can improve the 
diagnosis of IgE-mediated latex allergy by discriminating between genuine allergy and 
sensitization. 
10.2.4 Provocation test  
Occasionally, it is desirable to test the target (cutaneous, respiratory, or gastrointestinal) 
tissue responsiveness to the allergen under controlled conditions. Cutaneous provocation 
tests have been used in patients with suspect latex allergy: they wore a latex glove on one 
hand and a vinyl glove on the other hand for 15 minutes. Sensitivity is 90%, but some 
studies have indicated it may be more dangerous than skin testing in very allergic 
individuals. In the nasal provocation test, changes in nasal airways resistance and visible 
signs of congestion and rhinorrhea are observed after exposure to quantitative allergen 
challenge. To examine the responses in patients with positive SPT to nasal provocation test, 
Unsel et al. (2009) found that nasal provocation test has a sensitivity of 96%, specificity of 
100%, negative predictive value of 98% and positive predictive value of 100%. 
10.2.5 Path testing 
Path testing is helpful in differentiating irritant contact dermatitis from allergic contact 
dermatitis mediated by type IV hypersensitivity reactions. It’s a definitive test for diagnosis 
of patients with type IV hypersensitivity to latex products using a standard battery of 
rubber additives. The series of rubber allergen were applied on normal skin, usually on the 
patient’s back or arms, under a small semi occlusive dressing. It is left in place for 24-48 
hours. The results are first read in 30 minutes after removing patches, and again 24 or 48 h. 
The positive reaction can be accepted as the cause of the present eruption. Accelerators 
evoke positive patch tests in 82% patients with occupationally induced contact dermatitis 
associated with glove use. The allergens that most commonly yielded positive reactions 
have been carbamates, 4,4-dithiodimorpholine, thiurams mix, 2-mercaptobenzothiazole, and 
1,3-diphenylguanidine (Woods et al., 1997; Bendewald et al., 2010; Cao et al., 2010). 
11. Management and treatment 
At present, latex avoidance is the only available treatment and has been the key to 
preventing allergic reactions in latex-sensitized individuals. For patients, avoidance of 
exposure to the allergen is essential to minimizing perioperative complications (Heitz & 
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100%, negative predictive value of 98% and positive predictive value of 100%. 
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dermatitis mediated by type IV hypersensitivity reactions. It’s a definitive test for diagnosis 
of patients with type IV hypersensitivity to latex products using a standard battery of 
rubber additives. The series of rubber allergen were applied on normal skin, usually on the 
patient’s back or arms, under a small semi occlusive dressing. It is left in place for 24-48 
hours. The results are first read in 30 minutes after removing patches, and again 24 or 48 h. 
The positive reaction can be accepted as the cause of the present eruption. Accelerators 
evoke positive patch tests in 82% patients with occupationally induced contact dermatitis 
associated with glove use. The allergens that most commonly yielded positive reactions 
have been carbamates, 4,4-dithiodimorpholine, thiurams mix, 2-mercaptobenzothiazole, and 
1,3-diphenylguanidine (Woods et al., 1997; Bendewald et al., 2010; Cao et al., 2010). 
11. Management and treatment 
At present, latex avoidance is the only available treatment and has been the key to 
preventing allergic reactions in latex-sensitized individuals. For patients, avoidance of 
exposure to the allergen is essential to minimizing perioperative complications (Heitz & 
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Bader, 2010). In 1998, the Food and Drug Administration (FDA) started to require the 
labeling of medical devices made from rubber latex; since that time substantial progress had 
been made in identifying latex-free alternatives. 
Avoidance of exposure to allergen is essential to minimizing complications in patients 
suspected to be at risk. The patient must be aware of the long list of medical and consumer 
products containing latex. Because there is cross reactivity between latex and fruit antigens, 
patients should be careful when first consuming these fruits after diagnosis. Procedures 
performed on latex-sensitive patients should be performed in latex-safe environment. A 
latex-safe environment is one in which no latex gloves are used; in addition, there must be 
no latex accessories (masks, rebreathing, cannulas, catheters, adhesives, tourniquets, 
anesthesia equipment) that come in direct contact with the patients. Prophylactic 
premedication is used by many centers for surgical patients with high risk of latex allergy. 
The use must be begin 24 h before surgery. In cases of minor reactions, such as contact 
dermatitis, the gloves should be removed immediately. For severe cases involving pruritus 
and erythema, therapy with H1 antagonists should be initiated; H2 blockers also can be used. 
In cases of severe systemic anaphylaxis, initial attention should focus on pulmonary and 
cardiovascular manifestations of the reaction, because these are the major causes of death. 
The health care workers with latex allergy must be protected from adverse reaction to latex. 
Sensitization to latex antigens is commonly encountered in HCW wearing latex gloves with 
high latex allergen concentrations and in workers wearing powdered latex surgical gloves. 
HCW who have contact dermatitis to latex products can avoid it by changing to a different 
brand of gloves like vinyl and other synthetic gloves. Workers with a documented type I 
latex allergy must be protected from serious systemic reactions. Basically this involves latex 
avoidance. Low-protein, in powder-free gloves, decreases the sensitization potential of the 
latex and avoids some of the granuloma associated with the powder. Latex proteins are 
adsorbed by glove powder and may be airbone and the use of powder-free gloves can 
sometimes reduce the aerosol levels. In a review of claims data from 1997 to 2005 about the 
switch to powder-free latex gloves, Malerich et al. (2008) concluded that it was associated 
with a significant decrease in workers' compensation for latex-related illness. The cost of 
gloves increased but was partially offset by a decrease in workers' compensation payments 
and operating room expenses.  
Future strategies must focus not only on the reduction of allergens during latex manufacture 
and development of suitable non-latex gloves, but also the immunotherapy including 
desensitization of latex allergic individuals and development of candidate vaccine (Belleri & 
Crippa, 2008; Bernardini et al., 2008a; Rolland & O'Hehir, 2008; Nettis et al., 2010). 
In allergy desensitization treatment, the immune response itself can be altered. In practice, 
true desensitization is rare: specific IgE- mediated allergy is significantly lessened but not 
eliminated, even after many years of treatment. Immunological changes during 
desensitization therapy for IgE- mediated disease consist of increased IgG antibody levels 
and decreased IgE production. IgG are called “blocking antibody”. Sublingual 
immunotherapy (SLIT) with natural rubber latex (NRL) has recently been proposed and was 
safe and effective; no SLIT-related side effects had been observed. Bernardini et al. (2008a) 
used commercial latex SLIT in pediatric patients and observed the effect for three years. A 
significant reduction of the glove-use score was observed after 1, 2, and 3 years of treatment 
with SLIT. Baseline wheal areas of skin prick test and baseline values of serum specific IgE 
were significantly reduced. They concluded that three years of latex SLIT is safe, and it 
consolidates the efficacy of treatment in pediatric patients. In addition, current 
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subcutaneous immunotherapy schedules have been tested for treatment of latex allergy with 
evidence of efficacy, but the risks of adverse events have been high.  
For such potent allergens as latex, hypoallergenic but T cell-reactive preparations are 
required for clinical use. For this, it is essential to identify allergenic components of latex 
products with generation of monoclonal antibodies and recombinant allergens, allowing 
sequence determination and mapping of T cell and B cell epitopes. Potential hypoallergenic 
latex preparations identified include modified non-IgE-reactive allergen molecules and 
short T cell epitope peptides. Together, these reagents and data should facilitate improved 
diagnostics and investigation of novel-specific therapeutics. The co-administration of 
adjunct therapies, such as anti-IgE or corticosteroids, and appropriate adjuvant for 
induction of regulatory T cell response offer promise for clinically effective, and 
development of safe latex-specific candidate vaccines. 
12. Conclusion 
Latex products have had many useful roles in the medical fields. Unfortunately the allergic 
responses to latex have become causes of both morbidity and mortality. Avoidance of 
exposure to allergen is essential to minimizing complications in patients suspected to be at 
risk, butthere is lack of information concerning latex allergen content of medical equipment  
leading to an increased risk to sensitized patients. Occupational health need to be a 
guideline and should be prepared for any emergency. Patients with well documented latex 
hypersensitivity can undergo surgical procedures with proper panning and care. Further 
strategies must be focused not only on the reduction of allergens during latex manufacture 
and development of suitable non-latex gloves, but also on the immunotherapy and 
development of vaccine. 
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1. Introduction 
This subject is of interest as asthma has increased over the last two decades. Despite 
therapeutic advances, morbidity and mortality are increasing (Global Initiative for Asthma 
[GINA], 2010), particularly due to the development of western standards of living, where 
psychological factors have regained notability (Busse et al., 2000). This brings about a 
worsening in psychological factors and quality of life which entails high socioeconomic 
costs (direct and indirect) (Sulivan 1996; Suissa 2000). 
Since the most remote times of medical history (Maimonides 1990, Alexander 1940, Dunbar 
1948), it has been possible to determine a connection between asthma and emotional factors. 
In this study, besides the epidemiological aspects and the determinant psychopathological 
issues of this illness, some of the main psychological factors that influence and are 
influenced by this complex illness are reviewed in a multidimensional systemic vision 
(Gregerson, 2000; Jasnoski et al., 1994; Dirks et al., 1978).  
Parallel to the importance given to biological factors, social and physical variables have also 
been enhanced, as have conditionings brought about by stress, which intervene and 
condition psychoneuroimmunohormonal mechanisms in the evolution of the illness 
(Goodwin & Eaton, 2003).  
In the most severe cases of asthma, psychological factors such as depression, anxiety, stress, 
psychopathology, psychiatric expression of asthma and side effects of medication will be 
implicated. In this context, the coping mechanisms involved, as well as different life events 
and other psychosocial conditions are of the utmost importance. The transformation of these 
people’s lives inevitably involves their families, making problem solving difficult, and 
determining the outcome and the treatment of this pathology (Scott et al., 2007; Fernandes et 
al., 2010; Thomas et al., 2011; Di Marco et al., 2011). 
On the other hand, less adapted behaviours become related to minor compliance in the care of 
asthma, which leads to the worsening of the symptoms of asthma, causing self-perpetuation 
mechanisms, with chronically inflammatory processes, pulmonary remodelling and 
irreversibility in the size of the airways (Rietveld, 2000; Fonseca et al., 2004).  
Therapeutically, in people with moderate to severe asthma, besides the usual, preventive 
and pharmacological approaches, it is essential to turn to psychoeducational and 
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multifamily programmes, in order to increase the control of the illness, and allow more 
efficient treatment (Yorke et al., 2007; Smith et al., 2007).  
It is in this multisystemic context only by deepening the reciprocal relationships among 
psychological and biological, family and social factors can one find answers for the 
enormous complexity of the asthmatic illness. As a corollary of this, the confirmation that 
only a sufficiently widespread intervention that simultaneously combines the premises 
previously formulated, will allow an increased therapeutic effectiveness (Fernandes, 2009). 
This conceptual transformation into a multifactorial model influences also methodologically 
the psychosomatic research (Gregerson, 1995). The focus of this approach is based not so 
much on the causes (as in the linear model) but above all, in intervention and treatment 
(Mathison, 1993; Stout & Creer, 1997).  
Illustrating this, two studies will be presented. The first one, Psychological and Psychosocial 
Factors in Asthma, will study the influence of the psychological (anxiety, depression, 
psychopathology) and psychosocial variables of asthmatics with the clinical variables 
(symptoms, spirometry, inflammatory marker, severity and duration) and morbidity 
(quality of life, control of asthma, medication, use of health care and absenteeism). In the 
second study, Psychoeducational and Multifamily Interventions in asthma will presented 
the effectiveness of these interventions in this illness.  
2. Clinical review  
Asthma is a chronic inflammatory disease of the airways, which has a great impact on the 
quality of life of these patients. 
In Portugal, as in the majority of western countries, asthma is increasing, which brings about 
high socioeconomic costs and an increase in mortality and morbidity (GINA, 2010). 
For a long time the involvement of psychosocial factors in this disease has been known. 
Among different respiratory illnesses asthma presents the most profound links between 
psychological, social, biological and physiological factors. This is why it is considered the 
prototype of psychosomatic diseases (Isenberg et al., 1992; Lehrer et al., 1993; Mackenzie, 
1886). 
Much has been achieved since the 1960s, with the psychoanalytic approach to asthma in 
children, viewed as crying repression (French & Alexander, 1941). 
Great progress has been made in the field of medical knowledge namely concerning the 
neuroimunohormonal mechanisms involved in the etiopathogenesis of this disease. There is 
increasing evidence that the immune system is not working autonomously. In spite of this it 
will be connected with many psychophysiological processes under the regulatory 
modulation of the brain (Ader & Cohen, 1985). This branch of study we call 
psychoneuroimmunology. In this way it makes sense that we speak in the long term about 
changes that can stabilize resistance to the disease. This individual stability could be 
organized in each patient's personality structure, which could confront the different 
challenges and stress events of daily life (Goldstein & Dekker, 2001). 
However the precise physiological mechanisms involved are very complex, needing more 
profound research. The psychological disorders seem to produce systemic effects in the 
immune system function, in metabolic and hormonal processes and in the peripheral and 
central nervous system, in interactional and reciprocal mechanisms instead of being focused 
on one organ, as was commonly thought for a long time (Kang et al., 1997; Cohen et al., 
1991; Rietveld & Everaerd, 2000; Di Marco et al., 2011). 
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Nowadays in a more realistic perspective, it is considered that negative emotions (fear, 
panic, anger, anxiety and depression) are linked in a fluctuating process of 
bronchoconstriction of the airways, based on a mechanism of worsening crises of asthma 
(Hollaender & Florin, 1983; Silverglade et al., 1994; Lehrer, 1998; ten Brinke et al., 2001). 
In an indispensable holistic vision of this disease the psychological aspects become 
inseparable from the remaining symptoms when it is a question of making a diagnosis or 
prognosis or treating asthma (Lehrer et al., 2002). 
It is well known that these patients' behaviour strongly influences the course of the illness 
and the treatment, determining the exposure to allergic factors, in the perception and 
assessment of the symptoms, in the search for adequate medical care and compliance with 
the therapeutic plan, being strongly predictive for the frequency and severity of the 
worsening of the disease (Levy, 1994; van der Berg et al., 1997; Miller & Hotses, 1995; 
Devriese et al., 2000). 
Determinants of this behaviour are indubitable the psychopathology and familiar 
disorganization which is reflected in the worsening of the disease, in a decrease in quality of 
life as well as in the increasing health care costs involved.  In some more extreme conditions 
these factors increase risk to life (Nouwen et al., 1999). 
Near-fatal asthma deserves scrutiny due to the severity of these events and because of its 
impact on subsequent asthma morbidity and healthcare costs. The first studies emphasized 
the role of psychological variables (Campbell et al., 1994; Strunk et al., 1999; Innes et al., 
1998; Di Marco et al., 2011).  
Furthermore, special attention has to be devoted to the subgroup of severe asthma which is 
difficult and complex - implying avoidance of multiple environmental stimuli, with a variety 
of medications for controlling chronic inflammation or acute broncho-dilatation, with complex 
planning and high costs (Boulet et al., 1991; Woller et al., 1993; Kelloway et al., 2000). 
Besides that, knowing that asthma is not a behavioural disease, there is evidence that some 
changes in some asthmatic groups can condition the evolution of the disease. On the other 
hand there is also evidence that asthma has a role in the development of some psychiatric 
diseases (Lehrer et al., 2002; Scott et al., 2007). 
Some negative emotions, particularly panic and depression, even not severe enough to be 
classified as psychiatric disorders, can produce respiratory effects and lead to worsening of 
asthma, directly by psychophysiological effects or indirectly by neglecting self-management 
of the illness. Conversely, these emotional disorders can also be worsened by asthma itself 
(Nouwen et al., 1999; ten Brinke et al., 2001; Lehrer et al., 2004). 
A prospective Swiss community-based longitudinal cohort study (Hasler et al., 2005) reported 
that having a diagnosis of asthma may result in the subsequent development of panic in some 
patients with an odds ratio of 4.5. On the other hand, the same study also reported that the 
presence of panic disorder predicted subsequent asthma with an odds ratio of 6.3, suggesting 
that psychological dysfunction may precede the development of asthma.  
A UK primary care survey published in 2007 (Cooper et al., 2007), reported higher anxiety 
and depression scores in adults with asthma than the general community, and a prevalence 
of panic disorder of 16% in those with asthma. 
There are other psychological factors with a similar relationship to asthma worsening, 
which deserve a deeper study, particularly personality characteristics and their relation to 
the perception of asthma symptoms. The state of the art test pinpoints for endorphin activity 
on the basis of this respiratory sensitivity (Rietveld et al., 2000). 
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In a recent study (Fernandes et al., 2005) the predominance of neurotic characteristics in 
asthmatic patients was confirmed. They also presented lower extroversion, openness to 
experience, agreeableness and conscientiousness when compared to the general population. 
These characteristics were linked to the severity and duration of the disease.  
On the other hand, an increasing consensus is becoming established concerning the 
emotional triggers of asthma, focusing on psychophysiological mechanisms. This is 
demonstrated in recent studies where in response to emotional states there is a 
bronchoconstriction as well as registered cardiovascular and electrodermal modifications. 
Particularly in asthma the respiratory reaction in the airways is well known, when 
psychologically induced, including the variations in airways narrowing, which characterize 
the typical fluctuations of the disease (Lehrer et al., 2003, 2004). 
Nowadays bronchoconstriction in asthma is defined by direct sympathetic nervous system 
action or indirect parasympathetic nervous system action by a rebound effect (Manto, 1969; 
Isenberg et al., 1992; Lehrer et al., 1997), under some specific psychological states (sadness, 
stress, etc.), or by an inflammatory reaction. Although it remains less well-investigated, it is 
the last characteristic component in the pathology of asthma, i.e., blood vessel proliferations 
with increased airways wall thickness, as well as mucus hypersecrection (Lehrer et al., 1998). 
In some patients, stress in particular is the essential trigger for asthma attacks. Anxiety 
symptoms in asthmatics have been revealed as strong predictors of respiratory illness in 
those patients. Besides that, anxiety and depression seem to be much more prevalent in the 
asthmatic population than in the normal one (Rietveld et al., 2000; Thomas et al., 2011). 
Different surveys using different methodologies and instruments indicate that anxiety and 
depression disorders are up to six times more common in people with asthma than in the 
general population (Goodwin & Eaton, 2003; Lavoie et al., 2006).  
In a recent study (Fernandes et al., 2010) the high prevalence of anxiety in asthmatic patients 
as well as its associations with worse subjective asthma outcomes and increased used of 
medications/healthcare services was confirmed.  
Anxiety and depression are also particularly reported with severe and difficult to control 
asthma (Heaney et al., 2005) and impaired emotional coping mechanisms (Lavoie et al., 2010). 
Both psychological manifestations inherent in the asthmatic process itself and other clinical 
situations that can be asthma like, or present some aspects of this illness, have in core 
genesis a common mechanism: psychosomatic structure (Horton et al., 1978). 
Some of that asthma like illnesses have present in their origin above all a psychological 
mechanism. These kinds of clinical expressions can vary from somatoform disorder to 
factitious or conversion disorder. In any case it is mainly a functional disturbance, with a 
physiological minor component (Luparello et al., 1968). 
From an investigational perspective there has been a huge change in the techniques used. In 
the majority of the research, scientists look for physical data when trying to understand this 
complex system, where psychological factors and emotions are involved.  
In this context, some respiratory changes are measured and studied,   in some experiments 
with emotional content in films (Levenson, 1979), in contrast with saline solution inhalation, 
both by the action of suggestion (Luparello, 1968; McFadden et al., 1969; Neild & Cameron, 
1985).  
In spite of this, all researchers are using a model, which follows a linear mechanism of 
thinking. According to some authors (Ford, 1987; Ford & Urban, 1998), who mostly reflected 
on psychosomatic methodology research, this paradigm is considered completely 
inappropriate since we involve the behavioural component. In none of these studies, for 
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example, was the individual and unique experience of each patient taken into account, 
neither were their past nor their future hopes, considered as a part of the study context.  
In fact, any biological, physical or chemical system works like a complex system in which 
the inherent proprieties are not totally explained, by each constituent part (Gallagher & 
Appenzeller, 1999). This kind of approach has given rise to some findings in the chemical 
field (Whitesides & Ismagilov, 1999) in biological signal systems (Weng et al., 1999) and the 
nervous system (Koch & Laurent, 1999). 
Alternatively a new model was suggested, with particular relevance to human being 
studies. In this, as underlined by Borkovec (1997), the involved processes are linked in a 
nonlinear dynamic, just as with  attention, thinking, images, memory, emotion, physiology 
and behaviour, all in a permanent interaction, and answering to interpersonal and 
environmental changes, with a background of biological and developmental history.  
In an attempt to adapt this model to the investigation of emotional phenomena in asthma, it 
will probably be as difficult as to adapt it to the chemical field (Whitesides & Ismagilov, 1999). 
This becomes even more difficult if we take into consideration that asthma is particularly 
sensitive to the initial conditions with small variations, having a great number of independent 
components, which interact in multiple pathways, through which all of these mechanisms 
could be involved. These conditions raise a multiplicity of potential respiratory patterns.  
Through this kind of alternative approach, we will be able to allow a draw study project based 
above all on the reality of the phenomena investigated. This will bring us close to the necessary 
conditions to finally get solid evidence in the clarification of the complexity of all of these 
mechanisms involved with stress and emotions in the present disease. Not only will we get 
solutions for centuries of old mysteries but it will be possible to have new approaches in the 
treatment of asthma (Gallagher & Appenzeller, 1999; Koch & Laurent, 1999).  
It is in this new contextualization that the importance of psychoeducational programs in 
asthma is growing. The preliminary data about this intervention gives emphasis to 
educational, communicational and self-efficacy aspects (Yorke et al., 2007; Fernandes, 2009).  
There are already some series of randomized multicenter educational programmes for asthma 
(Taitel et al., 1995; Kotses et al., 1995; Wilson et al., 1996; Bruzzese et al., 2001). The focus of 
these programmes is in the clarification of the importance of specific components of the illness. 
In spite of this, feedback to patients with an assessment of these educational programmes is 
lacking, as well as an adaptation into short interventions that can work in clinical practice or 
even in a multifamily context (McFarlane et al., 1995; Devine, 1996; Fernandes, 2009).  
Furthermore, it will be important to establish this kind of intervention in more specific 
groups, such as children with more vulnerability in asthmatic crises, people in high risk 
groups where stress clearly triggers the worsening of the disease (Bernard-Bonnin et al., 
1995; Smith et al., 2005).  
There is also some relevance of specific programmes for tobacco reduction, with use of 
psychotherapy, particularly in the cognitive and family therapy fields. These studies took a 
privileged focus on the control and treatment in daily life, of this complex chronic disease 
(Irvine et al., 1999; Silagy, 1999; Gustafsson & Cederblad, 1986; Lask & Matthew, 1979; Sun 
et al., 2010).  
Another important aspect is the identification of some specific characteristics of these 
patients (in terms of severity, personality and even psychological aspects) in subpopulations 
that most benefit from these education programmes. Eventually the longitudinal assessment 
in different contexts will be fundamental.  
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 316 
In a recent study (Fernandes et al., 2005) the predominance of neurotic characteristics in 
asthmatic patients was confirmed. They also presented lower extroversion, openness to 
experience, agreeableness and conscientiousness when compared to the general population. 
These characteristics were linked to the severity and duration of the disease.  
On the other hand, an increasing consensus is becoming established concerning the 
emotional triggers of asthma, focusing on psychophysiological mechanisms. This is 
demonstrated in recent studies where in response to emotional states there is a 
bronchoconstriction as well as registered cardiovascular and electrodermal modifications. 
Particularly in asthma the respiratory reaction in the airways is well known, when 
psychologically induced, including the variations in airways narrowing, which characterize 
the typical fluctuations of the disease (Lehrer et al., 2003, 2004). 
Nowadays bronchoconstriction in asthma is defined by direct sympathetic nervous system 
action or indirect parasympathetic nervous system action by a rebound effect (Manto, 1969; 
Isenberg et al., 1992; Lehrer et al., 1997), under some specific psychological states (sadness, 
stress, etc.), or by an inflammatory reaction. Although it remains less well-investigated, it is 
the last characteristic component in the pathology of asthma, i.e., blood vessel proliferations 
with increased airways wall thickness, as well as mucus hypersecrection (Lehrer et al., 1998). 
In some patients, stress in particular is the essential trigger for asthma attacks. Anxiety 
symptoms in asthmatics have been revealed as strong predictors of respiratory illness in 
those patients. Besides that, anxiety and depression seem to be much more prevalent in the 
asthmatic population than in the normal one (Rietveld et al., 2000; Thomas et al., 2011). 
Different surveys using different methodologies and instruments indicate that anxiety and 
depression disorders are up to six times more common in people with asthma than in the 
general population (Goodwin & Eaton, 2003; Lavoie et al., 2006).  
In a recent study (Fernandes et al., 2010) the high prevalence of anxiety in asthmatic patients 
as well as its associations with worse subjective asthma outcomes and increased used of 
medications/healthcare services was confirmed.  
Anxiety and depression are also particularly reported with severe and difficult to control 
asthma (Heaney et al., 2005) and impaired emotional coping mechanisms (Lavoie et al., 2010). 
Both psychological manifestations inherent in the asthmatic process itself and other clinical 
situations that can be asthma like, or present some aspects of this illness, have in core 
genesis a common mechanism: psychosomatic structure (Horton et al., 1978). 
Some of that asthma like illnesses have present in their origin above all a psychological 
mechanism. These kinds of clinical expressions can vary from somatoform disorder to 
factitious or conversion disorder. In any case it is mainly a functional disturbance, with a 
physiological minor component (Luparello et al., 1968). 
From an investigational perspective there has been a huge change in the techniques used. In 
the majority of the research, scientists look for physical data when trying to understand this 
complex system, where psychological factors and emotions are involved.  
In this context, some respiratory changes are measured and studied,   in some experiments 
with emotional content in films (Levenson, 1979), in contrast with saline solution inhalation, 
both by the action of suggestion (Luparello, 1968; McFadden et al., 1969; Neild & Cameron, 
1985).  
In spite of this, all researchers are using a model, which follows a linear mechanism of 
thinking. According to some authors (Ford, 1987; Ford & Urban, 1998), who mostly reflected 
on psychosomatic methodology research, this paradigm is considered completely 
inappropriate since we involve the behavioural component. In none of these studies, for 
 
Psychological Factors in Asthma and Psychoeducational Interventions 317 
example, was the individual and unique experience of each patient taken into account, 
neither were their past nor their future hopes, considered as a part of the study context.  
In fact, any biological, physical or chemical system works like a complex system in which 
the inherent proprieties are not totally explained, by each constituent part (Gallagher & 
Appenzeller, 1999). This kind of approach has given rise to some findings in the chemical 
field (Whitesides & Ismagilov, 1999) in biological signal systems (Weng et al., 1999) and the 
nervous system (Koch & Laurent, 1999). 
Alternatively a new model was suggested, with particular relevance to human being 
studies. In this, as underlined by Borkovec (1997), the involved processes are linked in a 
nonlinear dynamic, just as with  attention, thinking, images, memory, emotion, physiology 
and behaviour, all in a permanent interaction, and answering to interpersonal and 
environmental changes, with a background of biological and developmental history.  
In an attempt to adapt this model to the investigation of emotional phenomena in asthma, it 
will probably be as difficult as to adapt it to the chemical field (Whitesides & Ismagilov, 1999). 
This becomes even more difficult if we take into consideration that asthma is particularly 
sensitive to the initial conditions with small variations, having a great number of independent 
components, which interact in multiple pathways, through which all of these mechanisms 
could be involved. These conditions raise a multiplicity of potential respiratory patterns.  
Through this kind of alternative approach, we will be able to allow a draw study project based 
above all on the reality of the phenomena investigated. This will bring us close to the necessary 
conditions to finally get solid evidence in the clarification of the complexity of all of these 
mechanisms involved with stress and emotions in the present disease. Not only will we get 
solutions for centuries of old mysteries but it will be possible to have new approaches in the 
treatment of asthma (Gallagher & Appenzeller, 1999; Koch & Laurent, 1999).  
It is in this new contextualization that the importance of psychoeducational programs in 
asthma is growing. The preliminary data about this intervention gives emphasis to 
educational, communicational and self-efficacy aspects (Yorke et al., 2007; Fernandes, 2009).  
There are already some series of randomized multicenter educational programmes for asthma 
(Taitel et al., 1995; Kotses et al., 1995; Wilson et al., 1996; Bruzzese et al., 2001). The focus of 
these programmes is in the clarification of the importance of specific components of the illness. 
In spite of this, feedback to patients with an assessment of these educational programmes is 
lacking, as well as an adaptation into short interventions that can work in clinical practice or 
even in a multifamily context (McFarlane et al., 1995; Devine, 1996; Fernandes, 2009).  
Furthermore, it will be important to establish this kind of intervention in more specific 
groups, such as children with more vulnerability in asthmatic crises, people in high risk 
groups where stress clearly triggers the worsening of the disease (Bernard-Bonnin et al., 
1995; Smith et al., 2005).  
There is also some relevance of specific programmes for tobacco reduction, with use of 
psychotherapy, particularly in the cognitive and family therapy fields. These studies took a 
privileged focus on the control and treatment in daily life, of this complex chronic disease 
(Irvine et al., 1999; Silagy, 1999; Gustafsson & Cederblad, 1986; Lask & Matthew, 1979; Sun 
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In conclusion, from a research perspective, a distinct kind of approach will be necessary, 
based on a reality of these phenomena studied, that allows  association mechanisms to be 
established among multiple factors involved, leading to a more modern methodology in a 
systemic framework, that puts emphasis on the multifactorial model (Fernandes, 2009). 
3. Study 1: Psychological and psychosocial factors 
3.1 Objectives 
The present study aims to study the influence of psychological factors (state and trait 
anxiety, anger, depression, psychopathology) and psychosocial variables of asthma with 
clinical characteristics (spirometry, inflammatory marker, severity and duration) and 
morbidity criteria (quality of life, control of asthma, medication, use of health care services 
and absenteeism).     
The second aim is to study the integration of these data into the cultural diversity of the 
present population, from a demographic perspective.   
3.2 Methods 
In this transversal study, 299 outpatients of the Immunoallergology department of the S. 
João Hospital, of both sexes, were recruited with asthma diagnosis, between the ages of 17 
and 75 years.  
With the 217 patients that participated, a psychiatric clinical interview was carried out, and 
psychiatric clinical cases were excluded, by the General Health Questionnaire – GHQ-28 
(Goldberg & Hillier, 1979), as well as alcohol and drug abuse cases. Inclusion criteria were 
previous medical diagnosis of asthma and specific criteria (anti-asthmatic therapy, tests of 
unspecified bronchial hyper-reactivity and bronchodilation, inflammatory marker, 
spirometry).  
Thus, 195 patients were studied according to the duration of the illness, symptoms, 
morbidity criteria (use of health care, medication and absenteeism), spirometry (FEV1, PEF), 
test of bronchial hyper-reactivity (PD20 metacolina), inflammatory markers (FENO), 
severity of asthma (GINA, 2010) and atopy and rhinitis. 
They were evaluated according to the following scales: Self Anxiety Scale – SAS (Zung, 
1971), State-Trait Anxiety Inventory – STAIY (Spielberger, 1983), State-Trait Anger 
Expression Inventory – STAXI (Spielberger, 1988), Beck Depression Inventory – BDI (Beck et 
al., 1961), Hopkins Symptom Distress Checklist 90-Revised – SCL90R (Derogatis & Savitz, 
1999), Ways of Coping with Asthma in Everyday Life – WCAEL (Aalto et al., 2002), Mini 
Asthma Quality of Life Questionnaire – MiniAQLQ (Juniper et al., 1999a) and Asthma 
Control Questionnaire – ACQ (Juniper et al., 1999b).  
Patient informed consent was obtained and the study was approved by the hospital Ethics 
Committee. 
3.3 Results  
In this sample (n=195), most of the patients were female (76.4%), with ages ranging from 17 
to 75 years. The mean (sd) age was 38(14.5) years. Most of the patients have low education 
(70.2%). There was a predominance of low and very low classes (72.4%), according to the 
Graffar social classification (Graffar, 1956).  
The mean duration of the disease was 19.8(14.0) years. The severity of the illness was 
distributed in the following way: Intermittent (8.2%), Mild persistent (12.8%), Moderate 
persistent (12.8%) and Severe persistent (66.2%).  
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The respiratory values found were: spirometry FEV1 83.5(22.4) (min.19%, max.120%), 
inflammatory marker FENO P50 28 (min.4, max.222).  Most of these patients concomitantly 
have atopy (80.9%) and rhinitis (60.3%). 
 
Total = 195   
Age (years) mean (sd) 38.0 (14.6) 
Gender n(%)   
Male 46 (23.6) 
Female 149 (76.4) 
Education n(%)   
≤ 9 137 (70.2) 
10-11 37 (19.0) 
> 12  21 (10.8) 
Socio-economic classification n(%)   
High and very high 16 (8.2) 
Median 38 (19.5) 
Low 59 (30.3) 
Very low 82 (42.1) 
Asthma duration (years) mean (sd) 19.8 (14.0) 
Asthma severity n (%)   
Intermittent 16 (8.2) 
Mild persistent 25 (12.8) 
Moderate persistent 25 (12.8) 
Severe persistent 129 (66.2) 
Table 1. Demographic and clinical characteristics of sample 
From a psychological point of view, the asthmatics of the sample were individuals with a 
high level of anxiety state (70%): 13.3% had scores suggesting anxiety and 56.4% suffered 
from high-anxiety (Ponciano et al., 1982). 
Considering the anxiety trait, assessed by STAIY, there was a mean (sd) value of 40.82 
(12.18). On this scale, state-anxiety had a mean (sd) of 44.8 (13.16).  
In this sample, the mean values of contained and manifested anger (mean 15.94, sd 4.05; 
mean 13.31, sd 12.0) were much higher than the mean standard results found in the 
normative Portuguese population (Martins, 1995).  
Additionally the analysis of the degree of depression, assessed by BDI, allowed us to 
conclude that in the majority of the sample (72%) depression was absent. Only 6.2% of these 
patients revealed symptoms of severe and 22% mild/moderate depression.  
Psychopathology assessed in the different list of symptoms of Hopkins-Review SCL-90-R, 
had in general normal values, with the exception for somatization (mean 1.4, dp 0.8) and 
anxiety (mean 1.06, dp 0.68), higher than the mean values standardized for the Portuguese 
population.  
In the present sample, the most important coping mechanism found was hiding asthma, 
with a mean (dp) value of 13.08 (2.21), followed by worry with the disease, with a mean (dp) 
value of 9 (2.12), corroborated by the global score (mean 82, dp 7.63).  
The mean (sd) values for quality of life, according to the MiniAQLQ were 4.9 (1.3), with a 
minimum of 2 and a maximum of 7.  
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For asthma control, assessed by ACQ (with 0 FEV1), P50 (min.0 /max. 5.2), the mean (sd) 
was 1.5 (1.2).  
In the present study we verified a correlation between sex (higher in women) and anxiety 
(p<0.001), as well as depression (p=0.000) and psychopathology (p=0.001). 
There was a positive correlation between age and anxiety state (p=0.006) and trait (p=0.037), 
depression (p=0.001), psychopathology (p=0.025), as well as coping mechanism (p<0.001). 
A worsening in breathing was noted (spirometry values) only with psychopathology – 
obsession (p=0.05).  
On the other hand, these psychological variables (anxiety p≤0.001, psychopathology - 
somatization p=0.001) were related to the decrease in the inflammatory marker, indicating 
higher health care use and an increase in medication intake (mainly preventative).  
Above all anxiety state was related to more hospitalization (p=0.007) as well as non-
scheduled consultations (p=0.008) and routine ones (p=0.001).  
Anxiety and depression also increased absenteeism (p=0.011; p=0.017).  
These psychological variables also increased with the severity (p≤0.001; p≤0.001) and with 
the duration of the disease (p=0.002; p=0.023). However, psychopathology only increased 
with severity (p=0.002). 
Another result found, was that anxiety (r=0.638; p≤0.001), anger (r=-0.343; ≤0.001) and 







Fig. 1. Correlation between anxiety and quality of life 
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Fig. 2. Correlation between depression and quality of life 
The control of asthma was correlated with anxiety state (r=0.554; p≤0.001) and trait (r=0.357; 
p=0.000), as well as anger (r=0.221; p=0.016) (Figure 3). Another clinical variable was also 
associated with control of asthma, which is depression (r=0.656; p≤0.001) (Figure 4). 
 
 
Fig. 3. Correlation between anxiety and asthma control 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 320 
For asthma control, assessed by ACQ (with 0 FEV1), P50 (min.0 /max. 5.2), the mean (sd) 
was 1.5 (1.2).  
In the present study we verified a correlation between sex (higher in women) and anxiety 
(p<0.001), as well as depression (p=0.000) and psychopathology (p=0.001). 
There was a positive correlation between age and anxiety state (p=0.006) and trait (p=0.037), 
depression (p=0.001), psychopathology (p=0.025), as well as coping mechanism (p<0.001). 
A worsening in breathing was noted (spirometry values) only with psychopathology – 
obsession (p=0.05).  
On the other hand, these psychological variables (anxiety p≤0.001, psychopathology - 
somatization p=0.001) were related to the decrease in the inflammatory marker, indicating 
higher health care use and an increase in medication intake (mainly preventative).  
Above all anxiety state was related to more hospitalization (p=0.007) as well as non-
scheduled consultations (p=0.008) and routine ones (p=0.001).  
Anxiety and depression also increased absenteeism (p=0.011; p=0.017).  
These psychological variables also increased with the severity (p≤0.001; p≤0.001) and with 
the duration of the disease (p=0.002; p=0.023). However, psychopathology only increased 
with severity (p=0.002). 
Another result found, was that anxiety (r=0.638; p≤0.001), anger (r=-0.343; ≤0.001) and 







Fig. 1. Correlation between anxiety and quality of life 
 
Psychological Factors in Asthma and Psychoeducational Interventions 321 
 
 
Fig. 2. Correlation between depression and quality of life 
The control of asthma was correlated with anxiety state (r=0.554; p≤0.001) and trait (r=0.357; 
p=0.000), as well as anger (r=0.221; p=0.016) (Figure 3). Another clinical variable was also 
associated with control of asthma, which is depression (r=0.656; p≤0.001) (Figure 4). 
 
 
Fig. 3. Correlation between anxiety and asthma control 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 322 
 
Fig. 4. Correlation between depression and asthma control 
Increase in age implied better disease adaptation (p≤0.001). The severity of asthma sustained 
lower total coping mechanisms (p=0.021), as well as positive reappraisal (p=0.009), assessed 
by WCAEL.  
Of special note, the coping mechanism restricted lifestyle (p=0.021) increased with duration 
of the disease. The positive reappraisal had a negative correlation with the duration of the 
disease (p=0.028).  
Absenteeism was also directly related to restricted lifestyle and reverse with seeking 
information, the two coping mechanisms.  
The coping mechanism worry with asthma decreased the quality of life (r=-0.239; p=0.044). 
The most mobilizing mechanism for looking for medical care: consultation (p=0.014) was 
restricted lifestyle. An opposite implication for denial (p=0.015) mechanism was found, and 
leading to less intake of corticosteroids.   
3.4 Discussion and conclusion  
According to the standard values for the Portuguese population (Ponciano et al., 1982), this 
group has a clear predominance of anxiety in 70% of the sample, as defined in the literature 
(Vila et al., 2000; Goodwin & Eaton, 2003). This is reinforced by the high levels of anger-in as 
well as anger-out, that almost all duplicated in this sample (when compared to the normal 
values of general population), which may be related to more physiological activation, as 
found for the studies with hypertension (Spielberger & London, 1990).  
In contrast we found lower psychopathology levels, particularly depression, probably 
explained by the selection criteria of the present sample and because the influence of the 
well-known low compliance in this kind of study of these particular patients.  
Anxiety, depression, psychopathology and coping increased with age. However, only 
anxiety was correlated with low socioeconomic level, as corroborated in other studies 
(Rumbak et al., 1993).  
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In the present sample a high correlation with sex, especially for women was found with 
anxiety, depression and psychopathology, which is in accordance in the previous studies 
(Eysenck, 1969; Dalton et al., 1975; Mayer-Cross et al., 1969; Thomas et al., 2011).  
Anxiety, anger and depression correlated with the duration of asthma episodes and their 
acuteness (in the GINA classification), which is in agreement with former studies (Mrazeck 
et al., 1998; Sandberg et al., 2000; ten Brinke et al., 2001; Barton et al., 2005; Wainwright et al., 
2007; Dahlem et al., 2009), associating the early onset of asthma with a negative impact on 
psychological adaptation to the disease, which implies the development of more clinical 
anxiety and depression. 
The use of healthcare services by asthmatic patients as well medication (especially relief and 
preventive ones) was also directly linked with anxiety. Particularly, anxiety is predicted due 
to hospitalizations (Dirks et al., 1978, 1981; Kinsman et al., 1982) and their duration (Put et 
al., 1999).    
These results agree with others, who argue that high anxiety leads to poor discrimination 
between anxiety symptoms and breathing symptoms, thus leading to an overuse of medical 
care (Spinhoven et al., 1997; Cluley & Cochrane, 2001). There was also a significant 
relationship between a great number of hospital admissions and higher scores of anxiety, 
which strengthens the conclusions of previous studies, where anxiety is predictive of more 
hospital admissions (Bender et al., 2006; Prueter & Norra, 2005) and longer duration.  
There was a relationship between exhaled nitric oxide (FENO) and anxiety and 
somatization. This marker for airway inflammation had a negative correlation with anxiety. 
In other words, as the levels of anxiety increase, there is evidence of a decrease in 
inflammation. A possible interpretation of this inverse association may be found in the 
characteristics of high anxiety of this sample, calling for the use of greater medical care (ten 
Brinke et al., 2001b). In turn physicians may be influenced by the increased expression of 
symptoms by the patients. As a consequence more anti-inflammatory treatment is 
prescribed as patients are identified as more acutely ill (Hibbert & Pilsbury, 1988; Hornsveld 
& Garssen, 1996). The inflammatory marker decreases because it is particularly sensitive to 
changes in medication, specifically corticosteroids (Chetta et al., 1998). However, the 
changes are not reflected in other, less sensitive markers of this disease, namely, lung-
function (FEV and PEF), for which no significant relationship with anxiety was found. This 
lack of association between lung function and anxiety has been previously reported 
(Thomas et al., 2001). 
This tendency toward increasing anxiety was seen for the greater degrees of asthma 
severity. This agrees with studies in which anxiety in asthmatics is seen as a risk factor for 
increase in asthma morbidity and mortality (Wright et al., 1998; Forsythe et al., 2004). A 
similar correlation was found for psychopathology which is corroborated by other studies 
(Chetta et al., 1998), namely when this is linked with near-fatal asthma attacks (Yellowees et 
al., 1988; Boulet et al., 1991; Garden et al., 1993; Campbell et al., 1995a; McQuaid et al., 2001). 
This severity was also correlated positively with depression, in accordance with other 
studies (Strunk et al., 195; Picado et al., 1989; Campbell et al., 1995a; Martin et al., 1995). This 
relation between depression and severity asthma is particularly relevant in the case of recent 
bereavement (Levitan, 1985), as well as death by asthma with hopelessness and despair in 
the days before the relative's death (Miller et al., 1989).  
By using STAI-Y, the average values for the anxiety trait (i.e., a measure for an individual’s 
tendency for anxiety) were higher than those found in other studies for the Portuguese 
population (Santos & Silva, 1997; Silva & Campos, 1998) and that have been used as 
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In the present sample a high correlation with sex, especially for women was found with 
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standard references. These characteristics agree with some other previous studies (Boulet et 
al., 1991; Chetta et al., 1998) which argue that there is a strong link between anxiety trait and 
asthma, as well as a greater manifestation of the symptoms of this ailment (Kinsman et al., 
1973; Dirks et al., 1978; Friedman & Booth-Kewley, 1987; Yellowlees & Kalucy, 1990). More 
recently Rimington et al (2001) further supports this notion and states that as anxiety 
increases (state and trait) a poorer quality of life is evidenced, and Baumeister et al (2005) 
makes similar observations between higher anxiety and less asthma control (Thomas et al., 
2011).  
The present study also recognized worse control of the disease with anger and depression, 
as found in other studies (Cluley & Cochrane, 2001; Thomas et al., 2011). Is well known that 
patients classified as non-adherent (those taking less 70% of the prescription) presented high 
anxiety and depression levels (Zigmond et al., 1983; Thomas et al., 2011).  
Corroborating former studies (Dirks et al., 1978; Staudenmayer et al., 1979; Dirks & 
Kinsman, 1981; Baron et al., 1986; Put et al., 1999), the data from this study suggest that the 
most anxious patients are more vigilant over their symptoms, use more medication and 
more often turn to healthcare services for help. With this behaviour they would suffer from 
great psychological stress with their disease in the short term (higher values of anxiety, with 
less quality of life associated with asthma), but in the long run it may result in better control 
over the illness. Thus, this anxiety which is specifically related to asthma can be beneficial, 
by making the individual aware of the bodily symptoms related to asthma, through a 
process of focusing attention. However, excessively high levels of anxiety may lead to 
super-perception of asthma symptoms, with the patient thus becoming more disorganized 
in behavioural terms, with negative consequences upon the development of the ailment. In 
this way we may understand the association observed: as the state of anxiety increases, 
asthma control becomes worse. 
The most important coping mechanism in this study was hiding asthma, considered as a 
passive one. This mechanism as well as avoidance and denial were linked with less 
mobilized strategies in chronic diseases (Felton et al., 1984; Santavirta, 1997; Osowiecki & 
Compas, 1999). In other studies, asthma denial has been recognized as an important risk 
factor for asthma attacks, and more emergency treatment (Dirks et al., 1978; Miller, 1987; 
Steiner et al., 1987; Yellowlees & Ruffin, 1989; Lavoie et al., 2010). The coping mechanism in 
general (total scores) and particularly the positive reappraisal were also correlated with 
greater severity of asthma.  
Another important mechanism found in this sample was worry about the disease, which is 
considered as the most emotionally involving, correlated with poor quality of life. This is in 
accordance with the worst adjustment to the disease, related to emotional involvement 
(Bombardier et al., 1990; Landreville & Veniza, 1994; Scharloo et al., 1998). 
Related also with poor quality of life are depressive symptoms (Goethe et al., 2001), which 
seem to measure negative feelings as well as neuroticism (Koivumaa-Honkanen et al., 2000), 
and this is corroborated in the present study.  
With these results we are witnessing a multiple confluence of biological, environmental, 
psychological and social factors in asthma, as well as in its evolution, treatment and 
prognosis, understandable in the complexity of systemic and multiple interaction of all these 
factors, which influence and are simultaneously influenced by the disease.  
The behavioral disorders found are translated by clinical and morbidity criteria, leading to 
higher use of healthcare and medication, and absenteeism, with poorer disease control and 
quality of life.  
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In this way, the need for  better and more accurate assessment emerge, not at a symptomatic 
level but also discriminating different types of anxiety, depression, associated 
psychopathology  that determine the  diagnosis and development of this disease.  
In future studies a cluster selection of individuals will be required who combine physical 
and psychological characteristics, above all with severe or unstable asthma, with more 
adequate clinical interventions. This is taking into account that even if we cannot change 
personalities, we can at least modify behaviour, with efficacy in healthy habits and attitudes, 
namely concerning compliance to treatment.  
4. Study 2: Psychoeducational and multifamily interventions in asthma 
4.1 Objectives 
This study aims to analyse the effects of psychoeducational and multifamily interventions in 
asthma, in biological variables (spirometry and inflammatory marker), morbidity criteria 
(health care use, absenteeism, medication, quality of life and control of disease) and 
psychological outcomes (anxiety, depression and coping mechanisms).  
4.2 Methods  
We conducted a five-month prospective study, randomized with simple occultation, with 
two intervention groups and a control group, according to the criteria defined and 
presented in the previous study, where 195 patients were studied. Of these, the ones with 
moderate or severe persistent asthma were selected.  
This Random Control Trial was carried out in the Allergy & Immunology outpatients' 
department of the University Hospital S. João in Oporto.  
The randomization resulted in the balanced inclusion of 141 patients, divided into three 
groups (according to levels of anxiety and depression). The studied sample, in two 
observations, was the following: Psychoeducational Group (PG) intervention and usual 
pharmacological treatment (n=38), Multifamily Group (MG) intervention and usual 
pharmacological treatment (n=29), Control group (CG) with only usual pharmacological 
treatment (n=44) (Figure 5).  
 
 
Fig. 5. Clinical study design  
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For comparison with the evaluation made in the second study, the following scales of 
evaluation were used: Self Anxiety Scale – SAS (Zung, 1971), State-Trait Anxiety Inventory – 
STAIY (Spielberger, 1983), Beck Depression Inventory – BDI (Beck et al., 1961), Ways of 
Coping with Asthma in Everyday Life – WCAEL (Aalto et al., 2002), Mini Asthma Quality of 
Life Questionnaire – MiniAQLQ (Juniper et al., 1999a) and Asthma Control Questionnaire – 
ACQ (Juniper et al., 1999b).  
They were still compared according to their asthma symptoms, spirometry, inflammatory 
marker and morbidity criteria.  
All psychological and clinical measures were assessed twice, before and after interventions.  
Only adding information and knowledge became incomplete (Costa & MacCrane, 1987; 
Clark et al., 2002). With these interventions the aim is not to modify personalities, but 
change behaviour and attitudes (Costa & MacCrane, 1986). 
In this context, the general principles of two interventions included both transmission of 
information, promoting behaviour change and improvement of self-efficacy. This implies a 
bidirectional process with interactions between health professionals and asthmatic patients 
and families. There are some objectives in this communication, mainly in answer to different 
issues, erasing false constructs, reduction of anxiety due to illness and promoting healthy 
habits and attitudes 
Specifically for the Psychoeducational programme, the present intervention was focused on 
results in three levels of learning: knowledge transmission, education for instrumental 
attitudes and finally integration of the former. This empowered the patients by increasing 
self-efficacy and improvement in problem-solving of asthma. These sessions were not only 
didactic but also interactive.   
The Multifamily programme was based on three distinct components: educational (sharing 
of experiences between families and patients, mediation by psychotherapists), social 
network (cross over difficult situations) and problem-solving (extending solutions, training 
strategies to deal with illness). This intervention was structured as a “group within a 
group”, based on the Multifamily Discussion Group of Gonzalez and Steinglass (Gonzalez 
et al., 1986, Gonzalez & Steinglass, 2002; Steinglass, 1998). 
4.3 Results 
The intervention groups and control group had balanced demographic, psychological and 
clinical characteristics (Table 2).  
Considering the total sample of asthmatics (n=141), the majority was female (78.7%), with a 
mean age (sd) of 39.3 (14.2). There was also a predominance of lower socio-economic classes 
(75.1%). The mean duration of the disease was 21.5 (14.8) years and most of the patients had 
severe persistent asthma (76.6%).  
There was an improvement in both intervention programmes, in psychological variables. 
Depression only achieved statistical significance in the PG (p≤0.05), but anxiety state was 
significant in all groups (MG p<0.01; PG p<0.01), as well as anxiety trait (MG p<0.001; PG 
p<0.01) (Table 3).  
In the MG, there was a relevant decrease in the coping mechanism of worry with asthma 
(p=0.000).  
In both programs there was an improvement in the quality of life (MG p<0.05; PG p<0.01), 
increasing in 0.8U in PG and 0.5U in MG, taking into consideration effective results since 
0.5U, according Juniper´s references (Juniper et al., 1999a).  
 







Age (years) mean (sd)         40.2(16.3) 37.8(14.1) 40.0(12.3) 
Gender n(%)    
   Male 7(15.2) 8(17.0) 15(31.3) 
   Female 39(84.8) 39(83.0) 33(68.8) 
Socio-economic classification n(%)    
   High and very high 3(6.5) 3(6.4) 5(10.4) 
   Median 6(13.0) 11(23.4) 7(14.6) 
   Low 12(26.1) 10(21.3) 14(29.2) 
   Very low 25(54.3) 23(48.9) 22(45.8) 
Disease duration (years) mean (sd) 24.4(15.0) 20.4(14.6) 19.7(14.8) 
Asthma severity n(%)    
   Moderate persistent 9(19.6) 8(17.0) 16(33.4) 
   Severe persistent 37(80.4) 39(83.0) 32(66.7) 
Table 2. Demographic and clinical characteristics of sample   
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Note: p<0.001 ***; p<0.01**; p<0.05*; NS – non-significant, imp. – improved; 1SAS; 2STAI-Y; 3BDI; 
4MiniAQLQ; 5ACQ 
Table 3. Psychological and clinical outcomes in experimental groups 
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There was also an increase in the control of asthma in both groups (MG p<0.05; PG p<0.05).  
In morbidity criteria, there was a reduction in the use of corticotherapy (p=0.01) in the MG, 
and in hospitalization (p=0.000) in the PG. There was an improvement in spirometry: FEV1 
(MG p<0.05, PG p<0.05) and PEF (MG p<0.05, PG p<0.01).  
4.4 Discussion and conclusion  
The intention of this pioneer study in Portugal was to contribute to the characterization of 
the clinical situation of asthmatic patients in a hospital context, as well as the importance of 
group interventions (mainly educational and communicational) carried out in the context of 
a multidisciplinary programme (Fernandes, 2009). 
Rejecting the linear model of etiological causality, the multisystemic model is strengthened 
with this psychoeducational intervention, in which all factors influence and are influenced 
by the illness.  
In moderate/severe asthma, besides the usual preventive and pharmacological approaches, 
it is essential to turn to a widespread intervention: psychoeducational and multifamily 
programmes, with a multidisciplinary team, to increase the control of the illness and allow 
therapeutic effectiveness (Wamboldt et al., 1995; Devine, 1996; Steinglass et al., 2002; Yorke 
et al., 2007) 
The innovative therapeutic interventions (Psychoeducational and Multifamily) revealed 
promising results, as demonstrated in the present study. Namely in both interventional 
groups, there were good results, with statistically significant improvement in quality of life, 
asthma control, psychological variables (anxiety state and trait, depression and coping 
mechanisms) and clinical parameters (spirometry). 
With the present intervention we try to demonstrate that behavioural changes brought 
about, improvement in the psychological parameters, as well as in the clinical parameters.   
The present results encourage further studies, with larger samples and longitudinal 
interventions, in order to evaluate the stability of the positive effects found. 
An accurate selection for a therapeutic approach is also necessary to cater for specific 
characteristics of these patients, more orientated for control and self-efficacy in 
psychoeducational or solution focused/emotional confrontation for more psychotherapeutic 
intervention.  
Only in this way, can we pursue a holistic comprehension of the complexity of these 
physiopathological processes involved in asthma, with a more integrated and efficient 
treatment.  
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There was also an increase in the control of asthma in both groups (MG p<0.05; PG p<0.05).  
In morbidity criteria, there was a reduction in the use of corticotherapy (p=0.01) in the MG, 
and in hospitalization (p=0.000) in the PG. There was an improvement in spirometry: FEV1 
(MG p<0.05, PG p<0.05) and PEF (MG p<0.05, PG p<0.01).  
4.4 Discussion and conclusion  
The intention of this pioneer study in Portugal was to contribute to the characterization of 
the clinical situation of asthmatic patients in a hospital context, as well as the importance of 
group interventions (mainly educational and communicational) carried out in the context of 
a multidisciplinary programme (Fernandes, 2009). 
Rejecting the linear model of etiological causality, the multisystemic model is strengthened 
with this psychoeducational intervention, in which all factors influence and are influenced 
by the illness.  
In moderate/severe asthma, besides the usual preventive and pharmacological approaches, 
it is essential to turn to a widespread intervention: psychoeducational and multifamily 
programmes, with a multidisciplinary team, to increase the control of the illness and allow 
therapeutic effectiveness (Wamboldt et al., 1995; Devine, 1996; Steinglass et al., 2002; Yorke 
et al., 2007) 
The innovative therapeutic interventions (Psychoeducational and Multifamily) revealed 
promising results, as demonstrated in the present study. Namely in both interventional 
groups, there were good results, with statistically significant improvement in quality of life, 
asthma control, psychological variables (anxiety state and trait, depression and coping 
mechanisms) and clinical parameters (spirometry). 
With the present intervention we try to demonstrate that behavioural changes brought 
about, improvement in the psychological parameters, as well as in the clinical parameters.   
The present results encourage further studies, with larger samples and longitudinal 
interventions, in order to evaluate the stability of the positive effects found. 
An accurate selection for a therapeutic approach is also necessary to cater for specific 
characteristics of these patients, more orientated for control and self-efficacy in 
psychoeducational or solution focused/emotional confrontation for more psychotherapeutic 
intervention.  
Only in this way, can we pursue a holistic comprehension of the complexity of these 
physiopathological processes involved in asthma, with a more integrated and efficient 
treatment.  
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1. Introduction 
During the past decades, an increase in several pediatric morbid conditions has been well 
documented. Two of the most important of these conditions are obesity and asthma. While 
the increase of asthma prevalence has been explained in part by the so-called hygiene 
hypothesis, which claims for a shift from a Th1 to a Th2 environment (if the immunological 
system does not have to deal with infections –Th1- due to a much more aseptic 
environment, it will turn to an allergic predisposition –Th2) (von Mutius, 2007). However, 
this hypothesis does not explain the high prevalences among inner city populations (Platts-
Mills et al., 2005) or developing countries as found in the International Study of Asthma and 
Allergies in Childhood (ISAAC) (Asher et al., 2006). On the other hand, the increased 
prevalence of obesity is most probably due to an imbalance between the energy intake (both 
in quantity as well as quality) and the expenditure, in which the lack of exercise is a key 
point. In this chapter we will explore the complex relationship between asthma, obesity diet 
and exercise in children. 
2. Obesity and asthma are linked together 
2.1 The epidemiological link 
In this section some of the epidemiological evidence regarding the link between asthma and 
obesity is reviewed.  
2.1.1 Obesity/overweight is associated and precedes asthma 
Numerous studies support the epidemiological association between asthma and obesity. 
Though many of them are cross-sectional, thus making it difficult to establish a casual 
relationship, some have been specifically aimed at disentangling the first question of which 
is first in those two apparently connected diseases. The meta-analysis by Sutherland and 
Beuther  (Beuther & Sutherland, 2007) included seven studies which fulfilled their criteria of 
including adult individuals followed for at least one year in which the main outcome 
variable was incident asthma and whose obesity was measured using body mass index 
(BMI). The aforementioned studies included more than 300,000 individuals and the result 
clearly demonstrated that BMI was associated to incident asthma in a dose-response 
manner: the association was higher with obesity than it was with overweight. 
There are also a number of epidemiological clues which suggest that obesity in childhood 
precedes asthma later in life. For instance, in a Tasmanian cohort study (Burgess et al., 2007) 
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There are also a number of epidemiological clues which suggest that obesity in childhood 
precedes asthma later in life. For instance, in a Tasmanian cohort study (Burgess et al., 2007) 
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of children recruited at the age of seven years, adiposity (defined as overweight at 7 years, 
or as highest quartile BMI) was associated with incident asthma between the ages of 21 and 
32 years in girls, but not in boys. Although the number of subjects was low, the association 
was considerably high. Similarly, females who became overweight or obese between 6 and 
11 years of age were seven times more likely to develop new asthma symptoms at ages 11 or 
13, according to the Tucson Children Respiratory Study (Castro-Rodriguez et al., 2001). 
However, not all studies have found a higher association in girls. In fact, in the Children's 
Health Study (Southern California) the risk of new-onset asthma was higher in boys than in 
girls, although it was significant in both genders. 
Not only do overweight or obesity seem to precede asthma but birth weight has also been 
shown to be related to later asthma. Although not all the reports coincide it does seem quite 
consistent that extreme high birth weights are strongly associated to asthma symptoms in 
school years (To et al., 2010). Furthermore, children with a predisposition for asthma may 
have a higher risk of developing asthma during childhood when their mothers are 
overweight before pregnancy, irrespective of the child's BMI (Scholtens et al., 2010). It is also 
of interest that infants breast fed for at least six moths have a better lung function, and this 
seems to be related to a lower weight gain. This was shown by Turner at al. (Turner et al., 
2008) who followed 154 infants from birth. Maximal flow at functional residual capacity 
(V'maxFRC) was measured at 1 and 12 months of life: the change in V'maxFRC was 
inversely associated with change in weight. The group with lower V'maxFRC at 1 month 
and reduced change in V'maxFRC over infancy had the greatest weight gain and increased 
risk for asthma symptoms by the age of three years but not afterwards. Those authors 
concluded that postnatal weight gain may be indirectly associated with early transient 
asthma symptoms which might be the result of impaired lung growth during infancy, a 
situation which could be modifiable by breast feeding. A Danish cohort study in which lung 
function was measured at 6 weeks of age showed that infants in the upper quartile of BMI 
had lower FEV0.5 (Bisgaard et al., 2009).  To what extent this circumstance of the early years 
can be translated to older ages and established asthma is difficult to say, although a 
connection between obesity and architectural changes in the lung is suggestive, especially if 
the action of adipokines (which will be reviewed later in this chapter) is taken into account.  
Taken together, epidemiological data indicate that body weight and asthma are related in 
some way, and that excess weight seems to precede asthma or asthma-related symptoms. 
This fact does not necessarily rule out that the two conditions develop in parallel with the 
former being apparent before. Furthermore, there are factors which modify the relationship 
between obesity and asthma. This has been shown in a cross-sectional study (Garcia-Marcos 
et al., 2008) including a very high number of children: although the association was highly 
significant for the whole group, it changed dramatically when the group was stratified 
between those asthmatics also suffering or not from rhinoconjunctivitis. Obesity was not a 
risk factor for those children with significant asthma who also suffered rhinoconjunctivitis. 
Although the study has limitations and rhinoconjunctivitis is not a perfect marker of atopy, 
it raises the question as to whether obesity may be related only to specific asthma 
phenotypes. 
2.1.2 Obesity and asthma develop in parallel, especially in periods of fast growth and 
maturation  
Rather than obesity being the cause of asthma, some findings support the hypothesis of 
parallel processes which may be related to a change of the environment in which children 
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develop. It is probably when development is more intense (immediately after birth and 
during puberty) when those processes may be more obvious. Some facts support this view: 
- Perinatal events (Jaakkola et al., 2006; Sukalich et al., 2006) or mother food consumption 
during pregnancy have an influence on later obesity and asthma (Chatzi et al., 2008; 
Castro-Rodriguez et al., 2010). 
- Breast feeding and dietary habits during infancy and later on, are related to obesity and 
asthma (Matheson et al., 2007); (Moreno & Rodriguez, 2007). 
- It is among pre-puberal girls where the association between obesity and asthma is most 
apparent (Castro-Rodriguez et al., 2001); (Garcia-Marcos et al., 2007), and obesity 
favours early menarche. 
- Epidemiological studies show that females who became overweight or obese between 6 
and 11 years of age were seven times more likely to develop new asthma symptoms at 
age 11 or 13 (Castro-Rodriguez et al., 2001). Moreover, the early onset of puberty has 
been associated with the persistence of asthma after puberty (Guerra et al., 2004). 
- Obesity and asthma are linked conditions during puberty. Although both obesity and 
asthma can start early in the child life, it is probably around puberty when the 
connections between those conditions may be better revealed, as some epidemiological 
studies have shown (Castro-Rodriguez et al., 2001); (Herrera-Trujillo et al., 2005). Some 
mechanisms might explain this process. For instance, leptin is a key permissive factor 
(Navarro et al., 2007) –probably through the activation of kisspeptin neurons (Kauffman 
et al., 2007)- for the onset of puberty. Furthermore, the increase in body weight which 
occurs during the pubertal spurt induces a corresponding increase of circulating leptin, 
but also of interleukin (IL)-6 and tumour necrosis factor alpha (TNF-α). 
- Several areas in the genome are common to mediators related both to asthma and 
obesity. 
2.1.3 The association between obesity/overweight and bronchial 
hyperresponsiveness is conflicting 
A recent review by Shore (Shore, 2010) lists eight studies dealing with the association of 
obesity and bronchial hyperresponsiveness (BHR) in adults and a further eight in children. 
Except for one, all the studies in adults were carried out using metacholine in the challenge 
test. In children, there were studies using metacholine (n=3), histamine (n=1) and exercise 
(n=3). The results do not point in the same direction even in the two longitudinal studies 
(one in adults and one in children). The study in adults reported that high initial BMI was 
un-linearly associated to later BHR; and weight gain was also associated linearly with the 
risk of later BHR. On the contrary, the study performed in children (Hancox et al., 2005) did 
not find any association. Interestingly, however, a high BMI was associated to asthma only 
in women. This might indicate that the link between obesity and asthma might not 
necessarily be mediated through airway inflammation revealed by metacholine challenge 
testing. The cross-sectional studies in children which used metacholine in the challenge test 
showed all types of results: no association; association only in males; or association only in 
females. On the contrary, all three cross-sectional studies using exercise as the challenge test 
found a positive association. The cross-sectional studies in adults (none of them using 
exercise) also found mixed results, including one study which observed that BMI increased 
BHR in non-asthmatics but not in asthmatics. 
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develop. It is probably when development is more intense (immediately after birth and 
during puberty) when those processes may be more obvious. Some facts support this view: 
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females. On the contrary, all three cross-sectional studies using exercise as the challenge test 
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Although a number of factors such as gender, type of challenge test, non-linear association 
between BMI and BHR (which might counteract the effect of BMI if both low and high BMI 
are associated to BHR), age groups, asthma control, lack of control for diet, etc. may explain 
the discrepancy between studies, it seems quite clear that the evidence of an association (if 
any) between BMI and BHR is not as strong as it is for asthma diagnosis or asthma 
symptoms. It is interesting that the results are concordant only for the exercise challenge test 
which does not produce smooth muscle reactivity (as metacholine does) but provokes mast 
cell activation. It might be hypothesized that obese individuals either create a different 
osmolality of the airways (the mechanism thought to be responsible for BHR with exercise) 
while exercising, which in turn causes a higher mast cell activation; or have more mast cells 
in their airways; or they are more sensitive to osmolality. Although findings in animal 
models are difficult to translate to humans, it is of great interest that obese mice sensitized 
and challenged with ovoalbumin have increased numbers of mast cells in their lungs as 
compared to lean controls (Mito et al., 2002). 
2.2 The clinical link 
Further evidence that obesity and asthma are related to each other is the fact that BMI 
predicts asthma control as an independent factor. For instance, in a very recent study, Farah 
et al. (Farah et al., 2011) reported on asthma control in 49 asthmatic subjects before and after 
three months of treatment with high doses of inhaled corticosteroids. The effects of 
treatment were stratified according to BMI (normal, overweight and obese) and the degree 
of control was assessed by means of the asthma control questionnaire (ACQ-5) although 
other variables, such as forced expiratory volume during the first second (FEV1), airways 
resistance (Rrs) and reactance (Xrs) as measured by the forced oscillation technique, BHR to 
metacholine, and exhaled nitric oxide (FeNO), were also measured before and after 
treatment. After the treatment period neither FeNO (as a surrogate of bronchial eosinophilic 
inflammation) nor FEV1 predicted asthma control according to ACQ-5. The two 
independent predictors of ACQ-5 were Rrs and BMI. The authors conclude that BMI is a 
factor which determines asthma control and is independent of airway inflammation, lung 
function and BHR. Furthermore, after ICS treatment, BMI again predicts ACQ-5, and this 
seems independent of obesity-related changes in lung mechanics. 
From a different angle, but adding some evidence to the argument, one study (Maniscalco et 
al., 2008) has shown that weight loss helps to control asthma in asthmatic individuals. In a 
series of 12 consecutive asthmatic females who had laparoscopic adjustable gastric banding 
and consecutively a significant weight loss, asthma control was significantly improved as 
compared to a control group. Interestingly, no changes in FeNO were found before and after 
the surgical procedure. Previously, another study showed that a small group of asthmatics 
(mainly women) significantly improved their asthma control after a very-low-calorie-diet 
period of 8 weeks (Hakala et al., 2000). In this case, spirometric variables significantly 
improved leading the authors to think that improvement may be due to better lung 
mechanics. To the best of our knowledge there are no controlled studies evaluating the 
effect of weight loss in obese children. 
2.3 A genetic link? 
There are some regions of the genome that are linked with both asthma and obesity, as 
occurs with chromosome 5q, 6, 11q13 and 12q (Tantisira & Weiss, 2001). Chromosome 5q 
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contains genes coding the β2-adrenergic receptor, which has been related to different asthma 
phenotypes, asthma severity and differential response to β2-agonists (Hall et al., 1995). A 
change of Gln for Glu in this receptor has been also associated to obesity (Ishiyama-
Shigemoto et al., 1999). Additionally, chromosome 5q contains the glucocorticoid receptor 
gene which has been involved in inflammatory responses associated to obesity and asthma. 
Chromosome 6 contains the gene for TNF-α, an interleukin which is important for both 
obesity and asthma. Another genome region which is linked with asthma and with obesity 
independently is that of chromosome 11q13 which contains genes for the uncoupling 
proteins UCP2-UCP3 (related to baseline metabolism) and for the low affinity receptor for 
IgE. To end, chromosome 12 contains the genes for inflammatory cytokines both related to 
asthma (such as IFN-γ, or nitric oxide synthase-1) and to obesity (such as signal transducer 
and activator of transcription protein 6 -STAT6-, or type 1 insulinoid growth factor) 
(Delgado et al., 2008). To what extent specific but very large areas of the genome are 
involved in the genesis of the parallel development of asthma and obesity is questionable. 
How epigenetic changes taking place under certain environments might influence genome 
areas related to both diseases is even more questionable. 
2.4 The inflammation link 
The hypothesis that the increase in the prevalence of asthma and obesity, being parallel, 
could be related to one another (Chinn & Rona, 2001) seems quite plausible. However, a 
definite link between the two conditions has yet to be definitely established, as it seems to be 
related to the age and gender of the studied population (Castro-Rodriguez et al., 2001; Chen 
et al., 2002; Garcia-Marcos et al., 2007), and also to the asthma phenotype (Garcia-Marcos et 
al., 2008; Gilliland et al., 2003). However, some of the epidemiological and experimental 
information reviewed in former sections seems to indicate that obesity may precede asthma. 
To explain this, several inflammatory mechanisms have been evoked: 
2.4.1 Adipokines 
Adipokines are cytokines produced by the adipose tissue. Some of them are associated both 
to obesity and to asthma. 
2.4.1.1 Leptin 
Leptin is mainly produced by white adipose tissue proportionally to the amount of such 
tissue. Leptin production is regulated by food intake: food consumption up regulates the 
ob gene, thus increasing leptin synthesis; conversely, fasting reduces leptin levels. 
Infection and sepsis and various pro-inflammatory cytokines including TNF-α and IL-1 
increase leptin. Conversely to this acute response, chronic inflammation causes a 
reduction in leptin levels. Leptin is also moderated by sex hormones: while testosterone 
inhibits leptin production, ovarian sex steroids increase it, a fact which keeps up with 
gender-related dimorphism of this adipokine: leptin levels are higher in females than BMI 
and age-matched males. The main target organ for leptin is the hypothalamus in which it 
triggers efector pathways to suppress appetite and increase energy expenditure. Apart 
from the metabolic processes, leptin is also involved in other functions, including the 
immune response both innate and adaptative: it increases several pro-inflammatory 
cytokines, such as TNF-α, IL-6 and IL-12, and increases chemotaxis and the functioning of 
natural killer cells. Overall, leptin increases Th1 and suppresses Th2 response by acting on 
T regulatory cells (Treg). The leptin receptor gene (db gene) is expressed in the lung tissue 
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of several animals and also in humans (Tsuchiya et al., 1999). Although the role of those 
receptors is not yet clear their presence indicates that the lung is a target organ for leptin. 
There is also some evidence that leptin can stimulate surfactant protein synthesis (Malli et 
al., 2010). However, the evidence that leptin influences lung growth and maturation 
comes from animal models, thus extrapolation to humans remains a major limitation. 
There also appears to be some role of leptin in respiratory function control, at least in mice 
(Groeben et al., 2004; Tankersley et al., 1996).  
Asthmatic 12-year-old children who are overweight have higher levels of leptin than 
overweight children who are not asthmatics, despite there being no difference of BMI 
between the two groups (Mai et al., 2004). This has been also shown in preschool children 
with normal weight, although reduced to male gender (Guler et al., 2004). Very 
interestingly, however, is that leptin and BMI are both associated to asthma in adults in an 
independent way, so when adjusting for leptin levels there is still an association of BMI with 
asthma (Sood et al., 2006). Furthermore, in asthmatic children leptin and IgE serum levels 
are highly correlated to each other (Guler et al., 2004). Atopic asthmatic boys have higher 
leptin levels than non-atopic asthmatic boys. The extent to which leptin has the ability to 
recruit eosinophils into the lungs and to augment leukotriene synthesis by macrophages 
may actually be the explanation of its association with atopy still remains controversial 
(Mancuso et al., 2004; Wong et al., 2007). Further than allergic inflammation as a possible 
pathway to asthma mediated by leptin, this hormone seems to also have some up-regulatory 
effect on the sympathetic nervous system, although it does not seem to be important in 
regulating airway smooth muscle tone (Nair et al., 2008), a fact which might be in 
connection to the non-consistent findings related to the association between obesity and 
BHR. However, its is interesting that leptin and leptin receptor are significantly reduced in 
bronchial epithelial cells in patients with mild asthma which is uncontrolled and in severe 
treated asthmatics as compared to mild asthmatics under good control, and healthy 
controls. Additionally, leptin and leptin receptor expression correlated inversely with the 
thickness of the basement membrane, which is a salient feature of lung remodeling (Bruno 
et al., 2009). 
2.4.1.2 Adiponectin 
Adiponectin has an anti-inflammatory role, and decreases with increasing obesity. Contrary 
to this apparent anti-inflammatory role favoured by obesity, adiponectin is increased in 
other chronic inflammatory conditions such as rheumatoid arthritis, systemic lupus 
erythematosus or inflammatory bowel disease. Moreover, elevated levels of adiponectin in 
cord blood have been associated with an increased risk of asthma in children born from 
atopic mothers (Rothenbacher et al., 2007). More importantly, adiponectin decreases during 
puberty only in boys, and remains unchanged in girls (Andersen et al., 2007), a situation that 
would make gender a modifying factor in the association between obesity and asthma 
during puberty. Adiponectin and all its currently known receptors are expressed in multiple 
cell types in the lung (Hug et al., 2004; Miller et al., 2009; Takemura et al., 2007) which makes 
it a suitable candidate for an additional link between obesity and asthma. In ovoalbumin 
sensitized mice, administration of exogenous adiponectin protects against cell infiltration 
and cytokine levels. Serum adiponectin reduces allergic airway inflammation and BHR in 
mice (Shore et al., 2006). On the other hand and also in mice, adiponectin inhibits the 
proliferation of vessels associated to smooth muscles although it does not affect muscle itself  
(Medoff et al., 2009). These findings suggest that adiponectin is involved in allergic 
inflammation and pulmonary vascular remodeling in a mouse model of chronic asthma. 
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The number of studies in humans is scarce and the study by Rothenbacher et al. 
(Rothenbacher et al., 2007) seems to be contradictory to the animal model. Among children 
with a maternal history of atopy, lower level of adiponectin was associated to lower 
incidence of asthma or obstructive bronchitis during the first two years of life. Conversely, 
higher levels of cord serum adiponectin were associated to higher incidence of those 
respiratory conditions. Among those children without a maternal history of atopy, there was 
no association of the adipokine and the incidence of asthma or obstructive bronchitis. Other 
epidemiological studies in humans have rendered inconclusive results. In two cross-
sectional studies with a relatively low number of school children, serum adiponectin was 
not associated to an ever diagnosis of asthma (Nagel et al., 2009) or to current asthma 
confirmed by metacholine challenge test (Kim et al., 2008). In two very large epidemiological 
studies in adults, although a clear association between higher BMI and asthma was found in 
both of them, adiponectin was only inversely associated with current asthma in 
premenopausal women in one. In a more recent study, 368 adolescent asthmatics were 
followed for one year: adiponectin was inversely associated to asthma symptoms and 
exacerbations and positively to FEV1/FVC but only in male subjects (Kattan et al., 2010). 
FeNO was not associated to serum adiponectin. Conversely, a study in adults did find that 
adiponectin was associated to lower values of FeNO in men but not in women. No further 
association of the adipokine and different asthma markers was found in any gender. 
(Sutherland et al., 2009). 
2.4.1.3 Resistin 
Resistin is also known as adipocyte-secreted factor or “found in inflammatory zone 3” 
(FIZZ3). It has recently been discovered and has been proposed as a link between obesity 
and diabetes. In contrast to mice, resistin is expressed in human adipocytes in low amounts; 
in fact it is in bone marrow where this adipokine is most expressed in humans (Filkova et 
al., 2009). Resistin has recently been shown to initiate a pro-inflammmatory state “in vitro” 
and “in vivo”. Pro-inflammatory mediators such as TNF-α, IL-1β or IL-6 can strongly 
increase the expression of resistin in peripheral mononuclear cells. As stated above, resistin 
is minimally expressed in human adipose tissue, but adipocytes may be targets for it. 
Nagaev et al. have demonstrated that resistin, similarly to its action on peripheral blood 
mononuclear cells, can induce adipocytes to express IL-6 and TNF-α (Nagaev et al., 2006). 
Resistin has been shown to be increased in the murine models of genetic as well as in diet-
induced obesity. This has also been shown in humans. In an asthma cohort study on adult 
asthma, levels of resistin were higher in asthmatic patients as compared to controls, and 
resistin levels increased with increased severity of the disease (Larochelle et al., 2007). 
Conversely, atopic asthmatic children have lower resistin levels as compared to the non-
atopic asthma and control groups (Kim et al., 2008). However, in a recent study (Arshi et al., 
2010) in children of a similar age to those in the previous study (11 years) resistin levels 
were not different between a group of atopic asthmatics and a control group. In fact, its 
levels in the former study were about double than in the latter both in the control and in the 
atopic asthmatic groups. More recently, a study has shown that in a group of non-obese 
corticosteroid naïve adult female recently diagnosed asthmatics resistin predicted 
favourable anti-inflammatory effects of inhaled corticosteroids as assessed by levels of 
eosinophil cationic protein, eosinophil protein X and myeloperoxidase. Furthermore, an “in 
vitro” assay found that fluticasone significantly reduced resistin-induced IL-6 and TNF-α 
production in cultured monocytes/macrophages (Leivo-Korpela et al., 2011). 
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This adipokine is the rate-limiting enzyme in the alternate pathway of complement 
activation and is primarily expressed by adipocytes and monocytes/macrophages in 
humans. Adipsin has however been barely studied in asthma or allergic diseases. In a group 
of non-obese corticosteroid naïve adult female recently diagnosed asthmatics and with a 
positive bronchodilator tests, levels of adipsin were similar to the control group (Leivo-
Korpela et al., 2011); however this adipokine has been reported to be significantly increased 
in individuals with seasonal allergic rhinitis, but only in males. Sublingual immunotherapy 
did not seem to affect adipsin levels (Ciprandi et al., 2009). Information regarding whether 
adipsin might have a role in asthma (if any) is still very scarce and we will have to wait until 
new studies publish their results. 
2.4.1.5 Visfatin 
Visfatin is identical to pre-B cell colony enhancing factor, a cytokine which is increased in 
the bronchoalveolar lavage fluid in animal models of acute lung injury and in neutrophils of 
septic patients. Exercise training with weight loss induced a significant reduction of plasma 
visfatin in non-diabetic women (Choi et al., 2007). Although this protein represents an 
additional link between obesity and inflammation, its role in asthma (if any) is still to be 
elucidated. 
2.4.2 Immunologic properties of adipose tissue 
The view of adipose tissue as a sole storage system has radically changed in the last decade. 
Further than being able to synthesize adipokines, adipocytes share some similarities with 
macrophages. In fact, preadipocytes can differentiate into macrophages, but the two cell types 
are distinct. On the other hand, about 10% of cells in the adipose tissue are macrophages. The 
number of macrophages in the adipose tissue is directly related to adiposity and to the size of 
adipocytes both in humans and in mice (Curat et al., 2004). Apart from secreting adipokines, 
adipocytes also secrete chemokines and cytokines, such as TNF-α, IL-6, Il-10, IL-1β and other 
factors such as monocyte chemoattractant protein-1 (MCP-1). It is thought that those mediators 
are secreted by the adipocyte itself since when adipose tissue is increased there is an up-
regulation of genes related to inflammation. Indeed macrophages of the adipose tissue are an 
additional source of inflammatory mediators. 
- TNF-α is the most important of cytokines produced by adipose tissue. It increases 
formation of Th2 cytokines such as IL-4 and Il-5, IL-6 and Il-1β by the bronchial 
epithelial cells. On the other hand, TNF-α increases the expression of leptin and 
adiponectin in cultured adipocytes (Kirchgessner et al., 1997). TNF-α is an important 
cytokine in the innate immune response and has been involved in the pathophysiology 
of several chronic inflammation diseases, including asthma (Thomas et al., 1995; 
Thomas & Heywood, 2002). This cytokine has an array of effects on the immunological 
system which have direct implications for the asthmatic response, such as recruitment 
of neutrophils, macrophages and mast cells; recruitment and activation of eosinophils; 
up-regulation of adhesion molecules both in the respiratory epithelium and on the 
vascular endothelium, which in turn can further increase inflammatory cell recruitment; 
proliferation and differentiation of fibroblasts (related to asthma remodeling and 
potentially to a more severe type of asthma); activation and increased release of 
cytokines by T cells of the Th2 arm; and induction of corticoisteroid resistance 
(Brightling et al., 2008). 
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- IL-6 is a proinflammatory cytokine which has a central role in host defence against 
infection and tissue injury. This interleukin derived from antigen presenting cells can 
induce production of IL-4 in naïve CD4+ cells, thus polarizing them into Th2 cells; i.e. to 
the allergic type of inflammation. This interleukin also modulates the intensity of the 
immune response by inhibiting Treg cell development. Additionally IL-6 promotes 
generation of Th17 cells (cells involved in autoimmune diseases) in mice, though its 
ability to do so in humans is subject to debate (Wilson et al., 2007). It has been recently 
shown that IL-6 levels are elevated in sputum of asthmatic patients as compared to 
healthy volunteers (Neveu et al., 2010). 
- IL-10 is a cytokine with important regulatory function, having multiple biological 
effects in different cell-types. IL-10 modulates allergic disease in humans: the expression 
of IL-10 by antigen presenting cells in the airway of healthy subjects is important for 
inducing and maintaining tolerance to allergens (Commins et al., 2008). 
- IL-1β is a potent mediator in response to infection and injury, and is increased in 
asthmatic airways as it is in other chronic inflammatory diseases. Apart from its pro-
inflammatory effects, IL-1β has been shown to induce migration of vascular smooth 
muscle cells in culture and to provoke migration of endothelial cells. Its potential effects 
on the airway epithelial cell have been recently shown in cell cultures (White et al., 
2008). 
It should not be forgotten that apart from adipocytes, adipose tissue contains a considerable 
number of macrophages. Those cells are located in the white adipose tissue, which –as 
compared to brown adipose tissue which has as main role non-shivering thermogenesis- is 
the majority of adipose tissue and serves as energy storage. The number of macrophages in 
this tissue is proportional to adiposity and adipocyte size, both in mice and humans, and no 
difference exists between visceral and subcutaneous white fat (Weisberg et al., 2003). 
2.4.3 Other endogenous molecules relating obesity with asthma 
There are other hormones which may be related to obesity and asthma since they can be 
associated with processes related to food intake/body weight and inflammation. 
2.4.3.1 Alpha-melanocyte stimulating hormone 
Alpha-melanocyte stimulating hormone (α-MSH) belongs to a group of hormones called 
melanocortins, which include ACTH among others, with a common precursor 
(proopiomelanocortin). This hormone produces a significant down-regulation of pro-
inflammatory cytokines such as IL-1β, IL-6 and TNF-α, as well as chemokines such as IL-8 
and interferon gamma (IFN-γ). Furthermore, chemotaxis induced by IL-8 in human 
neutrophils and monocytes is blunted by α-MSH. Additionally, this hormone has been 
shown to induce IL-10 production (Brzoska et al., 2010). In a murine model, α-MSH was able 
to inhibit airway inflammation induced by aerosol sensitization and subsequent challenges 
with OVA. Additionally, the levels of two important interleukins related to the allergic 
response, IL-4 and IL-13, were highly decreased in the broncho-alveolar lavage fluid of mice 
treated with α-MSH. In agreement with the important role of IL-10 as an anti-inflammatory 
mediator, the action of α-MSH was dependent on the presence of IL-10, as IL-10 knock-out 
mice were resistant to treatment with α-MSH (Raap et al., 2003). In the context of an 
association between asthma and obesity, what is on interest of α-MSH is the fact that the 
hormone is included in one of the main mechanisms of energy balance. There are 
melanocortin receptors in the CNS and effects on food intake and on energy expenditure 
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have been observed with treatments containing ligands of those receptors (Williams et al., 
2000). Those receptors are hypothesized to be downstream mediators of the effects of leptin 
signaling: leptin increases the expression of the proopiomelanocortin gene in neurons of the 
nucleus tractus solitarius  (Schwartz et al., 1997). Thus, α-MSH may play a role both in 
allergic inflammation and in food-intake control. In fact, the melanocortin system appears to 
be a common pathway for mediation of both leptin and ghrelin (Lebrethon et al., 2007). 
2.4.3.2 Ghrelin 
Ghrelin is not only a mere growth-hormone releasing factor but also an important appetite 
regulator, energy conservator and suppressor of the sympathetic nervous system. Ghrelin, 
secreted from the peripheral organ, has its regulatory region in the hypothalamic arcuate 
nucleus, where the regulatory region of appetite is located. Circulating ghrelin excites this 
region and stimulates food intake after passing through the blood-brain barrier. Additionally, 
this hormone can exert its action through receptors in the vagus nerve  (Kojima & Kangawa, 
2010). Apart from being an orexigenic hormone, ghrelin has an interesting association with IgE 
in humans. In a case-control study of obese school children, Matsuda et al. (Matsuda et al., 
2006) found that ghrelin was inversely and significantly correlated with BMI but also with IgE 
both in allergic and non-allergic subjects as defined from a combination of asthma and skin 
symptoms. This correlation with IgE is higher among overweight patients as compared to 
normal weight ones, in which the correlation is still significant (Okamatsu et al., 2009). The 
strong inverse correlation between plasma ghrelin and serum IgE levels suggests that ghrelin 
may inhibit IgE production in some manner. In this context, it is of interest that in splenic 
murine T lymphocytes, mRNA levels of IL-4 and IL-10, which both increase IgE synthesis, are 
suppressed by ghrelin (Xia et al., 2004). 
2.4.3.3 Eotaxin 
Eotaxin is a key chemotactic agent responsible for the eosinophil-mediated bronchial 
inflammation. In their pivotal study, Vasudevan et al. (Vasudevan et al., 2006) showed that 
eotaxin circulating levels are increased in diet-induced obese mice. They also showed that 
after weight loss in humans eotaxin was significantly reduced. In a group of obese and non-
obese Korean women it was shown that circulating eotaxin was similar in both groups, 
although women with central obesity had significantly higher levels of eotaxin than those 
without it. This study also showed that weight reduction after following an exercise 
program for 12 weeks was associated to a significant decrease in circulating eotaxin levels in 
the whole group (Choi et al., 2007). 
Not only has eotaxin been studied in relation to obesity but also as to how this chemokine 
interacts with allergy inflammation in the context of obesity. In a murine allergy model  
(Calixto et al., 2010), diet-induced obesity enhanced eosinophil trafficking from bone 
marrow to lung tissues, and delayed their transit through the airway epithelium into the 
airway lumen. Consequently, eosinophils remain longer in lung peribronchiolar segments. 
Furthermore, Kim et al.  (Kim et al., 2011) cultivated and differentiated pre-adypocites and 
investigated eotaxin expression during differentiation and found that levels of this 
chemokine increased as adipocytes differentiated. Eotaxin was further expressed when 
cultured cells were challenged with TNF-α and IL-4.  
2.4.3.4 Plasminogen activator inhibitor 1 
Remodeling of the airway is a key feature of asthma and is associated to a more severe type 
of disease. Plasminogen activator inhibitor 1 (PAI-1) is a potent inhibitor of both tissue-type 
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plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA). Both t-PA 
and u-PA are involved in the dissolution of fibrin and in the degradation of the extracellular 
matrix. Activated mast cells are a major source of PAI-1, and mast cell-derived PAI-1 is 
highly expressed in patients with fatal asthma (Cho et al., 2000). Furthermore, a gene 
polymorphism associated with PAI-1 levels is preferably transmitted to asthmatic patients; 
and deletion of PAI-1 prevents extracellular matrix deposition in a murine model of asthma 
(Cho et al., 2001); (Oh et al., 2002). In a very recent study (Cho et al., 2011), it was found that 
plasma levels of PAI-1 were significantly higher in obese subjects as compared to controls 
after adjusting for race and smoking status; furthermore, PAI-1 plasma levels were 
significantly and inversely correlated to forced vital capacity. Thus, it could be hypothesized 
that the reduction of FVC in obese patients may be in part mediated by PAI-1. Although 
research on the association of PAI-1 as a link between obesity and asthma is still very scarce, 
this is a field which warrants further investigation.  
2.5 The mechanical link 
The mechanical load of obesity might affect lung growth, leading to reduced pulmonary 
function. For instance, leptin-deficient mice which are obese very early in their development 
have substantially smaller lungs than normal ones (Shore et al., 2003). Maternal obesity in 
pregnancy increases the risk of pregnancy complications, caesarean sections and adverse 
birth outcomes, which have in turn been associated with respiratory illness in children. 
However, little is known of the effect of obesity in the mother during pregnancy with regard 
to respiratory diseases in the offspring. A recent Norwegian study (Haberg et al., 2009) 
(Norwegian and Child Study) which includes 100,000 pregnant mothers was able to analyse 
data from more than 33,000 mother-children pairs up to the age of 18 months of the infants 
and demonstrated that after adjustment for many factors including birth weight, preterm 
birth and pregnancy complications, infants born from obese mothers had a modest but 
significant increased risk (3.3%) of suffering from at least one episode of wheezing during 
the follow-up period. To what extent this finding is related to the low-grade inflammation 
status of mothers during pregnancy or to mechanical factors “in utero” and how they might 
affect lung development in the foetus is still to be determined. Furthermore, it is not known 
if this effect is maintained in later years. 
Independently of its effects on lung development either in the fetal period or later on, obese 
subjects have a low functional residual capacity due to changes in the elastic properties of 
the chest wall (Shore & Johnston, 2006). At low volumes, the retractile forces of the lung 
parenchyma are reduced, thus airway smooth muscle has a lower load when functional 
residual capacity is reduced. Consequently it might shorten still further when activated 
(either by parasympathetic tone or broncho-constricting agents such as metacholine) 
(Naimark & Cherniack, 1960). However, some studies have noted that there is bronchial 
constriction in obese subjects after correcting for lung volume, which suggests that other 
mechanisms are involved. Apparently low tidal volume (which is common in obese 
individuals) may be one such mechanism: stretching of the airways smooth muscles causes 
cross-bridging of actin-myosin to detach, and the bigger the tidal volume (stretch) the easier 
it is for bronchodilation to occur. Low tidal volume facilitates more cross-bridging between 
actin and myosin, thus making airway smooth muscle stiffer and harder to stretch. Hence 
reduction of tidal volume in obese subjects could lead to a vicious circle in which small 
airway muscle strain leads to greater stiffness, and this leads to even less muscle strain in 
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every breath (Shore, 2008). This paradigm is supported by the fact that both obese and 
asthmatic subjects have lower bronchodilation after deep breaths (Hakala et al., 1995; Skloot 
& Togias, 2003). 
There could be additional mechanical explanations as to the reasons why airways in obese 
subjects are more easily constricted than in normal ones. Closure of small peripheral 
airways is common in obese individuals, especially in the supine posture (Hakala et al., 
1995). Some authors have postulated that the frequent opening and closure of those airways 
may lead to the rupture of alveolar attachment to bronchioles, thus disconnecting airways 
from the attached parenchyma and exacerbating constriction (Milic-Emili et al., 2007). To 
what extent those less oxygenated areas could lead to higher artery pressures and 
pulmonary edema, further complicating the situation, is still very speculative although there 
is some evidence of edema in obese subjects and pulmonary hypertension in obese women  
(Bergeron et al., 2005); (Taraseviciute & Voelkel, 2006). Hypoxemia might exacerbate local 
hypoxia occurring in obese adipose tissue, a situation which contributes to the general 
inflammation of obesity (Hosogai et al., 2007; Ye et al., 2007). Situations related to obesity 
such as obesity hypoventilation syndrome or sleep disordered breathing could further 
aggravate this situation and although extreme and far from asthma, could add some clues to 
the mechanical associations between asthma and obesity. 
2.6 The experimental link (animal models) 
Three are several models in which the lung features of obese mice have been characterized. 
According to Shore (Shore, 2007), those are: 
- ob/ob Mice: This is a type of mice which is not capable of synthesizing leptin, which is a 
satiety hormone formed in the adipose tissue. These mice eat in excess and are already 
obese at four weeks of age. These mice have smaller lungs than the wild type. 
- db/db Mice: In this type of mice there is an altered leptin receptor in the hypothalamus 
(Ob-Rb) so the effect of leptin on satiety is lost. Thus, db/db mice are similar to ob/ob 
mice. As in the case of ob/ob mice, db/db mice have smaller lungs than the wild type. 
- Cpefat Mice: These mice have a missense mutation of the enzyme carboxipeptidase E 
(Cpe) which makes it inactive. Cpe cleaves neuropeptides such as corticotrophin-
releasing factor and neuropeptide Y which control eating behaviours and energy 
consumption. In the absence of Cpe mice become obese but not as fast as ob/ob or db/db 
mice. These mice have lung size comparable to that of the wild type. 
- Diet-induced obese mice: feeding recently weaned mice with a diet in which 45-60% of 
calories are derived from fat produces obesity. Obesity is milder than in the three prior 
models and lung size is again similar to that of the wild type. 
Taken together, the results from the studies from animal models in obese mice suggest that 
obesity might be related to asthma in several ways. In the first place very early obese mice 
have smaller lungs and this might have implications both at the mechanical and at the ultra-
structural level, in particular in the way lungs are alveolarized. Secondly, obesity either 
acquired very early or later on in the mice’s lives increases BHR and this neither seems to be 
directly mediated by leptin nor is secondary to a prior inflammation. Lastly, obesity might 
have some effect on asthma through allergic sensitization as that hormone seems to increase 
sensitization, and thus BHR to allergen challenge (Shore et al., 2005), this being dependent 
on when obesity and sensitization develop. 
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2.7 A distinct asthma phenotype in the obese? 
There seems to be enough epidemiological, clinical and mechanistic evidence that obesity 
and asthma “live” together in some individuals. Whether this comorbidity is a distinct 
phenotype as suggested by some authors; or obesity is a risk factor for asthma incidence and 
worse control, is difficult to say (Castro-Rodriguez & Garcia-Marcos, 2008; Lessard et al., 
2008; Lugogo et al., 2010). However, both the mechanical, hormonal and immunological 
links between the two conditions suggest that obesity probably leads to asthma in many 
cases and could be in part responsible for the “asthma epidemic”. Moreover, there are two 
other important factors –diet and exercise- which can favour both asthma and obesity in 
parallel. An official American Thoracic Society workshop report recently published 
concludes that obesity is a risk factor for asthma in all age groups and that asthma in the 
obese might represent a distinct phenotype with a more severe disease with a worse 
response to treatment (Dixon et al., 2010). The report states the urgent need to further 
investigate the mechanisms of asthma in this risk group and to develop new therapies 
directed to this specific population. 
3. Diet as an independent factor in the development of asthma and obesity 
Diet and exercise are probable common pathways for asthma and obesity irrespective of 
which of the two conditions starts first. This is quite well documented during the first 
months after birth. Infants who are breastfed have a different bacterial colonization of their 
intestine than those who are fed with artificial formulas (Harmsen et al., 2000). Similarly, 
children fed with the latter formulas gain weight more rapidly, although this does not seem 
to be translated into later obesity (Burdette et al., 2006). Although the information is still 
sparse, it is quite probable that the so-called microflora fingerprinting –which remains very 
stable throughout the years- is related to diet. Either by this mechanism which might be 
included into de hygiene hypothesis or by others, such as the antioxidant or pro-oxidant 
properties of some foods (Roberts et al., 2006), or the modulating  properties of prebiotics -
like fibers- to adjust intestinal microflora (Schley & Field, 2002), may have an effect on 
asthma and obesity. 
There are currently enough studies to conclude that there is an association between 
consumption of some types of nutrients or foods and asthma. An ecological analysis of the 
European Community Respiratory Health Survey (ECRHS) showed a trend towards 
decreasing sensitization (specific IgE) prevalence with higher intakes of fruit and vitamins A 
and C (Farchi et al., 2003). Furthermore, other studies have found an association between 
consuming citrus/kiwi fruit and a lower last year prevalence of several asthma symptoms 
(Forastiere et al., 2000; Wickens et al., 2005); and also of rhinitis. The frequent intake of 
vegetables showed an inverse relationship with prevalence rates of asthma, allergic 
rhinoconjunctivitis and atopic eczema (Weiland et al., 1999). The intake of cereals has also 
been shown to be associated to a lower prevalence of asthma (Garcia-Marcos et al., 2007; To 
et al., 2004). A recent meta-analysis on food intake and asthma arrived at interesting 
conclusions (Nurmatov et al., 2011) in spite of the limitations of applying the meta-analysis 
technique to epidemiological studies which cannot be –by definition- perfectly controlled. 
With respect to individual nutrients, vitamins A, D, E and zinc seem to be protective, while 
vitamin C and selenium do seem to be neither a protective nor a risk factor. Higher 
consumption of fruit and vegetables are associated to a lower prevalence of asthma, with 
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fruit having a higher impact. However the associations were not adjusted for obesity or 
exercise. 
Two different groups, including ours, have very recently associated Mediterranean diet to a 
lower prevalence of asthma at different ages (Castro-Rodriguez et al., 2008; Chatzi et al., 
2007; Garcia-Marcos et al., 2007) independently of exercise. Furthermore, Mediterranean diet 
also showed this protective effect in the offspring when the mother consumed it during 
pregnancy (Chatzi et al., 2008), although the effect might be restricted just to olive oil intake 
(Castro-Rodriguez et al., 2010). The reasons why this type of diet is associated with a lower 
prevalence of asthma could be explained in several ways. Considering that Mediterranean 
diet is rich in both antioxidants and cis monounsaturated fatty acids this is not an 
unexpected finding. Individually, a more frequent intake of seafood and also of cereals is 
associated with a lower prevalence of significant asthma. At 8-10 years of age atopy is a risk 
factor for a more severe asthma (Ponsonby et al., 2002), so it could be speculated that at least 
in part the protection offered by this diet is mediated through allergy modulation. The 
protection from asthma that Mediterranean diet seems to offer is probably due to a mixed 
effect of taking “protective” foods and avoiding “risky” foods. Protective foods may be 
those with antioxidant properties and rich in prebiotics, such as fibers (as in the 
Mediterranean diet); and risky foods may be those rich in trans fatty acids and unsaturated 
fat (as in fast foods)  (Garcia-Marcos et al., 2007; Innis & King, 1999; von Kries et al., 2001). In 
fact, Mediterranean diet has been shown to increase the total antioxidant capacity in healthy 
adults (Pitsavos et al., 2005). Mediterranean diet has additionally been associated to a 
reduced prevalence of obesity. Due to its content in fibre and unsaturated fat (olive oil, fish) 
this diet is associated to better weight control (Schroder, 2007). On the contrary, fast food is 
related to an increase of calorie intake (Schmidt et al., 2005) and is greatly related to the 
school and family environment, especially during the transition to adulthood (Nelson et al., 
2006)  
3.1 Oxidant-antioxidant imbalance in asthma 
Reactive oxygen species (ROS), formed in every cell during metabolic processes, are 
increased in asthma and can mediate pathophysiologic changes which are characteristic of 
this condition, such as initiating lipid peroxidation and favouring the release of arachidonic 
acid from cell membranes; contracting smooth muscle; increasing airway reactivity and 
vascular permeability; augmenting the synthesis and release of cytokines and chemokines; 
impairing the response to β2 adrenergic drugs; and decreasing cholinesterase and neutral 
endopeptidase activities (Nadeem et al., 2008). Lungs have several antioxidant mechanisms 
including enzymatic (catalase, glutathione peroxidase ans superoxide dismutase) and non-
enzymatic ones (vitamin C, E, albumin, uric acid, cerulopasmin and glutathione). Increased 
ROS generation is found when the activity of neutrophils, eosinophils, monocytes and 
macrophages is increased, as occurs in asthma (Kelly et al., 1988). Oxidative stress (a 
situation of imbalance between the production of ROS and the ability to detoxify the 
reactive intermediates or to repair the resulting damage) is an important consequence of 
asthma inflammation; is associated with an altered activity in anti-oxidation in lungs and 
blood; and also with airway reactivity (Katsumata et al., 1990; Nadeem et al., 2005; Sackesen 
et al., 2008). 
There are numerous reports showing deficiencies of antioxidants in asthma: low levels of 
vitamin C in airway lining fluid, serum, plasma, whole blood and brochoalveolar lavage 
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fluid; vitamin E in brochio-alveolar lavage fluid, red cells and plasma; or beta-carotene in 
serum (Kalayci et al., 2000; Kelly et al., 1999; Sackesen et al., 2008; Shanmugasundaram et al., 
2001; Vural & Uzun, 2000; Wood et al., 2008). The cooperation of several antioxidants 
provides a better defense against ROS, so the total antioxidant capacity of serum is probably 
a better index than the measurement of a specific antioxidant. Again, antioxidant capacity in 
serum is reduced in asthmatics during exacerbations as compared with healthy individuals 
and is less reduced in subjects with stable asthma (Katsoulis et al., 2003). Very recently, 
oxidative stress has been shown to be increased in children with previous bronchilitis 
obliterans (Mallol et al., 2011) and although in this study the authors did not find correlation 
with lung function tests, several studies have indeed shown an inverse relationship between 
oxidative stress and lung function in asthmatics (Nadeem et al., 2005; Ochs-Balcom et al., 
2006; Picado et al., 2001; Wood et al., 2000). 
Taken together these results indicate that an oxidant-antioxidant imbalance could play a 
crucial role in the development of asthma symptoms and in the severity of the disease. 
Accordingly, certain diets may favor or protect from asthma depending upon their ability to 
maintain a better oxidant-antioxidant balance. 
4. Exercise is an independent protective factor for asthma and obesity 
Although it would be expected that asthmatics perform less exercise and severe asthmatic 
perform even less, it is not so straightforward that the lack of exercise favours obesity, which 
in turn favours asthma. Although this causal pathway may be present in some asthmatics, 
more exercise –independently of BMI- has been associated to a lower prevalence of mild 
asthma, although it does not influence severe asthma. If the association of asthma with 
exercise was a reverse causation effect it should be expected that at least in severe 
asthmatics, there was an inverse association, which does not seem the case when diet and 
BMI are controlled: in their study Garcia-Marcos et al. showed that after adjusting for BMI 
and Mediterranean diet exercise was not associated with severe asthma; and mild asthma 
was less prevalent among children who exercise more (Garcia-Marcos et al., 2007). 
Therefore, it might be hypothesized that at least in mild cases, the lack of exercise is 
associated to asthma. In this context, a very interesting and challenging hypothesis was 
proposed by Alexander in 2005 who maintains that the increase of asthma prevalence might 
be due in part to a “disuse contracture” which reminds of the mechanical link between 
obesity and asthma (Alexander, 2005). The following paragraphs are a brief explanation of 
that hypothesis. 
Bronchial constriction and BHR are crucial features of asthma and are both driven by 
bronchial smooth muscle. When lumen is narrower than normal in a permanent way, there 
is also a reduction in the length of the annular components of the bronchii, namely smooth 
muscle fibres and collagen. Under-extension causes contracture:  elastic components 
(smooth muscle and collagen) need a certain tension to operate correctly and when this is 
not provided by intermittent stretching they either fail to extend during growth (infants and 
schoolchildren) or reduce in length (adults) to a point in which habitual usage is enough to 
provoke a peak tension needed for effective functioning. This situation maybe reversible in 
its first stages but becomes permanent with time due to fixed cross-linking (Akeson et al., 
1977). While this is typical of the joint tissues, it is most probably applicable to muscles and 
elastic tissues of the airways, which in continued growing (as in infancy and childhood) 
without stretching to their potential length the result would result in an increased thickness 
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of the wall and narrowing of the lumen, which, in turn, will start a vicious cycle: thicker 
wall, less ability to stretch and more difficult distension to inspiration, less distension, less 
lumen and thicker wall again. If lumen is reduced to a critical point and according to 
Laplace’s law, the product of atmospheric pressure times radius will not be able to 
counteract wall tension and bronchii would collapse. In this situation a very small increase 
of muscle tone will be enough to cause bronchial closure. Moreover, exercise increases 
respiratory rate and speed of airflow, thus reducing transmural pressure and further 
favouring collapse. 
In summary, this hypothesis contemplates asthma as a lack of lung expansion by exercise 
during growth. While just a hypothesis, the idea of a lack of “sufficient” inspiration has been 
contemplated as a feasible explanation for the influence in asthma prevalence of TV 
watching. The ALSPAC study, after following a large sample of more than 5,000 children, 
found that new asthma cases, as diagnosed by a doctor, between the ages of 3.5 and 11.5 
years were associated to the number of hours of TV watching after controlling for other risk 
factors including BMI: those watching more than 2h/day had double odds of having new 
onset asthma a compared to those watching 1-2h/day, while those watching less than 
1h/day had just half the odds (Sherriff et al., 2009). While previous studies showed that new 
cases of asthma during adolescence are associated to lower fitness (Rasmussen et al., 2000; 
Vogelberg et al., 2007), sometimes confused by smoking, children in the ALSPAC study 
were too young to consider smoking-related TV watching as a plausible explanation. 
Sedentary lifestyle (“disuse contracture”) is a more plausible explanation. Additionally, the 
ALSPAC group suggested as an additional explanation of their results that respiratory 
patterns associated to TV watching may also play a role: prolonged periods of watching a 
videotape are associated with lower sigh rates than while reading (Hark et al., 2005). Thus, 
“modern” as opposed to “classical” sedentary lifestyle maybe and additional factor 
favouring the “disuse contracture”. 
5. Conclusion 
Obesity and asthma are linked together, a link which has been shown at different levels and 
has plausible pathways. However, it is still to be established if obesity causes asthma (or a 
specific asthma phenotype) or if the two conditions are part of a parallel development in the 
context of the western lifestyle in which sedentary habits and unhealthy diets (together with 
lower contact with germs and/or with “non-traditional” germs) may interact to favour an 
internal environment in which not only obesity and asthma, but other diseases such as type 
II diabetes or rheumatoid arthritis develop more easily. 
The epidemiological and animal studies carried out to date have probably rendered all 
possible information and it is the time of more controlled trials. New pregnancy/birth 
cohort studies specifically designed to disentangle the interrelationship between asthma, 
obesity, exercise and diet are needed. Creative clinical trials will also have an important role 
here, although designing and performing them is a great challenge. The implications of the 
results of such studies on public health policies are crucial. 
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of the wall and narrowing of the lumen, which, in turn, will start a vicious cycle: thicker 
wall, less ability to stretch and more difficult distension to inspiration, less distension, less 
lumen and thicker wall again. If lumen is reduced to a critical point and according to 
Laplace’s law, the product of atmospheric pressure times radius will not be able to 
counteract wall tension and bronchii would collapse. In this situation a very small increase 
of muscle tone will be enough to cause bronchial closure. Moreover, exercise increases 
respiratory rate and speed of airflow, thus reducing transmural pressure and further 
favouring collapse. 
In summary, this hypothesis contemplates asthma as a lack of lung expansion by exercise 
during growth. While just a hypothesis, the idea of a lack of “sufficient” inspiration has been 
contemplated as a feasible explanation for the influence in asthma prevalence of TV 
watching. The ALSPAC study, after following a large sample of more than 5,000 children, 
found that new asthma cases, as diagnosed by a doctor, between the ages of 3.5 and 11.5 
years were associated to the number of hours of TV watching after controlling for other risk 
factors including BMI: those watching more than 2h/day had double odds of having new 
onset asthma a compared to those watching 1-2h/day, while those watching less than 
1h/day had just half the odds (Sherriff et al., 2009). While previous studies showed that new 
cases of asthma during adolescence are associated to lower fitness (Rasmussen et al., 2000; 
Vogelberg et al., 2007), sometimes confused by smoking, children in the ALSPAC study 
were too young to consider smoking-related TV watching as a plausible explanation. 
Sedentary lifestyle (“disuse contracture”) is a more plausible explanation. Additionally, the 
ALSPAC group suggested as an additional explanation of their results that respiratory 
patterns associated to TV watching may also play a role: prolonged periods of watching a 
videotape are associated with lower sigh rates than while reading (Hark et al., 2005). Thus, 
“modern” as opposed to “classical” sedentary lifestyle maybe and additional factor 
favouring the “disuse contracture”. 
5. Conclusion 
Obesity and asthma are linked together, a link which has been shown at different levels and 
has plausible pathways. However, it is still to be established if obesity causes asthma (or a 
specific asthma phenotype) or if the two conditions are part of a parallel development in the 
context of the western lifestyle in which sedentary habits and unhealthy diets (together with 
lower contact with germs and/or with “non-traditional” germs) may interact to favour an 
internal environment in which not only obesity and asthma, but other diseases such as type 
II diabetes or rheumatoid arthritis develop more easily. 
The epidemiological and animal studies carried out to date have probably rendered all 
possible information and it is the time of more controlled trials. New pregnancy/birth 
cohort studies specifically designed to disentangle the interrelationship between asthma, 
obesity, exercise and diet are needed. Creative clinical trials will also have an important role 
here, although designing and performing them is a great challenge. The implications of the 
results of such studies on public health policies are crucial. 
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1. Introduction 
Asthma is the most frequent chronic disorder in childhood. Asthma puts a serious burden 
on children’s health related quality of life, despite the availability of effective and safe 
treatment (Dalheim-Englund et al., 2004; Global Initiative for Asthma, 2010; Masoli et al., 
2004; Mohangoo et al., 2005). The overall goal of asthma management is to achieve optimal 
disease control and health related quality of life improvements (Bateman et al., 2007; 
Pedersen et al., 2011). The World Health Organization has defined the term health related 
quality of life as the individual’s perception of their position of life in the context of the 
culture and value systems in which they live and in relation to their goals, expectations and 
concerns (World Health Organization, 1993). The own perception is important because it 
emphasises that these are the impairments that patients themselves consider important. As 
in most medical conditions, the correlation between asthma control and health related 
quality of life is modest. Therefore, the impact that asthma has on a patient’s health related 
quality of life cannot be inferred from the conventional clinical measures of asthma (e.g. 
spirometry); it must be measured directly (Juniper et al., 1999a, 1999b). 
During the past decade, the use of health related quality of life as an essential outcome 
measure of childhood asthma treatment and management has increased (Merikallio et al., 
2005). This review summarises recent literature on: 1) health related quality of life 
instruments for childhood asthma, 2) the impact of childhood asthma on children’s health 
related quality of life, 3) the impact of children’s asthma on caregiver’s health related quality 
of life and 5) factors associated with health related quality of life in childhood asthma. 
2. Health related quality of life instruments and childhood asthma 
Several feasible, reliable and validated pediatric health related quality of life questionnaires 
are standardised and available to measure health related quality of life in asthmatic children 
(Fiese et al., 2005; Raat et al., 2006). Both generic and asthma-specific questionnaires are used 
to measure health related quality of life in school aged children. Generic health related 
quality of life questionnaires intend to measure all dimensions of health-related quality of 
life (Raat et al., 2006). Frequently applied generic health related quality of life questionnaires 
are: the Child Health Questionnaire (CHQ) (Gorelick et al., 2003), the Pediatric Quality of 
Life Inventory (PedsQL) (Varni et al., 2005), the TNO-AZL (Preschool) Children’s Quality of 
Life questionnaire (TAPQoL/TACQoL) (Bunge et al., 2005), the Infant-Toddler Quality of 
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Life (ITQOL) questionnaire (Spuijbroek et al., 2011) and the KIDSCREEN/DISABKIDS 
questionnaires (Petersen et al., 2005). Asthma-specific health related quality of life 
questionnaires focus on those dimensions that are likely to be affected by asthma disease or 
treatment. The most prominent asthma-specific health related quality of life questionnaires 
are the Pediatric Asthma Quality of Life Questionnaire (PAQLQ) (Juniper et al., 1996; Raat et 
al. 2005), the How Are You (HAY) (Le Coq et al., 2000) instrument and the Childhood 
Asthma Questionnaire (CAQ) (Christie et al., 1993). 
If children are unable to report about their own experience reliably, parents are appropriate 
sources of information about health related quality of life (Petsios et al., 2011). One study 
suggests that fathers may be better proxy reporters than mothers (Petsios et al., 2011). The 
correlation between child and parent reported quality of life improves with increasing age 
of the child (Annett et al., 2003). Although the agreement between child self-report and 
parent proxy report on health related quality of life has been showed as satisfactory, 
according to Petsios et al. (2011), parents may overestimate health related quality of life of 
their children with asthma. This has to be taken into account when interpreting results from 
parent reported health related quality of life questionnaires, in comparison with child self-
reports. 
The PAQLQ is the most frequently used disease-specific health related quality of life 
instrument with regard to childhood asthma. Therefore, using this instrument has the 
benefit for researchers that results can more easily be compared with previous findings. 
However, using the existing health related quality of life instruments may have some 
limitations. A recent study has investigated whether asthma-specific health related quality 
of life questionnaires actually include all relevant aspects of asthma-specific health related 
quality of life for children with asthma (Annett et al., 2003). They have found disagreement 
between distinct health related quality of life questionnaires on components of asthma-
specific health related quality of life: only some components of the asthma symptoms 
domain and of the activity limitations domain are part of all questionnaires. Furthermore, 
according to Van den Bemt et al. (2010), not all essential components of asthma-specific 
health related quality of life, according to childhood asthma, are part of existing asthma-
specific health related quality of life questionnaires. 
When classifying health related quality of life questionnaires into standardised and 
individualised health related quality of life instruments, another limitation is revealed. In 
standardised health related quality of life instruments the questions and range of answers 
are predetermined and the same for all patients. As opposed to standardised health related 
quality of life instruments, individualised health related quality of life instruments allow 
patients to define their quality of life in relation to their goals and expectations. Carr & 
Higginson (2001) conclude that standardised health related quality of life questionnaires 
have limited ability to capture the health related quality of life of individual asthma 
patients. 
The most appropriate approach to measure health related quality of life in asthmatic 
children would be to use a combination of parental and self-reports of both generic and 
asthma-specific health related quality of life by validated questionnaires (Raat et al., 2006). 
Whether such health related quality of life measures are truly patient centred and to what 
extent they actually represent the quality of life of individual or groups of asthmatic 
children should always be taken into account when one interprets study results (Carr & 
Higginson, 2001). 
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3. Impact of asthma on children’s health related quality of life 
Asthma might have physical, emotional and psychosocial impact on children’s lives 
(Grootenhuis et al., 2007; Juniper, 1997; Merikallio et al., 2005; Sawyer et al., 2004). Important 
components of health related quality of life are the effects on, and consequences of asthma 
on peer relationships (e.g., being bullied), the dependence on medication, shortness of 
breath, cough, limitations in activities and limitations due to the response on cigarette 
smoke exposure (Van den Bemt et al., 2010). Compared to preschool children without 
asthma symptoms, preschool children with asthma symptoms have significantly lower 
health related quality of life scores for lung problems, sleeping, appetite, communication 
and positive mood health related quality of life scales (Mohangoo et al., 2005). 
Most studies have focused on severity of symptoms to examine the impact of asthma 
symptoms on children’s health related quality life; the results are conflicting (Everhart & 
Fiese, 2009). For example, disease severity is not consistently associated with children’s 
health related quality of life in some studies (Erickson et al., 2002; Vila et al., 2003), whereas 
others report that children with moderate or severe asthma have a worse level of 
functioning in several domains of their health related quality of life compared to children 
with mild asthma (Annett et al., 2001; Merikallio et al., 2005; Mohangoo et al., 2007, 2011; 
Sawyer et al., 2000) suggesting there may be a ‘dose-response’ relationship between the 
frequency and intensity of children’s asthma symptoms and their health related quality of 
life. Mohangoo et al. (2007, 2011) evaluated health related quality of life in infants and 
adolescents with asthma-like symptoms, such as attacks of wheezing and shortness of 
breath (Mohangoo et al., 2007, 2011). Asthma-like symptoms during the first year of life are 
associated with impaired health related quality of life at the age of 12 months. Also, the 
presence of at least four wheezing attacks during the past year was associated with 
impaired adolescents’ health related quality of life. Frequent wheezing attacks mostly affect 
adolescents’ general health, bodily pain, self esteem and mental health (Mohangoo et al., 
2007). Previous studies have also found that wheezing attacks more often have a physical 
impact than a psychosocial impact (Merikallio et al., 2005). 
As described earlier, one of the main goals of asthma management is to achieve good 
asthma control. Asthma control has been defined as the minimisation of night time and 
daytime symptoms, activity limitation, rescue bronchodilator use and airway narrowing 
(Global Initiative for Asthma, 2010). Poorly controlled asthma symptoms impair health 
related quality of life in children (Guilbert et al., 2011). An important issue is whether proper 
asthma management improves quality of life in asthma patients, and whether poor health 
related quality of life makes disease management harder. Studies have found that poor 
health related quality of life is predictive of subsequent asthma-related emergency 
department visits, which implicates poor asthma control (Magid et al, 2004). Pont et al. (2004) 
show that proper asthma management improves health related quality of life. 
In short, children experience asthma as an interruption in daily life that influences them 
physically, emotionally and socially. 
4. Impact of children’s asthma on caregiver’s health related quality of life 
With childhood asthma, the family and particularly the primary caregiver may face a 
considerable burden. While there are several questionnaires for assessing 
parental/caregiver’s health related quality of life not directly related to asthma (Osman & 
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associated with impaired health related quality of life at the age of 12 months. Also, the 
presence of at least four wheezing attacks during the past year was associated with 
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adolescents’ general health, bodily pain, self esteem and mental health (Mohangoo et al., 
2007). Previous studies have also found that wheezing attacks more often have a physical 
impact than a psychosocial impact (Merikallio et al., 2005). 
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daytime symptoms, activity limitation, rescue bronchodilator use and airway narrowing 
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related quality of life in children (Guilbert et al., 2011). An important issue is whether proper 
asthma management improves quality of life in asthma patients, and whether poor health 
related quality of life makes disease management harder. Studies have found that poor 
health related quality of life is predictive of subsequent asthma-related emergency 
department visits, which implicates poor asthma control (Magid et al, 2004). Pont et al. (2004) 
show that proper asthma management improves health related quality of life. 
In short, children experience asthma as an interruption in daily life that influences them 
physically, emotionally and socially. 
4. Impact of children’s asthma on caregiver’s health related quality of life 
With childhood asthma, the family and particularly the primary caregiver may face a 
considerable burden. While there are several questionnaires for assessing 
parental/caregiver’s health related quality of life not directly related to asthma (Osman & 
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Silverman, 1996), there is only one instrument to examine the specific impact of childhood 
asthma on parental/caregiver functioning: The Pediatric Asthma Caregiver’s Quality of Life 
Questionnaire (PACQLQ) (Juniper et al., 1996).  
Whereas some studies find no association between caregiver’s health related quality of life 
and children’s asthma symptoms (Annett et al., 2003), duration of asthma illness and asthma 
pre-treatment severity (Vila et al., 2003), other studies report that caregiver’s and child’s 
health related quality of life are significantly associated with each other (Dean et al., 2009, 
2010; Garro, 2011; Halterman et al., 2004). Halterman et al. (2004) find that higher symptom 
levels with regard to childhood asthma are associated with lower parental health related 
quality of life. Further, when children’s symptoms improve, parents show higher health 
related quality of life. 
It should be considered how childhood asthma affects caregiver’s health related quality of 
life. Caregivers of asthmatic children appear to be more compromised in their resistance to 
stress, mood, emotional stability, amount of spare time and leisure activities (Garro, 2011). 
Caregivers of children with uncontrolled asthma report significantly higher absenteeism 
than their controlled counterparts (Dean et al., 2009, 2010). 
Both caregiver’s health related quality of life, caregiver’s perception of the child’s asthma 
symptoms, and the child’s health related quality of life may be important in diagnosis and 
control of established asthma in childhood (Skoner, 2002). While giving attention to the 
caregiver’s health related quality of life, it should be taken into account that the profile of 
health related quality of life impairment is different in asthmatic children and in their 
parents (Farnik et al., 2010). Where activity limitation seems to be the most impaired domain 
in children, asthma symptom perception and emotional health appear to be the most 
affected health related quality of life domains in parents.  
In addition to evaluation of the asthmatic child, the integral assessment of asthma requires 
the evaluation of caregiver’s health related quality of life. Giving attention to caregiver’s 
health related quality of life is needed in clinical practice in order to avoid possible 
interferences of the caregiver’s distress in the optimization of child’s asthma treatment 
outcomes (Majani et al., 2005). 
5. Factors associated with health related quality of life in asthmatic children 
As we described earlier, the frequency and severity of asthma attacks and effects of asthma 
management or treatment are associated with children’s health related quality of life. 
Researchers have also investigated other variables in association to health related quality of 
life in childhood asthma (Annett et al., 2003; Erickson et al., 2002; Mrazek, 1992; Sawyer et 
al., 2000, 2001). Hospital admissions, absences from school, limitations of sport and other 
activities, sleeping problems (and fatigue) are associated with health related quality of life in 
asthmatic children (Mrazek, 1992). Erickson et al. (2002) show that both asthma morbidity 
and health related quality of life are related to socioeconomic status. Also, household 
income is most consistently associated with the health related quality of life of asthmatic 
children and their caregivers. Sawyer et al. (2001) report the impact of family functioning on 
health related quality of life in children with asthma. They have found that the degree to 
which children are upset by their asthma is related to general functioning of their families, 
and their symptom levels are associated with several dimensions of family functioning 
(Sawyer et al., 2000, 2001). Children living in families with more clearly defined roles, 
greater interest and concern for the well-being of each other and clearer rules have been 
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found to be less bothered by their asthma symptoms (Sawyer et al., 2000). A study by 
Annett et al. (2003) didn’t find an association between health related quality of life of 
asthmatic children and family functioning, measured by the degree of cohesion among 
family members. 
Results suggest that several factors may impact health related quality of life of asthmatic 
children. Important predictors of the health related quality of life of asthmatic children are 
socioeconomic status and family functioning. These findings implicate the need of specific 
attention to health related quality of life in asthmatic children from families with low 
socioeconomic status and poor family functioning. 
6. Conclusion 
Health care workers should be aware of the impact of asthma on children’s life, their 
families and the factors associated with the health related quality of life of these children. 
Routine use of an health related quality of life questionnaire to evaluate health related 
quality of life in children with asthma symptoms and their caregivers should be 
recommended in health care. Specific application, for example, can be found in preventive 
child health care and in primary health care to prevent impairment of health related quality 
of life due to asthma symptoms and to realise adequate management of asthma symptoms. 
Attention should be given to health related quality of life in asthmatic children from families 
with low socioeconomic status and poor family functioning. Generally, a combination of 
parental and self-reports of both general and asthma-specific patient centred health related 
quality of life questionnaires should be applied. Further research should focus on which 
factors are responsible for the greatest burden on asthmatic children’s health related quality 
of life and their caregivers’ health related quality of life and how such risk factors should be 
prevented and managed. 
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1. Introduction 
Despite the current knowledge, the mechanisms by which the specific immunotherapy 
(SIT) achieves clinical improvement remains unclear. However, it is now clear that the 
immune tolerance is one of the major targets of this kind of treatment. Immune tolerance 
depends on different mechanisms, including T-cell anergy, T-cell depletion by apoptosis, 
and active immune suppression (Akdis & Akdis, 2011). One of the goals of SIT is the 
induction of tolerance to allergens to which the patient is sensitized. IL-10 is probably a 
relevant cytokine induced by this treatment and is associated to regulatory T cells (T-regs) 
that actively control or suppress the function of other cells, generally in an inhibitory 
pattern (Frew, 2010).  
The changes in microenvironment due to the decrease in histamine and PGE2 release by mast 
cell, and the IL-10 and TGF- release by dendritic cells (DC) could switch the T-cell population 
into T-regs. These alterations will then lead to tolerance (Schmidt-Weber & Blaser 2005).  
Much of the knowledge about SIT has been based on studies using subcutaneous route of 
administration (SCIT), but increasing data is now available based on studies using 
sublingual immunotherapy (SLIT).  
The sublingual mucosa, where the deposition of the extract occurs, has very particular 
characteristics, quite different from the cellular subcutaneous tissue. The dendritic cells 
present in the buccal region are distinct from the Langerhans cells present in the skin. These 
cells present, constitutively, receptors with high affinity for IgE, FcRI+, MHC class I and II 
molecules, as well as co-stimulation molecules, namely CD40, CD80/B7.1 and CD86/B7.2 
(Allam et al., 2006). There is also expression of CD14, a lipopolysaccharide (LPS) receptor, 
which is relevant for the modulation of Th2 and Th1. 
In SLIT, the allergen is captured by the DC cell by C-lectin endocytosis receptors and/or by 
ligation to the IgE on the surface. After the internalization, the migration to the regional 
lymphoid nodules occurs, and it is then presented to the T cells (Geijtenbeek, 2006). A study 
that compares the DC population in the oral and nasal mucosa was able to demonstrate that 
only the DC myeloid type is profusely present in the oral region, in contrast with the nasal 
mucosa where both populations are present (Allam et al., 2006). Another very important 
difference is the high expression levels of FcRI in the oral mucosa, which is almost absent in 
the skin’s Langerhans cells (Allam et al., 2003). Furthermore, the expression levels of MHC 
class I and II molecules, CD40, CD80 and CD86 is significantly higher in oral DC than in the 
skin. 
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The integrity of the lamina propria in the oral mucosa, along with the highly reduced 
population of mast cells, eosinophils and basophils, are the factors that limit the contact of 
the allergen with submucosal areas or with circulating blood cells. All of these together 
constitute the excellent security profile characteristic of the SLIT (Moingeon et al., 2006). The 
DC seems to be crucial in the induction of the tolerance profile due to the production of IL-
10 and TGF- after activation, as well as an increase in indoleamine dioxygenase type 2 
(IDO), necessary to the decrease in T cells proliferation. 
The allergen absorption through the intact mucosa and the interaction with local dendritic 
cells could switch on the process leading to immune-tolerance. In addition to the local effect, 
the swallowed allergen could induce a supplementary outcome based on a GALT-related 
mechanism (Akdis et al., 2001). In fact, the first method of sublingual administration of SIT, 
in which the allergen was spat out, was significantly less effective. Most of the 
immunological changes and mechanisms that occur with sublingual administration of high 
allergen dosage have been recently demonstrated (Moingeon et al., 2006).  
The aqueous extracts are highly effective, but induce more side-effects (local and systemic) 
than depot and modified vaccines (Larché et al., 2006). These have been developed in an 
attempt to reduce or remove allergenicity, while preserving or increasing the 
immunogenicity (Casanovas et al., 2005). Aqueous subcutaneous SIT is now the gold 
standard treatment for hymenoptera venom allergy and depot aeroallergen extracts for 
respiratory allergy (Wheeler & Woroniecki, 2004). The use of chemically modified allergens 
is not consensual. Although recent papers demonstrate a clinical benefit with allergoid 
therapy (Ibarrola et al., 2004), double blind placebo controlled studies comparing both 
extracts are still missing. On the other hand, the sublingual-swallowed administration of SIT 
in higher dosages had a clinical efficacy entirely demonstrated with similar immunological 
effects, namely the increase in allergen-blocking IgG, the induction of IgE-modulating CD8+ 
T cells, the reduction of mast cells and eosinophils on the target mucosa, the decrease in 
inflammatory mediators, and a modulation on the inflammatory trafficking cells by reduced 
expression of adhesion molecules (Bousquet, 2006). 
2. Kinetics of immunotherapy mechanism 
The studies on the dynamics of SIT are of extreme relevance, because they represent the 
only approach available to define, on a biological point of view, the mechanism by which 
the therapeutics works. Despite the current advances contributing to the wide knowledge of 
the modulator effect, these studies are extremely rare, as a result of several ethical, technical 
and economical boundaries. Furthermore, there are also several difficulties in transposing 
the results from experimental studies using laboratory animals to Humans.  
In a study using mice, the systemic activity of a modified aeroallergen, an allergoid 
administrated sublingually, was shown (Mistrello, 1994). However, before the study of an 
Italian group from Genoa in 1997, the kinetics and dynamics of the allergen in Humans was 
not known (Bagnasco, 1997). This study had the merit of assessing the response of the 
sublingual administration of a radioactively labeled allergen in a group of 9 healthy 
individuals (Bagnasco, 1997). Par j 1, the major Parietaria judaica allergen, was labeled with 
123I. In respect to the sublingual route, the application and deposition of the labeled allergen 
in 3 individuals was monitored for a period of 30 minutes before deglutition, by the 
acquisition of static images in the following 1, 2, 3, 5, 24 and 48 hours. In parallel, blood 
draws were collected for the determination of the radioactive counts at 5, 10, 20, 30 and 60 
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minutes, and then at 2, 3, 5 and 24 hours after the administration. A quantification of the 
same parameters in the urine was also performed. This study was able to demonstrate that 
the allergen was not degraded by the saliva and interestingly that there was no absorption 
by the sublingual mucosa. 
The plasma radioactive activity only occurs after the deglutition of the allergen. Another 
surprising fact is that an enormous radioactive activity of the labeled allergen in the sublingual 
region is still detected, even after 48hours and despite the deglutition. Furthermore, the study 
also compared the same methodology either with nasal and oral (immediate deglutition) 
administration. The results from the application of the allergen in a nasal pulverization 
demonstrated activity in the superior region of the pharynx and proximal esophagus, and 
persistence of the labeled allergen until 36hours, with no bronchial deposition, but having 
activity in the plasma since the beginning. The oral route is simultaneous to the detection of 
immediate activity in the plasma, characterized by a pick at 2hours, followed by a decline, but 
with no identification of the labeled allergen. Probably there is protein degradation and only 
small peptides are absorbed at the level on the intestinal mucosa. 
These results, done afterwards by the same group and obtained from healthy individuals, 
were crucial for the evaluation of the kinetics and dynamics of the allergen administration in 9 
allergic patients with rhinitis (Bagnasco, 2001). The study compared the different alternatives 
of sublingual administration of the Par j 1 allergen labeled with 123I. Namely non-modified 
allergen solution (drops), non-modified allergen in pills and modified allergen (allergoid) also 
in pills. The patients were monitored with dynamic acquisition in the first 20 minutes and 
static acquisitions of 5 minutes every hour until the 16th hour. Serial blood draws were also 
collected in order to quantify the radioactive plasmatic activity. The results confirmed 
persistent radioactive activity at the local of the administration of the allergen. For all the 
extracts, the plasmatic activity only occurs after deglutition. With the allergoid, the activity is 
higher, probably dependent of a lower enzymatic degradation and consequent lower 
possibility of intestinal absorption. The acquisitions in a gamma-rays camera only visualizes 
the activity after deglutition (1-5 minutes later), in the pharyngeal and esophagic region. 
The same group of investigators studied the kinetics of the intranasal administration of Par j 
1 labeled with 123I in a group of 3 patients with allergic rhinitis, using a similar methodology 
although with distinct time points (Passalacqua, 2005). The radioactive activity in the nasal 
region disappears rapidly in allergic patients when compared to healthy individuals. The 
clinic inflammation controlled by the administration of the therapeutic allergen in these 
patients may condition an increase in the depuration or clearance of the mucosa. Plasmatic 
activity is also observed after an effective deglutition of the allergen. Despite the reduced 
number of patients used to conducted this study, the results are significantly distinct from 
the results observed when using  the sublingual route, in which the radioactive activity 
persist at the local of administration, long after the deglutition of the therapeutic extract 
(Bagnasco, 2001).  
The same Italian group responsible for the study with allergens administrated by non-
injectable routes prompt the question of whether the results obtained up until that moment 
were restricted to specific characteristics of Parietaria judaica. Following this, the group 
published another study using a major allergen from Dermatophagoides pteronyssinus, the Der 
p 2 (Bagnasco, 2005). For the 7 patients with allergic rhinitis, the results were analogous to 
the ones mentioned above. This lead to the conclusion that the persistence of the radioactive 
activity at the local of administration of the allergen and the systemic absorption after the 
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deglutition is independent of the allergen used in the treatment and the chemical 
modification used. 
The studies regarding the kinetics and dynamics of immune-therapy administrated by non-
injectable routes were pioneer, even though its implementation was substantially more 
recent than conventional route, and interestingly they included the nasal route, which had 
no scientific validation for its efficacy (Bousquet, 1998; Alvarez-Cuesta, 2006). In respect to 
the subcutaneous route, our group has published in 2004 the first in vivo results regarding 
the dynamics of SIT in patients with allergic disease (Pereira, 2004). 
3. Dynamics of the immunotherapy mechanism 
The radioactive labeling of an allergen from the therapeutic extract is possible, but it would 
be restricted, exclusively, to one protein only. This could have been a strategy to evaluate 
the dynamics of the biological response to SIT. However, for patients under a maintenance 
treatment, the exclusion of some allergenic epitopes present in the therapeutic extracts 
would condition the interpretation of the results. Furthermore, it could, eventually, change 
the immunogenic structure of that epitope and as a consequence, the immune response that 
was induced. In these studies, the administration of the allergen extract, according to the 
maintenance scheme in place for each patient, would occur simultaneously with the 
reinjection of leucocytes labeled with 99mTc-HMPAO. The labeling of leucocytes with 99mTc-
HMPAO is a technique that, on the theoretical level, has affinity for all the cellular elements 
of the white series (mononuclear and polymorphonuclear) and all of these have a specific 
contribution in the inflammatory process (Kumar, 2005; Peters, 1986).  
The therapeutic allergenic extract injections always induce an inflammatory reaction at the 
local of the administration, detectable clinically by the presence of typical local signals. In 
the maintenance treatment, these symptoms have variable intensity and depend not only on 
the type of extract but also on the severity of the basal clinical features (Alvarez-Cuesta et 
al., 2006). The modified extracts and the extracts administrated sublingually are the ones 
that induce minor local secondary effects, as mentioned before. Therefore, although in a 
limited and controlled way, the SIT leads to an effective inflammatory allergic reaction in 
the area where the extract is applied, despite all the relevant immune-modulator 
mechanisms, which at the moment are well established for this therapeutic.  
This local inflammatory allergic reaction will be, presumably, responsible by the dynamics 
of a response highly similar to the one observed in the allergic response in general (Pereira, 
2009). Therefore, it can be admitted that the autologous reinjection of leucocytes will have a 
migration at that level by mechanisms dependent on the IgE-mediated mast cells activation 
(Bousquet, 1998; Alvarez-Cuesta et al., 2006). 
3.1 Patients studied 
Seventeen adult volunteer allergic patients were selected, 15 of them under maintenance 
therapeutic with specific immunotherapy. All were under a regular and programmed 
follow-up at the Immunoallergology department for the treatment of allergic pathology: 
respiratory allergy (bronchial asthma and rhinitis) and anaphylaxis (latex or hymenoptera 
venom). Until the date of selection of the patients, this treatment scheme has demonstrated 
clinical efficacy, translated by the complete remission of the symptoms, absent regular and 
preventive anti-allergic medication, no need of symptomatic medication in periods of 
worsening of the symptoms. Along with these criteria, it was also taken into account the 
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favorable evolution of the laboratory parameters, namely reduction of the cutaneous 
reactivity to the responsible allergen by allergic diathesis in cutaneous prick tests using 
standardized extracts, and the reduction in the levels of the serum specific IgE, relatively to 
the beginning of the treatment. For the study of the dynamics of this therapeutic, samples 
from patients using different routes of administration of SIT and different allergenic extracts 
were also included. Patients were selected according to the type of allergen extract and route 
of administration of the SIT (Table 1). 
 
Subcutaneous Administration Route 
 Aqueous subcutaneous extract (anaphylaxis) 
 4 patients: latex extract 
2 patients: Apis mellifera extract 
Subcutaneous depot extract (respiratory allergy) 
 2 patients: D pteronyssinus extract 
2 patients: pollen from Poaceae extract 
Subcutaneous modified allergen extract (respiratory allergy) 
 1 patient: pollen from Poaceae extract 
1 patient: pollen from Parietaria judaica extract 
Sublingual Administration Route (respiratory allergy) 
 2 patients: D pteronyssinus extract 
1 patient: pollen from Parietaria judaica extract 
Table 1. Patients under a specific immunotherapy treatment (extract, route of administration 
and allergic disease) 
The control group included 2 patients allergic to Dermatophagoides pteronyssinus, with 
asthma and rhinitis, non-submitted to SIT and controlled with daily inhaled corticotherapy 
(fluticasone furoate). None of the selected patients presented any other concomitant 
pathology, namely inflammatory, which could interfere with the interpretation of the 
results. Furthermore, neither of the patients was under any other medication, besides the 
ones mentioned. All female patients were submitted to a quick urinary test to exclude 
pregnancy. All the studies were conducted under strict hospital vigilance, and the day of the 
immunotherapy administration was exactly the one previously defined in the maintenance 
therapeutic scheme. This study was, obviously, submitted for the approval of the Ethics 
Committee of the Institution, according to the “Declaration of Helsinki” of the World 
Medical Association (Helsinki 1964; Tokyo 1975; Venice 1983; Hong-Kong 1989). 
3.2 Methodology for this study 
A standard technique was used for the labeling of circulating leucocytes with 99mTc-
HMPAO (Peters, 1986). 
The allergen extracts used in the patients with subcutaneous immunotherapy (aqueous and 
depot) or submitted to sublingual Dermatophagoides pteronyssinus treatment were produced 
by the ALK-Abelló Laboratory (Madrid, Spain). For another patient in SLIT, the Parietaria 
judaica extract was provided by the Stallergenes Laboratory (Paris-France). In respect to the 
SCIT with modified extracts (allergoid), the glutaraldehyde-modified extract from pollens of 
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Poaceae was supplied by BIAL-Aristegui Laboratory (Bilbao, Spain) and the Parietaria judaica 
extract modified by depigmentation was provided by the Leti Laboratory (Madrid, Spain).  
The maintenance dosage to which the patients were submitted on the day of the study 
corresponded to the one established on their treatment scheme, and was administrated on 
the pre-defined schedule. Two controls non-submitted to SIT with respiratory allergy to 
Dermatophagoides pteronyssinus were also studied. They were submitted, respectively to: 
-0,5cc of bacterial aqueous extract by the subcutaneous route, immune stimulant inductor of 
a IgG response (Ribomunyl ®, Pierre Fabre Médicament, France), containing ribosomal 
fractions of Klebsiella pneumoniae, Streptococcus pneumoniae, Streptococcus pyogenes, 
Haemophilus influenzae and membrane fractions of Klebsiella pneumoniae. 
-0,5cc of phenolated aqueous solution administrated by the subcutaneous route, diluting the 
solution from the ALK-Abelló Laboratory (Madrid, Spain). 
Patients were positioned in dorsal decubitus, under a gamma camera. The puncture of the 
cubital vein with a caliber 14 catheter allowed the reinjection of the autologous leucocytes 
labeled with a radio-labeled pharmaceutical compound in fast bolus, followed by a venous 
wash with physiological serum. Simultaneously, the allergenic extract was administrated 
subcutaneously, according to the usual technique (Bousquet  et al., 1998)  in the external 
surface of the arm contralateral to the administration of the labeled cells. Both injections 
occurred at the same time, simultaneously to the beginning of the scintigraphic acquisition. 
The 3 allergic patients submitted to SLIT were placed in dorsal decubitus under a gamma-
rays camera, and drops containing the allergenic extract were administrated at the same 
time that the reinjection of radio labeled leucocytes in the cubital vein was performed. Three 
minutes later the allergen was swallowed, according to the usual protocol. 
For the control group, the subcutaneous administration of the saline solution and the 
bacterial extract were performed the same way as for the patients in the active group.  
In all the studies, the residual activity of the syringe containing the autologous cells that 
were reinjected was assessed, in order to quantify the radioactive dosage effectively 
administrated. The scintigraphic studies were performed under a gamma rays camera (GE 
XR, Milwaukee, USA) using a low energy and parallel cavities collimator coupled to a 
Camstar acquisition unity and to a eNTEGRA processing unity. The dynamic acquisition 
was obtained in an anterior side view of the head and neck to 64x64 resolution matrixes 
during 60 minutes (120 images x 30 seconds), followed by a static study at 60, 120, 180, 240, 
300 and 360 minutes after the administration of the allergen and leucocytes labeled with 
99mTc-HMPAO, during 5 minutes for each acquisition (256 x 256 resolution elements). The 
static images were obtained in anterior and posterior side views for the following 
projections: head and neck, thorax and abdomen. During the acquisitions, patients were 
asked to remain at rest, despite the induction of nasal symptoms, in order to maintain the 
geometry of the projections, and at the same time minimizing the distance to the detector. 
A qualitative evaluation of the images obtained in the dynamic acquisition was then 
performed, either by sequential analysis or using a video of 120 images. The moment in 
which the activity in the nasal region started was determined, as well as the local of the 
administration and the subsequent focalizations of the inflammatory activity that was 
induced. In the same way, a qualitative evaluation of the focalized inflammatory activity on 
defined timings for the static acquisition was performed. For the quantitative results, a 
different approach was chosen, in respect to the type of image in study. For the dynamic 
images obtained from the head and neck, the regions of interest were drawn (ROIs, region of 
interest) at the local of the administration of the allergen extract and /or controls, the 
background area (muscle) and also the following areas: oropharynx, cranial calotte and 
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cervical lateral-external region of the neck. The dynamic acquisition was obtained in 
anterior view of the thorax and neck for matrixes with a resolution of 64 x 64 elements, 
during 60 minutes (120 images x 30 seconds), followed by a static study at 60, 120, 180, 240, 
300 and 360 minutes for 5 minutes each acquisition (256 x 256 elements of resolution), after 
the administration of leucocytes labeled with 99mTc-HMPAO and the therapeutic allergen. 
The static images were obtained in anterior and posterior view for the thoracic projection 
and in anterior view for the abdominal projection.  
A qualitative study of the images obtained in dynamic acquisition was then conducted by a 
sequential analysis or in a video of 120 images. The moment of the beginning of the activity 
at the local of the administration of the extract and in subsequent focalizations of the 
inflammatory activity that was induced was then determined. In the same way, a qualitative 
evaluation of the inflammatory activity focalized at defined timings for the static acquisition 
was performed. For the quantitative analysis a different approach was taken, regarding the 
type of image in study. For the dynamic thoracic images, ROIs were draw at the local of 
administration of the allergen and/or controls, as well as in the background area (muscle) 
and in possible focalizations (cervical, armpit and thoracic). For each ROI the total values, 
the average per pixel and the maximum values were determined. The uptake coefficient 
(UC, uptake coefficient ROI) was then calculated as the ratio between the maximum 
measurements of each ROI and the average value in the background area. For a best 
accuracy of the results it was also calculated the corrected uptake coefficient (UCC, corrected 
uptake coefficient ROI) by subtracting the uptake coefficient ROI in the background from the 
uptake coefficient ROI for each of the areas analyzed. 
3.3 Results 
The qualitative and quantitative results from patients submitted to specific treatment will be 
presented. 
3.3.1 Qualitative results 
All images from patients submitted to SIT were interpreted by analyzing the images with 
the same color scale, Figure 1. These crescent colors (from black to white) translate the 
inflammatory activity induced by the therapeutic action. 
 
 
Fig. 1. Color scale from minimum activity (black) to maximum activity (white). 
The studies regarding each type of SIT in analysis, namely regarding the type of extract and 
route of administration, are presented here (Figures 2 – 7). Besides the static images for the 
acquisitions of the thoracic and abdominal side view of each of the exemplified patients, an 
image from the dynamic sequence corresponding to the time point in which the beginning 
of the anti-inflammatory activity is observed at the site of administration of the extract will 
be presented. Furthermore, images obtained from two control patients will also be 
presented, namely with administration of a saline phenolated solution (SS) and a bacterial 
extract (BE). In all the studies the hepatosplenic region should be considered as an image of 
subtraction that should not be taken into account or interpreted. The spleen since it 
sequesters labeled erythrocytes, even though at residual levels, but always present in the 
pellet of isolated cells; the liver because it represents the preferential location for 
metabolization of the radio labeled pharmaceutical compound. 
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Fig. 2. Scintigraphic study of patient C1, control, with respiratory allergy to Dermatophagoides 
pteronyssinus, submitted to subcutaneous injection with bacterial extracts. Panel A shows the 
beginning of the activity at the external side of the arm after 45 minutes. Panels B and C show, 
respectively, thoracic and abdominal static acquisitions, in an anterior view. 
For patient C1, submitted to subcutaneous injection with bacterial extract (BE), at 45 minutes 
we can observe inflammatory activity focalized at the site of administration. Furthermore, 
we observe focalizations, in the static studies, with inflammatory activity in bone structures 
(humeral head and iliac crest), as well as in the suprasternal region. The activity observed in 
the sternum and spinal cord (in anterior side view, not shown) should be interpreted with 
caution since there are superimposed structures with potential involvement. We do not 
observe intrapulmonary or intra-abdominal (intestinal) focalizations. 
Regarding patient C2, submitted to subcutaneous injection of phenolate saline solution (SS) 
in the external face of the right arm, we notice minimum activity 50 minutes after the 




Fig. 3. Scintigraphic study of patient C2, control, with respiratory allergy to 
Dermatophagoides pteronyssinus, submitted to subcutaneous injection with phenolate saline 
solution. Panel A shows the beginning of the activity at the external side of the arm after 50 
minutes. Panel Panels B and C show, respectively, thoracic and abdominal static 
acquisitions, in an anterior view. 
 




Fig. 4. Scintigraphic study of patient 6 (anaphylaxis to Apis mellifera), submitted to 
subcutaneous injection with aqueous extract. Panel A shows the beginning of the activity at 
the external side of the arm after 35 minutes. Panel Panels B and C show, respectively, 
thoracic and abdominal static acquisitions, in an anterior view. 
For the patient (Figure 4), under treatment for anaphylaxis to hymenoptera venom, we 
observe inflammatory activity earlier at the local of administration of the therapeutic allergen 
extract, but the systemic involvement is also observed in all of the posterior scintigraphic 
images. Higher activity was detected in the bone structures, when compared to patient 3 with 
anaphylaxis to latex. We did not detect intra-abdominal (intestinal) focalizations in this 
patient. For these patients, as well as for all the other studies, the sternum bone structures and 
spinal cord will not be interpreted because of all the reasons already discussed. 
For the patient allergic to pollens (Figure 5), the beginning of the inflammatory activity was 
detected at 35 minutes on the site of administration of the therapeutic extract. A systemic 
involvement in all the acquisitions was observed. In the armpit homolateral to the injection 
of the extract, we detect activity that persists throughout the study, similar to what 
happened in the cervical-lateral region of the neck. In the intestinal area we only observe 
focalizations at 60 and 120 minutes. 
 
 
Fig. 5. Scintigraphic study of patient 8 with respiratory allergy (asthma and rhinitis) to grass 
pollen submitted to subcutaneous injection with depot extract. Panel A shows the beginning 
of the activity at the external side of the arm after 35 minutes. Panel Panels B and C show, 
respectively, thoracic and abdominal static acquisitions, in an anterior view. 
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Fig. 5. Scintigraphic study of patient 8 with respiratory allergy (asthma and rhinitis) to grass 
pollen submitted to subcutaneous injection with depot extract. Panel A shows the beginning 
of the activity at the external side of the arm after 35 minutes. Panel Panels B and C show, 
respectively, thoracic and abdominal static acquisitions, in an anterior view. 
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For patient on figure 6, the inflammatory activity at the site of administration of the 
allergoid extract is highly reduced, when compared to the patients previously described. 
The systemic activity persists in all the structures considered, including the intra-abdominal 
area, from minute 60 to 120. 
 
 
Fig. 6. Scintigraphic study of patient 11 with respiratory allergy (asthma and rhinitis) to 
grass pollens, submitted to subcutaneous injection of a glutaraldehyde modified extract. 
Panel A shows the beginning of the activity at the external side of the arm after 50 minutes. 
Panel Panels B and C show, respectively, thoracic and abdominal static acquisitions, in an 
anterior view. 
The SLIT administration induced a very precocious beginning of activity when compared to 
the subcutaneous route. Patient from Figure 7, submitted to treatment with D pt extract, the 
inflammatory activity in the oropharynx occurred 3 minutes after the administration of the 
drop extract. We also observed a more relevant involvement of the cervical-lateral structures 
of the neck, which persisted throughout the trial. The systemic involvement was also present 
in this patient in different structures: intrapulmonary, bones and suprasternal region. 
 
 
Fig. 7. Scintigraphic study of patient 13, with respiratory allergy (asthma and rhinitis) to 
Dermatophagoides pteronyssinus, submitted to sublingual administration. Panel A shows the 
beginning of the activity in the oral region after 3 minutes. Panel Panels B and C show, 
respectively, thoracic and abdominal static acquisitions, in an anterior view. 
 
Specific Immunotherapy and Central Immune System  
 
385 
3.3.2 Quantitative analysis 
All the scintigraphic studies were submitted to a quantitative evaluation in order to 
determine the corrected uptake coefficients. ROIs were draw in the areas with focalized 
activity, which included: local of administration of the allergenic extract, suprasternal 
region, humerus head and iliac crest. Besides this, every time intra-abdominal (intestinal) 
focalizations were present, the respective UCCs were calculated. Naturally, for each 
projection a ROI in the muscle area was draw, representing the background area.  
 
 
Fig. 8. Corrected uptake coefficients in the region of the administration of the allergenic 
therapeutic extract for the subcutaneous injectable treatments (1. Dynamic; 2. Static) 
throughout the study (expressed in minutes). A: aqueous extracts; B: depot extracts; C: 
chemically modified extracts (allergoid). 
The beginning of the inflammatory activity for patients submitted to SCIT was different 
between the groups of patients in this study. The aqueous extracts for the treatment of 
anaphylaxis were the ones that induced higher UCCs, both in the dynamic and static 
evaluations. However, for the same type of extract, it seems that there are no relevant 
differences in respect to the type of allergen in the treatment, Figure 8. 
Patients under treatment with the depot extracts showed intermediate levels between 
patients with aqueous extracts and allergoid. However, we should emphasize that a patient 
under depot extracts to dust mites showed a highly reduced UCC at the spot of the 
therapeutic injection, as well as a patient under treatment with pollinic extract modified 
with glutaraldehyde. The control patient submitted to BE, showed very significant UCCs at 
the local of administration in the evaluations made after the first 60 minutes. On the other 
side, for the patient submitted to SS, the quantification of the activity at the local of injection 
persisted always in much reduced levels.  
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For patients submitted to treatment with SLIT, the inflammatory activity is detected very 
early in the process, and persists throughout time at relatively constant levels, Figure 9. The 
patients allergic to dust mites showed higher levels when compared to the patient allergic to 
Parietaria judaica. However, for this patient, the study took place during the pollinic period, 
and therefore a reduced therapeutic dosage was administrated, which can justify, 
eventually, the results obtained.  
 
 
Fig. 9. Corrected uptake coefficients in the region of the administration of the sublingual 
allergenic therapeutic extract throughout the study (expressed in minutes). 1. Dynamic; 2. 
Static 
The area located above the sternal furcula presented an early inflammatory activity, even 
during the dynamic studies. Since this region includes an extremely rich set of vascular 
structures, the effect of leukocyte recirculation maintained in the beginning of the study 
cannot be excluded. Therefore, it was decided to only evaluate the coefficients acquired with 
the static studies, Figure 10. Globally, the results are substantially higher than the control 





Fig. 10. Corrected uptake coefficients, taken at different time points during the experiment 
(minutes), obtained in the suprasternal region after the administration of the therapeutic 
extract. A: aqueous extracts; B: depot extracts; C: chemically modified extracts (allergoid); D: 
sublingual extracts 
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The evaluation of the UCCs in the bone structures localized in the humeral head and iliac 





Fig. 11. Corrected uptake coefficients, taken at different time points during the experiment 
(minutes), obtained in the iliac crest after the administration of the therapeutic extract. A: 
aqueous extracts; B: depot extracts; C; chemically modified extracts (allergoid); D: 
sublingual extracts 
The coefficients obtained in the two bone structures were similar and, globally, there was an 
apparent progressive increase throughout the experiment. However, regarding the type of 
extract and the method of administration, there wasn’t a characteristic profile of the 
inflammatory activity in these structures. For the motives previously expressed, no other 





Fig. 12. Comparative results of the UCC obtained for the suprasternal of patients submitted 
to aqueous extracts (SCIT1) for the treatment of anaphylaxis; depot and allergoid extracts 
(SCIT2) for the treatment of respiratory allergy and sublingual aqueous extracts (SLIT), also 
for the treatment of respiratory allergy. The results obtained for control patients submitted 
to injection of bacterial extract (BE) or phenolated saline solution (SS). For all patients, 
samples were collected at 60, 180 and 360 minutes. 
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Fig. 13. Comparative results of the UCC obtained for the iliac crest of patients submitted to 
aqueous extracts (SCIT1) for the treatment of anaphylaxis; depot and alergoids extracts 
(SCIT2) for the treatment of respiratory allergy and sublingual aqueous extracts (SLIT), also 
for the treatment of respiratory allergy. The results obtained for control patients submitted 
to injection of bacterial extract (BE) or phenolated saline solution (SS). For all patients, 
samples were collected at 60, 180 and 360 minutes. 
In the inflammatory focalization dependent of the ROI from the suprasternal region, no 
prevalence for a type of extract or method of administration of the treatment seems to exist, 
Figure 12. Similarly, it can be observed an increase in UCCs throughout the experiment. The 
same considerations can be applied to the inflammatory activity induced in the iliac crest, 
Figure 13. 
3.4 Discussion 
The administration of an allergenic therapeutical extract induces, always, an inflammatory 
reaction at the administration site that is characterized by the presence of clinically validated 
local symptoms. The modified extracts and the extracts delivered sublingually are the ones 
that induced lower secondary effects, as previously described. Although the main 
immunomodulator mechanism is already well established in SIT, it can dictate, in a limited 
and controlled approach, the effective inflammatory allergic reaction at the administration site. 
Therefore, we can admit that the autologous reinjection of leucocytes will have a migration 
dependent of the mast cell activation mediated by IgE (Togias, 2004; Kelly, 2007). This local 
inflammatory allergic reaction is, presumably, responsible for the dynamics of a response 
similar to allergy. Regarding the lymphocyte population, the circulatory migration to the 
tissue where the specific allergic reaction took place, is mediated by the expression of 
specific adhesion molecules that specify the type of cell implicated in the migration to the 
tissue (Togias, 2004). The migration of Th2 cells is associated to the expression of VCAM-1 
and P-selectin, under effect of IL-4 and IL-13, that depends on the activation of lymphocyte 
transduction signals by transcription factors similar to STAT6 (Lukacs, 2000). On the other 
hand, the migration of Th1 cells seems to be dependent on the expression of STAT4, due to 
the effect of IL-12, and associated to the RANTES and ICAM-1 mechanism. In an interesting 
study with intradermic injection of allergenic peptides without the ability to induce an IgE 
response, it was possible to observe lymphocyte trafficking from the vascular department 
(Haselden, 1999). Also, the intervention of T-reg cell in the mechanisms of 
immunomodulation of SIT are well established either by inducing the population of Th1 
cells or reducing the number of Th2 (Woodfolk, 2007; Francis, 2003). 
Nevertheless, in these cells, it is not clear which is the specificity towards the allergen or 
what is the eligibility of the method of the induction (systemic or inhaled). Furthermore, it 
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was also not clear what is the dosage required for induction or what type of regulatory cells 
are induced (natural T-reg produced by the thymus and with an effect dependent of cellular 
contact or adaptive T-reg cells induced on the periphery and with the effect dependent of 
IL-10 or TGF-β) (Woodfolk, 2007). At the same time, other lymphocytes, such as CD8+ e 
NKT cells, have the ability to respond to the allergen and represent other vectors involved in 
the SIT mechanisms (Woodfolk, 2007, Agea, 2005)). 
As previously mentioned, DCs are considered central cells in inflammation and immune 
tolerance often reported in the SIT mechanisms. These cells represent the antigen presenting 
cells (APC) that, after migrating to the regional lymph node, induce an effective and 
differentiated immune response. Nevertheless, this is a very heterogeneous and diversified 
population, ubiquitously present, although in a reduced number when compared to other 
resident or circulation populations (von Bubnoff, 2002; Novak, 2004). Furthermore, it is 
known that myeloid DC cells can migrate from the blood to the tissues in order to capture 
antigens (Novak, 2004; Schmit-Weber, 2002, Allam, 2003). In specific situations, and under 
appropriated stimulus, the peripheral monocytes can differentiate into myeloid DC (von 
Bubnoff, 2002). 
The skin and sublingual mucosa are, naturally, distinct. Therefore the mechanisms derived 
from the administration of the therapeutical allergenic extract should reflect this difference. 
The Langerhans cell (LC) is a DC myeloid cell (DC1) and are the most representative APCs 
in the skin. After a correct local stimulus, the monocyte chemotactic protein (MCP) 
determines the recruitment of LC progenitors from the bone marrow to the skin and the 
subsequent migration to the peripheral lymph nodes (Novak, 2004). The DC in the oral 
mucosa presents differences relatively to the skin, namely it expresses a higher number of 
MHCI and MCHII molecules, as well as the co-stimulation molecules CD40, CD80 and 
CD86 and also more FcγRIII (CD16), FcγRI (CD64) and FcεRI receptors (Allam, 2003). 
Several lymphoid structures are present in the oropharynx: tonsils, lymphatic ganglions and 
diffuse lymphoid tissue (Bienestock, 2005). It is well established that plasmacytoid DCs 
(DC2) are the APC most abundant in the Waldeyer’s tonsillar ring and in the ganglion areas 
dependent on T cells, but that these cells are unable to effectively internalize the antigen 
(Novak, 2004). This is surely, a biologic characteristic of this region with consequences on 
the immune response on this area. 
The subcutaneous tissue is, undoubtedly, composed by a population of resident cells that 
are biologically less active that the ones present in the oral mucosa. Nevertheless, the 
therapeutical administration of allergenic extracts by both ways has proven to be effective 
and able to induce an immunomodulator response in patients of IgE mediated allergy. This 
project did not intended to validate the efficacy of this therapy, broadly documented, but to 
study the dynamic of the resulting mechanism due to the administration of the therapeutical 
extract in patients maintained in the previously determined individual dosage. 
Theoretically, it would be extremely relevant to have monitored, under the same 
methodology, this treatment in different periods throughout the year, but the radioactive 
dosage accumulated would be ethically unacceptable. 
In patients under subcutaneous injectable treatment, the anaphylaxis treatment with 
aqueous extracts induced the fastest signs of inflammatory activity in the administration 
site. The activity became visible 35 minutes after the administration, while with depot 
extracts, the activity was only visible between 40 and 45 minutes after the administration. In 
all patients, an increase in the intensity of the activities was observed throughout the 
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observation period. The higher activity induced by the aqueous extracts did not translate 
into more exuberant clinical signs. The patients in SCIT to latex presented local clinical signs 
more pronounced than two patients allergic to Apis. In these two patients, the inflammatory 
activity was bigger and deeper, which can be explained by a higher amount of protein and 
the volume of extract administered. 
In patients with respiratory allergy submitted to SCIT with depot extracts there were no 
evident differences connected to the extract composition, either mites or pollens. 
Regarding the allergoid extracts, a reduced inflammatory activity was observed at the 
administration site, similarly to what was previously reported in the literature and 
demonstrated in daily clinical practice (Casanovas et al., 2005, 2007; Ariano et al., 1999). The 
modification of the allergenic with glutaraldehyde reduced the local inflammatory activity 
to levels similar to the ones observed in the control patients submitted to SS. In patient C1, 
asthmatic allergic to dust mites submitted to subcutaneous injection with BE, a local 
inflammatory activity was observed 45 minutes after the administration. This is an extract 
with immunomodulator activity, which induces the response of an IgG polyclonal antibody 
well documented in the literature (Clot, 1997). Although the local demonstration of activity 
was expected, the time necessary to observe activity was also extremely reduced. 
The patient submitted to a phenolated solution presented a minimal local inflammatory 
activity only seen 60 minutes after the subcutaneous injection. Similarly to the patients 
studied in the previous chapter, it is considered that the irritation potential of this 
preservative can justify this result (Spiller et al., 1993). 
In this study it was possible to assess and confirm the dynamics of the inflammation 
induced by the subcutaneous application of an allergenic extract. These results, although not 
surprising, were not unequivocally demonstrated, namely in terms of extension, depth of 
the adjacent region or evolution of the reaction along the course of the experiment. One 
advantage of the depot extracts when compared to the aqueous extracts, besides the safety 
profile, was the slower release of the allergenic protein (Wheeler & Woroniecki, 2004). In our 
patients we clearly observed a lower activity of these extracts, despite the fact that the 
patients with the aqueous extracts presented a worse level of basal allergic disease. The 
lymphocyte traffic seemed to be more intense and persistent with these extracts since the 
soluble allergenic is more readily available. In all patients submitted to SCIT, it is possible to 
observe systemic focalizations before the locally induced inflammatory activity. In the 
dynamic acquisition during the first 60 minutes, the anterior thoracic projection only 
permits to infer the potential activity in this view. In the intramedullary area of the humeral 
head is evident a significant intensity, surely dependent on the recirculation of cells 
representing all leukocyte cell populations. 
In patients submitted to SCIT, the activity in bone structures and in thymic tissue presented 
a very intense activity that increased throughout the experiment. It should be noticed that 
these structures anatomically overlap to other organs from the central immune systems, but 
that in the peripheral immune lymphoid system, such as regional ganglion, and presumably 
in the region of the mediastinum, there is also evidence of activity. Furthermore, the mucosa 
immune system seems to be involved namely the pulmonary and less consistently the 
intestinal. The early involvement of the central lymphoid structures was an unexpected 
event, but was very consistent in all patients. 
Obviously, with the methodology used it is not possible to determine the cell type and 
profile that is responsible by the activity induced by the migration from the circulation to a 
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specific focalization. Nevertheless, given the actual knowledge regarding the mechanism 
that modulate this therapeutic, it is possible to admit that a diversified set of cells with 
different activation profiles and with divergent implications in the different structures. 
The subcutaneous administration of the allergenic extract, particularly with aqueous 
extracts, defines an evident local inflammatory process. To this level, we admit that some 
conjunctive mast cells can be activated, although with limited intensity. As described in the 
literature, we also admit that the presence of conjunctive DCs, with IgE receptors, can favor 
this type of reaction. However, the most likely mechanism can depend on an effective 
presentation of the allergen to presenting cells and posterior migration to local-regional 
structures. This mechanism could explain the ganglion activity observed in the homolateral 
arm, with the involvement of other ganglion structures more distant, such as the ones 
present in the cervical lateral-external area. 
On the other hand, we admit the influx from the circulation of DC or monocytes into the site of 
administration of the allergenic extract, since it is well known the ability of these cells to 
maturate into DCs or phagocytes. This dual mechanism, that simultaneously induce a 
biological defense from the aggression and favors an effective immune response, are probable 
local mechanisms. Therefore, the local administration of therapeutical allergens limits the local 
response that rapidly seems to have local-regional and systemic consequences. Probably, not 
only the biologic mediator produced in situ, as well as the following cell migration, 
presumably DCs, and the cellular limitations in venular structures in the proximity of the 
allergenic, allow the amplification of the systemic effect by mechanisms, possibly similar to the 
ones verified in the allergic reaction (Togias, 2004; Kelly, 2007). 
The qualitative analysis of our SCIT patients corroborates, although indirectly, the 
complexity of the tolerance mechanisms, well described in the literature. The anatomic 
involvement of structures implicated with organs of the central immune system seems to 
sustain these effects. The activity observed in the bone marrow areas allow us to speculate 
that it could limit the modification of cellular profiles, namely lymphocyte, that has been 
documented in these patients (Denburg et al., 2000). Also, the demonstration of the 
contribution of regulatory cells can be sustained by our results given the involvement of the 
anatomic region reported to the thymic tissue, whose function persists throughout life 
(Arellano et al., 2006). Nevertheless, the pace of this process and the systemic involvement, 
evidenced by the focalization of the inflammatory activity, is clearly higher than expected, 
given the present knowledge. It should be noticed that this dynamic study evaluates, in a 
certain way, the biologic response in the whole organism. This contrasts with the usage of 
small biologic samples (such as tissues or humors), a procedure that is very common in most 
clinical and experimental studies. 
We admit that the lungs are involved in the influx of leukocytes to the BALT, but it should 
be noticed that this is a preponderant location for the clinical symptoms that lead to 
treatment in patients with respiratory allergy. 
In patients in SLIT, the beginning of the inflammatory activity in the site of administration 
was substantially earlier than the observed in patients in SCIT. In the two patients allergic to 
mites and in the patient allergic to Parietaria judaica, the activity was noticed 3 and 5 minutes 
after the respective induction. Despite this early onset of activity, no substantial differences 
were registered when the final results were compared, namely in the effects of regional or 
distant structures. 
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observation period. The higher activity induced by the aqueous extracts did not translate 
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specific focalization. Nevertheless, given the actual knowledge regarding the mechanism 
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contribution of regulatory cells can be sustained by our results given the involvement of the 
anatomic region reported to the thymic tissue, whose function persists throughout life 
(Arellano et al., 2006). Nevertheless, the pace of this process and the systemic involvement, 
evidenced by the focalization of the inflammatory activity, is clearly higher than expected, 
given the present knowledge. It should be noticed that this dynamic study evaluates, in a 
certain way, the biologic response in the whole organism. This contrasts with the usage of 
small biologic samples (such as tissues or humors), a procedure that is very common in most 
clinical and experimental studies. 
We admit that the lungs are involved in the influx of leukocytes to the BALT, but it should 
be noticed that this is a preponderant location for the clinical symptoms that lead to 
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In patients in SLIT, the beginning of the inflammatory activity in the site of administration 
was substantially earlier than the observed in patients in SCIT. In the two patients allergic to 
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were registered when the final results were compared, namely in the effects of regional or 
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In fact, it seems evident that since the administration of the extract, a continuous increase of 
the local inflammatory activity as well as in cervical structures, particularly in the cervical 
lateral-external region. As described previously for SCIT patients, the venous recirculation 
at very early stages does not allow an effective validation of this effect, but the assessment in 
later periods, both in the dynamic or static acquisitions, there is an evident focalization in 
these cervical structures. For these patients, and with exception of the patient injected with 
extract modified with glutaraldehyde, and using the color scale, the intensity of the 
oropharynx is clearly inferior than the one verified in the injection site. Other clear 
difference, is the absence of a progressive increase of the inflammatory response focalized at 
the administration site verified in subsequent static evaluations. However, the systemic 
effect is very similar to the observed in patients under injectable treatment. We observe 
pulmonary focalizations as well as in regions reported to the organs from the immune 
central system. In these regions, the areas reported to the bones and in suprasternal, the 
images from the static studies support an increase of activity throughout the experiment. 
In patients under SLIT, the extract was swallowed 3 minutes after the administration. It 
would be expected an intra-abdominal involvement, with intestinal focalizations. However, 
in none of these 3 patients that effect was observed. We admit that the extract can be 
completely degraded in the stomach, which would prevent an effect in the intestinal 
mucosa. Our results seem to corroborate the therapeutic inefficiency of the oral 
immunotherapy, which is not scientifically validated by the literature (Bousquet et al., 1998). 
It is not possible to define and characterize the migrating population that focalizes in the 
distinct structures in patients under SLIT. Despite this, the available scientific knowledge 
allows us to assume that the allergenic persistence in the sublingual mucosa, as previously 
demonstrated (Bagnasco et al., 2005), allows the induction of the following immune 
response. As previously described, abundant lymphoid structures with specific biologic 
characteristics are present in this mucosa. The DC permits a fast transport to the tonsils and 
lymphatic ganglions in a magnitude that cannot be compared to the subcutaneous tissue. 
However, it is well established that the majority of DCs present in the tonsils are DC-2. 
These cells do not have the capacity to effectively internalize the allergenic protein and 
efficiently present it to the T-cell. Therefore, and although in smaller numbers, the DC-1 cells 
probably have a preponderant function. As a result, we admit that there might be an influx 
from the circulation of DC and monocytes, and that these, once in the mucosa, will 
differentiate and maturate. The early start of the activity will, presumably, result from the 
presence and availability of a biologically more active and diversified resident population. 
The reduced population of mast cells in the oral mucosa limits the local inflammatory 
response when compared to the subcutaneous administration. Therefore, and in theory, we 
can predict that the resulting mechanism derives from the activation of DCs and the 
presentation to lymphocytes in structures in the oral mucosa and that are dependent from 
the immune system. Thus, the therapeutical extract produces a powerful stimulus that 
initiates a local and systemic immune response, surely by regulating biologic mediators of 
cytokines and chemokines, as well as by limiting the entry of circulating cells from the 
vascular-lymphoid structures present in the oral mucosa. 
The systemic effects in areas of the central immune system, similarly to what was observed 
for the injectable extracts, can corroborate the tolerance and immunomodulation, presently 
well documented in the therapeutical intervention. 
In patients under injectable therapy, the UCCs results obtained in the homolateral armpit 
are higher that was expected by the exclusive visualization of the scintigraphic images. We 
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admit that the results obtained in this focalization are, eventually, due to the migration of 
lymphatic cells from the administration site of the therapeutical extract to the ganglion 
structures present in the armpit region that allow a therapeutical amplification with natural 
systemic effect. In fact, functional studies in melanoma using a radio-labeled pharmaceutical 
compound administered intradermally evidenced the high rate of lymphatic migration to 
distant ganglion structures (Alazraki et al., 2002). Since the most important ganglion 
structures of the subcutaneous cellular tissue of the arm are located in the armpit, that the 
effective presentation of the allergenic protein to the T-cell in the lymph node is mediated by 
the DC and that the intralymphatic migration is very fast, the UCCs obtained in our patients 
are, probably, justified. 
The eventual lymphatic migration proportions, are in fact, an amplification of the immune 
mechanism with characteristics that clearly favors tolerance. Therefore, it could lead not 
only to an effective diffusion of the response throughout the immune-lymphoid system, as 
well as a recirculation of cells from the allergenic administration site to distant central 
structures and organs that can allow the synergistic effects that concur with the 
immunomodulation of this therapy. 
Therefore, the presumed ascending drainage justifies the precocious and persistent UCCs 
induced by the subcutaneous administration of the allergen in other vascular-lymphatic 
structures, anatomically located in the lateral-external region of the neck. Eventually, this 
process allows an amplification of the response to cervical structures with high biological 
activity. To this level, we do not observe significant differences of UCCs due to usage of 
different injectable extracts. 
Although we verify focalization in the pulmonary region throughout the dynamic 
acquisition, we only calculated the coefficients in the static acquisition. The intense venous 
recirculation of leukocytes after the reinjection could falsify the results. However, all our 
patients presented intrapulmonary activity. Particularly in patients undergoing treatment 
for respiratory allergy, the influx of these cells to the targeted organ is compatible to the 
methods sensitivity. This way, the recirculation of leukocytes between the vascular 
compartment and the mucosa of the different organs of the immune system allow the 
convenient organic homeostasis that justifies the reduced numbers of pulmonary UCCs 
verified in control patients. 
Given the results obtained in the patient submitted to BE, we presume that the unspecific 
bacterial immunomodulators have, besides favoring an IgG polyclonal response, a more 
central and selective regulator effect than the one presumed until now, but for which the 
clinically efficacy has been shown (Bousquet & Fiocchi, 2006). Regarding the patient allergic 
to dust mites submitted to SS injection, the reduced UCCs values were consistent 
throughout the experiment, and we presume that are derived from the organic recirculation 
of leukocytes, and correspond to the basal function of this tissue 
The activity observed in the bone structures was confirmed by the UCCs calculated in the 
two considered ROIs. There were no differences in the results obtained in the medullary 
area of the humeral head or the iliac crest. 
Our results suggest that either the bone marrow or the functional thymic tissue, organs from 
the central immune system, are preferential targets of the induction mechanism of SCIT, 
regardless of the type of allergenic extract. It should be noticed that in patients treated with 
modified extracts, allergoid, the dosage of allergenic used was substantially higher than the 
dosages in the depot extracts, and that the UCCs obtained in the regions associated with 
bone marrow were also higher. However, the size of the sample does not allow us to 
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In fact, it seems evident that since the administration of the extract, a continuous increase of 
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effect is very similar to the observed in patients under injectable treatment. We observe 
pulmonary focalizations as well as in regions reported to the organs from the immune 
central system. In these regions, the areas reported to the bones and in suprasternal, the 
images from the static studies support an increase of activity throughout the experiment. 
In patients under SLIT, the extract was swallowed 3 minutes after the administration. It 
would be expected an intra-abdominal involvement, with intestinal focalizations. However, 
in none of these 3 patients that effect was observed. We admit that the extract can be 
completely degraded in the stomach, which would prevent an effect in the intestinal 
mucosa. Our results seem to corroborate the therapeutic inefficiency of the oral 
immunotherapy, which is not scientifically validated by the literature (Bousquet et al., 1998). 
It is not possible to define and characterize the migrating population that focalizes in the 
distinct structures in patients under SLIT. Despite this, the available scientific knowledge 
allows us to assume that the allergenic persistence in the sublingual mucosa, as previously 
demonstrated (Bagnasco et al., 2005), allows the induction of the following immune 
response. As previously described, abundant lymphoid structures with specific biologic 
characteristics are present in this mucosa. The DC permits a fast transport to the tonsils and 
lymphatic ganglions in a magnitude that cannot be compared to the subcutaneous tissue. 
However, it is well established that the majority of DCs present in the tonsils are DC-2. 
These cells do not have the capacity to effectively internalize the allergenic protein and 
efficiently present it to the T-cell. Therefore, and although in smaller numbers, the DC-1 cells 
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admit that the results obtained in this focalization are, eventually, due to the migration of 
lymphatic cells from the administration site of the therapeutical extract to the ganglion 
structures present in the armpit region that allow a therapeutical amplification with natural 
systemic effect. In fact, functional studies in melanoma using a radio-labeled pharmaceutical 
compound administered intradermally evidenced the high rate of lymphatic migration to 
distant ganglion structures (Alazraki et al., 2002). Since the most important ganglion 
structures of the subcutaneous cellular tissue of the arm are located in the armpit, that the 
effective presentation of the allergenic protein to the T-cell in the lymph node is mediated by 
the DC and that the intralymphatic migration is very fast, the UCCs obtained in our patients 
are, probably, justified. 
The eventual lymphatic migration proportions, are in fact, an amplification of the immune 
mechanism with characteristics that clearly favors tolerance. Therefore, it could lead not 
only to an effective diffusion of the response throughout the immune-lymphoid system, as 
well as a recirculation of cells from the allergenic administration site to distant central 
structures and organs that can allow the synergistic effects that concur with the 
immunomodulation of this therapy. 
Therefore, the presumed ascending drainage justifies the precocious and persistent UCCs 
induced by the subcutaneous administration of the allergen in other vascular-lymphatic 
structures, anatomically located in the lateral-external region of the neck. Eventually, this 
process allows an amplification of the response to cervical structures with high biological 
activity. To this level, we do not observe significant differences of UCCs due to usage of 
different injectable extracts. 
Although we verify focalization in the pulmonary region throughout the dynamic 
acquisition, we only calculated the coefficients in the static acquisition. The intense venous 
recirculation of leukocytes after the reinjection could falsify the results. However, all our 
patients presented intrapulmonary activity. Particularly in patients undergoing treatment 
for respiratory allergy, the influx of these cells to the targeted organ is compatible to the 
methods sensitivity. This way, the recirculation of leukocytes between the vascular 
compartment and the mucosa of the different organs of the immune system allow the 
convenient organic homeostasis that justifies the reduced numbers of pulmonary UCCs 
verified in control patients. 
Given the results obtained in the patient submitted to BE, we presume that the unspecific 
bacterial immunomodulators have, besides favoring an IgG polyclonal response, a more 
central and selective regulator effect than the one presumed until now, but for which the 
clinically efficacy has been shown (Bousquet & Fiocchi, 2006). Regarding the patient allergic 
to dust mites submitted to SS injection, the reduced UCCs values were consistent 
throughout the experiment, and we presume that are derived from the organic recirculation 
of leukocytes, and correspond to the basal function of this tissue 
The activity observed in the bone structures was confirmed by the UCCs calculated in the 
two considered ROIs. There were no differences in the results obtained in the medullary 
area of the humeral head or the iliac crest. 
Our results suggest that either the bone marrow or the functional thymic tissue, organs from 
the central immune system, are preferential targets of the induction mechanism of SCIT, 
regardless of the type of allergenic extract. It should be noticed that in patients treated with 
modified extracts, allergoid, the dosage of allergenic used was substantially higher than the 
dosages in the depot extracts, and that the UCCs obtained in the regions associated with 
bone marrow were also higher. However, the size of the sample does not allow us to 
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conclude if this treatment is more selective or effective. Nevertheless, we presume that given 
the previously described mechanisms, the bone marrow may participate in the SIT 
mechanism since earlier stages, right after the injection of the extracts. 
In the suprasternal region, the UCCs were very similar in the different groups under active 
treatment and significantly distinct from the ones obtained in the patient submitted to SS 
injection. This data corroborates the eventual physiological dynamic of the leukocytes, 
possibly dependent of the persistent limitation of the medulla, even in cells apparently 
mature that were collected from the venous compartment. 
In the intra-abdominal region, the UCCs obtained in the intestinal focalizations, observed 
occasionally in the scintigraphic images, confirmed the involvement of this mucosa. The 
calculations were only performed in focalizations areas during the first 4 hours, in order to 
minimize interferences due to faecal elimination. 
For the three patients under sublingual treatment we do not have a control that we can 
compare to. Despite this, the values obtained in the asthma and rhinitis patients allergic to 
dust mites submitted to BE or SS in the nasal region (see previous chapter), are similar to the 
type of response verified in SLIT patients.  
The capture and the inflammatory activity on the site of the administration of the 
therapeutic extract evidenced a very precocious activity that subdue in relatively high 
values throughout the experiment. These results are consistent with previously described 
dynamic studies (Bagnasco et al., 2005). The quantitative analysis does not evidence an 
increase of the local activity as seen in the majority of patients submitted to injectable 
extracts. In this mucosa, the presence of mast cells is extremely reduced which, despite the 
persistence of the extract (even after it was swallowed), does not induce a broader influx of 
circulating leukocytes due to this mechanism. Therefore, we presume that the much more 
limited activity observed can be due to circulating DCs and mast cells that have a 
recognized ability to mature and differentiate in the offended tissues. The readily 
availability of immune-lymphoid tissue in this localization will allow a fast amplification 
and dissemination of cells with the ability to induce an immunomodulator mechanism. 
In patient 15, submitted to sublingual treatment with Parietaria judaica extracts, the UCCs 
obtained throughout the observation period were the lowest in these three patients. In fact, 
since the test was conducted during the pollinic period, we established a reduction of the 
allergenic dosage during the pollination period of this herb. It is a clinical procedure well 
established in the therapeutic with injectable extracts, although not consensual in sublingual 
treatment (Bousquet, 2006; Bousquet et al., 1998). Despite this, and since this patient lives in 
a geographic area with high levels of aeropalinologics, it was decided to reduce the 
maintenance dosage to 2/3 (10:15 drops). Eventually, this procedure had implications in the 
type of response that was evidenced, not only in the local activity as well as in the distant 
focalizations. 
In patients under SLIT treatment, the UCCs obtained in the structures localized in the 
lateral-external region of the neck confirmed the analytic results from the scintigraphic 
images. The apparent descendent drainage in these vascular-lymphatic systems 
corroborates our proposal, particularly in the intrapulmonary capture. In the anatomic 
regions reported to the organs of the central immune system we observed UCCs with 
similar behavior than those verified in the patients under injectable treatment. Therefore, we 
presume that in SLIT there is also an early participation of the bone marrow and the 
functional thymic tissue. 
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4. Involvement of the organs from the immune system 
In SCIT, we admit that the APC migration to ganglion structures is determinant to obtain a 
systemic effect and to acquire an immunomodulator and/or tolerance state. In patients 
submitted to SLIT, the inflammatory activity was observed in the first minutes, much earlier 
but with clearly lower gradients throughout the experiment. As previously described, the 
morphological characteristics of the conjunctive subcutaneous tissue and the oral, in 
particular from the sublingual region, are completely distinct. Therefore, the local 
availability of the whole array of the adjacent immuno-lymphatic-ganglion structures allows 
the effectiveness of the early stages of the mechanism. Paradoxically, the characteristics of 
the DCs present in the oral mucosa, mainly from the plasmacytoid type, are responsible for 
a less effective response (Novak et al., 2004). Previous work evidenced the presence of the 
allergenic extract in the sublingual mucosa long after it was swallowed, but it was extremely 
reduced 24 hours after that administration (Bagnasco et al., 2005). This difference, relatively 
to the subcutaneous administration, has natural implications in the periodicity of the 
therapeutical application. The amplification of the systemic effect seems to result from a 
descending involvement of structures presumably vascular-lymphatic in the lateral-external 
of the neck by a mechanism similar to SCIT. 
Given the differences between the two administration methods and the type of therapeutic 
extract, the results obtained suggest a potentially selective influx of cells from the 
mononuclear-phagocyte system to the deposition site, similarly to the allergic reaction, 
which was documented in an interesting study done in ten patients submitted to an inhaled 
aggression (Upham et al., 2002). Naturally, the mediators produced locally will have a 
potential modulator effect in the adjacent vascular endothelium, which allows a possible 
immunomodulator effect in circulating leukocytes that allows a systemic involvement. 
The recirculation and following focalization of intrapulmonary leukocytes was observed in 
all patients. The presence of the bronchus-associated lymphoid tissue (BALT) supports these 
results, in particular since this mucosa is a potential target in patients undergoing treatment 
of respiratory allergy. However, regarding the involvement of the intestinal mucosa, where 
the gut associated lymphoid tissue (GALT) is located, focalization of the inflammatory 
activity was occasionally observed. The SLIT with allergenic deglutition three minutes after 
the deposition did not produced any additional gain. In fact, we admit that the protein 
degradation can occur as result of the gastric enzymatic degradation as proposed in the 
literature (Bousquet et al., 1998). 
The lymphocyte cellular modulation from a mainly Th2 profile into a lymphocyte profile 
mostly Th1, as well as the induction of T-lymphocytes with regulatory characteristics, are 
the most studied and documented mechanisms in the literature (Larché et al., 2006; Till et 
al., 2004; Canonica & Passalacqua, 2003). The complexity of the processes involved allows a 
constant effect throughout the treatment, but its dynamic mechanism is not well established. 
The need to extend in time the specific treatment translates the need to promote an 
immunologic memory status. The patients studied in this project were well documented, 
both clinically and laboratorial, and all were in maintenance treatment. Although we know 
several mechanisms involved, it is not known the dynamics and the regions implicated after 
the administration of the extract, nor in the induction stages or in maintenance periods. 
It seems obvious the involvement of organs from the central immune system in the SIT 
action mechanisms. It also appears, given the results obtained in allergic patients submitted 
to specific provocation, that the participation of these organs could have a dynamic and 
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conclude if this treatment is more selective or effective. Nevertheless, we presume that given 
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dust mites submitted to BE or SS in the nasal region (see previous chapter), are similar to the 
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4. Involvement of the organs from the immune system 
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pace with similar magnitude. These results look as redundant or expectable, but we had no 
previous knowledge about the location and timing of the immunomodulation process that 
has been so well characterized in the laboratory. 
The induction of medullar cellular clones with phenotypes that favor the secretion type Th1 or 
clones precursors of DCs with tolerogenic characteristics are events that sustain the activity of 
the bone marrow, and is present at an early stage in patients undergoing treatment (van 
Helvoort et al., 2004; Moingeon et al., 2006). The essential function of several regulatory T-cells, 
well placed and with central function in the SIT mechanism, is an element that supports not 
only the intervention of bone marrow as well as the thymic activity (Schmidt-Weber & Blaser, 
2005; Moingeon et al., 2006). Despite the anatomic involution, the organic function persists in 
adulthood (Hakim et al., 2005; Harris et al., 2005; Arellano et al., 2006). In this regard, we 
should notice that in one patient we had the opportunity to acquire a scintigraphic 21 hours 
after the simultaneous administration of leukocytes labeled with 99mTc-HMPAO and allergenic 
aqueous latex extract. In this patient we observe the persistence of the inflammatory activity in 
both the suprasternal and bone medullar areas, Figure 14. 
It should be noticed that the half-life of the radio-labeled compound is 6 hours, and 
therefore the acquisition occurred at a time well past its half life. Nevertheless, the activity 
persisted at the administration site, allowing the therapeutic effect to continue, as well as 
activity in intra-bone areas and in the suprasternal region, which we judge representative 
the functional thymic tissue. 
The study in this patient was done occasionally and was, in fact, a surprise, revealing 
activity that we supposed it was not possible due the anatomic physical conditionings. We 
proceeded with the quantitative evaluation that unequivocally contributed the qualitative 
assessment done in this patient. In Figure 15 we show the UCCs obtained for this patient 
after 6 hours (last programmed observation that coincides with 99mTc half-life) and 21 hours. 
Although the UCCs are lower after 21 hours when compared to the values obtained after 6 
hours, it is evident that, despite after nearly four half-lives, the activity reported is very 
significant. We should highlight that the UCC in the ROI draw in the homolateral armpit 
maintains constant values of activity, which supports a continuous involvement. 
The study in this patient, since it is not likely a continuous recirculation of leukocytes 
without focalization and influx to this organ, allows us to deduce that we were able to 
obtain an image of the functional thymic tissue.  
Our results support the research developed since 1985 by a Canadian group that sustains 
the involvement of the central immune system’s organs, mainly bone marrow, in the 
pathophysiology of the allergic inflammation (Denburg et al., 1998). The results obtained in 
experimental models and in humans with allergy are essential, regarding the participation 
of hematopoietic mechanisms during the response to an allergenic (Denburg et al., 1998; 
Denburg & van Eeden, 2006, Sehmi et al., 1996; Cyr & Denburg, 2001). 
In a comparative study with 153 patients with pollinic rhinoconjunctivitis, the effect of the 
administration of SIT either subcutaneously or intralymphatic was compared (Senti et al., 
2008). In the later group, the administration of the pollinic allergen directly in a inguinal 
lymphatic ganglion using ultrasound as a control, with only three injections separated by 4 
weeks, in the response to a specific nasal induction 4 months after the last administration, 
required a dosage ten times higher than the one required in patients under SCIT treatment 
for three years and with a cumulative dosage drastically higher and with multiple allergenic 
injections. In addition to the clinical efficacy, the adverse effects were neglectable and the 
lymphatic intraganglionic injection was very well tolerated. This promising and innovative 
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study can induce a complete reversion on the treatment of IgE mediated allergy. It should 
be noted that these results were obtained with conventional allergens. However we consider 
that the future use of highly selective peptides directly administered in immune structures 
can induce an even more elective therapeutical effect. 
 
 
Fig. 14. Scintigraphic study in patient with anaphylaxis to latex, submitted to subcutaneous 
aqueous extract. Static acquisitions, anterior thoracic (A) and abdominal (B) views, 21 hours 
after the beginning of the study. 
 
 
Fig. 15. Corrected uptake coefficient obtained in static acquisitions after 6 and 21 hours in 
different locations in patient with the diagnosis of latex anaphylaxis submitted to 
subcutaneous aqueous extract treatment. 
5. Final remarks 
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evolves throughout time and is significantly broader than the one verified in the clinic, by 
the observation of the inflammatory signals. The pollinic extract modified with 
glutaraldehyde does not present nearly any inflammation at the injection site. 
The involvement of the armpit’s region homolateral to the administration of the extract 
occurs very early, which is compatible with the focalization of the inflammatory activity in 
immune ganglia structures. We admit an ascending drainage effect from the site of the 
extract’s administration. 
In patients submitted to SLIT, the visualization of the inflammatory activity is evident three 
minutes after the therapeutical extract’s administration. In contrast to what was observed in 
SCIT patients, the inflammatory intensity, in the focalization, is relatively constant during 
the observation period, without an increase in later acquisitions. The SLIT also produced a 
very early systemic effect, namely with activity in the lateral-cervical region, where the 
presence of vascular-lymphatic structures have been reported. We admit that there is a 
descending drainage effect from the site of the extract’s administration. 
 
 
Fig. 16. Local and systemic events related to specific immunotherapy (A: subcutaneous; B: 
sublingual) 
The visualization of the activity with intra-abdominal (intestinal) focalization was 
occasional, but exclusive to patients in SCIT. In patients undergoing SLIT, despite the 
swallowing of the extract, there was no focalization in this area three minutes after the 
extract’s administration, Figure 16. 
A B
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The anatomic regions reported to the central immune system (bone marrow and 
suprasternal area) evidenced a constant growth in UCCs during the experiment. The SIT 
triggers an early and continuous influx of leukocytes, from the circulation into the central 
immune organs, with potential implications in the immunomodulatory mechanism.  
Regarding the response’s magnitude in the bone marrow and functional thymic tissue, there 
were no apparent differences regarding the type of extract and the administration type 
during the first six hours after the administration of the therapeutical extract. 
The persistence of the therapeutical extract administered subcutaneously indicates an 
inflammatory activity and a continuous influx of inflammatory cells. In the sublingual 
administration, the influx and local activity are lower, without any evidence of an increase 
in the inflammatory activity throughout the experiment. Therefore, patients under SLIT 
treatment will require administrations more frequent and with shorter breaks between 
administration in order to obtain a persistent therapeutic effect. 
Our results reinforce the need for new and elective pharmacologic investigation strategies, 
focusing on the mainstay function of the central immune organs in the treatment of systemic 
inflammatory disease such as allergy. In fact, in face of the current knowledge of the 
immunological effects induced by SIT, namely the effect on T-regs with a long-lasting 
biological effect, this would only be possible if a central immune cellular modulation had 
occurred. 
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1. Introduction 
1.1 2-adrenoceptor agonists and asthma 
The adrenergic receptors (adrenoceptors) are a member of the G protein-coupled receptor 
superfamily of membrane proteins that are targets of the catecholamines, norepinephrine 
and epinephrine. To date, two main groups of adrenoceptors,  and , with several subtypes 
have been identified. Many types of cells possess these receptors, and the binding of an 
agonist will generally cause a sympathetic response. Among them, 2-adrenoceptor agonists 
(2-agonists) are widely used as bronchodilators in the treatment of bronchial asthma 
because of their potent bronchodilating effects on airway smooth muscle. In addition to 
being bronchodilators, they may also have anti-inflammatory properties, including 
inhibition of granulocyte functions (Yasui et.al., 2006). However, concerns have been raised 
regarding the use of 2-agonists on a regular daily basis rather than only as needed for 
rescue therapy. More specifically, continuous and repetitive 2-agonist monotherapy has 
been considered to be associated with an increase in the degree of allergic inflammation 
(Cockcroft et.al., 1995), poor asthma outcomes (Paris et.al., 2008) and an increase in the risk 
of asthma death (Crane et.al., 1989; Nelson et.al., 2006). Although the precise molecular 
mechanisms underlying these undesirable effects of 2-agonists are not fully understood, 
several studies have independently demonstrated that 2-agonists have the potential to 
increase Th2 cytokine-mediated inflammation both in vivo and in vitro. For instance, 
Coqueret et.al. demonstrated that ovalbumin-sensitized mice treated with a daily injection 
of salbutamol showed increased anti-ovalbumin IgE levels in their serum, probably due to 
increased production of Th2 cytokines (Coqueret et.al., 1994). Panina-Bordignon et.al. 
demonstrated that 2-agonists prevented Th1 development by selectively inhibiting IL-12 
production (Panina-Bordignon et.al., 1997). More recently, Loza et.al. demonstrated that 
human Th2 cells express 2-adrenergic receptor and that 2-agonists augmented the 
accumulation of Th2 cells in human peripheral blood lymphocyte cultures subjected to 
bystander stimuli (Loza et.al., 2007). These findings suggest a mechanism by which 2-
agonist monotherapy may favor Th2 immune responses, which are believed to be involved 
in the pathogenesis of asthma. 
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bystander stimuli (Loza et.al., 2007). These findings suggest a mechanism by which 2-
agonist monotherapy may favor Th2 immune responses, which are believed to be involved 
in the pathogenesis of asthma. 
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1.2 TSLP and asthma 
Thymic stromal lymphopoietin (TSLP) is an IL-7-like cytokine which was originally 
identified in the supernatant of a murine thymic stromal cell line (Friend et.al., 1994). 
Increasing evidence suggests that TSLP plays important roles in the pathogenesis of allergic 
diseases such as asthma and atopic dermatitis (Al-Shami te.al., 2005; Yoo et.al., 2005). The 
most clinically relevant role of TSLP is mediated by dendritic cells (DCs) through induction 
of OX40 ligand expression on DCs (Ito et.al., 2005; Liu, 2007a). Naïve T cells receiving 
antigen-presentation from TSLP-primed DCs develop into Th2 cells that produce IL-4, -5, -
13 and TNF- but not IL-10 (Ito et.al., 2005; Liu, 2007a; Soumelis et.al., 2002). These Th2 cells 
are now referred as to “inflammatory Th2 cells” in consideration of their potential for 
releasing the proinflammatory cytokine, TNF-, in addition to Th2 cytokines (Orihara et.al.; 
2008). Furthermore, mice with transgenic overexpression of TSLP in the lung develop severe 
airway inflammation, including massive infiltration by inflammatory cells, goblet cell 
hyperplasia and airway hyperresponsiveness (Zhou et.al., 2005). Mice with transgenic 
overexpression of TSLP in skin keratinocytes develop severe dermatitis with itching, which 
is similar to the clinical features of atopic dermatitis in humans (Yoo et.al., 2005). On the 
other hand, mice lacking the TSLP receptor exhibit strong Th1 responses and fail to develop 
an inflammatory lung response to antigens (Al-Shami te.al., 2005). Thus, TSLP is an 
important cytokine that is necessary and sufficient for initiation of allergic inflammation. 
2. The enhancing effect of 2-adrenoceptor agonists on cytokine-induced 
TSLP production by human lung tissue cells 
2.1 Cytokine-induced production of TSLP by lung tissue cells 
It is widely accepted that TSLP is expressed predominantly in epithelial cells of the lung, 
intestine and skin keratinocytes (Soumelis et.al., 2002; Liu et.al., 2007b). We confirmed an 
earlier report (kato et.al., 2007) that a combination of IL-4 and TNF- synergistically induced 
TSLP production by normal human bronchial epithelial cells (NHBE) (Fig. 1A). Unlike 
NHBE, lung mesenchymal cells such as bronchial smooth muscle cells (BSMC) and normal 
human lung fibroblasts (NHLF) produced TSLP in response to TNF-, but not IL-4 alone. 
However, like NHBE, those cells produced greater amounts of TSLP as a result of 
synergistic effects between IL-4 and TNF- (Fig. 1B and 1C). Of note, these mesenchymal 
cells produce appreciable amounts of TSLP compared to NHBE, suggesting the possibility 
that lung mesenchymal cells are, like epithelial cells, important cellular sources of TSLP. 
2.2 Effects of 2-agonists on cytokine-induced TSLP production 
We next examined the effects of 2-agonists on the cytokine-induced TSLP production by the 
human lung tissue cells. Although 2-agonists act mainly on airway smooth muscle as 
bronchodilators, they are also known to express anti-inflammatory effects on granulocytes 
(Yasui et.al., 2006), epithelial cells (Koyama et.al., 1999) and fibroblasts (Spoelstra et.al., 2002). 
As shown in Fig 2A, when NHBE were stimulated with a combination of IL-4 and TNF-, 
simultaneous addition of various concentrations of two long-acting 2-agonists, i.e., salmeterol 
and formoterol, and a short-acting 2-agonist, salbutamol, showed significant enhancement of 
the cytokine-induced TSLP production. Optimal concentrations of these 2-agonists were 
employed, and then the mRNA expression of TSLP in NHBE was measured by quantitative 
real-time PCR. TSLP mRNA expression was significantly enhanced by 10-10 M salmeterol, 10-10 
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M formoterol and 10-8 M salbutamol (Fig. 2B), suggesting that the enhancing effects of 2-
agonists on TSLP production were transcriptionally-regulated. It should be noted that 2-
agonists enhanced TSLP production by airway smooth muscle cells and lung fibroblasts as 
well as bronchial epithelial cells (Fig. 2C and 2D). We suppose that the production of TSLP by 
these lung tissue cells is particularly important because dendritic cells have to migrate through 
these airway interstitial cells to lymphopoietic tissues in order to present antigen information 
to naïve T cells. Therefore, enhanced TSLP production by lung tissue cells in response to 2-
agonists may lead to exacerbation of allergic airway inflammation, and this may partly explain 
the undesirable clinical effects of continuous 2-agonist monotherapy. 
 
 
Fig. 1. Cytokines induce production of TSLP by lung tissue cells. NHBE (A), BSMC (B) and 
NHLF (C) were treated with 10 ng/ml IL-4 alone, 10 ng/ml TNF- alone and a combination 
of both for 48 h. TSLP concentrations in the culture supernatants were quantified by ELISA. 
Data are shown as the mean ± SD of quadruplicate samples and are representative of at least 
three separate experiments. ** p < .01 compared with unstimulated control. Reprinted from 
Futamura et. Al., 2010. 
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simultaneous addition of various concentrations of two long-acting 2-agonists, i.e., salmeterol 
and formoterol, and a short-acting 2-agonist, salbutamol, showed significant enhancement of 
the cytokine-induced TSLP production. Optimal concentrations of these 2-agonists were 
employed, and then the mRNA expression of TSLP in NHBE was measured by quantitative 
real-time PCR. TSLP mRNA expression was significantly enhanced by 10-10 M salmeterol, 10-10 
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M formoterol and 10-8 M salbutamol (Fig. 2B), suggesting that the enhancing effects of 2-
agonists on TSLP production were transcriptionally-regulated. It should be noted that 2-
agonists enhanced TSLP production by airway smooth muscle cells and lung fibroblasts as 
well as bronchial epithelial cells (Fig. 2C and 2D). We suppose that the production of TSLP by 
these lung tissue cells is particularly important because dendritic cells have to migrate through 
these airway interstitial cells to lymphopoietic tissues in order to present antigen information 
to naïve T cells. Therefore, enhanced TSLP production by lung tissue cells in response to 2-
agonists may lead to exacerbation of allergic airway inflammation, and this may partly explain 
the undesirable clinical effects of continuous 2-agonist monotherapy. 
 
 
Fig. 1. Cytokines induce production of TSLP by lung tissue cells. NHBE (A), BSMC (B) and 
NHLF (C) were treated with 10 ng/ml IL-4 alone, 10 ng/ml TNF- alone and a combination 
of both for 48 h. TSLP concentrations in the culture supernatants were quantified by ELISA. 
Data are shown as the mean ± SD of quadruplicate samples and are representative of at least 
three separate experiments. ** p < .01 compared with unstimulated control. Reprinted from 
Futamura et. Al., 2010. 
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Fig. 2. 2-agonists enhance cytokine-induced TSLP production by lung tissue cells. (A) 
NHBE were treated with different concentrations of two long-acting 2-agonists, salmeterol 
(SM) and formoterol (FM), or a short-acting 2-agonist, salbutamol (SB), in the presence of 10 
ng/ml IL-4 and 10 ng/ml TNF- for 48 h. TSLP concentrations in the culture supernatants 
were quantified by ELISA. (B) NHBE were treated with cytokines at 10 ng/ml in the 
presence and absence of the indicated concentrations of each 2-agonist (SM, FM, SB) for 6 h. 
The copy numbers of TSLP mRNA are shown. BSMC (C) and NHLF (D) were treated with 
the indicated concentrations of each 2-agonist (SM, FM, SB) in the presence of 10 ng/ml IL-
4 and 10 ng/ml TNF- for 48 h. TSLP concentrations in the culture supernatants were 
quantified by ELISA. All data are shown as the mean ± SD of quadruplicate samples and are 
representative of at least three separate experiments. ** p < .01 compared with IL-4 plus 
TNF-. Reprinted from Futamura et. Al., 2010. 
2.3 Effects of cAMP-elevating agents on cytokine-induced TSLP production 
It is well known that binding of 2-agonists to 2-adrenoceptors activates adenylate cyclase, 
resulting in generation of intracellular cAMP. We therefore examined the role of 
intracellular cAMP in the enhancement of TSLP production. The cells were stimulated with 
three cAMP-elevating agents, i.e., 8-bromoadenosine cyclic monophosphate, dibutyryl 
adenosine cyclic monophosphate (hereinafter referred to as 8-Br cAMP and db cAMP, 
respectively) and forskolin (an adenylate cyclase activator). All three agents caused 
significant enhancement of cytokine-induced TSLP production by the lung tissue cells (Fig. 
3). These results suggest that the enhancing effects of 2-agonists on TSLP production were 
mediated via upregulation of intracellular cAMP in these cells.  
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Fig. 3. Intracellular cAMP-elevating agents enhance cytokine-induced TSLP production by 
lung tissue cells. NHBE (A), BSMC (B) and NHLF (C) were treated with 10 ng/ml IL-4 and 
10 ng/ml TNF- in the presence and absence of the indicated concentrations of each cAMP-
elevating agent (8-Br cAMP, db cAMP, forskolin) for 48 h. TSLP concentrations in the 
culture supernatants were quantified by ELISA. Data are shown as the mean ± SD of 
quadruplicate samples and are representative of at least three separate experiments. * p < .05 
and ** p < .01 compared with IL-4 plus TNF-. Reprinted from Futamura et. Al., 2010. 
2.4 Effects of corticosteroid on cytokine-induced TSLP production 
According to the recently updated guidelines for asthma management, the preferred treatment 
regimen for patients with intermittent asthma is an inhaled short-acting 2-agonist, and the 
next step regimen is additional treatment with an inhaled corticosteroid. Therefore, we 
examined the effects of a corticosteroid, fluticasone, on the 2-agonist-induced increase in 
TSLP production. Simultaneous addition of various concentrations of fluticasone caused dose-
dependent, significant inhibition of both cytokine-induced (closed squares) and salmeterol-
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enhanced (closed triangles) TSLP production by NHBE (Fig. 4A, upper graph). Similar results 
were obtained in experiments using NHLF (Fig. 4A, lower graph) and BSMC (data not  
 
 
Fig. 4. Fluticasone inhibits TSLP production without affecting the intracellular cAMP level. (A) 
NHBE (upper graph) and NHLF (lower graph) were treated with 10 ng/ml IL-4 and 10 ng/ml 
TNF- with and without 10-10 M salmeterol (SM) for 48 h. The effects of simultaneous addition 
of the indicated concentrations of fluticasone on the TSLP production are shown. Data are 
shown as the mean ± SD of quadruplicate samples and are representative of at least three 
separate experiments. * p < .05 and ** p < .01 compared to without fluticasone. (B) NHBE were 
treated with 10 ng/ml IL-4 and 10 ng/ml TNF- with and without a 2-agonist (10-10 M SM, 10-
8 M SB) for 5 min. The effects of simultaneous addition of 10-8 M fluticasone on the intracellular 
cAMP levels are shown. Data are shown as the mean ± SD of triplicate samples and are 
representative of three separate experiments. Reprinted from Futamura et. al., 2010. 
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shown). Importantly, simultaneous treatment at the highest concentration of fluticasone  
(10-8 M), which can still considered to be clinically feasible, almost completely abrogated not 
only the cytokine-induced TSLP production but also the enhancement by the 2-agonists.  
2.5 Corticosteroid inhibition of TSLP production is not due to direct inhibition of 
cAMP signaling 
In order to clarify how corticosteroids might inhibit TSLP production, we examined the 
effects of fluticasone and 2-agonists on the intracellular cAMP level in NHBE. Addition of 
salmeterol or salbutamol significantly increased the cAMP level after 5 minutes of 
incubation. Addition of 10-8 M fluticasone showed no effect on the intracellular cAMP level 
whether in the presence or absence of a 2-agonist (Fig. 4B), indicating that corticosteroid 
inhibition of TSLP production is not due to direct inhibition of cAMP signaling. These 
results also suggest that corticosteroids inhibit TSLP synthesis by acting on the downstream 
signaling pathway of cAMP. 
To date, several mechanisms have been proposed to explain the synergistic action between 
corticosteroids and 2-agonists: induction and protection of 2-adrenoceptors by 
corticosteroids (Barnes, 2002), enhancement of translocation of glucocorticoid receptors into 
the nucleus by 2-agonists (Usami et.al., 2005) and post-transcriptional regulation to 
suppress expression of inflammatory genes (Kaur et.al., 2008). Our results may shed new 
light on the mechanisms by which combination therapy using an inhaled 2-agonist and an 
inhaled corticosteroid shows synergistic clinical efficacy in patients with asthma. 
3. Future challenges 
It remains to be clarified whether the enhancing effect of 2-agonists on cytokine production 
is specific to TSLP or not. Koyama et. al. demonstrated that TNF--induced production of 
granulocyte-macrophage colony-stimulating factor (GM-CSF), CCL5 and IL-8 by a human 
bronchial epithelial cell line, BEAS-2B, was significantly inhibited by procaterol, a 2-agonist 
(Koyama et. al., 1999). We confirmed that the cytokine-induced production of GM-CSF and 
CCL5, but not IL-8, by NHBE was significantly suppressed by 2-agonist treatment (data not 
shown). On the other hand, it was reported that rhinovirus-induced IL-6 production by 
NHBE was increased by salmeterol (Edwards et. Al., 2007), and we also found that the 
cytokine-induced production of IL-6 as well as TSLP by NHBE was significantly enhanced 
by simultaneous treatment with 2-agonists (data not shown). Thus, 2-agonists are able to 
crucially modulate the production of various inflammatory mediators through mechanisms 
that need to be further elucidated. 
4. Conclusion 
In this study, we focused on the effects of 2-agonists on the in vitro synthesis of TSLP, 
which is a key cytokine in the development of allergic diseases. We found that 2-agonists 
significantly enhanced cytokine-induced TSLP production by cultured primary human lung 
tissue cells. This enhancement may be partly responsible for the undesirable clinical effects 
of continuous 2-agonist monotherapy, and our other findings suggest that combination 
therapy with a corticosteroid might effectively inhibit TSLP-mediated allergic inflammation. 
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1. Introduction 
The update theory of hygiene implicates the gut microbiota in the increasing prevalence of 
allergy. Indeed, changes have been observed in the establishment of the gut microbiota over 
the last fifteen years, and dysbiosis has been demonstrated in allergic subjects by numerous 
clinical studies comparing the microbiota in subjects from countries with high and low 
prevalence of allergy, or subjects with or without allergic diseases. These results support the 
use of pro- and prebiotics to treat or prevent allergic diseases; however, randomized 
controlled trials, mainly concerning atopic dermatitis, rhinitis and asthma, provide 
conflicting data. The mechanism of action of probiotics has not been elucidated. 
Nevertheless, it appears that lactobacilli and bifidobacteria may mediate immune responses 
in a strain-specific way, and the interactions involved seem to include dendritic cells and 
detection of microbe-associated molecular patterns. Although these functional foods are 
promising, numerous issues, including the bacterial strains and doses to use, remain to be 
determined.  
1.1 The update theory of hygiene implicates the gut microbiota 
Over recent decades, the incidence of allergic diseases has been increasing in industrialized 
country whereas it is stable in developing countries (Mannino et al., 1998). This dichotomy 
and the large differences in the prevalence of allergy between genetically similar 
populations suggest that environmental factors make a large contribution to the 
development of allergies (Asher et al., 2010). Numerous studies agree on the importance of 
the T-helper CD4 lymphocyte population balance (Th1, Th2, Th17, T regulatory cells), and 
an imbalance towards Th2 is considered to be a major factor for the onset of allergic disease. 
Imbalances of this type have long been associated with the absence of triggers of the Th1 
immune response during childhood. Indeed, the increase in incidence of allergic diseases in 
industrialized countries coincides with widespread vaccination, antibiotic usage, declining 
family size, improvements in household amenities, and higher standards of personal 
cleanliness, all of which have reduced the opportunity for cross infection between children 
over the past century (the hygiene hypothesis, proposed by Strachan in 1989). However, the 
reduction of Th1 responses as a consequence of modern lifestyle cannot alone explain the 
high prevalence of allergic diseases in industrialized countries. Moreover, epidemiologic 
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studies show that the morbidity of autoimmune diseases, which are associated with a Th1 or 
Th17 profiles, are increasing and that helminthiasis, associated with a Th2 profile, are not 
associated with an increased risk of allergic disease (Bach, 2002). Recent work implicates 
therefore inadequate stimulation of either various regulatory T cell subsets, or Toll-like 
receptor (Okada et al., 2010;Akdis et al., 2004).  
Commensal bacteria of the intestinal microbiota play a crucial role in development of the 
intestinal immune system and modulation of the T helper cell balance. Rautava et al. 
extended this “hygiene hypothesis” and suggested that the initial composition of the infant 
gut microbiota may be a key determinant in the development of atopic disease (Rautava et 
al., 2004). Indeed, neonates are biased towards T helper type 2 responses with reference to 
adults (Adkins et al., 2004;Protonotariou et al., 2004), and the first bacteria to colonize the 
infant’s gut are the first stimuli for post-natal maturation of the T-helper balance. The 
immature Th2-dominant neonatal response undergoes environment-driven maturation via 
microbial contact during the early postnatal period resulting in a gradual inhibition of the 
Th2 response and an increase of the Th1 response and prevention of allergic diseases. This 
hypothesis is consistent with various observations: the delayed colonization of the digestive 
tract associated with changes in lifestyle over the last 15 years (Campeotto et al., 
2007;Adlerberth and Wold, 2009); and evidence that caesarian section (Kero et al., 
2002;Laubereau et al., 2004), prematurity (Agosti et al., 2003), and exposure to antibiotics 
during pregnancy (McKeever et al., 2002) —all factors which modify establishment of the 
gut microbiota— are associated with a higher risk of atopic disease. 
2. The gut microbiota and its functions 
The composition of microbial communities in the gut was first investigated through culture-
based studies, leading to estimates of 400 to 500 different species in the adult human 
intestinal tract (Manson et al., 2008). The dominant microbiota (109-1011 CFU.g-1) is composed 
of obligate anaerobes, including Gram-negative bacilli such as Bacteroides, Gram-positive 
bacilli such as Bifidobacterium, Eubacterium, and Gram-positive cocci. The subdominant 
microbiota (106-108 CFU.g-1) is composed of facultative anaerobes including various species 
of enterobacteria, notably Escherichia coli, and species of the Enterococcus and Lactobacillus 
genera. With population densities of below 106 CFU.g-1, this microbiota is often extremely 
variable and transient.  
The use of culture-independent approaches has provided novel insights into the gut 
microbiota community (Manson et al., 2008). Many of the techniques used are based on 
analysis of 16S rRNA gene sequences, and studies have exploited combinations of 16S rRNA 
gene libraries, DNA microarrays, 16S rRNA gene fingerprinting, fluorescent in situ 
hybridization, and quantitative PCR. These culture-independent techniques have shown 
that the intestinal microbiota community is more complex than previously described. The 
proportion of bacteria in the adult intestine that can be cultured varies between 15 and 85% 
(Eckburg et al., 2005); over 1200 bacterial species have been characterized (Rajilic-Stojanovic 
et al., 2007), and current estimates are that there are up to 1000 bacterial species per 
individual and over 5000 different species in total in human intestines (Zoetendal et al., 
2008). Most of the gut microbiota are from only four major phyla (Tap et al., 2009). Firmicutes 
and Bacteroidetes are the most abundant, and Actinobacteria - including bifidobacteria - and 
Proteobacteria are less abundant despite representing more than 1% of the total microbiota. 
Adult fecal microbiota has been demonstrated to be individual-specific and relatively stable 
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over time (Rajilic-Stojanovic et al., 2009). However, even though each individual harbors a 
unique microbiota, a number of microbial species are present in all individuals, consistent 
with the existence of a universal phylogenetic core to the human intestinal microbiota 
(Rajilic-Stojanovic et al., 2009;Tap et al., 2009). 
The intestinal ecosystem develops rapidly during the neonatal stage of life. The intestine is 
sterile at birth and is colonized by bacteria following contact with the maternal microbiota 
and the surrounding environment. Little is known about the factors that lead to the 
establishment of particular bacterial strains. Colonizing bacteria originate mainly from the 
mother; the maternal gut microbiota is a major source and other sources include the 
microbiota of the vagina, perineum, and skin. Breast milk has also been demonstrated to be 
a source of lactic acid bacteria (Martin et al., 2009;Gueimonde et al., 2007). Infants encounter 
numerous bacteria in the environment including the microbiota of food and the microbiota 
of the skin of parents, siblings and nurses. Consequently, the number of bacterial species, 
mainly obligate anaerobes, increases with time in the infant gut. As a result of the diversity 
of exposure, there is substantial inter-individual variability in the composition and patterns 
of bacterial colonization during the first weeks of life (Penders et al., 2006c;Palmer et al., 
2007;Vaishampayan et al., 2010). However, by the end of the first year of life, the bacterial 
composition in the gut converges toward an adult-like microbiota profile (Palmer et al., 
2007). Various external factors can affect the pattern of bacterial colonization (for review see 
(Adlerberth and Wold, 2009;Vael and Desager, 2009;Campeotto et al., 2007). Infants born by 
cesarean section are deprived of contact with their mother’s gut and vaginal microbiota, 
which decreases bacterial diversity and colonization by obligate anaerobes, particularly 
bifidobacteria and Bacteroides. The mode of infant feeding also strongly affects bacterial 
establishment, with a dominant colonization by bifidobacteria being a characteristic 
distinguishing breastfed from formula-fed infants. However, improvements in infant 
formulas have led to there now being only minor differences in colonization according to 
feeding method (Adlerberth and Wold, 2009;Campeotto et al., 2007). Finally, the 
establishment of gut microbiota in infants in industrialized countries appears to have been 
affected in modern times, most likely due to improved hygiene and general cleanliness in 
these countries, resulting in reduced bacterial exposure (Adlerberth and Wold, 
2009;Campeotto et al., 2007).  
Although the gut microbiota community was for several decades mostly studied to 
elucidate pathogenic relationships, it is now clear that most microorganism-host interactions 
in the gut are, in fact, commensal or even mutualistic (Bik, 2009;Dethlefsen et al., 2007). This 
complex ecosystem has various major functions (Fujimura et al., 2010). Colonic fermentation 
of non-digestible dietary residues and endogenous mucus supplies energy and nutritive 
products to the bacteria. It also plays a role in the trophic functions of the intestinal 
epithelium (Wong et al., 2006). The barrier effect, which involves secretion of antimicrobial 
molecules, competition for nutrients, and attachment to ecological niches, refers to a 
resistance to colonization by exogenous or opportunistic bacteria present at a low level in 
the gut (Stecher and Hardt, 2008). Finally, the gut microbial community has a major immune 
function. The contribution of the gut microbiota to immune system maturation has been 
demonstrated by the description of major abnormalities of the immune system in germ-free 
mice (Smith et al., 2007). Intestinal IgA-secreting plasma cells are rare in germ-free animals, 
and the Peyer’s patches are smaller and contain fewer lymphoid follicles than those in 
conventional mice. The T cell content of the mucosal immune system is also low in germ-
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free animals, and particularly the CD4+ cells of the lamina propria. Spleen and lymph nodes 
are relatively structureless with abnormal B- and T- cell zones. These morphologic features 
are associated with substantial functional abnormalities, such as hypogammaglobulinemia, 
a Th2 cell shift and defects in oral tolerance induction (Round et al., 2010). Recent reviews 
have highlighted how the microbiota elicits innate and adaptative immune mechanisms that 
cooperate to protect the host and maintain intestinal homeostasis (Hooper and Macpherson, 
2010;Garrett et al., 2010). Colonization of germ-free mice by a single species of bacteria e.g. 
Bacteroides fragilis (Mazmanian et al., 2005) or segmented filamentous bacteria (Gaboriau-
Routhiau et al., 2009), has been shown to be sufficient to restore the development of a 
multifaceted adaptative immune response. The capacity to stimulate steady-state gut T cell 
responses appears to be restricted to a small number of bacteria (Gaboriau-Routhiau et al., 
2009) and certain strains. Indeed, the immunostimulatory properties of Bifidobacterium are 
strain-specific (Medina et al., 2007;Menard et al., 2008) and only some strains of 
Bifidobacterium are able to induce Foxp3+ regulatory cells or be associated with protection 
from respiratory and oral allergy in mice (Lyons et al., 2010). B. infantis restored the 
susceptibility to oral tolerance induction in germ-free mice only if the inoculation was at the 
neonatal stage (Sudo et al., 1997). This suggests that there is a ‘time window of opportunity’ 
during the neonatal phase, consistent with observations with probiotics (Feleszko et al., 
2007).  
3. Microbiota and allergy 
The extended version of the hygiene hypothesis implicating the gut microbiota is supported 
by several clinical studies which have shown a relationship between allergic disease and gut 
microbiota. In particular, they have shown that the composition of the bacterial community 
in the feces differ between children who live in countries with high and low prevalence of 
allergy, as well between children with or without allergic diseases. 
3.1 Is gut microbiota different between healthy individuals and allergic subjects? 
Case-control studies 
Numerous studies have addressed the composition of the microbiota in healthy and allergic 
subjects. Some of the first studies (Bjorksten et al., 1999;Sepp et al., 1997) compared the 
microbiota between two-year old children in countries with high (Sweden) and low 
(Estonia) incidence of allergic diseases. Irrespective of country of residence, allergic children 
were colonized by fewer lactobacilli but had higher counts of aerobic bacteria, especially 
Enterobacteriaceae and staphylococci and lower counts of Bacteroides. A prospective study 
(Bjorksten et al., 2001) found that children who developed atopic dermatitis and/or positive 
skin prick test results during the two first years of life were less often colonized with 
enterococci during the first month of life and with bifidobacteria during the first year of life. 
Furthermore, allergic infants had higher counts of clostridia at 3 months of age and lower 
counts of Bacteroides at 12 months. The prevalence of colonization with Staphylococcus aureus 
was also higher in allergic children than the reference group at 6 months old.  
Case-control studies confirmed differences of the gut microbiota composition between 
allergic and healthy subjects but the differences identified concerned various particular 
genera and species, including Bifidobacterium, Clostridium, Bacteroides, Lactobacillus and 
Enterobacteriaceae. Indirect methods suggested an association between allergy and 
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Clostridium difficile. Allergic infants had higher fecal concentrations of the rarely detected i-
caproic acid, which has been associated with the presence of Clostridium difficile (Bottcher et 
al., 2000) and higher C. difficile IgG antibody levels at one year than non-allergic infants 
(Woodcock et al., 2002). However, counting bacteria by FISH analysis indicated that 
colonization by Clostridium sp. was lower in allergic than reference subjects (Mah et al., 2006) 
and no significant difference in Clostridium counts were found between preschool controls 
and children with allergy-associated atopic eczema/dermatitis syndrome (AAEDS) and 
non-allergic atopic eczema/dermatitis syndrome (NAAEDS) (Kendler et al., 2006) 
Numerous other studies reported quantitative differences in colonization with 
Bifidobacterium, a dominant genus in infant fecal microbiota which may have beneficial 
effects (Ventura et al., 2004). The prevalence of Bifidobacterium has been found to be similar 
in healthy and allergic subjects, whatever the allergic disease (Stsepetova et al., 
2007;Waligora-Dupriet et al., 2011), and for atopic dermatitis (Gore et al., 2008), and 
wheezing (Murray et al., 2005). However, the findings of one study are discordant (Sepp et 
al., 2005) with none of the 5-year-old children with atopic dermatitis and only one child with 
bronchial asthma colonized with bifidobacteria. Besides, low levels of bifidobacterial 
colonization have been observed in infants suffering from atopic dermatitis (Kirjavainen et 
al., 2001;Watanabe et al., 2003;Mah et al., 2006) and in infants suffering from atopic dermatitis 
and wheezing; note that these results have been contradicted by studies comparing healthy 
subjects with wheezing infants without other symptoms (Murray et al., 2005) and with 
patients suffering from both atopic dermatitis and food allergy (Penders et al., 2006a).  
3.2 Does dysbiosis precede allergic symptoms? Prospective studies 
Some prospective studies report that modifications of the composition of the intestinal 
microbiota can be detected before any atopic syndrome, suggesting that bacteria implicated 
in the maturation of the immune system may be important. The bacterial fatty acid profile in 
fecal samples differed significantly between 3-week-old infants in whom atopy was and was 
not developing. The stools of atopic subjects had more clostridia and tended to have fewer 
bifidobacteria than those of non atopic subjects, resulting in a reduced ratio of bifidobacteria 
to clostridia (Kalliomaki et al., 2001a). The Koala Birth Cohort Study in the Netherlands 
confirmed these results by showing that gut dysbiosis precedes the manifestation of atopic 
symptoms and atopic sensitization (Penders et al., 2007). In particular, C. difficile was 
associated with all atopic symptoms and sensitization. The presence of Escherichia coli was 
associated with a higher risk of developing (non-atopic) eczema, this risk increasing with 
increasing E. coli counts; infants colonized with C. difficile were at higher risk of developing 
atopic dermatitis, recurrent wheeze and allergic sensitisation. As E. coli was only associated 
with eczema and C. difficile was associated with all atopic outcomes, the underlying 
mechanisms may be different. Colonization with clostridia, including C. difficile, was 
associated with allergy development up to age 2 years in several studies (Kalliomaki et al., 
2001a;Bjorksten et al., 2001;Penders et al., 2007) but not in others (Adlerberth et al., 
2007;Sjogren et al., 2009;Songjinda et al., 2007). Fecal colonization at age 3 weeks with 
Clostridium coccoides subcluster XIVa species has been described as an early indicator of 
possible asthma later in life (Vael et al., 2008;Vael et al., 2011). However, Verhulst et al. (2008) 
found an association between antibiotics, anaerobic bacteria and wheezing during the first 
year of life, but increasing levels of Clostridium were protective against wheezing. These 
studies considered different Clostridium species and the genus Clostridium is a very 
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free animals, and particularly the CD4+ cells of the lamina propria. Spleen and lymph nodes 
are relatively structureless with abnormal B- and T- cell zones. These morphologic features 
are associated with substantial functional abnormalities, such as hypogammaglobulinemia, 
a Th2 cell shift and defects in oral tolerance induction (Round et al., 2010). Recent reviews 
have highlighted how the microbiota elicits innate and adaptative immune mechanisms that 
cooperate to protect the host and maintain intestinal homeostasis (Hooper and Macpherson, 
2010;Garrett et al., 2010). Colonization of germ-free mice by a single species of bacteria e.g. 
Bacteroides fragilis (Mazmanian et al., 2005) or segmented filamentous bacteria (Gaboriau-
Routhiau et al., 2009), has been shown to be sufficient to restore the development of a 
multifaceted adaptative immune response. The capacity to stimulate steady-state gut T cell 
responses appears to be restricted to a small number of bacteria (Gaboriau-Routhiau et al., 
2009) and certain strains. Indeed, the immunostimulatory properties of Bifidobacterium are 
strain-specific (Medina et al., 2007;Menard et al., 2008) and only some strains of 
Bifidobacterium are able to induce Foxp3+ regulatory cells or be associated with protection 
from respiratory and oral allergy in mice (Lyons et al., 2010). B. infantis restored the 
susceptibility to oral tolerance induction in germ-free mice only if the inoculation was at the 
neonatal stage (Sudo et al., 1997). This suggests that there is a ‘time window of opportunity’ 
during the neonatal phase, consistent with observations with probiotics (Feleszko et al., 
2007).  
3. Microbiota and allergy 
The extended version of the hygiene hypothesis implicating the gut microbiota is supported 
by several clinical studies which have shown a relationship between allergic disease and gut 
microbiota. In particular, they have shown that the composition of the bacterial community 
in the feces differ between children who live in countries with high and low prevalence of 
allergy, as well between children with or without allergic diseases. 
3.1 Is gut microbiota different between healthy individuals and allergic subjects? 
Case-control studies 
Numerous studies have addressed the composition of the microbiota in healthy and allergic 
subjects. Some of the first studies (Bjorksten et al., 1999;Sepp et al., 1997) compared the 
microbiota between two-year old children in countries with high (Sweden) and low 
(Estonia) incidence of allergic diseases. Irrespective of country of residence, allergic children 
were colonized by fewer lactobacilli but had higher counts of aerobic bacteria, especially 
Enterobacteriaceae and staphylococci and lower counts of Bacteroides. A prospective study 
(Bjorksten et al., 2001) found that children who developed atopic dermatitis and/or positive 
skin prick test results during the two first years of life were less often colonized with 
enterococci during the first month of life and with bifidobacteria during the first year of life. 
Furthermore, allergic infants had higher counts of clostridia at 3 months of age and lower 
counts of Bacteroides at 12 months. The prevalence of colonization with Staphylococcus aureus 
was also higher in allergic children than the reference group at 6 months old.  
Case-control studies confirmed differences of the gut microbiota composition between 
allergic and healthy subjects but the differences identified concerned various particular 
genera and species, including Bifidobacterium, Clostridium, Bacteroides, Lactobacillus and 
Enterobacteriaceae. Indirect methods suggested an association between allergy and 
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Clostridium difficile. Allergic infants had higher fecal concentrations of the rarely detected i-
caproic acid, which has been associated with the presence of Clostridium difficile (Bottcher et 
al., 2000) and higher C. difficile IgG antibody levels at one year than non-allergic infants 
(Woodcock et al., 2002). However, counting bacteria by FISH analysis indicated that 
colonization by Clostridium sp. was lower in allergic than reference subjects (Mah et al., 2006) 
and no significant difference in Clostridium counts were found between preschool controls 
and children with allergy-associated atopic eczema/dermatitis syndrome (AAEDS) and 
non-allergic atopic eczema/dermatitis syndrome (NAAEDS) (Kendler et al., 2006) 
Numerous other studies reported quantitative differences in colonization with 
Bifidobacterium, a dominant genus in infant fecal microbiota which may have beneficial 
effects (Ventura et al., 2004). The prevalence of Bifidobacterium has been found to be similar 
in healthy and allergic subjects, whatever the allergic disease (Stsepetova et al., 
2007;Waligora-Dupriet et al., 2011), and for atopic dermatitis (Gore et al., 2008), and 
wheezing (Murray et al., 2005). However, the findings of one study are discordant (Sepp et 
al., 2005) with none of the 5-year-old children with atopic dermatitis and only one child with 
bronchial asthma colonized with bifidobacteria. Besides, low levels of bifidobacterial 
colonization have been observed in infants suffering from atopic dermatitis (Kirjavainen et 
al., 2001;Watanabe et al., 2003;Mah et al., 2006) and in infants suffering from atopic dermatitis 
and wheezing; note that these results have been contradicted by studies comparing healthy 
subjects with wheezing infants without other symptoms (Murray et al., 2005) and with 
patients suffering from both atopic dermatitis and food allergy (Penders et al., 2006a).  
3.2 Does dysbiosis precede allergic symptoms? Prospective studies 
Some prospective studies report that modifications of the composition of the intestinal 
microbiota can be detected before any atopic syndrome, suggesting that bacteria implicated 
in the maturation of the immune system may be important. The bacterial fatty acid profile in 
fecal samples differed significantly between 3-week-old infants in whom atopy was and was 
not developing. The stools of atopic subjects had more clostridia and tended to have fewer 
bifidobacteria than those of non atopic subjects, resulting in a reduced ratio of bifidobacteria 
to clostridia (Kalliomaki et al., 2001a). The Koala Birth Cohort Study in the Netherlands 
confirmed these results by showing that gut dysbiosis precedes the manifestation of atopic 
symptoms and atopic sensitization (Penders et al., 2007). In particular, C. difficile was 
associated with all atopic symptoms and sensitization. The presence of Escherichia coli was 
associated with a higher risk of developing (non-atopic) eczema, this risk increasing with 
increasing E. coli counts; infants colonized with C. difficile were at higher risk of developing 
atopic dermatitis, recurrent wheeze and allergic sensitisation. As E. coli was only associated 
with eczema and C. difficile was associated with all atopic outcomes, the underlying 
mechanisms may be different. Colonization with clostridia, including C. difficile, was 
associated with allergy development up to age 2 years in several studies (Kalliomaki et al., 
2001a;Bjorksten et al., 2001;Penders et al., 2007) but not in others (Adlerberth et al., 
2007;Sjogren et al., 2009;Songjinda et al., 2007). Fecal colonization at age 3 weeks with 
Clostridium coccoides subcluster XIVa species has been described as an early indicator of 
possible asthma later in life (Vael et al., 2008;Vael et al., 2011). However, Verhulst et al. (2008) 
found an association between antibiotics, anaerobic bacteria and wheezing during the first 
year of life, but increasing levels of Clostridium were protective against wheezing. These 
studies considered different Clostridium species and the genus Clostridium is a very 
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heterogeneous group comprising several different clusters (Stackebrandt et al., 1999). 
Indeed, it seems unlikely that all members of this genus exert the same effects on the human 
immune system (Penders et al., 2007).  
Children not developing allergy before age 2 years have been shown to be more frequently 
colonized with bifidobacteria than children developing allergy (Bjorksten et al., 2001), but 
this decreased prevalence of Bifidobacterium in children suffering allergies was not confirmed 
in all studies (Songjinda et al., 2007;Penders et al., 2006a;Adlerberth et al., 2007). Differences 
in patterns of colonization by bifidobacteria species have also been observed but no clear 
consensus exists. Young et al (2004) compared the populations of bifidobacteria in feces from 
children aged 25 to 35 days in Ghana (which has a low prevalence of atopy), New Zealand, 
and the United Kingdom (high-prevalence countries): almost all fecal samples from Ghana 
contained Bifidobacterium longum subsp infantis whereas those from the children living in the 
other countries did not. The authors suggested that place of birth influences the patterns of 
bifidobacterial species present. B. adolescentis has been found in the fecal microbiota of both 
allergic infants (Ouwehand et al., 2001;He et al., 2001) and non-allergic infants (Sjogren et al., 
2009). Similarly, B. catenulatum/pseudocatenulatum has been isolated from both allergic (Gore 
et al., 2008) and non-allergic infants (Stsepetova et al., 2007). Some authors report that 
restricted Bifidobacterium diversity is linked with allergy (Stsepetova et al., 2007) but again, 
this was not confirmed in other studies at the species (Sjogren et al., 2009;Waligora-Dupriet 
et al., 2011) or strain level (Waligora-Dupriet et al., 2011). It has been suggested that the 
intrinsic properties of bacterial strains may be pertinent. Indeed, in vitro, bifidobacterial 
species differentially affected expression of cell surface markers and cytokine production by 
dendritic cells harvested from cord blood. B. bifidum, B. longum, and B. pseudocatenulatum, 
species commonly detected in children in New Zealand and the United Kingdom increased 
the expression of the dendritic-cell activation marker CD83 and induce IL-10 production, 
whereas B. infantis, a species commonly isolated in Ghana, does not (Young et al, 2004). By 
contrast, heat-inactivated B. longum subsp longum and B. adolescentis, known as adult-type 
bifidobacteria, were significantly stronger inducers of pro-inflammatory cytokine (IL-12 and 
TNF-alpha) production by a murine macrophage cell line than B. bifidum, B. breve, and B. 
longum subsp infantis usually isolated from infants (He et al., 2002). The Th1 stimulation 
profile induced by B. adolescentis (Karlsson et al., 2004;He et al., 2002) may intensify 
pathology in allergic infants (He et al., 2002). However, the properties of intestinal 
bifidobacteria are highly strain-dependent (Matto et al., 2004), and this is particularly true of 
immunostimulatory properties (Menard et al., 2008;Medina et al., 2007).  
Bacteroidaceae are also associated with allergic development, although, as for clostridia and 
bifidobacteria, findings are contradictory. Indeed, Bacteroides colonization of the gut was not 
found to be linked to allergy in several studies (Adlerberth et al., 2007;Kalliomaki et al., 
2001a; Bjorksten et al., 2001; Sjogren et al., 2009), but colonization with the B. fragilis group at 
age 3 weeks has been associated with a higher risk of developing asthma later in life (Vael et 
al., 2008;Vael et al., 2011). A high level of Bacteroides colonization positively correlated with 
IgE in children with atopic dermatitis (Kirjavainen et al., 2002). Moreover, fecal Bacteroides 
strains induced high levels of Th2 cytokine production by peripheral blood monocyte cells 
from patients suffering from Japanese Cedar Pollinosis (Odamaki et al., 2007). 
Discrepancies between studies might be the consequence of the methods used to study the 
gut microbiota. Indeed, in the same study, some differences were observed with FISH but 
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that were not detected by bacterial cultivation (Kalliomaki et al., 2001a). These discrepancies 
are such that it is not possible to conclude about the association of particular species, genera 
or groups with the development of allergy, although it seems that the diversity of the gut 
microbiota is a major determinant in allergy risk. Interestingly, a large recent study did not 
find any relationships between the presence of various particular bacteria and allergy 
development up to 18 months of age (Adlerberth et al., 2007), but showed that infants who 
developed allergy had a lower diversity in their gut microbiota at one week of age (Wang et 
al., 2008). 
Despite prospective studies showing that modifications of the gut microbiota composition 
can be detected before any atopic syndrome, these epidemiological studies cannot 
demonstrate which of these factors appears first. Atopy could be linked to a mucosal state 
favoring some bacterial populations to the detriment of others. In a mouse model of food 
allergy, mice with high and low anaphylaxis scores showed differences in intestinal 
microbiota composition: high responders exhibited less staphylococcus colonization 
(Rodriguez et al., 2011). The composition of the intestinal bacteria fluctuated significantly 
during the pollen season in adults with IgE-dependent pollinosis, with colonization by the 
Bacteroides fragilis group increasing with pollen dispersal, especially at the end of the pollen 
season (Odamaki et al., 2007). It is clear that the cause-and-effect relationship between the 
composition of the microbiota and allergic diseases remains to be determined.  
4. Probiotics and allergic diseases 
Despite discrepancies between studies, there is mounting evidence of a relationship between 
the intestinal microbiota and allergy. It therefore follows that a modulation of the gut 
microbiota may help prevent allergic diseases and this notion supports the use of probiotics, 
prebiotics and synbiotics. Probiotics are currently defined as “live microorganisms which 
when administered in adequate amounts confer a health benefit on the host” (FAO/WHO, 
2001; FAO/WHO 2001, 2002). The most widely used probiotics are lactic acid bacteria, 
specifically Lactobacillus and Bifidobacterium species (Williams, 2010). The yeast Saccharomyces 
boulardii is also used. Although the efficacy of probiotics is sometimes debatable, they offer 
substantial potential benefits to health and are safe for human use. 
The mechanisms of action of “probiotic” strains in allergic diseases may include modulation 
of the gut microbiota, maturation of the gut barrier, stimulation of the immune system and 
immunomodulation. However, the effects of probiotics described in experimental models 
need to be confirmed for human use through randomized controlled trials. We conducted 
bibliographic searches in the PubMed/Medline database for the following terms (all field): 
allergy AND probiotic*”, and results limited to randomized controlled trials identified 99 
publications. 
4.1 Clinical impact of probiotics in atopic/allergic diseases 
4.1.1 Probiotics in the treatment of atopic dermatitis 
Fifty studies have evaluated clinical consequences of probiotics in the treatment of atopic 
dermatitis (AD) in infants and children, and between them have studied about 1100 
subjects. AD is a chronic highly pruritic inflammatory skin disease including IgE- and non-
IgE-mediated mechanisms. It commonly occurs during early infancy but can persist or even 
start in adulthood. It includes a wide clinical spectrum from minor forms to major 
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heterogeneous group comprising several different clusters (Stackebrandt et al., 1999). 
Indeed, it seems unlikely that all members of this genus exert the same effects on the human 
immune system (Penders et al., 2007).  
Children not developing allergy before age 2 years have been shown to be more frequently 
colonized with bifidobacteria than children developing allergy (Bjorksten et al., 2001), but 
this decreased prevalence of Bifidobacterium in children suffering allergies was not confirmed 
in all studies (Songjinda et al., 2007;Penders et al., 2006a;Adlerberth et al., 2007). Differences 
in patterns of colonization by bifidobacteria species have also been observed but no clear 
consensus exists. Young et al (2004) compared the populations of bifidobacteria in feces from 
children aged 25 to 35 days in Ghana (which has a low prevalence of atopy), New Zealand, 
and the United Kingdom (high-prevalence countries): almost all fecal samples from Ghana 
contained Bifidobacterium longum subsp infantis whereas those from the children living in the 
other countries did not. The authors suggested that place of birth influences the patterns of 
bifidobacterial species present. B. adolescentis has been found in the fecal microbiota of both 
allergic infants (Ouwehand et al., 2001;He et al., 2001) and non-allergic infants (Sjogren et al., 
2009). Similarly, B. catenulatum/pseudocatenulatum has been isolated from both allergic (Gore 
et al., 2008) and non-allergic infants (Stsepetova et al., 2007). Some authors report that 
restricted Bifidobacterium diversity is linked with allergy (Stsepetova et al., 2007) but again, 
this was not confirmed in other studies at the species (Sjogren et al., 2009;Waligora-Dupriet 
et al., 2011) or strain level (Waligora-Dupriet et al., 2011). It has been suggested that the 
intrinsic properties of bacterial strains may be pertinent. Indeed, in vitro, bifidobacterial 
species differentially affected expression of cell surface markers and cytokine production by 
dendritic cells harvested from cord blood. B. bifidum, B. longum, and B. pseudocatenulatum, 
species commonly detected in children in New Zealand and the United Kingdom increased 
the expression of the dendritic-cell activation marker CD83 and induce IL-10 production, 
whereas B. infantis, a species commonly isolated in Ghana, does not (Young et al, 2004). By 
contrast, heat-inactivated B. longum subsp longum and B. adolescentis, known as adult-type 
bifidobacteria, were significantly stronger inducers of pro-inflammatory cytokine (IL-12 and 
TNF-alpha) production by a murine macrophage cell line than B. bifidum, B. breve, and B. 
longum subsp infantis usually isolated from infants (He et al., 2002). The Th1 stimulation 
profile induced by B. adolescentis (Karlsson et al., 2004;He et al., 2002) may intensify 
pathology in allergic infants (He et al., 2002). However, the properties of intestinal 
bifidobacteria are highly strain-dependent (Matto et al., 2004), and this is particularly true of 
immunostimulatory properties (Menard et al., 2008;Medina et al., 2007).  
Bacteroidaceae are also associated with allergic development, although, as for clostridia and 
bifidobacteria, findings are contradictory. Indeed, Bacteroides colonization of the gut was not 
found to be linked to allergy in several studies (Adlerberth et al., 2007;Kalliomaki et al., 
2001a; Bjorksten et al., 2001; Sjogren et al., 2009), but colonization with the B. fragilis group at 
age 3 weeks has been associated with a higher risk of developing asthma later in life (Vael et 
al., 2008;Vael et al., 2011). A high level of Bacteroides colonization positively correlated with 
IgE in children with atopic dermatitis (Kirjavainen et al., 2002). Moreover, fecal Bacteroides 
strains induced high levels of Th2 cytokine production by peripheral blood monocyte cells 
from patients suffering from Japanese Cedar Pollinosis (Odamaki et al., 2007). 
Discrepancies between studies might be the consequence of the methods used to study the 
gut microbiota. Indeed, in the same study, some differences were observed with FISH but 
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that were not detected by bacterial cultivation (Kalliomaki et al., 2001a). These discrepancies 
are such that it is not possible to conclude about the association of particular species, genera 
or groups with the development of allergy, although it seems that the diversity of the gut 
microbiota is a major determinant in allergy risk. Interestingly, a large recent study did not 
find any relationships between the presence of various particular bacteria and allergy 
development up to 18 months of age (Adlerberth et al., 2007), but showed that infants who 
developed allergy had a lower diversity in their gut microbiota at one week of age (Wang et 
al., 2008). 
Despite prospective studies showing that modifications of the gut microbiota composition 
can be detected before any atopic syndrome, these epidemiological studies cannot 
demonstrate which of these factors appears first. Atopy could be linked to a mucosal state 
favoring some bacterial populations to the detriment of others. In a mouse model of food 
allergy, mice with high and low anaphylaxis scores showed differences in intestinal 
microbiota composition: high responders exhibited less staphylococcus colonization 
(Rodriguez et al., 2011). The composition of the intestinal bacteria fluctuated significantly 
during the pollen season in adults with IgE-dependent pollinosis, with colonization by the 
Bacteroides fragilis group increasing with pollen dispersal, especially at the end of the pollen 
season (Odamaki et al., 2007). It is clear that the cause-and-effect relationship between the 
composition of the microbiota and allergic diseases remains to be determined.  
4. Probiotics and allergic diseases 
Despite discrepancies between studies, there is mounting evidence of a relationship between 
the intestinal microbiota and allergy. It therefore follows that a modulation of the gut 
microbiota may help prevent allergic diseases and this notion supports the use of probiotics, 
prebiotics and synbiotics. Probiotics are currently defined as “live microorganisms which 
when administered in adequate amounts confer a health benefit on the host” (FAO/WHO, 
2001; FAO/WHO 2001, 2002). The most widely used probiotics are lactic acid bacteria, 
specifically Lactobacillus and Bifidobacterium species (Williams, 2010). The yeast Saccharomyces 
boulardii is also used. Although the efficacy of probiotics is sometimes debatable, they offer 
substantial potential benefits to health and are safe for human use. 
The mechanisms of action of “probiotic” strains in allergic diseases may include modulation 
of the gut microbiota, maturation of the gut barrier, stimulation of the immune system and 
immunomodulation. However, the effects of probiotics described in experimental models 
need to be confirmed for human use through randomized controlled trials. We conducted 
bibliographic searches in the PubMed/Medline database for the following terms (all field): 
allergy AND probiotic*”, and results limited to randomized controlled trials identified 99 
publications. 
4.1 Clinical impact of probiotics in atopic/allergic diseases 
4.1.1 Probiotics in the treatment of atopic dermatitis 
Fifty studies have evaluated clinical consequences of probiotics in the treatment of atopic 
dermatitis (AD) in infants and children, and between them have studied about 1100 
subjects. AD is a chronic highly pruritic inflammatory skin disease including IgE- and non-
IgE-mediated mechanisms. It commonly occurs during early infancy but can persist or even 
start in adulthood. It includes a wide clinical spectrum from minor forms to major 
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symptoms including erythrodermic rash and can be associated with other atopic diseases 
such as food allergy, asthma, and allergic rhinitis. To evaluate the effects of probiotics on 
AD, a rigorous definition of study participants is necessary. The diagnosis of AD is currently 
based on diagnostic criteria scales developed by Hanifin and Rafka in 1980 and by the 
"United Kingdom Working party" in 1994 (in Roguedas-Contios and Misery, 2011). It is 
equally important that diseases outcome measures used in treatment studies are both valid 
and reliable. Three of the various eczema outcome measures have been shown to be reliable: 
SCORing Atopic Dermatitis (SCORAD), the Eczema Area and Severity Index (EASI) and the 
Patient Oriented Eczema Measure (POEM). SCORAD is commonly used in studies of 
probiotics. It combines an estimation of the intensity and extent of the eczema with a 
subjective itch. However, it assesses a clinical state of the disease at a particular time point 
without taking into account overall severity or evolution of the disease (Société Française de 
Dermatologie, 2005). Some quality of life scales are also used, for example the Infant 
Dermatitis Quality Of Life (IDQOL), Dermatitis Family Impact (DFI), and Dermatitis Family 
Impact Questionnaire (DFIQ) scores (Gerasimov et al., 2010; Weston et al., 2005) scores.  
The age range of subjects included varies between studies: around weaning (median 5 
months old) (Brouwer et al., 2006;Isolauri et al., 2000;Kirjavainen et al., 2003;Viljanen et al., 
2005b;Gruber et al., 2007), around 1 year old (Weston et al., 2005;Folster-Holst et al., 2006), 
and around 5 years old (Rosenfeldt et al., 2003, 2004; Sistek et al., 2006; Woo et al., 2010). 
Seven of these publications describe effects of Lactobacillus rhamnosus GG LGG in infants but 
report contradictory results (Brouwer et al., 2006;Isolauri et al., 2000;Kirjavainen et al., 
2003;Viljanen et al., 2005b;Gruber et al., 2007;Folster-Holst et al., 2006;Nermes et al., 2011). 
Two of them (Isolauri et al., 2000;Kirjavainen et al., 2003) showed a significant decrease of the 
SCORAD score, but both these studies included only small groups of infants (27 and 35). 
Moreover, the heat-inactivated LGG used in Kirjavainen’s study induced adverse 
gastrointestinal symptoms and diarrhea leading to the recruitment of patients being stopped 
after the pilot phase (Kirjavainen et al., 2003). Six other studies, similar in terms of subjects 
included and protocol, did not find any improvement in SCORAD scores following LGG 
supplementation (Folster-Holst et al., 2006;Brouwer et al., 2006;Gruber et al., 2007;Viljanen et 
al., 2005b;Nermes et al., 2011;Rose et al., 2010). Other probiotic strains have been studied, and 
Bifidobacterium lactis Bb12 (Isolauri et al., 2000), L. sakei KCTC 10755B0 and L. fermentum VRI-
003 (Weston et al., 2005) induced significant decreases in SCORAD scores. In the last of these 
studies, the effects of L. fermentum VRI-003 were found to persist two months after the end 
of supplementation. Four studies used a L. rhamnosus strain (not LGG) alone (Brouwer et al., 
2006) or mixed with L. reuteri (Rosenfeldt et al., 2003) or with other Lactobacillus sp. and 
Bifidobacterium sp. (Viljanen et al., 2005b;Sistek et al., 2006). These studies did not detect 
significant SCORAD score improvement although in the crossover study of Rosenfeldt et al 
(2003), which included children older than those in the other studies, patients felt better 
according to their subjective evaluations. Nevertheless, a pronounced decrease in SCORAD 
score was observed in patients with a positive skin prick-test response and increased IgE 
levels (Viljanen et al., 2005b;Rosenfeldt et al., 2003;Sistek et al., 2006). The administration of a 
probiotic mixture containing L. acidophilus DDS-1, B. lactis UABLA-12, and fructo-
oligosaccharide was associated with a significant clinical improvement in children with AD 
and in particular a large decrease in SCORAD score and increase in quality of life score 
relative to the placebo group (Gerasimov et al., 2010). This was not the case with a mixture of 
B. breve M-16V and galacto-/fructooligosaccharide (Immunofortis) (van der Aa et al., 2010), 
even though this synbiotic mixture seemed to prevent asthma-like symptoms in infants with 
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AD (van der Aa et al., 2011). To conclude, investigations of probiotics for the treatment of 
AD provide promising results, but are not conclusive, as confirmed by meta-analyzes (Lee et 
al., 2008;Osborn and Sinn, 2007) such that they do not provide sufficient basis to recommend 
the use of such products.  
4.1.2 Probiotics in the treatment of rhinitis and respiratory allergic diseases 
Eleven studies have evaluated clinical effects of probiotics in the treatment of allergic 
diseases of the respiratory tract, i.e. rhinitis and asthma, and altogether included about 890 
subjects.  
Lactobacillus paracasei-33, whether or not heat-inactivated, improved quality of life of patients 
with allergic rhinitis: both frequency and intensity of symptoms were significantly lower in 
the LP-33 group than the placebo group, after the 30-day treatment (Wang et al., 2004;Peng 
& Hsu, 2005). Likewise, Lactobacillus casei DN114 001 decreased the occurrence of rhinitis 
episodes and improved the health status of children with allergic rhinitis (Giovannini et al., 
2007). For patients with Japanese cedar pollen allergy, LGG and Lactobacillus gasseri 
TMC0356 reduced nasal symptoms (Kawase et al., 2009), and B. longum BB536 was able to 
relieve eye symptoms (Ishida et al., 2005;Xiao et al., 2007). The degree of eosinophil 
infiltration into the respiratory mucosa correlates directly with the intensity of allergic 
rhinitis and can be used as an objective marker of the disease. A mixture of L. acidophilus 
NCFMTM and B. lactis Bl-04 reduced nasal eosinophil infiltration (Ouwehand et al., 2009) as 
did Bacillus clausii which also reduced the number of days on which antihistamine was used 
in children with allergic rhinitis due to pollen sensitization (Ciprandi et al., 2005a). However, 
L. rhamnosus ATCC53103 was not beneficial to teenagers and young adults allergic to birch 
pollen or ingested apple and who had intermittent symptoms of atopic allergy and/or mild 
asthma (Helin et al., 2002). Similarly, L. casei Shirota was not found to reduce symptoms of 
Japanese cedar pollen allergy (Tamura et al., 2007), although the strain did reduce serum 
concentrations of IL-5, IL-6, IFN- and specific IgE in subjects with allergic rhinitis (Ivory et 
al., 2008). In children with recurrent wheeze and an atopic family history, LGG had no 
clinical effect on asthma-related events, and only a small effect on allergic sensitization 
(Rose et al., 2010); likewise, long-term consumption of fermented milk containing L. casei had 
no detectable effect in asthmatic children (Giovannini et al., 2007) 
4.1.3 Probiotics in the primary prevention of allergic diseases 
The prevention of allergy through an early administration of probiotics is appealing. 
Four studies investigating probiotic supplementation begun during pregnancy. The first 
study to be published was by the team of Isolauri and reported promising results on 
preventive effects of LGG (Kalliomaki et al., 2001b). LGG was given prenatally to 132 
mothers who had at least one first-degree relative (or partner) with atopic eczema, allergic 
rhinitis, or asthma, and postnatally for 6 months to their infants. Two years later, the 
frequency of atopic eczema in infants given probiotics was half that of those on placebo 
(Kalliomaki et al., 2001b). The reduction was greatest for infants who were exclusively 
breastfed, and therefore who did not receive the probiotic directly until 3 months of age 
(LGG being given to the mother) (Rautava et al., 2002a). Administration of probiotics to the 
mother during pregnancy and breast-feeding appeared to be a safe and effective method for 
enhancing the immunoprotective potential of breast milk and preventing atopic eczema in 
the infant. The protective effect of LGG extended beyond infancy until 7 years old 
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symptoms including erythrodermic rash and can be associated with other atopic diseases 
such as food allergy, asthma, and allergic rhinitis. To evaluate the effects of probiotics on 
AD, a rigorous definition of study participants is necessary. The diagnosis of AD is currently 
based on diagnostic criteria scales developed by Hanifin and Rafka in 1980 and by the 
"United Kingdom Working party" in 1994 (in Roguedas-Contios and Misery, 2011). It is 
equally important that diseases outcome measures used in treatment studies are both valid 
and reliable. Three of the various eczema outcome measures have been shown to be reliable: 
SCORing Atopic Dermatitis (SCORAD), the Eczema Area and Severity Index (EASI) and the 
Patient Oriented Eczema Measure (POEM). SCORAD is commonly used in studies of 
probiotics. It combines an estimation of the intensity and extent of the eczema with a 
subjective itch. However, it assesses a clinical state of the disease at a particular time point 
without taking into account overall severity or evolution of the disease (Société Française de 
Dermatologie, 2005). Some quality of life scales are also used, for example the Infant 
Dermatitis Quality Of Life (IDQOL), Dermatitis Family Impact (DFI), and Dermatitis Family 
Impact Questionnaire (DFIQ) scores (Gerasimov et al., 2010; Weston et al., 2005) scores.  
The age range of subjects included varies between studies: around weaning (median 5 
months old) (Brouwer et al., 2006;Isolauri et al., 2000;Kirjavainen et al., 2003;Viljanen et al., 
2005b;Gruber et al., 2007), around 1 year old (Weston et al., 2005;Folster-Holst et al., 2006), 
and around 5 years old (Rosenfeldt et al., 2003, 2004; Sistek et al., 2006; Woo et al., 2010). 
Seven of these publications describe effects of Lactobacillus rhamnosus GG LGG in infants but 
report contradictory results (Brouwer et al., 2006;Isolauri et al., 2000;Kirjavainen et al., 
2003;Viljanen et al., 2005b;Gruber et al., 2007;Folster-Holst et al., 2006;Nermes et al., 2011). 
Two of them (Isolauri et al., 2000;Kirjavainen et al., 2003) showed a significant decrease of the 
SCORAD score, but both these studies included only small groups of infants (27 and 35). 
Moreover, the heat-inactivated LGG used in Kirjavainen’s study induced adverse 
gastrointestinal symptoms and diarrhea leading to the recruitment of patients being stopped 
after the pilot phase (Kirjavainen et al., 2003). Six other studies, similar in terms of subjects 
included and protocol, did not find any improvement in SCORAD scores following LGG 
supplementation (Folster-Holst et al., 2006;Brouwer et al., 2006;Gruber et al., 2007;Viljanen et 
al., 2005b;Nermes et al., 2011;Rose et al., 2010). Other probiotic strains have been studied, and 
Bifidobacterium lactis Bb12 (Isolauri et al., 2000), L. sakei KCTC 10755B0 and L. fermentum VRI-
003 (Weston et al., 2005) induced significant decreases in SCORAD scores. In the last of these 
studies, the effects of L. fermentum VRI-003 were found to persist two months after the end 
of supplementation. Four studies used a L. rhamnosus strain (not LGG) alone (Brouwer et al., 
2006) or mixed with L. reuteri (Rosenfeldt et al., 2003) or with other Lactobacillus sp. and 
Bifidobacterium sp. (Viljanen et al., 2005b;Sistek et al., 2006). These studies did not detect 
significant SCORAD score improvement although in the crossover study of Rosenfeldt et al 
(2003), which included children older than those in the other studies, patients felt better 
according to their subjective evaluations. Nevertheless, a pronounced decrease in SCORAD 
score was observed in patients with a positive skin prick-test response and increased IgE 
levels (Viljanen et al., 2005b;Rosenfeldt et al., 2003;Sistek et al., 2006). The administration of a 
probiotic mixture containing L. acidophilus DDS-1, B. lactis UABLA-12, and fructo-
oligosaccharide was associated with a significant clinical improvement in children with AD 
and in particular a large decrease in SCORAD score and increase in quality of life score 
relative to the placebo group (Gerasimov et al., 2010). This was not the case with a mixture of 
B. breve M-16V and galacto-/fructooligosaccharide (Immunofortis) (van der Aa et al., 2010), 
even though this synbiotic mixture seemed to prevent asthma-like symptoms in infants with 
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AD (van der Aa et al., 2011). To conclude, investigations of probiotics for the treatment of 
AD provide promising results, but are not conclusive, as confirmed by meta-analyzes (Lee et 
al., 2008;Osborn and Sinn, 2007) such that they do not provide sufficient basis to recommend 
the use of such products.  
4.1.2 Probiotics in the treatment of rhinitis and respiratory allergic diseases 
Eleven studies have evaluated clinical effects of probiotics in the treatment of allergic 
diseases of the respiratory tract, i.e. rhinitis and asthma, and altogether included about 890 
subjects.  
Lactobacillus paracasei-33, whether or not heat-inactivated, improved quality of life of patients 
with allergic rhinitis: both frequency and intensity of symptoms were significantly lower in 
the LP-33 group than the placebo group, after the 30-day treatment (Wang et al., 2004;Peng 
& Hsu, 2005). Likewise, Lactobacillus casei DN114 001 decreased the occurrence of rhinitis 
episodes and improved the health status of children with allergic rhinitis (Giovannini et al., 
2007). For patients with Japanese cedar pollen allergy, LGG and Lactobacillus gasseri 
TMC0356 reduced nasal symptoms (Kawase et al., 2009), and B. longum BB536 was able to 
relieve eye symptoms (Ishida et al., 2005;Xiao et al., 2007). The degree of eosinophil 
infiltration into the respiratory mucosa correlates directly with the intensity of allergic 
rhinitis and can be used as an objective marker of the disease. A mixture of L. acidophilus 
NCFMTM and B. lactis Bl-04 reduced nasal eosinophil infiltration (Ouwehand et al., 2009) as 
did Bacillus clausii which also reduced the number of days on which antihistamine was used 
in children with allergic rhinitis due to pollen sensitization (Ciprandi et al., 2005a). However, 
L. rhamnosus ATCC53103 was not beneficial to teenagers and young adults allergic to birch 
pollen or ingested apple and who had intermittent symptoms of atopic allergy and/or mild 
asthma (Helin et al., 2002). Similarly, L. casei Shirota was not found to reduce symptoms of 
Japanese cedar pollen allergy (Tamura et al., 2007), although the strain did reduce serum 
concentrations of IL-5, IL-6, IFN- and specific IgE in subjects with allergic rhinitis (Ivory et 
al., 2008). In children with recurrent wheeze and an atopic family history, LGG had no 
clinical effect on asthma-related events, and only a small effect on allergic sensitization 
(Rose et al., 2010); likewise, long-term consumption of fermented milk containing L. casei had 
no detectable effect in asthmatic children (Giovannini et al., 2007) 
4.1.3 Probiotics in the primary prevention of allergic diseases 
The prevention of allergy through an early administration of probiotics is appealing. 
Four studies investigating probiotic supplementation begun during pregnancy. The first 
study to be published was by the team of Isolauri and reported promising results on 
preventive effects of LGG (Kalliomaki et al., 2001b). LGG was given prenatally to 132 
mothers who had at least one first-degree relative (or partner) with atopic eczema, allergic 
rhinitis, or asthma, and postnatally for 6 months to their infants. Two years later, the 
frequency of atopic eczema in infants given probiotics was half that of those on placebo 
(Kalliomaki et al., 2001b). The reduction was greatest for infants who were exclusively 
breastfed, and therefore who did not receive the probiotic directly until 3 months of age 
(LGG being given to the mother) (Rautava et al., 2002a). Administration of probiotics to the 
mother during pregnancy and breast-feeding appeared to be a safe and effective method for 
enhancing the immunoprotective potential of breast milk and preventing atopic eczema in 
the infant. The protective effect of LGG extended beyond infancy until 7 years old 
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(Kalliomaki et al., 2003; 2007). Infants most likely to benefit from probiotics might be those 
with an elevated cord blood IgE concentration (Rautava et al., 2002a), despite such high IgE 
levels not appearing as a risk factor for atopic diseases (Bergmann et al., 1998). However, 
LGG had no impact on sensitization: there was no difference between LGG and placebo 
groups at 2, 4 and 7 year old as concerns the numbers of infants with high levels of specific 
IgE and/or positive prick test results (Kalliomaki et al., 2001b; 2003; 2007).  
The preventive effect of LGG was not confirmed in a similar study by Kopp et al. (2008) with 
94 mother-infant couples. The discrepancies between the data of Kalliomaki et al and the 
data of Kopp et al cannot be explained by the minor differences between the study designs, 
but could be linked to the study populations. The German cohort (Kopp et al) was at higher 
risk of allergy than the Finnish cohort (Kalliomaki et al), the infants had older siblings, and 
the genetic contexts were different. Two other preventive studies considered prenatal and 
postnatal supplementation with probiotics. An investigation of L reuteri ATCC55730 
supplementation for infants with a family history of allergic disease did not confirm a 
preventive effect against infant eczema but found a decreased prevalence of IgE-associated 
eczema during the second year. The effect was larger in the subgroup of children of allergic 
mothers (Abrahamsson et al., 2007). Infants receiving L rhamnosus HN001 had a significantly 
lower risk of eczema than infants receiving placebo, but this was not the case for B animalis 
subsp lactis and there was no significant effect of these two strains on atopy (Wickens et al., 
2008). Taylor et al ( 2006a; 2006b; 2007a; 2007b) and of Soh et al (2009) studied newborns 
given, from birth to 6 months of life, L. acidophilus LAVRI-A1 (178 infants) and a mixture of 
L. rhamnosus LPR and B. longum BL999 (253 infants), respectively, and did not find any 
reduction of the risk of AD in high-risk infants as assessed from the numbers of patients 
affected, SCORAD score or IgE sensitization. Moreover, L. acidophilus was associated with 
increased allergen sensitization (Taylor et al., 2007a). Likewise, supplementation with LGG 
during pregnancy and early infancy did not alter the severity of atopic dermatitis in affected 
children and was associated with an increased rate of recurrent episodes of wheezing and 
bronchitis (Kalliomaki et al., 2003; 2007; Kopp et al., 2008).  
4.2 Mechanisms of probiotic action in atopic/allergic diseases in human 
Although no unambiguous clinical benefits were observed in several studies, probiotics may 
nevertheless have useful effects on microbiota composition, the immune system and the gut 
barrier in infants and in children.  
4.2.1 Effects of probiotics on microbiota composition 
Any effects of probiotic microorganisms on health and well-being may potentially be due, at 
least in part, to modulation of the intestinal microbiota. However, few of the studies on 
probiotics and allergic diseases assessed the consequences of probiotic use on gut 
microbiota composition. From the available evidence, it seems that probiotics have no 
impact on microbiota. In the treatment of rhinitis with L. acidophilus NCFMTM, fecal 
probiotic cell counts correlated positively with fecal acetic, propionic and butyric acid 
concentrations (Ouwehand et al., 2009), suggesting that the presence of L. acidophilus 
NCFMTM increases microbial fermentation in the colon. However, the colonization pattern 
did not differ between groups that consumed the probiotic strains and placebo. Similarly, no 
modification of the gut microbiota was observed following LGG supplementation in infants 
with AD (Kirjavainen et al, 2003). The fecal microbiota fluctuated in subjects with Japanese 
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cedar pollinosis during the pollen season and supplementation with BB536 yogurt 
modulated the microbiota in a manner that may possibly contribute to the alleviation of 
allergic symptoms (Odamaki et al, 2007). 
4.2.2 Gut immunity and barrier effect 
Probiotics may modulate local immune systems. Treatment with LGG resulted in a trend 
towards elevated fecal IgA levels, and this effect was significant in IgE-associated cow-milk 
allergy infants, suggesting maturation of intestinal immunity and triggering of a mechanism 
to protect the gut from the offending food (Viljanen et al., 2005a). In older subjects with a 
mature immune system and suffering from allergic rhinitis, fecal IgA concentrations 
increased in the placebo group during the pollen season; this increase was prevented by L. 
acidophilus NCFMTM (Ouwehand et al., 2009).  
Probiotics have also been reported to decrease the levels of fecal inflammatory markers, but 
this is controversial: findings differ between studies and strains used. Treatment of AD with 
LGG was associated with a decrease of TNF- and -antitrypsin levels suggesting that LGG 
may alleviate inflammation in the gut. Indeed, TNF- is a proinflammatory cytokine for 
both Th1- and Th2-type cells, and a marker of local inflammation. The presence of -
antitrypsin indicates protein loss in the intestine and is a marker of mucosal integrity. These 
results were not confirmed in the studies by Folster-Holt et al (2006) and Brouwer et al (2006) 
who did not observe any differences in -antitrypsin, or calprotectin, or eosinophilic 
cationic protein levels between infants receiving or not receiving LGG. Accumulation of 
eosinophilic cationic protein at sites of allergic inflammation demonstrates local eosinophil 
degranulation in the gut. Specific lactobacilli (L. rhamnosus 19070-2 and L reuteri DSM 12246) 
might reverse increased small intestinal permeability (such permeability is involved in the 
pathogenesis of atopic dermatitis) thereby stabilizing the intestinal barrier function and 
decreasing gastrointestinal symptoms in children with AD (Rosenfeldt et al., 2004).  
4.2.3 Th1/Th2 balance 
Certain strains of Lactobacillus and Bifidobacterium can modulate cytokine production. 
Bacillus clausii modulated the cytokine pattern in the nasal mucosa in allergic children with 
recurrent respiratory infections. In particular, B. clausii restored physiological Th1 
polarization and induced T-regulatory cell responses, as documented by increased levels of 
IL-10 and tumor growth factor (TGF)- after treatment (Ciprandi et al., 2005b). TGF- is a 
regulatory cytokine which may be responsible for a decrease in local inflammation (Shull et 
al., 1992). Interestingly, Rautava et al (2002b) observed high TGF-β2 concentrations in breast-
milk from mothers who had received LGG for prevention of allergic disease. The authors 
concluded that, first, direct supplementation of infant after birth is not necessary, and 
second that probiotics could increase the protective effects of breast milk.  
The effects on the Th1-Th2 balance of probiotic strains used for the treatment of AD in early 
infancy have been evaluated in several studies. Pohjavuori et al. (2004) were able to 
demonstrate greater IFN- production in anti-CD3/anti-CD28-stimulated in vitro peripheral 
blood mononuclear cells (PBMC) from infants treated with LGG than placebo. A different 
modulatory effect was observed with a mix of four bacterial strains including LGG: a 
significant increase in secretion of IL-4 in infants with cow milk allergy. By contrast, 
production of the predominant Th1 cytokine INF-, and the Th2 cytokines IL-4 or IL-5 after 
polyclonal or specific anti-CD3/anti-CD28 stimulation, was unaffected by supplementation 
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(Kalliomaki et al., 2003; 2007). Infants most likely to benefit from probiotics might be those 
with an elevated cord blood IgE concentration (Rautava et al., 2002a), despite such high IgE 
levels not appearing as a risk factor for atopic diseases (Bergmann et al., 1998). However, 
LGG had no impact on sensitization: there was no difference between LGG and placebo 
groups at 2, 4 and 7 year old as concerns the numbers of infants with high levels of specific 
IgE and/or positive prick test results (Kalliomaki et al., 2001b; 2003; 2007).  
The preventive effect of LGG was not confirmed in a similar study by Kopp et al. (2008) with 
94 mother-infant couples. The discrepancies between the data of Kalliomaki et al and the 
data of Kopp et al cannot be explained by the minor differences between the study designs, 
but could be linked to the study populations. The German cohort (Kopp et al) was at higher 
risk of allergy than the Finnish cohort (Kalliomaki et al), the infants had older siblings, and 
the genetic contexts were different. Two other preventive studies considered prenatal and 
postnatal supplementation with probiotics. An investigation of L reuteri ATCC55730 
supplementation for infants with a family history of allergic disease did not confirm a 
preventive effect against infant eczema but found a decreased prevalence of IgE-associated 
eczema during the second year. The effect was larger in the subgroup of children of allergic 
mothers (Abrahamsson et al., 2007). Infants receiving L rhamnosus HN001 had a significantly 
lower risk of eczema than infants receiving placebo, but this was not the case for B animalis 
subsp lactis and there was no significant effect of these two strains on atopy (Wickens et al., 
2008). Taylor et al ( 2006a; 2006b; 2007a; 2007b) and of Soh et al (2009) studied newborns 
given, from birth to 6 months of life, L. acidophilus LAVRI-A1 (178 infants) and a mixture of 
L. rhamnosus LPR and B. longum BL999 (253 infants), respectively, and did not find any 
reduction of the risk of AD in high-risk infants as assessed from the numbers of patients 
affected, SCORAD score or IgE sensitization. Moreover, L. acidophilus was associated with 
increased allergen sensitization (Taylor et al., 2007a). Likewise, supplementation with LGG 
during pregnancy and early infancy did not alter the severity of atopic dermatitis in affected 
children and was associated with an increased rate of recurrent episodes of wheezing and 
bronchitis (Kalliomaki et al., 2003; 2007; Kopp et al., 2008).  
4.2 Mechanisms of probiotic action in atopic/allergic diseases in human 
Although no unambiguous clinical benefits were observed in several studies, probiotics may 
nevertheless have useful effects on microbiota composition, the immune system and the gut 
barrier in infants and in children.  
4.2.1 Effects of probiotics on microbiota composition 
Any effects of probiotic microorganisms on health and well-being may potentially be due, at 
least in part, to modulation of the intestinal microbiota. However, few of the studies on 
probiotics and allergic diseases assessed the consequences of probiotic use on gut 
microbiota composition. From the available evidence, it seems that probiotics have no 
impact on microbiota. In the treatment of rhinitis with L. acidophilus NCFMTM, fecal 
probiotic cell counts correlated positively with fecal acetic, propionic and butyric acid 
concentrations (Ouwehand et al., 2009), suggesting that the presence of L. acidophilus 
NCFMTM increases microbial fermentation in the colon. However, the colonization pattern 
did not differ between groups that consumed the probiotic strains and placebo. Similarly, no 
modification of the gut microbiota was observed following LGG supplementation in infants 
with AD (Kirjavainen et al, 2003). The fecal microbiota fluctuated in subjects with Japanese 
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cedar pollinosis during the pollen season and supplementation with BB536 yogurt 
modulated the microbiota in a manner that may possibly contribute to the alleviation of 
allergic symptoms (Odamaki et al, 2007). 
4.2.2 Gut immunity and barrier effect 
Probiotics may modulate local immune systems. Treatment with LGG resulted in a trend 
towards elevated fecal IgA levels, and this effect was significant in IgE-associated cow-milk 
allergy infants, suggesting maturation of intestinal immunity and triggering of a mechanism 
to protect the gut from the offending food (Viljanen et al., 2005a). In older subjects with a 
mature immune system and suffering from allergic rhinitis, fecal IgA concentrations 
increased in the placebo group during the pollen season; this increase was prevented by L. 
acidophilus NCFMTM (Ouwehand et al., 2009).  
Probiotics have also been reported to decrease the levels of fecal inflammatory markers, but 
this is controversial: findings differ between studies and strains used. Treatment of AD with 
LGG was associated with a decrease of TNF- and -antitrypsin levels suggesting that LGG 
may alleviate inflammation in the gut. Indeed, TNF- is a proinflammatory cytokine for 
both Th1- and Th2-type cells, and a marker of local inflammation. The presence of -
antitrypsin indicates protein loss in the intestine and is a marker of mucosal integrity. These 
results were not confirmed in the studies by Folster-Holt et al (2006) and Brouwer et al (2006) 
who did not observe any differences in -antitrypsin, or calprotectin, or eosinophilic 
cationic protein levels between infants receiving or not receiving LGG. Accumulation of 
eosinophilic cationic protein at sites of allergic inflammation demonstrates local eosinophil 
degranulation in the gut. Specific lactobacilli (L. rhamnosus 19070-2 and L reuteri DSM 12246) 
might reverse increased small intestinal permeability (such permeability is involved in the 
pathogenesis of atopic dermatitis) thereby stabilizing the intestinal barrier function and 
decreasing gastrointestinal symptoms in children with AD (Rosenfeldt et al., 2004).  
4.2.3 Th1/Th2 balance 
Certain strains of Lactobacillus and Bifidobacterium can modulate cytokine production. 
Bacillus clausii modulated the cytokine pattern in the nasal mucosa in allergic children with 
recurrent respiratory infections. In particular, B. clausii restored physiological Th1 
polarization and induced T-regulatory cell responses, as documented by increased levels of 
IL-10 and tumor growth factor (TGF)- after treatment (Ciprandi et al., 2005b). TGF- is a 
regulatory cytokine which may be responsible for a decrease in local inflammation (Shull et 
al., 1992). Interestingly, Rautava et al (2002b) observed high TGF-β2 concentrations in breast-
milk from mothers who had received LGG for prevention of allergic disease. The authors 
concluded that, first, direct supplementation of infant after birth is not necessary, and 
second that probiotics could increase the protective effects of breast milk.  
The effects on the Th1-Th2 balance of probiotic strains used for the treatment of AD in early 
infancy have been evaluated in several studies. Pohjavuori et al. (2004) were able to 
demonstrate greater IFN- production in anti-CD3/anti-CD28-stimulated in vitro peripheral 
blood mononuclear cells (PBMC) from infants treated with LGG than placebo. A different 
modulatory effect was observed with a mix of four bacterial strains including LGG: a 
significant increase in secretion of IL-4 in infants with cow milk allergy. By contrast, 
production of the predominant Th1 cytokine INF-, and the Th2 cytokines IL-4 or IL-5 after 
polyclonal or specific anti-CD3/anti-CD28 stimulation, was unaffected by supplementation 
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with L rhamnosus, LGG (Brouwer et al., 2006) or a lactobacillus mix (Rosenfeldt et al., 2003). A 
decrease in circulating IgA-, IgG- and IgM-secreting cells and an increase in memory B cells 
during LGG supplementation has been described (Nermes et al., 2011).  
The oral administration of particular probiotic strains to patients with atopic dermatitis can 
modulate the cytokine pattern in vivo at site other than the intestine. L. casei Shirota reduced 
serum concentrations of IL-5, IL-6, IFN- and specific IgE in subjects with allergic rhinitis 
(Ivory et al., 2008) but was not found to be effective in reducing the symptoms of Japanese 
cedar pollen allergy (Tamura et al., 2007). Probiotics can be involved in both antagonistic 
and synergistic relationships with each other, and with members of the gut ecosystem. 
Indeed, mixtures of bacteria induced a response in human dendritic cells different to those 
of the component bacteria in isolation: antagonistic immunosuppressive effects were 
observed with certain strains of Lactobacillus and Bifidobacterium but synergistic effects were 
observed when these Lactobacillus and Bifidobacterium strains were combined with E. coli and 
K. pneumoniae strains (Zeuthen et al., 2006).  
5. Conclusion 
Despite some promising results, the role of probiotics in the treatment and the prevention of 
allergy and related diseases has not been clearly demonstrated. Indeed, clinical trials 
provide various contradictory findings that do not allow probiotic supplementation to be 
included in the guidelines for the management of allergic diseases. These conflicting data 
may be however attributable to the differences between studies. The populations studied 
have been very diverse in terms of size, age, sensitization and allergic disease, environment, 
and genetic background. Study designs included different probiotics in term of strains, 
preparations (alive/ killed; one strain/mixture/synbiotics), doses, duration of 
supplementation, and period of administration (prental/postnatal). In addition to these 
issues, progress in our basic knowledge of probiotic strains, in strain selection, and in 
understanding their mechanisms of action is needed to give credibility to the health claims 
made for probiotics and especially for the design of efficacious therapeutic agents.  
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with L rhamnosus, LGG (Brouwer et al., 2006) or a lactobacillus mix (Rosenfeldt et al., 2003). A 
decrease in circulating IgA-, IgG- and IgM-secreting cells and an increase in memory B cells 
during LGG supplementation has been described (Nermes et al., 2011).  
The oral administration of particular probiotic strains to patients with atopic dermatitis can 
modulate the cytokine pattern in vivo at site other than the intestine. L. casei Shirota reduced 
serum concentrations of IL-5, IL-6, IFN- and specific IgE in subjects with allergic rhinitis 
(Ivory et al., 2008) but was not found to be effective in reducing the symptoms of Japanese 
cedar pollen allergy (Tamura et al., 2007). Probiotics can be involved in both antagonistic 
and synergistic relationships with each other, and with members of the gut ecosystem. 
Indeed, mixtures of bacteria induced a response in human dendritic cells different to those 
of the component bacteria in isolation: antagonistic immunosuppressive effects were 
observed with certain strains of Lactobacillus and Bifidobacterium but synergistic effects were 
observed when these Lactobacillus and Bifidobacterium strains were combined with E. coli and 
K. pneumoniae strains (Zeuthen et al., 2006).  
5. Conclusion 
Despite some promising results, the role of probiotics in the treatment and the prevention of 
allergy and related diseases has not been clearly demonstrated. Indeed, clinical trials 
provide various contradictory findings that do not allow probiotic supplementation to be 
included in the guidelines for the management of allergic diseases. These conflicting data 
may be however attributable to the differences between studies. The populations studied 
have been very diverse in terms of size, age, sensitization and allergic disease, environment, 
and genetic background. Study designs included different probiotics in term of strains, 
preparations (alive/ killed; one strain/mixture/synbiotics), doses, duration of 
supplementation, and period of administration (prental/postnatal). In addition to these 
issues, progress in our basic knowledge of probiotic strains, in strain selection, and in 
understanding their mechanisms of action is needed to give credibility to the health claims 
made for probiotics and especially for the design of efficacious therapeutic agents.  
6. References 
Abrahamsson, T.R., Jakobsson, T., Bottcher, M.F., Fredrikson, M., Jenmalm, M.C., Bjorksten, 
B., and Oldaeus, G. (2007) Probiotics in prevention of IgE-associated eczema: a 
double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 119: 
1174-1180. ISSN: 0091-6749 
Adkins, B., Leclerc, C., and Marshall-Clarke, S. (2004) Neonatal adaptive immunity comes of 
age. Nat Rev Immunol 4: 553-564. ISSN: 1474-1733 
Adlerberth, I., Strachan, D.P., Matricardi, P.M., Ahrne, S., Orfei, L., Aberg, N. et al. (2007) 
Gut microbiota and development of atopic eczema in 3 European birth cohorts. J 
Allergy Clin Immunol 120: 343-350. ISSN: 0091-6749 
Adlerberth, I., and Wold, A.E. (2009) Establishment of the gut microbiota in Western infants. 
Acta Paediatr 98: 229-238. ISSN: 0803-5253 
Agosti, M., Vegni, C., Gangi, S., Benedetti, V., and Marini, A. (2003) Allergic manifestations 
in very low-birthweight infants: a 6-year follow-up. Acta Paediatr Suppl 91: 44-47. 
ISSN: 0803-5253 
 
Microbiota and Allergy: From Dysbiosis to Probiotics 
 
425 
Akdis, M., Verhagen, J., Taylor, A., Karamloo, F., Karagiannidis, C., Crameri, R. et al. (2004) 
Immune responses in healthy and allergic individuals are characterized by a fine 
balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 199: 
1567-1575. : 0022-1007 
Asher, M.I., Stewart, A.W., Mallol, J., Montefort, S., Lai, C.K., Ait-Khaled, N., and 
Odhiambo, J. (2010) Which population level environmental factors are associated 
with asthma, rhinoconjunctivitis and eczema? Review of the ecological analyses of 
ISAAC Phase One. Respir Res 11: 8. ISSN: 1465-9921 
Bach, J.F. (2002) The effect of infections on susceptibility to autoimmune and allergic 
diseases. N Engl J Med 347: 911-920. ISSN: 0028-4793 
Bergmann, R.L., Bergmann, K.E., and Wahn, U. (1998) Can we predict atopic disease using 
perinatal risk factors? Clin Exp Allergy 28: 905-907. ISSN: 0954-7894 
Bik, E.M. (2009) Composition and function of the human-associated microbiota. Nutr Rev 67 
Suppl 2: S164-S171. ISSN: 0029-6643 
Bjorksten, B., Naaber, P., Sepp, E., and Mikelsaar, M. (1999) The intestinal microflora in 
allergic Estonian and Swedish 2-year-old children. Clin Exp Allergy 29: 342-346. 
ISSN: 0954-7894 
Bjorksten, B., Sepp, E., Julge, K., Voor, T., and Mikelsaar, M. (2001) Allergy development 
and the intestinal microflora during the first year of life. J Allergy Clin Immunol 108: 
516-520. ISSN: 0091-6749 
Bottcher, M.F., Nordin, E.K., Sandin, A., Midtvedt, T., and Bjorksten, B. (2000) Microflora-
associated characteristics in faeces from allergic and nonallergic infants. Clin Exp 
Allergy 30: 1590-1596. ISSN: 0954-7894 
Brouwer, M.L., Wolt-Plompen, S.A., Dubois, A.E., van der, H.S., Jansen, D.F., Hoijer, M.A. et 
al. (2006) No effects of probiotics on atopic dermatitis in infancy: a randomized 
placebo-controlled trial. Clin Exp Allergy 36: 899-906. ISSN: 0954-7894 
Campeotto, F., Waligora-Dupriet, A.J., Doucet-Populaire, F., Kalach, N., Dupont, C., and 
Butel, M.J. (2007) [Establishment of the intestinal microflora in neonates]. 
Gastroenterol Clin Biol 31: 533-542. ISSN: 0399-8320 
Ciprandi, G., Vizzaccaro, A., Cirillo, I., and Tosca, M.A. (2005a) Bacillus clausii effects in 
children with allergic rhinitis. Allergy 60: 702-703. ISSN: 0105-4338 
Ciprandi, G., Vizzaccaro, A., Cirillo, I., and Tosca, M.A. (2005b) Bacillus clausii exerts 
immuno-modulatory activity in allergic subjects: a pilot study. Eur Ann Allergy Clin 
Immunol 37: 129-134. ISSN: 1764-1384 
Dethlefsen, L., McFall-Ngai, M., and Relman, D.A. (2007) An ecological and evolutionary 
perspective on human-microbe mutualism and disease. Nature 449: 811-818. ISSN: 
0028-0836 
Eckburg, P.B., Bik, E.M., Bernstein, C.N., Purdom, E., Dethlefsen, L., Sargent, M. et al. (2005) 
Diversity of the human intestinal microbial flora. Science 308: 1635-1638. ISSN: 0036-
8075 
FAO/WHO. Health and nutritional properties of probiotics in food includion powder milk 




Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
426 
FAO/WHO Working group. Guidelines for the evaluation of probiotics in food. 2002. 
London, 30 avril-1er mai.  
 http://www.who.int/entity/foodsafety/publications/fs_management/probiotics
2/en/index.html 
Feleszko, W., Jaworska, J., Rha, R.D., Steinhausen, S., Avagyan, A., Jaudszus, A. et al. (2007) 
Probiotic-induced suppression of allergic sensitization and airway inflammation is 
associated with an increase of T regulatory-dependent mechanisms in a murine 
model of asthma. Clin Exp Allergy 37: 498-505. ISSN: 0954-7894 
Folster-Holst, R., Muller, F., Schnopp, N., Abeck, D., Kreiselmaier, I., Lenz, T. et al. (2006) 
Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants 
with moderate to severe atopic dermatitis. Br J Dermatol 155: 1256-1261. ISSN: 
0007-0963 
Fujimura, K.E., Slusher, N.A., Cabana, M.D., and Lynch, S.V. (2010) Role of the gut 
microbiota in defining human health. Expert Rev Anti Infect Ther 8: 435-454. ISSN: 
1478-7210 
Gaboriau-Routhiau, V., Rakotobe, S., Lecuyer, E., Mulder, I., Lan, A., Bridonneau, C. et al. 
(2009) The key role of segmented filamentous bacteria in the coordinated 
maturation of gut helper T cell responses. Immunity 31: 677-689. ISSN:1074-7613 
Garrett, W.S., Gordon, J.I., and Glimcher, L.H. (2010) Homeostasis and inflammation in the 
intestine. Cell 140: 859-870. ISSN: 0092-8674 
Gerasimov, S.V., Vasjuta, V.V., Myhovych, O.O., and Bondarchuk, L.I. (2010) Probiotic 
supplement reduces atopic dermatitis in preschool children: a randomized, double-
blind, placebo-controlled, clinical trial. Am J Clin Dermatol 11: 351-361. ISSN: 1175-
0561 
Giovannini, M., Agostoni, C., Riva, E., Salvini, F., Ruscitto, A., Zuccotti, G.V., and Radaelli, 
G. (2007) A randomized prospective double blind controlled trial on effects of long-
term consumption of fermented milk containing Lactobacillus casei in pre-school 
children with allergic asthma and/or rhinitis. Pediatr Res 62: 215-220. ISSN: 0031-
3998 
Gore, C., Munro, K., Lay, C., Bibiloni, R., Morris, J., Woodcock, A. et al. (2008) Bifidobacterium 
pseudocatenulatum is associated with atopic eczema: A nested case-control study 
investigating the fecal microbiota of infants. J Allerg Clin Immunol 121: 135-140. 
ISSN 0091-6749 
Gruber, C., Wendt, M., Sulser, C., Lau, S., Kulig, M., Wahn, U. et al. (2007) Randomized, 
placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic 
dermatitis in infancy. Allergy 62: 1270-1276. ISSN 0105-4338 
Gueimonde, M., Laitinen, K., Salminen, S., and Isolauri, E. (2007) Breast milk: a source of 
bifidobacteria for infant gut development and maturation? Neonatology 92: 64-66. 
ISSN: 1661-7800 
He, F., Morita, H., Ouwehand, A.C., Hosoda, M., Hiramatsu, M., Kurisaki, J. et al. (2002) 
Stimulation of the secretion of pro-inflammatory cytokines by Bifidobacterium 
strains. Microbiol Immunol 46: 781-785. ISSN: 0385-5600 
He, F., Ouwehand, A.C., Isolauri, E., Hashimoto, H., Benno, Y., and Salminen, S. (2001) 
Comparison of mucosal adhesion and species identification of bifidobacteria 
 
Microbiota and Allergy: From Dysbiosis to Probiotics 
 
427 
isolated from healthy and allergic infants. FEMS Immunol Med Microbiol 30: 43-47. 
ISSN: 0928-8244 
Helin, T., Haahtela, S., and Haahtela, T. (2002) No effect of oral treatment with an intestinal 
bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch-pollen allergy: a 
placebo-controlled double-blind study. Allergy 57: 243-246. ISSN 0105-4338 
Hooper, L.V., and Macpherson, A.J. (2010) Immune adaptations that maintain homeostasis 
with the intestinal microbiota. Nat Rev Immunol 10: 159-169. ISSN: 1474-1733 
Ishida, Y., Nakamura, F., Kanzato, H., Sawada, D., Yamamoto, N., Kagata, H. et al. (2005) 
Effect of milk fermented with Lactobacillus acidophilus strain L-92 on symptoms of 
Japanese cedar pollen allergy: a randomized placebo-controlled trial. Biosci 
Biotechnol Biochem 69: 1652-1660. ISSN: 0916-8451 
Isolauri, E., Arvola, T., Sutas, Y., Moilanen, E., and Salminen, S. (2000) Probiotics in the 
management of atopic eczema. Clin Exp Allergy 30: 1604-1610. ISSN 0954-7894 
Ivory, K., Chambers, S.J., Pin, C., Prieto, E., Arques, J.L., and Nicoletti, C. (2008) Oral 
delivery of Lactobacillus casei Shirota modifies allergen-induced immune responses 
in allergic rhinitis. Clin Exp Allergy 38: 1282-1289. ISSN 0954-7894 
Kalliomaki, M., Kirjavainen, P., Eerola, E., Kero, P., Salminen, S., and Isolauri, E. (2001a) 
Distinct patterns of neonatal gut microflora in infants in whom atopy was and was 
not developing. J Allergy Clin Immunol 107: 129-134. ISSN 0091-6749 
Kalliomaki, M., Salminen, S., Arvilommi, H., Kero, P., Koskinen, P., and Isolauri, E. (2001b) 
Probiotics in primary prevention of atopic disease: a randomised placebo-
controlled trial. Lancet 357: 1076-1079. ISSN: 0140-6736 
Kalliomaki, M., Salminen, S., Poussa, T., Arvilommi, H., and Isolauri, E. (2003) Probiotics 
and prevention of atopic disease: 4-year follow-up of a randomised placebo-
controlled trial. Lancet 361: 1869-1871. ISSN: 0140-6736 
Kalliomaki, M., Salminen, S., Poussa, T., and Isolauri, E. (2007) Probiotics during the first 7 
years of life: a cumulative risk reduction of eczema in a randomized, placebo-
controlled trial. J Allergy Clin Immunol 119: 1019-1021. ISSN 0091-6749 
Karlsson, H., Larsson, P., Wold, A.E., and Rudin, A. (2004) Pattern of cytokine responses to 
gram-positive and gram-negative commensal bacteria is profoundly changed when 
monocytes differentiate into dendritic cells. Infect Immun 72: 2671-2678. ISSN: 0019-
9567 
Kawase, M., He, F., Kubota, A., Hiramatsu, M., Saito, H., Ishii, T. et al. (2009) Effect of 
fermented milk prepared with two probiotic strains on Japanese cedar pollinosis in 
a double-blind placebo-controlled clinical study. Int J Food Microbiol 128: 429-434. 
ISSN: 0168-1605 
Kendler, M., Uter, W., Rueffer, A., Shimshoni, R., and Jecht, E. (2006) Comparison of fecal 
microflora in children with atopic eczema/dermatitis syndrome according to IgE 
sensitization to food. Pediatr Allergy Immunol 17: 141-147. ISSN: 0905-6157 
Kero, J., Gissler, M., Gronlund, M.M., Kero, P., Koskinen, P., Hemminki, E., and Isolauri, E. 
(2002) Mode of delivery and asthma -- is there a connection? Pediatr Res 52: 6-11. 
ISSN: 0031-3998 
Kirjavainen, P.V., Apostolou, E., Arvola, T., Salminen, S.J., Gibson, G.R., and Isolauri, E. 
(2001) Characterizing the composition of intestinal microflora as a prospective 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
426 
FAO/WHO Working group. Guidelines for the evaluation of probiotics in food. 2002. 
London, 30 avril-1er mai.  
 http://www.who.int/entity/foodsafety/publications/fs_management/probiotics
2/en/index.html 
Feleszko, W., Jaworska, J., Rha, R.D., Steinhausen, S., Avagyan, A., Jaudszus, A. et al. (2007) 
Probiotic-induced suppression of allergic sensitization and airway inflammation is 
associated with an increase of T regulatory-dependent mechanisms in a murine 
model of asthma. Clin Exp Allergy 37: 498-505. ISSN: 0954-7894 
Folster-Holst, R., Muller, F., Schnopp, N., Abeck, D., Kreiselmaier, I., Lenz, T. et al. (2006) 
Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants 
with moderate to severe atopic dermatitis. Br J Dermatol 155: 1256-1261. ISSN: 
0007-0963 
Fujimura, K.E., Slusher, N.A., Cabana, M.D., and Lynch, S.V. (2010) Role of the gut 
microbiota in defining human health. Expert Rev Anti Infect Ther 8: 435-454. ISSN: 
1478-7210 
Gaboriau-Routhiau, V., Rakotobe, S., Lecuyer, E., Mulder, I., Lan, A., Bridonneau, C. et al. 
(2009) The key role of segmented filamentous bacteria in the coordinated 
maturation of gut helper T cell responses. Immunity 31: 677-689. ISSN:1074-7613 
Garrett, W.S., Gordon, J.I., and Glimcher, L.H. (2010) Homeostasis and inflammation in the 
intestine. Cell 140: 859-870. ISSN: 0092-8674 
Gerasimov, S.V., Vasjuta, V.V., Myhovych, O.O., and Bondarchuk, L.I. (2010) Probiotic 
supplement reduces atopic dermatitis in preschool children: a randomized, double-
blind, placebo-controlled, clinical trial. Am J Clin Dermatol 11: 351-361. ISSN: 1175-
0561 
Giovannini, M., Agostoni, C., Riva, E., Salvini, F., Ruscitto, A., Zuccotti, G.V., and Radaelli, 
G. (2007) A randomized prospective double blind controlled trial on effects of long-
term consumption of fermented milk containing Lactobacillus casei in pre-school 
children with allergic asthma and/or rhinitis. Pediatr Res 62: 215-220. ISSN: 0031-
3998 
Gore, C., Munro, K., Lay, C., Bibiloni, R., Morris, J., Woodcock, A. et al. (2008) Bifidobacterium 
pseudocatenulatum is associated with atopic eczema: A nested case-control study 
investigating the fecal microbiota of infants. J Allerg Clin Immunol 121: 135-140. 
ISSN 0091-6749 
Gruber, C., Wendt, M., Sulser, C., Lau, S., Kulig, M., Wahn, U. et al. (2007) Randomized, 
placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic 
dermatitis in infancy. Allergy 62: 1270-1276. ISSN 0105-4338 
Gueimonde, M., Laitinen, K., Salminen, S., and Isolauri, E. (2007) Breast milk: a source of 
bifidobacteria for infant gut development and maturation? Neonatology 92: 64-66. 
ISSN: 1661-7800 
He, F., Morita, H., Ouwehand, A.C., Hosoda, M., Hiramatsu, M., Kurisaki, J. et al. (2002) 
Stimulation of the secretion of pro-inflammatory cytokines by Bifidobacterium 
strains. Microbiol Immunol 46: 781-785. ISSN: 0385-5600 
He, F., Ouwehand, A.C., Isolauri, E., Hashimoto, H., Benno, Y., and Salminen, S. (2001) 
Comparison of mucosal adhesion and species identification of bifidobacteria 
 
Microbiota and Allergy: From Dysbiosis to Probiotics 
 
427 
isolated from healthy and allergic infants. FEMS Immunol Med Microbiol 30: 43-47. 
ISSN: 0928-8244 
Helin, T., Haahtela, S., and Haahtela, T. (2002) No effect of oral treatment with an intestinal 
bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch-pollen allergy: a 
placebo-controlled double-blind study. Allergy 57: 243-246. ISSN 0105-4338 
Hooper, L.V., and Macpherson, A.J. (2010) Immune adaptations that maintain homeostasis 
with the intestinal microbiota. Nat Rev Immunol 10: 159-169. ISSN: 1474-1733 
Ishida, Y., Nakamura, F., Kanzato, H., Sawada, D., Yamamoto, N., Kagata, H. et al. (2005) 
Effect of milk fermented with Lactobacillus acidophilus strain L-92 on symptoms of 
Japanese cedar pollen allergy: a randomized placebo-controlled trial. Biosci 
Biotechnol Biochem 69: 1652-1660. ISSN: 0916-8451 
Isolauri, E., Arvola, T., Sutas, Y., Moilanen, E., and Salminen, S. (2000) Probiotics in the 
management of atopic eczema. Clin Exp Allergy 30: 1604-1610. ISSN 0954-7894 
Ivory, K., Chambers, S.J., Pin, C., Prieto, E., Arques, J.L., and Nicoletti, C. (2008) Oral 
delivery of Lactobacillus casei Shirota modifies allergen-induced immune responses 
in allergic rhinitis. Clin Exp Allergy 38: 1282-1289. ISSN 0954-7894 
Kalliomaki, M., Kirjavainen, P., Eerola, E., Kero, P., Salminen, S., and Isolauri, E. (2001a) 
Distinct patterns of neonatal gut microflora in infants in whom atopy was and was 
not developing. J Allergy Clin Immunol 107: 129-134. ISSN 0091-6749 
Kalliomaki, M., Salminen, S., Arvilommi, H., Kero, P., Koskinen, P., and Isolauri, E. (2001b) 
Probiotics in primary prevention of atopic disease: a randomised placebo-
controlled trial. Lancet 357: 1076-1079. ISSN: 0140-6736 
Kalliomaki, M., Salminen, S., Poussa, T., Arvilommi, H., and Isolauri, E. (2003) Probiotics 
and prevention of atopic disease: 4-year follow-up of a randomised placebo-
controlled trial. Lancet 361: 1869-1871. ISSN: 0140-6736 
Kalliomaki, M., Salminen, S., Poussa, T., and Isolauri, E. (2007) Probiotics during the first 7 
years of life: a cumulative risk reduction of eczema in a randomized, placebo-
controlled trial. J Allergy Clin Immunol 119: 1019-1021. ISSN 0091-6749 
Karlsson, H., Larsson, P., Wold, A.E., and Rudin, A. (2004) Pattern of cytokine responses to 
gram-positive and gram-negative commensal bacteria is profoundly changed when 
monocytes differentiate into dendritic cells. Infect Immun 72: 2671-2678. ISSN: 0019-
9567 
Kawase, M., He, F., Kubota, A., Hiramatsu, M., Saito, H., Ishii, T. et al. (2009) Effect of 
fermented milk prepared with two probiotic strains on Japanese cedar pollinosis in 
a double-blind placebo-controlled clinical study. Int J Food Microbiol 128: 429-434. 
ISSN: 0168-1605 
Kendler, M., Uter, W., Rueffer, A., Shimshoni, R., and Jecht, E. (2006) Comparison of fecal 
microflora in children with atopic eczema/dermatitis syndrome according to IgE 
sensitization to food. Pediatr Allergy Immunol 17: 141-147. ISSN: 0905-6157 
Kero, J., Gissler, M., Gronlund, M.M., Kero, P., Koskinen, P., Hemminki, E., and Isolauri, E. 
(2002) Mode of delivery and asthma -- is there a connection? Pediatr Res 52: 6-11. 
ISSN: 0031-3998 
Kirjavainen, P.V., Apostolou, E., Arvola, T., Salminen, S.J., Gibson, G.R., and Isolauri, E. 
(2001) Characterizing the composition of intestinal microflora as a prospective 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
428 
treatment target in infant allergic disease. FEMS Immunol Med Microbiol 32: 1-7. 
ISSN: 0928-8244 
Kirjavainen, P.V., Arvola, T., Salminen, S.J., and Isolauri, E. (2002) Aberrant composition of 
gut microbiota of allergic infants: a target of bifidobacterial therapy at weaning? 
Gut 51: 51-55. ISSN: 0017-5749 
Kirjavainen, P.V., Salminen, S.J., and Isolauri, E. (2003) Probiotic bacteria in the management 
of atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol 
Nutr 36: 223-227. ISSN: 0277-2126 
Kopp, M.V., Hennemuth, I., Heinzmann, A., and Urbanek, R. (2008) Randomized, double-
blind, placebo-controlled trial of probiotics for primary prevention: no clinical 
effects of Lactobacillus GG supplementation. Pediatrics 121: e850-e856. ISSN: 0031-
4005 
Laubereau, B., Filipiak-Pittroff, B., von, B.A., Grubl, A., Reinhardt, D., Wichmann, H.E., and 
Koletzko, S. (2004) Caesarean section and gastrointestinal symptoms, atopic 
dermatitis, and sensitisation during the first year of life. Arch Dis Child 89: 993-997. 
ISSN: 0003-9888 
Lee, J., Seto, D., and Bielory, L. (2008) Meta-analysis of clinical trials of probiotics for 
prevention and treatment of pediatric atopic dermatitis. J Allergy Clin Immunol 121: 
116-121. ISSN 0091-6749 
Lyons, A., O'Mahony, D., O'Brien, F., MacSharry, J., Sheil, B., Ceddia, M. et al. (2010) 
Bacterial strain-specific induction of Foxp3+ T regulatory cells is protective in 
murine allergy models. Clin Exp Allergy 40: 811-819. ISSN 0954-7894 
Mah, K.W., Bjorksten, B., Lee, B.W., Van Bever, H.P., Shek, L.P., Tan, T.N. et al. (2006) 
Distinct pattern of commensal gut microbiota in toddlers with eczema. Int Arch 
Allergy Immunol 140: 157-163. ISSN: 1018-2438 
Mannino, D.M., Homa, D.M., Pertowski, C.A., Ashizawa, A., Nixon, L.L., Johnson, C.A. et al. 
(1998) Surveillance for asthma--United States, 1960-1995. MMWR CDC Surveill 
Summ 47: 1-27. ISSN: 0892-3787 
Manson, J.M., Rauch, M., and Gilmore, M.S. (2008) The commensal microbiology of the 
gastrointestinal tract. Adv Exp Med Biol 635: 15-28. ISSN: 0065-2598 
Martin, R., Jimenez, E., Heilig, H., Fernandez, L., Marin, M.L., Zoetendal, E.G., and 
Rodriguez, J.M. (2009) Isolation of bifidobacteria from breast milk and assessment 
of the bifidobacterial population by PCR-denaturing gradient gel electrophoresis 
and quantitative real-time PCR. Appl Environ Microbiol 75: 965-969.ISSN: 0099-2240 
Matto, J., Malinen, E., Suihko, M.L., Alander, M., Palva, A., and Saarela, M. (2004) Genetic 
heterogeneity and functional properties of intestinal bifidobacteria. J Appl Microbiol 
97: 459-470. ISSN: 1364-5072 
Mazmanian, S.K., Liu, C.H., Tzianabos, A.O., and Kasper, D.L. (2005) An 
immunomodulatory molecule of symbiotic bacteria directs maturation of the host 
immune system. Cell 122: 107-118. ISSN: 0092-8674 
McKeever, T.M., Lewis, S.A., Smith, C., and Hubbard, R. (2002) The importance of prenatal 
exposures on the development of allergic disease: a birth cohort study using the 
West Midlands General Practice Database. Am J Respir Crit Care Med 166: 827-832. 
ISSN: 1073-449X 
 
Microbiota and Allergy: From Dysbiosis to Probiotics 
 
429 
Medina, M., Izquierdo, E., Ennahar, S., and Sanz, Y. (2007) Differential immunomodulatory 
properties of Bifidobacterium longum strains: relevance to probiotic selection and 
clinical applications. Clin Exp Immunol 150: 531-538. ISSN: 0009-9104 
Menard, O., Butel, M.J., Gaboriau-Routhiau, V., and Waligora-Dupriet, A.J. (2008) 
Gnotobiotic mouse immune response induced by Bifidobacterium sp. strains isolated 
from infants. Appl Environ Microbiol 74: 660-666. ISSN: 0099-2240 
Murray, C.S., Tannock, G.W., Simon, M.A., Harmsen, H.J., Welling, G.W., Custovic, A., and 
Woodcock, A. (2005) Fecal microbiota in sensitized wheezy and non-sensitized 
non-wheezy children: a nested case-control study. Clin Exp Allergy 35: 741-745. 
ISSN 0954-7894 
Nermes, M., Kantele, J.M., Atosuo, T.J., Salminen, S., and Isolauri, E. (2011) Interaction of 
orally administered Lactobacillus rhamnosus GG with skin and gut microbiota and 
humoral immunity in infants with atopic dermatitis. Clin Exp Allergy 41: 370-377. 
ISSN 0954-7894 
Odamaki, T., Xiao, J.Z., Iwabuchi, N., Sakamoto, M., Takahashi, N., Kondo, S. et al. (2007) 
Fluctuation of fecal microbiota in individuals with Japanese cedar pollinosis during 
the pollen season and influence of probiotic intake. J Investig Allergol Clin Immunol 
17: 92-100. ISSN: 1018-9068 
Okada, H., Kuhn, C., Feillet, H., and Bach, J.F. (2010) The 'hygiene hypothesis' for 
autoimmune and allergic diseases: an update. Clin Exp Immunol 160: 1-9. ISSN: 
0009-9104 
Osborn, D.A., and Sinn, J.K. (2007) Probiotics in infants for prevention of allergic disease 
and food hypersensitivity. Cochrane Database Syst Rev: CD006475. ISSN: 1469-493X 
Ouwehand, A.C., Isolauri, E., He, F., Hashimoto, H., Benno, Y., and Salminen, S. (2001) 
Differences in Bifidobacterium flora composition in allergic and healthy infants. J 
Allergy Clin Immunol 108: 144-145. ISSN 0091-6749 
Ouwehand, A.C., Nermes, M., Collado, M.C., Rautonen, N., Salminen, S., and Isolauri, E. 
(2009) Specific probiotics alleviate allergic rhinitis during the birch pollen season. 
World J Gastroenterol 15: 3261-3268. ISSN: 1007-9327 
Palmer, C., Bik, E.M., DiGiulio, D.B., Relman, D.A., and Brown, P.O. (2007) Development of 
the human infant intestinal microbiota. PLoS Biol 5: e177. ISSN: 1544-9173 
Penders, J., Stobberingh, E.E., Thijs, C., Adams, H., Vink, C., van, R.R., and van den Brandt, 
P.A. (2006a) Molecular fingerprinting of the intestinal microbiota of infants in 
whom atopic eczema was or was not developing. Clin Exp Allergy 36: 1602-1608. 
ISSN 0954-7894 
Penders, J., Thijs, C., Vink, C., Stelma, F.F., Snijders, B., Kummeling, I. et al. (2006b) Factors 
influencing the composition of the intestinal microbiota in early infancy. Pediatrics 
118: 511-521. ISSN: 0031-4005 
Penders, J., Thijs, C., van den Brandt, P.A., Kummeling, I., Snijders, B., Stelma, F. et al. (2007) 
Gut microbiota composition and development of atopic manifestations in infancy: 
the KOALA Birth Cohort Study. Gut 56: 661-667. ISSN: 0017-5749 
Peng, G.C., and Hsu, C.H. (2005) The efficacy and safety of heat-killed Lactobacillus paracasei 
for treatment of perennial allergic rhinitis induced by house-dust mite. Pediatr 
Allergy Immunol 16: 433-438. ISSN: 0905-6157 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
428 
treatment target in infant allergic disease. FEMS Immunol Med Microbiol 32: 1-7. 
ISSN: 0928-8244 
Kirjavainen, P.V., Arvola, T., Salminen, S.J., and Isolauri, E. (2002) Aberrant composition of 
gut microbiota of allergic infants: a target of bifidobacterial therapy at weaning? 
Gut 51: 51-55. ISSN: 0017-5749 
Kirjavainen, P.V., Salminen, S.J., and Isolauri, E. (2003) Probiotic bacteria in the management 
of atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol 
Nutr 36: 223-227. ISSN: 0277-2126 
Kopp, M.V., Hennemuth, I., Heinzmann, A., and Urbanek, R. (2008) Randomized, double-
blind, placebo-controlled trial of probiotics for primary prevention: no clinical 
effects of Lactobacillus GG supplementation. Pediatrics 121: e850-e856. ISSN: 0031-
4005 
Laubereau, B., Filipiak-Pittroff, B., von, B.A., Grubl, A., Reinhardt, D., Wichmann, H.E., and 
Koletzko, S. (2004) Caesarean section and gastrointestinal symptoms, atopic 
dermatitis, and sensitisation during the first year of life. Arch Dis Child 89: 993-997. 
ISSN: 0003-9888 
Lee, J., Seto, D., and Bielory, L. (2008) Meta-analysis of clinical trials of probiotics for 
prevention and treatment of pediatric atopic dermatitis. J Allergy Clin Immunol 121: 
116-121. ISSN 0091-6749 
Lyons, A., O'Mahony, D., O'Brien, F., MacSharry, J., Sheil, B., Ceddia, M. et al. (2010) 
Bacterial strain-specific induction of Foxp3+ T regulatory cells is protective in 
murine allergy models. Clin Exp Allergy 40: 811-819. ISSN 0954-7894 
Mah, K.W., Bjorksten, B., Lee, B.W., Van Bever, H.P., Shek, L.P., Tan, T.N. et al. (2006) 
Distinct pattern of commensal gut microbiota in toddlers with eczema. Int Arch 
Allergy Immunol 140: 157-163. ISSN: 1018-2438 
Mannino, D.M., Homa, D.M., Pertowski, C.A., Ashizawa, A., Nixon, L.L., Johnson, C.A. et al. 
(1998) Surveillance for asthma--United States, 1960-1995. MMWR CDC Surveill 
Summ 47: 1-27. ISSN: 0892-3787 
Manson, J.M., Rauch, M., and Gilmore, M.S. (2008) The commensal microbiology of the 
gastrointestinal tract. Adv Exp Med Biol 635: 15-28. ISSN: 0065-2598 
Martin, R., Jimenez, E., Heilig, H., Fernandez, L., Marin, M.L., Zoetendal, E.G., and 
Rodriguez, J.M. (2009) Isolation of bifidobacteria from breast milk and assessment 
of the bifidobacterial population by PCR-denaturing gradient gel electrophoresis 
and quantitative real-time PCR. Appl Environ Microbiol 75: 965-969.ISSN: 0099-2240 
Matto, J., Malinen, E., Suihko, M.L., Alander, M., Palva, A., and Saarela, M. (2004) Genetic 
heterogeneity and functional properties of intestinal bifidobacteria. J Appl Microbiol 
97: 459-470. ISSN: 1364-5072 
Mazmanian, S.K., Liu, C.H., Tzianabos, A.O., and Kasper, D.L. (2005) An 
immunomodulatory molecule of symbiotic bacteria directs maturation of the host 
immune system. Cell 122: 107-118. ISSN: 0092-8674 
McKeever, T.M., Lewis, S.A., Smith, C., and Hubbard, R. (2002) The importance of prenatal 
exposures on the development of allergic disease: a birth cohort study using the 
West Midlands General Practice Database. Am J Respir Crit Care Med 166: 827-832. 
ISSN: 1073-449X 
 
Microbiota and Allergy: From Dysbiosis to Probiotics 
 
429 
Medina, M., Izquierdo, E., Ennahar, S., and Sanz, Y. (2007) Differential immunomodulatory 
properties of Bifidobacterium longum strains: relevance to probiotic selection and 
clinical applications. Clin Exp Immunol 150: 531-538. ISSN: 0009-9104 
Menard, O., Butel, M.J., Gaboriau-Routhiau, V., and Waligora-Dupriet, A.J. (2008) 
Gnotobiotic mouse immune response induced by Bifidobacterium sp. strains isolated 
from infants. Appl Environ Microbiol 74: 660-666. ISSN: 0099-2240 
Murray, C.S., Tannock, G.W., Simon, M.A., Harmsen, H.J., Welling, G.W., Custovic, A., and 
Woodcock, A. (2005) Fecal microbiota in sensitized wheezy and non-sensitized 
non-wheezy children: a nested case-control study. Clin Exp Allergy 35: 741-745. 
ISSN 0954-7894 
Nermes, M., Kantele, J.M., Atosuo, T.J., Salminen, S., and Isolauri, E. (2011) Interaction of 
orally administered Lactobacillus rhamnosus GG with skin and gut microbiota and 
humoral immunity in infants with atopic dermatitis. Clin Exp Allergy 41: 370-377. 
ISSN 0954-7894 
Odamaki, T., Xiao, J.Z., Iwabuchi, N., Sakamoto, M., Takahashi, N., Kondo, S. et al. (2007) 
Fluctuation of fecal microbiota in individuals with Japanese cedar pollinosis during 
the pollen season and influence of probiotic intake. J Investig Allergol Clin Immunol 
17: 92-100. ISSN: 1018-9068 
Okada, H., Kuhn, C., Feillet, H., and Bach, J.F. (2010) The 'hygiene hypothesis' for 
autoimmune and allergic diseases: an update. Clin Exp Immunol 160: 1-9. ISSN: 
0009-9104 
Osborn, D.A., and Sinn, J.K. (2007) Probiotics in infants for prevention of allergic disease 
and food hypersensitivity. Cochrane Database Syst Rev: CD006475. ISSN: 1469-493X 
Ouwehand, A.C., Isolauri, E., He, F., Hashimoto, H., Benno, Y., and Salminen, S. (2001) 
Differences in Bifidobacterium flora composition in allergic and healthy infants. J 
Allergy Clin Immunol 108: 144-145. ISSN 0091-6749 
Ouwehand, A.C., Nermes, M., Collado, M.C., Rautonen, N., Salminen, S., and Isolauri, E. 
(2009) Specific probiotics alleviate allergic rhinitis during the birch pollen season. 
World J Gastroenterol 15: 3261-3268. ISSN: 1007-9327 
Palmer, C., Bik, E.M., DiGiulio, D.B., Relman, D.A., and Brown, P.O. (2007) Development of 
the human infant intestinal microbiota. PLoS Biol 5: e177. ISSN: 1544-9173 
Penders, J., Stobberingh, E.E., Thijs, C., Adams, H., Vink, C., van, R.R., and van den Brandt, 
P.A. (2006a) Molecular fingerprinting of the intestinal microbiota of infants in 
whom atopic eczema was or was not developing. Clin Exp Allergy 36: 1602-1608. 
ISSN 0954-7894 
Penders, J., Thijs, C., Vink, C., Stelma, F.F., Snijders, B., Kummeling, I. et al. (2006b) Factors 
influencing the composition of the intestinal microbiota in early infancy. Pediatrics 
118: 511-521. ISSN: 0031-4005 
Penders, J., Thijs, C., van den Brandt, P.A., Kummeling, I., Snijders, B., Stelma, F. et al. (2007) 
Gut microbiota composition and development of atopic manifestations in infancy: 
the KOALA Birth Cohort Study. Gut 56: 661-667. ISSN: 0017-5749 
Peng, G.C., and Hsu, C.H. (2005) The efficacy and safety of heat-killed Lactobacillus paracasei 
for treatment of perennial allergic rhinitis induced by house-dust mite. Pediatr 
Allergy Immunol 16: 433-438. ISSN: 0905-6157 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
430 
Pohjavuori, E., Viljanen, M., Korpela, R., Kuitunen, M., Tiittanen, M., Vaarala, O., and 
Savilahti, E. (2004) Lactobacillus GG effect in increasing IFN-gamma production in 
infants with cow's milk allergy. J Allergy Clin Immunol 114: 131-136. ISSN 0091-
6749 
Protonotariou, E., Malamitsi-Puchner, A., Rizos, D., Papagianni, B., Moira, E., Sarandakou, 
A., and Botsis, D. (2004) Age-related differentiations of Th1/Th2 cytokines in 
newborn infants. Mediators Inflamm 13: 89-92. ISSN: 0962-9351  
Rajilic-Stojanovic, M., Heilig, H.G., Molenaar, D., Kajander, K., Surakka, A., Smidt, H., and 
De Vos, W.M. (2009) Development and application of the human intestinal tract 
chip, a phylogenetic microarray: analysis of universally conserved phylotypes in 
the abundant microbiota of young and elderly adults. Environ Microbiol 11: 1736-
1751. ISSN:1462-2912 
Rajilic-Stojanovic, M., Smidt, H., and De Vos, W.M. (2007) Diversity of the human 
gastrointestinal tract microbiota revisited. Environ Microbiol 9: 2125-2136. 
ISSN:1462-2912 
Rautava, S., Kalliomaki, M., and Isolauri, E. (2002a) Probiotics during pregnancy and breast-
feeding might confer immunomodulatory protection against atopic disease in the 
infant. J Allergy Clin Immunol 109: 119-121. ISSN 0091-6749 
Rautava, S., Kalliomaki, M., and Isolauri, E. (2002b) Probiotics during pregnancy and breast-
feeding might confer immunomodulatory protection against atopic disease in the 
infant. J Allergy Clin Immunol 109: 119-121. ISSN 0091-6749 
Rautava, S., Ruuskanen, O., Ouwehand, A., Salminen, S., and Isolauri, E. (2004) The hygiene 
hypothesis of atopic disease--an extended version. J Pediatr Gastroenterol Nutr 38: 
378-388. ISSN: 0277-2126 
Rodriguez, B., Prioult, G., Bibiloni, R., Nicolis, I., Mercenier, A., Butel, M.J., and Waligora-
Dupriet, A.J. (2011) Germ-free status and altered caecal subdominant microbiota 
are associated with a high susceptibility to cow's milk allergy in mice. FEMS 
Microbiol Ecol 76: 133-144. ISSN: 0168-6496 
Roguedas-Contios, A.M., and Misery, L. (2011) What is Intrinsic Atopic Dermatitis? Clin Rev 
Allergy Immunol. ISSN: 1080-0549  
Rose, M.A., Stieglitz, F., Koksal, A., Schubert, R., Schulze, J., and Zielen, S. (2010) Efficacy of 
probiotic Lactobacillus GG on allergic sensitization and asthma in infants at risk. 
Clin Exp Allergy 40: 1398-1405. ISSN 0954-7894 
Rosenfeldt, V., Benfeldt, E., Nielsen, S.D., Michaelsen, K.F., Jeppesen, D.L., Valerius, N.H., 
and Paerregaard, A. (2003) Effect of probiotic Lactobacillus strains in children with 
atopic dermatitis. J Allergy Clin Immunol 111: 389-395. ISSN 0091-6749 
Rosenfeldt, V., Benfeldt, E., Valerius, N.H., Paerregaard, A., and Michaelsen, K.F. (2004) 
Effect of probiotics on gastrointestinal symptoms and small intestinal permeability 
in children with atopic dermatitis. J Pediatr 145: 612-616. ISSN: 0022-3476 
Round, J.L., O'Connell, R.M., and Mazmanian, S.K. (2010) Coordination of tolerogenic 
immune responses by the commensal microbiota. J Autoimmun 34: J220-J225. ISSN: 
0896-8411 
Sepp, E., Julge, K., Mikelsaar, M., and Bjorksten, B. (2005) Intestinal microbiota and 
immunoglobulin E responses in 5-year-old Estonian children. Clin Exp Allergy 35: 
1141-1146. ISSN 0954-7894 
 
Microbiota and Allergy: From Dysbiosis to Probiotics 
 
431 
Sepp, E., Julge, K., Vasar, M., Naaber, P., Bjorksten, B., and Mikelsaar, M. (1997) Intestinal 
microflora of estonian and swedish infants. Acta Paediat 86: 956-961. ISSN: 0803-
5253 
Shull, M.M., Ormsby, I., Kier, A.B., Pawlowski, S., Diebold, R.J., Yin, M. et al. (1992) Targeted 
disruption of the mouse transforming growth factor-beta 1 gene results in 
multifocal inflammatory disease. Nature 359: 693-699. ISSN: 0028-0836 
Sistek, D., Kelly, R., Wickens, K., Stanley, T., Fitzharris, P., and Crane, J. (2006) Is the effect of 
probiotics on atopic dermatitis confined to food sensitized children? Clin Exp 
Allergy 36: 629-633. ISSN 0954-7894 
Sjogren, Y.M., Jenmalm, M.C., Bottcher, M.F., Bjorksten, B., and Sverremark-Ekstrom, E. 
(2009) Altered early infant gut microbiota in children developing allergy up to 5 
years of age. Clin Exp Allergy 39: 518-526. ISSN 0954-7894 
Smith, K., McCoy, K.D., and Macpherson, A.J. (2007) Use of axenic animals in studying the 
adaptation of mammals to their commensal intestinal microbiota. Semin Immunol 
19: 59-69. ISSN: 1044-5323 
Société Française de Dermatologie (2005) Conférence de consensus "Prise en charge de la 
dermatite atopique de l'enfant". Ann Dermatol Venereol 132: 1S19-1S33. ISSN: 0151-
9638 
Soh, S.E., Aw, M., Gerez, I., Chong, Y.S., Rauff, M., Ng, Y.P. et al. (2009) Probiotic 
supplementation in the first 6 months of life in at risk Asian infants--effects on 
eczema and atopic sensitization at the age of 1 year. Clin Exp Allergy 39: 571-578. 
ISSN 0954-7894 
Songjinda, P., Nakayama, J., Tateyama, A., Tanaka, S., Tsubouchi, M., Kiyohara, C. et al. 
(2007) Differences in developing intestinal microbiota between allergic and non-
allergic infants: a pilot study in Japan. Biosci Biotechnol Biochem 71: 2338-2342. ISSN: 
0916-8451 
Stackebrandt, E., Kramer, I., Swiderski, J., and Hippe, H. (1999) Phylogenetic basis for a 
taxonomic dissection of the genus Clostridium. FEMS Immunol Med Microbiol 24: 
253-258. ISSN: 0928-8244 
Stecher, B., and Hardt, W.D. (2008) The role of microbiota in infectious disease. Trends 
Microbiol 16: 107-114. ISSN: 0966-842X  
Strachan, D.P. (1989) Hay fever, hygiene, and household size. BMJ 299: 1259-1260. ISSN: 
0959-8138 
Stsepetova, J., Sepp, E., Julge, K., Vaughan, E., Mikelsaar, M., and De Vos, W.M. (2007) 
Molecularly assessed shifts of Bifidobacterium ssp. and less diverse microbial 
communities are characteristic of 5-year-old allergic children. FEMS Immunol Med 
Microbiol 51: 260-269. ISSN: 0928-8244 
Sudo, N., Sawamura, S., Tanaka, K., Aiba, Y., Kubo, C., and Koga, Y. (1997) The requirement 
of intestinal bacterial flora for the development of an IgE production system fully 
susceptible to oral tolerance induction. J Immunol 159: 1739-1745. ISSN: 0022-1767  
Tamura, M., Shikina, T., Morihana, T., Hayama, M., Kajimoto, O., Sakamoto, A. et al. (2007) 
Effects of probiotics on allergic rhinitis induced by Japanese cedar pollen: 
randomized double-blind, placebo-controlled clinical trial. Int Arch Allergy Immunol 
143: 75-82. ISSN: 1018-2438 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
430 
Pohjavuori, E., Viljanen, M., Korpela, R., Kuitunen, M., Tiittanen, M., Vaarala, O., and 
Savilahti, E. (2004) Lactobacillus GG effect in increasing IFN-gamma production in 
infants with cow's milk allergy. J Allergy Clin Immunol 114: 131-136. ISSN 0091-
6749 
Protonotariou, E., Malamitsi-Puchner, A., Rizos, D., Papagianni, B., Moira, E., Sarandakou, 
A., and Botsis, D. (2004) Age-related differentiations of Th1/Th2 cytokines in 
newborn infants. Mediators Inflamm 13: 89-92. ISSN: 0962-9351  
Rajilic-Stojanovic, M., Heilig, H.G., Molenaar, D., Kajander, K., Surakka, A., Smidt, H., and 
De Vos, W.M. (2009) Development and application of the human intestinal tract 
chip, a phylogenetic microarray: analysis of universally conserved phylotypes in 
the abundant microbiota of young and elderly adults. Environ Microbiol 11: 1736-
1751. ISSN:1462-2912 
Rajilic-Stojanovic, M., Smidt, H., and De Vos, W.M. (2007) Diversity of the human 
gastrointestinal tract microbiota revisited. Environ Microbiol 9: 2125-2136. 
ISSN:1462-2912 
Rautava, S., Kalliomaki, M., and Isolauri, E. (2002a) Probiotics during pregnancy and breast-
feeding might confer immunomodulatory protection against atopic disease in the 
infant. J Allergy Clin Immunol 109: 119-121. ISSN 0091-6749 
Rautava, S., Kalliomaki, M., and Isolauri, E. (2002b) Probiotics during pregnancy and breast-
feeding might confer immunomodulatory protection against atopic disease in the 
infant. J Allergy Clin Immunol 109: 119-121. ISSN 0091-6749 
Rautava, S., Ruuskanen, O., Ouwehand, A., Salminen, S., and Isolauri, E. (2004) The hygiene 
hypothesis of atopic disease--an extended version. J Pediatr Gastroenterol Nutr 38: 
378-388. ISSN: 0277-2126 
Rodriguez, B., Prioult, G., Bibiloni, R., Nicolis, I., Mercenier, A., Butel, M.J., and Waligora-
Dupriet, A.J. (2011) Germ-free status and altered caecal subdominant microbiota 
are associated with a high susceptibility to cow's milk allergy in mice. FEMS 
Microbiol Ecol 76: 133-144. ISSN: 0168-6496 
Roguedas-Contios, A.M., and Misery, L. (2011) What is Intrinsic Atopic Dermatitis? Clin Rev 
Allergy Immunol. ISSN: 1080-0549  
Rose, M.A., Stieglitz, F., Koksal, A., Schubert, R., Schulze, J., and Zielen, S. (2010) Efficacy of 
probiotic Lactobacillus GG on allergic sensitization and asthma in infants at risk. 
Clin Exp Allergy 40: 1398-1405. ISSN 0954-7894 
Rosenfeldt, V., Benfeldt, E., Nielsen, S.D., Michaelsen, K.F., Jeppesen, D.L., Valerius, N.H., 
and Paerregaard, A. (2003) Effect of probiotic Lactobacillus strains in children with 
atopic dermatitis. J Allergy Clin Immunol 111: 389-395. ISSN 0091-6749 
Rosenfeldt, V., Benfeldt, E., Valerius, N.H., Paerregaard, A., and Michaelsen, K.F. (2004) 
Effect of probiotics on gastrointestinal symptoms and small intestinal permeability 
in children with atopic dermatitis. J Pediatr 145: 612-616. ISSN: 0022-3476 
Round, J.L., O'Connell, R.M., and Mazmanian, S.K. (2010) Coordination of tolerogenic 
immune responses by the commensal microbiota. J Autoimmun 34: J220-J225. ISSN: 
0896-8411 
Sepp, E., Julge, K., Mikelsaar, M., and Bjorksten, B. (2005) Intestinal microbiota and 
immunoglobulin E responses in 5-year-old Estonian children. Clin Exp Allergy 35: 
1141-1146. ISSN 0954-7894 
 
Microbiota and Allergy: From Dysbiosis to Probiotics 
 
431 
Sepp, E., Julge, K., Vasar, M., Naaber, P., Bjorksten, B., and Mikelsaar, M. (1997) Intestinal 
microflora of estonian and swedish infants. Acta Paediat 86: 956-961. ISSN: 0803-
5253 
Shull, M.M., Ormsby, I., Kier, A.B., Pawlowski, S., Diebold, R.J., Yin, M. et al. (1992) Targeted 
disruption of the mouse transforming growth factor-beta 1 gene results in 
multifocal inflammatory disease. Nature 359: 693-699. ISSN: 0028-0836 
Sistek, D., Kelly, R., Wickens, K., Stanley, T., Fitzharris, P., and Crane, J. (2006) Is the effect of 
probiotics on atopic dermatitis confined to food sensitized children? Clin Exp 
Allergy 36: 629-633. ISSN 0954-7894 
Sjogren, Y.M., Jenmalm, M.C., Bottcher, M.F., Bjorksten, B., and Sverremark-Ekstrom, E. 
(2009) Altered early infant gut microbiota in children developing allergy up to 5 
years of age. Clin Exp Allergy 39: 518-526. ISSN 0954-7894 
Smith, K., McCoy, K.D., and Macpherson, A.J. (2007) Use of axenic animals in studying the 
adaptation of mammals to their commensal intestinal microbiota. Semin Immunol 
19: 59-69. ISSN: 1044-5323 
Société Française de Dermatologie (2005) Conférence de consensus "Prise en charge de la 
dermatite atopique de l'enfant". Ann Dermatol Venereol 132: 1S19-1S33. ISSN: 0151-
9638 
Soh, S.E., Aw, M., Gerez, I., Chong, Y.S., Rauff, M., Ng, Y.P. et al. (2009) Probiotic 
supplementation in the first 6 months of life in at risk Asian infants--effects on 
eczema and atopic sensitization at the age of 1 year. Clin Exp Allergy 39: 571-578. 
ISSN 0954-7894 
Songjinda, P., Nakayama, J., Tateyama, A., Tanaka, S., Tsubouchi, M., Kiyohara, C. et al. 
(2007) Differences in developing intestinal microbiota between allergic and non-
allergic infants: a pilot study in Japan. Biosci Biotechnol Biochem 71: 2338-2342. ISSN: 
0916-8451 
Stackebrandt, E., Kramer, I., Swiderski, J., and Hippe, H. (1999) Phylogenetic basis for a 
taxonomic dissection of the genus Clostridium. FEMS Immunol Med Microbiol 24: 
253-258. ISSN: 0928-8244 
Stecher, B., and Hardt, W.D. (2008) The role of microbiota in infectious disease. Trends 
Microbiol 16: 107-114. ISSN: 0966-842X  
Strachan, D.P. (1989) Hay fever, hygiene, and household size. BMJ 299: 1259-1260. ISSN: 
0959-8138 
Stsepetova, J., Sepp, E., Julge, K., Vaughan, E., Mikelsaar, M., and De Vos, W.M. (2007) 
Molecularly assessed shifts of Bifidobacterium ssp. and less diverse microbial 
communities are characteristic of 5-year-old allergic children. FEMS Immunol Med 
Microbiol 51: 260-269. ISSN: 0928-8244 
Sudo, N., Sawamura, S., Tanaka, K., Aiba, Y., Kubo, C., and Koga, Y. (1997) The requirement 
of intestinal bacterial flora for the development of an IgE production system fully 
susceptible to oral tolerance induction. J Immunol 159: 1739-1745. ISSN: 0022-1767  
Tamura, M., Shikina, T., Morihana, T., Hayama, M., Kajimoto, O., Sakamoto, A. et al. (2007) 
Effects of probiotics on allergic rhinitis induced by Japanese cedar pollen: 
randomized double-blind, placebo-controlled clinical trial. Int Arch Allergy Immunol 
143: 75-82. ISSN: 1018-2438 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
432 
Tap, J., Mondot, S., Levenez, F., Pelletier, E., Caron, C., Furet, J.P. et al. (2009) Towards the 
human intestinal microbiota phylogenetic core. Environ Microbiol 11: 2574-2584. 
ISSN: 1462-2912 
Taylor, A., Hale, J., Wiltschut, J., Lehmann, H., Dunstan, J.A., and Prescott, S.L. (2006a) 
Evaluation of the effects of probiotic supplementation from the neonatal period on 
innate immune development in infancy. Clin Exp Allergy 36: 1218-1226. ISSN 0954-
7894 
Taylor, A.L., Dunstan, J.A., and Prescott, S.L. (2007a) Probiotic supplementation for the first 
6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of 
allergen sensitization in high-risk children: a randomized controlled trial. J Allergy 
Clin Immunol 119: 184-191. ISSN 0091-6749 
Taylor, A.L., Hale, J., Hales, B.J., Dunstan, J.A., Thomas, W.R., and Prescott, S.L. (2007b) 
FOXP3 mRNA expression at 6 months of age is higher in infants who develop 
atopic dermatitis, but is not affected by giving probiotics from birth. Pediatr Allergy 
Immunol 18: 10-19. ISSN: 0905-6157  
Taylor, A.L., Hale, J., Wiltschut, J., Lehmann, H., Dunstan, J.A., and Prescott, S.L. (2006b) 
Effects of probiotic supplementation for the first 6 months of life on allergen- and 
vaccine-specific immune responses. Clin Exp Allergy 36: 1227-1235. ISSN 0954-7894 
Vael, C., and Desager, K. (2009) The importance of the development of the intestinal 
microbiota in infancy. Curr Opin Pediatr 21: 794-800. ISSN: 1040-8703  
Vael, C., Nelen, V., Verhulst, S.L., Goossens, H., and Desager, K.N. (2008) Early intestinal 
Bacteroides fragilis colonisation and development of asthma. BMC Pulm Med 8: 19. 
ISSN: 1471-2466  
Vael, C., Vanheirstraeten, L., Desager, K.N., and Goossens, H. (2011) Denaturing gradient 
gel electrophoresis of neonatal intestinal microbiota in relation to the development 
of asthma. BMC Microbiol 11: 68. ISSN: 1471-2180 
Vaishampayan, P.A., Kuehl, J.V., Froula, J.L., Morgan, J.L., Ochman, H., and Francino, M.P. 
(2010) Comparative metagenomics and population dynamics of the gut microbiota 
in mother and infant. Genome Biol Evol 2: 53-66. ISSN: 1759-6653 
van der Aa, L.B., Heymans, H.S., van Aalderen, W.M., Sillevis Smitt, J.H., Knol, J., Ben, A.K. 
et al. (2010) Effect of a new synbiotic mixture on atopic dermatitis in infants: a 
randomized-controlled trial. Clin Exp Allergy 40: 795-804. ISSN 0954-7894 
van der Aa, L.B., van Aalderen, W.M., Heymans, H.S., Henk Sillevis, S.J., Nauta, A.J., 
Knippels, L.M. et al. (2011) Synbiotics prevent asthma-like symptoms in infants 
with atopic dermatitis. Allergy 66: 170-177. ISSN 0105-4338 
Ventura, M., van, S.D., Fitzgerald, G.F., and Zink, R. (2004) Insights into the taxonomy, 
genetics and physiology of bifidobacteria. Antonie van Leeuwenhoek 86: 205-223. 
ISSN: 0003-6072  
Verhulst, S.L., Vael, C., Beunckens, C., Nelen, V., Goossens, H., and Desager, K. (2008) A 
longitudinal analysis on the association between antibiotic use, intestinal 
microflora, and wheezing during the first year of life. J Asthma 45: 828-832. ISSN: 
0277-0903 
Viljanen, M., Kuitunen, M., Haahtela, T., Juntunen-Backman, K., Korpela, R., and Savilahti, 
E. (2005a) Probiotic effects on faecal inflammatory markers and on faecal IgA in 
 
Microbiota and Allergy: From Dysbiosis to Probiotics 
 
433 
food allergic atopic eczema/dermatitis syndrome infants. Pediatr Allergy Immunol 
16: 65-71. ISSN: 0905-6157 
Viljanen, M., Savilahti, E., Haahtela, T., Juntunen-Backman, K., Korpela, R., Poussa, T. et 
al. (2005b) Probiotics in the treatment of atopic eczema/dermatitis syndrome in 
infants: a double-blind placebo-controlled trial. Allergy 60: 494-500. ISSN 0105-
4338 
Waligora-Dupriet, A.J., Campeotto, F., Romero, K., Mangin, I., Rouzaud, G., Menard, O. et 
al. (2011) Diversity of gut Bifidobacterium species is not altered between allergic and 
non-allergic French infants. Anaerobe. ISSN: 1075-9964 
Wang, M., Karlsson, C., Olsson, C., Adlerberth, I., Wold, A.E., Strachan, D.P. et al. (2008) 
Reduced diversity in the early fecal microbiota of infants with atopic eczema. J 
Allergy Clin Immunol 121: 129-134. ISSN 0091-6749 
Wang, M.F., Lin, H.C., Wang, Y.Y., and Hsu, C.H. (2004) Treatment of perennial allergic 
rhinitis with lactic acid bacteria. Pediatr Allergy Immunol 15: 152-158. ISSN: 0905-
6157 
Watanabe, S., Narisawa, Y., Arase, S., Okamatsu, H., Ikenaga, T., Tajiri, Y., and Kumemura, 
M. (2003) Differences in fecal microflora between patients with atopic dermatitis 
and healthy control subjects. J Allergy Clin Immunol 111: 587-591. ISSN 0091-6749 
Weston, S., Halbert, A., Richmond, P., and Prescott, S.L. (2005) Effects of probiotics on atopic 
dermatitis: a randomised controlled trial. Arch Dis Child 90: 892-897. ISSN: 0003-
9888 
Wickens, K., Black, P.N., Stanley, T.V., Mitchell, E., Fitzharris, P., Tannock, G.W. et al. (2008) 
A differential effect of 2 probiotics in the prevention of eczema and atopy: a 
double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 122: 788-
794. ISSN 0091-6749 
Williams, N.T. (2010) Probiotics. Am J Health Syst Pharm 67: 449-458. ISSN: 1079-2082  
Wong, J.M., de, S.R., Kendall, C.W., Emam, A., and Jenkins, D.J. (2006) Colonic health: 
fermentation and short chain fatty acids. J Clin Gastroenterol 40: 235-243. ISSN: 0192-
0790 
Woo, S.I., Kim, J.Y., Lee, Y.J., Kim, N.S., and Hahn, Y.S. (2010) Effect of Lactobacillus sakei 
supplementation in children with atopic eczema-dermatitis syndrome. Ann Allergy 
Asthma Immunol 104: 343-348. ISSN: 1081-1206 
Woodcock, A., Moradi, M., Smillie, F.I., Murray, C.S., Burnie, J.P., and Custovic, A. (2002) 
Clostridium difficile, atopy and wheeze during the first year of life. Pediatr Allergy 
Immunol 13: 357-360. ISSN: 0905-6157 
Xiao, J.Z., Kondo, S., Yanagisawa, N., Miyaji, K., Enomoto, K., Sakoda, T. et al. (2007) Clinical 
efficacy of probiotic Bifidobacterium longum for the treatment of symptoms of 
Japanese cedar pollen allergy in subjects evaluated in an environmental exposure 
unit. Allergol Int 56: 67-75. ISSN: 1323-8930 
Young, S.L., Simon, M.A., Baird, M.A., Tannock, G.W., Bibiloni, R., Spencely, K. et al. (2004) 
Bifidobacterial species differentially affect expression of cell surface markers and 
cytokines of dendritic cells harvested from cord blood. Clin Diagn Lab Immunol 11: 
686-690. ISSN: 1071-412X  
Zeuthen, L.H., Christensen, H.R., and Frokiaer, H. (2006) Lactic acid bacteria inducing a 
weak interleukin-12 and tumor necrosis factor alpha response in human dendritic 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
432 
Tap, J., Mondot, S., Levenez, F., Pelletier, E., Caron, C., Furet, J.P. et al. (2009) Towards the 
human intestinal microbiota phylogenetic core. Environ Microbiol 11: 2574-2584. 
ISSN: 1462-2912 
Taylor, A., Hale, J., Wiltschut, J., Lehmann, H., Dunstan, J.A., and Prescott, S.L. (2006a) 
Evaluation of the effects of probiotic supplementation from the neonatal period on 
innate immune development in infancy. Clin Exp Allergy 36: 1218-1226. ISSN 0954-
7894 
Taylor, A.L., Dunstan, J.A., and Prescott, S.L. (2007a) Probiotic supplementation for the first 
6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of 
allergen sensitization in high-risk children: a randomized controlled trial. J Allergy 
Clin Immunol 119: 184-191. ISSN 0091-6749 
Taylor, A.L., Hale, J., Hales, B.J., Dunstan, J.A., Thomas, W.R., and Prescott, S.L. (2007b) 
FOXP3 mRNA expression at 6 months of age is higher in infants who develop 
atopic dermatitis, but is not affected by giving probiotics from birth. Pediatr Allergy 
Immunol 18: 10-19. ISSN: 0905-6157  
Taylor, A.L., Hale, J., Wiltschut, J., Lehmann, H., Dunstan, J.A., and Prescott, S.L. (2006b) 
Effects of probiotic supplementation for the first 6 months of life on allergen- and 
vaccine-specific immune responses. Clin Exp Allergy 36: 1227-1235. ISSN 0954-7894 
Vael, C., and Desager, K. (2009) The importance of the development of the intestinal 
microbiota in infancy. Curr Opin Pediatr 21: 794-800. ISSN: 1040-8703  
Vael, C., Nelen, V., Verhulst, S.L., Goossens, H., and Desager, K.N. (2008) Early intestinal 
Bacteroides fragilis colonisation and development of asthma. BMC Pulm Med 8: 19. 
ISSN: 1471-2466  
Vael, C., Vanheirstraeten, L., Desager, K.N., and Goossens, H. (2011) Denaturing gradient 
gel electrophoresis of neonatal intestinal microbiota in relation to the development 
of asthma. BMC Microbiol 11: 68. ISSN: 1471-2180 
Vaishampayan, P.A., Kuehl, J.V., Froula, J.L., Morgan, J.L., Ochman, H., and Francino, M.P. 
(2010) Comparative metagenomics and population dynamics of the gut microbiota 
in mother and infant. Genome Biol Evol 2: 53-66. ISSN: 1759-6653 
van der Aa, L.B., Heymans, H.S., van Aalderen, W.M., Sillevis Smitt, J.H., Knol, J., Ben, A.K. 
et al. (2010) Effect of a new synbiotic mixture on atopic dermatitis in infants: a 
randomized-controlled trial. Clin Exp Allergy 40: 795-804. ISSN 0954-7894 
van der Aa, L.B., van Aalderen, W.M., Heymans, H.S., Henk Sillevis, S.J., Nauta, A.J., 
Knippels, L.M. et al. (2011) Synbiotics prevent asthma-like symptoms in infants 
with atopic dermatitis. Allergy 66: 170-177. ISSN 0105-4338 
Ventura, M., van, S.D., Fitzgerald, G.F., and Zink, R. (2004) Insights into the taxonomy, 
genetics and physiology of bifidobacteria. Antonie van Leeuwenhoek 86: 205-223. 
ISSN: 0003-6072  
Verhulst, S.L., Vael, C., Beunckens, C., Nelen, V., Goossens, H., and Desager, K. (2008) A 
longitudinal analysis on the association between antibiotic use, intestinal 
microflora, and wheezing during the first year of life. J Asthma 45: 828-832. ISSN: 
0277-0903 
Viljanen, M., Kuitunen, M., Haahtela, T., Juntunen-Backman, K., Korpela, R., and Savilahti, 
E. (2005a) Probiotic effects on faecal inflammatory markers and on faecal IgA in 
 
Microbiota and Allergy: From Dysbiosis to Probiotics 
 
433 
food allergic atopic eczema/dermatitis syndrome infants. Pediatr Allergy Immunol 
16: 65-71. ISSN: 0905-6157 
Viljanen, M., Savilahti, E., Haahtela, T., Juntunen-Backman, K., Korpela, R., Poussa, T. et 
al. (2005b) Probiotics in the treatment of atopic eczema/dermatitis syndrome in 
infants: a double-blind placebo-controlled trial. Allergy 60: 494-500. ISSN 0105-
4338 
Waligora-Dupriet, A.J., Campeotto, F., Romero, K., Mangin, I., Rouzaud, G., Menard, O. et 
al. (2011) Diversity of gut Bifidobacterium species is not altered between allergic and 
non-allergic French infants. Anaerobe. ISSN: 1075-9964 
Wang, M., Karlsson, C., Olsson, C., Adlerberth, I., Wold, A.E., Strachan, D.P. et al. (2008) 
Reduced diversity in the early fecal microbiota of infants with atopic eczema. J 
Allergy Clin Immunol 121: 129-134. ISSN 0091-6749 
Wang, M.F., Lin, H.C., Wang, Y.Y., and Hsu, C.H. (2004) Treatment of perennial allergic 
rhinitis with lactic acid bacteria. Pediatr Allergy Immunol 15: 152-158. ISSN: 0905-
6157 
Watanabe, S., Narisawa, Y., Arase, S., Okamatsu, H., Ikenaga, T., Tajiri, Y., and Kumemura, 
M. (2003) Differences in fecal microflora between patients with atopic dermatitis 
and healthy control subjects. J Allergy Clin Immunol 111: 587-591. ISSN 0091-6749 
Weston, S., Halbert, A., Richmond, P., and Prescott, S.L. (2005) Effects of probiotics on atopic 
dermatitis: a randomised controlled trial. Arch Dis Child 90: 892-897. ISSN: 0003-
9888 
Wickens, K., Black, P.N., Stanley, T.V., Mitchell, E., Fitzharris, P., Tannock, G.W. et al. (2008) 
A differential effect of 2 probiotics in the prevention of eczema and atopy: a 
double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 122: 788-
794. ISSN 0091-6749 
Williams, N.T. (2010) Probiotics. Am J Health Syst Pharm 67: 449-458. ISSN: 1079-2082  
Wong, J.M., de, S.R., Kendall, C.W., Emam, A., and Jenkins, D.J. (2006) Colonic health: 
fermentation and short chain fatty acids. J Clin Gastroenterol 40: 235-243. ISSN: 0192-
0790 
Woo, S.I., Kim, J.Y., Lee, Y.J., Kim, N.S., and Hahn, Y.S. (2010) Effect of Lactobacillus sakei 
supplementation in children with atopic eczema-dermatitis syndrome. Ann Allergy 
Asthma Immunol 104: 343-348. ISSN: 1081-1206 
Woodcock, A., Moradi, M., Smillie, F.I., Murray, C.S., Burnie, J.P., and Custovic, A. (2002) 
Clostridium difficile, atopy and wheeze during the first year of life. Pediatr Allergy 
Immunol 13: 357-360. ISSN: 0905-6157 
Xiao, J.Z., Kondo, S., Yanagisawa, N., Miyaji, K., Enomoto, K., Sakoda, T. et al. (2007) Clinical 
efficacy of probiotic Bifidobacterium longum for the treatment of symptoms of 
Japanese cedar pollen allergy in subjects evaluated in an environmental exposure 
unit. Allergol Int 56: 67-75. ISSN: 1323-8930 
Young, S.L., Simon, M.A., Baird, M.A., Tannock, G.W., Bibiloni, R., Spencely, K. et al. (2004) 
Bifidobacterial species differentially affect expression of cell surface markers and 
cytokines of dendritic cells harvested from cord blood. Clin Diagn Lab Immunol 11: 
686-690. ISSN: 1071-412X  
Zeuthen, L.H., Christensen, H.R., and Frokiaer, H. (2006) Lactic acid bacteria inducing a 
weak interleukin-12 and tumor necrosis factor alpha response in human dendritic 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
434 
cells inhibit strongly stimulating lactic acid bacteria but act synergistically with 
gram-negative bacteria. Clin Vaccine Immunol 13: 365-375. ISSN: 1556-6811  
Zoetendal, E.G., Rajilic-Stojanovic, M., and De Vos, W.M. (2008) High-throughput diversity 
and functionality analysis of the gastrointestinal tract microbiota. Gut 57: 1605-1615. 
ISSN: 0017-5749 
22 
Natural Products and Dermatological 
Hypersensitivity Diseases  
Clayton MacDonald and Marianna Kulka  
Institute for Nutriscience and Health, National Research Council, 
Canada 
1. Introduction  
The management of dermatological hypersensitivity diseases is a lifelong struggle for most 
patients. Often, patients are advised to avoid triggers and aggregating factors that lead to 
flare ups which eventually becomes second nature to them. However, when the symptoms 
of these conditions become unbearable and conventional medicine no longer provides relief, 
an increasing proportion of allergy patients are looking to alternative treatments for comfort. 
Natural products are compounds isolated from natural sources (usually plants or animals) that 
have potentially beneficial bioactivity. However, many types of compounds can be defined as 
natural bioactives including synthesized molecules that are based upon naturally occurring 
compounds. As such, we will define the term “natural bioactive” as any compound whose 
parent compound structure occurs in nature. Medical research is exploring these compounds 
as potential treatment sources for a myriad of conditions, including the dermatological 
hypersensitivity diseases. With the growing interest in natural health products it could be 
possible that disease sufferers, by self exploring alternative treatments, are potentially leading 
the search towards the next new approved and medically accepted treatment.  
2. Current treatments and management in dermatological hypersensitivity 
diseases  
The management of atopic and hypersensitivity diseases are initially addressed by life style 
modifications. With all hypersensitivity diseases, be it food allergies, contact 
hypersensitivity, or allergic asthma, suffers quickly become aware of their disease triggers 
and begin a lifelong course of avoidance (Custovic et al., 1998). Unknown triggers can be 
identified medically using a skin prick/patch test. This involves a controlled dermal 
exposure to the known and the most frequent allergens, and triggers are identified from the 
resultant skin reactions (Li, 2002). Pharmacological treatments are added into the treatment 
schedule as the severity of disease progresses, following well-developed treatment ladders 
(algorithms) (Schmitt et al., 2008). As the patient moves into the stronger classes of 
treatments in these schedules, the associated side effects become more severe, influencing 
treatment decisions, ultimately compliance rate and exploration of alternative treatments. 
2.1 Life style modifications and diet 
The effect of diet on allergies and atopic diseases mitigation has been well studied, but has 
produced conflicting results (Allan & Devereux, 2011; Devereaux & Yusuf, 2003; Finch et al., 
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produced conflicting results (Allan & Devereux, 2011; Devereaux & Yusuf, 2003; Finch et al., 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 436 
2010; Wichers, 2009). In children with a family history of atopic diseases, research has been 
focused towards the effects of maternal diet during pregnancy, lactation, and then 
subsequently in the infant when and which foods are introduced. Of particular interest is 
the effect of probiotics on the development of allergies which will be discussed below 
(section 4.2.4). In patients with food allergies triggers are eliminated from the diet, however 
other foods have been suggested which might be beneficial to allergy suffers. Some of these 
compounds include poly-unsaturated fatty acids (PUFA); Vitamins C (Chang et al., 2009), D, 
E, Zinc, Selenium. However, these findings have been meet with mixed results (Finch et al., 
2010).  
2.2 Medical treatment 
Medical treatments are initiated as the severity of symptoms become worse and the disease 
becomes intolerable (Schmitt et al., 2008). For each condition, drug classes have been 
recommended to be added in a specific order/time in the treatment schedule. However, due 
to the nature of these conditions treatment is individually tailored depending on patient 
response and their tolerance of the side effects. These patients follow a defined treatment 
plan consisting of pharmacological classes, based on their indications and complications. 
When treatment is initiated for a patient, the success of treatment always needs to balance 
with the side effect the treatment has on patient quality of life. (R. Finkel et al., 2009). The 
following is a brief overview of some conventional treatments for hypersensitivity disease 
such as sterioids and anti-histamines. Some of these compounds originated from natural 
sources but have been modified extensively to improve both their efficacy and potency. As 
such, these medications are not strictly considered “naturally sourced.” In section 3 below, 
we will address “naturally sourced” treatments for comparison. 
2.2.1 Corticosteroids 
Corticosterioids are a class of steroid hormones that are frequently used as a first line 
treatment in many immunological and dermatological diseases (Richard Finkel, 2009). They 
can be classified as short to long acting (1-55+ hours) and are applied topically or 
systematically. They are very effective at mitigating inflammation; however, their side 
effects limit their long term use. Many of the new treatments are being sought as 
corticosteroids sparing alternatives (Del Rosso & Friedlander, 2005).  
Mechanism of Action: Corticosteroids bind intracellular receptors forming dimers that bind to 
the glucocorticoid response element of the promoter region of steroid responsive genes, 
which up regulates 10-100 genes (Bolognia et al., 2008). They also act by inhibiting nuclear 
factor kB (NF-κB) which dramatically decreases the inflammatory response through the 
down regulation of certain cytokines, cell adhesion molecules and other inflammatory 
mediators. (Ex: TNFα, GM-CSF, several interleukins (ex. Il-1, IL-2, IL-6, Il-8); Intercellular 
adhesion molecule-1 and E-selectin; cyclooxygenase, etc). (D'Acquisto et al., 2002; Richard 
Finkel, 2009) 
Topical Benefits: Reduced itching, improvements in sleep, appearance of skin, self-esteem and 
quality of life (Miller & Eichenfield, 2006):. Side effects(Miller & Eichenfield, 2006) Short Term 
– stinging on application (for potent preparations); Medium to Long Term – local 
complications (i.e. skin thinning, striate, glaucoma from periocular use, contact sensitization 
and tolerance), etc. ; Systemic effects – suppression of the hypothalamic-pituitary-adrenal 
axis, Cushing’s syndrome, decreased immunity.  
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Systemic Benefits (Miller & Eichenfield, 2006): Relief from itching, skin redness and 
infiltration and reduced oozing; Side Effects(Miller & Eichenfield, 2006): Short term – 
increased appetite, psychosis and dyspepsia; Long term - hypertension, osteoporosis, 
adrenal suppression, striate and muscle atrophy, Cushing’s Syndrome, decreased immunity. 
2.2.2 Emollients 
Emollients are creams designed to alleviate the symptoms of pruritus in dermatitis 
(Bolognia et al., 2008). They are normally applied daily and act by coating the skin and 
creating an artificial barrier. They are composed of either water free or water-in-oil 
ointments with urea (10-20%) or lactic acid (5-12%). The underlying principle of this 
treatment is to ‘correct’ the barrier defect of the skin in AD. Benefits: Reduce skin dryness, 
itching and penetration of skin by irritants and allergens; prevention of skin cracking; 
possible reduced need for topical corticosteroids, possible enhanced response when used 
with topical corticosteroids. Side Effects: Possible stinging on application (R. Finkel et al., 
2009). 
2.2.3 Topical calcineurin inhibitors 
These compounds are among the newest class of immunomodulatory compounds that have 
been approved for use in inflammatory skin diseases (2000) (Grassberger et al., 2004). 
Members of this class include Pimecrolimus, Tacrolimus and Ascomycin. All originated as 
natural products isolated from the fermentation products of the bacteria Streptomyces sp. 
(Richard Finkel, 2009). This class has the advantage of treating AD refractory to 
corticosteroids and reducing the amount of corticosteroids required in severe cases (Spergel 
& Leung, 2006). 
Mechanism of Action: Inhibits calcineurin phosphatase by binding to FK506 binding protein 
which then complexes to calcineurin preventing its activation (Assmann et al., 2000). 
Activated calcineurin dephosphorylates the cytoplasmic subunit of the nuclear factor of 
activated T cells (NFAT), which then translocates to the nucleus where it forms a complex 
that assists in transcription of numerous cytokines (ex. Th1: IL2, INFϒ; Th2: IL4, IL5) 
(Grassberger et al., 1999; Sakuma et al., 2001). 
Indications: (Bolognia et al., 2008) 
Pimecrolmus – Mild to moderate atopic dermatitis, other inflammatory dermatoses 
Tacrolimus – Moderate to severe atopic dermatitis, other inflammatory dermatoses 
Benefits: Reduced itching and improvements in sleep, appearance of skin, self-esteem and 
quality of life (Grassberger et al., 2004; Miller & Eichenfield, 2006) 
Adverse Effects 
Short term – mild stinging or burning upon application; normally improves after a week 
Long term – (>5 years) – Tacrolimus: safety unknown, use with caution with excess 
exposure to UV light; Pimecrolimus: safety profile based on 5 years of use appears good. 
2.2.4 Immunomodulators 
This class of drugs/compounds function by attenuating the immune response underlying 
the hypersensitivity reaction. Some of these compounds have been used as 
immunosuppressants in transplant medicine while others are either components of the 
immune system or a new class of treatments known as ‘biological agents’ which are 
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2010; Wichers, 2009). In children with a family history of atopic diseases, research has been 
focused towards the effects of maternal diet during pregnancy, lactation, and then 
subsequently in the infant when and which foods are introduced. Of particular interest is 
the effect of probiotics on the development of allergies which will be discussed below 
(section 4.2.4). In patients with food allergies triggers are eliminated from the diet, however 
other foods have been suggested which might be beneficial to allergy suffers. Some of these 
compounds include poly-unsaturated fatty acids (PUFA); Vitamins C (Chang et al., 2009), D, 
E, Zinc, Selenium. However, these findings have been meet with mixed results (Finch et al., 
2010).  
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factor kB (NF-κB) which dramatically decreases the inflammatory response through the 
down regulation of certain cytokines, cell adhesion molecules and other inflammatory 
mediators. (Ex: TNFα, GM-CSF, several interleukins (ex. Il-1, IL-2, IL-6, Il-8); Intercellular 
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Topical Benefits: Reduced itching, improvements in sleep, appearance of skin, self-esteem and 
quality of life (Miller & Eichenfield, 2006):. Side effects(Miller & Eichenfield, 2006) Short Term 
– stinging on application (for potent preparations); Medium to Long Term – local 
complications (i.e. skin thinning, striate, glaucoma from periocular use, contact sensitization 
and tolerance), etc. ; Systemic effects – suppression of the hypothalamic-pituitary-adrenal 
axis, Cushing’s syndrome, decreased immunity.  
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Systemic Benefits (Miller & Eichenfield, 2006): Relief from itching, skin redness and 
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adrenal suppression, striate and muscle atrophy, Cushing’s Syndrome, decreased immunity. 
2.2.2 Emollients 
Emollients are creams designed to alleviate the symptoms of pruritus in dermatitis 
(Bolognia et al., 2008). They are normally applied daily and act by coating the skin and 
creating an artificial barrier. They are composed of either water free or water-in-oil 
ointments with urea (10-20%) or lactic acid (5-12%). The underlying principle of this 
treatment is to ‘correct’ the barrier defect of the skin in AD. Benefits: Reduce skin dryness, 
itching and penetration of skin by irritants and allergens; prevention of skin cracking; 
possible reduced need for topical corticosteroids, possible enhanced response when used 
with topical corticosteroids. Side Effects: Possible stinging on application (R. Finkel et al., 
2009). 
2.2.3 Topical calcineurin inhibitors 
These compounds are among the newest class of immunomodulatory compounds that have 
been approved for use in inflammatory skin diseases (2000) (Grassberger et al., 2004). 
Members of this class include Pimecrolimus, Tacrolimus and Ascomycin. All originated as 
natural products isolated from the fermentation products of the bacteria Streptomyces sp. 
(Richard Finkel, 2009). This class has the advantage of treating AD refractory to 
corticosteroids and reducing the amount of corticosteroids required in severe cases (Spergel 
& Leung, 2006). 
Mechanism of Action: Inhibits calcineurin phosphatase by binding to FK506 binding protein 
which then complexes to calcineurin preventing its activation (Assmann et al., 2000). 
Activated calcineurin dephosphorylates the cytoplasmic subunit of the nuclear factor of 
activated T cells (NFAT), which then translocates to the nucleus where it forms a complex 
that assists in transcription of numerous cytokines (ex. Th1: IL2, INFϒ; Th2: IL4, IL5) 
(Grassberger et al., 1999; Sakuma et al., 2001). 
Indications: (Bolognia et al., 2008) 
Pimecrolmus – Mild to moderate atopic dermatitis, other inflammatory dermatoses 
Tacrolimus – Moderate to severe atopic dermatitis, other inflammatory dermatoses 
Benefits: Reduced itching and improvements in sleep, appearance of skin, self-esteem and 
quality of life (Grassberger et al., 2004; Miller & Eichenfield, 2006) 
Adverse Effects 
Short term – mild stinging or burning upon application; normally improves after a week 
Long term – (>5 years) – Tacrolimus: safety unknown, use with caution with excess 
exposure to UV light; Pimecrolimus: safety profile based on 5 years of use appears good. 
2.2.4 Immunomodulators 
This class of drugs/compounds function by attenuating the immune response underlying 
the hypersensitivity reaction. Some of these compounds have been used as 
immunosuppressants in transplant medicine while others are either components of the 
immune system or a new class of treatments known as ‘biological agents’ which are 
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artificially created monoclonal antibody designed to target errant members of the immune 
system (R. Finkel et al., 2009). Interestingly some of the immunosuppressants have their 
origin as natural products including: cyclosporine (isolotaed from fungus Tolypocladium 
inflatum), mycophenolate mofetil (isolated from fungus Penicillium stoloniferum) tacrolimus 
(isolated from Streptomyces tsukubaensis) as well as others (R. Finkel et al., 2009). 
Interferon γ 
Was investigated for use in atopic dermatitis due to its pathological dysregulation, and was 
found to be effective in short term (Hanifin et al., 1993) and long term studies (Stevens et al., 
1998). However, its low response rate and high costs deter its regular use and 
implementation. 
Biological Agents – Monoclonal Antibodies 
These agents are biologically engineered antibodies directed against specific targets in the 
immune system. Some of these agents have made it to market for specific conditions (see 
table1). Omalizumab is a humanized mouse monocolonal antibody targeting the IgE Fc 
Region. It binds free IgE but not IgE bound to FcεRI on masts cells, so in this way it 
sequesters free IgE without activating bound IgE and causing mast cell degranulation 
(Presta et al., 1993). Omalizumab has been approved by the FDA for use in severe 
recalcitrant asthma (Strunk & Bloomberg, 2006) and has been investigated for severe cases of 
atopic dermatitis with positive results (Lane et al., 2006).  
 
AGENT  TARGET / MOA CONDITION 
Alefacept, Efalizumab T-cell activation,  T-cell trafficking Psoriasis 
Etanercept, Infliximab,  
Adalimumab TNFα Psoriasis 
Anakinra IL-1 Rheumatoid arthritis 
Rituximab CD20 (B-cells) B-cell mediated skin diseases 
Table 1. Examples of Biological Agents employed in Dermatological Conditions  
Immunosuppresants: Cyclosporine, methotrexate, Mycophenolate mofetil 
These drugs act by modulating different functions of the immune system and decreasing 
their activity. These drugs while very potent in activity require caution in use, because of 
associated side effects including nephro- , neuro-, and hepatictoxicity (R. Finkel et al., 
2009).  
2.2.5 Other medical treatments 
Anti-Microbial:  
This class of pharmaceuticals are commonly used against infections caused by pathological 
secondary barrier defects in the epidermis. Infections can be caused by intense scratching 
leading to excoriations or due to immune suppression from other treatments. Common 
infections associated with atopic dermatitis include bacterial (S. aurues), viral (Molluscum 
contagiosum, HSV) and fungal (Candida sp., Malassezia sp.) (Bolognia et al., 2008). 
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Retinoids 
Retinoids are related to Vitamin A and act by binding nuclear receptors (RAR, RXR) which 
directly and indirectly up regulate gene expression responsible for immune and 
inflammatory responses and proliferation and differentiation of epithelial cells (Bolognia et 
al., 2008). Retinoids require careful consideration before use due to side effects including 
local effects, systemic, psychological but more importantly teratogenic effects (David et al., 
1988).  
Anti-Histamines 
This class of drugs has multiple therapeutic targets including allergic and inflammatory 
conditions, motion sickness and nausea, gastric acid secretion and others (Richard Finkel, 
2009). They play a role in urticaria prevention (Jauregui et al., 2007) and symptomatic 
treatment in other mast cell conditions (Herman & Vender, 2003; Montoro et al., 2007) 
especially for edema control and pruritus.  
Mast Cell Stabilizers 
Members of this class of drugs include cromolyn and nedocromil, and are used in mast cell 
mediated allergic conditions. They function by inhibiting the IgE mediated release of 
histamine by stabilization of the membrane (Corin, 2000).  
2.2.6 Other treatments 
In addition to medicinal treatments prescribed by practitioners are a series of physical and 
alternative treatments. Very popular with dermatological treatment is the use of UV light 
and tanning beds, especially for psoriasis. Although the mechanism of action is unknown, it 
is thought that UV activates Psoralen which inhibits cellular proliferation. In certain 
conditions practitioners may prescribe Ichthyotherapy in which small fish (doctor fish) are 
employed to remove dead skin from lesions. Coal tar (mixture of hydrocarbons) is used as 
an emollient and remains a popular treatment in many dermatological centers (Bolognia et 
al., 2008).  
3. The use of Complementary and Alternative Medicine (CAM) 
Complementary and Alternative Medicine (CAM): Group of diverse medical and health care 
interventions, practices, products or disciplines that are not generally considered as part of 
conventional medicine (NCCAM, 2011) 
Complementary Medicine: Any of a range of medical therapies that fall beyond the scope of 
scientific medicine but may be used alongside it in the treatment of disease and ill health 
(NCCAM, 2011) 
Alternative Medicine: Medical therapies that are used in lieu of conventional therapy 
(NCCAM, 2011), 
(Note: There are many definitions that have been put forward for CAM, these are the ones 
designated by the National Center for Complementary and Alternative Medicine (USA)). 
Recognition of the rising interest and potential importance of Traditional Medicine (TM) 
and CAM lead the WHO to survey its membership on their respective national attitudes and 
regulatory status of this branch of health care. They found in 2005 that 71% of respondents 
have laws, legislative mandates and National regulatory bodies in place for TM/CAM 
(WHO, 2005). In 1991, the United States created the Office of Alternative Medicine to 
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artificially created monoclonal antibody designed to target errant members of the immune 
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1998). However, its low response rate and high costs deter its regular use and 
implementation. 
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These agents are biologically engineered antibodies directed against specific targets in the 
immune system. Some of these agents have made it to market for specific conditions (see 
table1). Omalizumab is a humanized mouse monocolonal antibody targeting the IgE Fc 
Region. It binds free IgE but not IgE bound to FcεRI on masts cells, so in this way it 
sequesters free IgE without activating bound IgE and causing mast cell degranulation 
(Presta et al., 1993). Omalizumab has been approved by the FDA for use in severe 
recalcitrant asthma (Strunk & Bloomberg, 2006) and has been investigated for severe cases of 
atopic dermatitis with positive results (Lane et al., 2006).  
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These drugs act by modulating different functions of the immune system and decreasing 
their activity. These drugs while very potent in activity require caution in use, because of 
associated side effects including nephro- , neuro-, and hepatictoxicity (R. Finkel et al., 
2009).  
2.2.5 Other medical treatments 
Anti-Microbial:  
This class of pharmaceuticals are commonly used against infections caused by pathological 
secondary barrier defects in the epidermis. Infections can be caused by intense scratching 
leading to excoriations or due to immune suppression from other treatments. Common 
infections associated with atopic dermatitis include bacterial (S. aurues), viral (Molluscum 
contagiosum, HSV) and fungal (Candida sp., Malassezia sp.) (Bolognia et al., 2008). 
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Retinoids 
Retinoids are related to Vitamin A and act by binding nuclear receptors (RAR, RXR) which 
directly and indirectly up regulate gene expression responsible for immune and 
inflammatory responses and proliferation and differentiation of epithelial cells (Bolognia et 
al., 2008). Retinoids require careful consideration before use due to side effects including 
local effects, systemic, psychological but more importantly teratogenic effects (David et al., 
1988).  
Anti-Histamines 
This class of drugs has multiple therapeutic targets including allergic and inflammatory 
conditions, motion sickness and nausea, gastric acid secretion and others (Richard Finkel, 
2009). They play a role in urticaria prevention (Jauregui et al., 2007) and symptomatic 
treatment in other mast cell conditions (Herman & Vender, 2003; Montoro et al., 2007) 
especially for edema control and pruritus.  
Mast Cell Stabilizers 
Members of this class of drugs include cromolyn and nedocromil, and are used in mast cell 
mediated allergic conditions. They function by inhibiting the IgE mediated release of 
histamine by stabilization of the membrane (Corin, 2000).  
2.2.6 Other treatments 
In addition to medicinal treatments prescribed by practitioners are a series of physical and 
alternative treatments. Very popular with dermatological treatment is the use of UV light 
and tanning beds, especially for psoriasis. Although the mechanism of action is unknown, it 
is thought that UV activates Psoralen which inhibits cellular proliferation. In certain 
conditions practitioners may prescribe Ichthyotherapy in which small fish (doctor fish) are 
employed to remove dead skin from lesions. Coal tar (mixture of hydrocarbons) is used as 
an emollient and remains a popular treatment in many dermatological centers (Bolognia et 
al., 2008).  
3. The use of Complementary and Alternative Medicine (CAM) 
Complementary and Alternative Medicine (CAM): Group of diverse medical and health care 
interventions, practices, products or disciplines that are not generally considered as part of 
conventional medicine (NCCAM, 2011) 
Complementary Medicine: Any of a range of medical therapies that fall beyond the scope of 
scientific medicine but may be used alongside it in the treatment of disease and ill health 
(NCCAM, 2011) 
Alternative Medicine: Medical therapies that are used in lieu of conventional therapy 
(NCCAM, 2011), 
(Note: There are many definitions that have been put forward for CAM, these are the ones 
designated by the National Center for Complementary and Alternative Medicine (USA)). 
Recognition of the rising interest and potential importance of Traditional Medicine (TM) 
and CAM lead the WHO to survey its membership on their respective national attitudes and 
regulatory status of this branch of health care. They found in 2005 that 71% of respondents 
have laws, legislative mandates and National regulatory bodies in place for TM/CAM 
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scientifically scrutinize alternative health practices for the benefit of public and health 
professionals knowledge. By 1998, due to increasing interest of the subject, this department 
was expanded into the National Center for Complementary and Alternative Medicine as a 
member institute of the United States Institutes of Health. It was from this department that a 
systematic classification of Complementary and Alternative Medicines was formed and 
grouped into 5 categories (Molassiotis et al., 2005), see Table 1. It is from the biological based 
therapies and the Alternative Medical systems that sources of natural products are being 
explored for as potential disease treatments and being entered into clinical trials. It should 
be noted that treatments from the other groups have entered clinical trials for certain 
conditions with mixed results including massage (Schachner et al., 1998), acupuncture 
(Salameh et al., 2008), meditation (Chida et al., 2007), prayer and others. 
 
CLASSIFICATION EXAMPLES 
I Alternative Medical Systems Traditional Chinese Medicine, Ayruveda 
II Mind-Body Interventions Meditation, Prayer, Healing or Support Groups 
III Biological Based Therapies Herbs, Dietary Supplements, Vitamins 
IV Manipulation and Body Based Massage, Chiropractive, Osteopathy 
V Energy Therapies Qi Gong, Reiki 
Table 2. Classification of CAM devised by Center for Complementary and Alternative 
Medicine 
3.1 Demographics of CAM use in industrialized nations 
There has been a well-recognized trend in the increasing use of CAM among the general 
public (Harris & Rees, 2000; Su & Li, 2011). In the 2002 US National Health Interview Survey 
(NHIS) of 31,044 adults, 36% of adults reported using CAM in the previous 12 months, and 
if a life time prevalence was included, this figure rose to 50% (Barnes et al., 2004). The results 
from the 2007 survey saw the 12 month prevalence figure rise to 38.6% and among those 
positive respondents, the most common CAM was listed as ‘natural products’ (Barnes et al., 
2008). Earlier smaller scale national surveys conducted by Eisenberg et al. found prevalence 
rates of 33.8% in 1990 and 42.1% in 1997, although these values are higher (possibly due to 
the small samples size) it is generally agreed that CAM use is continually increasing 
(Eisenberg et al., 1998). The NHIS surveys identified some demographic characteristics 
common among users which have been confirmed from other studies. CAM use is more 
prevalent among women, adults with higher education, those who engaged in leisure time 
and physical activity, those who had one or more existing health conditions and have made 
frequent medical visits in the past year (Barnes et al., 2008; Eisenberg et al., 1998; Metcalfe et 
al., 2010; Sirois & Gick, 2002). Other identified factors are higher socioeconomic status, being 
married, those who wished to take a more active role in health care decision making and 
most interestingly those with a chronic health condition (Metcalfe et al., 2010; Wiles & 
Rosenberg, 2001). The popularity of CAM use is also recognized in other industrialized 
countries ; the rates for Canada are estimated at 12-20% (Gavin & Boon, 2005) and 46% in 
Germany and 49% in France where alternative treatments are well engrained in the national 
consciousness (Fisher & Ward, 1994). The trend of increasing CAM can be identified from 
Germany (West) with its 12 months prevalence almost doubling since the 1970’s (See Figure 
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1) (Dixon et al., 2003). It should be kept in perspective when looking at the trends of 
TM/CAM use that (as defined by the WHO) up to 80% of the world’s population uses 
TM/CAM as their sole source of health care in the places where Western health care is 
inaccessible ((World Health Organization., 2009). 
 
 
Fig. 1. Reported Use of CAM in Western Germany from 1970s to 2002 
3.2 Patient and user attitude toward CAM 
There have been many attempts to identify the reasons and motivations as to why 
members of the public are exploring alternative options for their well-being and health 
care. A large European study of 956 Cancer patients in 12 countries, found a prevalence 
rate of CAM use of 38.2% (Range of 14.8% to 73.1%). From those who reported using 
CAM therapy they were investigated first, for their motivation and second, how found 
out about them. The most common motivation for CAM use was to increase their body’s 
ability to fight disease (50.7%), followed by improved physical well-being (40.6%), and 
improvement of emotional well-being (35.2%). Sources of information about CAM were 
identified as friends (56.5%), family (29.1%), media (28.4%) and only 18.6% said their 
physician was the source (Molassiotis et al., 2005). Use of CAM is associated with greater 
number of physical symptoms and with symptoms of greater intensity, longer disease 
duration (Sirois & Gick, 2002). The reasons for people to explore alternative treatment are 
varied, but what should be recognized is that are they exploring them. By having 
members of the public vetting these treatments in terms of personal satisfaction gives 
health care workers a unique opportunity by looking at the usage trends in members of 
the public as potential treatments sources.  
3.3 Health care practitioners attitude towards CAM 
The number of visits to practitioners of alternative therapies is now higher than the number 
of visits to all US primary care physicians (Pagan & Pauly, 2005). Physician and health care 
professionals response to CAM has been varied with differences depending on country, 
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scientifically scrutinize alternative health practices for the benefit of public and health 
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1) (Dixon et al., 2003). It should be kept in perspective when looking at the trends of 
TM/CAM use that (as defined by the WHO) up to 80% of the world’s population uses 
TM/CAM as their sole source of health care in the places where Western health care is 
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varied, but what should be recognized is that are they exploring them. By having 
members of the public vetting these treatments in terms of personal satisfaction gives 
health care workers a unique opportunity by looking at the usage trends in members of 
the public as potential treatments sources.  
3.3 Health care practitioners attitude towards CAM 
The number of visits to practitioners of alternative therapies is now higher than the number 
of visits to all US primary care physicians (Pagan & Pauly, 2005). Physician and health care 
professionals response to CAM has been varied with differences depending on country, 
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region, age, experience and even sex. In a literature review by Sewitch et al found that 
characteristics of physicians whom are more likely to recommend CAM are younger, 
female, less experienced; while those less likely to recommend CAMs were older, male, 
more experienced physicians (Sewitch & Rajput, 2010). Older physicians are less likely to 
use CAMs themselves or recommend it to their family (Kurtz et al., 2003). It should be 
noted that physicians are the most skeptical and least likely to recommend CAMs to 
patients, of all members of the health care profession. Rural health care providers offered 
CAM more frequently than their urban colleagues (Brems et al., 2006). Between 60-80% of 
surveyed physicians express interest in CAM therapy (Corbin Winslow & Shapiro, 2002; 
Milden & Stokols, 2004) but few as 14% have recommended it their patients. Among 
physicians there is prejudice about the different types if CAMs, established practices such 
as acupuncture, chiropractor tend to be surveyed as the most likely to be beneficial to the 
patient; While reiki, bioelectromagnetics, aromatherapy have been ranked by doctors as 
having the least potential to be beneficial or event harmful to the patient (Levine et al., 
2003). 
3.4 CAM and allergies 
In a German study of 351 subjects with hypersensitivity (hay fever, asthma, atopic eczema, 
food allergies), 93 (26%) were found to be users of CAM. Of the 93 users, 94% previously 
were treated conventionally before starting CAM while 3 users used CAM before starting 
conventional treatment. Of those treated conventionally the majority (85%) were treated 
more than 10 years before trying CAM, they also score the efficacy of conventional medicine 
lower in their experience. Their reported motivations for using CAM were: conviction that 
CAM has less side effects (78%), wish to try everything (72%), unsatisfying results from 
conventional medicine (66%), and belief CAM is more natural (61%) (Schafer et al., 2002) . In 
a review of 7 surveys of dermatological patients who used CAM they found life time 
prevalence of 35-65% (Ernst, 2000); among all the surveys they found severity of illness and 
length of disease had the greatest influence on CAM use. In Europe approximately 30% of 
patients with allergies report using CAM and this rises to approximately 50% of patients 
whom required in-patient treatment (Schafer, 2004). The use CAM is related to the severity 
of the symptoms of their conditions, patients who identify with having poor control are 
more likely to explore alternative treatments.  
4. Search for natural products 
Natural products are compounds that have been isolated from a living organism that have 
been found to be biologically active. A large proportion of the medicines in our current 
pharmacopeia have either originate as natural products or are inspired by a natural product 
using it chemical structure as framework on which to build on (Newman & Cragg, 2007). 
These compounds are being explore for, from all facets of nature including CAMs, our 
foodstocks, and on an increasing scale the marine sources. The remainder of the chapter will 
explore some of the natural products undergoing clinical trials for the treatment of Atopic 
dermatitis. Atopic dermatitis was selected due to its complex pathology, its association with 
the atopic march and the availability of an animal model which will be discussed below. The 
test compounds will be discussed below in the context of atopic dermatitis; however some 
of them are being tested in other related dermatological conditions.  
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4.1 Clinical trials 
Any medicinal compound before entering into an approved treatment system (i.e. National 
Pharmacopeia) requires rigorous study and clinical trials, which have a defined set of trial 
steps, before they can be approved for use by National Regulatory bodies. In the United 
States this task is mandated by the Food and Drug Administration (FDA), in Canada by 
Health Canada and in the European Union by the European Medicines Agency (Rawson, 
2000). All drug approvals required an evidence based approach to qualify their efficacy, 
evaluate the potential toxicity, and to prevent any unforeseen harm to patients. It is 
interesting to note that estimates now have the cost of marketed drugs from the R&D stage 
to consumer use at 500 million to 1 billion dollars and at a time frame of up to 10-15 years 
(DiMasi et al., 2003). Only about 1 out of 1000 drugs from the animal testing stage (or 
preclinical phase) make it into clinical trials and from there only 1 in 5-10 eventually become 
approved. In this manner only 21 new drugs were approved by the FDA in 2010, 25 in 2009 
and 21 in 2008 (Kaitin & DiMasi, 2011). However if natural compounds are identified from 
CAM treatment sources already employed by members of the public they may provide new 
treatment options which can enter rigorous evidence based trials which have already been 
vetted by members of the public.  
Pre-Clinical Studies / Phase 0: Pre-clinical studies are conducted as In vitro (cell culture) and In 
Vivo (animal studies) as initial investigations into suspected potential biological activity. 
Phase 0 studies are human trials using microdoses to determine if its biological effects are 
what is expected (Υσηα Ρανι, 2009) 
Phase I: Small scale study of 20-100 healthy subjects, testing the safety, pharmacodynamics 
and pharmacokinetics of the study compound (Streiner & Normam, 2009), consists usually 
of either single or multiple ascending doses trials. 
Phase II: Following the safety approval of drugs in Phase I, these are a small studies of 50-300 
diseased subjects , designed to assess dosing requirements, efficacy, (Streiner & Normam, 
2009) and safety profiles in people with the condition. 
Phase III: Randomized controlled multicenter trials on large group of diseased patients with 
the target condition, this study are used to determine if the study compound has targeted 
therapeutic effects (R. Finkel et al., 2009). 
Phase IV: These studies occur after the drug has enter the market and is known as Post-
Marketing Surveillance. They determine if any adverse events happen in large group of 
patients which were not previously identified. This phase is important is identifying any 
rare adverse events which occur in large treatment populations. This monitoring is 
responsible from removing from market approved drug which later have been found to be 
potentially harmful, examples are Troglitazone (Cohen, 2006; Gale, 2006) and Vioxx (Karha 
& Topol, 2004). 
4.2 Atopic Dermatitis  
Atopic dermatitis (AD) has been recognized since at least the 1500s (Wallach et al., 2005) 
with its first formal medical description in 1933(Wise & Sulzberger, 1933). This condition is 
currently a popular target of medical research due to its increasing incidence (Peroni et al., 
2008; H. Williams, 1992), distressing rash and intense pruritic symptoms(Hanifin & Rajka, 
1980), leading to general negative effects on the patients quality of life (Kiebert et al., 2002) 
and its being refractory to treatment, along with a host of other reasons . With is long 
recognition in recent medical history, has led to many treatment options being made 
available. If any new product is found to possess immunomodulatory effects they tend to be 
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region, age, experience and even sex. In a literature review by Sewitch et al found that 
characteristics of physicians whom are more likely to recommend CAM are younger, 
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noted that physicians are the most skeptical and least likely to recommend CAMs to 
patients, of all members of the health care profession. Rural health care providers offered 
CAM more frequently than their urban colleagues (Brems et al., 2006). Between 60-80% of 
surveyed physicians express interest in CAM therapy (Corbin Winslow & Shapiro, 2002; 
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as acupuncture, chiropractor tend to be surveyed as the most likely to be beneficial to the 
patient; While reiki, bioelectromagnetics, aromatherapy have been ranked by doctors as 
having the least potential to be beneficial or event harmful to the patient (Levine et al., 
2003). 
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food allergies), 93 (26%) were found to be users of CAM. Of the 93 users, 94% previously 
were treated conventionally before starting CAM while 3 users used CAM before starting 
conventional treatment. Of those treated conventionally the majority (85%) were treated 
more than 10 years before trying CAM, they also score the efficacy of conventional medicine 
lower in their experience. Their reported motivations for using CAM were: conviction that 
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of the symptoms of their conditions, patients who identify with having poor control are 
more likely to explore alternative treatments.  
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Natural products are compounds that have been isolated from a living organism that have 
been found to be biologically active. A large proportion of the medicines in our current 
pharmacopeia have either originate as natural products or are inspired by a natural product 
using it chemical structure as framework on which to build on (Newman & Cragg, 2007). 
These compounds are being explore for, from all facets of nature including CAMs, our 
foodstocks, and on an increasing scale the marine sources. The remainder of the chapter will 
explore some of the natural products undergoing clinical trials for the treatment of Atopic 
dermatitis. Atopic dermatitis was selected due to its complex pathology, its association with 
the atopic march and the availability of an animal model which will be discussed below. The 
test compounds will be discussed below in the context of atopic dermatitis; however some 
of them are being tested in other related dermatological conditions.  
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(DiMasi et al., 2003). Only about 1 out of 1000 drugs from the animal testing stage (or 
preclinical phase) make it into clinical trials and from there only 1 in 5-10 eventually become 
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treatment options which can enter rigorous evidence based trials which have already been 
vetted by members of the public.  
Pre-Clinical Studies / Phase 0: Pre-clinical studies are conducted as In vitro (cell culture) and In 
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and pharmacokinetics of the study compound (Streiner & Normam, 2009), consists usually 
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currently a popular target of medical research due to its increasing incidence (Peroni et al., 
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1980), leading to general negative effects on the patients quality of life (Kiebert et al., 2002) 
and its being refractory to treatment, along with a host of other reasons . With is long 
recognition in recent medical history, has led to many treatment options being made 
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investigated as possible treatments for AD. The remainder of this chapter will look at 




Pre-Clinical In-Vitro (Cell Culture) and In Vivo (Animal Studies), determines biological 
activity, toxicity, etc 
I Small group health subjects; Pharmacokinetic and Pharmacodynamic 
properties, Single Ascending Dose, Multiple Ascending Doses 
II Small group diseased subjects, determine dosing requirements, drug 
efficacy 
III Larger group diseased subjects; Randomized Controlled Multicenter trials 
IV Post Marketing Surveillance Trial 
Table 3. Phases of Clinical Trials 
4.2.1 Animal Models: NC/Nga mice 
One of the advantages of research into treatment for atopic dermatitis has been the 
development of an animal model that has been accepted to be representative of the disease 
(Suto et al., 1999). Using this model, researchers are able to easily test products prior to 
proceeding to human clinical trials. NC/Nga mice are a strain that originated from the 
Japanese fancy mice (Nishiki-Nezumi), established as an inbred strain in 1955 (Matsuda et 
al., 1997). Researchers noticed the development of spontaneous dermatitis like lesions that 
appeared just before or after weaning but the cause and pathogenesis had been unclear. A 
study was conducted to compare these lesions to those of human Atopic Dermatitis (Suto et 
al., 1999). Mice raised in specific pathogen free (SPF) air controlled bioclean rooms did not 
develop lesion, but when moved to air uncontrolled rooms, spontaneously several different 
type of lesions developed after 8 weeks. These mice developed clinical signs similar to AD: 
itching, erythema and hemorrhage, edema, superficial erosion, deep excoriation, scaling and 
dryness of the skin, and retarded growth. Infectious causes were ruled out by co-rearing 
with BALB/c mice which did not develop lesions. The histopathological changes which 
were consistent with Atopic Dermatitis as well as clinical labs values such as IgE 
hyperproduction (Matsuda et al., 1997), overproduction of Th2 specific cytokines (Suto et al., 
1999; Vestergaard et al., 1999).  A literature search conducted in May 2011 resulted in 245 
and 185 articles when the following keywords were used together: NC/Nga Mice, Atopic 
Dermatitis. 
4.2.2 Animal trials 
The following is a list of compounds (albeit not exhaustive) investigated using the NC/Nga 
mice model as potential treatments for Atopic Dermatitis. All were oral feeding studies in 
which the test compound was compared to a control. The efficacies of test compounds were 
determined by the improvement in symptoms of skin erythema, edema, excoriations, 
dryness, and scratching behavior. Other parameters measured depended on the trial and 
included plasma Ig levels, cytokines and chemokine profiles, and evaluation of skin 
biopsies. All of these studies had positive outcomes based on the design parameters and 
were recommended by their research teams for use in human clinical trials.  
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Rumex Japonicus Houtt 
Rumex is an herb used in the traditional medical systems originating from Eastern Asian 
countries (Japan, Korea, China) for the treatment of various skin diseases including AD (H. 
S. Lee et al., 2006). Previous studies have shown that it contains components with anti-
oxidant and antibacterial properties (Elzaawely et al., 2005). Identified Bioactive compounds 
include anthraquinone derivatives: emodin, chrysophanol, physcion.  These compounds 
studied from other natural sources are reported to have antibacterial, antifungal, anti-
inflammatory, immunosuppressive and antiviral properties (H. S. Lee et al., 2006) After 42 
days, mice treated with the test compound were found to have significant decreases in the 
severity of all symptoms when compared to the control, particularly the scratching 
behavior, which is the most distressing symptom of AD. There was a decrease in plasma IgE 
and IL4 (which mediate type I hypersensitivity) and noticeable decrease of inflammatory 
changes in the skin biopsies. The results were more pronounced in the higher concentration 
groups indicating this compound causes a dose response (H. S. Lee et al., 2006). 
PG 102 – Actinidia Arguta 
Actinidia Argurta, commonly known as Hardy Kiwi, is a fruit native to Korea, Northern 
China and Siberia. Compound PG102 and isolated from this fruit by Park et al. in 2005 and 
found to have oral immune modulating effects in mice (Park et al., 2005). A follow up study 
conducted to determine the effect on the NC/Nga mice model (Park et al., 2007), found that 
after 9 weeks, PG102 showed statistically significant beneficial effect on AD symptoms and 
scratching behavior, while noted immunomolecular effects showed a decrease in IgE, IgG, 
IL4 while IL12 was increased. Other reported effects including the prevention of 
eosinophilia, decreased levels of eotaxin and TARC, inhibiting the infiltration of 
inflammatory cells into the dermis, preventing the thickening of the epidermis and dermis 
and reduced expression of Th2 mediated cytokines and chemokines (Park et al., 2007). All of 
these effects are beneficial in attenuating the pathophysiological changes seen in Atopic 
dermatitis. Kim et al. tested the extract for efficacy compared to dexamethasone 
(corticosteriod) and tacrolimus and found PG102 attenuated the physical symptoms of AD 
similar to dexamethasone and more efficiently than tacrolimus. It also had positive effects 
on the molecular inflammatory markers as well (ex. IgE, IL4, INFϒ and others). However, all 
three compounds affected the physical changes in the dermis in a similar manner (Kim et al., 
2009). The initial results indicated this compound shows a promising potential for future use 
as an oral dietary supplement for the long term treatment of AD. 
Saururus Chinensis Baill 
Saururus is a perennial herbaceous plant used in Korean folk medicine for the treatment of 
various conditions such as edema, jaundice, gonorrhea and used has been employed as an 
antipyretic, diuretic, and anti-inflammatory agent (Choi et al., 2008). It has been shown to 
have anti-oxidant activity (Y. S. Lee et al., 2004) and has been used in the management of 
various skin diseases including AD in Eastern countries. It contains flavonoids (quercetin, 
quercitrin, isoquercitrin, rutin) as active components which are reported as possessing 
number of biological effects: antiallergic, anti-inflammatory, antiviral, antiproliferative, 
anticarcinogenic (Scalbert & Williamson, 2000). After 63 days this compound was found to 
significantly improve skin severity scores and improved itching behavior, with the higher 
concentration preforming better. Molecular evaluation found a decrease in IgE but no 
changes in IL4.  
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investigated as possible treatments for AD. The remainder of this chapter will look at 
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(Suto et al., 1999). Using this model, researchers are able to easily test products prior to 
proceeding to human clinical trials. NC/Nga mice are a strain that originated from the 
Japanese fancy mice (Nishiki-Nezumi), established as an inbred strain in 1955 (Matsuda et 
al., 1997). Researchers noticed the development of spontaneous dermatitis like lesions that 
appeared just before or after weaning but the cause and pathogenesis had been unclear. A 
study was conducted to compare these lesions to those of human Atopic Dermatitis (Suto et 
al., 1999). Mice raised in specific pathogen free (SPF) air controlled bioclean rooms did not 
develop lesion, but when moved to air uncontrolled rooms, spontaneously several different 
type of lesions developed after 8 weeks. These mice developed clinical signs similar to AD: 
itching, erythema and hemorrhage, edema, superficial erosion, deep excoriation, scaling and 
dryness of the skin, and retarded growth. Infectious causes were ruled out by co-rearing 
with BALB/c mice which did not develop lesions. The histopathological changes which 
were consistent with Atopic Dermatitis as well as clinical labs values such as IgE 
hyperproduction (Matsuda et al., 1997), overproduction of Th2 specific cytokines (Suto et al., 
1999; Vestergaard et al., 1999).  A literature search conducted in May 2011 resulted in 245 
and 185 articles when the following keywords were used together: NC/Nga Mice, Atopic 
Dermatitis. 
4.2.2 Animal trials 
The following is a list of compounds (albeit not exhaustive) investigated using the NC/Nga 
mice model as potential treatments for Atopic Dermatitis. All were oral feeding studies in 
which the test compound was compared to a control. The efficacies of test compounds were 
determined by the improvement in symptoms of skin erythema, edema, excoriations, 
dryness, and scratching behavior. Other parameters measured depended on the trial and 
included plasma Ig levels, cytokines and chemokine profiles, and evaluation of skin 
biopsies. All of these studies had positive outcomes based on the design parameters and 
were recommended by their research teams for use in human clinical trials.  
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Rumex Japonicus Houtt 
Rumex is an herb used in the traditional medical systems originating from Eastern Asian 
countries (Japan, Korea, China) for the treatment of various skin diseases including AD (H. 
S. Lee et al., 2006). Previous studies have shown that it contains components with anti-
oxidant and antibacterial properties (Elzaawely et al., 2005). Identified Bioactive compounds 
include anthraquinone derivatives: emodin, chrysophanol, physcion.  These compounds 
studied from other natural sources are reported to have antibacterial, antifungal, anti-
inflammatory, immunosuppressive and antiviral properties (H. S. Lee et al., 2006) After 42 
days, mice treated with the test compound were found to have significant decreases in the 
severity of all symptoms when compared to the control, particularly the scratching 
behavior, which is the most distressing symptom of AD. There was a decrease in plasma IgE 
and IL4 (which mediate type I hypersensitivity) and noticeable decrease of inflammatory 
changes in the skin biopsies. The results were more pronounced in the higher concentration 
groups indicating this compound causes a dose response (H. S. Lee et al., 2006). 
PG 102 – Actinidia Arguta 
Actinidia Argurta, commonly known as Hardy Kiwi, is a fruit native to Korea, Northern 
China and Siberia. Compound PG102 and isolated from this fruit by Park et al. in 2005 and 
found to have oral immune modulating effects in mice (Park et al., 2005). A follow up study 
conducted to determine the effect on the NC/Nga mice model (Park et al., 2007), found that 
after 9 weeks, PG102 showed statistically significant beneficial effect on AD symptoms and 
scratching behavior, while noted immunomolecular effects showed a decrease in IgE, IgG, 
IL4 while IL12 was increased. Other reported effects including the prevention of 
eosinophilia, decreased levels of eotaxin and TARC, inhibiting the infiltration of 
inflammatory cells into the dermis, preventing the thickening of the epidermis and dermis 
and reduced expression of Th2 mediated cytokines and chemokines (Park et al., 2007). All of 
these effects are beneficial in attenuating the pathophysiological changes seen in Atopic 
dermatitis. Kim et al. tested the extract for efficacy compared to dexamethasone 
(corticosteriod) and tacrolimus and found PG102 attenuated the physical symptoms of AD 
similar to dexamethasone and more efficiently than tacrolimus. It also had positive effects 
on the molecular inflammatory markers as well (ex. IgE, IL4, INFϒ and others). However, all 
three compounds affected the physical changes in the dermis in a similar manner (Kim et al., 
2009). The initial results indicated this compound shows a promising potential for future use 
as an oral dietary supplement for the long term treatment of AD. 
Saururus Chinensis Baill 
Saururus is a perennial herbaceous plant used in Korean folk medicine for the treatment of 
various conditions such as edema, jaundice, gonorrhea and used has been employed as an 
antipyretic, diuretic, and anti-inflammatory agent (Choi et al., 2008). It has been shown to 
have anti-oxidant activity (Y. S. Lee et al., 2004) and has been used in the management of 
various skin diseases including AD in Eastern countries. It contains flavonoids (quercetin, 
quercitrin, isoquercitrin, rutin) as active components which are reported as possessing 
number of biological effects: antiallergic, anti-inflammatory, antiviral, antiproliferative, 
anticarcinogenic (Scalbert & Williamson, 2000). After 63 days this compound was found to 
significantly improve skin severity scores and improved itching behavior, with the higher 
concentration preforming better. Molecular evaluation found a decrease in IgE but no 
changes in IL4.  
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Lyophyllum Decastes 
Lyophyllum is an edible mushroom cultivated in Japan that is commonly known as ‘Fried 
Chicken Mushroom’. In a previous study, 11 polysaccharide extracts were found to have 
anti-tumour activity (Ukawa et al., 2000) particularly (1-3)B-D-Glucan and (1-6)B-D-Glucan. 
In 2006, it was examined for its potential effect on the AD mice model (Ukawa et al., 2007) 
using a 6 week feeding study. At the end of the study the treatment group had significant 
decreases in skin severity scores, as well as decreases in serum IgE, Histamine, and IL-4.  
Persimmon Leaf Extract 
Persimmon is the edible fruit of the Diospyros kaki Thunberg (Ebenanceae) tree which 
grows in China, Korea and Japan (Matsumoto et al., 2002). Kaempferol, a flavonoid 
contained in the leaf, was found to inhibit antigen and calcium ionophore A23187 induced 
histamine release. Kaempferol-3-glucoside (astraglandin) has been shown to have anti-
pruritic effects(Ishiguro & Oku, 1997). Kotani et al. found the leaf extract inhibited the 
release of histamine from human basophilic cell line KU812 (M Kotani, 1999) promoting 
them to study the effect on NC/Nga model (Kotani et al., 2000). A 14 week oral feeding 
study using both Persimmon Leaf extract and Astraglandin alone found both were effective 
in decreasing the severity of skin scores, inhibiting IgE, IL4, IL13 and Histamine release 
(Kotani et al., 2000). A similar follow up study was conducted confirming these earlier 
results and included measurement of Transepidermal water loss (TEWL) (Major pathology 
in AD due to dermal barrier dysfunction) and was found to be improved by the extract 
(Matsumoto et al., 2002).  
Konjac Glucomannan 
Konjac is a plant found in eastern Asia and is very popular in Japan as cooking supplement. 
Two compounds of interest have been isolated from this product and tested as possible 
treatments: Konjac glucomannan which has been tested in mice and Konjac ceramide which 
entered human trials (see section 4.2.4). Glucomannan, a dietary fiber isolated from the 
tubers of Amorphophallus konjac, is a highly viscous polysaccharide composed of glucose and 
mannose residues (Onishi et al., 2005). During the 1970’s dietary fibers were investigated as 
part of the epidemiology of colon cancer (Burkitt, 1971a, 1971b). During mice feeding 
studies it was observed that serum IgE levels decreased and IgA and IgG increased(Lim et 
al., 1997) indicating dietary fibers indirectly influenced immunoglobulin production. This 
theory was investigated in NC/Nga mouse model during an 8 week controlled feeding trial. 
Skin severity symptoms were significantly improved and scratching events were decreased 
to 1/3 to 1/6 of controls. Serologically it almost totally suppressed IgE levels and decreased 
the total Immunoglobulin, with a noted decreased in IL-4 and INFϒ. Since the compound 
suppressed both Th1 and Th2 related cytokines it’s mechanism of action cannot be 
attributed to Th1/Th2 polarization (Onishi et al., 2004, 2005). Follow up studies found that it 
decreased scratching behvaiour in a dose dependent manner (OnishiKawamotoSuzuki et al., 
2007), and prevented IgE class switching in Balb/c mice following injection of keratinocyte 
extract (Oomizu et al., 2006). It was also found to suppress allergic rhinitis like inflammation 
following nasal challenge with ovalabumin (OnishiKawamotoUeda et al., 2007).  
Gyokuheifusan 
This is a traditional Chinese Medicine formulation that has been used for the treatment of 
allergic and respiratory disease (ex. infections, allergic rhinitis, asthma, and others) (Fang et 
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al., 2005).This preparation contains three herbal medications: Astragalus membranaceus, 
Atractylodes ovata, Saposhinkovia divaricate. In a study on the immunomodulatory effects of 
the formulation on allergic asthma, it was found to reduce the severity of asthma through 
normalization of INFϒ/IL4 ratio (Th1/Th2 balance) (Fang et al., 2005). These results were 
hypothesized to extent to AD, after a 4 week oral feeding treatment placebo control study it 
was found that dermatitis severity scores were improved significantly, as well as IgE and 
the IFNϒ/IL4 balance (Nakatsukasa et al., 2009). 
 
COMPOUND  PARAMETER IMPROVEMENT MOLECULAR IMPROVEMENTS 
Rumex Japonicus 
Houtt 
Skin Severity Scores, Scratching 
Behaviour, Skin inflammatory 
Changes 
Decrease IgE, IL4 
PG102 –  
Actinidia Arguta 
Skin Severity Scores, Scratching 
Behaviour; Prevented eosinophilia, 
inflammatory cells entering dermis
Decrease IgE, IgG, IL4, TARC, 
Eotaxin; Increase IL12; Reduce 









Skin Severity Scores, Scratching 
Behaviour 
Decrease IgE, IL4, Histamine 
Persimmon Leaf 
Extract 
Skin Severity Scores, 
Transepidermal Water Loss 
Decrease IgE, IL4, IL13, Histamine,  
Konjac 
Glucomannan 
Skin Severity Scores, Scratching 
Behaviour 
Decrease IgE, Ig, IL4, INFϒ 
Gyokuheifusan Skin Severity Scores Decrease IgE, IFNϒ/IL4 balance 
Table 4. Summary of Treatments Tested in Animal Models 
4.2.3 Human clinical trials 
When clinical trials are conducted for Atopic Dermatitis subjective symptoms such as 
erythema and pruritus, must be converted to objective and uniform results so that they may 
be compared with other studies. The following are some of the most commonly used 
systems and those employed in the following studies: 
Transepidermal Water Loss (TEWL) (Pinnagoda et al., 1990): This is a measure of integrity 
of stratum corneum’s water barrier function; it provides information about the integrity of 
the skin, which becomes compromised in AD and may be influenced and improved with 
treatment. It is measured using tewameter, with units expressed as g/m2/h; with 
improvement indicated by a lower value. 
Blood flow volume (BFV) :Measured as a parameter of inflammation using Laser Blood Flow 
Monitor; Arbitrary unit with improvement indicated by lower values. 
Skin Color (a* Value): Erythema quantified by skin color reflectance it is measured using 
colorimeter  
Visual Scoring – Visual judgment made by clinical investigator, scored 0-5 
SCORAD (SCORing Atopic Dermatitis) (SCORAD, 1993): Standardized method for reporting 
dermatitis severity first published in 1993 by the European Task Force on Atopic Dermatitis, 
allows dermatitis severity to be reported numerically ranging from 0-103. 
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Lyophyllum Decastes 
Lyophyllum is an edible mushroom cultivated in Japan that is commonly known as ‘Fried 
Chicken Mushroom’. In a previous study, 11 polysaccharide extracts were found to have 
anti-tumour activity (Ukawa et al., 2000) particularly (1-3)B-D-Glucan and (1-6)B-D-Glucan. 
In 2006, it was examined for its potential effect on the AD mice model (Ukawa et al., 2007) 
using a 6 week feeding study. At the end of the study the treatment group had significant 
decreases in skin severity scores, as well as decreases in serum IgE, Histamine, and IL-4.  
Persimmon Leaf Extract 
Persimmon is the edible fruit of the Diospyros kaki Thunberg (Ebenanceae) tree which 
grows in China, Korea and Japan (Matsumoto et al., 2002). Kaempferol, a flavonoid 
contained in the leaf, was found to inhibit antigen and calcium ionophore A23187 induced 
histamine release. Kaempferol-3-glucoside (astraglandin) has been shown to have anti-
pruritic effects(Ishiguro & Oku, 1997). Kotani et al. found the leaf extract inhibited the 
release of histamine from human basophilic cell line KU812 (M Kotani, 1999) promoting 
them to study the effect on NC/Nga model (Kotani et al., 2000). A 14 week oral feeding 
study using both Persimmon Leaf extract and Astraglandin alone found both were effective 
in decreasing the severity of skin scores, inhibiting IgE, IL4, IL13 and Histamine release 
(Kotani et al., 2000). A similar follow up study was conducted confirming these earlier 
results and included measurement of Transepidermal water loss (TEWL) (Major pathology 
in AD due to dermal barrier dysfunction) and was found to be improved by the extract 
(Matsumoto et al., 2002).  
Konjac Glucomannan 
Konjac is a plant found in eastern Asia and is very popular in Japan as cooking supplement. 
Two compounds of interest have been isolated from this product and tested as possible 
treatments: Konjac glucomannan which has been tested in mice and Konjac ceramide which 
entered human trials (see section 4.2.4). Glucomannan, a dietary fiber isolated from the 
tubers of Amorphophallus konjac, is a highly viscous polysaccharide composed of glucose and 
mannose residues (Onishi et al., 2005). During the 1970’s dietary fibers were investigated as 
part of the epidemiology of colon cancer (Burkitt, 1971a, 1971b). During mice feeding 
studies it was observed that serum IgE levels decreased and IgA and IgG increased(Lim et 
al., 1997) indicating dietary fibers indirectly influenced immunoglobulin production. This 
theory was investigated in NC/Nga mouse model during an 8 week controlled feeding trial. 
Skin severity symptoms were significantly improved and scratching events were decreased 
to 1/3 to 1/6 of controls. Serologically it almost totally suppressed IgE levels and decreased 
the total Immunoglobulin, with a noted decreased in IL-4 and INFϒ. Since the compound 
suppressed both Th1 and Th2 related cytokines it’s mechanism of action cannot be 
attributed to Th1/Th2 polarization (Onishi et al., 2004, 2005). Follow up studies found that it 
decreased scratching behvaiour in a dose dependent manner (OnishiKawamotoSuzuki et al., 
2007), and prevented IgE class switching in Balb/c mice following injection of keratinocyte 
extract (Oomizu et al., 2006). It was also found to suppress allergic rhinitis like inflammation 
following nasal challenge with ovalabumin (OnishiKawamotoUeda et al., 2007).  
Gyokuheifusan 
This is a traditional Chinese Medicine formulation that has been used for the treatment of 
allergic and respiratory disease (ex. infections, allergic rhinitis, asthma, and others) (Fang et 
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al., 2005).This preparation contains three herbal medications: Astragalus membranaceus, 
Atractylodes ovata, Saposhinkovia divaricate. In a study on the immunomodulatory effects of 
the formulation on allergic asthma, it was found to reduce the severity of asthma through 
normalization of INFϒ/IL4 ratio (Th1/Th2 balance) (Fang et al., 2005). These results were 
hypothesized to extent to AD, after a 4 week oral feeding treatment placebo control study it 
was found that dermatitis severity scores were improved significantly, as well as IgE and 
the IFNϒ/IL4 balance (Nakatsukasa et al., 2009). 
 
COMPOUND  PARAMETER IMPROVEMENT MOLECULAR IMPROVEMENTS 
Rumex Japonicus 
Houtt 
Skin Severity Scores, Scratching 
Behaviour, Skin inflammatory 
Changes 
Decrease IgE, IL4 
PG102 –  
Actinidia Arguta 
Skin Severity Scores, Scratching 
Behaviour; Prevented eosinophilia, 
inflammatory cells entering dermis
Decrease IgE, IgG, IL4, TARC, 
Eotaxin; Increase IL12; Reduce 
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Table 4. Summary of Treatments Tested in Animal Models 
4.2.3 Human clinical trials 
When clinical trials are conducted for Atopic Dermatitis subjective symptoms such as 
erythema and pruritus, must be converted to objective and uniform results so that they may 
be compared with other studies. The following are some of the most commonly used 
systems and those employed in the following studies: 
Transepidermal Water Loss (TEWL) (Pinnagoda et al., 1990): This is a measure of integrity 
of stratum corneum’s water barrier function; it provides information about the integrity of 
the skin, which becomes compromised in AD and may be influenced and improved with 
treatment. It is measured using tewameter, with units expressed as g/m2/h; with 
improvement indicated by a lower value. 
Blood flow volume (BFV) :Measured as a parameter of inflammation using Laser Blood Flow 
Monitor; Arbitrary unit with improvement indicated by lower values. 
Skin Color (a* Value): Erythema quantified by skin color reflectance it is measured using 
colorimeter  
Visual Scoring – Visual judgment made by clinical investigator, scored 0-5 
SCORAD (SCORing Atopic Dermatitis) (SCORAD, 1993): Standardized method for reporting 
dermatitis severity first published in 1993 by the European Task Force on Atopic Dermatitis, 
allows dermatitis severity to be reported numerically ranging from 0-103. 
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 SCORAD Calculation = A/5 + 7 (B/2) + C 
 
  PARAMETER TOTAL SCORE 
A SPREAD/BODY SURFACE AREA 100 
  Judge based on rule of 9 for body surface area 
B INTENSITY 18 
  Erythema (1-3)   
  Edema (1-3)   
  Oozing/Crusting (1-3)   
  Excoriation (1-3)   
  Lichenification (1-3)   
C SUBJECTIVE SYMPTOMS 20 
  Pruritus (1-10)   
  Insomnia (1-10)   
Table 5. Parameters for SCORAD Calculation 
4.2.4 Human clinical of trials of natural products 
WBI-1001 (IPBD: 2-isopropyl-5-[(E)-2-phenylethenyl] benzene-1,3-diol) 
This compound is derived from a metabolite of a unique group of bacterial symbiots of 
entomopathogenic nematodes. It was found to inhibit inflammatory cytokine secretion by 
activated T cells including: TNFα, INF ϒ as well as inhibit allergic contact dermatitis in a 
mouse edema model (Bissonnette et al., 2010). A phase 2A, double blind, vehicle controlled 
study resulted in statistically significant improvement in SCORAD, pruritus, and the 
amount of affected body surface area. These improvements were reached after 3-5 weeks of 
treatment. A 12 week Phase IIb trial was conducted (NCT01098734) as of June 9th 2011, the 
results are still pending publication.  
Konjac Ceramide 
Konjac ceramide is the second compound of interest isolated from konjac. Ceramides are a 
normal component of the lipid membrane, and their deficiency has been suggested as one of 
the pathological factors resulting in skin barrier disruption (Imokawa et al., 1991), having 
being previously studied in the treatment of dermatitis (Berardesca et al., 2001). 
Glucosylceramides are isolated, purified and produced as a nutritional supplement (Kimata, 
2006) and oral intake has been found to decrease transepidermal water loss in normal adults 
(Miyanishi et al., 2005). Konjac due to its high concentration of ceramide was studied for its 
effect on AD as an oral supplement. Following a 4 week oral feeding trial in 50 children, the 
SCORAD index was significantly improved when compared to the control group. INFϒ and 
IL-12 were significantly increased while IL-4 and IL-13 were decreased indicating a skewing 
of the cytokine pattern towards a Th1 type. Interestingly in this study, ceramide was found 
to attenuate allergen specific response to HDM (house dust mite) and JCP (Japanese cedar 
pollen) by improving skin symptoms and wheal response but had no effect following 
dermal challenge of Egg white, histamine or buckwheat (Kimata, 2006).  
Borage Oil: Gamma-Linolenic Acid 
In patients with AD, an abnormality in metabolism of polysaturated fatty acids (PUFA) is 
commonly observed (Wright, 1991). PUFA are structural components of cell membrane 
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phospholipids which are important in maintaining membrane fluidity (Wright, 1991), as 
well as being important as precursors for pharmacologically active immunological agents (ie 
Eicosanoids) (R. Finkel et al., 2009). Borage oil contains a high content (24%) of ϒ-linolenic 
acid (GLA) which is a metabolite of linoleic acid, one of the essential fatty acids. It is 
postulated an abnormality in essential fatty acid metabolism affects production of GLA and 
its incorporation into membranes, occurs in AD (Horrobin, 2000; Wright, 1991). Previous 
studies have shown GLA supplementation lead to improvements in multiple diseases 
including seborrheic dermatitis in children (Tollesson & Frithz, 1993). In a small Japanese 
study in a pediatric population, undershirts coated with Borage oil were given to 32 children 
in a double-blind, placebo controlled study (Kanehara et al., 2007) . After 2 weeks it was 
found that there was a statistically significant improvement in symptoms of itch and 
erythema, but no improvement papules, erosions, and trans-epidermal water loss (Kanehara 
et al., 2007). In a literature review of 12 trials (oral and topical) on the efficacy of Borage Oil 
in the treatment of AD by Foster et al. in 2010 found that 5 studies show statistically 
significant improvement, while 5 showed borage oil to be ineffective and 2 studies were 
shown only to have partial response (Foster et al., 2010). The efficacy of borage oil in the 
treatment of AD remains questionable, a previous product EpoGam used for treatment of 
AD was removed from market in 2002 in the UK when it was found to be ineffective. This 
product contained primrose oil which contains lower concentration of GLA then borage oil 
but was based on the same pathophysiologic principle(H. Williams, 2003). Borage oil while 
providing some benefit in some studies requires future study to determine its efficacy and it 
remains to be determine if it will be steroid sparing.  
Emollient Therapy 
Emollient therapy is a mainstay in the management of the symptoms of AD 
(Szczepanowska et al., 2008). While studies into the prevention of AD are less common, 
Simpson et al. proposed that ‘skin barrier protection from birth using bland emollients is a 
safe and feasible strategy for AD prevention’ (Simpson et al., 2010). This was based on the 
results from previous studies that found use of petrolatum early in life may be protective 
against AD development, there was trend towards increased TEWL and skin hydration 
before development of AD, use of emollients in premature infants protects against skin 
inflammation and emollients are effective at preventing flares in established AD (Simpson et 
al., 2010). In 20 high risk infants (based on the ISSAC criteria (Asher et al., 2006)) emollient 
therapy was initiated in the first week of life in order to maintain intact skin barrier. After 2 
years it was found that only 15% of subject developed AD when conservative estimates of 
high risk infants would be positive for AD in the range of 30-50% suggesting this treatment 
could have both a protective and preventative effect (Simpson et al., 2010). 
Probiotics 
Living or inactivated organisms that are claimed to exert beneficial effects on health when 
ingested are referred to as Probiotics (Schrezenmeir & de Vrese, 2001). The use of probiotic 
and prebiotics in the field of allergology is a controversial subject, with the results of 
prenatal and postnatal supplementation for the prevention of atopic dermatitis having 
mixed results (J. Lee et al., 2008). Probiotic intestinal colonization is theorized to affect the 
Th1/Th2 immunological maturation prior to the establishment of atopic dermatitis (Gruber 
et al., 2010). Physiologically the normal gut milieu has an immune system that is balance 
between protective mucosal immunity and systemic tolerance. In food allergies the balance 
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entomopathogenic nematodes. It was found to inhibit inflammatory cytokine secretion by 
activated T cells including: TNFα, INF ϒ as well as inhibit allergic contact dermatitis in a 
mouse edema model (Bissonnette et al., 2010). A phase 2A, double blind, vehicle controlled 
study resulted in statistically significant improvement in SCORAD, pruritus, and the 
amount of affected body surface area. These improvements were reached after 3-5 weeks of 
treatment. A 12 week Phase IIb trial was conducted (NCT01098734) as of June 9th 2011, the 
results are still pending publication.  
Konjac Ceramide 
Konjac ceramide is the second compound of interest isolated from konjac. Ceramides are a 
normal component of the lipid membrane, and their deficiency has been suggested as one of 
the pathological factors resulting in skin barrier disruption (Imokawa et al., 1991), having 
being previously studied in the treatment of dermatitis (Berardesca et al., 2001). 
Glucosylceramides are isolated, purified and produced as a nutritional supplement (Kimata, 
2006) and oral intake has been found to decrease transepidermal water loss in normal adults 
(Miyanishi et al., 2005). Konjac due to its high concentration of ceramide was studied for its 
effect on AD as an oral supplement. Following a 4 week oral feeding trial in 50 children, the 
SCORAD index was significantly improved when compared to the control group. INFϒ and 
IL-12 were significantly increased while IL-4 and IL-13 were decreased indicating a skewing 
of the cytokine pattern towards a Th1 type. Interestingly in this study, ceramide was found 
to attenuate allergen specific response to HDM (house dust mite) and JCP (Japanese cedar 
pollen) by improving skin symptoms and wheal response but had no effect following 
dermal challenge of Egg white, histamine or buckwheat (Kimata, 2006).  
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In patients with AD, an abnormality in metabolism of polysaturated fatty acids (PUFA) is 
commonly observed (Wright, 1991). PUFA are structural components of cell membrane 
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phospholipids which are important in maintaining membrane fluidity (Wright, 1991), as 
well as being important as precursors for pharmacologically active immunological agents (ie 
Eicosanoids) (R. Finkel et al., 2009). Borage oil contains a high content (24%) of ϒ-linolenic 
acid (GLA) which is a metabolite of linoleic acid, one of the essential fatty acids. It is 
postulated an abnormality in essential fatty acid metabolism affects production of GLA and 
its incorporation into membranes, occurs in AD (Horrobin, 2000; Wright, 1991). Previous 
studies have shown GLA supplementation lead to improvements in multiple diseases 
including seborrheic dermatitis in children (Tollesson & Frithz, 1993). In a small Japanese 
study in a pediatric population, undershirts coated with Borage oil were given to 32 children 
in a double-blind, placebo controlled study (Kanehara et al., 2007) . After 2 weeks it was 
found that there was a statistically significant improvement in symptoms of itch and 
erythema, but no improvement papules, erosions, and trans-epidermal water loss (Kanehara 
et al., 2007). In a literature review of 12 trials (oral and topical) on the efficacy of Borage Oil 
in the treatment of AD by Foster et al. in 2010 found that 5 studies show statistically 
significant improvement, while 5 showed borage oil to be ineffective and 2 studies were 
shown only to have partial response (Foster et al., 2010). The efficacy of borage oil in the 
treatment of AD remains questionable, a previous product EpoGam used for treatment of 
AD was removed from market in 2002 in the UK when it was found to be ineffective. This 
product contained primrose oil which contains lower concentration of GLA then borage oil 
but was based on the same pathophysiologic principle(H. Williams, 2003). Borage oil while 
providing some benefit in some studies requires future study to determine its efficacy and it 
remains to be determine if it will be steroid sparing.  
Emollient Therapy 
Emollient therapy is a mainstay in the management of the symptoms of AD 
(Szczepanowska et al., 2008). While studies into the prevention of AD are less common, 
Simpson et al. proposed that ‘skin barrier protection from birth using bland emollients is a 
safe and feasible strategy for AD prevention’ (Simpson et al., 2010). This was based on the 
results from previous studies that found use of petrolatum early in life may be protective 
against AD development, there was trend towards increased TEWL and skin hydration 
before development of AD, use of emollients in premature infants protects against skin 
inflammation and emollients are effective at preventing flares in established AD (Simpson et 
al., 2010). In 20 high risk infants (based on the ISSAC criteria (Asher et al., 2006)) emollient 
therapy was initiated in the first week of life in order to maintain intact skin barrier. After 2 
years it was found that only 15% of subject developed AD when conservative estimates of 
high risk infants would be positive for AD in the range of 30-50% suggesting this treatment 
could have both a protective and preventative effect (Simpson et al., 2010). 
Probiotics 
Living or inactivated organisms that are claimed to exert beneficial effects on health when 
ingested are referred to as Probiotics (Schrezenmeir & de Vrese, 2001). The use of probiotic 
and prebiotics in the field of allergology is a controversial subject, with the results of 
prenatal and postnatal supplementation for the prevention of atopic dermatitis having 
mixed results (J. Lee et al., 2008). Probiotic intestinal colonization is theorized to affect the 
Th1/Th2 immunological maturation prior to the establishment of atopic dermatitis (Gruber 
et al., 2010). Physiologically the normal gut milieu has an immune system that is balance 
between protective mucosal immunity and systemic tolerance. In food allergies the balance 
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is impaired and oral tolerance of dietary antigens is not achieved. Risk Factors for the 
development of food allergy include immature gut barrier and type II Th2 cell skewed 
cytokine profile are present in early infancy. This may lead to atopic sensitization as antigen 
uptake is aberrant and Th2 cells further produce IL4 a cytokine essential for B cell 
differentiation into IgE producing cells and IL5 which is important for eosinophils . Normal 
bacterial flora at birth is shown to counterbalance the Th2 activity and promote oral 
tolerance. The predilection of bacteria to promote the differentiation of Th1 cell lineage may 
be due to specific CpG motif characteristics of bacterial DNA which has been show to 
induce polycolonal B-cell activation and secretion of Th1 Cytokines IL6, IL12 and interferon 
Y (Passeron et al., 2006).The guts of infants born in poor areas of developing countries where 
allergy prevalence is lower, are colonized earlier by enterobacteria, enterococcim lactobacilli, 
and eubacteria and displays a higher turnover of different E. coli strains in the intestinal 
microflora ((Matricardi et al., 2003). In a meta-analysis of 21 studies (1997-2007) by Lee et al. 
(2007) containing 1898 subjects looking at Probiotics in the prevention of atopic dermatitis 
found a risk reduction of 61% in the development of atopic dermatitis in high risk infants (J. 
Lee et al., 2008). Newer studies have found conflicting results (Boyle et al., 2011) so its use 
remains controversial. Strains of bacteria that have been investigated include Lactobacillus 
rhamnosus GG (Gruber et al., 2007), Bifidobacterium lactis (Kukkonen et al., 2007), Mycobacterium 
vaccae and others (Matricardi et al., 2003). In studies of the use of the Probiotics following the 
establishment of AD has been met with mixed results. In one study it was found that while 
probiotics did improve SCORAD results they were not statistically significant when 
compared to placebo (Viljanen et al., 2005) . Other studies have shown the probiotics 
following established AD in children did improve SCORAD (Passeron et al., 2006) .  
St. John’s Wort Cream 
St. John Wort is a family of plants with worldwide distribution accounting for about 370 
species. It has been use as a herbal treatment for depression (Rapaport et al., 2011), ADHD 
(Chan, 2008) and other psychological condition, however without proven clinical effects. It 
has been traditionally used for the topical treatment of wounds, burns, nerve lesions and has 
used as a remedy for eczematous skin conditions (Schempp et al., 2000). Hypericin is a major 
component of St. John wort and has been found to have bioactive properties exhibiting dose 
dependent photosensitizing activity (Schempp et al., 2000). Hyperforin, a second compound, 
was found to have anti-bacterial activity (Gurevich et al., 1971). After a 7 day topical trial, the 
treatment compound was found to significantly improved SCORAD scores. Colony forming 
units of S. aureus were measured, and found to be decreased by the treatment compound 
when compared to control, however not significantly. No molecular markers of 
inflammation were measure in this study.  
Herbal Preparations – Traditional Chinese Medicine 
Multiple trials have been conducted using formulas of traditional Chinese medicine. These 
formulas have a long history of use and documentation within their medical systems. The 
difficulty in investigating these compounds are due to the manner of preparation and 
individuality of the treatment. In a 2007 study by Hon et al. of a five herb formulation (Flos 
lonicerae, Herba menthae, Cortex moutan, Rhizoma atractylodis, Cortex phellodendri) in a placebo 
controlled 12 week oral feeding trial found that while the treatment group and placebo 
group both improved symptoms there was no statistically significance between the two. 
However in the treatment group, the number of days of corticosteroids use during the 
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month was significantly decreased, improving the quality of life of the subject (Hon et al., 
2007). In a follow up study it was found the formulation suppressed brain-derived 
neurotrophic factor (BDNF), Thymus and activation regulated chemokine (TARC), INF-ϒ, 
and TNFα (Leung et al., 2008). 
 
COMPOUND  PARAMETER IMPROVEMENT MOLECULAR IMPROVEMENTS 
WBI-1001 SCORAD, Pruritus, Body Surface 
Area 
Inhibited TNFα, Increased INF ϒ 
Konjac Ceramide SCORAD, Transepidermal Water 
loss, Allergen specific response 
Increased INFϒ, IL12; Decreased 
IL4, IL13 
Borage Oil SCORAD?, Itch, Erythema Metabolism of PUFA 
Emollient Therapy Prevention of AD  
Probiotics   
St. John’s Wort 
Cream 
SCORAD, Decreased Staph. Aureus
CFUs 
 
TCM   
Table 6. Summary of Treatments Tested in Human Clinical Trials 
4.2.5 Approved compounds 
The calcineurin inhibitors are among the most recent example of natural products that had 
been identified having potential biological activity, then successfully proceeded through the 
clinical trial phase and have been approved for use in the treatment of AD and other 
dermatological hypersensitivity conditions.  The following natural product concoction is the 
most recent treatment approved for use in AD by the FDA. Using an understanding of the 
pathophysiology of AD, compounds were selected that targeted different facets of the 
pathology to work in concert in the treatment of AD.  
Atopiclair MAS063D (Atopiclair)  
Hydrolipidic cream developed for the management of Atopic dermatitis, containing 
moisturizing elements and natural products (Belloni et al., 2005): The agent contains a 
combination of the bioactive compounds from Vitis vinifera, glycyrrhetinic acid and 
Hyaluronic acid. Hyaluronic acid is barrier forming and hydrating agent, traditionally used 
as lubricant in surgery (Manuskiatti & Maibach, 1996). It is a naturally occurring 
glycosaminoglycan in the body found in healthy connective tissue and induces tissue 
hydration (traditionally used as lubricant in other areas of medicine – ocular surgery, 
orthopedic surgery).  Telmesterine and extracts from vitis viniferia have been found to have 
anti protease activities, (inhibiting harmful enzymes that exuded by damaged skin; and 
antioxidant effects protecting against free radicals (Belloni et al., 2005). Procyanidins found 
in vitis viniferia have been examined at the vascular endothelium, where they help to prevent 
oxidative damage, they also form a barrier to protect against elastase, collagenase, 
hyaluronidase, and B-glucuronidase. Glycyrrhetinic acid is a compound found to have anti-
inflammatory activity (Teelucksingh et al., 1990) In 2003, the first vehicle controlled, double 
blind study of Atopiclair was conducted in a study group of 20 subjects with contact 
dermatitis. Subjects applied vehicle to one arm and treatment compound to the other and 
were measured at 24, 48 and 72 hours. Results from this compound were promising, with 
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is impaired and oral tolerance of dietary antigens is not achieved. Risk Factors for the 
development of food allergy include immature gut barrier and type II Th2 cell skewed 
cytokine profile are present in early infancy. This may lead to atopic sensitization as antigen 
uptake is aberrant and Th2 cells further produce IL4 a cytokine essential for B cell 
differentiation into IgE producing cells and IL5 which is important for eosinophils . Normal 
bacterial flora at birth is shown to counterbalance the Th2 activity and promote oral 
tolerance. The predilection of bacteria to promote the differentiation of Th1 cell lineage may 
be due to specific CpG motif characteristics of bacterial DNA which has been show to 
induce polycolonal B-cell activation and secretion of Th1 Cytokines IL6, IL12 and interferon 
Y (Passeron et al., 2006).The guts of infants born in poor areas of developing countries where 
allergy prevalence is lower, are colonized earlier by enterobacteria, enterococcim lactobacilli, 
and eubacteria and displays a higher turnover of different E. coli strains in the intestinal 
microflora ((Matricardi et al., 2003). In a meta-analysis of 21 studies (1997-2007) by Lee et al. 
(2007) containing 1898 subjects looking at Probiotics in the prevention of atopic dermatitis 
found a risk reduction of 61% in the development of atopic dermatitis in high risk infants (J. 
Lee et al., 2008). Newer studies have found conflicting results (Boyle et al., 2011) so its use 
remains controversial. Strains of bacteria that have been investigated include Lactobacillus 
rhamnosus GG (Gruber et al., 2007), Bifidobacterium lactis (Kukkonen et al., 2007), Mycobacterium 
vaccae and others (Matricardi et al., 2003). In studies of the use of the Probiotics following the 
establishment of AD has been met with mixed results. In one study it was found that while 
probiotics did improve SCORAD results they were not statistically significant when 
compared to placebo (Viljanen et al., 2005) . Other studies have shown the probiotics 
following established AD in children did improve SCORAD (Passeron et al., 2006) .  
St. John’s Wort Cream 
St. John Wort is a family of plants with worldwide distribution accounting for about 370 
species. It has been use as a herbal treatment for depression (Rapaport et al., 2011), ADHD 
(Chan, 2008) and other psychological condition, however without proven clinical effects. It 
has been traditionally used for the topical treatment of wounds, burns, nerve lesions and has 
used as a remedy for eczematous skin conditions (Schempp et al., 2000). Hypericin is a major 
component of St. John wort and has been found to have bioactive properties exhibiting dose 
dependent photosensitizing activity (Schempp et al., 2000). Hyperforin, a second compound, 
was found to have anti-bacterial activity (Gurevich et al., 1971). After a 7 day topical trial, the 
treatment compound was found to significantly improved SCORAD scores. Colony forming 
units of S. aureus were measured, and found to be decreased by the treatment compound 
when compared to control, however not significantly. No molecular markers of 
inflammation were measure in this study.  
Herbal Preparations – Traditional Chinese Medicine 
Multiple trials have been conducted using formulas of traditional Chinese medicine. These 
formulas have a long history of use and documentation within their medical systems. The 
difficulty in investigating these compounds are due to the manner of preparation and 
individuality of the treatment. In a 2007 study by Hon et al. of a five herb formulation (Flos 
lonicerae, Herba menthae, Cortex moutan, Rhizoma atractylodis, Cortex phellodendri) in a placebo 
controlled 12 week oral feeding trial found that while the treatment group and placebo 
group both improved symptoms there was no statistically significance between the two. 
However in the treatment group, the number of days of corticosteroids use during the 
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month was significantly decreased, improving the quality of life of the subject (Hon et al., 
2007). In a follow up study it was found the formulation suppressed brain-derived 
neurotrophic factor (BDNF), Thymus and activation regulated chemokine (TARC), INF-ϒ, 
and TNFα (Leung et al., 2008). 
 
COMPOUND  PARAMETER IMPROVEMENT MOLECULAR IMPROVEMENTS 
WBI-1001 SCORAD, Pruritus, Body Surface 
Area 
Inhibited TNFα, Increased INF ϒ 
Konjac Ceramide SCORAD, Transepidermal Water 
loss, Allergen specific response 
Increased INFϒ, IL12; Decreased 
IL4, IL13 
Borage Oil SCORAD?, Itch, Erythema Metabolism of PUFA 
Emollient Therapy Prevention of AD  
Probiotics   
St. John’s Wort 
Cream 
SCORAD, Decreased Staph. Aureus
CFUs 
 
TCM   
Table 6. Summary of Treatments Tested in Human Clinical Trials 
4.2.5 Approved compounds 
The calcineurin inhibitors are among the most recent example of natural products that had 
been identified having potential biological activity, then successfully proceeded through the 
clinical trial phase and have been approved for use in the treatment of AD and other 
dermatological hypersensitivity conditions.  The following natural product concoction is the 
most recent treatment approved for use in AD by the FDA. Using an understanding of the 
pathophysiology of AD, compounds were selected that targeted different facets of the 
pathology to work in concert in the treatment of AD.  
Atopiclair MAS063D (Atopiclair)  
Hydrolipidic cream developed for the management of Atopic dermatitis, containing 
moisturizing elements and natural products (Belloni et al., 2005): The agent contains a 
combination of the bioactive compounds from Vitis vinifera, glycyrrhetinic acid and 
Hyaluronic acid. Hyaluronic acid is barrier forming and hydrating agent, traditionally used 
as lubricant in surgery (Manuskiatti & Maibach, 1996). It is a naturally occurring 
glycosaminoglycan in the body found in healthy connective tissue and induces tissue 
hydration (traditionally used as lubricant in other areas of medicine – ocular surgery, 
orthopedic surgery).  Telmesterine and extracts from vitis viniferia have been found to have 
anti protease activities, (inhibiting harmful enzymes that exuded by damaged skin; and 
antioxidant effects protecting against free radicals (Belloni et al., 2005). Procyanidins found 
in vitis viniferia have been examined at the vascular endothelium, where they help to prevent 
oxidative damage, they also form a barrier to protect against elastase, collagenase, 
hyaluronidase, and B-glucuronidase. Glycyrrhetinic acid is a compound found to have anti-
inflammatory activity (Teelucksingh et al., 1990) In 2003, the first vehicle controlled, double 
blind study of Atopiclair was conducted in a study group of 20 subjects with contact 
dermatitis. Subjects applied vehicle to one arm and treatment compound to the other and 
were measured at 24, 48 and 72 hours. Results from this compound were promising, with 
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significant improvements in Transepidermal water loss (by 50%), Blood flow volume, Skin 
color, Visual Scoring. Only itch magnitude results fell below significance but showed 
improvement (Hongbo Zhai, 2003). In a follow up study in 2004, Atopiclair was tested in 
patients with Atopic Dermatitis and found significant improvement in all patients after 22 
days. Statistically significant improvements were measure in total body surface area 
affected, Itch score, SCORAD value, and Quality of sleep. In an informal survery following 
the study 93% of subjects responded positively to the product (Belloni et al., 2005). Following 
this study Atopiclair was approved by the FDA for the use in the treatment of atopic 
dermatitis (Abramovitis & Perlmutter, 2007).  
5. Conclusions 
Natural Products have been identified as potential sources of bioactive compounds used in 
the treatment of immune disorders. Historically some of the major and most important 
pharmaceutical compounds have their origin as natural products (Newman & Cragg, 2007). 
Penicillin, discovered as a metabolite of mold in a petri dish, revolutionized the manner in 
which medicine has been practiced since wide spread implementation following World War 
II (R. Finkel et al., 2009). Many of the classes of treatment compounds currently being used 
in immunology and dermatology have originated from natural products. It might hold true 
that the next revolutionary treatment might likewise have its origin from the natural world, 
potentially being already explored by patients looking into CAMs. 
It is inevitable that nature will continue to provide pharmaceutical active compounds that 
will be used in all practices and disciplines of medicine. It is those conducting the 
exploration for these compounds to keep an open mind to the possibility that an already 
employed alternative medicine might provide the next clue or even a source unknown.  
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significant improvements in Transepidermal water loss (by 50%), Blood flow volume, Skin 
color, Visual Scoring. Only itch magnitude results fell below significance but showed 
improvement (Hongbo Zhai, 2003). In a follow up study in 2004, Atopiclair was tested in 
patients with Atopic Dermatitis and found significant improvement in all patients after 22 
days. Statistically significant improvements were measure in total body surface area 
affected, Itch score, SCORAD value, and Quality of sleep. In an informal survery following 
the study 93% of subjects responded positively to the product (Belloni et al., 2005). Following 
this study Atopiclair was approved by the FDA for the use in the treatment of atopic 
dermatitis (Abramovitis & Perlmutter, 2007).  
5. Conclusions 
Natural Products have been identified as potential sources of bioactive compounds used in 
the treatment of immune disorders. Historically some of the major and most important 
pharmaceutical compounds have their origin as natural products (Newman & Cragg, 2007). 
Penicillin, discovered as a metabolite of mold in a petri dish, revolutionized the manner in 
which medicine has been practiced since wide spread implementation following World War 
II (R. Finkel et al., 2009). Many of the classes of treatment compounds currently being used 
in immunology and dermatology have originated from natural products. It might hold true 
that the next revolutionary treatment might likewise have its origin from the natural world, 
potentially being already explored by patients looking into CAMs. 
It is inevitable that nature will continue to provide pharmaceutical active compounds that 
will be used in all practices and disciplines of medicine. It is those conducting the 
exploration for these compounds to keep an open mind to the possibility that an already 
employed alternative medicine might provide the next clue or even a source unknown.  
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1. Introduction  
Anaphylactic shock is an extreme and life-threatening allergic reaction that requires 
immediate action to prevent death from airway and blood pressure collapse. The acute 
management comprises the use of epinephrine (adrenaline), the first-line medication of 
choice, and H1-antihistaminic drugs in doses that will depend on the severity of symptoms, 
in order to preserve the airway function and maintain the blood pressure and oxygenation 
at acceptable levels (Kemp & Lockey, 2002). On the other hand, long-term management 
comprises identification of precipitants (e.g.: Medications, foods, latex, insect venom) and 
their avoidance, and also immunotherapy.  
One of the main mediators that are released and associated the many anaphylactic 
symptoms is histamine. H1-antihistamines are commonly used to relieve anaphylactic 
cutaneous symptoms such as itching, flushing, and urticaria, but play little role in the relief 
of bronchospasm or gastrointestinal symptoms, and fail to relieve upper airway edema or 
hypotension. Moreover, in usual doses, antihistamines alone do not prevent the explosive 
release of histamine and other mediators of inflammation from mast cells and basophils that 
culminate in the anaphylactic shock.  
Since bronchospasm, hypotension and edema are not reversed immediately with 
antihistamines, a rapid administration of epinephrine is required to revert these symptoms. It 
has potent life-saving β-1 adrenergic vasoconstrictor effects on the small arterioles and 
precapillary sphincters leading to decreased mucosal edema, thereby preventing and relieving 
upper airway obstruction, and also to increased blood pressure, thereby preventing and 
relieving shock. (Kemp et al, 2008). Its strong effect on β-1 adrenergic receptors activation lead 
to increased rate and force of cardiac contractions, while activation of β-2 adrenergic receptors 
leads to increased bronchodilation and decreased release of histamine, tryptase, and other 
mediators of inflammation from mast cells and basophils (T.C. Westfall & D.P. Westfall, 2006). 
The adverse effects of epinephrine therapy involve pallor, headache (β -1 adrenergic 
receptors), palpitations (β-1 adrenergic receptors), tremor, vasodilation, increased release of 
mediators (β-2 adrenergic receptors) and anxiety (central CNS stimulation) that altogether 
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may impose severe risk to patients with cardiac, central nervous system or thyroid diseases. 
On the other hand, glucocorticoids, that down-regulate β-2 while up-regulating β-1 adrenergic 
receptors and are mainstays in the treatment of asthma, have been shown not to reverse 
anaphylaxis symptoms (Simons, 2006). Therefore, in view of the hyper-acute nature of 
anaphylactic shock that limits adequate therapy, prevention is still the most adequate measure. 
Current prevention of anaphylaxis is based on allergen desensitization through specific 
immunotherapy of patients with high-risk of type I hypersensitivity reactions that involve 
immunoglobulin E (IgE)–mediated release of histamine and other mediators. The 
immunotherapy comprises the administration of increased doses of low-concentrated 
specific allergen solution that induce peripheral tolerance associated with differentiation of 
IL-10 and TGF-β - producing CD4+CD25+ regulatory T cells (Francis et al , 2003; Jutel et al, 
2003). The efficacy of immunotherapy is also associated with an increase of antigen-specific 
IgG antibodies that block IgE effects on mast cells and basophils (Akdis & Blaser, 2000). 
Table 1 summarizes the current measures available to treat and prevent anaphylactic shock: 
 
DRUG PHASE OF MANAGEMENT EFFECTS 
EPINEFRINE Acute 
Vasoconstriction, increased peripheral 
vascular resistance, increased blood 
pressure and relief of hypotension and 
shock; decreased mucosal edema and 
relief of upper airway obstruction and 
angioedema (effects through β-1 
adrenergic receptors). Bronchodilation, 
decreased release of mediators (effects 
through β-2 adrenergic receptors). 
H1-ANTIHISTAMINES Acute 
Relief of itching, flushing, urticaria, 




Reversion of bronchospasm by relaxing 
of airway smooth muscle and reduction 
of asphyxia. 
GLUCOCORTICOIDS Acute Inhibition of cytokine and arachidonic acid derivates production. 
IMMUNOTHERAPY Long-term 
Induction of antigen-specific tolerance 
and increase of blockers antigen-specific 
IgG antibodies production. 
Table 1. Summary of management of anaphylactic shock 
2. Plants as sources of anti-allergic substances 
Over the years, ethnobotanical studies allowed the association of plants with a diversity of 
biological activities and the discovery of new pharmaceutical drugs (Farnsworth et al., 
1994). In the period 1981 to 2006, 52% of the small molecules discovered and in the 
development process were natural products or had their origins in natural products 
(Newman et al., 2007). 
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There have been many reports on the anti-allergic effects of some plants and natural 
compounds (Table 2).  
 
SPECIES EXTRACT EXPERIMENTAL MODEL EFFECT REFERENCE 
Ailanthus 
altissima Swingle Rat 
Inhibits production of 
histamine, TNF, IL-6, and 
IL-8, and nuclear NF-
B/Rel A 





extract Guinea pig 
Inhibits ileum contraction 







Rat Inhibits mast cell degranulation 





extract Rat Inhibits paw edema 










Inhibits Src-family kinase 
and degranulation in mast 
cells, and passive 
cutaneous anaphylaxis. 








hirta Ethanol extract Rat and mouse 
Inhibits paw edema, 
passive cutaneous and 
systemic anaphylaxis, 






epiclusianone Guinea pig 
Inhibits allergen-evoked 










Prevents blood pressure 
fall and 













behavior and blood 
pressure decrease. 








fatal anaphylactic shock, 
IgE, eosinophilia, IL-5, IL-
10, IL-13 and TNF-α, and 
histamine release. 
Cruz et al, 2011, 





Alginic acid Rat 
Inhibits histamine release, 
IL-1β and TNF-α, but not 
IL-6 or IL-8 production. 
Jeong et al., 2006 
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Reduces compound 48/80 
induced anaphylaxis and 
histamine release 
Chandrashekhar 
et al., 2011 







Guinea pig, mouse 
and rat. 
Inhibits passive cutaneous 
anaphylaxis, ileum 
contraction but not 
bronchospasm induced by 
histamine. 















extract Rat and mouse 
Decrease histamine release, 
TNF-α and IL-6 secretion. Kim et al., 2005 
Table 2. Anti-anaphylactic natural products 
Chamomile (Matricaria recutita, Asteraceae) is one of the medicinal plants whose methanol 
extract containing flavonoids, tannins, terpenoids and coumarines has reported properties 
against compound 48/80 induced anaphylaxis in rats (Chandrashekhar et al., 2011). Not 
only plants but also seaweeds containing alginic acid (Jeong et al., 2006) and honeybees-
produced propolis have been marketed for their anticipated anti-allergic effects (revised by 
Sforcin, 2007). Propolis consists of approximately 300 plant-derived compounds including 
flavonoids, phenolic acids, cinnamic acid derivatives, terpenoids, cellulose and amino acids. 
It has demonstrated protection against OVA-sensitized airway inflammatory reaction 
associated with inihibition of mast cell degranulation, and chrysin and kaempferol present 
in the ethanol extract appears to be the main anti-allergic compounds (Nakamura et al., 
2010). Since 2005, there have been a number of double-blind, placebo-controlled clinical 
studies in China investigating the efficacy and safety of Chinese herbal products. The major 
findings of four promising herbal remedies, comprising at least three plant species, were 
revised by Li and Brown (2009).  
Most of the plant products that fight inflammation belong to the chemical groups of 
alkaloids, coumarins, polyphenols, terpenoids and flavonoids. In particular, flavonoids such 
as quercetin, luteolin, fisetin and apigenin have been described with potent 
immunomodulatory properties. Studies on structure-activity relationship of 45 flavonoids 
showed that oberall they were more potent in inhibiting the production of IL-4 which is 
largely associated with allergic reactions (Revised by Kawai et al. 2007). Comalada et al. 
(2006) studied the structure–activity relationship for several flavonoids using primary bone 
marrow-derived mouse macrophages. They observed that some flavonoids inhibit TNF-α 
production as well as iNOS expression and nitric oxide (NO) production in LPS-activated 
macrophages, an effect that has been associated with the inhibition of the NF-B pathway. 
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Suppression of of NF-B nuclear factor activation by Ailanthus altissima swingle has also 
been associated with the reduced production of TNF-α, IL-6, and IL-8 pro-inflammatory 
cytokines and reduced histamine release during induced anaphylaxis (Kang et al., 2010). 
Flavonoids are known to have potent antiallergic activity (Kawai et al, 2007). For instance, 
luteolin and quercetin flavonoids (Figure 1) are potent inducers of the anti-inflammatory 
cytokine IL-10. Structure–activity relationship showed that four hydroxylations at positions 
5, 7, 30 and 40, together with the double bond at C2–C3 and the position of the B ring at 2, 
seem to be necessary for the highest anti-inflammatory effect.  
 
 
Fig. 1. Chemical structures of quercetin and luteolin flavonoids. 
Due to the problematic curative therapeutics, preventive therapy may be an alternative 
life-saving therapy in highly allergic individuals prone to anaphylactic shock. It depends 
primarily on optimal management of risk factors, avoidance of allergen and other 
anaphylactic sensitizers (food, insect stings, plants and drugs), and immunomodulation. 
Since induced immunotolerance therapy involving the administration of increasing doses 
of a specific allergen has had limited success, and currently available immunosuppressive 
drugs are not safe enough to be continuously administered as a prophylactic measure, 
new anti-anaphylactic substances are highly needed in the market. In view of the 
enormous diversity of chemicals produced, medicinal plants are particularly interesting 
for the discovery of new anti-allergic agents as the safety of continuous consumption (e.g. 
herbal infusions) is popularly testified. This is the case of the plant Kalanchoe pinnata, 
whose potential use as source of anti-anaphylactic substances is described below in more 
detail.  
3. The Kalanchoe pinnata example 
Kalanchoe pinnata (Kp, syn Bryophyllum pinnatum Kentz., Bryophyllum calycinum Salisb., 
Crassulaceae) (Figure 2), is widely used in folk medicine in the form of infusions, juices and 
compresses to treat rheumatoid arthritis, gastric ulcer and in skin disorders (Lucas and 
Machado, 1946; Lorenzi and Abreu-Matos, 2008). It is native of Madagascar, Kp is now 
found in several countries such as India, China, and Brazil (Allorge-Boiteau, 1996).  
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Fig. 2. Kalanchoe pinnata (Crassulaceae) : Leaves and Inflorescences 
Antiparasitic (anti-leishmania), antibacterial, hepatoprotective and immunomodulatory 
activities have been described for Kp leaf extracts (Da Silva et al. 1995; Akinpelu, 2000; 
Muñoz et al. 2000; Yadav and Dixit, 2003; Rossi-Bergmann et al. 1994; Almeida et al., 2000). 
Exploratory toxicological studies in mice and humans have indicated absence of chronic and 
acute oral toxicity (Torres-Santos et al., 2003, Sousa et al., 2005). The clinical safety of Kp was 
also suggested during a study in 67 pregnant women (25 to 35 weeks of gestation) and their 
neonates (Plangger et al., 2006), corroborating its popular acceptance and pharmaceutical 
potential. 
Kp contains substances belonging to different chemical classes, including: terpenes 
(Siddiqui et al. 1989; Gaind et al., 1972), bufadienolidos (Yamagishi et al., 1989; Supratman 
et al., 2001) and flavonoids (Gaind and Gupta, 1971; Ichikawa, 1986; Muzitano et al., 
2006a, 2006b and 2009). Kp flavonoids are significantly more abundant when the leaves 
are collected during the summer (Muzitano et al., 2011). Quercitrin (quercetin 3-O--L-
rhamnopyranoside), kaempferol 3-O--L-arabinopyranosyl (12)--L-rhamnopyranoside 
(kapinnatoside), quercetin 3-O--L-arabinopyranosyl (12)--L-rhamnopyranoside and 
4’,5-dihydroxy-3’,8-dimethoxyflavone 7-O--D-glucopyranoside were isolated from a 
bioactive flavonoid fraction obtained from a Kp aqueous extract (Muzitano et al., 2006a, 
2006b and 2009).  
3.1 The anti-anaphylactic effect of the aqueous extract of Kalanchoe pinnata 
The anti-anaphylactic activity of the aqueous extract of Kp leaves given orally to ovalbumin 
(OVA)-sensitized mice indicated the potent immunomodulatory action, preferentially 
inhibiting Th2-type immune responses known to be committed with enhanced susceptibility 
to cutaneous leishmaniasis and to allergies (Rossi-Bergmann et al, 1994; Da Silva et al 1999, 
Cruz et al 2008, Gomes et al 2009). Despite the early reports on the antihistaminic activity of 
Kp using the experimental models of isolated guinea pig ileum contraction and 
vasodilatation in rats (Nassis et al, 1992); its fatty acid associated suppressive activity on T 
cells (Rossi-Bergmann et al, 1994, Almeida et al, 2000).), and its Th2-suppressive and iNOS-
suppressive association with oral protection against cutaneous and visceral leishmaniasis 
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(Da-Silva et al, 1995, Da-Silva et al, 1999, Gomes et al. 2009), only recently the therapeutic 
effect of Kp in allergy was more deeply explored.  
The antianaphylactic activity o Kp was studied using a murine model of OVA-induced 
anaphylactic shock. The intraplantar injection of OVA (2.5 mg/kg) into pre-sensitised mice 
elicited a severe systemic anaphylactic response with death occurring within 15 min-30 min 
of allergen challenge. This extreme allergic reaction was effectively prevented with 400 
mg/Kg of oral Kp during the 14-day sensitization process that maintained alive 100% for 
over 48 h of follow-up. Intraperitoneal injections with 200 mg/kg of Kp every other day 
during the same period of time was also effective, but to a lesser extent (80% of survival), 
similar to observed with 12.5 mg/Kg of i.p. cyclosporin A, an immunosuppressive drug also 
having anti-allergic effect. Interestingly, a single i.p. dose of 200 mg/Kg of Kp 3 h prior to 
OVA challenge was sufficient to protect 60% of the animals, suggesting that not only 




Fig. 3. Pre-treatment with Kp prevents fatal anaphylactic shock. BALB/c mice (n=5) were 
sensitized with OVA in adjuvant on days 1 and 7, and were challenged with 50 μg of OVA 
on day 14. During the sensitization period, they were treated as follows: i) by the oral route 
(daily doses of 400 mg/Kg of Kp for 14 days), ii) by the intraperitoneal route (7 doses of 200 
mg/Kg of Kp or 12.5 mg/Kg of Cyclosporin in alternate days; or a single dose of 200 
mg/Kg of Kp 3 h before OVA challenge). Controls were left untreated. Upon challenge on 
day 14, death events were monitored for up to 48 h and recorded as shown. The results are 
expressed as the percentage of surviving animals. *p<0.01 compared to untreated group. 
As allergic parameters, the effect of Kp treatment on the number of circulating eosinophils 
and in allergen-specific IgE response was investigated. The OVA-induced enhanced 
eosinophilia was prevented by Kp, especially in animals receiving multiple oral or i.p. 
doses, although a single i.p. dose of Kp could be effective (Figure 4A). The raised production 
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doses, although a single i.p. dose of Kp could be effective (Figure 4A). The raised production 
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of OVA-specific IgE in sensitized mice was prevented by Kp therapy, particularly in animals 
on the oral regimen (Figure 4B). 
 
    
Fig. 4. Decreased eosinophilia and OVA-specific IgE levels in Kp-treated mice. Mice were 
sensitized and treated with Kp as for Fig. 1. A group of animals was bled 1 h before allergen 
challenge for the percentage of eosinophils in total leukocytes (top) and for individual 
assessment of the serum levels of anti-OVA IgE (bottom). Means±S.D (n=4). *p≤0.05 and 
**p≤0.01 in relation to untreated controls. 
3.2 Quercitrin as an important anti-anaphylactic component of Kalanchoe pinnata 
Like the aqueous extract, the isolated quercitrin flavonoid (Figure 5) was found to to be 
active in mice against cutaneous leishmaniasis caused by Leishmania amazonensis infection 
(Muzitano et al, 2006). Since cutaneous leishmaniasis, like allergy, is a disease driven by 
Th2-type immune responses, quercitrin was tested in the mouse model of OVA-induced 
anaphylactic shock. The animals were treated daily with oral quercitrin during the 14-day 
OVA-sensitization, with a dose 5% of that used with Kp (400 mg/Kg), compatible with its 
content in the aqueous extract. We observed that oral treatment with quercitrin conferred 
resistance to fatal anaphylactic shock in 75% of the animals, as compared with 0% of 
resistance in untreated sensitized animals (Figure 6), suggesting that quercitrin is an 
important anti-anaphylactic component of Kp. 
 
 
Quercitrin: R= O-α-ramnopyranose 
Fig. 5. Chemical structure of quercitrin.  
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To better analyze the modulatory effect on Th2-type T cells, IL-5 and IL-10 cytokines were 
measured in the cell culture supernatants. Treatment of sensitized mice with oral or i.p. Kp 
reduced the capacity of their cells to respond to OVA with IL-5 and IL-10 production (Fig. 
7). The production of TNF-α was also inhibited by Kp treatment, and like IL-10, this effect 
was more pronounced when the i.p. route was used, indicating that cytokines that 
contribute to allergy are down regulated during i.p, and to a lesser extent oral Kp 
treatments. The importance of the TNF-α was confirmed in mice deficient in TNFR1, and 
corroborated with other studies on Ailanthus altissimain and Euphorbia hirta (Table 2). 
  
 
Fig. 6. Pre-treatment with quercitrin partially prevents death due to anaphylactic shock. 
BALB/c mice (n=8) were sensitized as for Fig. 1. During the sensitization period, they were 
daily treated with 20 mg/Kg of quercitrin by the oral route, during 14 days. Controls were 
left untreated. Naive were untreated non-immunized mice. Upon challenge on day 14, death 
events were monitored for up to 90 min and recorded as shown. The results are expressed as 
the percentage of surviving animals. *pb0.01 compared to untreated group. 
The effect of Kp on histamine release by anti-DNP IgE-sensitized mast cells challenged with 
DNP was also investigated, and a significant inhibition of secreted histamine was found in 
cells that were pre-treated with Kp prior to DNP challenge (Fig. 8).  
As mentioned above, cutaneous leishmaniasis and allergy are pathologies associated with 
expanded Th2-type immune responses, and they are benefited from the oral treatment with 
Kp. Although blockade of histamine release may ultimately contribute to the anti-
anaphylactic effect of Kp, it is conceivable that downregulation of Th2-type immune 
responses is more critical for the resistance phenotype. The immunological effects of Kp are 
summarized in Figure 9. 
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Fig. 7. Cytokine production in Kp-treated mice. Lymph nodes were obtained from mice that 
were sensitized and treated with Kp or Cyclosporin A (CyA) as indicated, and the cells 
restimulated in vitro with 1 mg/ml of OVA. After 48 h, the culture supernatants were 
collected for the determination of IL-5, IL-10 and TNF-α levels by ELISA.Means±S.D. (n=5). 
*p≤0.05 and **p≤0.01 in relation to untreated controls. 
 




Fig. 8. Prevention of mast cell histamine release by Kp in vitro. Rat peritoneal mast cells 
were sensitized in vitro with anti-DNP IgE and then incubated with 500 μg/ml of Kp for 30 
min prior to the 1-hour challenge with 50 μg/ml of DNP/BSA. Histamine was measured in 
the supernatants by a fluorimetric assay and expressed as the percentage of total histamine 
in cell lysates. Means±S.D (n=4). 
 
 
E: eosinophil, B: B lymphocyte, TH2: TH2 lymphocyte, Mast: mast cell. 
Fig. 9. Anti-anaphylactic mechanisms of Kp. Anaphylactic shock is mediated by 
immunological mechanisms involving the production of Th2 cytokines (IL-4, IL-5, IL-9 and 
IL-13), the production of antigen-specific IgE antibodies, the recruitment and activation of 
eosinophils (through IL-5) and mast cells. The subsequent contact with antigen causes 
crosslinking of IgE molecules that are linked to the surface of mast cells via Fc RI receptor 
and subsequent degranulation. After crosslinking, there is a systemic release of 
inflammatory mediators that responsible for the symptoms and the severity of anaphylaxis. 
Treatment with aqueous extract of Kp inhibits the production of IgE, the production of IL-
10, IL-5 and TNF- degranulation of mast cells and histamine release. 
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The safety of Kp to humans is substantiated by the fact that it is widely consumed in the 
popular medicine, and that a human case of cutaneous leishmaniasis displayed unaltered 
serum toxicological parameters following oral treatment (Torres-Santos et al, 2003). For its 
effectiveness in mice and expected clinical safeness, quercitrin-containing Kp or quercitrin 
alone are potential candidates for clinical tests aiming at a prophylactic therapy for 
hypersensitive people under the risk of anaphylactic shock. 
Anaphylaxis is a life-threatening allergic condition. Promising preventive measures include 
allergen nonspecific and allergen-specific immunotherapy. A range of plant species, 
including Kalanchoe pinnata, contain promising anti-allergic substances. Flavonoids extracted 
from K. pinnata, particularly quercitrin that down regulate Th2-type immune responses and 
also inflammatory reactions primarily induced by TNF-α, that together lead to overt release 
of histamine and other mediators by mast cells and basophils, culminating with 
anaphylactic shock.  
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1. Introduction  
Allergic diseases affect millions of people around the world. Enhanced prevalence and the 
chronic characteristics of these illnesses represent an important public health problem. Most 
prevalent allergic diseases are classified as immediate-type reactions such as urticaria, 
allergic conjuctivitis, food allergy, allergic rhinitis, anaphylaxis and asthma (Sicherer & 
Leung, 2004; Fonacier et al., 2010; Sicherer, 2011). The immediate-type reaction terminology 
is applied to allergic reactions because the symptoms develop few minutes after allergen 
contact. The immune mechanisms responsible for the initiation of these reactions depend on 
the production of immunoglobulins (IgG1 and/or IgE) that activate cells such as mast cells, 
eosinophils and basophils. Once activated, these cells are responsible for release of 
inflammatory mediators, contributing to the exacerbation and maintenance of the allergic 
processes (Lampinen et al., 2004). Urticaria is characterized by pruritic, edematous and 
erythematous lesions that affect 15% to 25% of individuals during their lives. Most of the 
cases are acute but about 30% of patients present symptoms for more than six weeks and are 
considered as having chronic disease. Women are more susceptible (75%) than men and 
only 1% to 5% of the cases are related to IgE-dependent reaction while most of the cases are 
considered to be induced by physical stimuli or of idiopathic nature, including autoimmune 
urticaria (Antunez et al., 2006). Allergic urticaria depends on skin mast cell activation which 
delivers preformed mediators, mainly histamine, few minutes after allergen exposure. On 
the other hand activated mast cells also produce and deliver neo-formed mediators, i.e., 
prostaglandin D2 (PGD2) and cisleukotrienes (cisLT) that stimulate inflammatory responses 
mediated by neutrophils, basophils, eosinophils and T lymphocytes (Funk, 2001; Harizi et 
al., 2008; Kambe et al., 2010). Another allergic disease of great importance in public health is 
allergic conjunctivitis. Allergic conjuctivities prevalence in the United States was estimated 
to affects about 40 million people. Allergic conjunctivitis is marked by the presence of 
eosinophil cells in conjunctiva mucosa (Bezerra & Santos, 2010). Food allergy, another 
allergic disorder, is related to the genetic susceptibility of individuals to eggs, peanuts, 
seafood (e.g. shrimp, lobsters, crabs, squids and mussels milk and others). Oral sensitization 
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with shrimp tropomyosin induces in mice allergen-specific IgE, T cell response and systemic 
anaphylactic reactions (Capobianco et al, 2008). Food allergy has been reported in some 
cohort studies which describe variable rates of food allergy prevalence in the United States, 
Canada, the United Kindom, Singapore and the Philippines (Berin & Mayer, 2009). 
Approximately 1% of food allergic patients develop signs and symptoms characterized by 
intense diarrhea, urticaria and anaphylaxis. There are divergences about the period of 
exposition to food allergens and development of disease symptoms. Studies showed that 
allergenic food ingested during pregnancy increases the risk of higher prevalence of allergic 
response in infants (Sausenthaler et al., 2011). In contrary to the aforementioned, other 
studies suggested that earlier exposure to food allergens may promote a protective response 
to allergic conditions. Serologic diagnosis of patients with food allergies have demonstrated 
high levels of specific IgE. The pathological immune response observed in these patients 
depended on: (i) the presence of an adjuvant responsible for stimulating inflammatory 
response which is considered one necessary step to initiate lymphocyte responses, (ii) 
allergen doses which can induce classical or alternative mechanisms of allergic process in 
response to food as seen in cutaneous sensitization to food allergens and (iii) the types of 
mediators delivered which can lead to systemic allergic reactions such as anaphilaxis (Berin 
& Mayer, 2009; Sicherer & Leung, 2011). In addition, asthma, which probably may be the 
most important allergic disorder, affects about 300 million people in the world and causes 
an estimated 250,000 deaths annually. This illness is characterized by a reversible lower 
airway inflammation, airway hyperresponsivenss, mucus hypersecretion, leukocyte 
recruitment to lung tissue and airway remodeling that might cause respiratory deficits. 
Increased prevalence and difficulties in asthma control are responsible for the elevated costs 
to health systems around the world (Busse & Lemanski, 2001; Mayr et al., 2003; Bateman et 
al., 2008).  
During asthmatic crises, patients develop an intense breathing difficulty called airway 
hyperreactivity (AHR). This response occurs as a consequence of the exposure of the inhaled 
route to the environmental allergen, thereby increasing the respiratory pause. An array of 
inflammatory mediators such as histamine, cisLT, PGs, cytokines, chemokines and others 
present in the lung tissue elicit smooth muscle cell contraction, mucus production, lung 
inflammation and airway remodeling. Mucus hypersecretion and bronchiole obstructions 
are important features of asthmatic patients. These effects of the inflammatory mediators 
may worsen the respiratory functions. In the last decade studies have shown the 
involvement of some mediators in stimulating the mucus production by cells named globlet 
cells. Concomitant to lung enhanced respiratory pause and lung obstruction, recruitment of 
inflammatory leukocytes to bronchoalveolar space initiates a cellular response that might 
become a destructive response to the lung tissue architecture in a chronic phase of the 
disease. Different leukocytes participate in the inflammatory process in the lung, i.e., 
neutrophils, mononuclear cells and mainly eosinophil cells (Cowden et al., 2010). Similar 
cellular and molecular immunological mechanisms related to asthma are described in 
allergic rhinitis demonstrating a strong correlation between these two allergic disorders 
with the same etiology. Rhinitis is an upper airway allergic inflammation and is considered 
co-morbidity to asthma as several studies have suggested that upper and lower airway 
inflammations are a unique entity. The prevalence of this disease has been increasing in 
many countries and an association between asthma and allergic rhinitis has been shown. 
Although asthma and allergic rhinitis show certain particularities, both present similar 
pathophysiology with IgE-dependent allergic reactions. Another severe IgE-dependent 
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allergic reaction is the anaphylactic shock triggered by allergens such as bee venom, 
domiciliary dust, cockroaches, food, pollen, and/or medicines after mast cell sensitization 
and activation (Bateman et al., 2008). The term ‘anaphylaxis’ was used for the first time by 
Richet and Portier (1902) to describe a potentially fatal reaction that may affect different 
organs and systems and the process by which all the symptoms derived from 
pharmacologic mediators, i.e. histamine, are released by blood leukocytes as eosinophils 
and basophils. Mortality rate of anaphylaxis have been increasing around the world in the 
last decades and at least twenty people die every year in UK due to anaphylactic reactions 
representing one death in three million habitants a year. Although the majority of the cases 
of anaphylactic reactions are related to high levels of IgE and histamine, some patients do 
not present these serum biologic markers, suggesting in these cases an IgE-independent 
mechanisms (Pumphrey, 2004; Moneret-Vautrin & Mertes, 2010; Seidel et al., 2010). 
2. Immune mechanisms for the initiation of allergic reactions 
The allergen sensitization phase is related to multiple factors including gene polymorphisms 
of HLA, FcεRI-β and IL-4 family, environmental factors like vaccination for prevention of 
diseases, pollutants present indoors and outdoors and viral infections. IgE is a critical 
participant in the onset of the effector phase of allergies due to its affinity to receptors 
(FcεRI) present on the surface of mast cells, basophils and/or eosinophils. The cross-linking 
between two IgE molecules and the allergen is responsible for cellular activation and 
subsequent release of preformed mediators, i.e., histamine from the cytoplasmic granules as 
well as neo-formed mediators such as eicosanoids (leukotrienes, prostaglandins and 
thromboxane) (Maddox & Schwartz, 2002). These mediators increase vascular permeability, 
induce smooth muscle contraction causing difficulty in breathing as well as the proliferation 
of fibroblasts and smooth muscle cells (Kanaoka & Boyce, 2004). The IgE production by 
allergen-specific B cells is associated with Th2 cell profile with IL-4, IL-5 and IL-13 
productions. The IL-4 and IL-13 induce in B cells the production of allegen-specific- IgE 
(Munitz et al., 2008) and IL-5 induces the production, activation and differentiation of bone 
marrow-derived eosinophil (Takatsu & Nakajima, 2008). Among the cell types mentioned 
above, mast cells are of fundamental importance in the first phase of allergic disease due to 
their wide distribution throughout the body including skin, lungs and gastrointestinal tract 
(Maurer & Metz, 2005). Recently, some scientific work showed that mast cells are able to 
migrate to the smooth muscles of the airways of asthma patients, corroborating the 
interaction between mediators released by mast cells and smooth muscle response in the 
asthmatic lung (Brightling et al., 2003).  
Another important cell population in the pathophysiology of asthma is the eosinophil. This 
cell participates in the late phase of the inflammatory response and it was initially described as 
a component of defense against intestinal parasites (Gleich et al., 1993; Weller, 1997; 
Rothenberg, 1998). However, there are several lines of evidence that contradicts this view, and 
demonstrate the eosinophils as multifunctional cells involved in the initial processes and 
propagation of various inflammatory diseases. They are also involved in the regulation of 
innate and adaptive immune responses (Rothenberger & Hogan, 2006). Eosinophils can 
respond to different stimuli as nonspecific tissue injury, viral infections, allograft, allergens, 
and tumors. Additionally, these cells release cationic proteins stored in granules as eosinophil 
peroxidase (EPO), major basic protein (MBP), eosinophil cationic protein (ECP) and eosinophil 
derived neurotoxin (EDN). Eosinophils also release a range of cytokines including the Th2 
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profile as well as chemokines RANTES, eotaxin 1 and MIP-1α (Rothenberger & Hogan, 2006). 
Eosinophils participate in many pathological processes such as parasite infections, 
gastrointestinal disorders and allergic processes such as asthma. Several studies have revealed 
the presence of high levels of MBP in bronchoalveolar lavage (BAL) of asthmatic patients that 
induces cytotoxicity to various body tissues, especially the airway epithelium (Rothenberg, 
1998). Additionally, MBP increases the reactivity of airway smooth muscle to cause 
dysfunction of the muscarinic M2 vagal nerve, known to contribute to the development of 
airway hyperreactivity, a key feature of asthma (Jacoby et al., 1993). Several studies have 
demonstrated that eosinophil activation in inflammatory reactions is associated with  
increasing number of lipid bodies (LBs) (Bozza et al., 2011). The LBs are defined as 
cytoplasmatic organelles rich in lipids, surrounded by a phospholipid monolayer, posses high 
amounts of enzymes that produce eicosanoids such as PLA2, 5-LO, 15-LO, COX, LTC4 and 
PGE synthases and also cytokines, chemokines and several kinases related with signal 
transductions. However LBs are found in small quantities in non-activated cells, they are 
associated with a wild range of pathological conditions such as cancers, infectious and 
inflammatory diseases like asthma (Bozza et al., 2009). Several inflammatory mediators are 
able to induce the leukocyte LB formation as platelet activator factor (PAF) (De Assis et al., 
2003). In eosinophils other stimuli such as prostaglandin D2 (PGD2) (Mesquita-Santos et al., 
2006), IL-5 (Bozza et al., 1998), RANTES and eotaxin also induced the LB formation (Vieira-de-
Abreu et al., 2005). In addition, in the allergic inflammation, the new LBs are observed and this 
process is mediated mainly by a cross-talk between eotaxin/RANTES via chemokine receptors 
(CCR3) with MAPK, PI3K and tyrosine kinases activation and PGD2 via an unknown receptor. 
The main site of cisLT generation in eosinophils is the LBs in the pulmonary allergic 
inflammation (Bozza et al., 2009). Moreover, the regulation of allergic reactions is carried out 
by T cells called Th1 cells (Teixeira et al., 2005), which secret cytokines such as IL-2 and INF-γ, 
and by the Th17 cells that produce IL-17. Both profiles can reduce the eosinophil onset in the 
lung and the bronchial hyperreactivity (Schnyder-Candrian, et al. 2006) (Figure 1). 
3. Conventional treatment of allergic diseases 
A wide variety of medicines are used to treat allergic diseases. The 2-adrenergic agonist 
therapy is widely used as first choice for addressing the crisis of asthma (O’Byrne, 2009). 
Phenoterol and salbutamol are members of this group and are largely used to reverse 
bronchoconstriction by binding directly to 2-receptors of lung smooth muscle cells and 
inducing breathing relieve due to bronchodilatation. In vitro studies showed these drugs are 
responsible for increasing the levels of cAMP described as a regulatory second messenger of 
intracellular calcium-dependent mechanisms. Calcium is one of several molecules 
responsible for the smooth muscle contraction during acute phase of asthma crises (Mahn et 
al., 2010). Of note, side effects are observed in patients under 2-agonists therapy, mainly 
cardiac frequency increases in response to activation of cardiac 1-receptors. Potent anti-
inflammatory steroid therapy is also used to control asthma manifestations. These 
medicines are indicated to block lung inflammation mediated by inflammatory leukocytes 
such as neutrophils, eosinophils, basophils and lymphocytes that contribute to exacerbation 
of inflammatory response (Jarjour et al., 2006). As consequence of inflammation, lung tissue 
might present a cell phenotype change, referred to as ‘remodeling’ which impairs the 
physiological lung function causing respiratory deficiency and death in some of asthmatic 
patients.  
Cissampelos sympodialis (Menispermaceae): 




Fig. 1. Mechanism of immediate allergic reactions. Immediate allergic reactions are 
orchestrated by Th2 lymphocytes and its major cytokines (IL-4, IL-5 and IL-13) responsible 
for inducing B cell activation and IgE secretion. Mast cell sensitization depends on IgE cross-
linking and binding with FcRI, subsequent cellular activation, histamine and leukotrienes 
releases that are crucial to bronchospasm induction. Concomitantly, eosinophils migrate to 
bronchoalveolar cavity by an IL-5 (and others) dependent mechanism. Lung damage and 
airway remodeling are caused by cationic proteins delivered by eosinophils and matrix 
extracellular protein deposition.  
Steroidal anti-inflammatory drugs are able to control these pathologic responses in airways 
by inhibition of lymphocyte functions and mainly inducing apoptosis in eosinophils, which 
is considered the major component of lung tissue damage. Steroids also can induce a variety 
of side effects like endocrine alterations, cardiovascular disturbances, psychotic crises and 
cancers (Belvisi, 2004). Combinations of 2-agonists and steroids are commonly used to 
control asthma. Another class of antiasthmatic drug that was developed about 10 years ago, 
the antileukotrienes (Montelukast® and derivatives). These drugs present both 
bronchodilator and anti-inflammatory properties. cisLT are known pro-inflammatory 
mediators and they induce vascular permeability, lung smooth muscle cell 
contraction/bronchospasm and leukocyte activation and chemotaxis (Funk, 2001). Previous 
studies reported cis-LT as the major bronchoconstrictor mediators in an asthmatic lung, 
causing sustained smooth muscle contraction. The anti-leukotriene drugs block leukotriene 
receptors in lung tissue, reversing bronchospasm in asthmatic patients. Additionally, 
leukotriene modifiers like zileutron act by blocking the 5-lipooxygenase enzyme (5-LO), 
thus inhibiting the leukotriene generation. Therefore, anti-leukotriene therapies strongly 
impair airway inflammatory response and ameliorate respiratory function (Terashima, et al. 
2002; Angelova-Fischer & Tsankov, 2005). Antagonists of the enzyme phosphodiesterase, 
aminophylline and theophylline as well as muscarinic blockers also occupy space in the 
therapeutic arsenal.  
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3.1 Immunotherapy of asthma 
Immunotherapy with anti-IgE has also contributed to the treatment of asthma patients who 
do not have a good response to conventional therapies (Lazaar & Panettieri, 2004; Foster et 
al., 2011). Despite anti-IgE therapy, which represents a major breakthrough in the treatment 
of asthma, the high cost of this therapy remains the major obstacle. 
4. Botanical and pharmacological study with Cissampelos sympodialis 
In northeastern Brazil, diseases such as asthma, influenza, bronchitis and rheumatism are 
traditionally treated with infusions of the root bark of Cissampelos sympodialis Eichl 
(Menispemaceae), popularly known in the region as milona, abuteira or orelha de onça 
(Correa, 1984). The Menispermaceae family was described by AL Jussieu (1789). This term is 
an allusion to the morphology of the seed that looks like the fourth form of the moon. This 
species belongs to the order Ranunculales, subdivided by Diels (1910) into eight tribes, three 
subtribes, 72 genera and approximately 400 species. These species are found on all 
continents, especially in tropical and subtropical regions. In Brazil, the Menispermaceae 
family is represented by 12 genera and 106 species distributed mostly in the Amazon forest 
(Barroso, 2004).  
The genus Cissampelos belongs to the tribe Cocculeae, and subtribe Cissampelinae and 
comprises 19 species of which nine occur in Brazil (Rhodes, 1975). This genus is one of the 
few among the angiosperms that shows diversity and uniformity. The diversity can be seen 
in vegetative habitat and leaves. The uniformity is found in the sexual expression of simple 
flowers, pistils and small flowers. In the state of Paraiba the genus Cissampelos is represented 
by three species: Cissampelos ovalifolia DC, Cissampelos glaberrima St. Hill and Cissampelos 
sympodialis Eichl. These species are found in different types of habitat, soil and vegetation, 
occurring mainly in rainforests on the Atlantic coast and hills (Barbosa-Filho et al., 1997). 
The species Cissampelos sympodialis is endemic in Brazil and is found in the Northeast and 
Southeast, from Ceara to Minas Gerais states. This species often occurs in open areas as 
shrubs in sandy soil and can be distinguished mainly by the shape of the deltoid leaves 
(Barbosa-Filho et al., 1997). The roots of Cissampelos sympodialis are widely used by Indian 
tribes and in folk medicine to treat various diseases such as diarrhea, diseases of the 
genitourinary tract and especially in respiratory tract diseases such as asthma (Corrêa, 1984). 
Both alcoholic fraction of roots (AFR) and of leaves (AFL) and some of the chemical 
components (bisbenzylisoquinolinic type alkaloids) isolated from these extracts have been 
studied. These alkaloids have been shown to have paralytic effect, cytotoxic activity 
(Kupchan et al., 1965), to stimulate the central nervous system (Sur & Pradhan, 1964), to 
prevent hypersecretion of reactive products from neutrophils and macrophages (Castranova 
et al., 1991), to inhibit the inflammatory cytokine production by peripheral blood 
mononuclear cells (Onai et al. , 1995) and bronchodilator activity (Thomas et al., 1995). 
Thomas et al (1995) showed that the AFR had a relaxing effect on smooth muscle of trachea 
and increased the cyclic adenosine monophosphate (cAMP) levels from alveolar leukocytes 
in guinea pigs in a manner similar to aminophylline which antagonizes bronchial muscle 
contractions. Similarly, studies of AFL showed inhibition of histamine and ovalbumin 
(OVA)-induced bronchospasm in guinea pigs (Thomas et al., 1997a), synthesis of 
phosphodiesterase (PDE) IV and V in the lungs of mice and induced increased levels of 
cAMP in guinea pig trachea muscle cells (Thomas et al. 1997b). Also AFL had an 
antidepressant effect probably associated with the phosphodiesterases inhibition in rat brain 
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(Almeida et al., 1998), inhibited human neutrophils degranulation (Thomas et al., 1999) and 
induced contraction of vascular smooth muscle (Freitas et al., 2000). 
5. Phytochemical study of Cissampelos sympodialis  
Chemical studies of Cissampelos sympodialis led to the isolation of different alkaloids (Barbosa-
Filho et al., 1997) such as bisbenzylisoquinolinic (warifteine,methilwarifteine, roraimine and 
simpodialine); morfinic (milonin); aporfinic (laurifolin) and oxoaporfinic (liriodenine) which 
have allowed for a more accurate immunopharmacological studies (Freitas et al., 1996, De Lira 
et al., 2002) (Table 1). Analysis of quality control of Cissampelos sympodialis extracts by 
thermogravimetry test showed that both AFL and AFR present alkaloids as major compounds 
and also both extracts showed the same kinetic behavior of bisbenzylisoquinolinic alkaloids 
(Aragão et al., 2002). Among these alkaloids warifteine showed spasmolytic activity by 
modifying various regulatory processes involving intracellular calcium channels and cAMP 
levels, which are essential for muscle contraction (Somlyo & Somlyo, 1994; Freitas et al., 1996). 
Therefore the purpose of our scientific study has been to develop a herbal medicine from the 
leaf extract of Cissampelos sympodialis to treat asthma as an alternative therapy. 
6. Current stage of knowledge of Cissampelos sympodialis 
6.1 Immunological study of Cissampelos sympodialis 
Since the relaxant effect of Cissampelos sympodialis extracts (roots and leaves) on bronchial 
smooth muscle cells (Thomas et al. 1995), inhibition of phosphodiesterases (PDE) IV and V 
in the lung with increased levels of cAMP in muscle cells of the trachea (Thomas et al. 
1997b), biological effects that corroborate with the anti-asthmatic activity of the plant were 
demonstrated, we began the immunological studies. Our research group, with laboratory 
complex located in the Laboratory of Pharmaceutical Technology (LTF), Federal University 
of Paraíba (UFPB), and in collaboration with Federal University of Rio de Janeiro and the 
Oswaldo Cruz Foundation/Rio, Brazil, has systematically studied the immunomodulatory 
effect of Cissampelos sympodialis since 1997. In vivo and in vitro tests have been conducted to 
understand the mechanisms of action of AFL as well as the isolated alkaloid warifteine in 
experimental models of allergy and inflammation. 
6.2 Toxicological study of Cissampelos sympodialis 
Several parameters can be analyzed to demonstrate the toxic potential of a plant (extracts or 
compounds) such as loss of weight, death, anorexia, and change of behavior. Therefore 
toxicological studies showed that the use of AFL in acute treatment was considered nontoxic 
with no deaths among rats after administration at dose of 5 g/kg orally (po) or of 2 g/kg 
intraperitoneally (ip) (Diniz et al., 2004). However AFL chronic treatment caused an 
anorexic effect in female rats and behavioral changes (Almeida et al., 2005).  
The alkaloids warifteine and milonine isolated from C. sympodialis showed cytotoxicity in 
fibroblast cell line (V79) derived from hamster and in hepatocytes of Wistar rats (Melo et al., 
2003). Given the mixed results of acute and chronic treatments in rats, our research group 
began studying the effect of chronic oral treatment (more than 15 days) with AFL into 
inbred BALB/c mice. We observed that this treatment induced weight gain throughout the 
treatment, suggesting lack of toxicity in these experimental animals (Bezerra-Santos et al., 
2004). 
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Structure Compound name References 
Warifteine Barbosa et al., 1997 
Methilwarifteine Barbosa et al., 1997 
Milonine Barbosa et al., 1997 
Laurifoline Alencar, 1994 












































Simpodialine -N-oxide Alencar, 1994 
Liriodenine De Lira et al., 2001 
Table 1. Alkaloids of Cissampelos sympodialis Eichl. 
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6.3 Anti-inflammatory activity of Cissampelos sympodialis 
The inflammatory process is a complex program of intracellular signal transduction and 
transcription events driven by multiple pro-inflammatory mediators and cytokines 
(Sherwood & Toliver-Kinsky, 2004). The acute inflammation is characterized by exudation 
of protein-rich fluid, edema, vasodilation and cell migration, primarily of neutrophils, into 
the site of injury (Sherwood & Toliver-Kinsky, 2004). Investigations on the anti-
inflammatory activity of AFL were performed in experimental models of acute 
inflammation using phlogistic agents in Swiss mice or rats. Prophylactic treatments (before 
the phlogistic administration) demonstrated an AFL inhibitory effect on the ear edema 
formation induced by either TPA (12-O-tetradecanoyl phorbol-13-acetate) or capsaicin in 
Swiss mice (Batista-Lima et al., 2001). The experimental model of edema induced by TPA 
involves the activation of phospholipase A2 and production of prostaglandins and 
leukotrienes while the edema induced by capsaicin involves the release of substance P, 
histamine and eicosanoids such as serotonin and prostaglandins. These mediators are 
produced and released mainly by inflammatory cells such as mast cells, basophils, 
eosinophils and macrophages (Funk, 2001). Based on the anti-inflammatory effect of AFL, 
we inferred that the plant acts on the inflammatory cells by modulating the production of 
mediators. Corroborating this hypothesis was the observation that prophylactic treatment of 
experimental animals (rats) with AFL also showed inhibition of neutrophil migration into 
the intraperitoneal cavity induced by carrageenan (Batista-Lima et al., 2001). The migration 
of neutrophils into the peritoneal cavity of rats induced by carrageenan is dependent on the 
release of eicosanoids and chemotactic agents such as leukotriene B4 and/or IL-8, 
respectively, produced by mast cells and/or resident macrophages (Lefebvre et al., 2010, 
Nakagome & Nagata, 2011). Taken together the results support the hypothesis that AFL 
treatment is modulating cytokines as well as antiinflammatory mediator effects. 
7. Immunomodulatory activity of Cissampelos sympodialis 
7.1 Effect of Cissampelos sympodialis on IL-10 and NO production 
Although eicosanoids and chemotactic agents produced by inflammatory cells are 
responsible for triggering the inflammatory process, these cells are also responsible for 
producing cytokines which control inflammation. IL-10 produced by mononuclear cells has 
been described as a potent regulatory molecule in the inflammatory process (Moore et al., 
2001). Surprisingly, in vitro studies showed, for the first time, that the inhibitory effect of 
AFL on the proliferative response of BALB/c mice spleen cells stimulated with the mitogen 
concanavalin A was associated with the production of IL-4 and IL-10 by these cells 
(Piuvezam et al., 1999). Macrophages are cells that produce IL-10 and from this perspective, 
we investigated the effect of AFL on murine resident and elicited (sodium thioglycollate) 
macrophages. The experimental model used for this purpose was the infection of 
macrophages with trypomastigote form of Trypanosoma cruzi. The AFL treatment induced an 
increase in the release of trypomastigote forms by the cells with increase in IL-10 
production. This phenomenon was shown in both types of macrophages (resident or 
elicited). The AFL was also able to increase the production of IL-10 even in the absence of 
the parasite. In addition, AFL inhibited the NO synthesis induced by interferon-gamma 
(IFN-) and lipopolysaccharide (Ding, et al., 1988; Alexandre-Moreira et al., 2003). 
Therefore these results confirm the effect of AFL in modulating the microbicidal activity of 
macrophages by increasing the IL-10 production as well as inhibition of NO synthesis. 
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Structure Compound name References 
Warifteine Barbosa et al., 1997 
Methilwarifteine Barbosa et al., 1997 
Milonine Barbosa et al., 1997 
Laurifoline Alencar, 1994 












































Simpodialine -N-oxide Alencar, 1994 
Liriodenine De Lira et al., 2001 
Table 1. Alkaloids of Cissampelos sympodialis Eichl. 
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6.3 Anti-inflammatory activity of Cissampelos sympodialis 
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Therefore these results confirm the effect of AFL in modulating the microbicidal activity of 
macrophages by increasing the IL-10 production as well as inhibition of NO synthesis. 
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7.2 Effect of Cissampelos sympodialis on the immunoglobulin production 
B cells are responsible for the production of immunoglobulins (Ig) after antigen recognition 
and activation (Snapper & Paul, 1987; Wong & Koh, 2000). Asthma reaction is an immediate-
type reaction mediated mainly by IgE (Busse & Lemanski, 2001; Mayr, et al., 2003). The 
release of mediators associated with the inflammatory cells to the reaction site induces the 
clinical symptoms of asthma (Maddox & Schwartz, 2002) such as bronchocontraction, 
mucus production and the strangling sensation (Funk, 2001). Based on the asthma 
symptoms and the fact that Brazilian folk medicine has systematically used Cissampelos 
sympodialis to prevent asthma symptoms, several studies have been conducted using the 
experimental model of asthma to demonstrate the AFL effect. The strain of inbred BALB/c 
mice is hypersensitive to ovalbumin (OVA) with the production of OVA-specific IgE, 
pulmonary hyperactivity and mucus production after sensitization and challenge with 
OVA. The chronic oral treatment (15 days before OVA sensitization) with AFL inhibited the  
total OVA-specific IgE production and increased the production of IFN-γ by spleen cells of 
these mice (Bezerra-Santos et al., 2004). Alexandre-Moreira and co-workers (2003) 
demonstrated that AFL inhibited activated B cell function through an increase in 
intracellular cAMP levels. Several studies have identified cAMP as an antagonist of B cell 
proliferation induced by mitogens (Cohen & Rothstein, 1989). Also it was demonstrated that 
cAMP is a second messenger that plays an important role in the regulation of B cell 
apoptosis (Myklebust et al., 1999). In general, an increase in cAMP levels is associated with 
anti-inflammatory and immunosuppressive effects (Cohen & Rothstein, 1989; Wong & Koh, 
2000; Torgersen et al., 2002). Finally, the finding that AFL inhibited immunoglobulin 
secretion suggests a therapeutic use for the Cissampelos sympodialis extract in conditions 
associated with up regulation of B cell function and enhanced immunoglobulin secretion 
such as allergic diseases as well as autoimmune disease. 
7.3 Activity of Cissampelos sympodialis in anaphylactic shock reaction 
Anaphylaxis is a severe allergic reaction and is often fatal. It is mediated by IgE antibodies, 
mast cells and their mediators such as histamine. Medicines, insect bites and certain foods 
can trigger anaphylactic shock in genetically predisposed individuals (Teo et al., 2009; 
Dybendal et al., 2003). To have a better understanding of the effect of AFL treatment in 
allergic reactions, we evaluated the therapeutic potential of the acute treatment (five days 
before sensitization) in experimental model of anaphylactic shock using ovalbumin (OVA) 
challenge. The results demonstrated that AFL treatment was able to inhibit up to 70% death 
of OVA-sensitized mice after 1 hour of the OVA challenge. However, the same treatment 
was not able to inhibit the anaphylactic shock induced by compound 48/80. These data 
show that the effect of the extract is dependent on mechanisms involving IgE production 
(Bezerra-Santos et al., 2005). 
7.4 Eosinophil lipid body inhibition by Cissampelos sympodialis 
LBs are specialized organelles in the synthesis and storage of arachidonic acid derivatives 
such as prostaglandins and leukotrienes, and are present in the cytoplasm of various 
leukocytes and activated eosinophils (Bozza & Viola, 2010). A single treatment with AFL 
inhibited the formation of lipid bodies in eosinophils from mice sensitized and challenged 
with OVA. These results suggest that the extract is capable of modulating the synthesis of 
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inflammatory mediators important in the chemotaxis of inflammatory cells to the lungs 
during asthma attacks, as well as contraction mediators that cause bronchospasm. 
8. Warifteine, a bisbenzylisoquinoline alkaloid from Cissampelos sympodialis 
Warifteine is a major bisbenzylisoquinolinic alkaloid found in AFR as well as AFL. The 
isolated compound is an amorphous yellow crystal and the chemical name is (R)-
2,8,13,13a,14,15,16,25-Octahydro- 18,30- dimethoxy-14 -methyl -4,6:9,12:21,24 -trietheno-3H 
pyrido (3',2':14,15) (1,11) dioxacycloeicosino (2,3,4- ij) isoquinoline-5,19-diol with molecular 
weight of 592.68084 g/mol. Warifteine is insoluble in polar solvents but in acidic conditions 
becomes a water-soluble salt, allowing its in vivo and in vitro analysis without addition of 
other toxic solvents. Warifteine becomes an important compound marker for the extract 
standardization of the plant as well as a candidate for a phytomedicine (Cerqueira-Lima et 
al., 2010). 
8.1 Warifteine inhibits the histamine release 
Allergic reactions trigger organic changes according to body region affected as atopic 
dermatitis (skin), hay fever or rhinitis (upper respiratory tract), asthma (lower respiratory 
tract), food allergy (digestive tract), anaphylactic shock (systemic reaction) (Cavalher-
Machado et al., 2004; Sicherer & Leung, 2011). All of these conditions are consequence of 
sensitized mast cell degranulation which releases several mediators (histamine, CisLT or 
prostaglandins) that cause smooth muscle contraction. Histamine is also of fundamental 
importance in triggering the allergic symptoms such as swelling (Baroody & Naclerio, 2000), 
itching (Davidson & Giesler, 2010), bronchospasm (Larsen, 2001) and anaphylactic shock 
(Valent et al., 2011). Warifteine effect in mast cell degranulation was then investigated. 
Initial findings came from in vitro assays which showed that warifteine was able to relax 
smooth muscle independently of endothelium, i.e., it did not only control the tone muscle in 
vessels but also relaxed the bronchioles muscles (Freitas et al., 1996). Warifteine then 
becomes an important tool in attempting to prevent or reverse the respiratory distress 
occurring during asthmatic attacks (Priel et al., 1994). To evaluate the alkaloid activity on 
mast cell degranulation we used several experimental models. At first OVA-sensitized mice 
were orally treated with warifteine then OVA-challenged in their paws. An inhibition of 
edema formation was observed (Costa et al., 2008). Passively IgE anti-DNP/BSA-sensitized-
paw of rats were treated with warifteine and challenged with DNP/BSA and the results 
demonstrated that the treatment inhibited the hyperalgesia reaction, showing modulation 
among mast cells, vessels and nerves. Mimicking a local allergic reaction like a bee sting, the 
intra dermal administration of the secretagogue compound 48/80 in mice induces mast cell 
degranulation with histamine release and consequently induction of scratching behavior 
(Inagaki et al., 2002). We demonstrated that warifteine treatment inhibited the itching, 
indicating a direct effect in mast cell degranulation (Costa et al., 2008). Mast cells from 
dorsal subcutaneous tissue and peritonea from OVA sensitized rats were cultured with 
warifteine and after OVA challenge the histamine release was measured. The warifteine 
inhibited significantly the histamine release from tissue and peritoneal mast cells in a similar 
manner to sodium cromoglycate (CGS) (Costa et al., 2008). These data indicate that 
warifteine is inhibiting the mast cell degranulation and histamine release. 
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8.2 Warifteine inhibits the B cell functions 
Several models have been employed for analyzing B cell response in vitro. Anti-IgM 
antibodies (Ab) have been used as a model for studying signals induced by binding to B cell 
surface Ig (Mond et al., 1995) and also T-independent type 2 antigens (TI-2), which activate 
B cells through a broad cross-linking of their Toll-like receptors (TLR) (Vos et al., 2000; Peng, 
2005). Warifteine was then analyzed on B cells. It was observed that warifteine inhibited 
both B cell proliferation and Ig secretion induced by TLR ligands (LPS, Pam3Cys and CpG 
oligodeoxynucleotide) or anti-IgM Ab. These effects were not due to a toxicity since 
warifteine neither induced alteration in propidium iodide labeling of fresh spleen B cells or 
modified XTT metabolization by the B cell line A20. Also the inhibitory effect of B cell 
activated with TLR activators or anti-IgM Ab did not modify the total protein 
phosphorylation pattern, however it attenuated the rise in intracellular calcium levels, the 
phosphorylation of mitogen-activated protein kinase (MAPK) ERK and the intracellular 
levels of transcription factor NFκB. Warifteine also increased the cAMP level. In vivo study 
showed that pre-treatment with warifteine inhibited the anti-TNP-ficoll titles in BALB/c 
mice immunized with TI-2 antigen TNP-ficoll (Rocha et al., 2010). Taken together, the data 
showed that the alkaloid present in the AFL of Cissampelos sympodialis is one of the 
compounds responsible for the B cell modulatory effect. 
8.3 Warifteine inhibits the eosinophil activity 
A characteristic feature of asthma is a chronic inflammation with degeneration of bronchial 
epithelium in an eosinophil-dependent mechanism. Eosinophils release cationic proteins, 
chemotactic agents (eotaxin) and eicosanoids (cis-LT) (Ono et al., 2008). The treatments with 
warifteine or AFL inhibited eosinophil migration into the pleural and bronchoalveolar 
cavities of OVA sensitized BALB/c mice. Both warifteine and AFL were also capable of 
inhibiting the secretion of cis-LT and eotaxin, suggesting a role for AFL and its alkaloid in 
controlling the inflammatory process, thus corroborating the belief of an alternative 
treatment for diseases associated with eosinophil activity. 
9. Cellular and molecular therapeutic targets for Cissampelos sympodialis 
Studies performed for 15 years have contributed to the unraveling of part of the 
immunopharmacological mechanisms involved in Cissampelos sympodialis and warifteine 
effects. Figure 2 presents different cellular and molecular therapeutic targets for the plant 
extract and its alkaloid. 
10. Relevance of the proposal for new herbal medicine 
Some allergic diseases of major public health concerns are classified as immediate-type 
hypersensitivity, atopic dermatitis, food allergy, rhinitis, allergic asthma and anaphylactic 
shock. The incidence of allergic asthma is increasing at an alarming rate in developing 
countries like Brazil where around 35% of the population experience allergic diseases 
including asthma (Brazilian Association of Allergy and Immunopathology. 2007). Asthma is 
considered a public health problem. A significant variety of medicines such as bronchodilators 
and potent anti-inflammatory drugs that mitigate the crisis is used to treat asthma but with 
undesirable side effects. Our research group, with multidisciplinary profile, has been studying 
in a systematic way, the plant extracts of Cissampelos sympodialis and its components on  
Cissampelos sympodialis (Menispermaceae): 





Fig. 2. Therapeutic targets for Cissampelos sympodialis. In vitro and in vivo studies showed that 
C. sympodialis induces IL-10 production by macrophages and IFN- production by 
splenocytes from OVA-sensitized mice. Oral treatment with AFL and warifteine inhibited 
OVA-specific IgE serum titer and mononuclear cell proliferation. Also both AFL as well as 
warifteine inhibited neutrophil and eosinophil migration and activation (PDE activity, 
leukotriene generation and lipid body formation) to the pleura and bronchoalveolar cavity 
induced by flogistic stimulus or allergens. Additionally, warifteine inhibited histamine 
delivery by mast cell and attenuated hyperalgesic reaction in rats.  
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experimental models of inflammation and allergy. The accumulated data showed that the 
extracts and its major alkaloid, warifteine, present potent anti-inflammatory effects, prolong 
the time of onset of anaphylactic shock reaction with reduction in allergen-specific IgE 
production, inhibit the inflammatory cell recruitment to the airways, relax airway smooth 
muscle in guinea pigs as well as modulate the production and release of inflammatory 
mediators such as histamine and cytokines. In addition, the great similarity in chemical 
structure among the alkaloids warifteine and milonine of Cissampelos sympodialis with drugs 
traditionally used in therapy: tubocurarine (potent muscle relaxant) and codeine (analgesic, 
antitussive and narcotic) respectively, (Figure 3), justified the popular use of the plant to 











































Fig. 3. Warifteine and tubocurarine are alkaloids that have the same chemical skeleton and 
belong to the class of bisbenzylisoquinoline. Milonine and codeine are alkaloids that have 
the same chemical skeleton and belong to the class of Morphinans. 
11. Why Cissampelos sympodialis has potential as a herbal medicine? 
1. Cissampelos sympodialis is used in folk medicine and by Indian tribes, in Northeast 
Brazil, for the treatment of disorders of airways such as asthma and rhinitis. 
2. The preclinical data showed low or no toxicity on oral administration of the extract 
depending on the animal model used. 
3. Studies of mechanisms of action of the extract have demonstrated efficacy in reduction 
of pathophysiological characteristics of allergic diseases associated with chronic 
inflammations such as asthma. 
4. The leaf extract of the plant presents milonine, which is a morphinic alkaloid with a 
codeine-like chemical structure. Codeine is a classic drug with antitussive and analgesic 
properties. 
5. Warifteine, one of the major alkaloids of the plant, presented similar effect of the extract 
in reducing asthma pathological profile. 
6. Chemical structure of warifteine is similar to the tubocurarine chemical structure. 
Tubocurarine is a classic drug with muscle relaxant property. 
7. Warifteine can be used as a molecular marker for the standardization of herbal 
medicine. 
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experimental models of inflammation and allergy. The accumulated data showed that the 
extracts and its major alkaloid, warifteine, present potent anti-inflammatory effects, prolong 
the time of onset of anaphylactic shock reaction with reduction in allergen-specific IgE 
production, inhibit the inflammatory cell recruitment to the airways, relax airway smooth 
muscle in guinea pigs as well as modulate the production and release of inflammatory 
mediators such as histamine and cytokines. In addition, the great similarity in chemical 
structure among the alkaloids warifteine and milonine of Cissampelos sympodialis with drugs 
traditionally used in therapy: tubocurarine (potent muscle relaxant) and codeine (analgesic, 
antitussive and narcotic) respectively, (Figure 3), justified the popular use of the plant to 











































Fig. 3. Warifteine and tubocurarine are alkaloids that have the same chemical skeleton and 
belong to the class of bisbenzylisoquinoline. Milonine and codeine are alkaloids that have 
the same chemical skeleton and belong to the class of Morphinans. 
11. Why Cissampelos sympodialis has potential as a herbal medicine? 
1. Cissampelos sympodialis is used in folk medicine and by Indian tribes, in Northeast 
Brazil, for the treatment of disorders of airways such as asthma and rhinitis. 
2. The preclinical data showed low or no toxicity on oral administration of the extract 
depending on the animal model used. 
3. Studies of mechanisms of action of the extract have demonstrated efficacy in reduction 
of pathophysiological characteristics of allergic diseases associated with chronic 
inflammations such as asthma. 
4. The leaf extract of the plant presents milonine, which is a morphinic alkaloid with a 
codeine-like chemical structure. Codeine is a classic drug with antitussive and analgesic 
properties. 
5. Warifteine, one of the major alkaloids of the plant, presented similar effect of the extract 
in reducing asthma pathological profile. 
6. Chemical structure of warifteine is similar to the tubocurarine chemical structure. 
Tubocurarine is a classic drug with muscle relaxant property. 
7. Warifteine can be used as a molecular marker for the standardization of herbal 
medicine. 
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1. Introduction  
Anaphylaxis is a life-threatening and systemic disorder that involves several organs and 
may lead to death. It is believed to be mostly triggered by release of mediators from 
activated mast cells, basophils and macrophages after allergen exposure. There are two 
major types of anaphylactic mechanisms: classical and alternative anaphylactic pathways. 
Classical anaphylactic pathway is triggered by cross-linking of IgE bound to FcRI, high 
affinity IgE receptors, on mast cell and basophil surfaces to release pre-formed vasoactive 
amines (e.g. histamine), lipid mediators and neutral proteases from secretory granules upon 
allergen exposure. The alternative anaphylactic pathway is an IgE-independent mechanism 
and involves basophils and macrophages. Upon allergen exposure, IgG-immune complexes 
binds to FcRIII, low affinity activating IgG receptor, and subsequent release PAF (platelet 
activating factor), but not histamine as major mediator. The understanding of immune 
mechanisms on triggering anaphylaxis is crucial for understanding how to manipulate the 
immune system to find better therapeutic interventions. 
 Helminth infection and their products have been demonstrated as potential therapeutic 
interventions in inflammatory disorders. Helminths use several imunomodulatory strategies 
to evade and/or modify the host immune response in order to survive in the host, including 
suppression or inactivation of host antigen-specific immune response. The modulation of 
the immune system has been considered beneficial for both host and parasites since it could 
avoid helminth eradication and protect the host from inflammatory responses which may 
damage host’s tissues and organs. Several helminth immunomodulatory molecules and 
strategies have been identified and reported, such as eotaxin metalloproteinase, calreticulin, 
antioxidants and neutrophil inhibitory factor. They interfere with antigen processing and 
presentation, cell proliferation, cause T cell death, decrease IgE responses, reduce B cell 
activation and stimulate regulatory T cells. Therefore, these immunomodulatory factors can 
affect both the inductive and effector immune response, being suitable to modulate the 
inflammatory, allergic and anaphylactic responses. 
Our studies have been focused in the immunossuppressive responses induced by 
roundworms Ascaris suum infection and a protein secreted by these worms named PAS-1 
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(protein from Ascaris suum). We have demonstrated that PAS-1 suppresses LPS-induced 
inflammation due to stimulating the secretion of IL-10 and TGF-. Furthermore, PAS-1 was 
demonstrated suppressing B and T cell responses against OVA. Besides playing a down-
modulatory effect in inflammatory responses induced by unrelated antigens, PAS-1 
suppresses the acute and chronic lung allergic inflammation induced by APAS-3 (allergenic 
protein from Ascaris suum). In OVA/alum lung inflammation model, PAS-1 down-
modulates the lung inflammatory response due CD4+CD25+FoxP3+ cells and CD8+TCR+ 
cells, which secretes IL-10/TGF- and IFN-, respectively. In chronic lung inflammation 
model using OVA/alum or alum/APAS-3, besides inhibiting the inflammation into the 
lungs, PAS-1 also inhibits the airway remodeling by decreasing the activity of 
metaloproteinases and the production of angiogenic factors (IL-13 and VEGF). Taken 
together, these findings demonstrated that PAS-1 inhibits both acute and chronic lung 
inflammation in mouse models.  
The understanding of immune modulatory mechanisms that control anaphylactic responses 
is critical to investigate therapeutic interventions for anaphylactic inflammatory disorders. 
The purpose of this chapter is to discuss the mechanisms triggered by allergic and 
anaphylactic reactions and potential therapeutic strategies using helminth products. 
2. Immune responses triggered by anaphylactic reactions  
2.1 Concept of anaphylaxis 
Anaphylaxis is a systemic and immediate hypersensitivity with multi-organ system 
involvement that can progress potentially to a life-threatening reaction causing thousands 
deaths in the world. The term anaphylaxis was named by Dr Charles Robert Richet, a Nobel 
laureate in Physiology or Medicine in 1913. In 1902, Richet and his colleague Paul Portier 
reported that dogs immunized with non-lethal dose of sea anemone venom display fatal 
reactions to the second injection of the venom even in small doses. Shibasaburo Kitasato and 
Emil von Behring had previously demonstrated that animals immunized with bacterial 
toxins are able to produce anti-toxins (neutralizing antibodies). Since then, this phenomenon 
was named anaphylaxis, which term is derived from the Greek words “a-” (against) and “–
phylaxis” (protection). 
Anaphylaxis can occur following exposure to several allergen sources including food 
allergens, aeroallergens, venoms, drugs and vaccination. The most common symptoms 
include itching, erythema and urticaria after the exposure to allergens. The most severe 
cases of anaphylaxis involve cardiovascular and respiratory system with drop of cardiac 
pressure, bronchoconstriction, laryngeal edema and shock (Brown, 2004). The 
gastrointestinal system may be also involved featuring vomiting, abdominal pain and 
diarrhea. The central nervous system can be affected leading to a felling of impending doom 
and lack of consciousness related to hypotension and hypoxia. Once the anaphylactic 
reactions occur rapidly, an effective treatment (usually epinephrine injection) may avoid the 
occurrence of severe symptoms (Simons et al., 2003). Thus, it is crucial to understand the 
molecular mechanisms involved on anaphylactic reactions for strategically managing the 
risk and preventing recurrence. 
2.2 Types of anaphylactic reactions 
Anaphylaxis occurs due to release of vasoactive and inflammatory mediators from mast 
cells, basophils and macrophages upon allergen exposure. When antigens cross-link FcRI-
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bound IgE or bind to IgGs, which are found as IgG-immune complexes attached to FcRs, 
mainly FcRIII, a signaling cascade is trigger to promote release of mediators which cause 
smooth muscle contraction and increase vascular permeability, leading to laryngeal edema 
(which may cause respiratory difficulty), hypotension, urticaria, abdominal muscular 
contraction, diarrhea (Ewan, 1998). It is reported that anaphylactic reactions in rodent 
models are induced by two different pathways: classical and alternative anaphylactic 
pathways (Figure 1). 
 
 
Fig. 1. Classical and alternative anaphylactic pathways. In the classical anaphylactic 
pathway, cross-linking among IgE-bound FcRI and specific antigen leads to mast cell and 
basophil degranulation and secretion of histamine as major mediator. In the alternative 
anaphylactic pathway, IgG-immune complexes bind to FcRIII on basophil and macrophage 
surfaces, triggering the secretion of PAF as major mediator. Basophils also secrete IL-4 that 
is crucial for IgE class-switching. 
Classical anaphylactic pathway is triggered by cross-linking of antigen and antigen-specific 
IgE bound to FcRI on mast cell and basophil surfaces, which stimulates these cells to 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
500 
(protein from Ascaris suum). We have demonstrated that PAS-1 suppresses LPS-induced 
inflammation due to stimulating the secretion of IL-10 and TGF-. Furthermore, PAS-1 was 
demonstrated suppressing B and T cell responses against OVA. Besides playing a down-
modulatory effect in inflammatory responses induced by unrelated antigens, PAS-1 
suppresses the acute and chronic lung allergic inflammation induced by APAS-3 (allergenic 
protein from Ascaris suum). In OVA/alum lung inflammation model, PAS-1 down-
modulates the lung inflammatory response due CD4+CD25+FoxP3+ cells and CD8+TCR+ 
cells, which secretes IL-10/TGF- and IFN-, respectively. In chronic lung inflammation 
model using OVA/alum or alum/APAS-3, besides inhibiting the inflammation into the 
lungs, PAS-1 also inhibits the airway remodeling by decreasing the activity of 
metaloproteinases and the production of angiogenic factors (IL-13 and VEGF). Taken 
together, these findings demonstrated that PAS-1 inhibits both acute and chronic lung 
inflammation in mouse models.  
The understanding of immune modulatory mechanisms that control anaphylactic responses 
is critical to investigate therapeutic interventions for anaphylactic inflammatory disorders. 
The purpose of this chapter is to discuss the mechanisms triggered by allergic and 
anaphylactic reactions and potential therapeutic strategies using helminth products. 
2. Immune responses triggered by anaphylactic reactions  
2.1 Concept of anaphylaxis 
Anaphylaxis is a systemic and immediate hypersensitivity with multi-organ system 
involvement that can progress potentially to a life-threatening reaction causing thousands 
deaths in the world. The term anaphylaxis was named by Dr Charles Robert Richet, a Nobel 
laureate in Physiology or Medicine in 1913. In 1902, Richet and his colleague Paul Portier 
reported that dogs immunized with non-lethal dose of sea anemone venom display fatal 
reactions to the second injection of the venom even in small doses. Shibasaburo Kitasato and 
Emil von Behring had previously demonstrated that animals immunized with bacterial 
toxins are able to produce anti-toxins (neutralizing antibodies). Since then, this phenomenon 
was named anaphylaxis, which term is derived from the Greek words “a-” (against) and “–
phylaxis” (protection). 
Anaphylaxis can occur following exposure to several allergen sources including food 
allergens, aeroallergens, venoms, drugs and vaccination. The most common symptoms 
include itching, erythema and urticaria after the exposure to allergens. The most severe 
cases of anaphylaxis involve cardiovascular and respiratory system with drop of cardiac 
pressure, bronchoconstriction, laryngeal edema and shock (Brown, 2004). The 
gastrointestinal system may be also involved featuring vomiting, abdominal pain and 
diarrhea. The central nervous system can be affected leading to a felling of impending doom 
and lack of consciousness related to hypotension and hypoxia. Once the anaphylactic 
reactions occur rapidly, an effective treatment (usually epinephrine injection) may avoid the 
occurrence of severe symptoms (Simons et al., 2003). Thus, it is crucial to understand the 
molecular mechanisms involved on anaphylactic reactions for strategically managing the 
risk and preventing recurrence. 
2.2 Types of anaphylactic reactions 
Anaphylaxis occurs due to release of vasoactive and inflammatory mediators from mast 
cells, basophils and macrophages upon allergen exposure. When antigens cross-link FcRI-
Derived Products of Helminth in  
the Treatment of Inflammation, Allergic Reactions and Anaphylaxis 
 
501 
bound IgE or bind to IgGs, which are found as IgG-immune complexes attached to FcRs, 
mainly FcRIII, a signaling cascade is trigger to promote release of mediators which cause 
smooth muscle contraction and increase vascular permeability, leading to laryngeal edema 
(which may cause respiratory difficulty), hypotension, urticaria, abdominal muscular 
contraction, diarrhea (Ewan, 1998). It is reported that anaphylactic reactions in rodent 
models are induced by two different pathways: classical and alternative anaphylactic 
pathways (Figure 1). 
 
 
Fig. 1. Classical and alternative anaphylactic pathways. In the classical anaphylactic 
pathway, cross-linking among IgE-bound FcRI and specific antigen leads to mast cell and 
basophil degranulation and secretion of histamine as major mediator. In the alternative 
anaphylactic pathway, IgG-immune complexes bind to FcRIII on basophil and macrophage 
surfaces, triggering the secretion of PAF as major mediator. Basophils also secrete IL-4 that 
is crucial for IgE class-switching. 
Classical anaphylactic pathway is triggered by cross-linking of antigen and antigen-specific 
IgE bound to FcRI on mast cell and basophil surfaces, which stimulates these cells to 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
502 
degranulate and release histamine, serotonin, lipid mediators (such as leukotrienes) and 
cytokines (such as IL-4, TNF, IL-1, VEGF) (Kumar & Sharma, 2010). Strait et al. (2003) have 
demonstrated that IgE-mediated anaphylaxis depends on IL-4/IL-4R, mast cells, FcRI, 
IgE, histamine and H1 receptor but does not depend on macrophages, serotonin and 
leukotrienes. Alternative anaphylactic pathway is triggered by IgG-immune complexes 
bound to FcRIII on basophils and macrophages, causing release of PAF (Mukai et al., 2009). 
2.3 Cells involved in anaphylactic reactions 
2.3.1 Mast cells 
Mast cells were identified by Paul Ehrlich in 1879 (reviewed in Beaven, 2009) as cells present 
in connective tissues that reacts metachromatically with aniline dyes. He named them 
Mastzellen due the presence of granules that he believed to have a nutritional role on this cell 
type (the word mast denotes fattening in German). Mast cells are generated from bone 
marrow immature cells that migrate to skin and intestine and differentiate into connective 
tissue mast cells and mucosal mast cells, respectively (Arinobu et al., 2005; Galli et al., 2005). 
Stem cell factor (SCF or c-kit ligand) and c-kit play an important role in the growth and 
differentiation of mast cells, which express c-kit constitutively at all stages of differentiaton 
(Hu et al., 2007). They serve as important effector cells of the innate immune system along 
with other cell types (i.e. macrophages, dendritic cells, neutrophils, NK cells).  
In anaphylactic reactions, mast cells are the effector cells in triggering the classical 
anaphylactic pathways. They express constitutively FcRI, high affinity IgE receptor, which 
are usually bound to monomeric IgE upon antigen exposure. This receptor-IgE complex is 
cross-linked with multivalent antigens that consequently stimulate the release of effector 
mediators such as histamine, lipid mediators, and cytokines, which are pre-formed and 
stored in secretory granules of mast cells (Kumar & Sharma, 2010; Kemp & Lockey, 2002). 
These mediators act on many cellular types, including vascular endothelial cells and 
bronchial smooth muscle, inducing anaphylactic manifestations such as hypotension and 
dyspnea (Winbery & Lieberman, 2002).  
2.3.2 Basophils 
Similarly to mast cells, basophils were identified as cells that present metachromatic granules 
in the cytoplasm. Unlike human, mouse basophils are exceptionally rare (Urbina et al., 1981). 
They are the least common circulating cells that comprise less than 1% of total circulating 
granulocytes and are not normally present in tissues although are recruited to inflammatory 
sites. Basophils may contribute to IgE-mediated allergic inflammation and IgG1-mediated 
systemic anaphylaxis (Mukai et al., 2005; Tsujimura et al, 2008). They arise from bone marrow 
progenitors and complete their terminal differentiation in bone marrow (Arinobu et al., 2005).  
Basophils constitutively express FcRI, high affinity IgE receptor, and upon cross-linking of 
FcRI-bound IgE with specific antigen, they release effector mediators such as histamine, 
leucotrienes, PAF and Th2 cytokines (IL-4, IL-5, IL-13) and TSLP (thymic stromal 
lymphopoietin) in response to protease allergens, causing immediate type hypersensitivity 
(Min, 2008). Mukai et al. (2009) have reported basophils as one of the major players in the 
IgG- but not IgE-mediated systemic anaphylaxis although basophils may function as 
initiator of allergic inflammation. Experiments from Tsujimura et al. (2008) demonstrated 
that mice passively transferred with anti-PenicillinV (PenV) monoclonal IgG1 antibody and 
challenged with PenV-conjugated BSA as allergen presented high drop of body temperature 
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in both mast cell sufficient or deficient mice. They found that mainly basophils captured 
IgG1-immune complexes (they possessed highest amount of allergen per cell in comparison 
with other cell types), the binding was greatly inhibited by treatment with anti-
FcRIIb/FcRIII antibody (against low affinity FcRs), and they secrete high amount of PAF 
when stimulated by IgG1-immune complexes, indicating basophils as a good candidate to 
trigger IgG1-mediated anaphylatic reactions.  
Besides their function as effector cells in IgG1-mediated anaphylaxis, basophils play a crucial 
role as early secretor of IL-4 that is essential to the development of anaphylactic reactions due 
to promoting class-switching to IgE. Sokol et al. (2008) have demonstrated that basophils are 
crucial for the initiation of Th2 cells in response to papain, a cystein protease, which activity is 
commonly found in most allergenic proteins. In addition, other findings reported that naïve 
CD4+ T cells stimulated with peptide-pulsed DCs could develop into Th2 cells when co-
cultured with basophils from wild type mice but not IL-4-deficient mice (Oh et al, 2007), 
enforcing the role of basophils as early source of IL-4 in the immune responses.  
2.3.3 Macrophages 
Macrophages are long lived cells that function as a first line of defense in the body. These 
cells serve as early detector of invading pathogens through PAMPs, as antigen-presenting 
cells which initiate the immune responses, as effector cytotoxic cells to kill directly 
pathogens and also they play a role as regulatory and suppressor cells in parasitic infections 
and tumor-bearing hosts (Gordon, 2003). They arise from monocytes which are released in 
the blood stream and migrate to tissues to differentiate in macrophages or dendritic cells 
according to the stem cell factors milieu (Geissmann et al., 2010). 
Macrophages have been involved in the development of IgG-dependent anaphylactic pathway 
(Oettgen et al., 1994; Miyajima et al., 1997; Strait et al., 2002). Passive immunization with 
allergen-specific monoclonal IgG1 antibody induce systemic anaphylaxis upon allergen 
exposure but this effect can be neutralized by treatment with anti-FcRIIb/FcRIII monoclonal 
antibodies (against low affinity FcRs) and after depletion of macrophages with gadolinium 
(Strait et al, 2002), indicating the participation of macrophages in triggering IgG1-mediated 
anaphylactic reactions. Although platelets and neutrophils have been implicated in IgG-
dependent anaphylaxis (Pinckard et al., 1977; Kimura et al., 1997), Strait et al. (2002) found in 
their studies that the techniques used for platelets and neutrophil depletion may inhibit IgE-
independent anaphylaxis by producing immune complexes that desensitize macrophages, 
mimicking these cells as contributors of FcRIII-dependent anaphylaxis.  
Macrophages along with basophils also contribute to IgG-mediated anaphylaxis by releasing 
PAF upon antigen exposure. It has been demonstrated that the injection of anti-
FcRIIb/FcRIII stimulates macrophages to release PAF by cross-linking FcRIII on these cells 
and also inhibits IgG-dependent anaphylactic responses to antigen by blocking IgG-immune 
complex activation of macrophages through FcRIII (Ujike et al., 1999; Strait et al., 2002). 
2.4 Mediators involved in classical and alternative anaphylactic reactions 
2.4.1 IgE and FcRI 
Ishizaka & Ishizaka (1976) discovered a new class of antibodies capable of transferring 
sensitivity to allergens. IgE antibodies are considered major players in allergic disorders 
such as anaphylaxis, asthma, atopic dermatitis, food allergy (Oettgen & Geha, 1999). It is 
considered the only antibody involved in classical anaphylactic reactions. It is also 
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degranulate and release histamine, serotonin, lipid mediators (such as leukotrienes) and 
cytokines (such as IL-4, TNF, IL-1, VEGF) (Kumar & Sharma, 2010). Strait et al. (2003) have 
demonstrated that IgE-mediated anaphylaxis depends on IL-4/IL-4R, mast cells, FcRI, 
IgE, histamine and H1 receptor but does not depend on macrophages, serotonin and 
leukotrienes. Alternative anaphylactic pathway is triggered by IgG-immune complexes 
bound to FcRIII on basophils and macrophages, causing release of PAF (Mukai et al., 2009). 
2.3 Cells involved in anaphylactic reactions 
2.3.1 Mast cells 
Mast cells were identified by Paul Ehrlich in 1879 (reviewed in Beaven, 2009) as cells present 
in connective tissues that reacts metachromatically with aniline dyes. He named them 
Mastzellen due the presence of granules that he believed to have a nutritional role on this cell 
type (the word mast denotes fattening in German). Mast cells are generated from bone 
marrow immature cells that migrate to skin and intestine and differentiate into connective 
tissue mast cells and mucosal mast cells, respectively (Arinobu et al., 2005; Galli et al., 2005). 
Stem cell factor (SCF or c-kit ligand) and c-kit play an important role in the growth and 
differentiation of mast cells, which express c-kit constitutively at all stages of differentiaton 
(Hu et al., 2007). They serve as important effector cells of the innate immune system along 
with other cell types (i.e. macrophages, dendritic cells, neutrophils, NK cells).  
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are usually bound to monomeric IgE upon antigen exposure. This receptor-IgE complex is 
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These mediators act on many cellular types, including vascular endothelial cells and 
bronchial smooth muscle, inducing anaphylactic manifestations such as hypotension and 
dyspnea (Winbery & Lieberman, 2002).  
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lymphopoietin) in response to protease allergens, causing immediate type hypersensitivity 
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IgG- but not IgE-mediated systemic anaphylaxis although basophils may function as 
initiator of allergic inflammation. Experiments from Tsujimura et al. (2008) demonstrated 
that mice passively transferred with anti-PenicillinV (PenV) monoclonal IgG1 antibody and 
challenged with PenV-conjugated BSA as allergen presented high drop of body temperature 
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in both mast cell sufficient or deficient mice. They found that mainly basophils captured 
IgG1-immune complexes (they possessed highest amount of allergen per cell in comparison 
with other cell types), the binding was greatly inhibited by treatment with anti-
FcRIIb/FcRIII antibody (against low affinity FcRs), and they secrete high amount of PAF 
when stimulated by IgG1-immune complexes, indicating basophils as a good candidate to 
trigger IgG1-mediated anaphylatic reactions.  
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to promoting class-switching to IgE. Sokol et al. (2008) have demonstrated that basophils are 
crucial for the initiation of Th2 cells in response to papain, a cystein protease, which activity is 
commonly found in most allergenic proteins. In addition, other findings reported that naïve 
CD4+ T cells stimulated with peptide-pulsed DCs could develop into Th2 cells when co-
cultured with basophils from wild type mice but not IL-4-deficient mice (Oh et al, 2007), 
enforcing the role of basophils as early source of IL-4 in the immune responses.  
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and tumor-bearing hosts (Gordon, 2003). They arise from monocytes which are released in 
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Macrophages have been involved in the development of IgG-dependent anaphylactic pathway 
(Oettgen et al., 1994; Miyajima et al., 1997; Strait et al., 2002). Passive immunization with 
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exposure but this effect can be neutralized by treatment with anti-FcRIIb/FcRIII monoclonal 
antibodies (against low affinity FcRs) and after depletion of macrophages with gadolinium 
(Strait et al, 2002), indicating the participation of macrophages in triggering IgG1-mediated 
anaphylactic reactions. Although platelets and neutrophils have been implicated in IgG-
dependent anaphylaxis (Pinckard et al., 1977; Kimura et al., 1997), Strait et al. (2002) found in 
their studies that the techniques used for platelets and neutrophil depletion may inhibit IgE-
independent anaphylaxis by producing immune complexes that desensitize macrophages, 
mimicking these cells as contributors of FcRIII-dependent anaphylaxis.  
Macrophages along with basophils also contribute to IgG-mediated anaphylaxis by releasing 
PAF upon antigen exposure. It has been demonstrated that the injection of anti-
FcRIIb/FcRIII stimulates macrophages to release PAF by cross-linking FcRIII on these cells 
and also inhibits IgG-dependent anaphylactic responses to antigen by blocking IgG-immune 
complex activation of macrophages through FcRIII (Ujike et al., 1999; Strait et al., 2002). 
2.4 Mediators involved in classical and alternative anaphylactic reactions 
2.4.1 IgE and FcRI 
Ishizaka & Ishizaka (1976) discovered a new class of antibodies capable of transferring 
sensitivity to allergens. IgE antibodies are considered major players in allergic disorders 
such as anaphylaxis, asthma, atopic dermatitis, food allergy (Oettgen & Geha, 1999). It is 
considered the only antibody involved in classical anaphylactic reactions. It is also 
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associated with protective immunity to parasitic infections (Capron et al., 1982). IgE consists 
of two identical heavy chains and two light chains with variable (V) and constant (C) 
regions and no hinge region which makes IgE to be less flexible. The -heavy chains contain 
one variable heavy chain and four constant region domains (C1-4) (Williams & Barclay, 
1988) and are highly glycosylated (Arnold et al., 2007). IgE is the less abundant antibody 
class in serum with normal concentration of 50-200 ng/mL in nonallergic individuals 
(Gould et al., 2003). Even during helminth infections or allergic reactions, human serum IgE 
levels are lower than serum IgG levels; IgG peaks at around 30 µg/mL whereas IgG4 peaks 
at around 680 µg/mL (Bell, 1996). IgE has the shortest half-life of all immunoglobulins. Its 
half-life is about 3 days in serum (Iio et al., 1987), 16 hours on cells in suspension (Ishizaka & 
Ishizaka, 1971) and 2 weeks in tissues when is receptor-bound on cell surfaces (Geha et al., 
1985). Its production requires class-switching from IgM, often via IgG to IgE by somatic 
recombination of germline genes in B cells“, which depends on Th2 cytokines (IL-4/IL-13) 
and CD40 ligation (Poulsen & Hummelshoj, 2007). 
It has been identified three IgE receptors in human (FcRI(2 and 2), galectin-3 and 
FcRII) and four receptors in mice (FcRI(2 and 2), galectin-3, FcRII and FcRIV). 
Most of IgE bind to high affinity IgE receptor (FcRI) that is present in mast cells, basophils 
(Gould et al., 2003) and antigen-presenting cells e.g. Langerhans cells (Bieber et al., 1992). 
FcRI has a central role in mediating the allergic disorders (Kinet, 1999). Cross-linking of 
FcRI associated to IgE with specific antigens induces the release of preformed mediators, 
newly formed lipid mediators and de novo synthesis of cytokines that potentially mediate 
anaphylactic reactions or prolonged allergic inflammation. FcRI shares a common 
oligomeric structure, comprising a ligand binding immunoglobulin-like -subunit 
associated to a -subunit and two -subunits (Daeron, 1997). It binds stably monomeric IgE 
on mast cell surface (Kd  10-10 M). The extracellular domain of -subunit is glycosilated 
which seem to be crucial to appropriate maturation during FcεRI traffic through 
endoplasmic reticulum (Fiebiger et al., 2005) although is not required for monomeric IgE 
binding (Garman et al., 1999). The β- and -subunits bear ITAM (immunoreceptor tyrosine-
based activation motif) that is phosphorylated in tyrosine residues by Lyn after cross-linking 
of FcεRI (Honda et al., 2000). The β-subunit possesses four transmembrane domains and the 
C-terminal domain has an ITAM motif. The -subunit belongs to T cell receptor (TCR) ( gene 
family and is associated to Fc receptors including FcRI, FcRIIA, FcRI (Takai, 2005). Other 
variant of FcεRI is constituted only by three chains (one -subunit and two -subunits) that 
are expressed in monocytes, macrophages and neutrophils (Gould & Sutton, 2008). The low 
affinity IgE receptor (FcεRII) or CD23 is expressed in several cell types including B cells, 
activated T cells, monocytes, eosinophils, platelets, follicular dendritic cells, and thymic 
epithelial cells. CD23 facilitates the antigen presentation to T cells upon binding to IgE-
antigen complex and also plays a role as negative regulator of IgE production (Gould & 
Sutton, 2008). Another IgE receptor is galectin-3 or ε-binding protein, which has been 
reported to be involved in neutrophil activation (Truong et al., 1993). In mice, it has been 
found a fourth type of IgE receptor, FcRIV, which binds IgE-immune complexes on 
macrophage surface, inducing lung inflammation (Mancardi et al., 2008).  
2.4.2 IgG and FcRIII 
IgG antibodies were identified by Tiselius and Kabat in 1939. They immunized rabbits with 
ovalbumin and fractionated the immune serum by electrophoresis into albumin, -globulin, 
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β-globulin and -globluin fractions. The fact that this rabbit serum binds to ovalbumin -
globulin fraction named the immune factor present in rabbit sera as immunoglobulin(Ig) or 
IgG (Tiselius & Kabat, 1939). Classically, there are four types of IgG subclasses in humans 
(IgG1-IgG4) and mice (IgG1, IgG2a, IgG2b, and IgG3). They are the most predominant 
antibody isotype (70-75% of total IgG) in the blood and extravascular compartiments. Four 
different types of FcRs have been identified in mice (FcRI, FcRIIb, FcRIII, and FcRIV). 
The human and primates FcRs have several allelic variants that codify six types of FcRs: 
FcRI, FcRIIa, FcRIIc, FcRIIb, FcRIIIa, FcIIIb.  
Traditionally, these receptors belong to two different categories – they are classified in high 
or low affinity FcRs according IgG affinity to them, and in activating or inhibitory FcRs if 
the type of signaling pathway is triggered by ITAMs (immunoreceptor tyrosine-based 
activation motif) or ITIMs (immunoreceptor tyrosine-based inhibitory motif). Then, FcRI is 
high affinity, activating FcRs in both mice and humans; FcRIII and FcRIV (in mice) and 
FcRIIa, FcRIIc, FcRIIIa, FcRIIIb (in human) are categorized as low affinity, activating 
FcRs; and FcRIIb is the only low affinity, inhibitory FcR in mice and humans. IgGs 
antibodies bind with different affinity and specificity to different FcRs (Dijstelbloem et al., 
2001). In general terms, monomeric IgG binds predominantly to high affinity FcRs (FcRI) 
and IgG-immune complexes binds to low affinity FcR. These receptors are widely 
expressed in haematopoietic cells (except T cells), endothelial cells, osteoclasts, and 
mesangial cells. In mice, monocytes and macrophages express all activating and inhibitory 
FcRs (FcRI-IV), neutrophils express mainly FcRIII, FcRIV and FcRIIb, dendritic cells 
express FcRI, FcRIII, FcRIIb, NK cells only express FcRIII and B cells only have FcRIIb 
(Nimmerjhan & Ravetch, 2008).  
IgG antibodies and FcRIII have been implicated in triggering alternative anaphylaxis 
pathway. Mice lacking mast cells, IgE or FcεRI alpha chain still develop systemic 
anaphylactic responses upon antigen exposure (Jacoby et al., 1984; Oettgen et al., 1994; 
Dombrowicz et al., 1997) whereas FcR deficient mice that lack the expression of Fc(RI and 
activating Fc ( receptors FcRI, FcRIII, FcRIV) have no apparent signal of systemic 
anaphylaxis (Miyajima et al., 1997). Furthermore, it has been found that mice passively 
transferred with allergen-specific monoclonal IgG, particularly monoclonal IgG1, developed 
systemic anaphylaxis upon allergen exposure; when these mice were pre-treated with anti-
FcRIIb/FcRIII, FcRIV monoclonal antibodies, the systemic anaphylaxis was inhibited, 
indicating the role of FcRIII in IgG-mediated anaphylaxis (Strait et al., 2002).  
2.4.3 Histamine and H1 receptor 
Histamine is an autacoid, also referred as 2-(1H-imidazol-4-yl)ethanamine, that modulates 
the cellular function in several tissues including dermis, small intestine, stomach, lungs and 
brain (Jones & Kearns, 2011). Its synthesis depends on histidine decarboxylase (HDC) that 
removes of carboxylic acid residue on the histidine side chain in the Golgi apparatus. It is 
stored basically in mast cells and basophils although it has been demonstrated that other cell 
types (e.g. neutrophils, lymphocytes, monocytes, dendritic cells, platelets, gastric cells and 
brain histaminergic cells) express HDC (MacGlashan, 2003). The release of histamine occurs 
in response to cross-link of antigen-specific IgE on mast cells and basophils surfaces upon 
antigen exposure during systemic anaphylaxis and the early phase of allergic responses. 
Large quantities of histamine (10-5 to 10-3 mol/L) are released within 30 minutes after 
allergen exposure (Simons, 2003). Histamine and other released mediators such as 
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associated with protective immunity to parasitic infections (Capron et al., 1982). IgE consists 
of two identical heavy chains and two light chains with variable (V) and constant (C) 
regions and no hinge region which makes IgE to be less flexible. The -heavy chains contain 
one variable heavy chain and four constant region domains (C1-4) (Williams & Barclay, 
1988) and are highly glycosylated (Arnold et al., 2007). IgE is the less abundant antibody 
class in serum with normal concentration of 50-200 ng/mL in nonallergic individuals 
(Gould et al., 2003). Even during helminth infections or allergic reactions, human serum IgE 
levels are lower than serum IgG levels; IgG peaks at around 30 µg/mL whereas IgG4 peaks 
at around 680 µg/mL (Bell, 1996). IgE has the shortest half-life of all immunoglobulins. Its 
half-life is about 3 days in serum (Iio et al., 1987), 16 hours on cells in suspension (Ishizaka & 
Ishizaka, 1971) and 2 weeks in tissues when is receptor-bound on cell surfaces (Geha et al., 
1985). Its production requires class-switching from IgM, often via IgG to IgE by somatic 
recombination of germline genes in B cells“, which depends on Th2 cytokines (IL-4/IL-13) 
and CD40 ligation (Poulsen & Hummelshoj, 2007). 
It has been identified three IgE receptors in human (FcRI(2 and 2), galectin-3 and 
FcRII) and four receptors in mice (FcRI(2 and 2), galectin-3, FcRII and FcRIV). 
Most of IgE bind to high affinity IgE receptor (FcRI) that is present in mast cells, basophils 
(Gould et al., 2003) and antigen-presenting cells e.g. Langerhans cells (Bieber et al., 1992). 
FcRI has a central role in mediating the allergic disorders (Kinet, 1999). Cross-linking of 
FcRI associated to IgE with specific antigens induces the release of preformed mediators, 
newly formed lipid mediators and de novo synthesis of cytokines that potentially mediate 
anaphylactic reactions or prolonged allergic inflammation. FcRI shares a common 
oligomeric structure, comprising a ligand binding immunoglobulin-like -subunit 
associated to a -subunit and two -subunits (Daeron, 1997). It binds stably monomeric IgE 
on mast cell surface (Kd  10-10 M). The extracellular domain of -subunit is glycosilated 
which seem to be crucial to appropriate maturation during FcεRI traffic through 
endoplasmic reticulum (Fiebiger et al., 2005) although is not required for monomeric IgE 
binding (Garman et al., 1999). The β- and -subunits bear ITAM (immunoreceptor tyrosine-
based activation motif) that is phosphorylated in tyrosine residues by Lyn after cross-linking 
of FcεRI (Honda et al., 2000). The β-subunit possesses four transmembrane domains and the 
C-terminal domain has an ITAM motif. The -subunit belongs to T cell receptor (TCR) ( gene 
family and is associated to Fc receptors including FcRI, FcRIIA, FcRI (Takai, 2005). Other 
variant of FcεRI is constituted only by three chains (one -subunit and two -subunits) that 
are expressed in monocytes, macrophages and neutrophils (Gould & Sutton, 2008). The low 
affinity IgE receptor (FcεRII) or CD23 is expressed in several cell types including B cells, 
activated T cells, monocytes, eosinophils, platelets, follicular dendritic cells, and thymic 
epithelial cells. CD23 facilitates the antigen presentation to T cells upon binding to IgE-
antigen complex and also plays a role as negative regulator of IgE production (Gould & 
Sutton, 2008). Another IgE receptor is galectin-3 or ε-binding protein, which has been 
reported to be involved in neutrophil activation (Truong et al., 1993). In mice, it has been 
found a fourth type of IgE receptor, FcRIV, which binds IgE-immune complexes on 
macrophage surface, inducing lung inflammation (Mancardi et al., 2008).  
2.4.2 IgG and FcRIII 
IgG antibodies were identified by Tiselius and Kabat in 1939. They immunized rabbits with 
ovalbumin and fractionated the immune serum by electrophoresis into albumin, -globulin, 
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β-globulin and -globluin fractions. The fact that this rabbit serum binds to ovalbumin -
globulin fraction named the immune factor present in rabbit sera as immunoglobulin(Ig) or 
IgG (Tiselius & Kabat, 1939). Classically, there are four types of IgG subclasses in humans 
(IgG1-IgG4) and mice (IgG1, IgG2a, IgG2b, and IgG3). They are the most predominant 
antibody isotype (70-75% of total IgG) in the blood and extravascular compartiments. Four 
different types of FcRs have been identified in mice (FcRI, FcRIIb, FcRIII, and FcRIV). 
The human and primates FcRs have several allelic variants that codify six types of FcRs: 
FcRI, FcRIIa, FcRIIc, FcRIIb, FcRIIIa, FcIIIb.  
Traditionally, these receptors belong to two different categories – they are classified in high 
or low affinity FcRs according IgG affinity to them, and in activating or inhibitory FcRs if 
the type of signaling pathway is triggered by ITAMs (immunoreceptor tyrosine-based 
activation motif) or ITIMs (immunoreceptor tyrosine-based inhibitory motif). Then, FcRI is 
high affinity, activating FcRs in both mice and humans; FcRIII and FcRIV (in mice) and 
FcRIIa, FcRIIc, FcRIIIa, FcRIIIb (in human) are categorized as low affinity, activating 
FcRs; and FcRIIb is the only low affinity, inhibitory FcR in mice and humans. IgGs 
antibodies bind with different affinity and specificity to different FcRs (Dijstelbloem et al., 
2001). In general terms, monomeric IgG binds predominantly to high affinity FcRs (FcRI) 
and IgG-immune complexes binds to low affinity FcR. These receptors are widely 
expressed in haematopoietic cells (except T cells), endothelial cells, osteoclasts, and 
mesangial cells. In mice, monocytes and macrophages express all activating and inhibitory 
FcRs (FcRI-IV), neutrophils express mainly FcRIII, FcRIV and FcRIIb, dendritic cells 
express FcRI, FcRIII, FcRIIb, NK cells only express FcRIII and B cells only have FcRIIb 
(Nimmerjhan & Ravetch, 2008).  
IgG antibodies and FcRIII have been implicated in triggering alternative anaphylaxis 
pathway. Mice lacking mast cells, IgE or FcεRI alpha chain still develop systemic 
anaphylactic responses upon antigen exposure (Jacoby et al., 1984; Oettgen et al., 1994; 
Dombrowicz et al., 1997) whereas FcR deficient mice that lack the expression of Fc(RI and 
activating Fc ( receptors FcRI, FcRIII, FcRIV) have no apparent signal of systemic 
anaphylaxis (Miyajima et al., 1997). Furthermore, it has been found that mice passively 
transferred with allergen-specific monoclonal IgG, particularly monoclonal IgG1, developed 
systemic anaphylaxis upon allergen exposure; when these mice were pre-treated with anti-
FcRIIb/FcRIII, FcRIV monoclonal antibodies, the systemic anaphylaxis was inhibited, 
indicating the role of FcRIII in IgG-mediated anaphylaxis (Strait et al., 2002).  
2.4.3 Histamine and H1 receptor 
Histamine is an autacoid, also referred as 2-(1H-imidazol-4-yl)ethanamine, that modulates 
the cellular function in several tissues including dermis, small intestine, stomach, lungs and 
brain (Jones & Kearns, 2011). Its synthesis depends on histidine decarboxylase (HDC) that 
removes of carboxylic acid residue on the histidine side chain in the Golgi apparatus. It is 
stored basically in mast cells and basophils although it has been demonstrated that other cell 
types (e.g. neutrophils, lymphocytes, monocytes, dendritic cells, platelets, gastric cells and 
brain histaminergic cells) express HDC (MacGlashan, 2003). The release of histamine occurs 
in response to cross-link of antigen-specific IgE on mast cells and basophils surfaces upon 
antigen exposure during systemic anaphylaxis and the early phase of allergic responses. 
Large quantities of histamine (10-5 to 10-3 mol/L) are released within 30 minutes after 
allergen exposure (Simons, 2003). Histamine and other released mediators such as 
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leukotrienes and prostaglandins produce the acute symptoms including pruritus of nasal 
mucosa, eyes, skin and increased vascular permeability, vasodilatation and edema resulting 
in nasal congestion, rhinorrea and conjuntival edema and erythema (Clough et al., 1998). 
Histamine can cause bronchoconstriction due to mucus accumulation by activated globet 
cells in the lung (Golightly & Greos, 2005) and may be involved in airway remodeling 
(Kunzmann et al, 2007). Histamine is responsible for mast cell activation by stimulating the 
secretion of cytokines and chemokines from T and B lymphocytes which up-regulates 
adhesion molecules in epithelial cells (Akdis & Blaser, 2003). 
Histamine binds to four major receptors (H1, H2, H3 and H4) which belong to G-protein 
seven transmembrane receptor family. H1 receptor has been widely discussed in 
anaphylactic disorders. Histamine binds to H1R that activates inositol-1, 4, 5 pathway, 
mobilizing intracellular calcium which induces the vascular endothelium to release nitric 
oxide and stimulate guanyl cyclase to increase the production of cyclic GMP in vascular 
endothelial cells. This cascade promotes vasodilatation, erythema, vascular permeability 
and edema (Li et al, 2003). Activation of H1R produces direct effect in bronchial smooth 
muscle leading to bronchoconstriction. H1 and H2 receptors are overexpressed in patients 
with asthma in contrast to patients with rhinitis only (Botturi et al, 2010). The H2 receptor is 
expressed on gastric mucosa, vascular smooth muscle, brain, adipocytes and immune cells. 
Activation of H2 results in relaxation of smooth muscle in the airway and vasculature 
(Akdis & Simons, 2006). The stimulation of H3 receptor is been involved in pruritus 
(Sugimoto et al, 2004) and H4 receptor may play a role in inflammatory processes by 
inducing chemotaxis and calcium influx in bone marrow-derived and tracheal mast cells 
migration from connective tissue toward epithelium (Thurmond et al, 2004).  
2.4.4 Platelet activation factor (PAF) 
The term PAF was first used to describe the factors that aggregate and activate platelets 
(Benveniste et al., 1972). PAF is a potent proinflammatory phospholipid synthesized from the 
cleavage of glycerophospholipids by phospholipase A2 that binds to PAF receptor, a G-protein 
coupled seven-transmembrane receptor. It is active at concentration as low as 10-12M (Stafforini 
et al, 2003). Since its discovery, pleiotropic effects of PAF have been demonstrated, including 
its role in bronchoconstriction, hypotension, vascular permeability, chemotaxis, degranulation 
of eosinophils and neutrophils (Hanahan, 1986). PAF is released from mast cells, basophils and 
macrophages upon antigen stimulation in human and experimental anaphylactic reactions 
(Vadas et al., 2008; Finkelman, 2007). Histamine, which can be secreted by mast cells and 
basophils, effectors cells in classical anaphylactic pathway, is a potent agonist for PAF 
synthesis by human endothelial cells (McIntyre et al., 1985). Circulating levels of PAF are 
controlled by the activity of PAF acetylhydrolase, enzyme that rapidly degrades PAF, making 
its half-life very short; it ranges from 3 to 13 minutes (Karasawa, 2006).  
Vadas et al. (2008) have found that PAF levels positively correlate with the severity of 
anaphylaxis and may be pivotal for anaphylaxis outcome. Serum PAF levels is significantly 
elevated in allergic patients with severe anaphylaxis than those with milder manifestations 
of anaphylaxis. PAF has been identified as relevant vascular leak mediator in anaphylaxis 
(Camerer et al., 2009). The deletion of PAF receptor impairs anaphylactic responses in 
genetically manipulated mice (Ishii et al., 1998). In addition, recombinant PAF 
acetylhydrolase is protective and reduces mortality in experimental models of anaphylaxis 
(Fukuda et al., 2000; Gomes et al., 2006). Furthermore, PAF stimulate NO (nitric oxide) 
production by enhancing the activity of NOS (constitutive nitric oxide synthase), instead of 
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iNOS (inducible nitric oxide synthase), which relaxes vascular smooth muscle, leading to 
hypotension and death (Cauwels et al., 2006). 
2.4.5 IL-4 and IL-4Ralpha 
IL-4 is a pleiotropic type I cytokine, recognized as signature cytokine of Th2 immune 
responses (Swain et al., 1990). It is produced by Th2 CD4+ T cells, basophils, mast cells, 
eosinophils and CD1-restricted NKT cells upon stimulation (Paul, 1997). IL-4 binds to IL-4 
receptor, which is a heterodimer of IL-4 receptor  chain and common  chain, resulting in 
phosphorylation of STAT6 (signal transducer and activator of transcription 6) (Nelms et al., 
1999).  
IL-4 exacerbates anaphylaxis through a direct effect on mast cell and basophils or through 
enhancing antibody production. Strait et al. (2003) have demonstrated that IL-4R signaling 
increase the responsiveness of mast cell- and macrophage-secreted mediators such as 
histamine, PAF, serotonin and leukotriene C4. IL-4 increases anaphylactic responses in a 
mouse model infected with Thrichinella spiralis by increasing histamine and PAF, but also 
enhances anaphylaxis at doses lower than those produced by helminth infections (Conrad et 
al., 1990). The contribution of IL-4/IL-4R in the anaphylaxis is also associated to their role 
in antibody production. IL-4 promotes class-switching to IgE antibodies (Finkelman et al., 
1988) but it does not seem crucial to IgG1 production since high IgG1 levels is found in mice 
treated with anti-IL-4, and in IL-4 or STAT-6 deficient mice (Finkelman et al., 1989; Kuhn et 
al., 1991; Shimoda et al., 1996).  
3. Helminth infections as predisposed factors to allergic and anaphylactic 
reactions 
Helminths are known to cause widespread infections, mainly in tropical and subtropical 
areas in the developing world where the water suply and sanitation conditions are not 
adequate (De Silva et al., 2003). Although they did not cause high mortality, they tend to 
cause chronic infections in populations that live in endemic area, leading to iron-deficiency 
anemia and malnourishment and interfering with physical and mental growth in children 
(Stephenson et al., 2000).  
The immune response against helminth infections is associated with high production of IgE 
levels and tissue infiltration of eosinophils, mast cells and Th2 cells which secrete IL-4, -5 
and -13 (Fallon & Mangan, 2007). Th2 immune responses are believed to mediate protective 
immunity against these parasites (Anthony et al., 2007). Certain parasites such as Schistosome 
mansoni produce a strong Th2 immune response that is correlated with the formation of Th2 
granuloma around schistosoma eggs (Wilson et al., 2007). 
Several studies have demonstrated that helminth infection may increase allergic 
inflammation. Individuals exposed to helminthes for a short time often have allergic-like 
manifestations (Cooper, 2009). Lynch and collaborators (Lynch et al., 1984, 1987, 1992, 1997) 
have shown that the intensity of helminth transmission determines the effect of helminth 
infection on allergic reactivity - in high income urban areas where the transmission is low, 
the allergic reactivity is high whereas in urban and rural areas where people are chronically 
infected by helminthes, the allergic reactivity is low. Geohelminth parasite with pulmonary 
larval stages, such as Ascaris lumbricoides, Necator americanus, Ancylostoma duodenale and 
Strongyloides stercoralis, are found to cause Loeffler’s syndrome which is characterized by 
eosinophilic infiltrate into the lungs after parasitic infection (Loefller, 1959).  
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leukotrienes and prostaglandins produce the acute symptoms including pruritus of nasal 
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Corroborating with Lynch’s studies, it has been reported high association between dust 
mites and parasitic diseases in tropical allergies (Caraballo & Acevedo, 2011). Mites are 
important source of allergens in tropical areas (Fernandez-Caldas et al., 1993, 2008). The 
warm temperatures and high humidity facilitate the proliferation of dust mites such as 
Blomia tropicalis and Dermatophagoides pteronyssinus (Puerta et al., 1993). Likewise, nematodes 
are highly prevalent in tropical areas. Ascaris lumbricoides is the most prevalent, affecting 
around 1.5 million people worldwide (McSharry et al., 1999) by oral contamination with 
embryonated eggs that differentiate in migratory larvae, compromising intestine, liver, and 
lungs (Bradley & Jackson, 2004). Cross-reactivity between mites and Ascaris could explain 
why there is a positive correlation between allergies caused by dust mites and nematode 
infections in tropical areas. Acevedo et al. (2009) found cross-reactivity of specific IgE and 
tropomyosin from B. tropicalis, D. pteronyssinus and A. lumbricoides in asthmatic patients. It is 
postulated that high prevalence of specific IgE to mites in a tropical environment may be 
influenced by cross-reactivity with Ascaris spp. allergens (Acevedo et al., 2011). Another study 
also suggested that nematode infections may induce reactivity to tropomyosin in atopic 
individuals. Santiago et al. (2011) have demonstrated that there is 72% of amino acid identity 
between tropomyosin from D. pteronyssinus (Der p10) and Onchocerca volvulus in sera from O. 
volvulus-infected and non-infected atopic individuals and the prevalence of Der p10-specific 
IgE and IgG was increased in O. volvulus-infected individuals. Besides Ascaris infection, HDM 
(house dust mite) sensitization is strongly associated to wheeze symptoms in individuals from 
urban areas than in rural areas that had Trichuris infection (Scrivener et al., 2001).  
Cooper (2009) and Smits et al. (2010) have listed four factors that may determine the effect of 
helminthic infections in promoting allergic responses (Figure 2): 1) Timing - periodic 
helminth infections in adult age (acute infections) may induce allergic manifestations 
whereas long-lasting helminthic infections in early age (childhood) (chronic infections) may 
suppress allergic inflammation due to inducing an immunomodulatory environment. 2) 
Intensity of infection – light parasite burden may induce allergic manifestations and heavy 
parasite burdens may induce down-modulation of allergic symptoms. 3) Host genetics – 
atopic individuals may be more likely to develop allergic manifestations than non-atopic 
individuals. 4) Parasite – different helminthes have different effects on atopy and allergies, 
parasites with larvae stages in the lung and skin than in other organs/tissues may be more 
predisposed to allergic manifestations. 
4. Helminths and their products as anti-inflammatory modulators for allergic 
and anaphylactic disorders  
Despite inducing strong Th2 and being considered predisposing factor to allergic 
manifestations, helminth infections can induce suppression of allergic diseases. Smits et al. 
(2010) related that chronic helminth infections may protect against allergic diseases by 
stimulating regulatory B and T cells and modulating dendritic cell functions. The 
immunosuppressive effect of helminthes and their products in the immune response have 
been widely reported in the literature (Smits et al., 2010; Hewitson et al., 2009; Soares & 
Araujo, 2008; Harnett & Harnett, 2008; Maizels et al., 2004). Helminth molecules can degrade 
some host molecules such as eotaxin and antibodies, inhibit the formation of reactive 
oxygen and nitrogen intermediates, interfere with macrophage activaction, down-modulate 
the antigen presentation by dendritic cell and macrophages, and mimic cytokines such as 
IFN-, TGF- and MIF. 
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Fig. 2. Helminth paradigm. Helminthes can stimulate allergic manifestations or suppress 
inflammatory/anaphylactic responses depending on time and intensity of the infection, host 
genetic background and parasite life cycle. 
Helminth infections can impair immune response toward heterologous antigen (Stewart et 
al., 1999), allografts (Liwski et al., 2000), viral infections (Actor et al., 1993) and other 
helminth infections (Jenkins, 1975). Helminths employ several immunomodulatory 
strategies in order to evade and/or modify the host immune response and, consequently, 
perpetuate their survival in the host (Playfair, 1982), including inactivation and/or 
modulation of the host protective immune response. The immunomodulation has been 
considered beneficial both to the host and the parasites since it could avoid helminth 
erradication and protect the host from inflammatory responses that may damage the host´s 
tissue (van Riet et al., 2007). 
It has been identified several immunomodulatory molecules and strategies by which the 
helminths evade the host immune system, permitting that the parasites subvert the host 
protective responses. Some of these molecules include eotaxin metalloproteinase (Culley et 
al., 2000), calreticulin (Pritchard et al., 1999), antioxidants (Brophy et al., 1995) and 
neutrophil inhibitory factor (Moyle et al., 1994). They can interfere with antigen processing 
and presentation (Dainichi et al., 2001), cell proliferation (Allen & MacDonalds, 1998), cause 
T cell death (Semnani et al., 2003), decrease IgE responses (Langlet et al., 1984), reduce B cell 
activation (Deehan et al., 1997) and stimulate regulatory T cells (Belkaid et al., 2006). In this 
section, we will discuss about some helminth products and their immunomodulatory effect 
in the immune system (Figure 3). 
Children 
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Fig. 3. Some immunosuppressive products secreted by helminthes that may be used as 
therapeutic strategies for anaphylactic disorders. Helminth can secrete molecules that 
possess down-modulatory effect on the host’s immune system. The upper panel show some 
molecules secreted by helminthes and the lower panel show the cell targets of the helminth-
secreted products. Abs, antibodies; Ag, antigen; ES, excretory/secretory products; MIF, 
macrophage-migration inhibition factor; MDSC, myeloid-derived suppressor cells; NO, 
nitric oxide; iNOS, inducible nitric oxide synthase; PAF, platelets-activating factor; PAS-1, 
protein from Ascaris suum; Treg, regulatory T cells. 
4.1 Helminth products and their strategies to immunomodulate the host immune 
responses 
4.1.1 Cleavage of host immune system molecules  
It has been described several helminth defense mechanisms that can block host immune 
system by cleaving immune factors. The adult stage of Nippostrongylus brasiliensis releases in 
in vitro culture a product with acetylhydrolase activity that promotes cleavage of platelet-
activating factor (PAF), promoting bronchoconstriction and increasing vascular 
permeability (Blackburn & Selkirk, 1992). Excretory/secretory (ES) products from 
hookworm Necator americanus cleave eotaxin (Culley et al., 2000), and in this way inhibit the 
recruitment of eosinophils, pivotal cells in development of the late phase of allergic 
responses. 
Helminth serpins can also interfere in the immune response by cleaving immune factors. 
Serpins are an extensive family of serine proteinase inhibitors which regulate a wide variety 
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of proteinase-dependent physiological functions, such as blood coagulation, fibrinolysis, 
activation of complement, and the inflammatory response (Potempa et al., 1994). A serpin 
produced by microfilarial stage of Brugia malayi, Bm-SPN-2, inhibits the enzymatic activity 
of serine proteinases, cathepsin G and elastase from human neutrophils (Zang et al., 1999). 
In addition, Smpi56, a serpin from Schistosoma mansoni, inhibits the neutrophil elastase 
(Ghendler et al., 1994), protecting the parasite from activated neutrophils during 
inflammation. 
Besides promoting the cleavage of PAF, eotaxin and inactivation of neutrophil enzymes, 
helminth products also can cleave host antibody. Antibody cleavage is critical for the 
parasite evasion because it inhibits ADCC (antibody-dependent cell cytotoxity) and 
promotes IgG degradation, which blocks FcR-mediated cytokine release. For instance, ES 
products from Fasciola hepatica cleave all human IgG subclasses at the hinge region (Berasain 
et al., 2000). In addition, S. mansoni schitosomula produces a trypsine-like proteinase or 
aminopeptidase that cleave Fab fragment when Fc receptor of the worm binds IgG (Auriault 
et al., 1981). Recombinant schistosome aspartic proteases from S. japonicum cleave 
specifically human IgG, suggesting that these proteases may play a role in the degradation 
of host serum proteins ingested as part of the schistosome bloodmeal (Verity et al., 2001). 
4.1.2 Modulation of nitric oxide production  
Nitric oxide (NO) is a potent microbicidal agent that plays a role in host defense against 
parasites. This effect has been demonstrated toward several helminthes. It has been found 
that ES products from parasites such as Spirometra erinacei (Fukumoto et al., 1997), Anisakis 
simplex (Cuellar et al., 1998), Heligmosomoides polygyrus (Rzepecka et al., 2006) suppress the 
expression of iNOS in LPS-activated macrophages in a dose dependent manner. However, 
filarial nematode cystatins (Hartmann et al., 2002) up-regulate NO production from IFN--
activacted macrophages. In spite of the susceptibility of parasites to NO, its stimulation in 
the host by helminth products is critical to promote nitration and oxidation of host´s 
molecules and damage several biological processes. Moreover, in filariasis murine model 
NO production was associated with suppression of T cell proliferation (O’Connor et al., 
2000), suggesting that the secretion of NO is linked to microfilariae killing and T cell 
response inhibition. 
4.1.3 Interference with antigen presentation and T cell responses 
Helminth cystatins are thought to be the most important molecules that interfere with 
antigen presentation. Cystatins constitute a family of cysteine protease inhibitors that are 
widely distributed and play essential roles in a spectrum of physiological processes (Barrett, 
1986). Nematode cystatins could lead to severe changes in antigen processing and inhibit 
efficient generation of peptide-MHC class II molecule, decreasing the antigen presentation 
by APC. These molecules target cysteine proteases such as cathepsins, which play a role in 
two catalytic processes (Hartmann & Lucius, 2003). First, cysteine proteases degrade 
proteins within the endosomal-lysosomal compartment of APC. Second, cysteine proteases 
are involved in the cleavage of the MHC class II-associated invariant chain, which leads to 
the formation of MHC molecules associated to CLIP (class II-associated invariant chain 
peptide). Then, synthesized CLIP molecules allow the binding of peptides to MHC class II 
molecules to promote antigen presentation. The invariant chain cleavage is promoted by 
cathepsins S in B cells and dendritic cells (Riese et al., 1996), cathepsins L in thymus 
epithelial cells (Nakagawa et al., 1998) and cathepsin F in macrophages (Shi et al., 2000).  
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Nematode cystatins are homologous to mamalian cystatin C, which are highly expressed by 
immature dendritic cells and are down-regulated during dendritic cells maturation process 
to permit the transport of MHC II molecules to cell surface. Parasite cystatins maintain 
dendritic cells in immature state, preventing the antigen presentation by these cells and also 
down-regulate in vitro cellular proliferation (Pierre & Mellman, 1998). The first described 
parasite cystatin was onchocystatin, derived from Onchocerca volvulus (Lustigman et al., 
1992), that down-regulates the HLA-DR expression by human monocytes after 72 hours of 
co-culture (Hartman et al., 1997). Brugia malayi nematodes secrete two homologues cystatins 
(Schonemeyer et al., 2001; Manoury et al., 2001): Bm-CPI-1, which is selectively expressed by 
L2 and L3 stage into the mosquito vector and Bm-CPI-2, which is constitutively expressed 
during the parasite life and interferes with two classes of proteases in the MHC class II 
antigen presentation: cathepsins B, L and S and asparagine endopeptidase. Also, Bm-CPI-2 
blocks the presentation of peptide derived from tetanus toxoid by human B cells. 
Nippocystatin, a cysteine protease inhibitor found in ES products from N. brasiliensis, 
modulate the antigen processing and interfere with antigen presentation due to inhibiting 
multiple cysteine protease activities found in endosomes/lysosomes of B cells (Dainichi et 
al., 2001). In addition, Litomosoides sigmodontis cystatins upregulate the production of tumor 
necrosis factor alpha (TNF-) and decrease antigen-specific proliferation of spleen cells in 
mice (Pfaff et al., 2002). Besides inhibiting proteases from MHC classe II pathway, cystatins 
can also down-modulate T cell proliferation and up-regulate IL-10 production (Hartmann et 
al., 1997; Schonemeyer et al., 2001). ES62, a phosphorylcholine-bearing filarial product, 
secreted by Acanthocheilonema viteae, desensitizes LPS-stimulated mouse peritoneal 
macrophages to produce IFN- (Goodridge et al., 2001). ES-62 also reduces lymphocyte 
proliferation and stimulates anti-inflammatory properties (Harnett & Harnett, 2001). 
Phosphorylcholine(PC)-containing glycosphingolipids from Ascaris suum are 
immunomodulatory molecules due to the fact that they inhibit BCR-mediated B cell 
proliferation by causing apoptosis, inhibit LPS-induced activation of B cells by decreasing 
Erk phosphorylation, modulate IL-12p40 production in LPS/IFN--induced peritoneal 
macrophages (Deehan et al., 2002) indicating the PC moiety is important to induce the 
immunomodulatory effect. In addition, lysophosphatidylserine from S. mansoni can 
specifically target the immune system via TLR-2, interacts to dendritic cells and induce IL-
10-producing regulatory T cells involved in immunosuppression (van der Kleij et al., 2002).  
4.1.4 Stimulation of myeloid-derived suppressor cells 
Several carbohydrate components derived from helminthes also modulate the immune 
response by stimulating myeloid-derived suppressor cells (MDSC) (Reyes & Terazas, 2007) 
These cells are a heterogeneous population of cells that express CD11b and Gr-1 and 
consists of early myeloid progenitors and immature myeloid cells (macrophages, 
granulocytes and dendritic cells) at different stages of differentitation (Gabrilovich & 
Nagaraj, 2009). The basic concept about suppressor cells is based on the findings of 
Gordon’s group who observed a direct in vitro effect of IL-4 on the expression of mannose 
receptor in macrophages (reviewed in Gordon, 2003). This observations lead to 
macrophages being categorized in classically-activated (CA) macrophages which are NO- 
and IFN--dependent (Kusmartsev et al., 2000) and alternatively-activated (AA) 
macrophages which are IL-4- or IL-13-dependent (Kreider et al., 2007; Goerdt et al., 1999). In 
this regard, Mantovani et al. (2004) proposed that macrophages can be polarized in 
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inflammatory (M1) or anti-inflammatory (M2) conditions. Besides, M2 macrophages can be 
classified into subpopulations M2a (which are AA macrophages) and M2b (which are IL-10-
secreting cells upon immune complex activation), and M3c (which are IL-10-induced 
deactivated macrophages). All these type of macrophages (and other suppressor cells) can 
be found in several different of immunological situations, including tumors, autoimmunity, 
intracellular pathogen infections, helminthic infections.  
Two glycans derived from Schistosoma eggs, lacto-N-fucopentaose III and lacto-N-
neotetraose, have been related to induce IL-10 production, suppressing T cell proliferation 
(Terrazas et al., 2001). Soluble egg antigens (SEA) from S. mansoni, which are rich in lacto-N-
fucopentaose III, suppress the LPS-induced inflammation by inducing Th2 responses 
(Pearce & MacDonald, 2002), by enhancing production of IL-10 and impairing dendritic cell 
(DC) activation. This latter property is due to the fact that SEA inhibit MyD88-independent, 
but not dependent-, pathways which result in IL-10 production (Kane et al., 2004), 
suggesting that SEA regulate multiple signaling pathways downstream and may target the 
initiation signaling in DC. The suppression of DC activation could be through the ligation of 
mannose receptor or DC-SIGN (DC-specific intercellular adhesion molecule-grabbing non-
integrin) that results in inhibition of DC to secrete IL-12 in response to TLR ligands (Nigou 
et al., 2001). DC-SIGN ligation leads to IL-10 production, which has been implicated in 
suppression of DC function (Geijtenbeek et al., 2001). It has been found that lacto-N-
fucopentaose III presents an anti-inflammatory effect due to inducing Th2 response and 
functioning as an adjuvant (Okano et al., 2001). High levels of IL-4, IL-5, IL-10, but not IFN-
, are secreted by nasal lymphocytes from mouse immunized with human serum albumin 
conjugated to lacto-N-fucopentaose III. Lacto-N-fucopentaose III is also able to expand 
peritoneal macrophages that bear Gr1+ marker and act as suppressor cells, inhibiting CD4+ 
T cell proliferation via NO- and IFN--dependent mechanisms (Atochina et al., 2001).  
Carbohydrate components from Taenia crassiceps also favor Th2 responses, stimulating IgG1 
and polyclonal IgE responses, IL-4, IL-5, IL-10 production to a bystander antigen and are 
critical to induce gene expression in AA macrophages (Gomes-Garcia et al., 2006), indicating 
that these components enhance Th2 responses as an adjuvant and trigger anti-inflammatory 
responses by stimulating AA macrophages. Glycans from Taenia crassiceps in their 
conformational structure recruit F4/80+ Gr1+ peritoneal exudate cells and suppresses 
proliferation of CD90+ cells (T cells) via cell-to-cell contact, not via IFN- and NO (Gomes-
Garcia et al., 2005). Moreover, T. crassiceps glycans did not activate F4/80+ Gr1+ cells (M2a 
macrophages) through TLR-4 as has been proposed to synthetic and natural glycoconjugates 
(Terrazas et al., 2001; Atochina et al., 2001). In addition, the treatment of intact glycans with 
sodium periodate, which removes glycosilation, decrease M2a macrophages indicating that 
intact glycans are essential to recruit F4/80+ Gr1+ cells. 
4.1.5 Inititation of Th2 immune responses 
S. mansoni eggs secrete two proteins that have been implicated in Th2 differentiation: alpha-
1 and omega-1. Alpha-1 is a dimer that cross-link IgE-FcRI complex on basophils, in an 
antigen-dependent manner, hence being named IL-4 inducing principle of schistosoma eggs 
(IPSE). It induces the degranulation of mouse and human basophils and releases of IL-4 
release (Schramm et al., 2003, 2007), initiating Th2 differentiation. Omega-1 is a ribonuclease 
also secreted by schistosoma eggs which is necessary to egg transit into the host tissues 
(Fitzsimmons et al., 2005). It is believed to be involved in Th2 responses by conditioning 
 
Allergic Diseases – Highlights in the Clinic, Mechanisms and Treatment 
 
512 
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human monocyte-derived dendritic cells to drive Th2 polarization (Everts et al., 2009; 
Steinfelder et al., 2009).  
4.1.6 Mimicry of cytokines and other mediators 
Helminthes can produce homologous proteins to immune system mediators/receptors, such 
as TGF-, IFN-, TNF-R and histamine that play a role in regulating anti-parasite 
responses. Parasite-encoded TGF- molecules have been characterized in filarial nematodes 
Brugia malayi and B. pahrangi. They are two TGF- homologues that show to be differentially 
regulated during the filarial life cycle: tgh-1 in Brugia malayi and B. pahangi (Gomez-Escobar 
et al., 1997), and tgh-2 in B. malayi (Gomes-Escobar et al., 2000). Tgh-1 molecule is required 
for filarial development within the human host (Gomes-Escobar et al., 1998) and Tgh-2 is 
predominantly expressed in adult stages and binds to the human TGF- receptor (Hirata et 
al., 2005), mimicking human TGF- and stimulating regulatory responses in the host. In 
addition to Brugia species, TGF- immunorective molecules have been detected at the 
surface of cervical bodies, in tegument and subtegumental cells of other parasite stages of 
Schistosoma japonicum, during the whole life cycle (eggs, cercariae, schistosomula and adult 
worms), although being distinctly regulated at each developmental stage (Davies et al., 
1998). 
Besides TGF- homologues, TGF- receptor homologues have also been described in Brugia 
and Schistosoma species. SmTR1 or SmRK1, a homologue of type I TGF- receptor and a 
type of TGF- family of receptor serine/threonine kinase, have been shown in Schistosoma 
mansoni surface following its entry into the mammalian host (Forrester et al., 2004). In 
addition to expressing SmRK1, S. mansoni expresses another type I TGF- receptor, SmRK2, 
from schistosomula and adult stages and it is located predominantly to the tegumental 
surface of parasite (Grencis & Entwistle, 1997). Type I TGF- receptor (Bp-trk-1) has been 
also isolated from the filarial parasitic nematode Brugia pahangi in the three main stages of 
its life cycle: microfilariae, infective larvae and adults; although the ligand remains 
unknown, it may likely act as a receptor for host TGF- rather than for parasite ligands 
(Gomes-Escobar et al., 2000). 
Helminths also produce homologues that mimic IFN-. Trichuris muris-derived molecules 
share cross reactive epitopes with the host IFN-. Moreover, these molecules can be shown 
to bind to IFN- receptor and induce change in lymphoid cells similar to those induced by 
murine IFN- (Calandra & Bucala, 1997). Thus, it possible that the host immune system 
produces IL-4 to expulse the worms, the IFN- homologue production may perpetuate the 
parasite survival into the host.  
Other types of molecules that mimic the host cytokines are macrophage-migration inhibition 
factors (MIFs), which are produced by several nematodes. Mammalian MIFs are small 
proteins produced by non-haematopoietic cells that act as pro-inflammatory cytokines and 
induce TNF production by macrophages in acute settings, such as septic shock (Pastrana et 
al, 1998). The first MIF homologue to be characterized from a nematode was BM-MIF-1 
identified in the filarial parasite Brugia malayi, but Wuchereria bancrofti and O. volvulus also 
encode MIF family proteins (Reyes & Terrazas, 2007). It may play multiple roles in host-
parasite interaction due being located in several tissue types and being found in both cell-
associated and secreted forms. Possibly, helminthes may secrete MIF molecules down-
modulate the inflammatory response, mainly by stimulating myeloid-derived suppressor 
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cells that has been found to play down-regulatory functions in helminth infections, such as 
T cell proliferation inhibition and IL-10 and TGF- release. 
5. PAS-1, an anti-inflammatory protein from Ascaris suum 
Our research group has been investigating the effect of Ascaris suum infection and secreted 
products in the inflammatory response. We have been demonstrated that components from 
Ascaris suum body extract modulate the antibody response and the cell-mediated response 
in mice. Soares et al. (1987) have demonstrated that, besides inhibiting the IgE production, 
A. suum extract suppresses the IgG1 and IgG2a antibody production. Ferreira et al. (1995) 
have shown that DBA/2 mice immunized subcutaneouly with OVA + A. suum extract and 
challenged with OVA in the footpad present suppression of immediate (3 hour after 
challenge) and late (24 hours after challenge) type IV hypersensitivity reaction. The isolation 
of protein fractions from A. suum extract by Sephacryl S-300 gel filtration chromatography 
yields three peaks (PI, PII, and PIII). PI is constituted by high weight components that 
suppress anti-OVA IgE antibody production in mice immunized with OVA + PI (Soares et 
al., 1992; Faquim-Mauro & Macedo, 1998). Thus, the suppressive effect observed in A. suum 
extract is due to high molecular weight components. PI protein fraction was used to obtain 
the monoclonal antibody MAIP-1, which recognizes one of the suppressive components in 
the A. suum extract; it is a 200-kDa-protein named PAS-1 (protein from Ascaris suum) (Oshiro 
et al., 2004). 
PAS-1 suppresses the LPS-induced leukocyte migration and pro-inflammatory (IL-1, IL-6 
and TNF-) cytokines production in air pouches exudates and macrophage culture 
supernatant; moreover, it stimulates the production of IL-10 and TGF- (Oshiro et al., 2005), 
indicating that the modulatory effect of PAS-1 in LPS-induced inflammation is likely due to 
these two cytokine. Furthermore, PAS-1 was demonstrated modulating the humoral and 
cellular immune response against OVA. It inhibits the production of IgM, IgG1, IgG2a, IgE 
and anaphylactic IgG1 toward T-dependent but not T-independent, antigens and anti-OVA 
type IV hypersensitivity reaction in mouse footpad injected with carrageenan (Oshiro et al., 
2006), suggesting that PAS-1 suppresses B and T cell responses. 
PAS-1 also down-modulates antibody production, Th2 cytokine secretion, cellular 
recruitment and airway hyperesponsiveness induced by APAS-3, allergenic protein from A. 
suum (Itami et al., 2005). We have demonstrated that regulatory T CD4+CD25+ cells and T 
CD8+ cells secrete IL-10/TGF- and IFN-, respectively and they are involved in the 
mechanisms by which PAS-1 down-modulate the acute lung allergic inflammation in mice 
since OVA-induced inflammation is reverted when PAS-1-primed regulatory T CD4+CD25+ 
cells or T CD8+ cells are adoptively transferred to OVA-immunized mice (Araujo et al., 
2008; De Araujo et al., 2010). Besides playing an immunosuppressive role in the acute lung 
inflammation, we recently found that PAS-1 decreases the airway remodeling and 
angiogenesis in a mouse chronic lung inflammation model induced by OVA or APAS-3 by 
inhibiting metaloproteinases (MMP-2, MMP-9, ADAM-33) and angiogenic factors (VEGF 
and IL-13) (Araujo et al., manuscript in preparation). 
6. Conclusion 
In conclusion, anaphylaxis is a life-threatening and systemic disorder that involves two 
different pathways: classical anaphylactic pathway which is IgE-dependent mechanism 
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modulate the inflammatory response, mainly by stimulating myeloid-derived suppressor 
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cells that has been found to play down-regulatory functions in helminth infections, such as 
T cell proliferation inhibition and IL-10 and TGF- release. 
5. PAS-1, an anti-inflammatory protein from Ascaris suum 
Our research group has been investigating the effect of Ascaris suum infection and secreted 
products in the inflammatory response. We have been demonstrated that components from 
Ascaris suum body extract modulate the antibody response and the cell-mediated response 
in mice. Soares et al. (1987) have demonstrated that, besides inhibiting the IgE production, 
A. suum extract suppresses the IgG1 and IgG2a antibody production. Ferreira et al. (1995) 
have shown that DBA/2 mice immunized subcutaneouly with OVA + A. suum extract and 
challenged with OVA in the footpad present suppression of immediate (3 hour after 
challenge) and late (24 hours after challenge) type IV hypersensitivity reaction. The isolation 
of protein fractions from A. suum extract by Sephacryl S-300 gel filtration chromatography 
yields three peaks (PI, PII, and PIII). PI is constituted by high weight components that 
suppress anti-OVA IgE antibody production in mice immunized with OVA + PI (Soares et 
al., 1992; Faquim-Mauro & Macedo, 1998). Thus, the suppressive effect observed in A. suum 
extract is due to high molecular weight components. PI protein fraction was used to obtain 
the monoclonal antibody MAIP-1, which recognizes one of the suppressive components in 
the A. suum extract; it is a 200-kDa-protein named PAS-1 (protein from Ascaris suum) (Oshiro 
et al., 2004). 
PAS-1 suppresses the LPS-induced leukocyte migration and pro-inflammatory (IL-1, IL-6 
and TNF-) cytokines production in air pouches exudates and macrophage culture 
supernatant; moreover, it stimulates the production of IL-10 and TGF- (Oshiro et al., 2005), 
indicating that the modulatory effect of PAS-1 in LPS-induced inflammation is likely due to 
these two cytokine. Furthermore, PAS-1 was demonstrated modulating the humoral and 
cellular immune response against OVA. It inhibits the production of IgM, IgG1, IgG2a, IgE 
and anaphylactic IgG1 toward T-dependent but not T-independent, antigens and anti-OVA 
type IV hypersensitivity reaction in mouse footpad injected with carrageenan (Oshiro et al., 
2006), suggesting that PAS-1 suppresses B and T cell responses. 
PAS-1 also down-modulates antibody production, Th2 cytokine secretion, cellular 
recruitment and airway hyperesponsiveness induced by APAS-3, allergenic protein from A. 
suum (Itami et al., 2005). We have demonstrated that regulatory T CD4+CD25+ cells and T 
CD8+ cells secrete IL-10/TGF- and IFN-, respectively and they are involved in the 
mechanisms by which PAS-1 down-modulate the acute lung allergic inflammation in mice 
since OVA-induced inflammation is reverted when PAS-1-primed regulatory T CD4+CD25+ 
cells or T CD8+ cells are adoptively transferred to OVA-immunized mice (Araujo et al., 
2008; De Araujo et al., 2010). Besides playing an immunosuppressive role in the acute lung 
inflammation, we recently found that PAS-1 decreases the airway remodeling and 
angiogenesis in a mouse chronic lung inflammation model induced by OVA or APAS-3 by 
inhibiting metaloproteinases (MMP-2, MMP-9, ADAM-33) and angiogenic factors (VEGF 
and IL-13) (Araujo et al., manuscript in preparation). 
6. Conclusion 
In conclusion, anaphylaxis is a life-threatening and systemic disorder that involves two 
different pathways: classical anaphylactic pathway which is IgE-dependent mechanism 
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triggered by IgE-FcRI signaling on mast cell and basophils to secrete histamine, and 
alternative anaphylactic pathway which is IgG-dependent triggered by IgG-immune 
complex bound to FcRIII on basophils and macrophages to secrete PAF. The understanding 
of molecular and cellular mechanisms involved in the anaphylactic disorders is crucial to 
investigate terapeuthic strategies for preventing anaphylaxis risk and recurrence. 
Helminths secrete several immmunomodulatory factors that can modulate inflammatory 
response. Some helminth products can cleave host molecules, such as chemokines, 
antibodies, and enzymes; modulate the NO production; interfere with antigen presentation 
and T cell responses by down-modulating DC functions; mimic cytokines such as IFN- and 
TGF- and MIF. Other potent immunodulatory molecule from helminth is PAS-1, a protein 
from A. suum, that down-modulate acute inflammatory responses and chronic lung allergic 
inflammation, decreasing IgG1 and IgE production, eosinophil infiltrate, and Th2 cytokines 
and interfering with metaloproteinase activity and production of angiogenic factors. Thus, 
due to their capacity to induce immunomodulation, these helminth products may be useful 
for therapeutic interventions in inflammatory, allergic and anaphylactic disorders.  
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triggered by IgE-FcRI signaling on mast cell and basophils to secrete histamine, and 
alternative anaphylactic pathway which is IgG-dependent triggered by IgG-immune 
complex bound to FcRIII on basophils and macrophages to secrete PAF. The understanding 
of molecular and cellular mechanisms involved in the anaphylactic disorders is crucial to 
investigate terapeuthic strategies for preventing anaphylaxis risk and recurrence. 
Helminths secrete several immmunomodulatory factors that can modulate inflammatory 
response. Some helminth products can cleave host molecules, such as chemokines, 
antibodies, and enzymes; modulate the NO production; interfere with antigen presentation 
and T cell responses by down-modulating DC functions; mimic cytokines such as IFN- and 
TGF- and MIF. Other potent immunodulatory molecule from helminth is PAS-1, a protein 
from A. suum, that down-modulate acute inflammatory responses and chronic lung allergic 
inflammation, decreasing IgG1 and IgE production, eosinophil infiltrate, and Th2 cytokines 
and interfering with metaloproteinase activity and production of angiogenic factors. Thus, 
due to their capacity to induce immunomodulation, these helminth products may be useful 
for therapeutic interventions in inflammatory, allergic and anaphylactic disorders.  
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1. Introduction 
The prevalence of allergic disease and asthma has increased dramatically during the last 30-40 
years. Atopic disorders comprise a range of allergic diseases including asthma, anaphylaxis, 
allergic rhinitis, and atopic dermatitis; these diseases have been seen a precipitous increase in 
the last four decades. Intriguingly, geographic regions with a high helminth infection burden 
tend to have a lower incidence of asthma (1). The effects of parasitic infections on the incidence 
of allergic disease has been receiving increased attention from researchers of late, with studies 
conducted in Ethiopia and Gabon demonstrating that parasitic infestation is associated with 
reduced atopic sensitization and dust mite skin test sensitivity (2-4). Children treated 
repeatedly for Trichuris trichiura and Ascaris lumbricoides exhibited increased dust-mite skin 
responses as compared with children that had not been treated for asymptomatic soil-
associated helminthic infections (5). Several molecules from helminthes induce pronounced 
Th2 responses in a manner similar to that seen in cases of full-blown parasitic infection. 
Excretory-secretory (ES) glycoproteins isolated from the rodent nematode, Nippostrongylus 
brasiliensis, have been shown to evidence Th2-promoting activity on dendrite cells, however, 
the exact nature of the molecules involved in N. brasiliensis ES proteins remain to be clearly 
elucidated. This activity is heat-labile and protease-sensitive, thereby suggesting that the active 
component is proteinaceous in nature (6). Also, in schistosomiasis, the soluble extract of 
Schistosoma mansoni eggs (SEA) was shown to induce SEA-specific Th2 responses when 
injected into mice (7), and SEA was also demonstrated to condition human dendrite cells 
(DCs) to polarize Th response in a Th2 direction in vitro (8). When exposed to Th2 cytokines, 
these molecules can also activate host CD4+CD25+Foxp3+ T cells (regulatory T cells, Treg) 
which subsequently release IL-10 and tumor growth factor β (TGF-β), which may be 
functionally involved in the suppression of the level of Th2 cytokines IL-4, IL-5, and IL-13. 
These parasites can establish a chronic infection, which highlights important issues (9), in that 
the presence of these metabolically active pathogens indicates that the immune system is being 
relentlessly challenged with foreign antigens; this continuous immune reactivity, if 
uncontrolled, could eventuate severe pathology. In addition, these pathogens may have 
developed evolutionary strategies by which they may evade the immune system for long-term 
survival in an immunocompetent host (10).  
In order to ascertain, then, whether parasitic infections can reduce allergic reactions and 
whether their infective stage influences the immune system of the host, we have mimicked 
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injected into mice (7), and SEA was also demonstrated to condition human dendrite cells 
(DCs) to polarize Th response in a Th2 direction in vitro (8). When exposed to Th2 cytokines, 
these molecules can also activate host CD4+CD25+Foxp3+ T cells (regulatory T cells, Treg) 
which subsequently release IL-10 and tumor growth factor β (TGF-β), which may be 
functionally involved in the suppression of the level of Th2 cytokines IL-4, IL-5, and IL-13. 
These parasites can establish a chronic infection, which highlights important issues (9), in that 
the presence of these metabolically active pathogens indicates that the immune system is being 
relentlessly challenged with foreign antigens; this continuous immune reactivity, if 
uncontrolled, could eventuate severe pathology. In addition, these pathogens may have 
developed evolutionary strategies by which they may evade the immune system for long-term 
survival in an immunocompetent host (10).  
In order to ascertain, then, whether parasitic infections can reduce allergic reactions and 
whether their infective stage influences the immune system of the host, we have mimicked 
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chronic infection conditions in our experiment via treatment with parasite-derived proteins 
for one month prior to allergen treatment. We attempted to determine whether or not these 
parasite-derived proteins suppressed allergy-specific Th2 reactions. 
2. Immunization of parasite derived proteins inhibits allergic specific Th2 
response 
Long-lived parasites are highly accomplished practitioners of immune evasion and 
manipulation, utilizing strategies honed during their long co-evolutionary interaction with 
the mammalian immune system (10, 11). How is the host affected by these parasitic 
strategies? Although many hypotheses have been advanced, until the present time there has 
been little evidence to support these theories. Th2 host response as the result of parasitic 
infection was apparent, although this is the result of parasitic strategies to escape from the 
host immune system or the result of a human protective system associated with parasitic 
infection. Additionally, we could readily detect Th2 responses in allergic patients. Thus, 
until now, there has been considerable controversy regarding the relationship between 
parasites and allergic reactions; particularly, whether parasites can evoke some allergic-
specific response or can reduce allergen-specific responses (12-14).  
We have attempted to determine whether parasite-derived proteins can accelerate or reduce 
asthma symptoms in accordance with the treatment period (15). We have mimicked chronic 
infection conditions in our experiment via treatment with parasite (Toxascaris leonina adult 
worm)-derived proteins [ES protein (Tl-ES) and total proteins (Tl-TP)] for one month prior 
to the administration of allergen treatment. We mentioned this group as Immunized group; 
also Challenged with OVA group were mentioned which were administrated Tl-ES and Tl-
TP at the same challenge days in airway allergic reaction procedure. As results, the 
immunized Tl-ES and Tl-TP groups evidenced a thinning of the bronchial epithelial and 
muscle layer, a disruption and shedding of the epithelial cells, a reduction in the number of 
goblet cells as compared to the OVA-challenged groups (Fig. 1). When the airway functions 
of these mice were monitored, we detected that the Penh values by methacholine treatment 
(from 2.5 mg/ml to 25 mg/ml) were significantly higher in the OVA-inhalation mice than 
those of Tl-TP and Tl-ES immunized group (Fig. 2A). The numbers of most inflammatory 
cells (macrophages, eosinophils, lymphocytes and neutrophils) in the BAL fluids were 
significantly increased in all of the OVA-challenged groups (Fig. 2B & 2C). The 
administration of Tl-ES and Tl-TP prior to asthma induction (immunized group) and the Tl-
ES and Tl-TP with OVA challenge (challenged with OVA groups) evidenced inhibited 
recruitment of inflammatory cells into the airway (Fig. 2B & 2C). In particular, neutrophils 
and lymphocytes were significantly reduced by the parasite proteins at any administration 
time (p value < 0.05). The total number of eosinophils of the immunized and OVA-
challenged group were slightly reduced; however, this reduction was not statistically 
significant (P value > 0.05).  
Although some articles have previously asserted that nematodes can induce allergic 
reactions during their larval migration period (16, 17), many articles have reported that 
parasitic infections, particularly chronic parasitism, help to reduce host allergic reactions 
and to modulate host immune responses (14, 18, 19). We have determined that 
immunization with T. leonina adult worm ES and total proteins induces a down-regulation 
of asthma-associated cytokines, including IL-4 and IL-5, in the bronchial alveolar lavage 
(BAL) fluids (Fig. 3). However, these proteins did not significantly influence allergic airway 
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inflammation response as the result of simultaneous OVA challenge, as compared to the 
immunization method. In particular, the Tl-ES treatment with OVA challenge group 
exhibited more severe lung inflammation than was observed in the immunized group. We 
believe that certain allergens or proteases might be included in the ES proteins, and parasitic 
proteases have also been identified as allergens (20-23). Sokol et al. previously suggested 
that a host-derived sensor of proteolytic activity might involve cleavage via parasite or 
allergic proteases. This sensor, once cleaved, activates the cells of the innate immune system 
to induce a Th2 response (13).  
 
 
Fig. 1. Histological findings of airway inflammation in ova-challenged control mice and the 
effect of immunization and challenge with OVA groups. Female and 6 weeks of age mice 
were induced airway allergic reaction using intraperitoneally (I.P.) sensitizing with 75 ug of 
ovalbumin (OVA, Sigma, Grade V) and 2 mg of aluminium hydroxide gel, on days 0 and 7. 
One week after the final sensitization, the mice were intra nasal challenged with 50 ug of OVA 
on 4 consecutive days (days 13, 14, 19, and 20). We mentioned “Immunized group” that were 
injected by I.P. with 100 ul of 10 ug/ml Toxascaris leonina excretory-secretory (Tl-ES) and T. 
leonina total protein (Tl-TP), respectively, on 7 and 14 days before airway allergic reaction 
procedure. Also “Challenged with OVA” group were mentioned which were injected by I.P. 
with 100 ul of 10 ug/ml of Tl-ES and Tl-TP respectively at the same challenge days in airway 
allergic reaction procedure. The negative control group was challenged with PBS (I.N.) on the 
same challenge day in airway allergic reaction procedure. A; PBS-treated,  B-F; OVA+ alum-
treated (induced asthma), (C) immunized Tl-ES protein, (D) immunized Tl-TP, (E) Tl-ES 
protein treatment with OVA challenge, (F) Tl-TP protein with OVA challenge. 
IL-4 has been demonstrated to regulate isotype class switching in B cells to IgE synthesis, and 
IL-5 stimulates eosinophil growth, activates these cells, and prolongs eosinophil survival. T. 
leonina-derived proteins could inhibit increases in the levels of IL-4 and IL-5 from OVA 
challenge. In particular, the level of IL-4 in the BAL fluid in the immunized group was almost 
half of that observed in the OVA-only challenge group. This result was consistent with the 
results regarding the IgE concentration in the blood (15). Although levels of the IL-5 cytokine 
of T. leonina ES and total protein-immunized mice were lower than those observed in asthma 
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chronic infection conditions in our experiment via treatment with parasite-derived proteins 
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control mice, this effect was not remarkable. Also, the total number of eosinophils was not 
substantially reduced as the result of immunization. Eosinophils and IgE proved vitally 
important in allergy-induced Th2 response; additionally, the elevation of the numbers of these 
cells and IgE levels were identified as specific responses to parasite infection and this response 





Fig. 2. Airway hyperresponsiveness measurements and comparison of differential cell 
counts obtained via airway inflammation in ova-sensitized PBS mice and the effects in 
immunized and OVA-challenged groups. Total protein of T. leonina immunization group 
[Tl-TP (I)] has lower penh value than those of OVA challenge group (A). The numbers of 
inflammatory cells were significantly lower in the parasite-derived protein-treated mice (B 
& C). The data were expressed as the means + SD of individual mice.  
 




Fig. 3. Th1 and Th2 cytokines levels in the BAL fluids of Tl-ES and Tl-TP treated mice. 
The levels of all Th2 cytokines of the immunized group were contrasted with those of the 
OVA-challenged control mice. The data were expressed as the means + SD of individual 
mice (* ; p value <0.05, **; p value <0.01).  
How does helminth infection protect against allergy? Many hypotheses have been 
advanced thus far regarding this theme. One of these hypotheses is that non-specific IgE 
generated as the result of helminthic infection may inhibit allergen-specific IgE binding 
sites on mast cells or basophils. Although Jarrett suggested in 1980 that parasite-induced 
'nonspecific' IgE does not protect against host allergic reactions (26). However, other 
scientists have suggested that nonspecific IgE can modulate host immune responses, as in 
the case of insulin-dependent diabetes, as well as Th2 response by allergens (25, 27-29). 
The other hypothesis states that helminth parasites stimulate the production of 
immunoregulatory mediators, which are likely to perform a function in the maintenance 
of the chronicity of infection, with no marked induction of pathology. In particular, 
elevated IL-10 levels have been associated previously with protection against allergic 
diseases in helminth-infected African children (4). Helminth infections can induce Treg 
cells from hosts, and these cells secrete IL-10 and suppress the proliferation of other CD4+ 
T cells (30-32). We also found that parasite proteins could also induce the IL-10 cytokine, 
particularly in the Tl-TP immunized group (Fig. 4).  
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Fig. 4. Treg cell related cytokines levels in the BAL fluids of Tl-ES and Tl-TP treated mice. 
The data were expressed as the means + SD of individual mice (* ; p value <0.05, **; p value 
<0.01).  
Finally, the data presented herein demonstrate that T. leonina-derived proteins may 
perform a crucial function in resistance against Th2 immune responses. We suggested that 
this inhibition may be related to the IL-10 cytokine, which was induced by parasite 
proteins. Further steps are currently being taken in an effort to gain a greater 
understanding of the molecular basis of immune evasion by nematodes. Thus, we are 
attempting to gain new insights into the immune regulation strategies of nematodes, and 
the growing number of new strategies employed by parasites to exert their marked down-
regulatory effects. 
3. Macrophage migration inhibitory factor homologues of parasite suppress 
Th2 response in allergic airway inflammation model via Treg cell recruitment 
A number of parasite-derived proteins, glycoconjugates, and small lipid moieties have been 
demonstrated to perform known or hypothesized functions in immune interference. Other 
researchers have already isolated several other immune downregulatory molecules from 
parasites, and these molecules have been identified as mammal cytokine homologues, 
protease inhibitors, abundant larval transcript antigens, glyco-networks, and venom 
allergen-like proteins (33-39). The cytokine network is a crucial component of host defense 
against pathogens. It is not, therefore, surprising to find that one of the immune evasion 
strategies utilized by infectious organisms is the generation of mammalian cytokine 
homologues, including TGF-β and the macrophage migration inhibitory factor (MIF)  
(40, 41).  
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MIF was described initially as one of the earliest cytokines to be derived from activated T-cells, 
and was believed to prevent the random migration of macrophages (42). MIF has also been 
demonstrated to be generated abundantly by monocytes/macrophages and to function in an 
autocrine/paracrine manner in the upregulation and sustenance of the activation of diverse 
cell types (43). The profile of the activities of MIF, both in vivo and in vitro, is reflective of a role 
for MIF in the pathogenesis of a variety of inflammatory diseases, including rheumatoid 
arthritis, inflammatory bowel disease, ankylosing spondylitis, and psoriasis (44). MIF performs 
a crucial function in airway inflammation and airway hyper-responsiveness in asthma (45).  
Recently, several MIF homologues have been isolated from parasitic nematodes. Two types 
of MIF homologues have thus far been identified in nematodes (34). The type 1 MIF 
homologues bear a greater amino acid similarity with the mammalian MIFs than do the type 
2 MIF homologues (46). The type 1 MIF homologues isolated from Brugia malayi (Bm-MIF1) 
induce eosinophil recruitment, and alternatively activated macrophage recruitment in vivo 
when injected into the peritoneal cavities of mice. Mutation of the conserved proline residue 
induces the abrogation of this activity (47). This ability of parasite MIF homologues was 
similar to those of mammalian MIF. However, recently Cho et al. reported that hookworm 
MIF (structurally type 2 MIF) functions differently from mammalian MIF (48, 49).  
We have cloned another type 2 MIF homologue (As-MIF) from Anisakis simplex (whale 
worm) 3rd stage larva, which causes anisakidosis in humans (50). Recombinant As-MIF (rAs-
MIF) proved highly effective with regard to the inhibition of goblet cell hyperplasia and 
inflammatory responses in the airways of OVA-induced asthma model mice (Fig. 5). 
Increasing concentrations of rAs-MIF induced an increase in the anti-inflammatory effects 
on asthma model mice. Additionally, the function of rAs-MIF was antagonized as compared 
to the function of host MIF (59).  
How does As-MIF suppress allergy responses in mice? There have been many reports 
demonstrating that Th2-type effector responses may be regulated by Treg cells (51-53). 
Additionally, nematode infections can induce and expand naturally occurring Treg cells in 
both humans and mice (4, 54), thereby suggesting a role for these Treg cells in the helminth-
induced modulation of inflammatory diseases (55, 56). In particular, the clinical symptoms 
of allergic airway inflammation in the mouse model was clearly modulated by Treg cell 
mediated immune suppression, which was itself activated by helminth infection or antigen 
treatment (57, 58). We could determine the increase in Treg cells as the result of rAs-MIF 
treatment in OVA-alum asthma-induced mice (Fig. 6).  
IL-10 and TGF-β were produced primarily by Treg cells, and they are known to suppress 
immune response effects. The IL-10 and TGF-β levels measured in BALFs from rAs-MIF-
treated asthma-induced mice were higher than those of the asthma-induced mice; the IL-10 
and TGF-β levels occurred in accordance with their treated concentrations (59). The 
helminthic parasites stimulate the production of immunoregulatory mediators, which likely 
perform a function in the maintenance of the chronicity of infection, without any marked 
induction of pathology. In particular, elevated IL-10 levels have been associated with 
responses against allergic diseases in helminth-infected individuals (4). Also, Nagler-
Anderson et al. showed that in mice sensitized with peanut plus cholera toxin, anti-IL-10 
treatment abrogated the ability of helminths to protect against allergic symptoms and to 
downregulate allergen-specific IgE. IL-10, which is referred to as the cytokine synthesis 
inhibitory factor, is an anti-inflammatory cytokine, which is capable of inhibiting the 
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synthesis of pro-inflammatory cytokines (60). The IL-10 requirement is critical to several 
important human diseases, including schistosomiasis, wherein marked increases in host 
morbidity and mortality are observed when IL-10 levels are low or absent (61). In cases of 
murine S. mansoni infection, IL-10 attenuates the hepatocyte damage induced by the eggs of 
the parasite. IL-10 is also essential for the maintenance of non-lethal chronic infections, in 
addition to the inhibition of inappropriate immune responses in experimental models (62). 
TGF-β1 is also a strong candidate for immune suppression by Treg cells from helminth-
infected mice, and has already been recognized to alleviate experimental airway allergy 
symptoms (63) and to instruct peripheral T cells to develop their regulatory capacities (64). 
Thus, the inhibition of asthma response by rAs-MIF may be associated with the principal 




Fig. 5. Histologic appearance of lungs after challenge with PBS, OVA, and rAs-MIF by 
concentration (H-E stain). (A; x 100, B; x 600; C; PAS stain), C; a, f, and k; phosphate-
buffered saline (PBS) treated, b-e, g-j, and l-o; OVA plus alum-treated (induced asthma), c, h 
and m; challenged with 1 μg/ml rAs-MIF, d, i, and n; challenged with 10 μg/ml rAs-MIF. e, 
j, and o; challenged with 100μg/ml rAs-MIF. In asthma-induced mice, a massive peri-
bronchial infiltration with immune-related cells and hyperplasia of bronchial epithelial cells 
were observed. Upon challenge with 1μg/ml rAs-MIF treatment (c, h and m), asthma-
induced mice evidenced thinner bronchial epithelial cells than were observed in the asthma-
induced mice (b, g, and l). Mice challenged with treatment with 10 and 100μg/ml rAs-MIF 
evidenced thinner than normal bronchial epithelial cells and decreased numbers of immune-
related cells. Goblet cells and immune-related cells in the airway walls of mice exposed to 
PBS, OVA and OVA challenge with 1, 10, and 100 μg/ml rAs-MIF. In asthma-induced mice 
(g), a massive peri-bronchial infiltration of inflammatory cells and hyperplasia of bronchial 
epithelial cells were detected. However, goblet cell hyperplasia was reduced in the bronchial 
epithelial cells of the rAs-MIF-treated mice (h-j).  
 




Fig. 6. Treg cell production could be induced by rAs-MIF treatment. Treg cell populations in 
the lungs and spleen were significantly increased by rAs-MIF treatment, but this effect was 
inhibited by rAnti-As-MIF. (*; p < 0. 05, **; p < 0.01, n = 5 mice per group, 3 independent 
experiments). 
4. Conclusion 
We showed that parasite derived proteins may perform a crucial function in resistance 
against allergic airway inflammation via IL-10 cytokine induction and Treg cell recruitment. 
Parasites regulate or suppress their host immune response, maintaining their parasitism for 
a prolonged period, using unknown molecules. As-MIF might be one of the molecules that 
affect host immune regulation. The further characterization of parasite derived proteins 
might ultimately result in the design of novel therapeutic intervention strategies for the 
treatment of asthma.  
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the parasite. IL-10 is also essential for the maintenance of non-lethal chronic infections, in 
addition to the inhibition of inappropriate immune responses in experimental models (62). 
TGF-β1 is also a strong candidate for immune suppression by Treg cells from helminth-
infected mice, and has already been recognized to alleviate experimental airway allergy 
symptoms (63) and to instruct peripheral T cells to develop their regulatory capacities (64). 
Thus, the inhibition of asthma response by rAs-MIF may be associated with the principal 




Fig. 5. Histologic appearance of lungs after challenge with PBS, OVA, and rAs-MIF by 
concentration (H-E stain). (A; x 100, B; x 600; C; PAS stain), C; a, f, and k; phosphate-
buffered saline (PBS) treated, b-e, g-j, and l-o; OVA plus alum-treated (induced asthma), c, h 
and m; challenged with 1 μg/ml rAs-MIF, d, i, and n; challenged with 10 μg/ml rAs-MIF. e, 
j, and o; challenged with 100μg/ml rAs-MIF. In asthma-induced mice, a massive peri-
bronchial infiltration with immune-related cells and hyperplasia of bronchial epithelial cells 
were observed. Upon challenge with 1μg/ml rAs-MIF treatment (c, h and m), asthma-
induced mice evidenced thinner bronchial epithelial cells than were observed in the asthma-
induced mice (b, g, and l). Mice challenged with treatment with 10 and 100μg/ml rAs-MIF 
evidenced thinner than normal bronchial epithelial cells and decreased numbers of immune-
related cells. Goblet cells and immune-related cells in the airway walls of mice exposed to 
PBS, OVA and OVA challenge with 1, 10, and 100 μg/ml rAs-MIF. In asthma-induced mice 
(g), a massive peri-bronchial infiltration of inflammatory cells and hyperplasia of bronchial 
epithelial cells were detected. However, goblet cell hyperplasia was reduced in the bronchial 
epithelial cells of the rAs-MIF-treated mice (h-j).  
 




Fig. 6. Treg cell production could be induced by rAs-MIF treatment. Treg cell populations in 
the lungs and spleen were significantly increased by rAs-MIF treatment, but this effect was 
inhibited by rAnti-As-MIF. (*; p < 0. 05, **; p < 0.01, n = 5 mice per group, 3 independent 
experiments). 
4. Conclusion 
We showed that parasite derived proteins may perform a crucial function in resistance 
against allergic airway inflammation via IL-10 cytokine induction and Treg cell recruitment. 
Parasites regulate or suppress their host immune response, maintaining their parasitism for 
a prolonged period, using unknown molecules. As-MIF might be one of the molecules that 
affect host immune regulation. The further characterization of parasite derived proteins 
might ultimately result in the design of novel therapeutic intervention strategies for the 
treatment of asthma.  
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According to the World Health Organization (WHO), 300 million people suffer from asthma, a 
disease which is increasing in western societies, and furthermore asthma is the most common 
chronic disease among children, adolescents and young adults. A steady increase in the 
prevalence of asthma, has been seen in most countries in recent decades (Thomsen et al 2011) 
and the higher frequency of asthma in young people may partly explain the high frequency 
found in elite athletes – although both frequency of asthma symptoms and use of anti-
asthmatic medication are different than expected. Moreover, the frequency of airway 
hyperresponsiveness (AHR) in elite athletes is higher than expected as well as the frequency of 
asthma-like symptoms (cough, wheeze, shortness of breath and chest tightness) which might 
be caused by exhaustive ventilation, but the pathogenesis is still unknown. 
The frequency of asthma among the general population is around 7-10%; whereas the 
frequency of asthma among elite athletes is found to be higher, especially among endurance 
athletes (Pedersen et al 2008b). It seems as asthma is something they gain, as only one third 
of Olympic athletes had childhood asthma. Although asthma among the general public is a 
permanent phenomenon, it seems to be different in elite athletes, as asthma apparently 
disappeared after retiring from the sport (Fitch et al 2008).   
2. Asthma among athletes 
Asthma is a chronic respiratory condition classically characterised by airway inflammation 
and airway hyperresponsiveness (AHR) to multiple stimuli (Anderson et al 2009). AHR is 
defined as a pathological bronchoconstrictive response to a given stimulus . AHR to a direct 
stimulus (e.g. methacholine) acts through airway smooth muscles and the response is 
thought to be independent of airway inflammation. Whereas response to an indirect 
stimulus (e.g. exercise, hyperventilation, mannitol) acts through a release of inflammatory 
mediators, such as histamine, prostaglandins, and leukotrienes, which causes contraction of 
the airway smooth muscle cells. Airway inflammation in asthma is characterised by 
inflammatory cells, such as eosinophils, mast cells, and macrophages. The inflammation 
causes remodelling of the basal membrane, enlargement of the mass of smooth muscles, and 
disturbance of the surface area. Permanent use of controller therapy with inhaled steroids 
(ICS) is needed in asthma, as well as relief therapy with short-acting beta2-agonists (SABA), 
long-acting beta2-agonists (LABA) or others. 
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Elite athletes, with or without asthma, have asthma-like symptoms during their training 
season, especially cough, phlegm and shortness of breath is a dominant complain among 
athletes (Lund et al 2009). Furthermore, athletes are more often found with AHR to direct 
stimuli and less to direct stimuli than found in normal subjects thus suggesting a respiratory 
illness. Variation in action of the different provocative agents is related to the fact that 
response to an indirect challenge would reflect an ongoing inflammation better than would 
direct tests, and perhaps thus reflect the presence of classical asthma, whereas AHR to direct 
agents indicates airway smooth muscle dysfunction and, in some cases, asthma (Pedersen et 
al 2008a, Sue-Chu et al 2010).  
The definition of asthma includes respiratory symptoms, variable airway obstruction and 
airway hyperresponsiveness to multiple agents. The respiratory symptoms in patients with 
common asthma and the elite athletes with or without asthma are similar, which leave a 
diagnostic problem in these cases where symptoms are the single diagnostic parameter 
available. Whereas, the differences between common asthma and asthma among elite 
athletes are predominantly related to the airway responsiveness to inhaled agents, the day-
to-day variability of lung function as well as the content of the inflammatory cells which 
predominantly are neutrophilic cells and not eosinophilic. 
3. Exercise-induced asthma and bronchoconstriction in elite athletes  
Exercise-induced bronchoconstriction (EIB) is an acute, transient narrowing of the airway 
that occurs during and particularly after exercise. In most scientific papers, exercise-induced 
asthma (EIA) are defined as respiratory symptoms and a significant reduction in FEV1 after 
exercise, i.e. ∆ FEV1 ≥ 10%, whereas EIB is a significant reduction in FEV1 (≥10%) when 
tested, independent of symptoms or not. In population samples, the prevalence of EIB (16%) 
is the same as the findings of AHR to histamine (16%), although only 6% had responsiveness 
to both test (Backer et al 1992). EIB is believed to be more specific to asthma, but less 
sensitive, as the number of false negative results is a problem when research and clinical 
situations settings are evaluated (Anderson & Kippelen 2005). The frequency of AHR is 
frequently found above 40%, which is higher than the frequency of asthma.  Elite athletes 
claim that exercise is the most prominent trigger of asthma symptoms, as they very seldom 
complain of respiratory symptoms at rest or during the night.  
The pathogenesis of asthma-like symptoms in elite athletes is multifactorial, and is not 
completely understood. However, deep, exhaustive ventilation during exercise brings 
atmospheric air which is cold and dry and this manoeuvre overcomes the ability of the 
upper airways to warm up and humidify the air reaching the smaller airways(Anderson 
& Kippelen 2005). This brings about airway narrowing due to osmotic and thermal 
evaporative water loss, and some vascular involvement. These airway differences, 
together with some degree of inflammation, lead to a respiratory condition described as 
EIB or sports asthma. This abnormal response is most often found in endurance sports, 
such as cross-country skiing , swimming, rowing, cycling, fast-track skating and long 
distance running.   
The symptoms of exercise-induced bronchoconstriction range from mild impairment of 
performance with minor reduction in lung function after exercise to severe bronchospasm 
with large reduction in FEV1. In athletes, however, the most common symptoms include 
cough, wheezing, chest tightness, dyspnoea, and fatigue. These symptoms are frequently 
found in healthy subjects, subjects with asthma, subjects who are not in good condition and 
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sometimes in subjects suffering from an extrathoracal disorder such as vocal cord 
dysfunction (VCD).  
In conclusion, the most frequent complaint among healthy and diseased athletes is 
respiratory symptoms during exercise.  Furthermore, healthy elite athletes often have AHR  
with a pattern which differ from the general asthma patient. Lastly, the types of cells 
involved in the inflammation are different from those in normal asthmatics. 
4. Diseases mimicking exercise-induced asthma 
Not all that wheezes is asthma. When the diagnosis of asthma is based on respiratory 
symptoms alone, misdiagnosis may occur. Patients may present with respiratory distress, 
such as wheezy, when experiencing a low level of fitness, a psychological condition, 
inhalation of airborne irritants, rhinosinusitis, or gastroesophageal reflux disease. Moreover, 
exercise-induced symptoms can occur as periodic occurance of laryngeal obstruction 
(POLO) or exercise induced laryngeal obstruction (EILO) and present with asthma like 
symptoms. These diseases include conditions such as vocal cord dysfunction (VCD), 
exercise-induced paradoxical arytenoid motion (EPAM), exercise-induced laryngomalacia 
(EIL), exercise-induced laryngochalasia, angioedema, vocal cord tumours, and vocal cord 
paralysis. There seems to be a substantial overlap between EILO and EIA, at least in elite 
athletes. It could be of minor importance, but it could also have a major influence on the 
diagnostic procedure in the daily care settings of those with asthma-like symptoms. When 
POLO/EILO is misdiagnosed as asthma, patient are erroneously treated with anti-asthma 
therapy, even high doses because of  “resistant disease”.    
These diseases are easily recognized by performing a Flow/Volume curve where a classical 
cutoff of the inspiratory loop is apparent. On the other hand, a specific diagnose of the 
actual pathology need laryngeal examination during exercise. The definitive diagnosis of 
laryngeal obstruction might require laryngoscopy during strenuous exercise. Heimdal et al 
(Heimdal et al 2006) recently published a paper describing a model for use when 
performing the continuous laryngoscopy exercise test (CLE). Patients with asthma should 
start asthma medication, and for those with satisfactory adherence who do not achieve well-
controlled disease, other reasons for persistent respiratory symptoms should be explored. In 
such cases CLE should be performed.  
5. Treatment 
Treatment of elite athletes with asthma can be divided into non-pharmacological and 
pharmacological treatment. During the last decades the International Olympic Committee 
(IOC) increased their focus on the increasing use of anti-asthmatic medication by Olympic 
and other elite athletes. At the 1996 Olympic Games in Atlanta 3.7% of the athletes used 
beta2-agonists, 5.6% at the 1998 Winter Games in Nagano, and 5.7% at the Sydney Games 
2000. The IOC and the World Anti Doping Agency (WADA) have had many changes in the 
anti-doping regulations on beta2-agonists through the years, partly due to concerns 
regarding ergogenic effects and partly because of health risk concerns. Due to the increased 
use of beta2-agonists as mentioned above the IOC introduced a criterion of demonstration of 
asthma by an objective measure of reversibility or bronchial airway hyperresponsiveness in 
order approved use of beta2-agonist. This resulted in a 27% reduction in the use of beta2-
agonists in the 2004 Games in Athen.  
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5.1 Pharmacological treatment 
Treatment of asthma and exercise-induced bronchoconstriction (EIB) in elite athletes should 
follow international asthma treatment guidelines like the Global Initiative for Asthma 
(GINA), see Figure 1 (Bateman et al 2008). The main purpose of pharmacotherapy is control 
of asthma symptoms, reducing airway inflammation and airway hyperresponsiveness, 
achieving normal lung function, and prevent exacerbations 
 















































Fig. 1. Management approach. Adapted from GINA. 
5.2 Beta2-agonists 
Inhaled short acting beta2-agonists (SABA), e.g. salbutamol and terbutaline, are first choice 
therapy for fast relief of EIB. Moreover, SABA is useful in preventing EIB if taken 15 minutes 
before exercise. Frequent and increased use indicates uncontrolled asthma and should result 
in reassessment of treatment strategies. Side effects are tremor, tachycardia, palpitations and 
headache, which increase in frequency and intensity with higher doses. With high systemic 
doses hypopotassemia and muscle convulsions can occur. Systemic use of beta2-agonists by 
elite athletes is entirely prohibited according to the Prohibited List, see Table 1. 
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Inhaled long acting beta2-agonists (LABA), e.g. salmeterol and formoterol, are used in 
management of uncontrolled asthma treated with inhaled corticosteroid alone. LABA is 
used as add-on therapy to inhaled corticosteroids, either as fixed combination or in two 
separate devices. LABA should never be used as monotherapy in asthma due to risk of 
serious adverse events with increased risk of mortality in case of exacerbation. In a review 
from 2005 it was concluded that combined fluticasone and salmeterol was superior to 
fluticasone as monotherapy in preventing EIA. Furthermore, in a randomized, double-
blinded study combined budesonide/formoterol was compared with budesonide alone, 
asthma control was better with reduced symptoms when treated with combination of 
budesonide/formoterol. A new study from 2010 confirms previous findings with more 
efficacy when inhaled budesonide is combined with formoterol among adults and 
adolescents with moderate to severe asthma. These findings indicate that it is not an effect 
related to the specific drug, but a class effect of the combination. 
 
I SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES  
(IN- AND OUT-OF-COMPETITION): 
S0. Non-approved substances 
S1. Anabolic agents 
S2. Peptide hormones, growth factors and related substances 
S3. Beta2-agonists 
S4. Hormone antagonists and modulators  
S5. Diuretics and other masking agents   
M1. Enhancement of oxygen transfer  
M2. Chemical and physical manipulation  
M3. Gene doping 
  
II SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION:  
S0-5 and M1-3 defined above 





III SUBSTANCES PROHIBITED IN PARTICULAR SPORTS:  
P1. Alcohol  
P2. Beta-Blockers 
Table 1. The 2011 Prohibited List by World Anti-Doping Agency. 
It is well known that regular use of beta2-agonist could lead to development of tolerance to 
bronchodilation (i.e. reduced bronchodilator response during acute asthma) and 
bronchoprotection (i.e. reduced ability to prevent exercise-induced bronchoconstriction). 
Tolerance to bronchodilator develops rapidly, after only few doses, and regardless of 
ongoing treatment with inhaled corticosteroid. Tolerance to bronchoprotection develops 
after few weeks of treatment and regardless of ongoing treatment with inhaled 
corticosteroids. The decreased bronchoprotection might result in increased use of beta2-
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agonist and higher risk of side effects. Though theoretical concerns that regular beta2-
agonist treatment may lead to tolerance and failure to respond to emergency asthma 
treatment, there is little evidence that this is a clinical problem. However, as elite athletes 
exercise daily and often several times a day, use of beta2-agonists, either before exercise to 
prevent bronchoconstriction or during/after due to bronchoconstriction, would exceed the 
maximal recommend weekly use in the GINA guidelines, indicating that other treatment 
strategies than SABA in case of EIB are needed.  
5.3 Inhaled corticosteroids 
Inhaled corticosteroids (ICS) are the most used and most effective inhaled anti-inflammatory 
drug available. ICS improves asthma symptoms, self-reported quality of life and lung 
function, reduces airway inflammation and airway hyperresponsiveness and furthermore, ICS 
has been found to reduce number and severity of exacerbations and asthma mortality (Jeffery 
et al 1992, Suissa et al 2000). GINA guidelines recommend ICS when asthma is uncontrolled 
with non-pharmacological interventions and rescue therapy alone. Effects are observed after 7-
14 days, while full effects are seen after eight weeks of treatment. 
Our current knowledge about effects of ICS on exercise-induced bronchoconstriction is 
based on adults and children with asthma. Existing studies ranges from three weeks to two 
years duration of treatment, mostly conducted in a parallel design. A study with 40 adult 
asthmatic subjects randomized to 6 weeks treatment with placebo or 800 micrograms 
budesonide twice a day showed a post-exercise fall in FEV1 of 7% in the budesonide group 
and to 22% in the placebo group.  Similar findings are reported in asthmatic children. 
5.4 Leukotriene modifiers 
Leukotriene modifiers have anti-inflammatory and bronchodilatory effects. Leukotriene 
modifiers are administered orally and once daily for montelukast and twice daily for 
zileuton. Montelukast is used as add-on treatment in case of uncontrolled asthma with 
medium dose ICS as monotherapy(Lofdahl et al 1999). Prevention of EIA is another 
indication in elite athletes with asthma. Studies report a reduced post-exercise fall in FEV1 
and a reduced period of bronchoconstriction after exercise when treated with montelukast 
compared to placebo in non-smoking asthmatic subjects. No studies have reported 
development of tolerance during regular use.  
5.5 Cromoglycate 
In a study from 2010 treatment with sodium cromoglycate decreased the FEV1 fall after a 
eucapnic voluntary hyperpnoea (EVH) challenge in elite athletes with EIB (Anderson et al 
2010). This finding support that release of mast cell mediators is an important factor for the 
severity of EIB. However, use of cromones in asthmatic elite athletes is limited. 
6. Non-pharmacological interventions 
Asthmatic athletes with pollen allergy should avoid prolonged outdoor endurance exercise 
in areas with high pollen counts. Exercise in temperatures below minus 15 degrees Celsius 
should be avoided, particularly in areas with air pollution or other airway irritants. 
Few studies have investigated correlation between physical warm-up and degree of EIA 
in asthmatic athletes and a warm-up period has been shown to induce refractoriness to 
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EIA without itself inducing significant bronchoconstriction. The protective effect of 
different types of warm-up has been compared in controlled studies, but no consensus is 
found. Different study protocols and designs make it difficult to compare the existing 
studies, but physical warm-up in some form and extent seems generally to have a 
protective effect on EIA, and physical warm-up should be advised for all athletes with 
asthma. Breathing filters may reduce EIB among those exercising in cold conditions. A 
study from 2000 compared response to exercise in cold air (decrease in FEV1) in nine 
patients with EIA when given no treatment, given premedication with a beta2-agonist, 
wearing a heat-and-moisture-exchanging facemask, and given both premedication and 
facemask. The mean maximal change in FEV1 was 27% with no treatment, 12% with 
facemask, 7% with premedication, and no change with the combination of premedication 
and facemask. Another study from 2006 examined effects of a heat exchanger mask, 
placebo mask, and premedication with a beta2-agonist. Five patients with EIA performed 
a treadmill exercise test while breathing cold air. It was concluded that a heat exchanger 
mask prevented cold exercise-induced fall in lung function as effectively as treatment 
with beta2 agonist before exercise in cold air.  
During the last decade some research has focused on nutritional factors, especially omega-3-
polyunsaturated fatty acids’ influence on airway inflammation and exercise-induced 
bronchoconstriction. A review from 2005 concluded that omega-3-polyunsaturated fatty 
acid supplementation reduces the degree of exercise-induced bronchoconstriction compared 
with placebo in patients with EIA. The review was based on a small number of studies with 
limited range of clinically important outcomes. Further controlled and well-designed 
research is needed to establish any evidence-based recommendations.  
7. Treatment or doping 
As mentioned above the IOC and WADA have increased their attention on the status of 
beta2-agonists on the “The 2010 Prohibited List” (www.wada-ama.org). Until the end of 
2009 granting of a Therapeutic Use Exemption (TUE) was necessary for use of inhaled 
salbutamol, terbutaline, salmeterol and formoterol. From 2010 use of inhaled salbutamol 
and salmeterol in therapeutic doses are allowed. From 2010 use of inhaled terbutaline and 
formoterol is still prohibited and requires a TUE and a reasonable explanation of why these 
drugs are prescribed when other equal drugs are permitted. Use of inhaled corticosteroids 
in therapeutic doses is permitted, except when used in a fixed combination with formoterol, 
which requires a TUE. Use of oral or topical antihistamines or leukotriene modifiers is 
permitted. Use of systemic corticosteroids is prohibited during competition. Systemic intake 
of beta2-agonist and clenbuterol is strictly prohibited in elite athletes. The criteria for 
granting a TUE, the “Prohibited List”, and guidelines are available on WADA’s website 
(www.wada-ama.org). As the anti-doping legislation and the prohibited list are continually 
updated, it is important to be familiar with the current regulations before prescribing 
asthma medication to an elite athlete with asthma. The 2011 Prohibited List is shown in 
Table 2. For details visit WADA´s website. 
In the academic societies of sports and pulmonary medicine it is discussed whether or not 
beta2-agonists have any ergogenic, i.e. performance enhancing effects, and if it should be 
considered doping or not. According to the World Anti-Doping Agency (WADA) minimum 
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two of three criteria must be met in order to consider a substance or method for inclusion on 
the Prohibited List: 
1. The substance or method can be performance enhancing 
2. The use of the substance or the method can endanger the athlete´s health 
3. The use of the substance or method is against the spirit of sport 
As it appears a substance or method can be listed without being performance enhancing. 
Due to health issues the IOC considers inhaled use of beta2-agonist without need 
unacceptable. Beta2-agonists have received much attention the last decades because of side 
effects, and few studies have reported and the US Food and Drug Administration have 
issued some concerns about beta2-agonists and side effects/serious adverse events. 
Regarding health issues in elite athletes using beta2-agonists the IOC is concerned about 
athletes using beta2-agonists without need and in supratherapeutic doses. Studies in 
asthmatic children have shown both significant raised and normal blood levels of 
myocardial stress markers after inhalation of beta2-agonists in ten times prophylactic doses. 
Studies with unrestrained rats have documented dose-response myocyte apoptosis after 
administration of the beta2-agonists formoterol and clenbuterol. Significant changes in 
human cardiac electrophysiological properties is seen after administration of salbutamol 5 
mg as a single dose.  
Several studies have investigated the ergogenic effects of inhaled and oral beta2-agonists 
conducted with healthy well-trained men, most studies in therapeutic doses. The 
extensive research on therapeutic doses of inhaled beta2-agonsits clearly rules out any 
ergogenic effects. Only few studies have shown ergogenic effects of inhaled salbutamol, 
but these are limited by enrolment of recreational subjects. It is now a common opinion 
that inhaled beta2-agonists in therapeutic doses has no advantageous effects in healthy 
athletes. However, animal and human studies, where beta2-agonists are given in systemic 
supra-therapeutic doses daily for few weeks, have shown evidence of improvement of 
muscle strength and endurance performance. Pluim et al. concluded in a systematic 
review and meta-analyses of randomized controlled trials on beta2-agonists and physical 
performance published in 2011 that there is some evidence indicating that systemic beta2-
agonists may have a positive effect on physical performance in healthy subjects(Pluim et 
al 2011). Clenbuterol, another beta2-agonist used in veterinary medicine via prescription 
as a bronchodilator, cardiotonic and tocolytic agent. However used in supratherapeutic 
doses in animals and humans it is misused as a growth promotor with anabolic and 
lipolytic effects.  
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The present Edition “Allergic diseases - highlights in the clinic, mechanisms and 
treatment” aims to present some recent aspects related to one of the most prevalent 
daily clinical expression disease. The effort of a group of outstanding experts from 
many countries reflects a set of scientific studies very promising for a better clinical 
care and also to the treatment and control of the allergy. This book provides a valuable 
reference text in several topics of the clinical allergy and basic issues related to the 
immune system response. The inflammatory reaction understanding in allergic disease 
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